<SEC-DOCUMENT>0000950123-15-009540.txt : 20150909
<SEC-HEADER>0000950123-15-009540.hdr.sgml : 20150909
<ACCEPTANCE-DATETIME>20150818171230
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-15-009540
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		18
FILED AS OF DATE:		20150818
<PUBLIC-REL-DATE>20150909
DATE AS OF CHANGE:		20150831

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAPTYSBIO INC
		CENTRAL INDEX KEY:			0001370053
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				203828755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-01073
		FILM NUMBER:		151062120

	BUSINESS ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-362-6295

	MAIL ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANAPTYS BIOSCIENCES INC
		DATE OF NAME CHANGE:	20060724
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A (Amendment No. 1)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Confidential Draft No. 2 confidentially submitted to the Securities and Exchange Commission
on August 18, 2015. </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>This draft registration statement has not been publicly filed with the Securities and Exchange Commission
and all information herein remains strictly confidential. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration
No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>FORM S-1
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>NAPTYS</SMALL>B<SMALL>IO</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>20-3828755</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>10421 Pacific Center Court, Suite 200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, CA 92121 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858)
362-6295 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices)
</B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Hamza Suria </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>10421 Pacific Center Court, Suite 200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, CA 92121 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858)
362-6295 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Effie Toshav, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Matthew S. Rossiter, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Robert A. Freedman, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fenwick &amp; West LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>555
California Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Francisco, CA 94104</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(415) 875-2300</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Charles S. Kim, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Robert W. Phillips, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Sean M. Clayton, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>4401 Eastgate
Mall</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, CA 92121</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858) 550-6000</B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this registration
statement. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to
Rule&nbsp;415 under the Securities Act of 1933 check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If
this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to
Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>
</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. (Check one): </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; font-size:0pt">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>securities to be registered</B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>aggregate
offering<BR>price<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>registration fee</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common stock, $0.001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-size:0pt">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(o) of the Securities Act of 1933, as amended. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Includes the offering price of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares that the underwriters have the option to purchase. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:8pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration
Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><FONT COLOR="#de1a1e">The information in this preliminary prospectus is not complete and may be changed. These securities
may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the
offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #0079c1">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="73%"> <P STYLE="margin-bottom:1pt; font-size:9pt; font-family:ARIAL">Preliminary Prospectus </P></TD>
<TD>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="right"><FONT COLOR="#de1a1e"><I>Subject&nbsp;to&nbsp;Completion,&nbsp;dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2015 </I></FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:6.00pt solid #0079c1">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g92n73.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Per Share </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">This is the initial public offering of shares of our common stock. We are offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
of our common stock. We anticipate that the initial public offering price of our common stock will be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock. We intend&nbsp;to list our common stock on the NASDAQ Global Market under the symbol
&#147;ANAB.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, we have
elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Investing in our common stock involves a
high degree of risk. See &#147;<A HREF="#toc942137_2">Risk Factors</A>&#148; beginning on page&nbsp;12 of this prospectus. </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000">Per&nbsp;Share</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000">Total</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Underwriting discounts and commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Proceeds to AnaptysBio, Inc. (before expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We refer you to &#147;Underwriting&#148; beginning on page&nbsp;146 of this prospectus for additional information regarding total underwriter compensation. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">To the extent the underwriters sell more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, the underwriters have the
option for a 30-day period to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares from us at the initial public offering price less the underwriting discount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is
truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The underwriters expect to deliver the shares of common stock to the purchasers
on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #0079c1">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Joint Book-Running Managers </I></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:18pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:18pt">
<TD VALIGN="top"><B>BMO&nbsp;Capital&nbsp;Markets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Stifel</B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Co-Managers </I></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="51%"></TD></TR>

<TR STYLE="font-family:ARIAL; font-size:12pt">
<TD VALIGN="top"><B>JMP&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Wedbush&nbsp;PacGrow</B></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #0079c1">&nbsp;</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Prospectus
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_24">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_4">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_9">Selected Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_10">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_13">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_14">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_15">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_16">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_18">Material U.S. Federal Income Tax Considerations for Non-U.S. Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_20">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_22">Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc942137_23">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those
contained in this prospectus or in any free writing prospectuses we have prepared. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to
sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through and including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not
participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who come into possession of this prospectus and any applicable free writing prospectus in jurisdictions outside the United States are
required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus and any such free writing prospectus applicable to that jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you should consider in
making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes thereto and the information set forth under the sections
&#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; in each case included in this prospectus. Unless the context otherwise requires, we use the terms
&#147;AnaptysBio,&#148; &#147;company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; in this prospectus to refer to AnaptysBio, Inc. and our subsidiary. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biotechnology company developing
first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. We develop our product candidates using our proprietary antibody discovery technology platform, which is designed to replicate, <I>in
vitro,</I> the natural process of antibody generation. Our platform is based upon a breakthrough understanding of somatic hypermutation, the key biological process utilized to generate antibodies, which enables us to rapidly develop highly
functional antibody drug candidates against emerging biological targets. Our most advanced, wholly-owned programs, ANB020 and ANB019, are being developed to treat severe inflammatory disorders with unmet medical need. In 2016, we plan to initiate
clinical trials of ANB020, an antibody that inhibits the activity of interleukin-33 for the treatment of severe adult asthma and severe adult peanut allergy, and ANB019, an antibody that inhibits the interleukin-36 receptor for the treatment of rare
inflammatory diseases called generalized pustular psoriasis (GPP) and palmo-plantar pustular psoriasis (PPP). Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep
experience in antibody discovery and development, collaborations, operations and corporate finance. Our investors include Biotechnology Value Fund, Cormorant Asset Management, Frazier Healthcare, HBM Partners, Longwood Capital Partners and Novo A/S.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we have entered into multiple collaborations from which we expect four programs will enter the clinic by the end of 2016. Our
collaborations include an immuno-oncology-focused collaboration with TESARO, Inc. and TESARO Development, Ltd., or collectively, TESARO, and an inflammation-focused collaboration with Celgene Corporation, or Celgene. Through July 31, 2015, we have
received non-dilutive funding of $48.7&nbsp;million from our collaborators. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have developed, and will continue to develop, antibody product candidates that leverage emerging insights into biological mechanisms to treat severe
diseases with unmet medical need. The following table summarizes certain key information about our wholly-owned and partnered product candidates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g07x01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most advanced, wholly-owned product candidates are
summarized below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>ANB020</B> is an antibody that inhibits the activity of interleukin-33, or IL-33, a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases, including asthma, food
allergies and atopic dermatitis. IL-33 acts on several cell types, including white blood cells that initiate and orchestrate atopic responses. IL-33 also directly mediates release of disease-associated cytokines, which recruit pro-inflammatory cells
that mediate atopic disease. Because ANB020 inhibits IL-33 function, and acts upstream broadly across the key cell types and cytokines involved in atopy, we believe that its mechanism has advantages in the treatment of atopic diseases over competing
agents that block only a subset of the cytokines responsible for atopic diseases. We believe ANB020 is potentially the first-in-class therapy targeting IL-33. We anticipate filing an Australian Clinical Trial Notification, or CTN, for ANB020 during
the fourth quarter of 2015, the approval of which would allow us to commence clinical trials in Australia. We plan to commence a Phase&nbsp;1 healthy volunteer trial in Australia in early 2016, followed by patient trials in severe adult asthma and
severe adult peanut allergy in other countries, including the United States after submitting an Investigational New Drug application, or IND, to the U.S. Food and Drug Administration, or FDA. We estimate, based on our analysis of publicly available
data sources and interviews with physicians and key opinion leaders in the field, that asthma affects approximately 7.7% of the adult U.S. population, or approximately 19.0 million individuals, of which 19%, or approximately 3.6 million have severe,
persistent occurrence of this respiratory disease. Peanut allergy is the most common cause of food-induced allergy in the United States. Based on our analysis, we estimate approximately 1.7 million adults are affected by peanut allergy, of which
approximately 600,000 are treated by allergists and approximately 400,000 are at risk for severe reactions and therefore we believe are suitable for treatment with systemic biological therapies. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>ANB019</B> is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which we are initially developing as a potential first-in-class therapy for GPP patients. GPP is a life-threatening,
rare, systemic inflammatory disorder that, based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders in the field, we estimate affects approximately 3,000 patients in the United States with no
approved therapies. Studies have shown that GPP is associated with mutations that lead to abnormally high signaling through the IL-36R, which we believe can be addressed by treatment with ANB019. We believe ANB019 is the most advanced therapeutic
antibody targeting the IL-36R in development. We anticipate filing an Australian CTN for ANB019 during the second half of 2016, the approval of which would allow us to initiate Phase I trials in Australia during the second half of 2016. We plan to
subsequently develop ANB019 in the United States after submitting an IND to the FDA and to seek FDA Orphan Drug Designation for the treatment of GPP and PPP. The FDA may grant Orphan Drug Designation to a drug intended to treat a disease or
condition, that generally affects fewer than 200,000 individuals in the United States. </TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our SHM-XEL Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our approach to developing novel therapeutic antibody product candidates relies upon somatic hypermutation, or SHM, a critical, endogenous process that
generates the essential antibody diversity required to develop a natural immune response to pathogens. Our proprietary antibody generation platform, called <FONT STYLE="white-space:nowrap">SHM-XEL,</FONT> is designed to replicate the natural process
of SHM <I>in vitro.</I> Competing antibody discovery technologies include mouse immunization methodologies, microbial antibody display and human B-cell screening. We believe <FONT STYLE="white-space:nowrap">SHM-XEL</FONT> overcomes several key
limitations associated with these competing technologies and has the following competitive advantages: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Diversity against difficult targets.</B> By applying SHM without the constraints of an <I>in vivo</I> environment we are able to generate an unprecedented diversity of antibodies. This enables us to develop
antibodies against human targets that we believe have not otherwise been accessible to other technologies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>High potency.</B> Because our platform generates highly-potent antibodies, we are potentially able to modulate every extracellular target associated with human disease, and believe only small therapeutic doses may be
required to mediate therapeutic effect <I>in vivo</I>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Functional activity selection.</B> Our mammalian cell system simultaneously displays and secretes antibodies during the antibody discovery process, allowing us to incorporate functional assays throughout the process
and focus on product candidates that are optimized for the desired therapeutic activity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Speed.</B> Our platform technology enables us to generate therapeutic-grade antibodies and initiate subsequent preclinical manufacturing and toxicology studies, typically in less than 12 months. We believe this
timeline is significantly shorter than conventional approaches based upon mouse immunization and microbial display systems. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Manufacturability.</B> By utilizing our mammalian cell display system, we believe our approach increases the probability of success in manufacturing and commercialization by mitigating risks associated with antibody
expression, formulation and stability during the antibody generation process. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Bispecific antibodies.</B> Our novel approach for the generation of bispecific antibodies leverages SHM to combine two therapeutic mechanisms into a single natural antibody molecule. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Collaborations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have established collaborations with pharmaceutical and biotechnology companies that have provided us with $48.7&nbsp;million in payments through July 31,
2015. In addition to our wholly-owned antibody programs, we are developing antibody product candidates for immuno-oncology and inflammation targets through strategic collaborations. Our collaborations with TESARO and Celgene are described below:
</P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TESARO Programs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our March 2014
immuno-oncology collaboration with TESARO, we have granted exclusive rights to TESARO to develop and commercialize antibodies generated using our SHM-XEL platform consisting of the following antibody product candidates: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-PD-1 Monospecific Antagonist Antibody (TSR-042)</I>: currently in preclinical development with an IND submission anticipated in the fourth quarter of 2015 and first-in-human dosing in early 2016;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-TIM-3 Monospecific Antagonist Antibody</I>: currently in preclinical development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-LAG-3 Monospecific Antagonist Antibody</I>: currently in preclinical development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-PD-1/TIM-3 Bispecific Antagonist Antibody</I>: currently in lead selection process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-PD-1/LAG-3 Bispecific Antagonist Antibody</I>: currently in lead selection process; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Undisclosed Bispecific Antagonist Antibody</I>: currently in lead selection process. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Celgene
Programs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our December 2011 collaboration with Celgene, we developed therapeutic antibodies against multiple targets. We granted Celgene the
option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters
pertaining to each target under collaboration. We successfully delivered antibodies against three targets. Celgene is currently advancing two anti-inflammatory antibody programs to the clinic. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a leading antibody development
company with a pipeline of novel therapeutic antibodies, which is being further expanded by applying our technology platform to emerging biological targets. The key elements of our strategy include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Advancing our lead product candidates into the clinic. </B>We plan to initiate a Phase 1 healthy volunteer trial for ANB020 in early 2016, followed by trials in severe adult asthma and severe adult peanut allergy
patients. We plan to initiate a Phase 1 healthy volunteer trial for ANB019 during the second half of 2016, followed by a registration study in GPP patients. For both ANB020 and ANB019, we plan to conduct our initial clinical trials in Australia, and
to then conduct further clinical development in the United States and other countries. We have elected to pursue this strategy in order to benefit from Australia&#146;s rapid regulatory review processes for first-in-human studies and from certain
financial incentives that Australia makes available for biotechnology research and development, and because we believe that clinical data generated in Australia will subsequently be accepted by the FDA and its foreign equivalents outside of
Australia. </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Identifying emerging opportunities in key therapeutic areas.</B> We intend to remain at the forefront of discovery and development of new
therapeutic opportunities in inflammation and immuno-oncology by understanding and translating biological breakthroughs into first-in-class therapeutic antibodies. Our </P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
approach includes assessment of human genetics and tissue pathology to understand the relevance of emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to
create new product candidates and position our current and future programs for rapid clinical proof-of-concept achievement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Continuing to expand our proprietary pipeline by generating new product candidates using our technology platform. </B>Using our proprietary antibody generation platform, we are able to rapidly develop novel
therapeutic antibodies against emerging targets. Our goal is to advance one or more wholly-owned new therapeutic antibody program to an IND submission to the FDA, or foreign equivalent, each year. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Retaining rights to strategic products in key commercial markets. </B>We intend to retain ownership and control of our pipeline programs to key inflection points. We may build sales and marketing capabilities in
selected specialty markets that we believe can be served with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing resources to advance through
development and commercialization. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Affecting Us </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks and uncertainties, including those highlighted in the section titled &#147;Risk Factors&#148; immediately
following this prospectus summary. These risks include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our product candidates are in early stages of development and may fail in development or suffer delays that adversely affect their commercial viability. If we or our collaborators are unable to complete development of
or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, required regulatory approvals in the United States or in foreign jurisdictions, which would materially impair our ability to
commercialize and generate revenue from our product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may not be successful in our efforts to use and expand our technology platform to build a pipeline of product candidates and develop marketable products. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have no history of conducting clinical trials or commercializing biotechnology products, which may make it difficult to evaluate the prospects for our future viability. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have never dosed any of our product candidates in humans. Our planned clinical trials or those of our collaborators may reveal significant adverse events, toxicities or other side effects not seen in our preclinical
studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We face significant competition, and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our existing collaborations, including those with TESARO and Celgene, are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if
these collaborations are not successful, our business could be adversely affected. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The manufacture of biologics is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of
our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have limited operating revenue and a history of operational losses and may not achieve or sustain profitability. We have no products approved for commercial sale, and to date we have not generated any revenue or
profit from product sales. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of our product
candidates or develop new product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our executive officers, directors, current 5% or greater stockholders and entities affiliated with any of them, together will own &nbsp;&nbsp;&nbsp;&nbsp;% of our common stock based on the number of shares outstanding
as of June 30, 2015; the concentration of our capital stock ownership will likely limit your ability to influence corporate matters. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated under the
laws of the State of Delaware in November 2005. Our principal executive offices are located at 10421 Pacific Center Court, Suite 200, San Diego, California 92121, and our telephone number is (858)&nbsp;362-6295. Our website address is
www.anaptysbio.com. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated by reference into, this prospectus. Investors should not rely on any such information in deciding whether to
purchase our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mark &#147;AnaptysBio&#148; is our common law trademark. All other service marks, trademarks and trade names appearing in
this prospectus are the property of their respective owners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a company with less than $1.0 billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as defined in the
Jumpstart Our Business Startups Act of 2012, or JOBS Act, enacted in April 2012. An &#147;emerging growth company&#148; may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include,
but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being permitted to present only two years of audited financial statements and only two years of related Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations in this prospectus;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may use these provisions until the last day of our fiscal year following the fifth anniversary of the closing of this offering. However, if certain events
occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer,&#148; our annual gross revenues exceed $1.0 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will
cease to be an emerging growth company prior to the end of such five-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure
obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different
than you might receive from other public reporting companies in which you hold equity interests. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The JOBS Act provides that an emerging growth company can take advantage of an extended transition period
for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not
emerging growth companies. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_24"></A>The Offering </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares to be offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock to be outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their option to purchase
additional shares in full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Voting rights </P></TD>
<TD>Each share of our common stock is entitled to one vote on all matters submitted to a vote of stockholders, including the election of directors. See &#147;Description of Capital Stock.&#148; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million (or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their option to purchase additional shares in full), based upon the assumed initial offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds that we receive in this offering for product discovery and development and general corporate purposes. We may use a portion of the proceeds to acquire other complementary businesses or
technologies. See &#147;Use of Proceeds&#148; for a more complete description of the intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed NASDAQ Global Market symbol </P></TD>
<TD>&#147;ANAB&#148; </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on
98,456,544 shares of our common stock outstanding as of June 30, 2015, and gives effect to the sale and issuance of 38,436,851 shares of Series D convertible preferred stock at a price of $1.06 per share in a private placement by us in July 2015.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">8,657,422 shares of common stock issuable upon the exercise of options outstanding as of June 30, 2015, with a weighted-average exercise price of $0.1870 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,496,050 shares of common stock issuable upon the exercise of options granted between June 30, 2015 and August 17, 2015, with an exercise price of $0.99 per share; </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under our stock-based compensation plans, consisting of (a)&nbsp;3,176,670 shares of common
stock reserved for future issuance under our 2006 Equity Incentive Plan as of August&nbsp;17, 2015, (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under our 2015
Equity Incentive Plan, which will become effective on the date immediately prior to the date of this prospectus and (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under our 2015 Employee
Stock Purchase Plan, which will become effective on the date of this prospectus. Upon closing of this offering, any remaining shares available for issuance under our 2006 Equity Incentive Plan will be added to the shares reserved under our 2015
Equity Incentive Plan and we will cease granting awards under our 2006 Equity Incentive Plan. Our 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan also provide for automatic annual increases in the number of shares reserved under the
plans each year, as more fully described in &#147;Executive Compensation&#151;Employee Benefit and Stock Plans;&#148; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">822,386 shares of our common stock issuable upon exercise of warrants for shares of common stock with an exercise price of $0.65 per share, that do not expire upon the closing of this offering; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,063,484 shares of common stock issuable upon the exercise of warrants to purchase shares of our Series C convertible preferred stock that were outstanding as of June 30, 2015, with an exercise price of $0.65 per
share, that do not expire upon the closing of this offering. </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this
prospectus assumes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the automatic conversion of all outstanding shares of our convertible preferred stock as of June 30, 2015 into an aggregate of 42,208,202 shares of common stock immediately prior to the closing of this offering;
</TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the automatic conversion of 38,436,851 shares of Series D convertible preferred stock into 38,436,851 shares of common stock immediately prior to the closing of this offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reverse stock split, which will become effective prior to the completion of this offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our restated certificate of incorporation in connection with the closing of this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of outstanding stock options or warrants subsequent to June 30, 2015; and </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of the underwriters&#146; option to purchase additional shares. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary statements of operations data presented below for the years ended December&nbsp;31, 2013 and 2014 are derived from our audited
financial statements included elsewhere in this prospectus. The summary consolidated statements of operations data for the six months ended June 30, 2014 and 2015 and our consolidated balance sheet data as of June 30, 2015 are derived from our
unaudited consolidated financial statements included elsewhere in this prospectus. The unaudited consolidated financial statements were prepared on a basis consistent with our audited financial statements and reflect, in the opinion of management,
all adjustments of a normal recurring nature that are necessary for the fair presentation of the financial statements. The following summary consolidated financial data should be read with &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations&#148; and our financial statements and related notes included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in any future period, and the
results for the six months ended June 30, 2015 are not necessarily indicative of results to be expected for the full year. The summary financial data in this section are not intended to replace the financial statements and are qualified in their
entirety by the financial statements and related notes included elsewhere in this prospectus. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of liability for preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributed to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributed to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per common share:<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares outstanding:<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss) per common share (unaudited):<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average number of shares outstanding (unaudited):<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:3%;border-bottom:1px solid #000000; width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See Note 2 to our annual and interim consolidated financial statements for an explanation of the method used to calculate basic and diluted net income (loss) per common share, unaudited pro forma basic and diluted net
income (loss) per common share and the weighted-average number of shares used in the computation of the per share amounts. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>June 30, 2015</B><br><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;as<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16,894</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">22,291</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">634</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, noncurrent portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4,214</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,720</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">36,828</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">(30,975</TD>
<TD NOWRAP VALIGN="top">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:3%;border-bottom:1px solid #000000; width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The pro forma consolidated balance sheet data give effect to: (i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock into 42,208,202 shares of common stock immediately prior to
the closing of this offering; (ii)&nbsp;the sale and issuance of 38,436,851 shares of our Series D convertible preferred stock in a private placement by us in July 2015; (iii)&nbsp;the automatic conversion of 38,436,851 shares of Series D
convertible preferred stock into 38,436,851 shares of common stock immediately prior to the closing of this offering; and (iv)&nbsp;the related reclassification of the preferred stock warrant liability to additional paid-in capital upon the
conversion of the shares of convertible preferred stock underlying the warrants that make up the liability. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted balance sheet data give effect to the pro forma adjustments and the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock by us in this
offering, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase (decrease) in the assumed initial public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover
page of this prospectus, would increase (decrease) each of our pro forma as adjusted cash and cash equivalents, total assets and total stockholders&#146; equity (deficit) by approximately $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, remains the same and after deducting estimated underwriting discounts and commissions. Similarly, each increase
(decrease) of one million shares in the number of shares offered by us would increase (decrease) each of our pro forma as adjusted cash and cash equivalents, total assets and total stockholders&#146; equity (deficit) by approximately $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial public offering price remains the same and after deducting estimated underwriting discounts and commissions. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you
should carefully consider the risks described below, together with the other information contained in this prospectus, including our financial statements and the related notes appearing at the end of this prospectus. We cannot assure you that any of
the events discussed below will not occur. These events could have a material and adverse impact on our business, results of operations, financial condition and cash flows. If that were to happen, the trading price of our common stock could decline,
and you could lose all or part of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Discovery and Development of Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates are in early stages of development and may fail in development or suffer delays that adversely affect their commercial
viability.&nbsp;If we or our collaborators are unable to complete development of or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are using our proprietary technology platform to develop therapeutic antibodies, including our two lead wholly-owned product candidates,
ANB019 and ANB020, as well as other programs that are being developed by our collaborators. However, all of our wholly-owned and partnered product candidates are in the early stages of development, and, for a wide variety of reasons discussed below,
may fail in development or suffer delays that adversely affect their commercial viability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product candidate can unexpectedly fail at
any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical
testing or early clinical trials of a product candidate may not predict the results that will be obtained in later phase clinical trials of the product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our current product candidates, and any other product candidates we may develop in the future, will depend on many factors,
including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining regulatory permission to initiate clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful enrollment of patients in, and the completion of, our planned clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receiving marketing approvals from applicable regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and their components; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enforcing and defending intellectual property rights and claims; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achieving desirable therapeutic properties for our product candidates&#146; intended indications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with third parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively competing with other therapies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining an acceptable safety profile of our product candidates through clinical trials and following regulatory approval. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not achieve one or more of these factors in a timely manner or at all, we could
experience significant delays or an inability to successfully commercialize our product candidates, which would harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs,
longer development times or termination of a clinical trial. Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the product candidate is
intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, the age and condition of the
patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites and the availability of effective treatments for the relevant disease. We may not be able to initiate our planned clinical trials if
we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the U.S. Food and Drug Administration, or FDA, or foreign regulatory authorities. More specifically, some of our product
candidates, including ANB019, initially target indications that are very rare, which can prolong the clinical trial&nbsp;timeline for the regulatory process if sufficient patients cannot be enrolled in a timely manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and/or our collaborators may be unable to obtain, or may be delayed in obtaining, required regulatory approvals in the United States or in foreign
jurisdictions, which would materially impair our ability to commercialize and generate revenue from our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
ability to continue to develop our product candidates, and to have the potential to achieve and sustain profitability, depends on the FDA and foreign regulatory authorities permitting us to conduct human clinical trials and, if our products are safe
and effective, obtaining approval from the FDA and foreign regulatory authorities to market them and subsequently successfully commercializing them, either alone or with our collaborators. The research, testing, manufacturing, labeling, approval,
selling, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and foreign regulatory authorities. Before commencing clinical trials in the United States for any product candidate, we must submit an
IND to the FDA; foreign regulatory authorities enforce similar requirements for initiation of clinical trials in other countries. An IND or foreign equivalent requires extensive preclinical studies, and there is no guarantee that the FDA or foreign
regulatory authorities will allow clinical trials to proceed based on the IND or equivalent submission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we or our collaborators
initiate and complete clinical trials for our product candidates, we will not be permitted to market our product candidates in the United States until we receive approval of a Biologics License Application, or BLA, from the FDA, and will not be
permitted to market in other countries without marketing approval from foreign regulatory authorities. Obtaining approval of a BLA or other marketing approvals is often a lengthy, expensive and uncertain process over which the FDA and foreign
regulatory authorities have substantial discretion. We have not yet discussed with the FDA or foreign regulatory authorities the development plans for any of our product candidates or the designs of any of our clinical or preclinical studies, and we
thus do not have the benefit of the FDA&#146;s or foreign regulatory authorities&#146; current thinking on trial designs or product development for our target indications. For example, although we believe a small pivotal trial, potentially with
fewer than 100 patients, may be sufficient to demonstrate substantial evidence of efficacy of ANB019 in generalized pustular psoriasis, or GPP, patients who have IL-36RA genetic mutations, we have not yet discussed clinical trial design for this
indication with the FDA, and the FDA may disagree with our proposed trial design, including the number of patients necessary to demonstrate efficacy and/or may require us to conduct more than one pivotal study in order to obtain approval of a BLA.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies and clinical trials are expensive, difficult to design and implement, can
take many years to complete and are uncertain as to outcome. Products, on average, take ten to 15 years to be developed from the time they are discovered to the time they are approved and available for treating patients. The start or end of a
clinical trial is often delayed or halted for many reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of a clinical hold for safety reasons or following an inspection of our clinical trial operations or site by the FDA or other regulatory authorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing challenges; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">insufficient supply or quality of product candidates or other materials necessary to conduct clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching or failure to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and contract research organizations, or CROs, or failure by such CROs or
trials sites to carry out the clinical trial in accordance with our agreed-upon terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical sites electing to terminate their participation in one of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability or unwillingness of patients or medical investigators to follow our clinical trial protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">required clinical trial administrative actions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">slower than anticipated patient enrollment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changing standards of care; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safety concerns; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability or prevalence of use of a comparative drug or required prior therapy; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical outcomes or financial constraints. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates may not be effective, may
be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. Regulatory authorities may refuse to
accept any application or may decide that our data are insufficient for approval and require additional preclinical or other studies or clinical trials. In addition, varying interpretations of the data obtained from preclinical and clinical testing
could delay, limit or prevent marketing approval of a product candidate. Moreover, regulatory authorities may determine that the clinical and other benefits of a product candidate do not outweigh the safety or other risks. Changes in marketing
approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may also cause delays in or prevent the approval of an
application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we experience any of the issues described above, or other similar or related issues, we may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be delayed in obtaining marketing approval for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not obtain marketing approval at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain marketing approval in some countries and not in others; obtain approval for indications or patient populations that are not as broad as intended or desired; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be subject to additional post-marketing testing requirements; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have the product removed from the market after obtaining marketing approval. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to use and expand our technology platform to build a pipeline of
product candidates and develop marketable products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus on
research programs and product candidates that we identify for specific indications. Our business depends on our successful development and commercialization of the limited number of internal product candidates we have in preclinical development.
Even if we are successful in continuing to build our pipeline, development of the potential product candidates that we identify will require substantial investment in additional clinical development, management of clinical, preclinical and
manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply capability, building a commercial organization, and significant marketing efforts before we generate any revenue from product sales. Furthermore,
such product candidates may not be suitable for clinical development, including as a result of their harmful side effects, limited efficacy or other characteristics that indicate that they are unlikely to be products that will receive marketing
approval and achieve market acceptance. If we cannot validate our technology platform by successfully developing and commercializing product candidates based upon our technological approach, we may not be able to obtain product or partnership
revenue in future periods, which would adversely affect our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a
result of our current focus on our lead product candidates, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation
decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any
commercially viable products. Our understanding and evaluation of biological targets for the discovery and development of new product candidates may fail to identify challenges encountered in subsequent preclinical and clinical development. If we do
not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it
would have been more advantageous for us to retain sole development and commercialization rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no history of conducting clinical trials
or commercializing biotechnology products, which may make it difficult to evaluate the prospects for our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
operations to date have been limited to financing and staffing our company, developing our technology and developing our two lead product candidates, ANB019 and ANB020, and other product candidates with and without our collaborators. Although we
have recruited a team that has experience with clinical trials, as a company we have no experience conducting clinical trials and have not had previous experience commercializing product candidates, including submitting an IND or a BLA to the FDA,
or similar submissions to initiate clinical trials or obtain marketing authorization to foreign regulatory authorities. In part because of this lack of experience, we cannot be certain that planned clinical trials will begin or be completed on time,
if at all, that our planned development programs would be acceptable to the FDA or other regulatory authorities, or that, if approval is obtained, such product candidates can be successfully commercialized. Clinical trials and commercializing our
wholly-owned product candidates will require significant additional financial and management resources, and reliance on third-party clinical investigators, CROs, consultants or collaborators. Relying on third-party clinical investigators, CROs or
collaborators may result in delays that are outside of our control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we may not have the financial resources to continue
development of, or to enter into collaborations for, a product candidate if we experience any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or
clinical trials or abandon a program; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial
once commenced; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conditions imposed by the FDA or foreign regulatory authorities regarding the number, scope or design of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in enrolling research subjects in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">high drop-out rates of research subjects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inadequate supply or quality of clinical trial materials or other supplies necessary for the conduct of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">greater than anticipated clinical trial costs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">poor effectiveness or unacceptable side effects of our product candidates during clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">serious and unexpected drug-related side effects experienced by participants in our planned clinical trials or by individuals using drugs similar to our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">varying interpretations of data by the FDA and foreign regulatory authorities. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently,
any predictions you make about our future success or viability based on our short operating history may not be as accurate as they could be if we had a longer operating history or an established track record in conducting clinical trials or
commercializing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other
known and unknown factors. We will need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never dosed any of our product candidates in humans. Our planned clinical trials or those of our collaborators may reveal significant adverse
events, toxicities or other side effects not seen in our preclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to obtain marketing approval for any of our product candidates, we must demonstrate the safety and efficacy of the product candidate
for the relevant clinical indication or indications through preclinical studies and clinical trials as well as additional supporting data. If our product candidates are associated with undesirable side effects in preclinical studies or clinical
trials or have characteristics that are unexpected, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less
prevalent, less severe or more acceptable from a risk-benefit perspective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not yet initiated any clinical trials or dosed any of
our product candidates, including ANB019 and ANB020, in humans. We have conducted various preclinical studies of our product candidates, but we do not know the predictive value of these studies for humans, and we cannot guarantee that any positive
results in preclinical studies will successfully translate to human patients. It is not uncommon to observe results in human clinical trials that are unexpected based on preclinical testing, and many product candidates fail in clinical trials
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
despite promising preclinical results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product
candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products. Subjects in our planned clinical trials may suffer significant adverse events or other side
effects not observed in our preclinical studies, including, but not limited to, immunogenic responses, organ toxicities such as liver, heart or kidney or other tolerability issues. The observed potency and kinetics of our product candidates in
preclinical studies may not be observed in human clinical trials. We have tested the dosing frequency and route of administration of our product candidates in preclinical studies, which will inform our dosing strategy for future clinical trials,
however such dose and route of administration may not result in sufficient exposure or pharmacological effect in humans, and may lead to unforeseen toxicity not previously observed in preclinical testing. Further, if clinical trials of our product
candidates fail to demonstrate efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the
development and commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If significant adverse events or other side effects are observed in any of
our future clinical trials, we may have difficulty recruiting patients to the clinical trial, patients may drop out of our trial, or we may be required to abandon the trial or our development efforts of that product candidate altogether. We, the
FDA, or other applicable regulatory authorities, or an Institutional Review Board, or IRB, may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to
unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies have later been found to cause side effects that prevented their
further development. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies.
Any of these developments could materially harm our business, financial condition and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, if any of our product
candidates obtains marketing approval, toxicities associated with our product candidates may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional warnings being added to the labeling,
significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory
approval based on preclinical studies or early stage clinical testing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition, and if our competitors develop and market
products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology industry is highly competitive and subject to rapid and significant technological change. Products we may develop in the
future are also likely to face competition from other drugs and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical and biotechnology
companies, established biotechnology companies, specialty biotechnology companies, emerging and start-up companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing,
drug development, technical and human resources and commercial expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients
and manufacturing biotechnology products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative
arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel
compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or approval from the FDA or foreign regulatory authorities or discovering,
developing and commercializing products in our field before we do. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For asthma, our competitors include omalizumab (Xolair; Roche) which has received FDA
approval and functions by inhibiting the binding between free IgE and FceRI; antibodies that bind IL-5 and inhibit its interaction with the IL-5 receptor such as mepolizumab (Glaxosmithkline), which a federal Advisory Committee has recently
recommended that the FDA approve for the add-on maintenance treatment in patients aged 18 years or older with severe eosinophilic asthma, and reslizumab (Teva), the BLA for which has been submitted to the FDA for approval; antibodies such as
benralizumab (AstraZeneca) that bind the IL-5 receptor; antibodies that bind to IL-13 such as lebrikizumab (Roche), tralokinumab (AstraZeneca) and anrukinzumab (Pfizer), which are in clinical testing; antibodies that bind the IL-4 receptor alpha
chain, such as dupilumab (Regeneron) and AMG317 (Amgen) each in clinical testing and antibodies that bind the ST2 receptor including AMG282 (Amgen), which is in clinical testing. For peanut allergy, our competitors include DBV Technologies, which is
developing transdermal products for tolerization of food allergies, while Aimmune Therapeutics is developing oral products for peanut allergy desensitization. For GPP and PPP, our competitors include marketed therapies such as secukinumab (Cosentyx;
Novartis) which binds IL-17A; ustekinumab (Stelara; Janssen) which blocks IL-12 and 23 cytokine function; and acitretin (Soriatane; Glaxosmithkline), as well as therapies in development such as guselkumab (Janssen) which blocks IL-23 cytokine
function and gevokizumab (Xoma 052) which binds IL-1 beta. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the enactment of the Biologics Price Competition and Innovation Act
of 2009, or BPCIA, an abbreviated pathway for the approval of biosimilar and interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics,
including the possible designation of a biosimilar as interchangeable based on its similarity to an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original
branded product is approved under a biologics license application, or BLA. On March&nbsp;6, 2015, the FDA approved the first biosimilar product under the BPCIA. However, the law is complex and is still being interpreted and implemented by the FDA.
As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect
on the future commercial prospects for our biological products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that if any of our product candidates are approved as a
biological product under a BLA it should qualify for the 12-year period of exclusivity. However, there is a risk that the FDA will not consider any of our product candidates to be reference products for competing products, potentially creating the
opportunity for biosimilar competition sooner than anticipated. Additionally, this period of regulatory exclusivity does not apply to companies pursuing regulatory approval via their own traditional BLA, rather than via the abbreviated pathway.
Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a
number of marketplace and regulatory factors that are still developing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our
competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, are less expensive or capture significant market share prior to or during our commercialization. Our competitors
also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition,
our ability to compete may be affected in many cases by insurers or other third party payors seeking to encourage the use of biosimilar products. Even if our product candidates achieve marketing approval, they may be priced at a significant premium
over competitive biosimilar products if any have been approved by then. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller and other early stage companies may also prove to be
significant competitors, particularly through collaborative arrangements with large and established companies. These companies compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial
sites and patient registration for planned clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biotechnology industry is characterized by rapid technological change. If we fail to
stay at the forefront </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less
competitive or not economical. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and
others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if our product candidates receive regulatory approval, they
may not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efficacy and safety profile as demonstrated in planned clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction of the product candidate as well as competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which the product candidate is approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the use of our products, if approved, such as boxed warnings or contraindications in labeling, or a risk evaluation and mitigation strategy, or REMS, if any, which may not be required of alternative
treatments and competitor products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of the product candidate as a safe and effective treatment by physicians, clinics and patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages of product candidates over alternative treatments, including any similar generic treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of treatment in relation to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of coverage and adequate reimbursement and pricing by third parties and government authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the frequency and severity of adverse events; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of sales and marketing efforts; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unfavorable publicity relating to the product candidate. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any product candidate is approved
but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If companion diagnostics for our product candidates for which such diagnostics are required, are not successfully, and in a timely manner, validated,
developed or approved, we may not achieve marketing approval or realize the full commercial potential of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If companion diagnostics are developed in conjunction with clinical programs, the FDA may require regulatory approval of a companion diagnostic
as a condition to approval of the product candidate. For example, if, as is currently planned, we use a genetic test to determine which patients are most likely to benefit from ANB019 for the treatment of GPP by designing our pivotal trial or trials
of ANB019 in that indication to require that subjects test positive for specific genetic mutations as a criterion for enrollment, then we will likely be required to obtain FDA approval or clearance of a companion diagnostic, concurrent with approval
of ANB019, to test for those genetic mutations; we may also be required to demonstrate to the FDA the predictive utility of the companion diagnostic&#151;namely, that the diagnostic selects for patients in whom the biologic therapy will be effective
or more effective compared to patients not selected for by the diagnostic. We do not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on third parties to perform these functions. We do not
currently have any agreement in place with any third party to develop or commercialize companion diagnostics for any of our product candidates. Companion diagnostics are subject to regulation by the FDA and foreign regulatory authorities as medical
devices and require separate regulatory approval prior to commercialization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our partners, or any third party, are unable to successfully develop companion
diagnostics for our product candidates, or experience delays in doing so: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the development of our product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our planned clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our product candidates may not receive marketing approval if their safe and effective use depends on a companion diagnostic; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not realize the full commercial potential of any product candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify patients with the specific genetic alterations
targeted by our product candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, although we believe genetic testing is becoming more prevalent in the
diagnosis and treatment of various diseases and conditions, our product candidates may be perceived negatively compared to alternative treatments that do not require the use of companion diagnostics, either due to the additional cost of the
companion diagnostic or the need to complete additional procedures to identify genetic markers prior to administering our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these events were to occur, our business would be harmed, possibly materially. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of biologics is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party
manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of manufacturing biologics is complex, highly-regulated and subject to multiple risks. Manufacturing biologics is highly
susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the
production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered at the facilities of
our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost
overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. Even if we or our collaborators obtain regulatory
approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to
meet the requirements for the potential launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be
impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scaling up a biologic manufacturing process is a difficult and uncertain task, and we may not be successful in transferring our production
system or the manufacturer may not have the necessary capabilities to complete the implementation and development process. If we are unable to adequately validate or scale-up the manufacturing process with our current manufacturer, we will need to
transfer to another manufacturer and complete the manufacturing validation process, which can be lengthy. If we are able to adequately validate and scale-up the manufacturing process for our product candidates with a contract manufacturer, we will
still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Capital Needs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited operating revenue and a history of operational losses and may not achieve or sustain profitability. We have no products approved for
commercial sale, and to date we have not generated any revenue or profit from product sales. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an early-stage biotechnology
company with a limited operating history. We have no approved products and none of our product candidates have progressed to clinical development. To date, our revenue has been primarily derived from our research collaboration and license agreements
with third parties, including TESARO, Inc. and TESARO Development, Ltd., or collectively, TESARO, and Celgene Corporation, or Celgene, and we are significantly dependent on such collaborators for the successful development of product candidates in
these collaborations. Our ability to generate revenue and become profitable depends upon our ability, alone or with our collaborators, to successfully complete the development of our product candidates for our target indications and to obtain
necessary regulatory approvals. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant operating losses in every year except fiscal year
2014 and we do not expect to be profitable in 2015. Our collaboration revenue was $9.0 million and net loss was $0.4 million for the six months ended June 30, 2015 and our collaboration revenue was $15.8 million and our net income was $3.5 million
for the year ended December&nbsp;31, 2014. As of June 30, 2015, we had an accumulated deficit of $45.7 million. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have financed our
operations primarily through private placements of our preferred stock and the issuance of debt. We have devoted substantially all of our efforts to research and development. We have not initiated clinical development of any product candidates and
expect that it will be many years, if ever, before we have a product candidate ready for commercialization. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, and the net losses we incur
may fluctuate significantly from quarter to quarter. Our revenue has been historically derived from amortization of upfront payments, research and development funding and milestone payments under collaboration and license agreements with our
collaborators. Our ability to generate future product revenue from our current or future product candidates depends on a number of additional factors, including our or our collaborators&#146; ability to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue our research and preclinical development of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify additional product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain existing and enter into new collaboration agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct additional preclinical studies and initiate clinical trials for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approvals for the product candidates we develop or developed under our collaboration arrangements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional executive, clinical, quality control and scientific personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems and personnel, including personnel to support our product development; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of our products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain coverage and adequate product reimbursement from third-party payors, including government payors; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquire or in-license other product candidates and technologies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achieve market acceptance for our or our collaborators&#146; products, if any. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are unable
to predict the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability because of the numerous risks and uncertainties associated with product development. In addition, our expenses could increase
significantly beyond expectations if we are required by the FDA or other regulatory authorities to perform studies or trials in addition to those that we currently anticipate. Even if ANB019 and ANB020, or any of our other product candidates, are
approved for commercial sale, we anticipate incurring significant costs associated with the commercial launch of any product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently only in the preclinical development stages for our most advanced product candidates. If we do achieve profitability, we may
not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain or expand our research and
development efforts, expand our business or continue our operations. A decline in the value of our company would also cause you to lose part or even all of your investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require additional capital to finance our operations, which may not be available to us on acceptable terms, or at all. As a result, we may not
complete the development and commercialization of our product candidates or develop new product candidates. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a research and
development company, our operations have consumed substantial amounts of cash since our inception. We expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we continue our
discovery and preclinical development to identify new clinical candidates, and we and our collaborators initiate clinical trials of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our
product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with
operating as a public company. We believe that the net proceeds from this offering, together with our existing cash and cash equivalents and funding we expect to receive under existing collaboration agreements, will fund our projected operating
requirements through at least the next 24 months. However, circumstances may cause us to consume capital more rapidly than we currently anticipate. For example, as we move our lead product candidates through preclinical studies and submit INDs or
foreign equivalents, which may occur as early as at the end of 2015, we may have adverse results requiring us to find new product candidates, or our collaborators may not elect to pursue the development and commercialization of any of our product
candidates that are subject to their respective agreements with us. Any of these events may increase our development costs more than we expect. We may need to raise additional funds or otherwise obtain funding through product collaborations to
continue development of our product candidates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we need to secure additional financing, such additional fundraising efforts may
divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize future product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on
terms acceptable to us, if at all. If we do not raise additional capital when required or on acceptable terms, we may need to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significantly delay, scale back or discontinue the development or commercialization of any product candidates or cease operations altogether; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek strategic alliances for research and development programs at an earlier stage than we would otherwise desire or on terms less favorable than might otherwise be available; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relinquish, or license on unfavorable terms, our rights to technologies or any future product candidates that we otherwise would seek to develop or commercialize ourselves; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminate staff to conserve resources. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we need to conduct additional fundraising activities and we do not raise additional capital in
sufficient amounts or on terms acceptable to us, we may be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our forecast of the period of time through which our financial resources will adequately support our operations is a forward-looking statement
and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &#147;Risk Factors&#148; section. We have based this estimate on assumptions that may prove to
be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements, both short and long-term, will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates and future product candidates we may develop; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and size of clinical trials needed to show safety, efficacy and an acceptable risk/benefit profile for any of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and foreign regulatory authorities, including the potential for such authorities to require that we perform more studies or trials
than those that we currently expect; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain existing and enter into new collaboration agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost to establish, maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with
licensing, preparing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of competing technological and market developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market acceptance of any approved product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of acquiring, licensing or investing in additional businesses, products, product candidates and technologies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of recruiting and retaining key employees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of selecting, auditing and potentially validating a manufacturing site for commercial-scale manufacturing; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of establishing sales, marketing and distribution capabilities for our product candidates for which we may receive regulatory approval and that we determine to commercialize ourselves or in collaboration with
our collaborators. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a lack of available capital means that we cannot expand our operations or otherwise capitalize on our
business opportunities, our business, financial condition and results of operations could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may
cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek additional capital through a variety of means, including through public or private equity, debt financings or other sources,
including up-front payments and milestone payments from strategic collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt or equity securities, your ownership interest will be diluted, and the
terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations, or other restrictions
that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable
market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to
Managing Growth, Operations and Macroeconomic Conditions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We must attract and retain highly skilled employees in order to succeed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face
significant competition for experienced personnel. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan, harm our operating
results and increase our capabilities to successfully commercialize our product candidates. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner.
The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement
personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other
resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality
candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover and develop product candidates and our business will be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no marketing and sales force. If we are unable to establish effective sales or marketing capabilities or enter into agreements with
third parties to sell or market our product candidates, we may not be able to effectively sell or market our product candidates, if approved, or generate product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates that are able to
obtain regulatory approval. In order to commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to
perform these services, and we may not be successful in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with technical expertise and supporting distribution capabilities
to commercialize our product candidates, which will be expensive and time-consuming and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution
capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval to market. With respect to the commercialization of all or certain of our product candidates, we may choose to collaborate, either
globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution
systems. If we are unable to enter into such arrangements when needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may
experience delays or limitations. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant
additional losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our
growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in the number of our employees and the
scope of our operations, particularly in the areas of product candidate development and growing our capability to conduct clinical trials. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational
and financial systems, expand our facilities and continue to recruit and train additional qualified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage
the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could
delay the execution of our business plans or disrupt our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We conduct significant operations through our Australian wholly-owned
subsidiary. If we lose our ability to operate in Australia, or if our subsidiary is unable to receive the research and development tax credit allowed by Australian regulations, our business and results of operations will suffer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2015, we formed a wholly-owned Australian subsidiary, AnaptysBio Pty Ltd, or AnaptysBio Pty, to develop and commercialize our ANB019
and ANB020 antibody program in Australia. Due to the geographical distance and lack of employees currently in Australia, as well as our lack of experience operating in Australia, we may not be able to efficiently or successfully monitor, develop and
commercialize our lead products or antibody program in Australia, including conducting clinical trials. Furthermore, we have no assurance that the results of any clinical trials that we conduct for our product candidates in Australia will be
accepted by the FDA or foreign regulatory authorities for development and commercialization approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, current Australian
tax regulations provide for a refundable research and development tax credit equal to 43.5% of qualified expenditures. If we lose our ability to operate AnaptysBio Pty in Australia, or if we are ineligible or unable to receive the research and
development tax credit, or the Australian government significantly reduces or eliminates the tax credit, our business and results of operation would be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of biotechnology products is complex and manufacturers often encounter difficulties in production. If we or any of our third-party
manufacturers encounter any loss of our master cell banks or if any of our third-party manufacturers encounter other difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide product candidates for clinical
trials or our products to patients, once approved, the development or commercialization of our product candidates could be delayed or stopped. </I></B><B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacture of biotechnology products is complex and requires significant expertise and capital investment, including the development of
advanced manufacturing techniques and process controls. We and our contract manufacturers must comply with current good manufacturing practices, or cGMP, regulations and guidelines for the manufacturing of biologics used in clinical trials and, if
approved, marketed products. To date, neither we nor our contract manufacturers has manufactured or attempted to manufacture cGMP batches of our products. Manufacturers of biotechnology products often encounter difficulties in production,
particularly in scaling up and validating initial production. Furthermore, if microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing facilities
may need to be closed for an extended period of time to investigate and remedy the contamination. Delays in raw materials availability and supply may also extend the period of time required to develop our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our therapeutic antibodies are manufactured by starting with cells which are stored in a cell bank. We have one master cell bank for
each antibody manufactured in accordance with cGMP and multiple working cell banks and believe we would have adequate backup should any cell bank be lost in a catastrophic event. However, it is possible that we could lose multiple cell banks and
have our manufacturing severely impacted by the need to replace the cell banks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that any stability or other issues
relating to the manufacture of any of our product candidates or products will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable
political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their contractual obligations, our ability to provide any product candidates to patients in planned clinical trials and products to patients, once approved, would be jeopardized. Any delay or
interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new
clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product candidates or products may result in shipment delays, inventory shortages, lot
failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and incur other charges and expenses for product candidates or products that fail to
meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the
development and commercialization of any of our product candidates or products and could have an adverse effect on our business, prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be vulnerable to disruption, damage and financial obligation as a result of system failures. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, any of the internal computer systems belonging to us, our collaborators or our third-party
service providers are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failure. Any system failure, accident or security breach that causes interruptions in our
own, in collaborators&#146; or in third-party service vendors&#146; operations could result in a material disruption of our drug discovery and development programs. For example, the loss of clinical trial data from completed or future clinical
trials could result in delays in our or our collaborators&#146; regulatory approval efforts and significantly increase our costs in order to recover or reproduce the lost data. To the extent that any disruption or security breach results in a loss
or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability as a result, our drug discovery programs and competitive position may be adversely affected and the further
development of our product candidates may be delayed. Furthermore, we may incur additional costs to remedy the damages caused by these disruptions or security breaches. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operations are vulnerable to interruption by fire, earthquake, power loss, telecommunications failure, terrorist activity and other events beyond
our control, which could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our facility is located in a seismically active region, which has also historically
been subject to electrical blackouts as a result of a shortage of available electrical power. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major earthquake, fire, power loss,
terrorist activity or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or
damages incurred by us could harm our business. We maintain multiple copies of each of our antibody sequences and electronic data records, most of which we maintain at our headquarters. If our facility was impacted by a seismic event, we could lose
all our antibody sequences, which would have an adverse effect on our ability to perform our obligations under our collaborations and discover new targets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our existing collaborations, including those with TESARO and Celgene, are important to our business, and future collaborations may also be important to
us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into collaborations with other biotechnology companies to develop several of our product candidates, and such collaborations
currently represent a significant portion of our product pipeline. In addition, we have entered into other collaborations pursuant to which we have provided access to our technology platform to our collaborators to enable the optimization of their
own product candidates. We have entered into antibody </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generation and/or development collaborations with various collaborators, including TESARO and Celgene, under which we have generated therapeutic quality antibodies using our technology platform
and conducted certain preclinical studies in collaboration. These collaborations have provided us with $48.7 million in non-dilutive funding through July 31, 2015. We are currently aware that TESARO and Celgene are advancing multiple antibodies
generated through our collaboration to clinical trials. If our collaborators terminate any of our collaborations, we may not receive all or any of this funding, which would adversely affect our business or financial condition. Other than TESARO, our
operational obligations under each of our collaborations has ended. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are unable to predict the success of our collaborations. Our
collaborators have discretion in determining and directing the efforts and resources, including the ability to discontinue all efforts and resources, they apply to the development and, if approval is obtained, commercialization and marketing of the
product candidates covered by such collaborations. As a result, our collaborators may elect to de-prioritize our programs, change their strategic focus or pursue alternative technologies in a manner that results in reduced, delayed or no revenue to
us. Our collaborators may have other marketed products and product candidates under collaboration with other companies, including some of our competitors, and their corporate objectives may not be consistent with our best interests. Our
collaborators may also be unsuccessful in developing or commercializing our products. If our collaborations are unsuccessful, our business, financial condition, results of operations and prospects could be adversely affected. In addition, any
dispute or litigation proceedings we may have with our collaborators in the future could delay development programs, create uncertainty as to ownership of intellectual property rights, distract management from other business activities and generate
substantial expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not succeed in establishing and maintaining additional development collaborations, which could adversely affect our
ability to develop and commercialize product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our current licensing arrangements with TESARO and
Celgene, a part of our strategy is to enter into additional strategic product development collaborations in the future, including collaborations to broaden and accelerate clinical development and potential commercialization of our product
candidates. We may face significant competition in seeking appropriate development partners and the negotiation process is time-consuming and complex. Moreover, we may not succeed in our efforts to establish a development collaboration or other
alternative arrangements for any of our other existing or future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of
development for collaborative effort and/or third parties may not view our product candidates and programs as having the requisite potential to demonstrate safety and efficacy. Even if we are successful in our efforts to establish new development
collaborations, the terms that we agree upon may not be favorable to us and we may not be able to maintain such development collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product
candidate are disappointing. Any delay in entering into new development collaboration agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness if they
reach the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, if we fail to establish and maintain additional development collaborations related to our product candidates:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the development of certain of our current or future product candidates may be terminated or delayed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our cash expenditures related to development of certain of our current or future product candidates would increase significantly and we may need to seek additional financing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to hire additional employees or otherwise develop expertise, such as sales and marketing expertise, for which we have not budgeted; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will bear all of the risk related to the development of any such product candidates. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If third parties on which we depend to conduct our planned preclinical studies, or any future clinical
trials, do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with adverse effects on our business, financial condition, results of operations
and prospects. </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third party clinical investigators, contract research organizations, or CROs, clinical data management
organizations, or CMOs, and consultants to design, conduct, supervise and monitor preclinical studies of our product candidates and will do the same for any clinical trials. Because we rely on third parties and do not have the ability to conduct
preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs, CMOs and
consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors,
which may draw time and resources from our programs. The third parties we contract with might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being
delayed or unsuccessful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these
third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise
adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Our reliance on third parties
that we do not control does not relieve us of these responsibilities and requirements. Any such event could have an adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we may receive for our product candidates will require surveillance to monitor the safety and efficacy of the
product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the
FDA may require a risk evaluation and mitigation strategy in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted
distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event
reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing
information and reports, registration, as well as continued compliance with cGMPs and cGCPs for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and
periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity
or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market
or suspension of manufacturing. In addition, failure to comply with FDA and foreign regulatory requirements may, either before or after product approval, if any, subject our company to administrative or judicially imposed sanctions, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the products, manufacturers or manufacturing process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning or untitled letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">civil and criminal penalties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or withdrawal of regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizures, detentions or import bans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voluntary or mandatory product recalls and publicity requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">total or partial suspension of production; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of restrictions on operations, including costly new manufacturing requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to approve pending BLAs or supplements to approved BLAs. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any event
or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advertising and
promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by the FDA, the Department of Justice, the Department of Health and Human Services&#146; Office of Inspector General, state attorneys general,
members of Congress and the public. Violations, including promotion of our products for unapproved (or off-label) uses, are subject to enforcement letters, inquiries and investigations, and civil and criminal sanctions by the government.
Additionally, comparable foreign regulatory authorities will heavily scrutinize advertising and promotion of any product candidate that obtains approval outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, engaging in the impermissible promotion of our products for off-label uses can also subject us to false claims
litigation under federal and state statutes, which can lead to civil and criminal penalties and fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. These false claims statutes include
the federal False Claims Act, which allows any individual to bring a lawsuit against a biotechnology company on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent
claims, for payment by a federal program such as Medicare or Medicaid. If the government prevails in the lawsuit, the individual will share in any fines or settlement funds. Since 2004, these False Claims Act lawsuits against biotechnology companies
have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements regarding certain sales practices promoting off-label drug uses involving fines in excess of $1.0 billion. This growth in litigation
has increased the risk that a biotechnology company will have to defend a false claim action, pay settlement fines or restitution, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid and
other federal and state healthcare programs. If we do not lawfully promote our approved products, we may become subject to such litigation and, if we do not successfully defend against such actions, those actions may have an adverse effect on our
business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to obtain regulatory approval in international jurisdictions would prevent us
from marketing our product candidates outside the United States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market and sell our products in other jurisdictions,
we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially
from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, we must secure
product reimbursement approvals before regulatory authorities will approve the product for sale </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or
prevent the introduction of our products in certain countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, clinical trials conducted in one country may not be accepted by
regulatory authorities in other countries and regulatory approval in one country does not ensure approval in any other country, while a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory
approval process in others. For example, our initial clinical development of ANB020 and ANB019 is planned in Australia, and we believe that clinical data generated in Australia will subsequently be accepted by the FDA and its foreign equivalents
outside of Australia. Also, regulatory approval for any of our product candidates may be withdrawn. If we fail to comply with the regulatory requirements in international markets and receive applicable marketing approvals, our target market will be
reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be adversely affected. We may not obtain foreign regulatory approvals on a timely basis, if at all. Our failure to obtain
approval of any of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and our business prospects could decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We plan to seek Orphan Drug Designation for ANB019 or certain of our other product candidates and we&nbsp;may not&nbsp;be able to obtain or
maintain&nbsp;orphan designation&nbsp;or obtain the benefits associated with Orphan Drug status, including market exclusivity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
plan to seek Orphan Drug Designation for ANB019 or certain of our other product candidates. Regulatory authorities in some jurisdictions, including the United States and the European Union, or EU, may designate biologics for relatively small patient
populations as Orphan Drugs. Under the Orphan Drug Act, the FDA may designate a biologic as an Orphan Drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals
in the United States. Generally, if a biologic with an Orphan Drug Designation subsequently receives the first marketing approval for the indication for which it has such designation, the biologic is entitled to a period of marketing exclusivity,
which precludes the FDA, in the United States, or the European Medicines Agency, or EMA, in the EU, from approving another marketing application for a drug containing the same active moiety for the same indication for that time period. The
applicable period is seven years in the United States and ten years in the European Union. The EU exclusivity period can be reduced to six years if a biologic no longer meets the criteria for Orphan Drug Designation or if the biologic is
sufficiently profitable so that market exclusivity is no longer justified. Orphan Drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure
sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. In addition, the Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. Also,
regulatory approval for any product candidate may be withdrawn and other candidates may obtain approval before us. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not
applied for Orphan Drug Designation&nbsp;for ANB019 for any indication, and&nbsp;may not&nbsp;be able to obtain designation or any of the potential benefits associated with it. For example, we plan to seek FDA Orphan Drug Designation for ANB019 for
the treatment of GPP and PPP, which will likely require that we demonstrate to FDA that GPP and PPP are distinct diseases from psoriasis generally (a non-rare disease) or that use of ANB019 may be appropriate for the treatment of GPP and PPP but not
appropriate for use in the general psoriasis population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain Orphan Drug Designation, we may not receive Orphan Drug
exclusivity, and such exclusivity, if obtained, may not effectively protect the candidate from competition because different drugs or biologics can be approved for the same condition and only the first biologic with an Orphan Drug Designation to
receive regulatory approval for a particular indication will receive marketing exclusivity. Even after a drug or biological with Orphan Drug Designation is approved, the FDA can subsequently approve another biologic containing the same active moiety
(which in the case of an antibody is the principal molecular structure) for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
same condition if the FDA concludes that the later biologic is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any drugs we develop may become subject to unfavorable third-party reimbursement practices and pricing regulations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability and extent of coverage and adequate reimbursement by governmental and private payors is essential for most patients to be able
to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be paid
by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is
not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or
maintain pricing sufficient to realize a sufficient return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not
available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the
principal decisions about reimbursement for new products are typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services because CMS decides whether and to what
extent a new product will be covered and reimbursed under Medicare. Private payors often follow CMS&#146;s decisions regarding coverage and reimbursement to a substantial degree. However, one payor&#146;s determination to provide coverage for a drug
product does not assure that other payors will also provide coverage for the drug product. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support
for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are
challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity, and reviewing the cost effectiveness of medical drug products. There may be especially significant
delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific drug products on an approved list, known as a formulary, which might not include all FDA approved drugs for a particular
indication. We or our collaborators may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or
cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, international operations are generally subject to extensive governmental price controls and other market
regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many
countries, particularly the countries of the European Union, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities
can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product
candidate to other available therapies. In general, the prices of products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company
profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient
to generate commercially reasonable revenue and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by governmental and third-party payors, in the
United States and internationally, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our
product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional
legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry
of new products into the healthcare market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to CMS and private payors, professional organizations such as the American
Medical Association, or AMA, can influence decisions about reimbursement for new products by determining standards for care. In addition, many private payors contract with commercial vendors who sell software that provide guidelines that attempt to
limit utilization of, and therefore reimbursement for, certain products deemed to provide limited benefit to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, some of our target indications, including for GPP, are rare diseases with small patient populations. In order for therapeutics
that are designed to treat smaller patient populations to be commercially viable, the reimbursement for such therapeutics must be higher, on a relative basis to account for the low volume of sales. Accordingly, we will need to implement a coverage
and reimbursement strategy for any approved product candidate that accounts for the smaller potential market size. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to
establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to
market or sell those product candidates, if approved. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our
collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently
enacted legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and/or affect our ability to profitably sell any product candidates for which we obtain marketing
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, in March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the
Health Care and Education Affordability Reconciliation Act, or collectively the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add
transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the provisions of the ACA of importance to our potential product candidates are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage
gap period, as a condition for a manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requirements to report certain financial arrangements with physicians and teaching hospitals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may face difficulties from changes to current regulations and future legislation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory
approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt
to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain
profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included
aggregate reductions to Medicare payments to providers of up to 2%&nbsp;per fiscal year, effective April&nbsp;1 2013, which, due to subsequent legislative amendments, will stay in effect through 2024 unless additional Congressional action is taken.
In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover
overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our
financial operations. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Likewise, the annual Medicare Physician Fee Schedule update, which, until recently, was based on a
target-setting formula system called the Sustainable Growth Rate (&#147;SGR&#148;), was adjusted to reflect the comparison of actual expenditures to target expenditures. Because one of the factors for calculating the SGR was linked to the growth in
the U.S. gross domestic product (&#147;GDP&#148;), the SGR formula often resulted in a negative payment update when growth in Medicare beneficiaries&#146; use of services exceeded GDP growth.&nbsp;Congress repeatedly intervened to delay the
implementation of negative SGR payment updates.&nbsp;For example, on April 1, 2014, with the enactment of the Protecting Access to Medicare Act of 2014, Congress prevented the 24 percent cut that was to occur by continuing the previously implemented
0.5 percent payment increase through December 31, 2014 and maintaining a zero percent payment update from January 1, 2015 through March 31, 2015.&nbsp;However, on April 14, 2015, Congress passed the Medicare Access and CHIP Reauthorization Act of
2015, which was signed into law by President Obama on April 16, 2015.&nbsp;This law repeals the SGR methodology from the physician payment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
formula, institutes a 0% update to the Medicare Physician Fee Schedule for the January 1 to July 1, 2015 period, a 0.5% payment update for July 2015 through the end of 2019, and a 0% payment
update for 2020 through 2025, along with a merit-based incentive payment system beginning January&nbsp;1, 2019, that will replace current incentive programs. For 2026 and subsequent years, the payment update will be either 0.75% or 0.25%, depending
on which Alternate Payment Model the physician participates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the ACA, as well as other healthcare reform measures
that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may
result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional
activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals
of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and
post-marketing testing and other requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business entails a significant risk of product liability and our ability to obtain sufficient
insurance coverage could have an adverse effect on our business, financial condition, results of operations or prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we
succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more
serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our
products, injury to our reputation, costs to defend the related litigation, a diversion of management&#146;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have
product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage
against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by
product liability claims that could have an adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers and third-party payors will be subject
to applicable anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens
and diminished profits and future earnings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers and third-party payors play a primary role in the recommendation
and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may
constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations,
include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or
providing remuneration, directly or indirectly, in cash or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a
federal healthcare program such as Medicare and Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal false claims and civil monetary penalties laws, including the civil False Claims Act, impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities
for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal
government; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for, among other things, executing or attempting to execute a scheme to defraud any healthcare
benefit program or making false statements relating to healthcare matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding
the privacy, security and transmission of individually identifiable health information; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#146;s
Health Insurance Program, with specific exceptions, to report to CMS annually information regarding payments and other transfers of value to physicians and teaching hospitals as well as information regarding ownership and investment interests help
by physicians and their immediate family members. The information was made publicly available on a searchable website in September 2014 and will be disclosed on an annual basis; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by
non-governmental third-party payors, including private insurers. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some state laws require biotechnology companies to comply
with the biotechnology industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of
value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often
are not preempted by HIPAA, thus complicating compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our current and future business arrangements
with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes,
regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject
to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, contractual damages,
reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources.
Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business
is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees may engage in misconduct or other improper activities, including noncompliance with
regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud or other misconduct.
Misconduct by employees could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data
accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks,
self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee
misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We intend to adopt a code of conduct prior to the closing of this
offering, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from
governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those
actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to
Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain or protect intellectual property rights, we may not be able to compete effectively in our
market. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in significant part on our and our licensors&#146;, licensees&#146; or collaborators&#146; ability to
establish, maintain and protect patents and other intellectual property rights and operate without infringing the intellectual property rights of others. We have filed numerous patent applications both in the United States and in foreign
jurisdictions to obtain patent rights to inventions we have discovered. We have also licensed from third parties rights to patent portfolios. Some of these licenses give us the right to prepare, file and prosecute patent applications and maintain
and enforce patents we have licensed, and other licenses may not give us such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive and
time-consuming, and we and our current or future licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that
we or our licensors, licensees or collaborators will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Moreover, in some
circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors,
licensees or collaborators. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. If our current or future licensors, licensees or collaborators fail to
establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors, licensees or collaborators are not fully cooperative or disagree with us as to the prosecution,
maintenance or enforcement of any patent rights, such patent rights could be compromised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology companies
generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future
licensors&#146;, licensees&#146; or collaborators&#146; patent rights are highly uncertain. Our and our licensors&#146;, licensees&#146; or collaborators&#146; pending and future patent applications may not result in patents being issued which
protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our licensors, licensees or collaborators to
narrow the scope of the claims of our or our licensors&#146;, licensees&#146; or collaborators&#146; pending and future patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications, which may limit the scope of patent protection that may be obtained. In the past, we have not always been able to obtain the full scope of patent protection we have initially sought
in our patent applications, and as described above and as is typical for most biotechnology patent prosecution, we have been required to narrow or eliminate patent claims as part of the patent prosecution process.&nbsp;In addition, some patent
applications that we or our licensors have filed have not resulted in issued patents because we or our licensors have abandoned those patent applications as changes in business and/or legal strategies dictated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such
prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may an initiate opposition,
interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in
the patent claims being narrowed or invalidated. Our and our licensors&#146;, licensees&#146; or collaborators&#146; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until
a patent issues from such applications, and then only to the extent the issued claims cover the technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because patent applications
in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to a product
candidate. Furthermore, if third parties have filed such patent applications on or before March&nbsp;15, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was the first to invent any of the
subject matter covered by the patent claims of our applications. If third parties have filed such applications after March&nbsp;15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our
invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date
or the other party benefits from a compulsory license. In addition, patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S.
filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to
competition from competitive medications, including biosimilar or generic medications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, given the amount of time required for
the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not
provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms where these are available in any countries where we are prosecuting patents. This includes
in the United States under the Drug Price Competition and Patent Term Restoration Act of 1984, which permits a patent term extension of up to five years beyond the expiration of the patent. However the applicable authorities, including the FDA and
the U.S. Patent and Trademark Office, or USPTO, in the United States, and any equivalent foreign regulatory authority, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or
may grant more limited extensions than we request. If this occurs, our competitors may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might
otherwise be the case. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, enforcing and defending patents on product candidates in all countries throughout the world would be prohibitively
expensive, and our or our licensors&#146; or collaborators&#146; intellectual property rights may not exist in some countries outside the United States or may be less extensive in some countries than in the United States. In addition, the laws of
some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we and our licensors or collaborators </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may not be able to prevent third parties from practicing our and our licensors&#146; or collaborators&#146; inventions in all countries outside the United States, or from selling or importing
products made using our and our licensors&#146; or collaborators&#146; inventions in and into the United States or other jurisdictions. Competitors may use our and our licensors&#146; or collaborators&#146; technologies in jurisdictions where we
have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors or collaborators have patent protection, but enforcement is not as strong as that in
the United States. These products may compete with our product candidates, and our and our licensors&#146; or collaborators&#146; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us and
our licensors or collaborators to stop the infringement of our and our licensors&#146; or collaborators&#146; patents or marketing of competing products in violation of our and our licensors&#146; or collaborators&#146; proprietary rights generally.
Proceedings to enforce our and our licensors&#146; or collaborators&#146; patent rights in foreign jurisdictions could result in substantial costs and divert our and our licensors&#146; or collaborators&#146; efforts and attention from other aspects
of our business, could put our and our licensors&#146; or collaborators&#146; patents at risk of being invalidated or interpreted narrowly and our and our licensors&#146; or collaborators&#146; patent applications at risk of not issuing and could
provoke third parties to assert claims against us or our licensors or collaborators. We or our licensors or collaborators may not prevail in any lawsuits that we or our licensors or collaborators initiate, and the damages or other remedies awarded,
if any, may not be commercially meaningful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent law could diminish the value of patents in general, thereby impairing our ability to
protect our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, our success is heavily dependent on
intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve technological and legal complexity, and obtaining and enforcing biopharmaceutical patents is costly, time-consuming, and
inherently uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our and
our licensors&#146; or collaborators&#146; patent applications and the enforcement or defense of our or our licensors&#146; or collaborators&#146; issued patents. On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith
Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An important change introduced by the AIA is that, as of March&nbsp;16, 2013, the United States transitioned to a &#147;first-to-file&#148;
system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us
could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent
application, but circumstances could prevent us from promptly filing patent applications on our inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among some of the other
changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those
issued before March&nbsp;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide
evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use
the USPTO procedures to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The Leahy-Smith Act and its implementation
could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive
changes to patent law associated with the Leahy-Smith Act, and, in particular, the first to file provisions, only became effective on March&nbsp;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the
operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#146; or collaborators&#146; patent applications and the enforcement or
defense of our or our licensors&#146; or collaborators&#146; issued patents, all of which could have an adverse effect on our business and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, in recent years, the Supreme Court and the U.S. Court of Appeals for the Federal Circuit have rendered decisions in several patent
cases such as Association for Molecular Pathology v. Myriad Genetics, Inc. (Myriad I), BRCA1- &amp; BRCA2-Based Hereditary Cancer Test Patent Litig., (Myriad II), Mayo Collaborative Services v. Prometheus Laboratories, Inc., and Alice Corporation
Pty. Ltd. v. CLS Bank International, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our
licensors&#146; or collaborators&#146; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts, and the
USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensors&#146; or collaborators&#146; ability to obtain new patents or to enforce existing patents and patents that we and our
licensors or collaborators may obtain in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural,
document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over
the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent
lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in
partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits,
non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors or collaborators fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter
the market, which would have an adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance on third parties requires us to share our trade secrets, which
increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we collaborate with various collaborators on the development and commercialization of one or more of our product candidates and because
we rely on third parties to manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our wholly-owned technology in part by entering into confidentiality agreements and, if applicable, material
transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third
parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk
that such trade secrets become known by our competitors, are inadvertently incorporated into the technology </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#146;s discovery of
our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish
data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with in the future may be granted rights to publish data arising
out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of intellectual property rights arising from the collaboration,
in addition to the opportunity to remove confidential or trade secret information from any such publication. Our existing collaborative research and development programs may require us to share trade secrets under the terms of our research and
development collaborations or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of
information by any of our third-party collaborators. A competitor&#146;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have
an adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may infringe our or our licensors&#146; or collaborators&#146;
patents or misappropriate or otherwise violate our or our licensors&#146; or collaborators&#146; intellectual property rights. In the future, we or our licensors or collaborators may initiate legal proceedings to enforce or defend our or our
licensors&#146; or collaborators&#146; intellectual property rights, to protect our or our licensors&#146; or collaborators&#146; trade secrets or to determine the validity or scope of intellectual property rights we own or control. Also, third
parties may initiate legal proceedings against us or our licensors or collaborators to challenge the validity or scope of intellectual property rights we own or control. These proceedings can be expensive and time-consuming, and many of our or our
licensors&#146; or collaborators&#146; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaborators. In addition, in an infringement
proceeding, a court may decide that a patent owned by or licensed to us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our or our licensors&#146; or collaborators&#146;
patents do not cover the technology in question. Furthermore, an adverse result in any litigation or administrative proceeding could put one or more of our or our licensors&#146; or collaborators&#146; patents at risk of being invalidated, held
unenforceable or interpreted narrowly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, despite our or our licensors&#146; or collaborators&#146; efforts, we or our
licensors or collaborators may not prevent third parties from infringing upon or misappropriating intellectual property rights we own or control, particularly in countries where the laws may not protect those rights as fully as in the United States.
In addition, litigation and administrative proceedings could result in substantial costs and diversion of management resources, which could harm our business and financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within and outside of the United States, there has been a substantial amount of litigation and administrative proceedings regarding patent and
other intellectual property rights in the pharmaceutical industry including opposition, derivation, reexamination, inter partes review or interference proceedings, or other preissuance or post-grant proceedings in the United States or other
jurisdictions. Such proceedings may be provoked by third parties or by us or our licensors or collaborators to protect or enforce our or our licensors&#146; or collaborators&#146; patents or patent applications. Additionally, third-party preissuance
submission of prior art to the USPTO or other foreign jurisdictions may jeopardize the issuance or scope of our or our licensors&#146; or collaborators&#146; patent applications. An unfavorable outcome in any such proceedings could require us or our
licensors or collaborators to cease using the related technology, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our licensors or collaborators a license on
commercially reasonable terms or at all, and we could be forced to stop commercializing our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Even if we or our licensors or collaborators obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our licensors or
collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if the breadth or strength of protection provided by our or our licensors&#146; or collaborators&#146;
patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Even if we successfully defend such litigation or proceeding, we may
incur substantial costs, and it may distract our management and other employees. We could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts
or investors perceive these results to be negative, it could have an adverse effect on the price of shares of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we breach the
license agreements related to our product candidates, we could lose the ability to continue the development and commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends upon our ability, and the ability of our licensors and collaborators, to develop, manufacture, market and sell
our product candidates and use our and our licensors&#146; or collaborators&#146; wholly-owned technologies without infringing the proprietary rights of third parties. A third party may hold intellectual property, including patent rights that are
important or necessary to the development of our products. As a result, we are a party to a number of technology licenses that are important to our business and expect to enter into additional licenses in the future. For example, we have in-licensed
the rights to certain intellectual property relating to SHM under our in-license agreement with the Medical Research Council, which is the subject of issued patents and pending patent applications in certain countries. If we fail to comply with the
obligations under these agreements, including payment and diligence terms, our licensors may have the right to terminate these agreements, in which event we may not be able to develop, manufacture, market or sell any product that is covered by these
agreements or may face other penalties under the agreements. Such an occurrence could adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our
rights under these agreements may result in our having to negotiate new or reinstated agreements, which may not be available to us on equally favorable terms, or at all, or cause us to lose our rights under these agreements, including our rights to
intellectual property or technology important to our development programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may arise regarding intellectual property subject to
a licensing agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of rights granted under the license agreement and other interpretation-related issues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sublicensing of patent and other rights under any collaboration relationships we might enter into in the future; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the priority of invention of patented technology. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that
we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may initiate legal proceedings against us alleging that we infringe their intellectual
property rights or we may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be uncertain and could have an adverse effect on
the success of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may initiate legal proceedings against us or our licensors or collaborators alleging
that we or our licensors or collaborators infringe their intellectual property rights, or we or our licensors or collaborators may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights
controlled by third parties, including in oppositions, interferences, reexaminations, inter partes reviews or derivation proceedings in the United States or other jurisdictions. These proceedings can be expensive and time-consuming, and many of our
or our licensors&#146; or collaborators&#146; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop
and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. An
unfavorable outcome could require us or our licensors or collaborators to cease using the related technology or developing or commercializing our product candidates, or to attempt to license rights to it from the prevailing party. Our business could
be harmed if the prevailing party does not offer us or our licensors or collaborators a license on commercially reasonable terms or at all. Even if we or our licensors or collaborators obtain a license, it may be non-exclusive, thereby giving our
competitors access to the same technologies licensed to us or our licensors or collaborators. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees, if we are found to have willfully infringed
a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership
of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees, including our senior management, were previously
employed at universities or at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous
employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed confidential information or
intellectual property, including trade secrets or other proprietary information, of any such employee&#146;s former employer. Litigation may be necessary to defend against these claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be
available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our inability to protect our confidential information and trade secrets would harm our business and competitive position. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented know-how,
technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our
employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our
proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and
time-consuming, and the outcome is unpredictable. In addition, some courts both within and outside the United States may be less willing or unwilling to protect trade secrets. Furthermore, if a competitor lawfully obtained or independently developed
any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Additionally, if the steps taken to maintain our trade secrets are
deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain protection
under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be
eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a
patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to
apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such
extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened, and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable
products could be reduced, possibly materially. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering and Ownership of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not know whether an active, liquid and orderly trading market will develop for our common stock or what the market price of our common stock will
be and as a result it may be difficult for you to sell your shares of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, no market for
shares of our common stock existed and an active trading market for our shares may never develop or be sustained following this offering. We will determine the initial public offering price for our common stock through negotiations with the
underwriters, and the negotiated price may not be indicative of the market price of our common stock after this offering. The market value of our common stock may decrease from the initial public offering price. As a result of these and other
factors, you may be unable to resell your shares of our common stock at or above the initial public offering price. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you
consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to
enter into strategic collaborations or acquire companies or products by using our shares of common stock as consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our
stock may be volatile, and you could lose all or part of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading price of our common stock following this
offering is likely to be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this
prospectus, these factors include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory actions with respect to our products or our competitors&#146; products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">actual or anticipated changes in our growth rate relative to our competitors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results of preclinical studies and clinical trials of our product candidates or those of our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory or legal developments in the United States and other countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning patent applications, issued patents or other proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the recruitment or departure of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of expenses related to any of our product candidates or clinical development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments with respect to our existing collaboration agreements and announcements of new collaboration agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our efforts to in-license or acquire additional product candidates or products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">variations in our financial results or those of companies that are perceived to be similar to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fluctuations in the valuation of companies perceived by investors to be comparable to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcement or expectation of additional financing efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of our common stock by us, our insiders or our other stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the structure of healthcare payment systems; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market conditions in the biotechnology sector; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic, industry and market conditions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general,
and the NASDAQ Global Market and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and
industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this
&#147;Risk Factors&#148; section, could have a dramatic and adverse impact on the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion
in the use of the net proceeds from this offering and may not use them effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in
the application of the net proceeds from this offering, and you will be relying on the judgment of our management regarding the application of these proceeds. You will not have the opportunity, as part of your investment decision, to assess whether
we are using the proceeds appropriately. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder
value, we may fail to achieve expected financial results, which could cause our stock price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to securities litigation,
which is expensive and could divert management attention. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of our common stock may be volatile and, in the past,
companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in
substantial costs and divert our management&#146;s attention from other business concerns, which could seriously harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders and management own a significant percentage of our stock and will be able to
exert significant control over matters subject to stockholder approval. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, our executive officers,
directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 84.6% of our voting stock and, upon the closing of this offering, that same group will hold approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding voting stock (assuming no exercise of the underwriters&#146; over-allotment option, no exercise of outstanding options or warrants and no purchases of shares in this offering by
any of this group), in each case assuming the conversion of all outstanding shares of our convertible preferred stock into shares of our common stock immediately prior to the closing of this offering. After this offering, this group of stockholders
will have the ability to control us through this ownership position even if they do not purchase any additional shares in this offering. These stockholders may be able to determine all matters requiring stockholder approval. For example, these
stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals
or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in
a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price is substantially higher than the net tangible book value per share of our common stock. Investors purchasing
common stock in this offering will pay a price per share that substantially exceeds the book value of our tangible assets after subtracting our liabilities. As a result, investors purchasing common stock in this offering will incur immediate
dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, based upon an assumed initial public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the price range set forth on the cover page
of this prospectus). Further, investors purchasing common stock in this offering will contribute approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the total amount invested by stockholders since our inception, but will own only approximately
&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of common stock outstanding after giving effect to this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This dilution is due to our
investors who purchased shares prior to this offering having paid substantially less when they purchased their shares than the price offered to the public in this offering and the exercise of stock options granted to our employees. In addition, as
of June 30, 2015, options to purchase 8,657,422 shares of our common stock at a weighted-average exercise price of $0.1870 per share, warrants exercisable for 822,386 shares of our common stock at an exercise price of $0.65 per share and warrants
exercisable for Series C convertible preferred stock convertible into 2,063,484 shares of our common stock at an exercise price of $0.65 per share were outstanding. Additional options to purchase 5,496,050 shares of our common stock at an exercise
price of $0.99 per share were granted between June 30, 2015 and August 17, 2015. The exercise of any of these options would result in additional dilution. As a result of the dilution to investors purchasing shares in this offering, investors may
receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. For a further description of the dilution that you will experience immediately after this offering, see &#147;Dilution.&#148;
</P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will
make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the Jumpstart Our Business
Startups Act of 2012, or JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth
companies, including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in this prospectus and our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some
investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of (i)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth
anniversary of the closing of our initial public offering, (b)&nbsp;in which we have total annual gross revenue of at least $1 billion or (c)&nbsp;in which we are deemed to be a large accelerated filer, which requires the market value of our common
stock that is held by non-affiliates to exceed $700 million as of the prior June&nbsp;30th, and (ii)&nbsp;the date on which we have issued more than $1 billion in non-convertible debt during the prior three-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards
apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that
are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could
significantly affect our financial position and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public company,
and our management will devote substantial time to new compliance initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will incur significant
legal, accounting and other expenses that we did not incur as a private company, and these expenses may increase even more after we are no longer an &#147;emerging growth company.&#148; We will be subject to the reporting requirements of the
Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and the NASDAQ Global Market. Our management and other personnel will need to devote a substantial
amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. The increased costs will
increase our net loss. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the
sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified
persons to serve on our board of directors, our board committees or as executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our common
stock in the public market could cause our stock price to fall. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in
the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we will have
outstanding &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock based on the number of shares outstanding as of June 30, 2015, assuming: (i)&nbsp;no exercise of the underwriters&#146; option to purchase
additional shares and (ii)&nbsp;the conversion of all outstanding shares of our convertible preferred stock into 80,645,053 shares of common stock immediately prior to the closing of this offering. This includes the shares that we sell in this
offering, which may be resold in the public market immediately without restriction, unless purchased by our affiliates. Of the remaining shares, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock are
currently restricted as a result of securities laws or lock-up agreements but will be able to be sold after this offering as described in the &#147;Shares Eligible for Future Sale&#148; section of this prospectus. Moreover, after this offering,
holders of an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will have rights, subject to certain conditions, to require us to file registration statements covering their shares or to
include their shares in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration statements that we may file for ourselves or other stockholders. We also intend to register all shares of common stock that we may issue under our equity incentive plans. Once we
register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the lock-up agreements described in the &#147;Underwriting&#148; section of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in
additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that
significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public
company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other
equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our
common stock, including shares of common stock sold in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our disclosure controls and procedures may not prevent or detect all errors
or acts of fraud. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, we will become subject to the periodic reporting requirements of the Exchange
Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and
reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These inherent limitations include the realities that judgments in
decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of
the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the
development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our restated certificate of incorporation and restated bylaws and Delaware law might discourage, delay or prevent a change in control of
our company or changes in our management and, therefore, depress the market price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of
incorporation and restated bylaws, as we expect they will be in effect upon closing of the offering, will contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our
company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a classified board of directors so that not all members of our board are elected at one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">permit only the board of directors to establish the number of directors and fill vacancies on the board; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that directors may only be removed &#147;for cause&#148; and only with the approval of two-thirds of our stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize the issuance of &#147;blank check&#148; preferred stock that our board could use to implement a stockholder rights plan (also known as a &#147;poison pill&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminate the ability of our stockholders to call special meetings of stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibit cumulative voting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;203 of the Delaware General Corporation Law may discourage, delay or prevent a change in control of our company.
Section&nbsp;203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding
our stock, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will be influenced by the
research and reports that industry or securities analysts publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few securities or industry analysts commence
coverage of us, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business
model, our intellectual property or our stock performance, or if our target animal studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us
or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We plan to use potential future operating losses and our federal and state net operating loss, or NOL, carryforwards to offset taxable income from
revenue generated from operations or corporate collaborations. However, our ability to use NOL carryforwards could be limited as a result of issuance of equity securities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to use our current year operating losses to offset taxable income from any revenue generated from operations or corporate
collaborations. To the extent that our taxable income exceeds any current year operating losses, we plan to use our NOL carryforwards to offset income that would otherwise be taxable. However, under the Tax Reform Act of 1986, the amount of benefits
from our NOL carryforwards may be impaired or limited if we incur a cumulative ownership change of more than 50%, as interpreted by the U.S. Internal Revenue Service, over a three-year period. As a result, our use of federal NOL carryforwards could
be limited by the provisions of Section&nbsp;382 of the U.S. Internal Revenue Code of 1986, as amended, depending upon the timing and amount of additional equity securities that we have issued or will issue, including as a result of this offering.
State NOL carryforwards may be similarly limited. Any such disallowances may result in greater tax liabilities than we would incur in the absence of such a limitation and any increased liabilities could adversely affect our business, results of
operations, financial condition and cash flow. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, including the sections entitled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Use of Proceeds,&#148;
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and &#147;Business&#148; contains forward-looking statements. The words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148;
&#147;potentially,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;could,&#148; &#147;would,&#148; &#147;project,&#148; &#147;plan&#148; &#147;expect,&#148; and similar expressions that convey
uncertainty of future events or outcomes are intended to identify forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this
prospectus include, among other things, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success, cost and timing of our product candidate development activities and planned clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to develop and commercialize antibodies, including our lead product candidates ANB020 for patients with severe allergic and atopic diseases and ANB019 for patients with GPP and PPP; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood that the clinical data generated in Australia will be subsequently accepted by the FDA and its foreign equivalents outside of Australia. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and ability of our collaborators to develop and commercialize our partnered product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential benefits and advantages of our product candidates and approaches versus those of our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to execute on our strategy, including advancing our lead product candidates, identifying emerging opportunities in key therapeutic areas, continuing to expand our wholly-owned pipeline and retaining rights
to strategic products in key commercial markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of and our ability to obtain and maintain regulatory approvals for ANB020 and ANB019 and our other product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate and degree of market acceptance and clinical utility of any approved product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size and growth potential of the markets for any approved product candidates, and our ability to serve those markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our commercialization, marketing and manufacturing capabilities and strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments in the United States, Australia and other foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of competing therapies that are or may become available; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to attract and retain key scientific or management personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our use of the net proceeds from this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#147;Risk
Factors&#148; and elsewhere in this prospectus. Moreover, we operate in a competitive and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or
the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking
events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in
the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation
to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations, except as required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the
registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_4"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including
our general expectations and market position, market opportunity, and market size, is based on information from various sources on assumptions that we have made that are based on those data and other similar sources and on our knowledge of the
markets for our products. This information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe the market position, market opportunity and market size information
included in this prospectus is generally reliable, such information is inherently imprecise. In addition, projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate is necessarily
subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors&#148; and elsewhere in this prospectus. These and other factors could cause results to differ materially from those
expressed in the estimates made by the independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from our sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the
underwriters exercise their option to purchase additional shares in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial public
offering price would increase (decrease) the net proceeds to us from this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, remains the same, and after deducting estimated
underwriting discounts and commissions. Similarly, each increase or decrease of one million in the number of shares of common stock offered by us would increase or decrease the net proceeds that we receive from this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the assumed initial public offering price remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds we receive from this offering as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund development of ANB019 and ANB020 through initial clinical trials intended to demonstrate efficacy in multiple indications;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund continued development of other wholly-owned product candidates and discovery of new product candidates to further expand our
proprietary pipeline;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any remaining amounts to fund working capital, including general corporate purposes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on
our planned use of the net proceeds, we estimate such funds, together with our existing cash and cash equivalents, will be sufficient for us to fund our operating expenses and capital expenditure requirements through at least the next 24 months.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected use of the net proceeds from the offering represents our intentions based upon our current plans and business conditions. As
of the date of this prospectus, we cannot predict with any certainty all of the particular uses for the net proceeds or the amounts that we will actually spend on the uses set forth above. We may use a portion of the net proceeds for the acquisition
of, or investment in, technologies, solutions or businesses that complement our business, although we have no present commitments or agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts and timing of our clinical expenditures and the extent of clinical development may vary significantly depending on numerous
factors, including the status, results and timing of our current preclinical studies and clinical trials we may commence in the future, product approval process with the FDA and other regulatory agencies, our current collaborations and any new
collaborations we may enter into with third parties and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected net proceeds of this offering will not be sufficient for us to fund any of our product candidates through regulatory approval,
and we will need to raise substantial additional capital to complete the development and commercialization of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending their use as described above, we intend to invest the net proceeds from this offering in short term, investment-grade interest-bearing
securities such as money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings
for use in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend
on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. In addition, under the terms of our current credit facility, we are prohibited from
paying cash dividends without the consent of Silicon Valley Bank. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and capitalization as of June 30, 2015 on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an actual basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a pro forma basis, giving effect to (i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock into 42,208,202 shares of common stock immediately prior to the closing of this
offering, (ii)&nbsp;the sale and issuance of 38,436,851 shares of our Series D convertible preferred stock in a private placement by us in July 2015, (iii)&nbsp;the automatic conversion of 38,436,851 shares of Series&nbsp;D convertible preferred
stock into 38,436,851 shares of common stock immediately prior to the closing of this offering, (iv)&nbsp;the related reclassification of the preferred stock warrant liability to additional paid-in capital upon the conversion of the shares of
convertible preferred stock underlying the warrants that make up the liability, and (v)&nbsp;the effectiveness of our restated certificate of incorporation in connection with the closing of this offering; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a pro forma as adjusted basis, giving effect to the pro forma adjustments and the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock by us in this offering, based on
an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted information set forth in the table below is illustrative only and
will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should
read this table together with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our audited and unaudited consolidated financial statements and related notes included elsewhere in this
prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30, 2015</B><br><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands, except share and par value data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Series B convertible preferred stock, $0.001 par value; 27,742,879 shares authorized, 27,742,879 shares issued and outstanding,
actual; no shares designated, issued or outstanding pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Series C convertible preferred stock, $0.001 par value; 17,982,024 shares authorized, 11,147,269 shares issued and outstanding,
actual; no shares designated, issued or outstanding pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Series C-1 convertible preferred stock, $0.001 par value; 10,500,000 shares authorized, 3,318,054 shares issued and outstanding,
actual; no shares designated, issued or outstanding pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Series D convertible preferred stock, $0.001 par value; no shares designated, issued or outstanding, actual, pro forma and pro forma
as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Preferred Stock, $0.001 par value; no shares authorized, issued or outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Common stock, $0.001 par value; 79,000,000 shares authorized, 17,811,491 shares issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(45,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus,
would increase (decrease) each of our pro forma as adjusted cash and cash equivalents, additional paid-in capital, total stockholders&#146; equity (deficit) and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
million, assuming that the number of shares offered by us remains the same and after deducting estimated underwriting discounts and commissions. Similarly, each increase (decrease) of one million shares in the number of shares offered by us would
increase (decrease) each of our pro forma as adjusted cash and cash equivalents, additional paid-in capital, total stockholders&#146; equity (deficit) and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
million, assuming the assumed initial public offering price remains the same and after deducting estimated underwriting discounts and commissions. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 98,456,544 shares of our common stock outstanding
as of June 30, 2015, and gives effect to the sale and issuance of 38,436,851 shares of Series D convertible preferred stock at a price of $1.06 per share in a private placement by us in July 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">8,657,422 shares of common stock issuable upon the exercise of options outstanding as of June 30, 2015, with a weighted-average exercise price of $0.1870 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,496,050 shares of common stock issuable upon the exercise of options granted between June 30, 2015 and August 17, 2015, with an exercise price of $0.99 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under our stock-based compensation plans, consisting of (a)&nbsp;3,176,670 shares of common
stock reserved for future issuance under our 2006 Equity Incentive Plan as of August 17, 2015, (b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under our 2015 Equity
Incentive Plan, which will become effective on the date immediately prior to the date of this prospectus and (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under
our 2015 Employee Stock Purchase Plan, which will become effective on the date of this prospectus. Upon the closing of this offering, any remaining shares available for issuance under our 2006 Equity Incentive Plan will be added to the shares
reserved under our 2015 Equity Incentive Plan and we will cease granting awards under our 2006 Equity Incentive Plan. Our 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan also provide for automatic annual increases in the number of
shares reserved under the plans each year, as more fully described in &#147;Executive Compensation&#151;Employee Benefit and Stock Plans&#148;; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">822,386 shares of our common stock issuable upon exercise of warrants for shares of common stock with an exercise price of $0.65 per share, that do not expire upon the closing of this offering; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,063,484 shares of common stock issuable upon the exercise of warrants to purchase shares of Series C convertible preferred stock that were outstanding as of June 30, 2015, with an exercise price of $0.65 per share,
that do not expire upon the closing of this offering. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock, your interest will be diluted to the extent of the difference between the amount per share paid by
purchasers of shares of common stock in this initial public offering and the pro forma as adjusted net tangible book value per share of common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2015, our pro forma net tangible book value was approximately $47.8&nbsp;million, or $0.49&nbsp;per share of common stock. Our
pro forma net tangible book value per share represents the amount of our total tangible assets reduced by the amount of our total liabilities and divided by the total number of shares of our common stock outstanding as of June 30, 2015, assuming
(i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock into 42,208,202 shares of common stock as of immediately prior to the closing of this offering, (ii)&nbsp;the sale and issuance of 38,436,851 shares of
our Series D convertible preferred stock in a private placement by us in July 2015, (iii)&nbsp;the automatic conversion of 38,436,851 shares of Series D convertible preferred stock into 38,436,851 shares of common stock immediately prior to the
closing of this offering, and (iv)&nbsp;the related reclassification of the preferred stock warrant liability to additional paid-in capital upon the conversion of the shares of convertible preferred stock underlying the warrants that make up the
liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to our sale in this offering of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth
on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma net tangible book value as of June 30, 2015 would have been approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of our common stock. This represents an immediate increase in pro forma net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing stockholders and an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to investors purchasing shares in this offering, as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of June 30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) our pro forma net tangible book value, as adjusted to give effect to this
offering, by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the increase (decrease) attributable to this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and the dilution in pro forma as adjusted net tangible
book value per share to new investors in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase of one million shares in the number of shares offered by us in this offering would increase our pro forma as adjusted
net tangible book value per share, and decrease the dilution per share to investors in this offering, by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. Each decrease of one million shares in the number of shares offered by us would
decrease our pro forma as adjusted net tangible book value per share, and increase the dilution per share to investors in this offering, by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option in full to purchase additional shares, the pro forma net tangible book value per share of our common
stock after giving effect to this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and the dilution in net tangible book value per share to investors in this offering would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes, on a pro forma as adjusted basis as of
June 30, 2015 after giving effect to (i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock into 42,208,202 shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock as of immediately prior to the closing of this offering, (ii)&nbsp;the sale and issuance of 38,436,851 shares of our Series D convertible preferred stock in a private placement by us
in July 2015, (iii)&nbsp;the automatic conversion of 38,436,851 shares of Series D convertible preferred stock into 38,436,851 shares of common stock immediately prior to the closing of this offering, and (iv)&nbsp;the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price
range set forth on the cover page of this prospectus, the difference between existing stockholders and new investors with respect to the number of shares of common stock purchased from us, the total consideration paid to us, and the average price
per share paid, before deducting underwriting discounts and commissions and estimated offering expenses payable by us: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average</B><br><B>Price Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="16" ALIGN="center"><B>(in thousands, except percentage and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New public investors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) total consideration paid by new investors and total consideration paid by all
stockholders by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any outstanding options are
exercised, investors will experience further dilution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, the above discussion and tables assume no exercise
of the underwriters&#146; option to purchase additional shares. If the underwriters exercise their option to purchase additional shares in full, our existing stockholders would own &nbsp;&nbsp;&nbsp;&nbsp;% and our new investors would own
&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding upon the closing of this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number
of shares of our common stock to be outstanding after this offering is based on 98,456,544 shares of our common stock outstanding as of June 30, 2015, and gives effect to the sale and issuance of 38,436,851 shares of Series&nbsp;D convertible
preferred stock at a price of $1.06 per share in a private placement by us in July 2015. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to
be outstanding after this offering excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">8,657,422 shares of common stock issuable upon the exercise of options outstanding as of June 30, 2015, with a weighted-average exercise price of $0.1870 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,496,050 shares of common stock issuable upon the exercise of options granted between June 30, 2015 and August 17, 2015, with an exercise price of $0.99 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under our stock-based
compensation plans, consisting of (a)&nbsp;3,176,670 shares of common stock reserved for future issuance under our 2006 Equity Incentive Plan as of August 17, 2015,
(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under our 2015 Equity Incentive Plan, which will become effective on the date immediately prior to the date of this
prospectus and (c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for future issuance under our 2015 Employee Stock Purchase Plan, which will become effective on the date of this
prospectus. Upon the closing of this offering, any remaining shares available for issuance under our 2006 Equity Incentive Plan will be added to the shares reserved under our 2015 Equity Incentive Plan and we will cease granting awards under our
2015 Equity Incentive Plan. Our 2015 Equity Incentive Plan and 2015 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
Employee Stock Purchase Plan also provide for automatic annual increases in the number of shares reserved under the plans each year, as more fully described in &#147;Executive
Compensation&#151;Employee Benefit and Stock Plans&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">822,386 shares of our common stock issuable upon exercise of warrants for shares of common stock with an exercise price of $0.65 per share, that do not expire upon the closing of this offering; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,063,484 shares of common stock issuable upon the exercise of warrants to purchase shares of Series C convertible preferred stock that were outstanding as of June 30, 2015, with an exercise price of $0.65 per share,
that do not expire upon the closing of this offering. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_9"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected statements of operations data for the years ended December&nbsp;31, 2013 and 2014 and the balance sheet data as of
December&nbsp;31, 2013 and 2014 are derived from our audited financial statements included elsewhere in this prospectus. The selected consolidated statement of operations data for the six months ended June 30, 2014 and 2015 and the consolidated
balance sheet data as of June 30, 2015 have been derived from our unaudited consolidated financial statements included elsewhere in this prospectus. Our unaudited consolidated financial statements have been prepared on the same basis as our audited
financial statements and, in the opinion of management, reflect all adjustments, which consist only of normal recurring adjustments, necessary for the fair statement of those unaudited consolidated financial statements. The selected consolidated
financial data below should be read in conjunction with the section entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and related notes included elsewhere in
this prospectus. Our historical results are not necessarily indicative of the results that may be expected in any future period and the results for the six months ended June 30, 2015 are not necessarily indicative of results to be expected for the
full year. The selected financial data in this section are not intended to replace the financial statements and are qualified in their entirety by the financial statements and related notes included elsewhere in this prospectus. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>Consolidated Statements of Operations Data:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of liability for preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributed to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributed to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per common share:<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares outstanding:<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss) per common share (unaudited):<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average number of shares outstanding (unaudited):<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:3%;border-bottom:1px solid #000000; width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See Note 2 to our annual and interim consolidated financial statements for an explanation of the method used to calculate basic and diluted net income (loss) per common share, unaudited pro forma basic and diluted net
income (loss) per common share and the weighted-average number of shares used in the computation of the per share amounts. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>June 30,<BR>2015</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory notes, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, noncurrent portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,527</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our
consolidated financial statements and related notes thereto included elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set
forth in the &#147;Risk Factors&#148; section of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company
developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. We develop our product candidates using our proprietary antibody discovery technology platform, which is designed to replicate,
<I>in vitro</I>, the natural process of antibody generation. Our platform is based upon a breakthrough understanding of somatic hypermutation, the key biological process utilized to generate antibodies, which enables us to rapidly develop highly
functional antibody drug candidates against emerging biological targets. Our most advanced, wholly-owned programs, ANB020 and ANB019, are being developed to treat severe inflammatory disorders with unmet medical need. In 2016, we plan to initiate
clinical trials of ANB020, an antibody that inhibits the activity of interleukin-33 for the treatment of severe adult asthma and severe adult peanut allergy, and ANB019, an antibody that inhibits the interleukin-36 receptor for the treatment of rare
inflammatory diseases called generalized pustular psoriasis and palmo-plantar pustular psoriasis. Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in
antibody discovery and development, collaborations, operations and corporate finance. Our investors include Biotechnology Value Fund, Cormorant Asset Management, Frazier Healthcare, HBM Partners, Longwood Capital Partners and Novo A/S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we have entered into multiple collaborations from which we expect four programs will enter the clinic in the next 18 months. Our
collaborations include an immuno-oncology-focused collaboration with TESARO and an inflammation-focused collaboration with Celgene. Through July 31, 2015, we have received non-dilutive funding of $48.7 million from our collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to continue generating additional therapeutic antibodies against emerging biological targets across various disease applications,
including immuno-oncology, inflammation and other unmet medical needs. In general, our strategy is to advance our pipeline programs to key inflection points, and leverage partnerships with pharmaceutical and biotechnology companies where
appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have generated multiple antibodies by using our SHM-XEL platform certain of which are currently being advanced by our
partners to key preclinical, clinical and commercial milestones, which we anticipate will generate additional cash receipts for us. To the extent that these product candidates are commercialized, we will also be entitled to royalty payments upon
commercial sales of the associated products. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred losses in each period since our inception in 2005, except for 2014 in
which we received $19.0 million from two upfront payments and recognized revenue of $11.5 million during 2014 following the execution of our strategic collaboration with TESARO. Accordingly, for the year ended December&nbsp;31, 2014 we reported net
income of $3.5 million. As of June 30, 2015, we had an accumulated deficit of $45.7&nbsp;million. We expect to continue to incur net operating losses for at least the next several years as we advance our products through clinical development, seek
regulatory approval, prepare for and, if approved, proceed to, commercialization, expand our operations and facilities and grow in new and existing markets, territories and industries. We will need substantial additional funding to pay expenses
relating to our operating activities, including significant research and development expenses. Adequate funding may not be available to us on acceptable terms, or at all. Our failure to obtain sufficient funds on acceptable terms when needed could
have a material adverse effect on our business, results of operations or financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not
generated any revenue from product sales. Our revenue has been derived from amortization of upfront payments, research and development funding and milestone payments under collaboration and license agreements with our collaborators. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Collaboration and Exclusive License Agreement with TESARO </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March&nbsp;2014, we entered into an exclusive worldwide license and collaboration agreement with TESARO for the development and
commercialization of therapeutic monospecific and bispecific antibodies that antagonize PD-1, TIM-3 and/or LAG-3. We received $17.0 million in upfront fees from TESARO in March 2014, and in November 2014, we amended the agreement with TESARO to
include the development and commercialization of bispecific antibodies to another undisclosed target, for an additional upfront fee of $2.0 million. Both upfront fees are being recognized as revenue through March 2016, which is the same period that
our research and development services, for which we are reimbursed, are performed. From inception of the agreement through June 30, 2015, we have recognized $20.5 million in total revenue from TESARO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each of the four targets under the TESARO agreement, we are eligible to receive up to $273.0 million in milestone payments, which are
comprised of $18.0 million for preclinical and clinical development milestone payments, $90.0 million upon certain regulatory events and $165.0 million upon worldwide commercial sales thresholds. In addition, TESARO is obligated to pay us tiered
single-digit royalties on annualized net sales of each antibody commercialized from the collaboration. In June 2015, TESARO initiated <I>in vivo</I> toxicology studies using good laboratory practices for the anti-PD-1 antagonist antibody mentioned
above, which resulted in us receiving a $1.0 million milestone in July 2015. We expect to receive an additional aggregate of $14.0 million in preclinical and IND-related payments by the end of 2016 based upon further development of the anti-PD-1
antagonist and two of the other targets mentioned above. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Antibody Generation Agreement with Celgene Corporation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2011, we entered into a license and collaboration agreement with Celgene to develop therapeutic antibodies against multiple
targets. We granted Celgene the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting
certain pre-specified parameters pertaining to each target under the agreement. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement provided for an upfront payment of $6.0
million from Celgene, which we received in 2011, milestone payments of up to $53.0 million per target, low single-digit royalties on net sales of antibodies against each target, and reimbursement of specified research and development costs. From
inception of the agreement through June 30, 2015, we have recognized $8.5 million in total revenue from Celgene. For one of the two programs being advanced by Celgene, we expect to receive up to an aggregate of $1.5 million in preclinical and
IND-related milestone payments by the end of 2016. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Collaborative Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to other collaboration agreements for which in 2013 and 2014 we recognized $1.7 million and $3.7 million, respectively, in
collaboration revenue. We have completed our obligations under these agreements and do not anticipate any additional revenue from them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of costs associated with our research and development activities, including drug discovery efforts
and preclinical development of our programs. Our research and development expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">External research and development expenses incurred under arrangements with third-parties, such as CROs, consultants, members of our scientific and therapeutic advisory boards, and clinical manufacturers;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Employee-related expenses, including salaries, benefits, travel and stock-based compensation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory supplies;
and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">License and sublicense fees. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research and development costs as incurred. We
account for advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are conducting research and development activities on several inflammation and immuno-oncology programs. We have a research and development
team that conducts antibody discovery, characterization, translational studies, IND-enabling preclinical studies and clinical development. We conduct some of our early research and preclinical activities internally and plan to rely on third parties,
such as CROs and CMOs, for the execution of certain of our research and development activities, such as <I>in vivo </I>toxicology and pharmacology studies, drug product manufacturing and clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are planning to conduct initial clinical trials in Australia to rapidly enter into first-in-human studies for ANB020 and ANB019 and benefit
from research and development-related financial incentives related to the development of ANB020 and ANB019. Taking into account any financial incentives, we expect our research and development expenses to be higher in 2015 and 2016 as we advance our
product candidates into clinical development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, for our executive,
finance, legal, business development, human resource and support functions. Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses, travel expenses and
professional fees for auditing, tax and legal services, including intellectual property-related legal services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense consists of stated interest and amortization of discounts on our outstanding notes payable relating to our Loan and Security
Agreement with Oxford Finance LLC and Silicon Valley Bank, which we refer to as the Loan Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value of Liability for Preferred
Stock Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income and expense from the change in fair value of our liability for preferred stock warrants is from the
valuation of our outstanding warrants to purchase shares of our preferred stock, which is valued at each period end. Upon the closing of our initial public offering, the warrants to purchase shares of preferred stock will
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convert into warrants to purchase shares of common stock, the preferred stock warrant liabilities will be reclassified to additional paid-in capital and periodic fair value adjustments will no
longer be recorded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Operating Loss and Research and Development Tax Credit Carryforwards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From our inception to December&nbsp;31, 2013, we accumulated net operating losses, or NOLs. For the year ended December&nbsp;31, 2014, we
generated net income of $3.5 million primarily as a result of our collaboration agreement with TESARO. While we utilized NOLs in 2014, we continue to have a valuation allowance against our net deferred tax assets due to the uncertainty surrounding
the realization of such assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2014, we had federal and state NOL carryforwards of $41.4 million each. The federal
and state NOLs will begin to expire in 2027 and 2017, respectively, unless previously utilized. At December&nbsp;31, 2014 we had federal and California research tax credit carryforwards of $1.6 million and $1.4 million, respectively. The federal
research tax credit carryforward will begin to expire in 2026 and the California state credits carry forward indefinitely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The NOL
carryforward and the research tax credit carryforwards may be subject to an annual limitation under Section&nbsp;382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if we experience one or more ownership changes which
would limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change as defined by Section&nbsp;382 and 383, results from transactions increasing
ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. We have not completed an IRC Section&nbsp;382/383 analysis. If a change in ownership were to have occurred
or occurs as a result of this offering, NOL and tax credits carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation
allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact our effective tax rate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which
have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities,
revenues, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under
the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. The effects of
material revisions in estimates, if any, will be reflected in the financial statements prospectively from the date of change in estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail in the notes to our financial statements appearing elsewhere in this
prospectus, we believe the following accounting policies used in the preparation of our financial statements require the most significant judgments and estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is
recognized in accordance with revenue recognition accounting guidance, which requires that four basic criteria be met before revenue can be recognized: (i)&nbsp;persuasive evidence that an arrangement exists; (ii)&nbsp;delivery has occurred and
title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (iii)&nbsp;the price is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple-Element Revenue Arrangements</I>. We evaluate deliverables in a multiple-element
arrangement to determine whether each deliverable represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value to the customer. If the delivered element does not have standalone value
without one of the undelivered elements in the arrangement, we combine such elements and account for them as a single unit of accounting. We allocate the consideration to each unit of accounting at the inception of the arrangement based on the
relative selling price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize consideration allocated to an individual element when all other revenue recognition criteria are met
for that element. Our multiple-element revenue arrangements may include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">License Arrangements. The deliverables under our collaboration and license agreements generally include exclusive or nonexclusive licenses to one or more products generated using our technologies. As the delivered
licenses have not historically had standalone value apart from the undelivered elements, these have been recognized as revenue as a combined unit of accounting. Accordingly, we recognize revenue from nonrefundable upfront fees in the same manner as
the undelivered item or items, which is generally the period over which we provide research and developments services. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Research and Development Services. The deliverables under our collaboration and license arrangements may include research and development services we perform on behalf of or with our collaborators. As the provision of
research and development services is an integral part of our operations and we may be principally responsible for the performance of these services under the agreements, we recognize revenue on a gross basis for research and development services as
we perform those services. Additionally, we recognize research related funding under collaboration research and development efforts as revenue as we perform or deliver the related services in accordance with contract terms. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Milestone Revenue.</I> Our collaboration and license agreements generally include contingent contractual payments related to achievement of
specific research, development and regulatory milestones and sales-based milestones that are dependent upon the performance of the licensor or collaborator. A milestone is defined as an event (i) that can only be achieved based in whole or in part
on either the entity&#146;s performance or on the occurrence of a specific outcome resulting from the entity&#146;s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be
achieved and (iii) that would result in additional payments being due to us. Contingent consideration for which payment is either contingent solely upon the passage of time or the result of a counterparty&#146;s performance is not considered
substantive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period
in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consideration is commensurate with either the entity&#146;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the
entity&#146;s performance to achieve the milestone; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consideration relates solely to past performance; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Milestones that are not considered substantive are generally recognized in the same manner as the undelivered item(s), which is generally the
period over which we provide research and developments services. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of each balance sheet date.
This process involves reviewing open contracts and purchase orders, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we
have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of
each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research
and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to
quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances
in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the
level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Advance payments for goods and services that will be
used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing
of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our
estimates of such expenses and the amounts actually incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense the fair value of stock awards to employees, net of estimated forfeitures, adjusted to reflect actual forfeitures, over the
requisite service period, which is typically the vesting period. We estimate the fair value of options granted to employees at the date of grant using the Black-Scholes option-pricing model that requires management to apply judgment and make
estimates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>fair value of the underlying common shares</I>, as approved by our board of directors, which was determined using the option-pricing method, or OPM, in periods through December&nbsp;31, 2014, and the
probability-weighted expected return method, or PWERM, beginning March&nbsp;31, 2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>risk-free interest rate</I>, which is based on observed interest rates appropriate for the expected term of the stock option grants, historically U.S. Treasury constant maturities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>expected volatility</I>, which is calculated based on reported volatility data for a representative peer group of publicly traded biotechnology companies for which historical information is available. Because we are
privately held as of the date of these financial statements, we do not have relevant historical data to support our expected volatility; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>expected dividend yield</I>, which is zero as we have never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>expected term</I>, which we calculate using the simplified method, which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches, as we
have insufficient historical information regarding our stock options to provide a basis for an estimate. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have computed the fair value of stock options at the date of grant using the following
assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.5%-1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">71.0%-72.5</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.1-9.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense related to unvested stock option grants not yet recognized as of June 30,
2015 was $0.5 million and the weighted average period over which these grants are expected to vest is 3.3 years. We expect to continue to grant stock options in the future, and to the extent we do, our actual stock-based compensation expense
recognized in future periods will likely increase. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock Valuations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a private company with no active public market for our common stock. Therefore, we have periodically determined the estimated per share
fair value of our common stock at various dates using contemporaneous valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, <I>Valuation of Privately-Held Company Equity
Securities Issued as Compensation</I>, or Practice Aid. Once a public trading market for our common stock has been established in connection with the closing of this offering, it will no longer be necessary for us to estimate the fair value of our
common stock in connection with our accounting for stock options and restricted stock, as the fair value of our common stock will be its trading price on the NASDAQ Global Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock Valuation Methodologies. </I></B>Our contemporaneous and retrospective valuations were prepared in accordance with the
guidelines in the Practice Aid, which prescribes several valuation approaches for determining the value of an enterprise, such as the cost, market and income approaches, and various methodologies for allocating the value of an enterprise to its
capital structure and specifically the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We used the market approach as this approach is based on the assumption that the
value of an asset, including a company, is equal to the value of a substitute asset with the same characteristics. Therefore, the value of an asset can be inferred by finding similar assets, or an interest in similar assets, that have been sold in
recent arm&#146;s-length transactions. The following market approaches were considered in our valuations: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Guideline Public Company Method.</B> The guideline public company method, or GPC method, compares the subject company with guideline publicly traded companies. Valuation multiples are calculated from selected
guideline companies to provide an indication of how much a current investor in the marketplace would be willing to pay for a company with characteristics similar (such as similar business, size, geographic region, and other operating
characteristics) to the subject company. These valuation multiples are evaluated and adjusted based on the strengths and weaknesses of the subject company relative to the selected guideline companies. Finally, the multiples are applied to the
subject company&#146;s operating data to arrive at an indication of fair market value. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Similar Transaction Method.</B> The similar transaction method, or ST method, relies on data of actual transactions, such as mergers and acquisitions or completed initial public offerings, that have occurred in the
subject company&#146;s industry or in related industries. As in the GPC method, valuation multiples are developed and applied to the subject company&#146;s operating data to estimate fair value. Again, the ST method can be used if there are recent
transactions involving companies similar to the subject company. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Methods Used to Allocate Our Enterprise Value to Classes of Securities</I></B>. In
accordance with the Practice Aid, we considered the various methods for allocating the enterprise value across our classes and series of capital stock to determine the fair value of our common stock at each valuation date. The methods we utilized
consisted of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Option Pricing Method.</B> Under OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values of the
preferred and common stock are inferred by analyzing these options. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Probability-Weighted Expected Return Method</B>. PWERM is a scenario based analysis that estimates the value per share based on the probability-weighted present value of expected future investment returns,
considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our per share common stock value was estimated by allocating the equity value using the OPM at each valuation date up through
December&nbsp;31, 2014. Starting from our March&nbsp;31, 2015 contemporaneous valuation, we used PWERM to allocate the equity value to each element of our capital structure, including our common stock. For both approaches, we applied a discount to
the valuations due to the lack of marketability of the ordinary shares. We calculated the discount for lack of marketability using a strike put option model and applied it as appropriate to each allocation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Warrant Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for warrants for shares of preferred stock with conversion features that provide for adjustments in the warrant price as derivative
liabilities in the accompanying consolidated balance sheets at their fair value on the date of issuance. The derivative liabilities are revalued at each balance sheet date until such instruments, so long as they remain exercisable for shares of
preferred stock, are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use the Black-Scholes option pricing model to estimate the fair value of the preferred stock warrant liabilities. Inputs we used in the
Black-Scholes option pricing model to determine estimated fair value include the estimated fair value of the underlying convertible preferred stock at the valuation measurement date, the remaining contractual term of the warrants, risk-free interest
rates, expected dividends and the expected volatility of the price of the underlying convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting Pronouncements
Recently Adopted </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU,
No.&nbsp;2014-10, <I>Development Stage Entities (Topic 915)</I>, which eliminated the distinction of a Development Stage Entity along with the inception to date reporting requirements. As permitted by this ASU, we elected to early adopt the
amendment beginning with our annual reporting period ended December&nbsp;31, 2014, with retrospective application of the amended guidance. Upon adoption, there was no effect to our consolidated financial statements, other than the elimination of
inception to date disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2015, the FASB issued ASU No.&nbsp;2015-03, <I>Simplifying the Presentation of Debt Issuance
Costs</I>. This update requires the presentation of debt issuance costs in financial statements as a direct reduction of related debt liabilities rather than as an asset. Amortization of debt issuance costs continue to be reported as interest
expense. As permitted by the ASU, we elected to early adopt the amendment beginning with its annual reporting period ended December&nbsp;31, 2014, with retrospective application of the amended guidance. The adoption of this ASU resulted in the
reclassification $37,000 and $85,000 in deferred debt issuance costs from prepaid expenses and other current assets to a direct reduction to the carrying values of notes payable and convertible promissory notes reported in the balance sheets at
December&nbsp;31, 2013 and 2014, respectively. The adoption of this guidance did not have any effect on our statement of operations during the years ended December&nbsp;31, 2013 or 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU 2014-09, <I>Revenue from Contracts with Customers</I>, which outlines a single comprehensive model for
entities to use in accounting for revenue from contracts with customers and supersedes most current revenue recognition guidance in FASB ASC 605, Revenue Recognition, including industry-specific guidance. This standard is based on the principle that
an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard also requires
additional disclosure about the nature, amount, timing and uncertainty of assets recognized from costs incurred to fulfill a contract. ASU 2014-09 becomes effective for our annual reporting period beginning January&nbsp;1, 2018, including interim
periods within that reporting period, with adoption permitted as early as January 1, 2017. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. We are currently
assessing the impact that this standard will have on our consolidated financial statements. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU
2014-15, <I>Presentation of Financial Statements&#151;Going Concern</I>, which provides guidance on management&#146;s responsibility in evaluating whether there is substantial doubt about a company&#146;s ability to continue as a going concern and
the related footnote disclosure. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company&#146;s ability to continue as a going concern within one year
from the date the financials are issued. When management identifies conditions or events that raise substantial doubt about the entity&#146;s ability to continue as a going concern, this standard also outlines disclosures that are required in our
footnotes based on whether or not there are any plans intended to mitigate the relevant conditions or events to alleviate the substantial doubt. This standard becomes effective for our annual reporting period ending December&nbsp;31, 2016, and for
annual and interim periods thereafter. Early application is permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The JOBS Act </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2012, the JOBS Act
was enacted. Section&nbsp;107 of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the
adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards
on the relevant dates on which adoption of such standards is required for other public companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to take advantage of the
reduced reporting requirements and to rely on certain other exemptions provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an &#147;emerging growth company,&#148; the exemptions that we may rely on include, without
limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being permitted to present only two years of audited financial statements and only two years of related Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations in this prospectus;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may use these provisions until the last day of our fiscal year following the fifth anniversary of the closing of this offering. However, if
certain events occur prior to the end of such five-year period, including if we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
become a &#147;large accelerated filer,&#148; our annual gross revenues exceed $1.0 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to
be an emerging growth company prior to the end of such five-year period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the Six Months Ended June 30, 2014 and 2015 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration revenue was $6.0 million and $9.0 million during the six months ended June 30, 2014 and 2015, respectively, an increase of $3.0
million. A comparison of revenue by collaborator is as follows: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months<BR>Ended&nbsp;June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase<BR>(Decrease)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TESARO-amortization of upfront payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">$2,605</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TESARO-funding of research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TESARO-milestone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Celgene Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the first and fourth quarter of 2014 we received $17.0 million and $2.0 million, respectively,
in upfront fees under our collaboration and exclusive license agreement with TESARO. For the six months ended June&nbsp;30, 2014 and 2015, we recognized the amortized portion of these upfront fees in the amounts of $2.6 million and $5.0 million,
respectively. The upfront fees will continue to be recognized ratably through March 2016. We also recognized revenue of $1.5&nbsp;million and $3.4 million during the six months ended June&nbsp;30, 2014 and 2015, respectively, for research and
development services performed under the agreement. We recognized revenue of $0.6 million during the six months ended June 30, 2015, for the achievement of a $1.0 million milestone upon initiation of <I>in vivo</I> toxicology studies, under the
principles of good laboratory practice, using our anti-PD-1 antagonist antibody (TSR-042) by TESARO. The remaining $0.4 million of the milestone will be recognized ratably through March 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The final deliverable under our 2011 antibody generation agreement with Celgene was completed in 2014. During the six months ended June 30,
2014, we recognized revenue of $0.6 million, which relates to $0.5 million for a success fee and $92,000 for research and development services performed under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to other collaboration agreements for which in the six months ended June 30, 2014 we recognized $1.3 million in collaboration
revenue. We completed our obligations under these agreements in 2014 and do not anticipate any additional revenue from them beyond 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that any collaboration revenue we generate will continue to fluctuate from period to period as a result of the timing and amount of
milestones and other payments from our existing collaborations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $3.9 million during the six months ended June 30, 2014 and $6.4 million for the six months ended June
30, 2015. The increase of $2.5 million is primarily related to a $1.5 million increase in external services and preclinical manufacturing consultation cost relating to our ANB020 and ANB019 programs, a $0.6 million increase in payroll and related
expenses, including stock-based compensation, and a $0.3 million increase in laboratory supplies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase as we advance our development
programs further and, in particular, as we enter into clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $1.2 million during the six months ended June 30, 2014 and $1.6 million for the six months ended June
30, 2015. The $0.4 million increase is due primarily to a $0.2 million increase in audit and tax fees and a $0.1 million increase in recruiting expenses incurred for key senior positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our general and administrative expenses will increase for the foreseeable future as we incur additional costs associated with
being a publicly traded company, including legal, auditing and filing fees, additional insurance premiums, investor relations expenses and general compliance and consulting expenses. Also, we expect our intellectual property related legal expenses,
including those related to preparing, filing, prosecuting and maintaining patent applications, to increase as our intellectual property portfolio expands. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest
expense during the six months ended June 30, 2014 was $1.3 million and represents stated interest of 10.0% on our convertible promissory notes principal of $2.0&nbsp;million and amortization of the related beneficial conversion feature. All
outstanding principal and accrued interest on the convertible promissory notes were converted in April 2014 into shares of Series C-1 preferred stock. Interest expense during the six months ended June&nbsp;30, 2015 was $0.2 million and represents
effective interest of 9.25% on our outstanding Term A Loans, which have an outstanding principal of $5.0 million as of June 30, 2015. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change
in Fair Value of Liabilities for Preferred Stock Warrants </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expense from the change in fair value of the liabilities for
stock warrants increased by $1.1 million during the six months ended June 30, 2015 when compared to the three months ended June 30, 2014, and primarily reflects an increase in the valuation of our Series C convertible preferred stock at June 30,
2015 which had the effect of increasing the estimated fair value of the warrants. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the Years Ended December&nbsp;31, 2013 and 2014
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration revenue was $5.5 million and $15.8 million during 2013 and 2014, respectively, an increase of $10.4 million. Our license and
collaboration agreement with TESARO accounted for the majority of the increase in collaboration revenue during 2014. A comparison of revenue by collaborator is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase<BR>(Decrease)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B></B><B>(in thousands)</B><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TESARO-amortization of upfront payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TESARO-funding of research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Celgene Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2014, we received an aggregate of $19.0 million in upfront fees under our collaboration and exclusive
license agreement with TESARO, which were deferred and are recognized ratably through March 2016. We also recognized revenue of $4.6 million during 2014 for research and development services performed under the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our 2011 antibody generation agreement with Celgene, we recognized revenue of $2.0
million during 2013 from the amortization of the upfront payment received in 2011. We also received $1.0 million and $0.5 million in success fees during 2013 and 2014, respectively, and recognized revenue of $0.7 million and $0.1 million for
research and development services performed under this agreement during the years ended December&nbsp;31, 2013 and 2014, respectively. The final deliverable under this agreement was completed in 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2013 and 2014, we recognized revenues aggregating $1.7 million and $3.7 million, respectively from other collaborative agreements for
which our obligations were completed in 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $8.8 million and $8.6 million during 2013 and 2014, respectively, a decrease of $0.2 million. The
decrease is due primarily to $0.4 million in lower salaries and related expenses resulting from reduced research and development positions, due to the completion of multiple collaborations during 2013 and early 2014, $0.3 million in lower
depreciation expense, and $0.1 million in lower in-licensing fees due to the expiration of one of our contracts. These decreases were partially offset by $0.6 million in higher reimbursable external expense costs incurred under our collaboration
with TESARO. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $2.0 million and $2.4 million during 2013 and 2014, respectively, an increase of $0.4 million. The
increase is due primarily to $0.2 million in recruiting expenses for key senior hires during 2014, $0.1 million in higher salaries and related expenses for new senior level positions, and $0.1 million in higher legal expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense
was $0.9 million during 2013 compared to $1.3 million during 2014, an increase of $0.4 million and represents stated interest of 10.0% on our convertible promissory notes principal of $2.0 million and amortization of the related beneficial
conversion feature. The increase is due primarily to the $0.4 million write-off of the remaining discount on our convertible promissory notes upon conversion of the notes to into shares of Series C-1 Preferred stock during 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Fair Value of Liabilities for Stock Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of the liabilities for stock warrants resulted in an expense of $59,000 in 2014 and income of $0.6 million in 2013.
The change to an expense in 2014 resulted primarily from an increase in the valuation of our Series C convertible preferred stock which has the effect of increasing the estimated fair value of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From
our inception through June 30, 2015, we have received an aggregate of $99.5&nbsp;million to fund our operations including $44.1 million from the sale of equity securities, $46.0&nbsp;million from our collaboration agreements and $9.4 million from
venture debt. As of June 30, 2015, we had $16.9 million in cash and cash equivalents. In July, 2015, we issued an aggregate of 38,436,851 shares of Series D Preferred Stock at a purchase price of $1.06 per share, for aggregate net proceeds of $40.6
million. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our existing cash and cash equivalents, we are eligible to receive research and development funding and to
earn milestone and other contingent payments for the achievement of defined collaboration objectives and certain nonclinical, clinical, regulatory and sales-based events, and royalty payments under our collaboration agreements. Our ability to earn
these milestone and contingent payments and the timing of achieving these milestones is primarily dependent upon the outcome of our collaborators&#146; research and development activities and is uncertain at this time. Our Loan Agreement and our
rights to payments under our collaboration agreements are our only committed external source of funds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Loan Agreement, we may borrow up to $15.0 million in three separate draws of $5.0
million each, of which $5.0 million of the Term A Loans were outstanding at June 30, 2015. The Term B Loans for an aggregate of $5.0 million are available for draw through December&nbsp;31, 2015, contingent upon our first multi-dose PK/toxicology
studies on at least two development programs and the Term C Loans for an aggregate of $5.0 million are available for draw through December&nbsp;31, 2016, contingent upon receiving FDA approval on IND submission on at least two development programs.
Final maturity of the loans pursuant to the Loan Agreement is in January 2019. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary uses of capital are, and we expect will continue to be, third-party clinical and preclinical research and development services,
including manufacturing, laboratory and related supplies, compensation and related expenses, legal, patent and other regulatory expenses and general overhead costs. We believe our use of CROs and CMOs provides us with flexibility in managing our
spending and limits our cost commitments at any point in time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our research and development plans and our timing expectations
related to the progress of our programs, we expect that the net proceeds from this offering, together with our existing cash and cash equivalents, and research funding that we expect to receive under our existing collaborations, will enable us to
fund our operating expenses and capital expenditure requirements through at least the next 24 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally,
the process of testing drug candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash
provided by operating activities during the six months ended June 30, 2014 of $13.4 million was primarily due to cash received pursuant to our collaboration agreement with TESARO that resulted in an increase in deferred revenue of $13.5 million. Net
cash used in operating activities during the six months ended June 30, 2015 of $5.2 million, was primarily due to the use of cash for research and development activities and consisted of $0.4 million of net loss in addition to a reduction of
deferred revenue of $4.6 million related to the amortization of our upfront payment received from TESARO. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating
activities during the year ended December&nbsp;31, 2013 of $5.8 million was primarily due to our net loss for the period. Net cash provided by operating activities of $14.6 million during the year ended December&nbsp;31, 2014 was primarily due to
cash received pursuant to our collaboration agreement with TESARO and consisted of net income of $3.5 million in addition to an increase of $10.7 million in deferred revenues and non-cash interest expense of $1.3 million, partially offset by an
increase in receivables from our collaborative partner of $1.5 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in investing activities during the six months ended June 30, 2014 and 2015 and years ended December&nbsp;31, 2013 and 2014, were due
to our purchases of property and equipment. As of this time, we plan to focus on our growth strategies and do not plan on using a significant amount of our cash resources in investing activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash
provided by financing activities during the six months ended June 30, 2014 and 2015 was zero and $29,000, respectively. The cash proceeds during 2015 are from the exercise of stock options, offset by payments related to deferred offering costs. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities was $2.0 million during the year ended December&nbsp;31,
2013 and represents the net cash proceeds from the issuance of our convertible promissory notes in August 2013. Cash provided by financing activities during the year ended December&nbsp;31, 2014 was $4.9 million and represents the net cash proceeds
from the issuance of our Term A Loans in December 2014.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations as of December&nbsp;31, 2014: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B></B><I>(</I><B>in thousands)</B><I></I><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;Than<BR>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1-3<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3-5<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;Than<BR>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, including interest and final payment fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Future minimum guaranteed payment obligations for annual royalty payments under all collaborative in-license agreements at December&nbsp;31, 2014 aggregated $0.2 million. These obligations are excluded from the table
above as the annual minimum payments are payable through ten years from the first commercial sale, if any, or expiration of the last patent to expire, the dates of which are not determinable at this time. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturing organizations and with
vendors for preclinical studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included in the
table above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and
regulations of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary
exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term duration of our investment portfolio and the low-risk profile of our investments, we would not
expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our investment portfolio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not believe that our cash and cash equivalents have significant risk of default or illiquidity. While we believe our cash and cash
equivalents do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at
one or more financial institutions that are in excess of federally insured limits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our debt obligations bear interest at fixed rates and,
therefore, have no exposure to changes in interest rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Exchange Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2015, we formed a wholly-owned subsidiary in Australia, which exposes us to foreign currency exchange risk. The functional currency of
our subsidiary in Australia is the United States dollar. Assets and liabilities of our foreign subsidiary that are not denominated in the functional currency are remeasured into U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets and capital accounts, which are remeasured at historical foreign currency exchange
rates in effect at the date of transaction. Expenses are generally remeasured at monthly foreign currency exchange rates which approximate average rates in effect during each period. Net realized and unrealized gains and losses from foreign currency
transactions and remeasurement are reported in other income (expense), net, in the consolidated statements of operations. We do not expect the effects of changes in exchange rates to have a material impact on our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not hedged exposures denominated in foreign currencies, but may do so in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company
developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. We develop our product candidates using our proprietary antibody discovery technology platform, which is designed to replicate,
<I>in vitro,</I> the natural process of antibody generation. Our platform is based upon a breakthrough understanding of somatic hypermutation, the key biological process utilized to generate antibodies, which enables us to rapidly develop highly
functional antibody drug candidates against emerging biological targets. Our most advanced, wholly-owned programs, ANB020 and ANB019, are being developed to treat severe inflammatory disorders with unmet medical need. In 2016, we plan to initiate
clinical trials of ANB020, an antibody that inhibits the activity of interleukin-33 for the treatment of severe adult asthma and severe adult peanut allergy, and ANB019, an antibody that inhibits the interleukin-36 receptor for the treatment of rare
inflammatory diseases called generalized pustular psoriasis and palmo-plantar pustular psoriasis. Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in
antibody discovery and development, collaborations, operations and corporate finance. Our investors include Biotechnology Value Fund, Cormorant Asset Management, Frazier Healthcare, HBM Partners, Longwood Capital Partners and Novo A/S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we have entered into multiple collaborations from which we expect four programs will enter the clinic in the next 18 months. Our
collaborations include an immuno-oncology-focused collaboration with TESARO and an inflammation-focused collaboration with Celgene. Through July 31, 2015, we have received significant, non-dilutive funding of $48.7 million from our collaborators.
</P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
developed, and will continue to develop, antibody product candidates that leverage emerging insights into biological mechanisms to treat severe diseases with unmet medical need. The following table summarizes certain key information about our
wholly-owned and partnered product candidates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g07x01.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced, wholly-owned product candidates are summarized below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>ANB020</B> is an antibody that inhibits the activity of interleukin-33, or IL-33, a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases, including asthma, food
allergies and atopic dermatitis. IL-33 acts on several cell types, including white blood cells that initiate and orchestrate atopic responses. IL-33 also directly mediates release of disease-associated cytokines, which recruit pro-inflammatory cells
that mediate atopic disease. Because ANB020 inhibits IL-33 function, and acts upstream broadly across the key cell types and cytokines involved in atopy, we believe that its mechanism has advantages in the treatment of atopic diseases over competing
agents that block only a subset of the cytokines responsible for atopic diseases. We believe ANB020 is potentially the first-in-class therapy targeting IL-33. We anticipate filing an Australian Clinical Trial Notification, or CTN, for ANB020 during
the fourth quarter of 2015, the approval of which would allow us to commence clinical trials in Australia. We plan to commence a Phase&nbsp;1 healthy volunteer trial in Australia in early 2016, followed by patient trials in severe adult asthma and
severe adult peanut allergy in other countries, including the United States after submitting an IND to the FDA. We estimate, based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders in the
field, that asthma affects approximately 7.7% of the adult U.S. population, or approximately 19.0 million individuals, of which 19%, or approximately 3.6 million have severe, persistent occurrence of this respiratory disease. Peanut allergy is the
most common cause of <FONT STYLE="white-space:nowrap">food-induced</FONT> allergy in the United States. Based on our analysis, we estimate approximately 1.7 million adults are affected by peanut allergy, of which approximately 600,000 are regularly
treated by allergists and approximately 400,000 are at risk for severe reactions and therefore we believe are suitable for treatment with systemic biological therapies. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>ANB019</B> is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which we are initially developing as a potential first-in-class therapy for GPP patients. GPP is a life-threatening,
rare, systemic inflammatory disorder that, based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders in the field, we estimate affects approximately 3,000 patients in the United States with no
approved therapies. Studies have shown that GPP is associated with mutations, that lead to abnormally high signaling through the IL-36R, which we believe can be addressed by treatment with ANB019. We believe ANB019 is the most advanced therapeutic
antibody targeting the IL-36R in development. We anticipate filing an Australian CTN for ANB019 during the second half of 2016, the approval of which would allow us to initiate Phase&nbsp;1 trials in Australia during the second half of 2016. We plan
to subsequently develop ANB019 in the United States after submitting an IND to the FDA and to seek FDA Orphan Drug Designation for the treatment of GPP and PPP. The FDA may grant Orphan Drug Designation to a drug intended to treat a disease or
condition that generally affects fewer than 200,000 individuals in the United States. </TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our SHM-XEL Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our approach to developing novel therapeutic antibody product candidates relies upon somatic hypermutation, or SHM, a critical, endogenous
process that generates the essential antibody diversity required to develop a natural immune response to pathogens. Our proprietary antibody generation platform, called <FONT STYLE="white-space:nowrap">SHM-XEL,</FONT> is designed to replicate the
natural process of SHM <I>in vitro. </I>Competing antibody discovery technologies include mouse immunization methodologies, microbial antibody display and human B-cell screening. We believe <FONT STYLE="white-space:nowrap">SHM-XEL</FONT> overcomes
several key limitations associated with these competing technologies and has the following competitive advantages: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Diversity against difficult targets.</B> By applying SHM without the constraints of an <I>in vivo</I> environment we are able to generate an unprecedented diversity of antibodies. This enables us to develop
antibodies against human targets that we believe have not otherwise been accessible to other technologies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>High potency.</B> Because our platform generates highly-potent antibodies, we are potentially able to modulate every extracellular target associated with human disease, and believe only small therapeutic doses may be
required to mediate therapeutic effect <I>in vivo</I>. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Functional activity selection.</B> Our mammalian cell system simultaneously displays and secretes antibodies during the antibody discovery process, allowing us to incorporate functional assays throughout the process
and focus on producing product candidates that are optimized for the desired therapeutic activity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Speed.</B> Our platform technology enables us to generate therapeutic-grade antibodies and initiate subsequent preclinical manufacturing and toxicology studies, typically in less than 12 months. We believe this
timeline is significantly shorter than conventional approaches based upon mouse immunization and microbial display systems. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Manufacturability.</B> By utilizing our mammalian cell display system, we believe our approach increases the probability of success in manufacturing and commercialization by mitigating risks associated with antibody
expression, formulation and stability during the antibody generation process. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Bispecific antibodies.</B> A bispecific antibody is a single therapeutic molecule designed to bind two different targets. Bispecific antibodies have the advantage of combining two therapeutic mechanisms with the goal
of increasing therapeutic efficacy, in comparison to monospecific antibodies that bind either of the targets individually. We believe our competitors&#146; bispecific strategies generally rely on proteins with non-natural formats, resulting in
unpredictable pharmacokinetics and manufacturing properties. Our strategy is to develop bispecific antibodies that are composed of two different heavy chains with a common shared light chain that resemble the natural antibody structure and exhibit
the desired functional activity to each target. Utilizing our proprietary SHM-XEL platform, we are able to generate a large diversity of heavy and light chain varieties against each therapeutic target, and then co-mature a common light chain in the
context of two different heavy chains, which permits us to identify bispecific antibodies with sufficient potency against each of the two targets that we believe will provide greater therapeutic benefit. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a leading
antibody development company with a pipeline of novel therapeutic antibodies, which is being further expanded by applying our technology platform to emerging biological targets. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Advancing our lead product candidates into the clinic. </B>We plan to initiate a Phase 1 healthy volunteer trial for ANB020 in early 2016, followed by trials in severe adult asthma and severe adult peanut allergy
patients. We plan to initiate a Phase 1 healthy volunteer trial for ANB019 during the second half of 2016, followed by a registration study in GPP patients. For both ANB020 and ANB019, we plan to conduct our initial clinical trials in Australia, and
to then conduct further clinical development in the United States and other countries. We have elected to pursue this strategy in order to benefit from Australia&#146;s rapid regulatory review processes for first-in-human studies and from certain
financial incentives that Australia makes available for biotechnology research and development, and because we believe that clinical data generated in Australia will subsequently be accepted by the FDA and its foreign equivalents outside of
Australia. </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Identifying emerging opportunities in key therapeutic areas.</B> We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation and immuno-oncology by understanding
and translating biological breakthroughs into first-in-class therapeutic antibodies. Our approach includes assessment of human genetics and tissue pathology to understand the relevance of emerging targets to patients with unmet medical needs. We
plan to leverage this knowledge to create new product candidates and position our current and future programs for rapid clinical proof-of-concept achievement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Continuing to expand our proprietary pipeline by generating new product candidates using our technology platform. </B>Using our proprietary antibody generation platform, we are able to rapidly develop novel
therapeutic antibodies against emerging targets. Our goal is to advance one or more wholly-owned new therapeutic antibody program to an IND submission to the FDA, or foreign equivalent, each year. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Retaining rights to strategic products in key commercial markets. </B>We intend to retain ownership and control of our pipeline programs to key inflection points. We may build sales and marketing capabilities in
selected specialty markets that we believe can be served with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing resources to advance through
development and commercialization. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Collaborations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established collaborations with pharmaceutical and biotechnology companies that have provided us with $48.7 million in payments through
July 31, 2015. In addition to our wholly-owned antibody programs, we are developing antibody product candidates for immuno-oncology and inflammation targets through strategic collaborations. Our collaborations with TESARO and Celgene are described
below: </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TESARO Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our March 2014 immuno-oncology collaboration with TESARO, we have granted exclusive rights to TESARO to develop and commercialize
antibodies generated using our SHM-XEL platform consisting of the following antibody product candidates: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-PD-1 Monospecific Antagonist Antibody (TSR-042)</I>: currently in preclinical development with an IND submission anticipated in the fourth quarter of 2015 and first-in-human dosing in early 2016;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-TIM-3 Monospecific Antagonist Antibody</I>: currently in preclinical development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-LAG-3 Monospecific Antagonist Antibody</I>: currently in preclinical development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-PD-1/TIM-3 Bispecific Antagonist Antibody</I>: currently in lead selection process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Anti-PD-1/LAG-3 Bispecific Antagonist Antibody</I>: currently in lead selection process; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Undisclosed Bispecific Antagonist Antibody</I>: currently in lead selection process. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Celgene
Programs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our December 2011 collaboration with Celgene, we developed therapeutic antibodies against multiple targets. We
granted Celgene the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain
pre-specified parameters pertaining to each target under collaboration. We successfully delivered antibodies against three targets. Celgene is currently advancing two anti-inflammatory antibody programs to the clinic. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Wholly-Owned Product Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most
advanced, wholly-owned pipeline programs, ANB020 and ANB019, are described below: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ANB020: Anti-IL-33 Antibody </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANB020 is an antibody that inhibits the activity of IL-33 and is being developed to treat atopic diseases, including severe adult asthma and
severe adult peanut allergy. Despite the key role of IL-33 in atopic diseases, it has been historically difficult for other antibody technologies to generate a functional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-33</FONT></FONT> therapeutic agent. We believe ANB020 is the most advanced antibody therapeutic candidate in development targeting the
<FONT STYLE="white-space:nowrap">IL-33</FONT> cytokine. We anticipate filing an Australian CTN for ANB020 by the fourth quarter of 2015 and plan to commence a Phase 1 trial in Australia in early 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IL-33 Target Biology </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IL-33 is a
pro-inflammatory cytokine that signals through the ST2 receptor, which multiple studies suggest serves as a central mediator of various immune responses leading to Th2-type inflammatory disorders, including asthma, food allergies, atopic dermatitis
and other atopic diseases. In response to pathogens, viruses, toxins or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
allergens, IL-33 is rapidly released from mucosal epithelial and endothelial cells. For example, a recent scientific study has indicated that individuals with asthma symptoms express higher
levels of IL-33 than healthy control subjects. IL-33 initiates a diverse array of cellular immune responses, including the activation of mast cells, basophils and eosinophils, leading to production of downstream cytokines, such as <FONT
STYLE="white-space:nowrap">IL-4,</FONT> IL-5 and IL-13, associated with atopic diseases. IL-33 also acts on T helper 2, or Th2, effector cells and Innate Lymphoid Cell Type 2, or ILC2, two types of white blood cells that initiate and orchestrate
atopic responses. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because ANB020 inhibits IL-33 function and acts upstream of key cell types involved in atopy and the subsequent
release of Th2 cytokines, we believe that its mechanism has advantages over that of competing therapeutic antibodies which block only a subset of IL-4, IL-5 or IL-13 cytokines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genetic studies support the importance of the IL-33 pathway in atopic diseases. These studies have demonstrated that certain ST2 mutations
reduce IL-33 mediated signaling and thereby protect individuals with mutated ST2 from asthma. This supports the hypothesis that an anti-IL-33 antibody, such as ANB020, has the potential to benefit asthma patients. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g24a08.jpg" ALT="LOGO">
 </P>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>Figure 1. Types of cells and cytokines modulated by IL-33. When triggered by pathogens, toxins, viruses or allergens, IL-33 is an upstream mediator of Th2
cells, mast cells, basophils, eosinophils and ILC2 cells, which lead to the secretion of IL-4, IL-5, IL-13 and other chemokines. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g14k10.jpg" ALT="LOGO">
 </P>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>Figure&nbsp;2. IL-33 intracellular signaling. IL-33 binds to ST2 that is expressed on the cell surface and triggers the activation of the IL-1 receptor
accessory protein, or IL-1RAP, leading to the activation of MYD88, IRAK4 and downstream kinases and inducing cytokine release. Soluble ST2 acts as a decoy receptor, inhibiting IL-33 before it engages ST2 on the cell surface. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that targeting IL-33 activity is a more promising therapeutic intervention strategy
than targeting its receptor, ST2, because (i)&nbsp;ST2 is present in significantly larger quantities, in comparison to IL-33, which will likely require high anti-ST2 antibody dosing levels and (ii)&nbsp;soluble ST2 inhibits IL-33 function, therefore
blocking ST2, and likely leading to the release of additional IL-33, thereby exacerbating atopic disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ANB020 Description </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANB020, which is potentially a first-in-class therapeutic antibody, is our wholly-owned anti-IL-33 antibody product candidate generated using
our SHM-XEL technology platform. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preclinical studies have provided evidence of ANB020&#146;s favorable potency and functional
activity in human and cynomolgus monkey <I>in vitro</I> assays. The high potency and functional activity of ANB020 for human and cynomolgus monkey <FONT STYLE="white-space:nowrap">IL-33</FONT> was measured using standard <I>in vitro </I>assays:
equilibrium dissociation constant, or K<SUB STYLE="font-size:85%; vertical-align:bottom">D</SUB>, and half-maximal inhibitory concentration values, or IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB>. ANB020 demonstrated highly potent K<SUB
STYLE="font-size:85%; vertical-align:bottom">D</SUB> values of approximately 1 pM and 37 pM for human and cynomolgus monkey <FONT STYLE="white-space:nowrap">IL-33,</FONT> respectively. ANB020 inhibits secretion of IL-5 from primary basophils
purified from peripheral blood of healthy subjects with an IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> of approximately 1.5 nM, which is approximately 15-fold greater than that of the soluble ST2 antagonist, as shown in Figure 3
below. Lower K<SUB STYLE="font-size:85%; vertical-align:bottom">D</SUB> and IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> values indicate higher potency and functional activity, respectively. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g95u36.jpg" ALT="LOGO">
 </P>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>Figure 3. Results from Anaptys </B><B><I>in vitro</I></B><B> assay comparing effectiveness of ANB020 and soluble ST2 in inhibiting IL-5 release. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using peripheral blood mononuclear cells, or PBMC, ANB020 inhibited human and cynomolgus
monkey interferon-gamma release with an IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> of approximately 1.1&nbsp;nM and approximately 20.4&nbsp;nM, respectively as shown in Figure&nbsp;4 below. We have developed a whole blood version
of the PBMC assay, which we plan to utilize to understand the pharmacodynamic activity of ANB020 in clinical trials. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g85n14.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>Figure
4. Activity read out of interferon-gamma release for PBMCs pretreated overnight with 100mg/ml IL-12, challenged with ten (human) or five (cynomolgus) nM IL-33 for 48 hours. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preclinical development has also demonstrated that ANB020 has favorable manufacturability, pharmacokinetics and toxicology to support
development. Studies have demonstrated desirable manufacturing properties for ANB020, including robust expression from Chinese hamster ovary cells, or CHO cells, efficient purification using standard downstream techniques and stable formulation up
to concentrations required for subcutaneous dosing in humans. ANB020 demonstrated a half-life of approximately seven days in cynomolgus monkeys, retained full functional activity when incubated in normal human serum at 37 &deg;C for one week and
proved to be fully active in cynomolgus monkey sera two weeks after dosing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to submit a CTN filing for ANB020 in the fourth quarter of 2015 to obtain approval for initial clinical testing of ANB020 in Australia.
Conducting early clinical trials in Australia permits us to benefit from Australia&#146;s rapid regulatory review processes for first-in-human studies. We subsequently plan to initiate a healthy volunteer Phase&nbsp;1 trial, intended to assess, in
single and multiple ascending doses, safety, tolerability and pharmacokinetic characteristics of ANB020. We will concurrently utilize a whole blood <I>ex vivo</I> assay to identify its pharmacodynamic activity range. These tests are also expected to
take place in Australia, and following completion of these tests we plan to submit a U.S. IND and conduct further clinical trials in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once pharmacodynamic activity has been established in healthy volunteers, we plan to test the clinical activity of ANB020 in atopic dermatitis
patients challenged with an allergen, after dosing with ANB020 or placebo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After submitting a U.S. IND, we plan to test ANB020 in Phase 2
trials in patients with severe adult asthma and severe adult peanut allergy. Upon demonstrating proof-of-concept in Phase 2 trials, we intend to conduct Phase 3 registration trials for ANB020 in these indications. These later-stage trials may be
conducted through collaboration with a leading pharmaceutical company with strong commercial infrastructure in respiratory and allergic therapeutic areas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are exploring the potential to develop ANB020 as a treatment for myeloproliferative neoplasms where the survival, expansion or
transformation of pathogenic precursor cells may be dependent upon IL-33. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Figure 5 below describes our current anticipated clinical development strategy for ANB020 and
our current estimate of the approximate timeframe in which our anticipated development activities will occur. However, as described in the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus, the clinical development of drug
product candidates is subject to a wide range of risks and uncertainties, any of which could cause our actual development strategy or timeframes to vary from the description in the figure below. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g65f78.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>Figure
5. Anticipated ANB020 clinical development strategy. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above, we plan to pursue a clinical development strategy that
involves conducting our initial clinical trials in Australia. We have elected to pursue this strategy in order to benefit from Australia&#146;s rapid regulatory review processes for first-in-human studies and from certain financial incentives that
Australia makes available for biotechnology research and development. In addition, we believe that clinical data generated in Australia will subsequently be accepted by the FDA and its foreign equivalents outside of Australia, and therefore may
enable us to commence Phase 2 clinical trials in the United States immediately following submission of an IND, without any need for us to repeat our Phase 1 trial in the United States. However, the FDA is not required to accept Phase 1 data
generated in Australia, and our ability to use the Phase 1 data generated in our Australian clinical trials to avoid the need to repeat Phase 1 clinical trials in the United States will depend on the results of our Australian clinical trials and the
outcome of subsequent discussions with the FDA. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ANB020 Market Opportunity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A significant portion of individuals in the U.S. population experiences at least one atopic disease during their lifetime, and it is well
understood that most patients with one type of atopic condition tend to present with other allergic conditions. While we believe ANB020 may be effective across atopic diseases, we have prioritized our development efforts based on unmet medical need
and potential market opportunity. We have chosen to focus our ANB020 program initially on two indications: severe adult asthma and severe adult peanut allergy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Asthma.</I> We estimate, based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders in the field, that
asthma affects approximately 7.7% of the adult U.S. population, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
19.0&nbsp;million individuals, of which 19%, or 3.6&nbsp;million individuals, have severe, persistent occurrence of this respiratory disease. As a chronic inflammatory disorder, severe asthma can
lead to permanent structural damage to the airways and long-term reductions in lung function. Although many mild-to-moderate asthmatics respond well to currently available treatments, which include inhaled corticosteroids, or ICS, and long-acting
beta agonists, or LABA, severe asthma in patients is generally not adequately controlled by such available therapies. We will initially focus on the treatment of severe asthma that, based on our analysis, includes 1.1 million adult patients whose
disease is not sufficiently controlled through standard-of-care therapy. We have conducted primary market studies that estimate approximately 45% of these patients are candidates for biologic therapies, such as ANB020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Existing biologic therapies include Xolair, which is approved for the treatment of moderate to severe persistent allergic asthma patients
whose asthma symptoms are not controlled by ICS. Xolair&#146;s approved labeling carries a black box warning about the risk of anaphylaxis, a severe, potentially fatal, allergic reaction. Other emerging therapies currently in development, such as
lebrikizumab, have yet to be approved by the FDA for treatment of asthma while a federal Advisory Committee has recently recommended that the FDA approve mepolizumab for add-on maintenance treatment in patients aged 18 years or older with severe
eosinophilic asthma. Xolair is a difficult drug to prescribe due to complex dosing algorithms, frequent administration and risk of anaphylaxis, and we expect the indications for mepolizumab and lebrikizumab will be limited to subsets of the asthma
market defined by biomarkers. Because we do not currently intend to use biomarkers as inclusion criteria for our pivotal trials for ANB020, we anticipate that ANB020 will have significant market potential in the treatment of severe adult asthma
patients, without biomarker restrictions, who are refractory to ICS. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Peanut Allergy.</I> Peanuts are the most common cause of food-induced allergy
in the United States. We estimate, based on our analysis of publicly available data sources and interviews with physicians and key opinion leaders in the field, that approximately 1.7 million adults in the United States have allergic responses to
peanut. We estimate approximately 600,000 are treated by allergists and approximately 400,000 are at risk for severe reactions and therefore we believe are suitable for treatment with systemic biological therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Existing therapies have failed to prevent the occurrence of severe reactions due to accidental peanut exposure, which often results in
systemic anaphylaxis and can lead to death. Immunotherapy approaches, such as oral desensitization, currently being developed for this indication require patients to be dosed with increasing quantities of peanut antigens over time. If patients are
able to overcome the toxicities of this allergen-based approach, therapeutic benefit may be observed after 12-24 months of oral or skin patch based delivery of peanut allergens. The long-term safety and efficacy of immunotherapy is still uncertain,
and these desensitization treatments have not yet been approved by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANB020 has the potential to rapidly suppress severe adult
peanut allergy through its cytokine targeting mechanism, which is allergen non-specific, allowing patients with multiple allergic responses to benefit from a single therapy, and avoids tolerability issues by acting without allergen dosing. If
approved, we anticipate that ANB020 could become the standard-of-care for the treatment of severe adult peanut allergy patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANB019: Anti-IL-36R
Antibody </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANB019
is an antibody that inhibits the function of IL-36R, which we are initially developing as a potential first-in-class therapy for GPP patients. GPP is a life-threatening, rare systemic inflammatory disorder reported to affect approximately 3,000
patients in the United States alone, with no currently approved therapies. Studies have shown that GPP is associated with mutations in the gene encoding the <FONT STYLE="white-space:nowrap">IL-36R</FONT> antagonist, or IL-36RA, that lead to
abnormally high signaling through the IL-36R and thereby cause the systemic inflammatory condition, GPP. We believe ANB019 is the most advanced antibody targeting the IL-36R in development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate filing an Australian CTN for ANB019 during the second half of 2016 and initiating a Phase 1 trial in Australia during the second
half of 2016. We also plan to develop ANB019 for other IL-36R driven inflammatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions, including PPP, which is reported to affect approximately 150,000 patients in the United States. We plan to seek FDA Orphan Drug Designation for ANB019 for the treatment of GPP and
PPP, which we believe may be differentiated from the non-rare plaque psoriasis, or psoriasis vulgaris, based upon distinctive genetic and translational features unique to GPP and/or PPP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IL-36R Target Biology </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The IL-36
subfamily of proteins consists of the IL-36 receptor antagonist, or IL-36RA, as well as IL-36 alpha, IL-36 beta and IL-36 gamma, all of which have agonistic characteristics and signal through IL-36R. These IL-36 proteins are mainly expressed in
keratinocytes, the predominant cell type in the epidermis. The role of the <FONT STYLE="white-space:nowrap">IL-36RA</FONT> is to dampen the inflammatory effects of IL-36 alpha, IL-36 beta and IL-36 gamma. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g92a42.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>Figure
6. IL-36 Receptor Signaling. Signaling is maintained in balance by the receptor antagonist. Mutations render the receptor antagonist dysfunctional and lead to uncontrolled signaling GPP. PPP is caused by excess cytokine signaling that overcomes a
normal receptor antagonist. </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Studies have demonstrated the relevance of IL-36 in regulating inflammation in the skin. Mice
over-expressing the IL-36 alpha cytokine undergo a psoriasis-like condition when challenged with an inflammatory stimulus. Additionally, immuno-deficient mice transplanted with human psoriatic skin have been shown to require the IL-36R signaling to
maintain disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent human studies have demonstrated that mutations in the <FONT STYLE="white-space:nowrap">IL-36RA</FONT> lead to
the occurrence of GPP by rendering it non-functional and unable to dampen IL-36R signaling<I>.</I> These findings support our hypothesis that IL-36 signaling plays a significant role in GPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that ANB019 has the potential to be the first-in-class therapeutic antibody targeting IL-36R, serving as a therapeutic opportunity
for patients with IL-36 signaling mediated inflammatory disease, including GPP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ANB019 Description </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANB019 was generated using our SHM-XEL technology platform and has demonstrated high functional potency in blocking human and cynomolgus monkey
IL-36 signaling in preclinical studies. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANB019 blocks signal transduction through the human
<FONT STYLE="white-space:nowrap">IL-36R</FONT> and cynomolgus monkey IL-36R by inhibiting the interaction between the receptor and IL-36 alpha, IL-36 beta, and IL-36 gamma cytokines. The high potency and functional activity of ANB019 for human and
cynomolgus monkey <FONT STYLE="white-space:nowrap">IL-36R</FONT> was measured using standard <I>in vitro </I>assays to determine K<SUB STYLE="font-size:85%; vertical-align:bottom">D</SUB>, and IC<SUB STYLE="font-size:85%; vertical-align:bottom">50
</SUB>values. ANB019 has demonstrated potent K<SUB STYLE="font-size:85%; vertical-align:bottom">D</SUB> values of approximately of 71 pM and 209 pM for human <FONT STYLE="white-space:nowrap">IL-36R</FONT> and cynomolgus monkey IL-36R, respectively.
The antibody exhibits high specificity for IL-36R, displaying no detectable binding to related proteins. As shown in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Figure 7 below, functional potency of ANB019 is at least 100-fold greater than IL-36RA in both human and cynomolgus systems, which is measured as the IC<SUB
STYLE="font-size:85%; vertical-align:bottom">50 </SUB>of inhibition of interleukin-8, or <FONT STYLE="white-space:nowrap">IL-8,</FONT> release from human and cynomolgus keratinocytes. ANB019 functional activity has been demonstrated through
inhibition of IL-8 secretion from human and cynomolgus primary keratinocytes when stimulated by IL-36 gamma of approximately 0.15 nM and 1.2 nM, respectively. Lower K<SUB STYLE="font-size:85%; vertical-align:bottom">D</SUB> and IC<SUB
STYLE="font-size:85%; vertical-align:bottom">50</SUB> values indicate higher potency and functional activity, respectively. Similar IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> values were observed in those same preclinical studies
when keratinocytes were stimulated with IL-36 alpha or beta. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g58e15.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>Figure
7. ANB019 demonstrated functional inhibition in our preclinical studies and inhibited functional activity of IL-36 cytokines with at least 100-fold greater potency than IL-36RA. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have initiated manufacturing, pharmacokinetic and safety studies with ANB019, and plan to initiate clinical development during the second
half of 2016. To date, we have demonstrated that the half-life of ANB019 in cynomolgus monkeys is more than nine days. ANB019 is well-expressed from CHO mammalian cells and is readily purified using standard methodologies. In addition, the antibody
retained full functional activity when incubated in normal human serum at 37 &deg;C for one week. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to initiate clinical development of ANB019 in Australia with a healthy volunteer, Phase 1 dose escalation trial involving single and
multiple ascending dose protocols, while also utilizing <I>ex vivo</I> assays to determine the antibody&#146;s pharmacodynamic activity range. Following completion of this initial Phase 1 trial, we plan to conduct further clinical testing in the
United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our initial clinical testing of ANB019 will focus primarily on GPP patients. We currently plan to conduct a registration
program in the United States with ANB019 in GPP patients who have mutations that render their IL-36RA dysfunctional, starting with an initial signal study with five to ten patients. Based on the therapeutic effect we anticipate ANB019 will have in
the treatment of patients with GPP who have the relevant genetic defect, we believe a small trial, potentially with fewer than 100 patients, may be sufficient to demonstrate substantial evidence of efficacy and safety.&nbsp;We intend to obtain input
from FDA on clinical trial design before conducting a pivotal clinical trial in patients with GPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the aforementioned GPP
registration study has been initiated, we intend to develop ANB019 for PPP. We anticipate a dose-ranging Phase 2 trial for PPP with United States and foreign testing sites, followed by one or more Phase 3 pivotal registration trials. If we use a
diagnostic test to select patients for inclusion in our registration program, such as a genetic test for <FONT STYLE="white-space:nowrap">IL-36RA</FONT> mutations, the FDA may require that the companion diagnostic be approved or cleared for use at
the time the product receives marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human studies have shown that IL-36 cytokines are highly upregulated in psoriasis
vulgaris, in conjunction with some upregulation of other inflammatory cytokines such as TNF-alpha, IL-17A, IL-6 and IL-12. Therefore, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we may, as part of our initial clinical testing of ANB019, conduct a proof-of-mechanism clinical trial with psoriasis vulgaris patients who are not currently on any biological therapies. In
addition, we may also consider clinical development of ANB019 for patients with psoriasis vulgaris that have failed treatment with the current standard of care, including Stelara (ustekinumab) and Cosentyx (secukinumab). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Figure 8 below describes our current anticipated clinical development strategy for ANB019 and our current estimate of the approximate
timeframe in which our anticipated development activities will occur. However, as described in the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus, the clinical development of drug product candidates is subject to a wide
range of risks and uncertainties, any of which could cause our actual development strategy or timeframes to vary from the description in the figure below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g35u60.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>Figure
8. Anticipated ANB019 clinical development strategy. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above, we plan to pursue a clinical development strategy that
involves conducting our initial clinical trials in Australia. We have elected to pursue this strategy in order to benefit from Australia&#146;s rapid regulatory review processes for first-in-human studies and from certain financial incentives that
Australia makes available for biotechnology research and development. In addition, we believe that clinical data generated in Australia will subsequently be accepted by the FDA and its foreign equivalents outside of Australia, and therefore may
enable us to commence Phase 2 and possibly registration clinical trials in the United States immediately following submission of an IND, without any need for us to repeat our Phase 1 trial in the United States. However, the FDA is not required to
accept Phase 1 data generated in Australia, and our ability to use the Phase 1 data generated in our Australian clinical trials to avoid the need to repeat Phase 1 clinical trials in the United States will depend on the results of our Australian
clinical trials and the outcome of subsequent discussions with the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ANB019 Market Opportunity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IL-36R cytokine dysfunction is implicated in multiple inflammatory disorders including GPP, PPP, and potentially in severe, refractory cases of
psoriasis vulgaris. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Generalized Pustular Psoraisis. </I>GPP is a chronic, life-threatening, rare disease with no currently approved therapies. GPP is
a systemic inflammatory disease characterized by the development of widespread pustules marked by idiopathic exacerbations. In severe cases, GPP patients can die from cardio-pulmonary failure, exhaustion, toxicity and/or infection subsequent to
occurrences of pustular flares. Patients with GPP suffer without robust therapeutic options because currently approved psoriasis management therapies have not demonstrated clear efficacy in the treatment of this condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through assessment of public literature and primary key opinion leader discussions, we estimate GPP affects approximately 3,000 individuals in
the United States. We have conducted, and will continue to conduct, genotyping studies to identify GPP patients for potential enrollment in our upcoming clinical trials in this indication. Given the limited size of this patient population in the
United States, we plan to seek Orphan Drug Designation from the FDA for ANB019 for the treatment of GPP.&nbsp;The FDA may grant Orphan Drug Designation to a product intended to treat a rare disease or condition&#151;generally one that affects fewer
than 200,000 individuals in the United States.&nbsp;If we obtain Orphan Drug Designation for ANB019 for the treatment of GPP and subsequently are the first BLA applicant to receive FDA approval for a product containing the same active molecular
structure as ANB019, ANB019 would be entitled to a seven-year exclusive marketing period in the United States for the treatment of GPP.&nbsp;Although the GPP patient population is small, we believe there is an unmet medical need that ANB019 may be
able to address. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Palmo-plantar Pustular Psoriasis. </I>PPP is a non-fatal form of pustular psoriasis that we estimate affects approximately 2% of
total psoriasis cases, approximately 150,000 patients in the United States alone. Patients experience a chronic occurrence of sterile pustules on their hands and feet, while systemic levels of IL-36 cytokines and other inflammatory disease
biomarkers are also elevated. Patients with severe symptoms may have significant pain and be unable to stand, walk or do manual work, resulting in greatly diminished quality of life. Existing anti-inflammatory therapeutic options to our knowledge
have not proven to be consistently effective in treating PPP. As we believe the PPP patient population to be less than 200,000 individuals in the United States, we plan to seek Orphan Drug Designation from the FDA for ANB019 in this indication as
well. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Refractory Psoriasis Vulgaris.</I> Refractory psoriasis vulgaris is another potential market opportunity for the development of ANB019. While
the approved biologics that target these three cytokine pathways, including Stelara (ustekinumab) and Cosentyx (secukinumab), are effective for the majority of psoriasis vulgaris patients, a subset of the population is refractory to approved
biologics. For purposes of developing an estimate, we have defined the refractory population as the subset of the patient population that does not have at least a 75% response to the leading approved therapy, which is Cosentyx. Based on this
definition and our analysis publicly-available information and literature, we estimate that approximately 5% of the patient population, representing approximately 375,000 patients, is refractory to the leading approved therapy for psoriasis
vulgaris. We hypothesize that IL-36 cytokine function is the key inflammatory driver in such refractory patients, and therefore these patients may benefit from ANB019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discovery-Stage Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy
includes the discovery and development of therapeutic antibodies targeting emerging opportunities in inflammation and immuno-oncology. In addition to the programs described above, we are currently developing wholly-owned (i)&nbsp;anti-inflammatory
antibodies that agonize checkpoint receptors to suppress T cell function and (ii)&nbsp;potentially first-in-class immuno-oncology antibodies against checkpoint receptors that are primarily expressed in distal stages of T cell activation. Each of
these programs is in lead selection stages and we anticipate moving at least one new product to IND-enabling manufacturing and preclinical studies during 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our SHM-XEL Antibody Discovery Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Antibody Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Antibodies are
complex proteins naturally generated by the immune system to neutralize foreign pathogens such as bacteria or viruses. B cells, a white blood cell type responsible for the generation of antibodies in response to pathogens, secrete billions of
antibodies with different specificities into the bloodstream. Antibodies are structurally distinct Y-shaped proteins formed through the combination of two long proteins, called heavy chains, and two short proteins, called light chains. Each heavy
and light chain pair forms a binding site where the antibody specifically binds its target, otherwise known as an antigen, at the Fab domain of the antibody molecule. The specificity of each antibody to a target, and the potency of its binding
strength to that target are defined by the amino acid sequences of heavy and light chains in the Fab domain of the antibody molecule. The other end of the antibody, called the Fc domain, is responsible for communication between the antibody and the
rest of the immune system. Fc domains bind to various receptors and cause immune system effector responses. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g71b55.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Figure 9. Antibody structure. Antibodies are composed of two heavy and light chains paired into a Y-shaped formation. Antigen binding occurs at the antigen
binding site, formed by the heavy and light chain Fab domains, while the Fc domain of the heavy chains form the effector end of the antibody. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therapeutic antibodies are typically non-naturally occurring, or recombinant, antibodies specifically developed to treat human diseases by
binding to certain proteins, and thereby modulating key biological processes. Therapeutic antibodies are injectable products that are typically dosed subcutaneously or intravenously, unlike synthetic chemistry-based &#147;small molecule&#148;
therapeutics that may also be administered orally. Therapeutic antibodies have the following key features that we believe make them more predictable than small molecules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Target Specificity.</B> Due to the large size and complex nature of the antibody Fab domain, antibodies generally bind with high specificity to the desired therapeutic target and tend to exhibit less off-target
binding to unrelated proteins, which lowers the risk of unintended biological side effects such as toxicity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Pharmacokinetics and Dosing Frequency</B>. As complex proteins, antibodies are metabolized and distributed differently than small molecules. Full length antibodies tend to exhibit serum half-lives of seven to 24 days
in humans, leading to bi-weekly or monthly dosing as typical practice for therapeutic antibodies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Potency and Dose Quantities.</B> Antibodies are typically highly potent in binding to their desired target, with binding dissociation constants in the low nanomolar to picomolar range. Hence, antibodies tend to be
dosed at low amounts (less than 1 gram quantities per course of therapy). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that therapeutic antibodies can be
significantly de-risked pre-clinically for specificity, toxicology and pharmacokinetics, which is not generally true for small molecule drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the first therapeutic antibody was approved by the FDA in 1986, the pharmaceutical industry has sought opportunities to leverage
antibodies as therapeutic agents to treat human disease. Global sales of therapeutic antibodies have reached over $40 billion annually and are predicted to remain a fast-growing segment of the therapeutic market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations of Competing Antibody Technologies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the promise of antibodies as a therapeutic modality, historically it has been difficult and time-consuming to generate
therapeutic-grade antibodies utilizing competing antibody discovery technologies. Such technologies have relied primarily on mouse immunization methodologies (such as wild-type or engineered mice), microbial antibody display libraries (such as phage
or yeast cell display) or human B cell screening to generate antibodies against therapeutic targets of interest. We believe the key limitations of these competitive approaches include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Insufficient Diversity</B>. Each of the prior technologies has limited, and often static, diversity of antibodies available for selection. The number of therapeutic targets that can be addressed by the available
antibodies is therefore limited. It is particularly difficult for mouse immunization approaches to identify therapeutics against conserved proteins that are homologous between human and mouse species; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Lack of Functional Activity Selection.</B> Competing technologies have not been able to drive antibody selection on the basis of functional activity. Even if antibodies are available against a certain target, they
may not bind the correct region or epitope of the protein to achieve the intended functional therapeutic effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Low Potency. </B>Antibodies from competing technologies tend to demonstrate low binding potencies against their targets. Such incomplete binding may not result in therapeutic effect that is sufficient to change
disease outcomes, or require impractically high doses to convey therapeutic benefit; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Unpredictable Manufacturing Properties. </B>Using microbial display systems such as phage and yeast display libraries has resulted in unpredictable expression, stability and formulation when manufacturing is
initiated using mammalian cells, thus leading to poor production yields and product stability. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mouse immunization methodologies</I>.
Mouse immunization methodologies involve the administration of human target antigen to mice with wild-type or engineered immune systems, with the assumption that their immune systems will generate antibodies with sufficient potency against the
desired human antigen epitope to convey biological effect. A key limitation of this approach is that when the mouse is dosed with an antigen that is similar in the human and mouse, the antigen is seen by the mouse immune system as a one of its own
proteins, and very few, if any, antibodies are generated. In addition, the mouse immune system often generates mouse antibodies to epitopes that are not therapeutically relevant to humans, leading the resulting antibodies to bind the human target
but failing to convey therapeutic effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Microbial antibody display systems</I>. Microbial antibody display systems require screening of antibodies,
typically formatted as antibody fragments, from a static library diversity displayed on a bacterial or yeast microbial cell surface. The static nature of these libraries limits the range of antibody specificities to 10<SUP
STYLE="font-size:85%; vertical-align:top">9</SUP> or 10<SUP STYLE="font-size:85%; vertical-align:top">10</SUP> range, which is generally insufficient to avail high-affinity antibodies against many antigens. This can lead to suboptimal potency, and
subsequently require phage/yeast antibodies to be matured significantly, typically with random mutagenesis, to obtain therapeutic level potencies, which is a labor-intensive and inefficient process. In addition, antibodies selected using this
approach are expressed through the microbial cell expression machinery, which differs significantly in terms of manufacturability (expression level, glycosylation, formulation and stability) from mammalian cell expression typically utilized for
clinical and commercial manufacturing of therapeutic antibodies. Such differences typically lead to difficulties in mammalian cell manufacturing of microbial display-derived antibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Human B cell screening methodologies</I>. Human B cell screening methodologies involve the screening and isolation of antibodies from peripheral human
blood against therapeutic antigens of interest. The key limitation of this approach is that circulating human B cells generally do not develop antibodies against endogenous proteins because their function is to develop humoral immunity against
foreign pathogens, such as bacteria and viruses. Therefore, it is challenging to obtain therapeutic antibodies against human antigens through this approach. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Technology Solution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our innovative platform is designed to replicate the natural process of SHM embedded within the human immune system to rapidly develop a
diverse range of therapeutic-grade antibodies <I>in vitro</I>. SHM is a critical, endogenous process that generates the essential antibody diversity required to develop a natural immune response to pathogens. Our genomes encode a limited number of
antibody genes, which are insufficient to generate antibodies against the wide variety of foreign pathogens encountered from the external environment. SHM enables our immune system to expand the limited diversity encoded within our genomes to the
billions of antibody specificities required to defend ourselves against external pathogens. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g15o09.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman"><B>Figure
10. Mechanism of SHM. SHM is initiated by the Activation-Induced Cytidine Deaminase, or AID, which converts cytidine to uracil at key positions, resulting in subsequent replication, DNA repair and base excision processes that generate either
wild-type (wt) or mutant DNA molecules. </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key enzyme required for SHM is called activation-induced cytidine deaminase, or AID.
AID has been genetically conserved throughout mammalian biology and is required for the non-random mutagenesis pattern associated with SHM. AID is specifically expressed by B cells after contact with a foreign pathogen and modifies antibody
sequences in a non-random fashion. Through SHM, B cells evolve antibodies with the potency and specificity required to clear the foreign pathogen. However, within the <I>in vivo</I> environment, SHM does not generally progress to the creation of
high potency antibodies or develop antibodies against the body&#146;s own proteins. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By coupling <I>in vitro</I> SHM with our mammalian
cell system that simultaneously displays and secretes antibodies, we believe SHM-XEL is able to rapidly identify and mature antibodies with desired functional activity to high potency while simultaneously mitigating the risks associated with
manufacturing. We introduce AID into mammalian cells to replicate the non-random mutagenesis SHM pattern observed within B cells <I>in vivo</I>. Starting with a library of either fully-human or humanized antibodies, our platform generates AID-based
variants of the starting antibody library throughout the process. We have demonstrated that the pattern of mutagenesis we observe <I>in vitro</I> using our platform technology closely mimics the pattern observed among <I>in vivo</I> generated
antibodies, thereby increasing confidence that antibodies generated by our platform will be tolerated when used as therapeutic drugs in humans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By selecting antibodies based on their antigen binding from the broad antibody library population
SHM-XEL develops, we are able to evolve in an iterative fashion the binding potency and function of antibodies to levels that we believe will be required for therapeutic use. We believe this approach allows us to rapidly generate antibodies with
high binding potency against a target. Through this approach, we have successfully generated therapeutic antibody product candidates to more than 25 targets, including targets that have been challenging for competing antibody technology platforms to
generate such as IL-33 and TIM-3. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g83r03.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Figure 11. SHM-XEL Antibody Generation Process. Our platform initiates antibody selection from starting libraries of human and non-human diversity, which is
further optimized through iterative rounds of SHM and selection. </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each evolving antibody is expressed within the SHM-active
mammalian cell to concurrently (i)&nbsp;display the evolved antibody on the cell surface to permit cell sorting selection for potency properties while (ii)&nbsp;the same antibody is secreted into the extracellular media at sufficient quantities to
permit functional assays to be conducted. In this manner, the evolving antibodies expressed by each transfected cell are assessed in a high-throughput fashion for the desired functional activity relevant to the therapeutic mechanism. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our antibody discovery platform, as described above, has the following advantages over competing approaches: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Diversity against difficult targets.</B> We are able to generate an unprecedented diversity of antibodies by applying SHM-based diversification outside of the constraints of an <I>in vivo</I> environment. This
enables us to develop antibodies against human targets that we believe have not otherwise been accessible to prior technologies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>High potency.</B> Because our platform generates highly-potent antibodies, we are potentially able to modulate every extracellular target associated with human disease, and believe only small therapeutic doses may be
required to mediate therapeutic effect <I>in vivo</I>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Functional activity selection.</B> Our mammalian cell system simultaneously displays and secretes antibodies during the antibody discovery process, allowing us to incorporate functional assays throughout the process
and focus on producing product candidates that are optimized for the desired therapeutic activity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Speed.</B> Our platform technology enables us to generate therapeutic-grade antibodies and initiate subsequent preclinical manufacturing and toxicology studies, typically in less than 12 months. We believe this
timeline is significantly shorter than conventional approaches based upon mouse immunization and microbial display systems. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Manufacturability.</B> By utilizing our mammalian cell display system, we believe our approach increases the probability of success in manufacturing and commercialization by mitigating the risks associated with
antibody expression, formulation and stability during the antibody generation process. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Bispecific antibodies.</B> A bispecific antibody is a single therapeutic molecule designed to bind two different targets. Bispecific antibodies
have the advantage of combining two therapeutic mechanisms with the goal of increasing therapeutic efficacy, in comparison to monospecific antibodies that bind </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
either of the targets individually. We believe our competitors&#146; bispecific strategies generally rely on proteins with non-natural formats, resulting in unpredictable pharmacokinetics and
manufacturing properties. Our strategy is to develop bispecific antibodies that are composed of two different heavy chains with a common shared light chain that resemble the natural antibody structure and exhibit the desired functional activity to
each target. Utilizing our proprietary SHM-XEL platform, we are able to generate a large diversity of heavy and light chain varieties against each therapeutic target, and then co-mature a common light chain in the context of two different heavy
chains, which permits us to identify bispecific antibodies with sufficient potency against each of the two targets that we believe will provide greater therapeutic benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaborations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TESARO </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2014, we entered into a collaboration and exclusive license agreement with TESARO. We executed an amendment in November 2014 to add an
additional dual-reactive antibody product candidate. Under the terms of the amended agreement, we granted TESARO an exclusive, royalty-bearing, sublicensable worldwide license to research, develop, manufacture, market and sell products based on our
proprietary technology for the discovery, generation and optimization of certain specified immunotherapy antibodies. Specifically, we granted TESARO exclusive rights to three monospecific antibody product candidates targeting TIM-3, LAG-3 and PD-1
(TSR-042) and three bispecific antibody product candidates targeting PD-1/TIM-3, <FONT STYLE="white-space:nowrap">PD-1/LAG-3</FONT> and an undisclosed target. Under the amended agreement, we are responsible for performing initial discovery and
development of therapeutic antibodies with the goal of generating immunotherapy antibodies for use in the treatment of cancer. TESARO is responsible for all subsequent preclinical, clinical, regulatory, manufacturing and other activities necessary
to develop and commercialize antibodies selected under each of six development programs, and TESARO is obligated to use commercially reasonable efforts to research, develop and commercialize at least one product to each of the four targets. During
the term, other than under the collaboration, both TESARO and we are prohibited from developing and commercializing, independently or with a third party, any agents targeting LAG-3, PD-1 or TIM-3, as single agents or in combination with other
therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of this agreement, TESARO made up-front, non-creditable and non-refundable cash payments aggregating $19.0
million to us during 2014. TESARO is also required to reimburse us on a quarterly basis for specified costs incurred by us in our initial discovery and development activities covered by the agreement. For products to each of the four targets, TESARO
is required to make milestone payments to us of up to $18.0&nbsp;million if certain research and development milestone events are achieved, and up to an additional $90.0 million of milestone payments if certain U.S. and non-U.S. regulatory
submissions and approvals occur in initial and subsequent indications. TESARO will also be required to pay us tiered single-digit royalties, on a product-by-product basis, on worldwide annual net sales, and additional commercial milestone payments
if specified levels of annual net sales of a product are attained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This agreement expires when no further payments are due to us, unless
earlier terminated. Either party may terminate the agreement in the event of an uncured material breach by the other party. TESARO may terminate the agreement at any time upon 90 days&#146; prior written notice to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Celgene </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2011, we
entered into a collaboration agreement with Celgene, or the Collaboration Agreement, to develop human therapeutic antibodies against multiple biological targets. We completed our responsibilities under the terms of the agreement to generate
antibodies against various mutually agreed biological targets. On a target-by-target basis, we provided Celgene an option to obtain rights to develop and commercialize a defined number of antibodies against each target. We were successful in
generating antibodies against multiple targets and Celgene has exercised its option with respect to antibodies against three targets. Celgene is currently advancing two anti-flammatory antibodies to the clinic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the Collaboration Agreement in 2011, Celgene paid us a one-time,
non-refundable, non-creditable initial fee of $6.0 million. Celgene has reimbursed us for specified research costs in accordance with the research plans. Celgene is also obligated, on a project-by-project basis, to pay us up to a total of an
additional $18.0 million if certain research and development milestone events are achieved under such project and up to a total of an additional $35.0 million if certain regulatory milestone events are achieved under such project. Celgene will also
be required to pay us single digit royalties on net sales of products containing the delivered antibodies on a product-by-product and country-by-country basis until the later of the expiration of the last patent right that covers manufacture, use or
sale of such product in such country, and in any case at least ten years after the first commercial sale of the product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Collaboration Agreement continues until our royalty rights on any Celgene product resulting from the collaboration expire, which period
will last at least ten years after any such product first goes to market. Either we or Celgene may terminate the agreement in the event of an uncured material breach by the other party. Celgene may also terminate the agreement at any time prior to
the delivery of any of the contemplated antibodies upon 90 days&#146; prior written notice to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In-Licensing Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with MRC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
2006, we entered into an exclusive worldwide license agreement with the Medical Research Council, or MRC, to obtain rights to multiple patents and patent applications relating to fundamental discoveries with respect to SHM and AID by
Dr.&nbsp;Michael Neuberger and his colleagues. We since amended this license agreement to include additional subject matter. Under the terms of the agreement, or the MRC Agreement, we obtained an exclusive, worldwide, sublicensable license under
specified patent rights to manufacture, use, sell and commercialize products and methods covered by such patents for all fields of use. We are responsible for prosecution of the licensed patents and the development of therapeutic products covered by
the intellectual property. We are obligated to research and develop licensed methods and licensed products for the purpose of commercializing such methods and products at least as diligently as we research and develop our other products of similar
market potential and stages of development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are responsible for paying MRC an annual fee of $55,000. Additionally, for each product
developed and commercialized under the MRC Agreement, we are obligated to pay MRC up to an additional $175,000 upon the achievement of specified development milestone events and up to an additional $275,000 upon the achievement of specified
regulatory milestone events. In addition we owe MRC royalties at 0.25% of net sales for worldwide sales on a product-by-product at or below $750 million and 1% of net sales of products worldwide above $1 billion, payable on a country-by-country
basis until the expiration of the last licensed patent covering such product in such country. Under this license agreement, we have filed 41 patent applications and have obtained issuance of 16 patents worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the MRC Agreement will expire upon expiration of all royalty payment obligations under the MRC Agreement. Either
party may terminate the MRC Agreement in the event of an uncured material breach by the other party or upon the occurrence of specified bankruptcy events for the other party. We may terminate the MRC Agreement upon 60 days&#146; notice to MRC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with Millipore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2009, we signed a non-exclusive research and commercial license agreement with Millipore Corporation, or Millipore, to obtain a
non-exclusive license to patents and patent applications directed to the ubiquitous chromatin opening elements technology for the expression of proteins, particularly antibodies, generated by us, which license may be sublicensed to our contractors
and partners. Under the terms of the agreement, or the Millipore Agreement. we are obligated to pay Millipore $87,500 in annual license fees. Additionally, for each product developed and commercialized under the Millipore Agreement, we are obligated
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to pay Millipore up to an additional $75,000 upon the achievement of specified development milestone events and up to an additional $4.4&nbsp;million upon the achievement of specified commercial
milestone events.&nbsp;We do not owe Millipore any royalties on net sales of products commercialized under the Millipore Agreement.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless affirmatively terminated by one of the parties, the Millipore Agreement will continue in effect. Either party may terminate the
Millipore Agreement in the event of an uncured material breach by the other party. We may terminate the Millipore Agreement upon 90 days&#146; notice to Millipore. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AnaptysBio Pty. Ltd </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2015, we
established a wholly-owned Australian subsidiary called AnaptysBio Pty. Ltd, in order to conduct various preclinical and clinical activities for ANB020 and ANB019. By establishing an Australian subsidiary, we are able to access an established
network of manufacturing and clinical development support contractors located in Australia, and to benefit from Australia&#146;s rapid regulatory review processes for first-in-human studies. In addition, we believe our Australian subsidiary will be
eligible for certain financial incentives made available by the Australian government for biotech research and development expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual
Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our intellectual property is critical to our business and we strive to protect it, including by obtaining and maintaining
patent protection in the United States and internationally for our technology platform, product candidates, novel biological discoveries, epitopes, new therapeutic approaches and potential indications, and other inventions that are important to our
business.&nbsp;In total, our current patent portfolio, including patents to our technology platform licensed from MRC, consists of 28 issued patents and 32 pending patent applications as of June&nbsp;30, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our product candidates, generally we initially pursue patent protection covering compositions of matter, antibody sequence diversity,
epitopes, functional activity and methods of use. Throughout the development of our product candidates, we seek to identify additional means of obtaining patent protection that would potentially enhance commercial success, including through
additional methods of use and biomarker and companion diagnostic related claims.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent portfolios for our two internal programs and
platform technology are outlined below:</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ANB020 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015, we own one international patent application, filed under the Patent Cooperation Treaty, or PCT, which is directed to
the antibody sequence of ANB020 and its variants, epitopes, methods of use and related matters. We intend to prosecute the pending international application and pursue patent issuance and protection in key commercial markets where significant
product sales may occur. Patents that may issue from this pending international application would provide protection until January 2035. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ANB019
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2015, we own one U.S. provisional patent application, which is directed to the antibody sequence of ANB019 and
its variants, epitopes, methods of use and related matters. We intend to pursue an international patent application, filed under the PCT in due course, based on the pending U.S. provisional patent application, and pursue patent issuance and
protection in key commercial markets where significant product sales may occur. Patents that may issue from the expected international application would provide protection until April 2036. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Platform Technology </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our platform technology is covered by U.S. and foreign issued patents and pending patent applications, emanating from our in-licensed portfolio
and wholly owned portfolio, currently under prosecution in various jurisdictions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our wholly owned portfolio includes patents and
patent applications directed to platform technology related inventions associated with antibody library design, antibody humanization, mammalian cell display and secretion, and other technical attributes relating to the discovery, maturation and
optimization of antibodies using our technology platform. Patents relating to our platform technology that have been issued to date provide protection through 2028. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of biotechnology companies like ours are generally uncertain and involve complex legal, scientific and factual questions.
In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we may not obtain or maintain adequate patent protection for any of
our product candidates or for our technology platform. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide
sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. For a more comprehensive discussion of the risks related to our intellectual property, please see
&#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of
the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application related to the patent. A U.S. patent also may be accorded
a PTA under certain circumstances to compensate for delays in obtaining the patent from the USPTO. In some instances, such a PTA may result in a U.S. patent term extending beyond 20 years from the earliest date of filing a non-provisional patent
application related to the U.S. patent. In addition, in the United States, the term of a U.S. patent that covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for the
patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the
drug is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions
are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering
those products. We plan to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with
our assessment of whether such extensions should be granted, and if granted, the length of such extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely on trade secrets
relating to our technology platform and product candidates and seek to protect and maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for,
patent protection. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary
information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific
collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business
or financial affairs developed or made known to the individual during the course of the individual&#146;s relationship with us is to be kept confidential and not disclosed to third </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
parties except in specific circumstances. Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or from the employee&#146;s
use of our confidential information are our exclusive property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must manufacture drug product for clinical trial use in compliance with cGMP. The cGMP regulations include requirements relating to
organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records
and reports, and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP requirements and FDA satisfaction before any product is approved and we can manufacture commercial products. Our third-party
manufacturers will also be subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of our products to assess our compliance with applicable regulations.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our internal manufacturing capabilities include non-cGMP antibody and reagent production using small scale quantities for
characterization and <I>in vitro</I> and <I>in vivo</I> preclinical assessment of product candidates. We do not have and we do not currently plan to acquire or develop the facilities or capabilities to manufacture cGMP drug substance or filled drug
product for use in human clinical trials. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third-party manufacturers to generate cGMP-grade cell lines and will rely on
them to produce cGMP drug product required for our planned clinical trials, and expect to continue to rely on third parties to manufacture clinical trial drug supplies for the foreseeable future. We also contract with additional third parties for
the filling, labeling, packaging, storage and distribution of investigational drug products. We have personnel with significant technical, manufacturing, analytical, quality, including cGMP, and project management experience to oversee our
third-party manufacturers and to manage manufacturing and quality data and information for regulatory compliance purposes. While our contract manufacturers have not yet produced cGMP batches of our product candidates, they have previously produced
batches for other companies in compliance with cGMP and have been previously inspected by regulatory authorities for compliance with cGMP standards. Similarly, our personnel have had experience with cGMP at previous positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including warning
letters, the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. These actions could have a material impact on the availability of
our products. Contract manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and
pharmaceutical industries are characterized by continuing technological advancement and significant competition. While we believe that our product candidates, technology, knowledge, experience and scientific resources provide us with competitive
advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Any product candidates that we successfully develop and
commercialize will compete with existing therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and
convenience of our products and the ease of use and effectiveness of any companion diagnostics. The level of generic competition and the availability of reimbursement from government and other third-party payors will also significantly affect the
pricing and competitiveness of our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market
position before we are able to enter the market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the companies against which we may compete have significantly greater financial resources
and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites
and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, there are several companies developing or marketing treatments that may be approved for the same indications and/or diseases as
our lead product candidates, ANB019 and ANB020, including major pharmaceutical companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For asthma, our competitors include omalizumab
(Xolair; Roche), which has received FDA approval and functions by inhibiting the binding between free IgE and FceRI; antibodies that bind IL-5 and inhibit its interaction with the IL-5 receptor such as mepolizumab (Glaxosmithkline), which a Federal
Advisory Committee has recently recommended that the FDA approve for the add-on maintenance treatment in patients aged 18 years or older with severe eosinophilic asthma, and reslizumab (Teva), the BLA for which has been submitted to the FDA for
approval; antibodies, such as benralizumab (AstraZeneca) that bind the IL-5 receptor; antibodies that bind to <FONT STYLE="white-space:nowrap">IL-13</FONT> such as lebrikizumab (Roche), tralokinumab (AstraZeneca) and anrukinzumab (Pfizer) which are
in clinical testing; antibodies that bind the IL-4 receptor alpha chain such as dupilumab (Regeneron) and AMG317 (Amgen) each in clinical testing; and antibodies that bind the ST2 receptor including AMG282 (Amgen), which is in clinical testing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For peanut allergy, our competitors include DBV Technologies, which is developing transdermal products for tolerization of food allergies,
while Aimmune Therapeutics is developing oral products for peanut allergy desensitization. For GPP and PPP, our competitors include marketed therapies such as secukinumab (Cosentyx; Novartis) which binds IL-17A, ustekinumab (Stelara; Janssen) which
blocks IL-12 and 23 cytokine function; and acitretin (Soriatane; Glaxosmithkline), as well as therapies in development such as guselkumab (Janssen) which blocks IL-23 cytokine function and gevokizumab (Xoma 052) which binds IL-1 beta. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the
European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval
monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes
and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA approval process
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic
Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval
monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention, treatment, or cure of a disease or condition of a human being are subject to regulation under the FDC Act, except the
section of the FDC Act which governs the approval of new drug applications, or NDAs. Biological products are approved for marketing under provisions of the Public Health Service Act, or PHSA, via a Biologics License Application, or BLA. However, the
application process and requirements for approval of BLAs are similar to those for NDAs, and biologics are associated with similar approval risks and costs as drugs. Failure to comply with applicable U.S. requirements may subject a company to a
variety of administrative or judicial sanctions, such as clinical hold, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FDA refusal to approve pending NDAs or BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil
penalties, and criminal prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biological product development for a new product or certain changes to an approved product in the
United States typically involves preclinical laboratory and animal tests, the submission to the FDA of an IND, which must become effective before clinical testing may commence in the United States, and adequate and well- controlled clinical trials
to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based
upon the type, complexity, and novelty of the product or disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical tests include laboratory evaluation of product chemistry,
formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory
practices. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long term
preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in
humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. Clinical trials involve the administration of the investigational biologic to healthy volunteers or
patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with good clinical practice, or GCP, an international standard meant to protect
the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&nbsp;under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the
effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions if it believes that
the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The trial protocol and informed consent information for patients in clinical trials must also be
submitted to an institutional review board, or IRB, for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#146;s requirements, or may impose other
conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials to support BLAs for marketing approval are typically conducted in three sequential phases, but the phases may
overlap. In Phase 1, the initial introduction of the biologic into healthy human subjects or patients, the product is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if
possible, early evidence on effectiveness. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug or biologic for a particular indication, dosage tolerance, and optimal dosage, and to identify
common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and
safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit risk relationship of the drug or biologic and to provide adequate information for the labeling of
the product. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the biologic. A single Phase 3 trial with other confirmatory evidence may be sufficient in rare instances where the
trial is a large multicenter trial demonstrating internal consistency and a statistically persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and
confirmation of the result in a second trial would be practically or ethically impossible. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After completion of the required clinical testing, a BLA is prepared and submitted to the FDA.
FDA approval of the BLA is required before marketing of the product may begin in the United States. The BLA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product&#146;s
pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting a BLA is substantial. The submission of most BLAs is additionally subject to a substantial application user fee, and the applicant under an approved BLA is also
subject to annual product and establishment user fees. These fees are typically increased annually. The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#146;s threshold
determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of BLAs. Most such applications
for standard review biologic products are reviewed within ten months of the date the FDA files the BLA; most applications for priority review biologics are reviewed within six months of the date the FDA files the BLA. Priority review can be applied
to a biologic that the FDA determines has the potential to treat a serious or life-threatening condition and, if approved, would be a significant improvement in safety or effectiveness compared to available therapies. The review process for both
standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also refer applications for novel biologic products, or biologic products that present difficult questions of safety or efficacy,
to an advisory committee&#151;typically a panel that includes clinicians and other experts&#151;for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory
committee, but it generally follows such recommendations. Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the
biologic product is manufactured. The FDA will not approve the product unless compliance with current good manufacturing practice, or cGMP, is satisfactory and the BLA contains data that provide substantial evidence that the biologic is safe, pure,
potent and effective in the indication studied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates the BLA and the manufacturing facilities, it issues either an
approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. If,
or when, those deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of
information included. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. As a condition of BLA approval, the FDA may require a REMS to help ensure that the benefits of
the biologic outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification
for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the product. Moreover,
product approval may require substantial post-approval testing and surveillance to monitor the product&#146;s safety or efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once
granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing. Changes to some of the conditions established in an approved application, including changes
in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement before the change can be implemented. A BLA supplement for a new indication typically requires clinical data
similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan drug designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan drug designation to biological products intended to treat a rare disease or
condition&#151;generally a disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and
making a product available in the United States for such disease or condition will be recovered from sales of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan drug
designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the biological product and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not
convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first BLA applicant to receive FDA approval for a biological product containing a particular active moiety to treat a particular disease with FDA
orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that product for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market a biological
product containing the same active moiety for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. A product is clinically superior if it is safer, more effective
or makes a major contribution to patient care. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biological product for the same disease or condition, or the same biological product for a different disease or
condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA user fee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure of
clinical trial information </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sponsors of clinical trials of FDA-regulated products, including biological products, are required to
register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the
registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. Competitors
may use this publicly available information to gain knowledge regarding the progress of development programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pediatric information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act, or PREA, NDAs or BLAs or supplements to NDAs or BLAs must contain data to assess the safety and
effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA
may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional controls for biologics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for
products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages
and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing
process, the manufacturer is required to perform certain tests on each lot of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a
release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral
vaccines, before releasing the lots for distribution by the manufacturer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the FDA conducts laboratory research related to
the regulatory standards on the safety, purity, potency, and effectiveness of biological products. As with drugs, after approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in
manufacturing, and are subject to periodic inspection after approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent term restoration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After approval, owners of relevant drug or biologic patents may apply for up to a five year patent extension. The allowable patent term
extension is calculated as half of the drug&#146;s testing phase&#151;the time between IND application and NDA or BLA submission&#151;and all of the review phase&#151;the time between NDA or BLA submission and approval up to a maximum of five years.
The time can be shortened if FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed 14&nbsp;years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent
extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the United States Patent and Trademark Office
must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug or biologic for which an NDA or BLA has not been submitted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biologics Price
Competition and Innovation Act of 2009, or BPCIA, creates an abbreviated approval pathway for biological products shown to be highly similar to or interchangeable with an FDA licensed reference biological product. Biosimilarity sufficient to
reference a prior FDA-approved product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological product and the reference product
in terms of safety, purity, and potency. Biosimilarity must be shown through analytical trials, animal trials, and a clinical trial or trials, unless the Secretary of Health and Human Services waives a required element. A biosimilar product may be
deemed interchangeable with a prior approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and
the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. On March&nbsp;6, 2015, the FDA approved the first
biosimilar product under the BPCIA. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation, which
is still being evaluated by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reference biologic is granted 12 years of exclusivity from the time of first licensure of the
reference product, and no application for a biosimilar can be submitted for four years from the date of licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be
interchangeable with the reference product has exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i)&nbsp;one year after first commercial marketing of the first interchangeable
biosimilar, (ii)&nbsp;18 months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii)&nbsp;18 months after resolution of a lawsuit over the patents </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv)&nbsp;42 months after the first interchangeable biosimilar&#146;s application has been approved if a
patent lawsuit is ongoing within the 42-month period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-approval requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once a BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the
post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the
internet. Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse event reporting and submission of periodic reports is required following FDA approval of a BLA. The FDA also may require
post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality
control, biological product manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Biologic manufacturers and certain of their subcontractors are required to register their establishments with the FDA and
certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue
to expend time, money, and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory
standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA
regulation of companion diagnostics </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If use of an <I>in vitro</I> diagnostic is essential to safe and effective use of a drug or
biologic product, then the FDA generally will require approval or clearance of the diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. The review of an <I>in vitro</I> companion diagnostic in
conjunction with the review of a biologic involves coordination of review by the FDA&#146;s Center for Biologics Evaluation and Research and by the FDA&#146;s Center for Devices and Radiological Health. The PMA process, including the gathering of
clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the
device&#146;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee, which exceeds $250,000 for most
PMAs. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA
approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. As part of the PMA
review, the FDA will typically inspect the manufacturer&#146;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on
deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA&#146;s evaluation of the PMA application is favorable, the
FDA typically issues an approvable letter requiring the applicant&#146;s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of
the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device,
including, among other things, restrictions on labeling, promotion, sale and distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a device is placed on the market, it
remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA.
A medical device manufacturer&#146;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes,
controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that
export products to the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. healthcare laws and compliance requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the
FDA, including but not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (such as the Office of Inspector General), the U.S. Department of Justice, or DOJ, and
individual U.S. Attorney offices within the DOJ, and state and local governments. For example, sales, marketing and scientific/educational grant programs may have to comply with the anti-fraud and abuse provisions of the Social Security Act, the
false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as amended, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying,
soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable
under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical
manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors
are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of
the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis
based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act, or ACA, to a
stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or
services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented
or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal false claims and false statement laws, including the federal False Claims Act, prohibit, among other things, any person or entity from
knowingly presenting, or causing to be presented, a false or fraudulent claim for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment to, or approval by, the federal healthcare programs, including Medicare and Medicaid, or knowingly making, using, or causing to be made or used a false record or statement material to a
false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government.
Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other
companies have been prosecuted for causing false claims to be submitted because of the companies&#146; marketing of the product for unapproved, and thus generally non-reimbursable, uses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to
execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party
payors, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent
statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, the ACA amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no
longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, many
states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Additionally, to the extent that our product is
sold in a foreign country, we may be subject to similar foreign laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to data privacy and security regulations by both
the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements relating to the
privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to business associates, independent contractors or agents of covered
entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties
directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#146; fees and costs associated with pursuing federal
civil actions. In addition, many state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance
efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain
manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain
payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain
ownership and investment interests held by physicians and their immediate family members. Moreover, the Drug Supply Chain Security Act imposes new obligations on manufacturers of pharmaceutical products related to product tracking and tracing.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale
distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states
also impose requirements on manufacturers and distributors to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it
moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on
sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and
biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental
regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and
Medicaid, injunctions, private &#147;qui tam&#148; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens,
diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage, pricing and reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval.
In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate
reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process for determining whether a
third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to
specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and
reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and
cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#146;s decision to provide coverage for a product does not
imply that an adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement
may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products
through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only
be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to
currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become intense. As a result, increasingly high barriers
are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and
third-party payors fail to provide adequate coverage and reimbursement. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement
rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the
future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare reform </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
March 2010, President Obama enacted the ACA, which has the potential to substantially change healthcare financing and delivery by both governmental and private insurers, and significantly impact the pharmaceutical and biotechnology industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the ACA provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above, are
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some
government healthcare programs that began in 2011; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January&nbsp;1, 2010, to 23.1% and 13% of the average manufacturer price for most branded and
generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage
gap period, as a condition for the manufacturers&#146; outpatient drugs to be covered under Medicare Part D; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals beginning in 2014 and by adding new mandatory eligibility categories
for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requirements to report certain financial arrangements with physicians and teaching hospitals; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that the ACA will result in additional downward pressure on coverage and the price that we receive for any approved product, and
could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare
reforms may prevent us from being able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenues from product candidates that we may successfully develop
and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. In addition, it is possible that there will be further legislation or regulation that could harm our business,
financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, in August&nbsp;2011, the President signed into law the Budget Control Act of
2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at
least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2%&nbsp;per fiscal year,
which went into effect beginning on April&nbsp;1, 2013 and will stay in effect through 2024 unless additional Congressional action is taken. Additionally, in January&nbsp;2013, the American Taxpayer Relief Act of 2012 was signed into law, which,
among other things, reduced Medicare payments to several providers, including hospitals and imaging centers. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on
customers for our drugs, if approved, and, accordingly, our financial operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Foreign Corrupt Practices Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering
of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining
business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation,
including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition
to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our
business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose
individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse
effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Europe / rest of world government
regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions
governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries
prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior
to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country&#146;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once
the clinical trial application is approved in accordance with a country&#146;s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in some countries. The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical
trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit a marketing
authorization application. The application used to file the BLA in the United States is similar to that required in the EU, with the exception of, among other things, country-specific document requirements. For other countries outside of the EU,
such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted
in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things,
fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Australia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting clinical
trials for product candidates in Australia is subject to regulation by Australian governmental entities. Approval for inclusion in the Australian Register of Therapeutic Goods is required before a pharmaceutical drug product may be marketed in
Australia. This process generally involves: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Completion of preclinical laboratory and animal testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Submission to the Therapeutics Goods Administration, or TGA, of a clinical trial notification, or CTN, application for human trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In the case of a CTN, submission of, an investigator&#146;s brochure, clinical protocols, related patient information and supporting documentation to the Human Research Ethics Committee, or HREC, of each institution at
which the trial is to be conducted; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adequate and well-controlled clinical trials to demonstrate the safety and efficacy of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Compilation of evidence which demonstrates that the manufacture of the product complies with the principles of cGMP; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Submission of the manufacturing and clinical data to, and approval by, the Drug Safety and Evaluation Branch of the TGA. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies include laboratory evaluation of the product as well as animal studies to assess the potential safety and efficacy of the
product. The results of the preclinical studies are submitted to each investigator&#146;s HREC and in some instances, to the TGA. Approval by each HREC and by the TGA is generally necessary before clinical trials can commence. An HREC is an
independent review committee at each institution at which a study is conducted and is set up under guidelines of the Australian National Health and Medical Research Council. The role of an HREC is to ensure the protection of rights, safety, and
wellbeing of human subjects involved in a clinical trial by, among other things, reviewing, approving, and providing continuing review of trial protocols and amendments, and of the methods and material to be used in obtaining and documenting
informed consent of the trial subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve administering the investigational product to healthy volunteers or
patients under the supervision of a qualified principal investigator. The TGA has developed guidelines for a CTN and a CTX, the two routes for conducting clinical trials in Australia. Under the CTN scheme, all material relating to the proposed trial
is submitted directly to the HREC. The TGA is formally notified by submission of a CTN application but does not review the safety of the drug or any aspect of the proposed trial. The HREC is responsible for approving
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the protocol for the clinical trial. The approving authority of each institution gives the final approval for the conduct of the clinical trial, having due regard to advice from the HREC.
Following approval, responsibility for all aspects of the trial conducted under a CTN application remains with the HREC of each investigator&#146;s institution and with us. The role of the TGA is primarily to assess safety issues. The role of the
HREC is to consider the scientific and ethical issues of the proposed clinical trial protocols. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other regulations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices,
environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now or in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July 31, 2015, we
had 44 full-time employees and one part-time employee. Of these employees, 34 were primarily engaged in research and development activities and nine have an M.D. or a Ph.D. None of our employees are represented by a labor union or covered by
collective bargaining agreements, and we believe our relationship with our employees is good. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Properties and Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive office is located in San Diego, California, and consists of approximately 25,000 square feet of leased office and
laboratory space under a lease that expires on August&nbsp;31, 2016. We use these facilities for our administrative, research and development and other activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our facilities are adequate to meet our needs for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we
may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of
outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table provides information regarding our executive officers and directors as of July&nbsp;15, 2015: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="59%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:27.50pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Londei, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Development Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert E. Hoffman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-Employee Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tiba Aynechi, Ph.D.*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D., FRS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hollings Renton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John P. Schmid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James N. Topper, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Aynechi has notified us that she will resign from our board of directors contingent upon and effective immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Hamza Suria</I> has served as our President and Chief Executive Officer and a member of our board of directors since July 2011. From January
2009 to June 2011 Mr.&nbsp;Suria served as Vice President of Corporate Development. Before joining our company in December 2008, Mr.&nbsp;Suria worked at Maxygen, Inc., a biopharmaceutical company, where he was responsible for partnering and
alliance management of next-generation protein therapeutics in oncology supportive care, hematology and autoimmunity, including partnerships with healthcare and pharmaceutical companies, such as Roche, Sanofi S.A., Bayer Corporation and Astellas
Pharma. Mr.&nbsp;Suria received his M.S. in immunology from the University of Western Ontario, his Executive M.B.A. from the Richard Ivey School of Business of the University of Western Ontario and his B.S. in biochemistry from Kalamazoo College.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Mr.&nbsp;Suria&#146;s thorough knowledge of our company and technology, and his scientific and business experience,
provide him with the qualifications and skills to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Marco Londei, M.D.</I> has served as our Chief
Development Officer since October 2014. Before joining our company, Dr.&nbsp;Londei worked as Therapeutic Area Head Immunosciences, at Bristol-Myers Squibb, a biopharmaceutical company, from November 2012 to September 2014. Before starting at
Bristol-Myers Squibb, Dr.&nbsp;Londei served as Global Head Translational Medicine of the Autoimmunity, Transplantation &amp; Inflammation Department at Novartis AG and Translational Science Officer at the Genomics Institute of the Novartis Research
Foundation from October 2005 to October 2012. Dr.&nbsp;Londei was Professor at the Kennedy Institute of Rheumatology, Imperial College School of Medicine, London, from July 1999 to July 2003 and then Professor and head of the gastroenterology unit
at University College London, Medical School UK, from July 2003 through September 2007. Dr.&nbsp;Londei received his M.D. from Universit&agrave; di Bologna. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Robert E. Hoffman</I> has served as our Chief Financial Officer since July 2015. Before joining our company, Mr.&nbsp;Hoffman served as
Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc., a biopharmaceutical company, from June 2012 to July 2015, as Vice President, Finance and Chief Financial Officer from August 2011 to June 2012 and December
2005 to March 2011. From March 2011 to August 2011, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Mr.&nbsp;Hoffman served as Chief Financial Officer for Polaris Group, a biopharmaceutical drug company. Mr.&nbsp;Hoffman is a member of the board of directors of CombiMatrix Corporation, a
molecular diagnostics company, Kura Oncology, Inc., a biotechnology company, and MabVax Therapeutics Holdings, Inc., a biopharmaceutical company. He also serves as a member of the Financial Accounting Standards Board&#146;s Small Business Advisory
Committee and the steering committee of the Association of Bioscience Financial Officers. Mr.&nbsp;Hoffman received his B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. (inactive) in the State of California. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Non-Employee Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Tiba Aynechi, Ph.D.</I> has served as a member of our board of directors since April 2015.&nbsp;Dr. Aynechi is employed as a Partner at Novo
Ventures (US) Inc., which provides certain consultancy services to Novo A/S, a Danish limited liability company that manages investments and financial assets.&nbsp;Prior to joining Novo Ventures (US) Inc. in March 2010, Dr.&nbsp;Aynechi was employed
from June 2006 to March 2010 by Burrill&nbsp;&amp; Company, a private financial firm specializing in biotechnology and life sciences investment, in various positions, including from January 2009 to March 2010 as a Director in Merchant Banking where
she was responsible for regional and cross-border mergers and acquisitions, licensing, and financing transactions. Dr.&nbsp;Aynechi has served as a member of the board of directors of several private biotechnology and medical device companies.
Dr.&nbsp;Aynechi received her Ph.D. in biophysics from the University of California, San Francisco, where her research involved developing computational methods for drug discovery.&nbsp;She received her B.S. in physics from the University of
California, Irvine.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>We believe that Dr.&nbsp;Aynechi&#146;s extensive experience in the biotechnology and pharmaceutical
industries, makes her qualified to serve on our own board of directors.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Carol G. Gallagher, Pharm.D.</I> has served as a member
of our board of directors since October 2011. Dr.&nbsp;Gallagher has been a partner at New Enterprise Associates, a venture-capital firm, since October 2014.&nbsp;She has served as a director at Atara Biotherapeutics, Inc., a public
biopharmaceutical company, since February 2013 and she became lead director in October 2014. She has also served as a director at Atterocor, Inc. since October 2012, as chairperson of the board of directors of eFFECTOR Therapeutics, Inc. from
October 2012 to 2014 and as a director of Aragon Pharmaceuticals, Inc. from February 2012 to July 2013. Dr.&nbsp;Gallagher was a venture partner with Frazier Healthcare, a venture-capital firm, from November 2013 to July 2014. Dr.&nbsp;Gallagher
served as the President and Chief Executive Officer of Calistoga Pharmaceuticals, a biopharmaceutical company, from September 2008 to April 2011, when the company was acquired by Gilead Sciences. From 2007 to 2008, Dr.&nbsp;Gallagher was the
President and Chief Executive Officer of Metastatix, Inc., a biopharmaceutical company. Dr.&nbsp;Gallagher attended Vanderbilt University and received her B.S. and Pharm.D. degrees from the University of Kentucky. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Dr.&nbsp;Gallagher&#146;s extensive experience in the life sciences industry and as a chief executive officer provide her with
the qualifications and skills to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Nicholas B. Lydon, Ph.D., FRS</I> is a co-founder of our company and
has served on our board of directors since our company was founded in November 2005.&nbsp;Dr. Lydon also co-founded and has served on the board of directors of BluePrint Medicines Inc. since April 2011. Since 2011, Dr.&nbsp;Lydon has served as
Managing Member at Staurus Pharma, LLC, a biotechnology company. Dr.&nbsp;Lydon is also the founder of Granite Biopharma LLC, a consulting company, and has served as sole member of Granite Biopharma since 2003. Dr.&nbsp;Lydon also previously served
as Vice President, Small Molecule Drug Discovery at Amgen Inc. from 2000 to 2002. Prior&nbsp;to joining Amgen, he was the Chief Executive Officer and founder of Kinetix Pharmaceuticals, Inc., a biotechnology&nbsp;company focused on the discovery and
development of selective protein kinase inhibitors, from 1997 to 2000. Kinetix Pharmaceuticals was&nbsp;acquired&nbsp;by Amgen&nbsp;in&nbsp;2000.&nbsp;Prior to joining Kinetix, Dr.&nbsp;Lydon worked at CIBA-GEIGY, AG (Novartis) in Basel, Switzerland
from 1985 to 1997, where he was responsible for the protein kinase inhibitor program, including the discovery and preclinical development of Imatinib (Gleevec).&nbsp;Dr. Lydon began his pharmaceutical career at Schering-Plough Corporation from 1982
to 1985 where his research involved studies on recombinant interferons. Dr. Lydon has been awarded the Lasker~DeBakey Clinical Medical Research Award and the Japan Prize for his work on Imatinib. Other awards include the Warren Alpert Foundation
Prize, the AACR Bruce F. Cain Memorial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Award and the Charles F. Kettering&nbsp;Prize from the General Motors Cancer Research Foundation.&nbsp;Dr. Lydon earned his B.S. in Biochemistry and Zoology from the University of Leeds, England,
and received his Ph.D. in Biochemistry from the Medical Sciences Institute, University of Dundee, Scotland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that
Dr.&nbsp;Lydon&#146;s extensive industry experience and significant knowledge of scientific matters provide him with the qualifications and skills to serve on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Hollings Renton</I> has served as a member of our board of directors since June 2015. Mr.&nbsp;Renton previously served as the Chief
Executive Officer and President of Onyx Pharmaceuticals, Inc. from 1993 to 2008 and as the chairperson of the board of directors from 2000 to 2008. Before joining Onyx Pharmaceuticals, Mr.&nbsp;Renton worked for Chiron Corporation, a pharmaceutical
company, as President and Chief Operating Officer from 1991 to 1993, following its acquisition of Cetus Corporation. Before joining Onyx Pharmaceuticals, Mr.&nbsp;Renton worked for Cetus Corporation as President from 1990 to 1991, as Chief Operating
Officer from 1987 to 1990, and as Chief Financial Officer from 1983 to 1987.&nbsp;Mr.&nbsp;Renton currently serves as a director of multiple life sciences companies, including as chairperson of the board of directors of Portola Pharmaceuticals,
Inc., and is a member of the board of directors of Cepheid Inc. and Kythera Biopharmaceuticals, Inc. He previously served on the boards of directors of Rigel Pharmaceuticals, Inc., Affymax Inc., Sangstat Medical Corporation, Special Olympics
Northern California and the Biotechnology Industry Organization. Mr.&nbsp;Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Mr.&nbsp;Renton&#146;s extensive industry experience and board memberships provide him with the qualifications and skills to
serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>John P. Schmid</I> has served as a member of our board of directors since June 2015. Mr.&nbsp;Schmid
served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 to June 2015. Before joining Auspex Pharmaceuticals, Mr.&nbsp;Schmid co-founded Trius Therapeutics, Inc., a publicly traded biopharmaceutical company, where he
served as the Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc., in September 2013. Before he joined Trius Therapeutics, Inc., Mr.&nbsp;Schmid served as the Chief Financial Officer at GeneFormatics, Inc., a
private biotechnology company, from 1998 to 2003, and at Endonetics, Inc., a private medical device company, from 1995 to 1998. Mr.&nbsp;Schmid currently serves a member of the board of directors of Neos Therapeutics, Inc., a pharmaceutical company,
and as the chairman of the board of directors of Speak, Inc., a speakers bureau, which he helped found in 1989. Mr.&nbsp;Schmid received his M.B.A. from the University of San Diego and B.A. from Wesleyan University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Mr.&nbsp;Schmid&#146;s extensive industry experience and executive positions at multiple biopharmaceutical companies qualify
him to serve on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>James N. Topper, M.D., Ph.D.</I> has served as a member of our board of directors since
November 2007. Dr.&nbsp;Topper has been a partner with Frazier Healthcare since August 2003, serving as General Partner since 2005. Before joining Frazier Healthcare, Dr.&nbsp;Topper served as head of the Cardiovascular Research and Development
Division of Millennium Pharmaceuticals, Inc. and ran Millennium San Francisco (formerly COR Therapeutics, Inc.) from 2002 until 2003. Before the merger of COR and Millennium in 2002, Dr.&nbsp;Topper served as the Vice President of Biology at COR
from August 1999 to February 2002. Dr.&nbsp;Topper has served on numerous boards of directors, including Amicus Therapeutics, Inc. and Portola Pharmaceuticals, Inc. Dr.&nbsp;Topper received his M.D. and Ph.D. in biophysics from Stanford University
and his B.S. in biology from the University of Michigan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Dr.&nbsp;Topper&#146;s experience overseeing Frazier Healthcare
investments in biotechnology, senior-management experience in our industry, significant knowledge of medical and scientific matters affecting our business, and understanding of our industry provide him with the qualifications and skills to serve on
our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Election of Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive officers are appointed by, and serve at the discretion of, our board of directors. There are no family relationships among any of
our directors or executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted a code of business conduct and ethics that applies to all of our employees, officers and directors,
including our Chief Executive Officer, Chief Financial Officer and other executive and senior officers. The full text of our code of conduct will be posted on the investor relations section of our website. The reference to our website address in
this prospectus does not include or incorporate by reference the information on our website into this prospectus. We intend to disclose future amendments to certain provisions of our code of conduct, or waivers of these provisions, on our website or
in public filings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and affairs are organized under the direction of our board of directors, which currently consists of seven members. Our current
certificate of incorporation and a voting agreement by and among us and certain of our investors provide for up to seven directors, of which (i)&nbsp;up to two directors are designated by holders of our Series B, Series B-1 and Series B-2 Preferred
Stock, voting together as a single class on an as-converted basis, (ii)&nbsp;one director is designed by holders of our common stock, voting as a separate class and (iii)&nbsp;all remaining directors are designated by the holders of our common stock
and convertible preferred stock, voting together as a single class on an as-converted basis. Drs. Aynechi and Topper are the current designees of holders of our Series&nbsp;B, Series B-1 and Series B-2 convertible preferred stock, voting together as
a single class on an as-converted basis. Mr.&nbsp;Suria is the current designee of holders of our common stock. Dr.&nbsp;Gallagher, Dr.&nbsp;Lydon, Mr.&nbsp;Renton and Mr.&nbsp;Schmid are the current designees of holders of our common stock and
convertible preferred stock, voting together as a single class on an as-converted basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The voting agreement and the provisions of our
certificate of incorporation that govern the election and designation of our directors will terminate in connection with our initial public offering, after which no contractual obligations will concern the election of our directors. Each of our
current directors will continue to serve until the election and qualification of his or her successor, or until his or her earlier death, resignation or removal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Classified Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to this offering, our board of directors will be divided into three staggered classes of directors. At each annual meeting of
stockholders, a class of directors will be subject to re-election for a three-year term. As a result, only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of
their respective three-year terms. Our directors will be divided among the three classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class I directors will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and their terms will expire at the annual
meeting of stockholders to be held in 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class II directors will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and their terms will expire at the
annual meeting of stockholders to be held in 2017; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class III directors will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and their terms will expire at the annual meeting of stockholders to be held in 2018. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each director&#146;s term continues until the election and qualification of his or her successor, or his or her earlier death, resignation or
removal. Our restated certificate of incorporation and restated bylaws that will be in effect upon the closing of this offering authorize only our board of directors to fill vacancies on our board of directors. Any increase or decrease in the number
of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. This classification of our board of directors may have the effect of delaying or preventing changes in
control of our company. See &#147;Description of Capital Stock&#151;Anti-Takeover Provisions&#151;Restated Certificate of Incorporation and Restated Bylaw Provisions.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we intend to list our common stock on the NASDAQ Global Market. Under the rules of the NADAQ Stock Market, or
NASDAQ, independent directors must comprise a majority of a listed company&#146;s board of directors within a specified period of the closing of this offering. In addition, the rules of NASDAQ require that, subject to specified exceptions, each
member of a listed company&#146;s audit, compensation and nominating and corporate governance committees be independent. Under the rules of NASDAQ, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that
company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Audit committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as
amended. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board
committee: (1)&nbsp;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries; or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. We
intend to satisfy the audit committee independence requirements of Rule 10A-3 as of the closing of this initial public offering. Additionally, compensation committee members must not have a relationship with us that is material to the
director&#146;s ability to be independent from management in connection with the duties of a compensation committee member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of
directors has undertaken a review of the independence of each director and considered whether each director has a material relationship with us that could compromise his ability to exercise independent judgment in carrying out his responsibilities.
As a result of this review, our board of directors determined that
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;, representing &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of our seven directors, are &#147;independent directors&#148; as defined under the applicable rules and regulations of the Securities and Exchange Commission, or SEC, and the
listing requirements and rules of NASDAQ. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has an audit committee, a compensation committee and a nominating and corporate governance committee, each of which will
have the composition and responsibilities described below as of the closing of our initial public offering. Members serve on these committees until their resignation or until otherwise determined by our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee is comprised of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is the chairman of our
audit committee. The composition of our audit committee meets the requirements for independence under the current NASDAQ and SEC rules and regulations. In addition, our board of directors has determined that
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is an &#147;audit committee financial expert&#148; as defined in Item&nbsp;407(d)(5)(ii) of Regulation&nbsp;S-K promulgated under the Securities Act. This designation does not
impose on him any duties, obligations or liabilities that are greater than are generally imposed on members of our audit committee and our board of directors. Our audit committee is directly responsible for, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selecting a firm to serve as the independent registered public accounting firm to audit our financial statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ensuring the independence of the independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and that firm, our interim and year-end operating results; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing procedures for employees to anonymously submit concerns about questionable accounting or audit matters; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">considering the adequacy of our internal controls and internal audit function; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing material related party transactions or those that require disclosure; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approving or, as permitted, pre-approving all audit and non-audit services to be performed by the independent registered public accounting firm. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee is comprised of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is the chairperson of our
compensation committee. Each member of this committee is a non-employee director, as defined by Rule 16b-3 promulgated under the Exchange Act, and an outside director, as defined pursuant to Section&nbsp;162(m) of the Internal Revenue Code of 1984,
as amended, or the Code, and meets the requirements for independence under the current NASDAQ listing standards and SEC rules and regulations. Our compensation committee is responsible for, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or recommending that our board of directors approve, the compensation of our executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending to our board of directors the compensation of our directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending to our board of directors the terms of any compensatory agreements with our executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering our stock and equity incentive plans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or making recommendations to our board of directors with respect to, incentive compensation and equity plans; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing our overall compensation philosophy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">oversight of risks related to compensation of our directors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evaluating the risk-taking incentives, if any, and risk management of our compensation policies and practices. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and governance committee is comprised of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is the chairman of our nominating and governance committee. Each member of the Committee meets the
requirements for independence under the current NASDAQ listing standards. Our nominating and governance committee is responsible for, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying and recommending candidates for membership on our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending directors to serve on board committees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending our corporate governance guidelines and policies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing proposed waivers of the code of conduct for directors and executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evaluating, and overseeing the process of evaluating, the performance of our board of directors and individual directors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assisting our board of directors on corporate governance matters. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and
Insider Participation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our executive officers has served as a member of our board of directors, or as a member of our
compensation or similar committee, of any entity that has one or more executive officers who served on our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
board of directors or compensation committee during the year ended December&nbsp;31, 2014. Prior to establishing the compensation committee, our full board of directors made decisions relating to
the compensation of our officers. For a description of transactions between us and members of our compensation committee and affiliates of such members, please see &#147;Certain Relationships and Related Party Transactions.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-Employee Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table presents the total compensation earned or paid in the year ended December&nbsp;31, 2014, for each member of our board of directors, except for our President and Chief Executive Officer, Mr.&nbsp;Suria, who receives no additional
compensation for his service as a director. Other than as described below, none of our non-employee directors received any fees or reimbursement of any expenses (other than customary expenses in connection with the attendance of meetings of our
board of directors) or any equity or non-equity awards in the year ended December&nbsp;31, 2014. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or</B><br><B>Paid in Cash<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)(4)</SUP>&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other</B><br><B>Compensation<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D., FRS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Gallagher was paid a $50,000 annual retainer fee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Lydon was granted an early-exercisable stock-option award on July&nbsp;11, 2014 under our 2006 Equity Incentive Plan to purchase up to 239,000 shares of our common stock at a per-share price of $0.10. 1/4 of
the shares underlying the option vest on January&nbsp;1, 2015, and, thereafter, 1/48 of the underlying shares vest on the first day of each succeeding calendar month, starting February&nbsp;1, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The amount reported in this column represents the aggregate grant date fair value of stock options as computed in accordance with FASB ASC Topic 718. The amounts reported in this column reflect the accounting cost for
these stock options, and do not correspond to the actual economic value that may be received by the non-employee directors from the awards. The assumptions used in calculating the grant date fair value of the stock options reported in this column
are set forth in Note 8 to our financial statements. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">The following table sets forth information on stock options granted to non-employee directors in 2014 and the aggregate number of shares of our common stock subject to outstanding stock options held by our non-employee
directors as of December&nbsp;31, 2014: </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Granite Biopharma, LLC was paid $50,000 pursuant to a Therapeutic Advisory Agreement entered into on April&nbsp;1, 2014 between Granite Biopharma, LLC and us. Dr.&nbsp;Lydon is the sole member of Granite Biopharma, LLC.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:50.85pt; font-size:8pt; font-family:Times New Roman"><B>Director Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B><br><B>Underlying Stock</B><br><B>Options Granted</B><br><B>in 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B><br><B>Underlying Stock</B><br><B>Options Held as of<BR>December&nbsp;31,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D., FRS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">478,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_13"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables and accompanying narrative disclosure set forth information about the compensation provided to our executive officers
during the year ended December&nbsp;31, 2014. These executive officers, who include our principal executive officer and the two most highly-compensated executive officers (other than our principal executive officer) who were serving as executive
officers as of December&nbsp;31, 2014, the end of our last completed fiscal year, were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Hamza Suria, President, Chief Executive Officer and Director; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">David King, our former Chief Scientific Officer; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Marco Londei, Chief Development Officer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We refer to these individuals in this section as our
&#147;named executive officers.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents summary information regarding the total compensation for services rendered in all capacities that was awarded to
and earned by our named executive officers during the year ended December&nbsp;31, 2014. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:97.90pt; font-size:8pt; font-family:Times New Roman"><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">326,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">166,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">546,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David King, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">297,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">357,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Londei, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">167,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD VALIGN="bottom" ALIGN="right">28,657<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">278,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Development Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent bonuses awarded at the discretion of our board of directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent the aggregate grant-date fair value of the awards granted under our 2006 Equity Incentive Plan to our named executive officers during the year ended December&nbsp;31, 2014,
as computed in accordance with FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of the awards reported in the Stock Option Awards column are set forth in Note&nbsp;8 to our financial statements. Note that the amounts
reported in this column reflect the aggregate accounting cost for these awards, and do not necessarily correspond to the actual economic value that may be received by the named executive officers from the awards. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;King&#146;s employment as our Chief Scientific Officer terminated as of April&nbsp;30, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Reflects Dr.&nbsp;Londei&#146;s salary from the commencement of his employment on September&nbsp;26, 2014, through December&nbsp;31, 2014. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Reflects reimbursements paid to, or on behalf of, Dr. Londei during the year ended December 31, 2014, consisting of (a) $28,011 for temporary housing and moving expenses, including tax gross-up with respect to temporary
housing payments and (b) $646 for travel expenses. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial terms and conditions of employment of each of Mr.&nbsp;Suria and Drs. Londei and King were set forth in written employment
agreements. Each of these arrangements was approved by our board of directors. We believed these employment agreements were necessary to induce these individuals to forego other employment opportunities or leave their current employer for the
uncertainty of a demanding position in a new and unfamiliar organization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mr.&nbsp;Suria&#146;s Employment Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to an employment agreement effective as of January&nbsp;1, 2012 and amended October&nbsp;9, 2012 and September&nbsp;16, 2014, or
collectively the Suria Employment Agreement, Mr.&nbsp;Suria serves as our President and Chief Executive Officer. The Suria Employment Agreement sets forth the principal terms and conditions of his employment, including his initial annual base salary
of $285,000 and an annual target cash bonus opportunity of 25% of his base salary, subject to pro rata adjustment for any partial years worked, which bonus is earned based on our achievement of specified milestones and performance objectives, as
well as Mr.&nbsp;Suria&#146;s performance relative to one or more performance objectives established by Mr.&nbsp;Suria, our compensation committee and our board of directors, the achievement of which is evaluated by us. The Suria Employment
Agreement provided for the grant of a time-based stock option to purchase up to 1,499,684 shares of our common stock under our 2006 Equity Incentive Plan. The Suria Employment Agreement also provided for the grant of a performance-based stock option
to purchase up to 684,056 shares of our common stock under our 2006 Equity Incentive Plan, all of which would vest immediately in the event of a change of control or qualified initial public offering. These options were granted with an exercise
price equal to the fair value of our common stock on the date of grant and vest over four years as described in more detail in &#147;&#151;Outstanding Equity Awards at Fiscal Year-End Table&#148; below. Mr.&nbsp;Suria&#146;s employment is at will
and may be terminated at any time, with or without cause. However, pursuant to the terms of the Suria Employment Agreement, Mr.&nbsp;Suria will be entitled to severance benefits upon a qualifying termination of employment as described in
&#147;&#151;Potential Payments upon IPO, Termination or Change in Control&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr.&nbsp;King&#146;s Employment Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to an Employment Agreement effective as of January&nbsp;1, 2012 and amended October&nbsp;4, 2012, or collectively the King Employment
Agreement, Dr.&nbsp;King served as our Chief Scientific Officer until April&nbsp;30, 2015. Effective on May&nbsp;1, 2015, Dr.&nbsp;King joined our Scientific Advisory Board as a consultant pursuant to a consulting agreement dated May&nbsp;1, 2015,
or the King Consulting Agreement. The King Consulting Agreement sets forth the principal terms and conditions of his consulting position and provides that as compensation for his services, all of Dr. King&#146;s options will continue to vest during
his term as a consultant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because Dr.&nbsp;King remained an employee as of December&nbsp;31, 2014, we are including a description of the
King Employment Agreement even though it is no longer in effect. The King Employment Agreement set forth the principal terms and conditions of his employment, including his initial annual base salary of $275,000 and an annual target cash bonus
opportunity of 20% of his base salary, subject to pro rata adjustment for any partial years worked, which bonus is earned based on our achievement of specified milestones and performance objectives, as well as Dr.&nbsp;King&#146;s performance
relative to one or more performance objectives established by Dr.&nbsp;King, our compensation committee and our board of directors, the achievement of which is evaluated by us. Dr.&nbsp;King&#146;s employment was at will and could be terminated at
any time, with or without cause. However, pursuant to the terms of the King Employment Agreement, Dr.&nbsp;King was entitled to severance benefits upon a qualifying termination of employment as described in &#147;&#151;Potential Payments upon IPO,
Termination or Change in Control&#148; below. Dr.&nbsp;King received 9 months of severance benefits upon his termination under the King Employment Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr.&nbsp;Londei&#146;s Employment Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to an employment agreement effective as of October&nbsp;20, 2014, or the Londei Employment Agreement, Dr.&nbsp;Londei serves as our
Chief Development Officer. The Londei Employment Agreement sets forth the principal terms and conditions of his employment, including his initial annual base salary of $350,000 and an annual target cash bonus opportunity of 25% of his base salary,
which bonus is earned based on our achievement of specified milestones and performance objectives, as well as Dr.&nbsp;Londei&#146;s performance relative to one or more performance objectives established by Dr.&nbsp;Londei, our compensation
committee and our board of directors, the achievement of which is evaluated by us. Likewise, the Londei Employment Agreement provides for additional discretionary performance-based bonuses. The Londei Employment Agreement provides for the grant of a
time-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
based stock option to purchase 1,126,756 shares of our common stock under our 2006 Equity Incentive Plan. This option was granted with an exercise price equal to the fair value of our common
stock on the date of grant and vests over four years as described in more detail in &#147;&#151;Outstanding Equity Awards at Fiscal Year-End Table&#148; below. Dr.&nbsp;Londei&#146;s employment is at will and may be terminated at any time, with or
without cause. However, pursuant to the terms of the Londei Employment Agreement, Dr.&nbsp;Londei will be entitled to severance benefits upon a qualifying termination of employment as described in &#147;&#151;Potential Payments upon IPO, Termination
or Change in Control&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal Year-End Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents, for each of the named executive officers, information regarding outstanding stock options held as of
December&nbsp;31, 2014. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/9/2008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/8/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/10/2010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/9/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/24/2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/23/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/9/2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">986,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/8/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/31/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/31/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/17/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/16/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/16/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/15/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David King, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/9/2008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/8/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/10/2010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/9/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/24/2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/23/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/9/2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">986,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/8/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/17/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/16/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Londei, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/28/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,126,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/27/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">All stock-option awards have been granted under our 2006 Equity Incentive Plan. Except where otherwise noted, the underlying shares of each option vest over four years, with 1/4 of the underlying shares vesting on the
first calendar anniversary of the grant date and, thereafter, 1/48 of the underlying shares vest on the same day of each succeeding calendar month, subject to the optionee&#146;s employment through each applicable vesting date, such that 100% of the
underlying shares will have vested on the fourth calendar anniversary of the grant date. See &#147;&#151;2006 Equity Incentive Plan&#148; below for a description of the plan. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">These options are early-exercisable, so they are exercisable as to all the underlying shares. (i)&nbsp;All the shares underlying the options granted
on December&nbsp;9, 2008,&nbsp;February&nbsp;10, 2010, and February&nbsp;24, 2011 have fully vested; (ii)&nbsp;of the 986,642 shares underlying the option granted on December&nbsp;9, 2011, 1/4 vested on December&nbsp;9, 2012, and thereafter, 1/48
vest on the ninth day of each succeeding calendar month, starting January&nbsp;9, 2013, provided that if Mr.&nbsp;Suria is terminated without Cause or resigns for Good Reason (as each is defined in his option agreement) in connection with a Change
in Control (as defined in the 2006 Equity Incentive Plan), then all of the shares underlying the option shall vest at that time; (iii)&nbsp;of the 684,056 shares underlying an option granted on February&nbsp;1, 2012, all vest only upon a Change in
Control (as defined in the 2006 Equity Incentive Plan) or Qualified IPO (as defined in our restated certificate of incorporation) that is approved by our board of directors, subject to Mr.&nbsp;Suria&#146;s employment on such date; (iv)&nbsp;of the
513,042 shares underlying the option granted on February&nbsp;1, 2012, 1/4 vested on January&nbsp;1, 2013, and thereafter, 1/48 vest on the first day of each succeeding calendar month, starting February&nbsp;1, 2013, provided that if Mr.&nbsp;Suria
is terminated without Cause or resigns for Good Reason (as each is defined in his option agreement) in connection with a Change in Control (as defined in the 2006 Equity Incentive Plan), then all of the shares underlying the option shall vest at
that time; (v)&nbsp;of the 135,978 shares underlying the option </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
granted on December&nbsp;17, 2012, 1/4 vested on December&nbsp;17, 2013, and thereafter, 1/48 vest on the seventeenth day of each succeeding calendar month, starting January&nbsp;17, 2014; and
(vi)&nbsp;of the 362,880 shares underlying the option granted on September&nbsp;16, 2014, 1/4 vest on September&nbsp;16, 2015, and 1/48 vest on the sixteenth day of each succeeding calendar month, starting October&nbsp;16 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">These options are early-exercisable, except for the option granted on December&nbsp;9, 2008. The options vest as to their underlying shares as follows: (i)&nbsp;the shares underlying the options granted on
December&nbsp;9, 2008,&nbsp;February&nbsp;10, 2010, and February&nbsp;24, 2011 have fully vested; (ii)&nbsp;of the 986,642 shares underlying the option granted on December&nbsp;9, 2011, 1/4 vested on December&nbsp;9, 2012, and thereafter, 1/48 vest
on the ninth day of each succeeding calendar month, starting January&nbsp;9, 2013, provided that if Dr.&nbsp;King is terminated without Cause or resigns for Good Reason (as each is defined in his option agreement) in connection with a Change in
Control (as defined in the 2006 Equity Incentive Plan), then all of the shares underlying the option shall vest at that time; and (iv)&nbsp;of the 135,978 shares underlying the option granted on December&nbsp;17, 2012, 1/4 vested on
December&nbsp;17, 2013, and, thereafter, 1/48 vest on the seventeenth day of each succeeding calendar month, starting January&nbsp;17, 2014. Dr.&nbsp;King&#146;s employment was terminated on April&nbsp;30, 2015, and he joined our Scientific Advisory
Board as a consultant on May&nbsp;1, 2015. Pursuant to the terms of his consulting agreement these options continue to vest according to the schedules detailed above. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">These options are early-exercisable. The options vest as to their underlying shares as follows: 1/4 of the shares vest on October&nbsp;24, 2015, and 1/48 vest on the 24th day of each succeeding calendar month, starting
November&nbsp;24, 2015, provided that if Dr.&nbsp;Londei is terminated without Cause or resigns for Good Reason (as each is defined in his option agreement) in connection with a Change in Control (as defined in the 2006 Equity Incentive Plan), then
all of the shares underlying the option shall vest at that time. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Payments upon IPO, Termination or Change in Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IPO </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Suria
Employment Agreement, his option granted on February&nbsp;1, 2012 will vest in full upon a Change in Control (as defined in the 2006 Equity Incentive Plan) or Qualified IPO (as defined in our restated certificate of incorporation) that is approved
by our board of directors, subject to Mr.&nbsp;Suria&#146;s employment on such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Suria Employment Agreement, the King Employment Agreement and the Londei Employment Agreement, in the event that
Mr.&nbsp;Suria, Dr.&nbsp;King or Dr.&nbsp;Londei is terminated without &#147;Cause&#148; or resigns for &#147;Good Reason&#148; (each as defined in the applicable employment agreement), provided that each delivers a signed settlement and general
release in favor of us and satisfies all conditions to make such release effective, (i)&nbsp;each will receive continued severance payments for 12 months, nine months and nine months, respectively and (ii)&nbsp;and if each elects continuation
coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, or COBRA, we will pay directly to the insurance provider of our group health plans, the monthly premium for such continuation coverage, for 12 months, nine months and nine
months, respectively, or such earlier date on which coverage with a new employer is obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;King&#146;s employment terminated
on April&nbsp;30, 2015; nine months of severance benefits were paid to him upon his termination, including six months of COBRA premiums, pursuant to a Release and Waiver of Claims between Dr.&nbsp;King and us. Dr.&nbsp;King&#146;s consulting
agreement does not provide for severance benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Control </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Suria Employment Agreement and certain of his outstanding stock option agreements, if we experience a change in control and
Mr.&nbsp;Suria is terminated without &#147;cause&#148; or resigns for &#147;good reason&#148; (each as defined in the employment agreement) upon the occurrence of or within 13 months following such change in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
control, and provided that Mr.&nbsp;Suria delivers a signed settlement and general release in favor of us and satisfies all conditions to make such release effective, (i)&nbsp;Mr.&nbsp;Suria will
receive the continued severance payments and COBRA premiums described above for 12 months and (ii)&nbsp;certain of his currently outstanding stock options will vest in full as described in more detail in &#147;&#151;Outstanding Equity Awards at
Fiscal Year-End Table&#148; above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Mr.&nbsp;Suria&#146;s option granted on February&nbsp;1, 2012, will vest in full upon a
change in control, subject to Mr.&nbsp;Suria&#146;s employment on such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the King Employment Agreement and certain of his
outstanding stock option agreements, if we experience a change in control and Dr.&nbsp;King is terminated without &#147;cause&#148; or resigns for &#147;good reason&#148; (each as defined in the employment agreement) upon the occurrence of or within
13 months following such change in control, and provided that Dr.&nbsp;King delivers a signed settlement and general release in favor of us and satisfies all conditions to make such release effective, Dr.&nbsp;King will receive the severance
payments and COBRA premiums described above for nine months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, Dr.&nbsp;King had his employment terminated on
April&nbsp;30, 2015 and he is being paid nine months of severance pursuant to the King Employment Agreement; however, in connection with his consulting services, his stock options remain outstanding and continue to be eligible for the vesting
acceleration provisions described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Londei Employment Agreement, if we experience a change in control and
Dr.&nbsp;Londei is terminated without &#147;cause&#148; or resigns for &#147;good reason&#148; (each as defined in the employment agreement or applicable option agreement) upon the occurrence of or within 13 months following such change in control,
and provided that Dr.&nbsp;Londei delivers a signed settlement and general release in favor of us and satisfies all conditions to make such release effective, (i)&nbsp;Dr.&nbsp;Londei will receive the severance payments and COBRA premiums described
above for nine months and (ii)&nbsp;each of his currently outstanding stock options will vest in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each employment agreement contains
a &#147;better after-tax&#148; provision, which provides that if any of the payments to Mr.&nbsp;Suria, Dr.&nbsp;King or Dr.&nbsp;Londei, respectively, constitutes a parachute payment under Section&nbsp;280G of the Code, the payments will either be
(i)&nbsp;reduced or (ii)&nbsp;provided in full to the executive, whichever results in the executive receiving the greater amount after taking into consideration the payment of all taxes, including the excise tax under Section&nbsp;4999 of the Code,
in each case based upon the highest marginal rate for the applicable tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefit and Stock Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2006 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
2006 Equity Incentive Plan was adopted by our board of directors on April&nbsp;24, 2006 and approved by our stockholders on May&nbsp;26, 2006, and was most recently amended by our board of directors on July&nbsp;11, 2014 and approved by our
stockholders on April&nbsp;29, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2006 Equity Incentive Plan provides for the grant of both incentive stock options, which qualify
for favorable tax treatment to their recipients under Section&nbsp;422 of the Code, and nonstatutory stock options, as well as for the issuance of shares of restricted stock and stock appreciation rights. We may grant incentive stock options only to
our employees, including officers and directors who are also employees. We may grant nonstatutory stock options to our employees, officers, directors and consultants. We have only granted stock options under our 2006 Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2006 Equity Incentive Plan is administered by our board of directors. Our board of directors has the authority to construe and interpret
our 2006 Equity Incentive Plan, grant awards, determine the terms of such awards and make all other determinations necessary or advisable for the administration of the plan. Subject to the terms of our 2006 equity incentive plan and the consent of
any adversely affected participant, our board of directors also has the authority to reduce the exercise or strike price of any outstanding stock option or stock appreciation right, cancel any outstanding stock option or stock appreciation right in
exchange for a new stock option or stock appreciation right, or take any other action that is treated as a repricing under generally accepted accounting principles. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price of each stock option must be at least equal to the fair market value of our
common stock on the date of grant. The exercise price of incentive stock options granted to 10% stockholders must be at least equal to 110% of the fair market value of our common stock on the date of grant. The maximum permitted term of options
granted under our 2006 Equity Incentive Plan is ten years, except that the maximum permitted term of incentive stock options granted to 10% stockholders is five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options granted under our 2006 Equity Incentive Plan generally vest over a four-year period based on employment through certain vesting dates.
Options granted under our 2006 Equity Incentive Plan may not be transferred in any manner other than by will or by the laws of descent and distribution or as determined by our board of directors. Unless otherwise permitted by our board of directors,
stock options may be exercised during the lifetime of the optionee only by the optionee or the optionee&#146;s guardian or legal representative. Options granted under our 2006 Equity Incentive Plan generally may be exercised for a period of three
months after the termination of the optionee&#146;s service to us for any reason other than due to death or disability, for a period of 12 months in the case of death, and 18 months in the case of disability, or such longer period as our board of
directors may provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined in the 2006 Equity Incentive Plan), the 2006 Equity Incentive
Plan provides that awards may be assumed, continued or substituted by the successor or acquiring entity. If any surviving or acquiring corporation fails to assume, continue or substitute such stock awards, stock awards held by participants whose
continuous service has not terminated will accelerate vesting in full prior to the corporate transaction. All stock awards will terminate at or prior to the corporate transaction. In addition, our board may also provide, in its sole discretion, that
the holder of a stock award that will terminate upon the occurrence of a corporate transaction will receive a payment, if any, equal to the excess of (1)&nbsp;the value of the property the participant would have received upon exercise of the stock
award over (2)&nbsp;the exercise price otherwise payable in connection with the stock award. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2015, we had reserved
14,104,420 shares of our common stock for issuance under our 2006 Equity Incentive Plan. As of June 30, 2015, options to purchase 1,871,130 of these shares had been exercised, options to purchase 8,657,422 of these shares remained outstanding and
3,825,868 of these shares remained available for grant. Our board of directors approved a plan increase of 4,766,852 shares of common stock under our 2006 Equity Incentive Plan on July&nbsp;9, 2015. The options outstanding as of June 30, 2015 had a
weighted-average exercise price of $0.1870 per share. We will cease issuing awards under our 2006 Equity Incentive Plan upon the effective date of our 2015 Equity Incentive Plan. Our 2015 Equity Incentive Plan will be effective on the date
immediately prior to the date of this prospectus. As a result, we will not grant any additional options under the 2006 Equity Incentive Plan following that date, and the 2006 Equity Incentive Plan will be terminated at that time. However, any
outstanding options granted under the 2006 Equity Incentive Plan will remain outstanding, subject to the terms of our 2006 Equity Incentive Plan and stock option agreements, until such outstanding options are exercised or until they terminate or
expire by their terms. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2015 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a 2015 Equity Incentive Plan that will become effective on the date immediately prior to the date of this prospectus and will
serve as the successor to our 2006 Equity Incentive Plan. We reserved &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock to be issued under our 2015 Equity Incentive Plan. The number of shares reserved
for issuance under our 2015 Equity Incentive Plan will increase automatically on January&nbsp;1 of each of 2016 through 2025 by the number of shares equal to &nbsp;&nbsp;&nbsp;&nbsp;% of the aggregate number of outstanding shares of our common stock
as of the immediately preceding December&nbsp;31. However, our board of directors may reduce the amount of the increase in any particular year. In addition, the following shares will again be available for grant and issuance under our 2015 Equity
Incentive Plan: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares subject to options or stock appreciation rights granted under our 2015 Equity Incentive Plan that cease to be subject to the option or stock appreciation right for any reason other than exercise of the option or
stock appreciation right;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares subject to awards granted under our 2015 Equity Incentive Plan that are subsequently forfeited or repurchased by us at the original issue price;</TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares subject to awards granted under our 2015 Equity Incentive Plan that otherwise terminate without shares being issued;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares surrendered, cancelled or exchanged for cash or a different award (or combination thereof);</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares of common stock reserved but not issued or subject to outstanding grants under our 2006 Equity Incentive Plan on the date of this prospectus will be available for grant and issuance under our 2015 Equity
Incentive Plan;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares of common stock issuable upon the exercise of options or subject to other awards under our 2006 Equity Incentive Plan prior to the date of this prospectus that cease to be subject to such options or other awards
by forfeiture or otherwise after the date of this prospectus will be available for grant and issuance under our 2015 Equity Incentive Plan;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares of common stock issued under our 2006 Equity Incentive Plan that are forfeited or repurchased by us after the date of this prospectus will be available for grant and issuance under our 2015 Equity Incentive Plan;
and</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares of common stock subject to awards under our 2006 Equity Incentive Plan that are used to pay the exercise price of an option or withheld to satisfy the tax withholding obligations related to any award will be
available for grant and issuance under our 2015 Equity Incentive Plan. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2015 Equity Incentive Plan authorizes the award
of stock options, restricted stock awards, or RSAs, stock appreciation rights, or SARs, restricted stock units, or RSUs, performance awards and stock bonuses. No person will be eligible to receive more than
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares in any calendar year under our 2015 Equity Incentive Plan other than a new employee of ours, who will be eligible to receive no more than
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares under the plan in the calendar year in which the employee commences employment. No more than
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be issued pursuant to the exercise of incentive stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2015 Equity Incentive Plan will be administered by our compensation committee, all of the members of which are outside directors as
defined under applicable federal tax laws, or by our board of directors acting in place of our compensation committee. The compensation committee will have the authority to construe and interpret our 2015 Equity Incentive Plan, grant awards,
determine the terms of such awards and make all other determinations necessary or advisable for the administration of the plan, including, but not limited to, repricing options or SARs without prior stockholder approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2015 Equity Incentive Plan will provide for the grant of awards to our employees, directors, consultants, independent contractors and
advisors, provided the consultants, independent contractors, directors and advisors are natural persons that render services not in connection with the offer and sale of securities in a capital-raising transaction. The exercise price of stock
options must be at least equal to the fair market value of our common stock on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that in general, options
will vest over a four-year period. Options may vest based on time or achievement of performance conditions. Our compensation committee may provide for options to be exercised only as they vest or to be immediately exercisable with any shares issued
on exercise being subject to our right of repurchase that lapses as the shares vest. The maximum term of options granted under our 2015 Equity Incentive Plan is ten years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An RSA is an offer by us to sell shares of our common stock subject to restrictions, which may vest based on time or achievement of
performance conditions. The price (if any) of an RSA will be determined by the compensation committee. Unless otherwise determined by the compensation committee at the time of award, vesting will cease on the date the participant no longer provides
services to us and unvested shares will be forfeited to or repurchased by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SARs provide for a payment, or payments, in cash or shares of our common stock, to the holder
based upon the difference between the fair market value of our common stock on the date of exercise and the stated exercise price up to a maximum amount of cash or number of shares. SARs may vest based on time or achievement of performance
conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RSUs represent the right to receive shares of our common stock at a specified date in the future, subject to forfeiture of
that right because of termination of employment or failure to achieve certain performance conditions. If an RSU has not been forfeited, then on the date specified in the RSU agreement, we will deliver to the holder of the RSU whole shares of our
common stock (which may be subject to additional restrictions), cash or a combination of our common stock and cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Performance shares
are performance awards that cover a number of shares of our common stock that may be settled upon achievement of the pre-established performance conditions in cash or by issuance of the underlying shares. These awards are subject to forfeiture prior
to settlement because of termination of employment or failure to achieve the performance conditions. No participant will be eligible to receive more than $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in performance awards in any calendar year.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock bonuses may be granted as additional compensation for service or performance and, therefore, will not be issued in exchange for
cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in our capital structure without our receipt of consideration, such as a stock
split, appropriate adjustments will be made to the number of shares reserved under our 2015 Equity Incentive Plan, the maximum number of shares that can be granted in a calendar year and the number of shares and exercise price, if applicable, of all
outstanding awards under our 2015 Equity Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Awards granted under our 2015 Equity Incentive Plan may not be transferred in
any manner other than by will or by the laws of descent and distribution or as determined by our compensation committee. Unless otherwise permitted by our compensation committee, stock options may be exercised during the lifetime of the optionee
only by the optionee or the optionee&#146;s guardian or legal representative. Options granted under our 2015 Equity Incentive Plan generally may be exercised for a period of three months after the termination of the optionee&#146;s service to us for
any reason other than for cause or due to death or disability, for a period of 12 months in the case of death or disability, or such longer period as our compensation committee may provide. Options generally terminate immediately upon termination of
employment for cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a merger or consolidation, any and all outstanding awards may be assumed or replaced by the
successor corporation. In the alternative, the successor corporation may substitute equivalent awards or provide substantially similar consideration to participants as was provided to stockholders. If the outstanding awards are not assumed,
substituted or cashed out, the awards will expire upon the closing of the merger or consolidation; and our compensation committee may accelerate the vesting and exercisability (as applicable) of the awards in connection with the transaction. In the
event of a merger or consolidation, the vesting of all awards granted to non-employee directors shall accelerate and such awards shall become exercisable (as applicable) in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2015 Equity Incentive Plan will terminate ten years from the date our board of directors adopts the plan, unless it is terminated earlier
by our board of directors. Our board of directors may amend or terminate our 2015 Equity Incentive Plan at any time. Our board of directors generally may amend our 2015 Equity Incentive Plan, without stockholder approval unless required by
applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2015 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a 2015 Employee Stock Purchase Plan that will become effective on the date of this prospectus that will enable eligible
employees to purchase shares of our common stock at a discount following the date of this offering. Purchases will be accomplished through participation in discrete offering periods. We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
initially reserved&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock for issuance under our 2015 Employee Stock Purchase Plan. The number of
shares reserved for issuance under our 2015 Employee Stock Purchase Plan will increase automatically on January&nbsp;1st of each of the first &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;fiscal years following the first
offering date by the number of shares equal to the greater of &nbsp;&nbsp;&nbsp;&nbsp;% of the total outstanding shares of our common stock as of the immediately preceding December&nbsp;31 (rounded to the nearest whole share) or the actual number of
shares purchased under the 2015 Employee Stock Purchase Plan in the immediately preceding fiscal year. However, our board of directors or compensation committee may reduce the amount of the increase in any particular year. The aggregate number of
shares issued over the term of our 2015 Employee Stock Purchase Plan will not exceed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. Our 2015 Employee Stock Purchase Plan is intended to
qualify as an employee stock purchase plan under Section&nbsp;423 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee will administer our 2015
Employee Stock Purchase Plan. While our employees generally are eligible to participate in our 2015 Employee Stock Purchase Plan, our compensation committee may in its discretion elect to exclude employees who work less than 20 hours per week or
less than five months in a calendar year. In addition, employees who are 5% stockholders, or would become 5% stockholders as a result of their participation in our 2015 Employee Stock Purchase Plan, are ineligible to participate in our 2015 Employee
Stock Purchase Plan. We may impose additional restrictions on eligibility. Under our 2015 Employee Stock Purchase Plan, eligible employees will be able to acquire shares of our common stock by accumulating funds through payroll deductions. Our
eligible employees will be able to select a rate of payroll deduction between &nbsp;&nbsp;&nbsp;&nbsp;% and &nbsp;&nbsp;&nbsp;&nbsp;% of their base cash compensation. The purchase price of the shares will be 85% of the lower of the fair market value
of our common stock on the first day of an offering or on the date of purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When the first purchase period commences, our employees
who meet the eligibility requirements for participation in that purchase period will automatically be granted a nontransferable option to purchase shares in that purchase period. For subsequent purchase periods, new participants will be required to
enroll in a timely manner. Once an employee is enrolled, participation will be automatic in subsequent purchase periods. Each purchase period will run for no more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months.
An employee&#146;s participation automatically ends upon termination of employment for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for the first purchase period,
each purchase period will be for six months (commencing each&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;). The first purchase period
will begin upon the effective date of this offering and will end on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No participant will have the right to purchase our shares in an amount, when aggregated with purchase rights under all our employee stock
purchase plans that are also in effect in the same calendar years, that has a fair market value of more than $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, determined as of the first day of the applicable purchase period, for each calendar year
in which that right is outstanding. In addition, no participant will be permitted to purchase more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares during any one purchase period or such lesser amount determined by
our compensation committee. The purchase price for shares of our common stock purchased under our 2015 Employee Stock Purchase Plan will be &nbsp;&nbsp;&nbsp;&nbsp;% of the lesser of the fair market value of our common stock on (i)&nbsp;the first
trading day of the applicable offering period or (ii)&nbsp;the last trading day of each purchase period in the applicable offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we experience a change in control transaction, each outstanding right to purchase shares under our 2015 Employee Stock Purchase Plan may be
assumed or an equivalent option substituted by the successor corporation. In the event that the successor corporation refuses to assume or substitute the outstanding purchase rights, any offering period that commenced prior to the closing of the
proposed change in control transaction will be shortened and terminated on a new purchase date. The new purchase date will occur prior to the closing of the proposed change in control transaction and our 2015 Employee Stock Purchase Plan will then
terminate on the closing of the proposed change in control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also have the right to amend or terminate our 2015 Employee Stock Purchase Plan at any
time. Our 2015 Employee Stock Purchase Plan will terminate on the tenth anniversary of the last day of the first purchase period, unless it is terminated earlier by our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We sponsor a
retirement savings plan established January&nbsp;1, 2007, that is intended to qualify for favorable tax treatment under Section&nbsp;401(a) of the Code, and contains a cash or deferred feature that is intended to meet the requirements of
Section&nbsp;401(k) of the Code. Participants may make pre-tax and certain after-tax (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the Code. Participants who are 50
years of age or older may contribute additional amounts based on the statutory limits for catch-up contributions. Participant contributions are held in trust as required by law. No minimum benefit is provided under the plan. An employee&#146;s
interest in his or her salary deferral contributions is 100% vested when contributed. We have the ability to make discretionary contributions under the plan but have not done so to date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Benefits </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named
executive officers are eligible to participate in our employee benefit plans on the same basis as our other employees, including our health and welfare plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation that will become effective in connection with the closing of this offering contains provisions that
limit the liability of our directors for monetary damages to the fullest extent permitted by the Delaware General Corporation Law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any
breach of fiduciary duties as directors, except liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any breach of the director&#146;s duty of loyalty to us or our stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the Delaware General Corporation Law; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction from which the director derived an improper personal benefit. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated
certificate of incorporation and our restated bylaws that will become effective in connection with the closing of this offering require us to indemnify our directors and officers to the maximum extent not prohibited by the Delaware General
Corporation Law and allow us to indemnify other employees and agents as set forth in the Delaware General Corporation Law. Subject to certain limitations, our restated bylaws also require us to advance expenses incurred by our directors and officers
for the defense of any action for which indemnification is required or permitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered, and intend to continue to enter, into
separate indemnification agreements with our directors, officers and certain of our key employees, in addition to the indemnification provided for in our restated certificate of incorporation and restated bylaws. These agreements, among other
things, require us to indemnify our directors, officers and key employees for certain expenses, including attorneys&#146; fees, judgments, penalties, fines and settlement amounts actually incurred by these individuals in any action or proceeding
arising out of their service to us or any of our subsidiaries or any other company or enterprise to which these individuals provide services at our request. Subject to certain limitations, our indemnification agreements also require us to advance
expenses incurred by our directors, officers and key employees for the defense of any action for which indemnification is required or permitted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that these indemnification provisions and agreements are necessary to attract and
retain qualified directors, officers and key employees. We also maintain directors&#146; and officers&#146; liability insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
limitation of liability and indemnification provisions in our restated certificate of incorporation and restated bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They
may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the
extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, there is no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification is
required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, executive officers or persons
controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We describe below transactions and series of similar transactions since January&nbsp;1, 2012 to which we were a party or will be a party, in
which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amounts involved exceeded or will exceed $120,000; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any of our directors, executive officers or beneficial holders of more than 5% of any class of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect
material interest. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as described below, there have not been, nor are there any currently proposed, transactions
or series of similar transactions to which we have been or will be a party other than compensation arrangements, which are described where required under &#147;Executive Compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Financings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series&nbsp;C-1 Preferred Stock
Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, we issued an aggregate of 3,318,054 shares of our Series C-1 convertible preferred stock at a purchase
price of $0.65 per share, in exchange for the cancellation of secured convertible promissory notes originally issued in July 2013, which as of April 2014 had an aggregate principal and unpaid interest of $2.2 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Series C-1 convertible preferred stock issued to our executive officers, members of our board of directors
and persons who hold more than 5% of our outstanding capital stock: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:71.95pt; font-size:8pt; font-family:Times New Roman"><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>Series C-1<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,370,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">890,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo A/S<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,370,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">890,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alloy Ventures 2005, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">541,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Represents shares held by Frazier Healthcare V, L.P., an affiliate of Frazier Healthcare Ventures. Dr.&nbsp;Topper, a member of our Board of Directors, is a General Partner of Frazier Healthcare and may be deemed to
have voting and investment power with respect to these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Aynechi, a member of our board of directors, is employed as a Partner at Novo Ventures (US) Inc., which provides certain consultancy services to Novo A/S, and Dr.&nbsp;Aynechi has no beneficial ownership of or
pecuniary interest in these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Suria is our President and Chief Executive Officer and is a member of our Board of Directors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of our Series C-1 convertible preferred stock will convert automatically into one share of our common stock upon the closing of
this offering. The purchasers of our Series C-1 convertible preferred stock are entitled to specified registration rights, as described below under &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series D Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2015, we sold an aggregate of 38,436,851 shares of our Series D convertible preferred stock at a purchase price of $1.06 per share, for
an aggregate cash purchase price of $40.8 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Series D convertible preferred stock purchased by our
executive officers, members of our board of directors and persons who hold more than 5% of our outstanding capital stock: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:71.95pt; font-size:8pt; font-family:Times New Roman"><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>Series D<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,599,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo A/S<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,714,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D., FRS<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">471,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">159,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert E. Hoffman<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Londei, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares held by Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P., both affiliates of Frazier Healthcare. Dr.&nbsp;Topper, a member of our Board of Directors, is a General Partner of Frazier
Healthcare and may be deemed to have voting and investment power with respect to these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Aynechi, a member of our board of directors, is employed as a Partner at Novo Ventures (US) Inc., which provides certain consultancy services to Novo A/S, and Dr.&nbsp;Aynechi has no beneficial ownership of or
pecuniary interest in these shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Lydon is a member of our Board of Directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Gallagher is a member of our Board of Directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Hoffman is our Chief Financial Officer. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Suria is our President and Chief Executive Officer and is a member of our Board of Directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Londei is our Chief Development Officer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of our Series D convertible
preferred stock will convert automatically into one share of our common stock upon the closing of this offering. The purchasers of our Series D convertible preferred stock are entitled to specified registration rights, as described below under
&#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amended and Restated Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an amended and restated investors&#146; rights agreement with certain holders of our convertible preferred stock,
including entities with which certain of our directors are affiliated. These stockholders are entitled to rights with respect to the registration of their shares following our initial public offering under the Securities Act. For a description of
these registration rights, see &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers. The indemnification agreements, our restated
certificate of incorporation and our restated bylaws will require us to indemnify our directors to the fullest extent not prohibited by Delaware law. Subject to certain limitations, our restated bylaws also require us to advance expenses incurred by
our directors and officers. For more information regarding these agreements, see &#147;Executive Compensation&#151;Limitations on Liability and Indemnification Matters.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to adopt a written related person transactions policy that our executive officers, directors, nominees for election as a director,
beneficial owners of more than 5% of our common stock, and any members </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a material related person transaction with us without the review and
approval of our audit committee, or a committee composed solely of independent directors in the event it is inappropriate for our audit committee to review such transaction due to a conflict of interest. We expect the policy to provide that any
request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of our common stock or with any of their immediate family members or affiliates in which the amount
involved exceeds $120,000 will be presented to our audit committee for review, consideration and approval. In approving or rejecting any such proposal, we expect that our audit committee will consider the relevant facts and circumstances available
and deemed relevant to the audit committee, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of
the related person&#146;s interest in the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of our common stock at July 31, 2015, and as
adjusted to reflect the sale of common stock in this offering, for: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our named executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our current directors and executive officers as a group; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person, or group of affiliated persons, who beneficially owned more than 5% of our common stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC, and the information is not necessarily indicative of
beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect
to all shares of common stock that they beneficially owned, subject to applicable community property laws. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable percentage
ownership is based on 98,456,542 shares of common stock outstanding as of July 31, 2015 and assumes (i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock into 80,645,051 shares of common stock as of
immediately prior to the closing of this offering. For purposes of the table below, we have assumed that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock will be issued by us in our initial public
offering. In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed to be outstanding all shares of common stock subject to options held by that person or entity that are
currently exercisable or that will become exercisable within 60 days of July 31, 2015. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the
address of each beneficial owner listed in the table below is c/o AnaptysBio, Inc., 10421 Pacific Center Court, Suite 200, San Diego, California 92121. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial Ownership<BR>Prior to this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial&nbsp;Ownership<BR>After this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:89.90pt; font-size:8pt; font-family:Times New Roman"><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% Stockholders</I></B><I>:</I><B><I></I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Frazier Healthcare<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,019,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novo A/S<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,133,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avalon Ventures VII, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,080,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alloy Ventures 2005, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,977,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value Fund, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,074,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HBM Healthcare Investments (Cayman) Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,599,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors and Named Executive Officers</I></B><I>:</I><B><I></I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hamza Suria<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,928,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David King, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,333,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Londei, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,140,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tiba Aynechi, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carol G. Gallagher, Pharm.D.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,134,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas B. Lydon, Ph.D., FRS<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,229,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hollings Renton<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Schmid<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James N. Topper, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,019,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (ten persons)<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,341,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;15,598,652 shares of common stock following conversion of convertible preferred stock held directly by Frazier Healthcare V, L.P., (b)&nbsp;5,136,185 shares of common stock following conversion of
convertible preferred stock held directly by Frazier Healthcare VII, L.P., (c)&nbsp;1,463,665 shares of common stock following conversion of convertible preferred stock held directly by Frazier Healthcare VII-A, L.P. and (d)&nbsp;820,647&nbsp;shares
of common stock issuable upon the exercise of a warrant held directly by Frazier Healthcare V, L.P. The general partner of Frazier Healthcare V, L.P. is FHM V, L.P., a Delaware limited partnership. The general partner of FHM V, L.P. is FHM V, LLC, a
Delaware limited liability company. The general partner of Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. is FHM VII, L.P., a Delaware limited partnership. The general partner of FHM VII, L.P. is FHM VII, LLC, a Delaware limited
liability company Dr.&nbsp;Topper, a member of our Board of Directors, is a member of FHM&nbsp;V, LLC and FHM&nbsp;VII, LLC and may be deemed to have voting and investment power with respect to the shares held by FHM&nbsp;V, LLC and FHM VII, LLC.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;20,312,831 shares of common stock following conversion of convertible preferred stock held directly by Novo A/S and (b)&nbsp;820,647&nbsp;shares of common stock issuable upon the exercise of a
warrants held directly by Novo A/S. The board of directors of Novo A/S, which is currently comprised of Sten Scheibye, G&ouml;ran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared voting and investment power with respect to
these shares and may exercise such control only with the support of a majority of the board. As such, no individual member of the board is deemed to hold any beneficiary ownership in these shares. Dr. Aynechi, a member of our board of directors, is
employed as a Partner at Novo Ventures (US) Inc., which provides certain consultancy services to Novo A/S, and Dr.&nbsp;Aynechi has no beneficial ownership of or pecuniary interest in these shares. The address of Novo A/S is Tuborg Havnevej&nbsp;19,
2900&nbsp;Hellerup, Denmark. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;14,258,530 shares of common stock held directly by Avalon Ventures VII, L.P. and (b)&nbsp;822,386 shares of common stock issuable upon the exercise of a warrant held directly by Avalon
Ventures&nbsp;VII, L.P. The general partner of Avalon Ventures&nbsp;II, L.P. is Avalon Ventures&nbsp;VII GP, LLC. The managing members of Avalon Ventures&nbsp;VII GP, LLC are Kevin&nbsp;J. Kinsella and Stephen&nbsp;L. Tomlin. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 8,977,414 shares of common stock following conversion of convertible preferred stock held directly by Alloy Ventures 2005, L.P. The general partner of Alloy Ventures 2005, L.P. is Alloy Ventures 2005, LLC.
The managing members of Alloy Ventures 2005, LLC are Craig Taylor, Doug Kelly John Shoch, Dan Rubin and Tony Di Bona. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;3,449,203 shares of common stock following conversion of convertible preferred stock held directly by Biotechnology Value Fund, L.P., (b)&nbsp;1,974,000 shares of common stock following conversion
of convertible preferred stock held directly by Biotechnology Value Fund II, L.P., (c)&nbsp;637,000 shares of common stock following conversion of convertible preferred stock held directly by Investment 10, L.L.C. and (d)&nbsp;1,014,000 shares of
common stock following conversion of convertible preferred stock held directly by MSI BVF SPV, L.L.C. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Represents 6,599,851 shares of common stock following conversion of convertible preferred stock held directly by HBM Healthcare Investments (Cayman) Ltd. The board of directors of HBM Healthcare Investments (Cayman)
Ltd. has sole vesting and investment power with respect to the shares. The board of directors of HBM Healthcare Investments (Cayman) Ltd. is comprised of Jean-Mar Lesieur, Richard Coles, Sophia Harris, Dr.&nbsp;Andrea Wicki, Paul Woodhouse and John
Urquhart, none of whom has individual voting or investment power with respect to the shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;34,996 shares of common stock following conversion of convertible preferred stock held directly by Mr.&nbsp;Suria and (b)&nbsp;2,893,055 shares of common stock issuable to Mr.&nbsp;Suria upon the
exercise of stock options that are exercisable within 60 days of July 31, 2015, of which 1,103,130 shares were unvested but were early exercisable, as of 60 days after July 31, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Represents 1,333,077 shares of common stock issuable to Dr.&nbsp;King upon the exercise of stock options that are exercisable within 60 days of July 31, 2015, of which 104,160 shares were unvested but were early
exercisable, as of 60 days after July 31, 2015. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;14,142 shares of common stock following conversion of convertible preferred stock held directly by Dr.&nbsp;Londei and (b)&nbsp;1,126,756 shares of common stock issuable to Dr.&nbsp;Londei upon the
exercise of stock options that are exercisable within 60 days of July 31, 2015, of which 1,126,756 shares were unvested but were early exercisable, as of 60 days after July 31, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;450,075 shares of common stock following conversion of convertible preferred stock held directly by Dr.&nbsp;Gallagher and (b)&nbsp;684,057 shares of common stock issuable to Dr.&nbsp;Gallagher upon
the exercise of stock options that are exercisable within 60 days of July 31, 2015, of which 14,252 shares were unvested but were early exercisable, as of 60 days after July 31, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;471,332 shares of common stock held directly by Dr.&nbsp;Lydon, (b)&nbsp;1,425,385 shares of common stock following conversion of convertible preferred stock held directly by Dr.&nbsp;Lydon,
(c)&nbsp;115,384&nbsp;shares of common stock issuable upon the exercise of a warrant held directly by Dr.&nbsp;Lydon and (d)&nbsp;217,088 shares of common stock issuable to Dr.&nbsp;Lydon upon the exercise of stock options that are exercisable
within 60 days of July 31, 2015, of which 153,756 shares were unvested but were early exercisable, as of 60 days after July 31, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Represents 358,098 shares of common stock issuable to Mr.&nbsp;Renton upon the exercise of stock options that are exercisable within 60 days of July 31, 2015, of which 338,205 shares were unvested but were early
exercisable, as of 60 days after July 31, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">Represents 151,849 shares of common stock issuable to Mr.&nbsp;Schmid upon the exercise of stock options that are exercisable within 60 days of July 31, 2015, of which 139,195 shares were unvested but were early
exercisable, as of 60 days after July 31, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top">Includes shares beneficially owned by our current executive officers and directors. Consists of (a)&nbsp;471,332 shares of common stock, (b)&nbsp;24,641,572&nbsp;shares of common stock following conversion of
convertible preferred stock, (c)&nbsp;936,031&nbsp;shares of common stock issuable upon the exercise of warrants and (d)&nbsp;6,763,980 shares of common stock issuable upon the exercise of stock options that are exercisable within 60 days of July
31, 2015, of which 2,979,454 shares were unvested but early exercisable, as of 60 days after July 31, 2015. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, our authorized capital stock will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, $0.001 par value per share, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of undesignated preferred stock, $0.001
par value per share. The following description summarizes the most important terms of our capital stock. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description, you should refer
to our restated certificate of incorporation and restated bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part, and to the applicable provisions of Delaware law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the provisions of our certificate of incorporation all of the outstanding convertible preferred stock will automatically convert
into common stock in connection with the closing of this offering. Assuming the effectiveness of this conversion as of June 30, 2015, there were 98,456,544 shares of our common stock issued, giving effect to the sale and issuance of 38,436,851
shares of Series D convertible preferred stock, held by approximately 54 stockholders of record, and no shares of our preferred stock outstanding. Our board of directors is authorized, without stockholder approval, to issue additional shares of our
capital stock. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled to
receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. See &#147;Dividend Policy&#148;
above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not
provided for cumulative voting for the election of directors in our restated certificate of incorporation. Accordingly, pursuant to our restated certificate of incorporation that will be in effect upon the closing of this offering, holders of a
majority of the shares of our common stock will be able to elect all of our directors. Our restated certificate of incorporation establishes a classified board of directors, to be divided into three classes with staggered three-year terms. Only one
class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>No Preemptive or Similar Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Right to Receive Liquidation Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable
ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation
preferences, if any, on any outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the provisions of our certificate of incorporation, all of our outstanding convertible preferred stock will automatically convert
into common stock, with such conversion to be effective in connection with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
closing of this offering. As a result, each currently outstanding share of convertible preferred stock will be converted into common stock. All series of convertible preferred stock will convert
at a ratio of one share of common stock for each share of convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following this offering, our board of directors
will be authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences
and rights of the shares of each series and any of their qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. Our board of directors can also increase or decrease the number of shares of any
series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion
rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among
other things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. We have no
current plan to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2015, we had outstanding the following warrants to purchase shares of our capital stock: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:74.40pt; font-size:8pt; font-family:Times New Roman"><B>Type of Capital Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Number<BR>of Shares<BR>Subject to<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>Price<BR>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiration Dates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">822,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">November&nbsp;2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,775,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">November 2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">288,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">December 2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2015, we had outstanding options to purchase an aggregate 8,657,422 shares of our common stock, with a weighted-average exercise
price of $0.1870. Additional options to purchase 5,496,050 shares of our common stock, with an exercise price of $0.99 were granted between June 30, 2015 and August 17, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
terms of our Amended and Restated Investor Rights Agreement, immediately following this offering, the holders of 98,456,544 shares of our common stock will be entitled to rights with respect to the registration of these shares under the Securities
Act, as described below. We refer to these shares collectively as registrable securities. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning 180&nbsp;days after the closing of this offering, the holders of at least a majority of the then-outstanding registrable
securities may make a written request to us for the registration of any of the registrable securities under the Securities Act. Within 30&nbsp;days of such request, we are obligated provide written notice of such request to all stockholders to
file&nbsp;a registration statement under the Securities Act covering all registrable securities that the initiating holders requested to be registered and any additional registrable securities requested to be included in such registration by any
other holders. We are only required to file two registration statements that are declared effective upon exercise of these demand registration rights. We may postpone taking action with respect to such filing not more than once during any 12-month
period for a total period of not more than 60&nbsp;days if our board of directors determines in its good faith judgment that it would be seriously detrimental to us and our stockholders for such registration statement to be effected at such time.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Form S-3 Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any holder of then-outstanding registrable securities can request that we register all or part of their shares on Form&nbsp;S-3 if we are
eligible to file&nbsp;a registration statement on Form&nbsp;S-3 and if the aggregate price to the public of the shares offered is at least $2,000,000. The stockholders may only require us to effect two registration statements on Form&nbsp;S-3 in a
12-month period. We may postpone taking action with respect to such filing once during any 12-month period for a total cumulative period of not more than 90&nbsp;days if our board of directors determines in its good faith judgment that the filing
would be materially detrimental to us and our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, holders of registrable securities were entitled to, and the necessary percentage of holders waived, their
rights to notice of this offering and to include their registrable securities in this offering. If we register any of our securities for public sale in another offering, holders of registrable securities will have the right to include their shares
in the registration statement. However, this right does not apply to a registration relating to employee benefit plans, a registration relating to a corporate reorganization or a registration of only common stock issuable upon conversion of debt
securities that are also being registered. We have the right to terminate any registration we have initiated before the effective date of such registration, whether or not any holder has elected to include registrable securities in such
registration. The underwriters of any underwritten offering will have the right to limit the number of shares registered by these holders if they determine in good faith that marketing factors require limitation, in which case the number of shares
to be registered will be apportioned pro rata among these holders, according to the total amount of securities entitled to be included by each holder, or in a manner mutually agreed upon by the holders. However, in any underwriting not in connection
with an initial public offering, the number of shares to be registered by these holders cannot be reduced below 30% of the total shares covered by the registration statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Expenses of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally will pay all expenses, other than underwriting discounts and commissions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Expiration of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration rights described above will expire, with respect to any particular holder of these rights, on the earlier of the fifth
anniversary of the closing of this offering, a merger, consolidation, sale or disposition of our company or a sale by a holder of equity securities representing at least a majority of the voting power of our company, or when that holder can sell all
of its registrable securities in a three-month period without restriction under Rule&nbsp;144 of the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of Delaware law, our restated certificate of incorporation and our restated bylaws, as we expect they will be in effect upon the
closing of this offering, could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are
also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or
unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law regulating corporate takeovers. In general,
Section&nbsp;203 prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date on which the person became an interested stockholder unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the
outstanding voting stock owned by the interested stockholder, (1)&nbsp;shares owned by persons who are directors and also officers and (2)&nbsp;shares owned by employee stock plans in which employee participants do not have the right to determine
confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">At or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written
consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of transactions together resulting in
a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a
corporation&#146;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section&nbsp;203 may also
discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Restated Certificate of Incorporation and Restated Bylaw Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation and our restated bylaws, as we expect they will be in effect upon the closing of this offering,
include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Board of Directors Vacancies.</I> Our restated certificate of incorporation and restated bylaws will authorize only our board of directors to fill vacant directorships, including newly created seats. In addition, the
number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire board of directors. These provisions would prevent a stockholder from increasing the size of our board of
directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Classified Board.</I> Our restated certificate of incorporation and restated bylaws will provide that our board is classified into three classes of directors, each with staggered three-year terms. A third party may
be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors. See
&#147;Management&#151;Board Composition.&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><I>Stockholder Action; Special Meetings of Stockholders.</I> Our restated certificate of incorporation will provide that our stockholders may not take
action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our restated bylaws or remove directors without
holding a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
meeting of our stockholders called in accordance with our restated bylaws. Further, our restated bylaws will provide that special meetings of our stockholders may be called only by a majority of
our board of directors, the chairman of our board of directors, our Chief Executive Officer or our President, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force
consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Advance Notice Requirements for Stockholder Proposals and Director Nominations.</I> Our restated bylaws will provide advance notice procedures for stockholders seeking to bring business before our annual meeting of
stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also will specify certain requirements regarding the form and content of a stockholder&#146;s notice. These provisions might
preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might
also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to obtain control of our company. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>No Cumulative Voting.</I> The Delaware General Corporation Law provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#146;s certificate of
incorporation provides otherwise. Our restated certificate of incorporation and restated bylaws will not provide for cumulative voting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Directors Removed Only for Cause.</I> Our restated certificate of incorporation will provide that stockholders may remove directors only for cause and only by the affirmative vote of the holders of at least
two-thirds of our outstanding common stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Amendment of Charter Provisions.</I> Any amendment of the above expected provisions in our restated certificate of incorporation would require approval by holders of at least two-thirds of our outstanding common
stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Issuance of Undesignated Preferred Stock.</I> Our board of directors has the authority, without further action by the stockholders, to issue up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized
but unissued shares of preferred stock would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by merger, tender offer, proxy contest or other means. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Choice of Forum.</I> Our restated certificate of incorporation will provide that the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our
behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our restated certificate of incorporation or our restated bylaws; or any action asserting a
claim against us that is governed by the internal affairs doctrine. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, the transfer agent and registrar for our common stock is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The transfer agent&#146;s address is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and its
telephone number is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange
Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to list our common stock on the NASDAQ Global Market under the symbol &#147;ANAB.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock, and we cannot predict the effect, if any, that market sales of
shares of our common stock or the availability of shares of our common stock for sale will have on the market price of our common stock prevailing from time to time. Nevertheless, sales of substantial amounts of our common stock, including shares
issued upon exercise of outstanding options and warrants, in the public market following this offering could adversely affect market prices prevailing from time to time and could impair our ability to raise capital through the sale of our equity
securities. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, we will have a total of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock outstanding, based on the 98,456,544 shares of our capital stock outstanding as of June 30, 2015, assuming (i)&nbsp;the automatic conversion of all
outstanding shares of our convertible preferred stock into 42,208,202 shares of common stock as of immediately prior to the closing of this offering, (ii)&nbsp;the sale and issuance of 38,436,851 shares of our Series D convertible preferred stock in
a private placement by us in July 2015 and (iii)&nbsp;the automatic conversion of 38,436,851 shares of Series D convertible preferred stock into 38,436,851 shares of common stock immediately prior to the closing of this offering. Of these
outstanding shares, all of the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock sold in this offering will be freely tradable, except that any shares purchased in this offering by our affiliates, as that
term is defined in Rule 144 under the Securities Act, could only be sold in compliance with Rule&nbsp;144. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining outstanding
shares of our common stock will be deemed &#147;restricted securities&#148; as defined in Rule 144. Restricted securities may be sold in the public market only if they are registered under the Securities Act or if they qualify for an exemption from
registration under Rule 144 or Rule 701 promulgated under the Securities Act, which rules are summarized below. In addition, substantially all of our security holders have entered into market standoff agreements with us or lock-up agreements with
the underwriters under which they have agreed, subject to specific exceptions, not to sell any of our stock for at least 180 days following the date of this prospectus, as described below. As a result of these agreements and the provisions of our
amended and restated investors&#146; rights agreement described above under &#147;Description of Capital Stock&#151;Registration Rights,&#148; subject to the provisions of Rule 144 or Rule 701,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be available for sale in the public market as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Beginning on the date of this prospectus, all of the shares sold in this offering will be immediately available for sale in the public market; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Beginning 181 days after the date of this prospectus, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares will become eligible for sale in the public market, of which
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be held by affiliates and subject to the volume and other restrictions of Rule 144, as described below, and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be unvested and subject to our right of repurchase. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lock-Up/Market Standoff Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
of our directors and officers and substantially all of our security holders are subject to lock-up agreements or market standoff provisions that prohibit them from offering for sale, selling, contracting to sell, granting any option for the sale of,
transferring or otherwise disposing of any shares of our common stock, options or warrants to acquire shares of our common stock or any security or instrument related to our common stock, or entering into any swap, hedge or other arrangement that
transfers any of the economic consequences of ownership of our common stock, for a period of 180 days following the date of this prospectus without the prior written consent of BMO Capital Markets and Stifel, Nicolaus&nbsp;&amp; Company,
Incorporated. See &#147;Underwriting.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144 as currently in effect, once we have been subject to public company reporting requirements for at least 90 days, a
person who is not deemed to have been one of our affiliates for purposes of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Securities Act at any time during the 90 days preceding a sale and who has beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior
owner other than our affiliates, is entitled to sell those shares without complying with the manner of sale, volume limitation or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. If such a
person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then that person would be entitled to sell those shares without complying with any of the
requirements of Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule&nbsp;144, as currently in effect, our affiliates or persons selling shares on behalf of
our affiliates are entitled to sell upon expiration of the lock-up and market standoff agreements described above, within any three-month period, a number of shares that does not exceed the greater of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of shares of our common stock then outstanding, which will equal approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares immediately after this offering; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume of our common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to that sale. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale
provisions and notice requirements and to the availability of current public information about us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 701 generally allows a stockholder who purchased shares of our common stock pursuant to a written compensatory plan or contract and who is
not deemed to have been an affiliate of our company during the immediately preceding 90 days to sell these shares in reliance upon Rule 144, but without being required to comply with the public information, holding period, volume limitation or
notice provisions of Rule 144. Rule 701 also permits affiliates of our company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required by
that rule to wait until 90 days after the date of this prospectus before selling those shares pursuant to Rule 701. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As soon as practicable after the closing of this offering, we intend to file one or more registration statements on Form S-8 under the
Securities Act covering all of the shares of our common stock subject to outstanding options and the shares of our common stock reserved for issuance under our stock plans. However, the shares registered on Form S-8 may be subject to the volume
limitations and the manner of sale, notice and public information requirements of Rule 144 and will not be eligible for resale until expiration of the lock-up and market standoff agreements to which they are subject. Of the 8,657,422 shares of our
common stock that were subject to stock options outstanding as of June 30, 2015, options to purchase 4,794,791 shares of common stock were vested as of June 30, 2015. Shares of our common stock underlying outstanding options will not be eligible for
sale until expiration of the 180 day lock-up and market standoff agreements to which they are subject. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted demand, piggyback and Form S-3 registration rights to certain of our stockholders to sell our common stock. Registration of the
sale of these shares under the Securities Act would result in these shares becoming freely tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. For a
further description of these rights, see &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section summarizes the material U.S. federal income tax considerations relating to the acquisition, ownership and disposition of
our common stock by &#147;non-U.S. holders&#148; (as defined below) pursuant to this offering. This summary does not provide a complete analysis of all potential U.S. federal income tax considerations relating thereto. The information provided below
is based upon provisions of the Internal Revenue Code of 1986, as amended, or the Code, Treasury regulations promulgated thereunder, administrative rulings and judicial decisions currently in effect. These authorities may change at any time,
possibly retroactively, or the Internal Revenue Service, or IRS, might interpret the existing authorities differently. In either case, the tax considerations of owning or disposing of our common stock could differ from those described below. As a
result, we cannot assure you that the tax consequences described in this discussion will not be challenged by the IRS or will be sustained by a court if challenged by the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary does not address the tax considerations arising under the laws of any non-U.S., state or local jurisdiction, or under U.S.
federal gift and estate tax laws, except to the limited extent provided below. In addition, this discussion does not address tax considerations applicable to an investor&#146;s particular circumstances or to investors that may be subject to special
tax rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">banks, insurance companies or other financial institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnerships or entities or arrangements treated as partnerships or other pass-through entities for U.S. federal tax purposes (or investors in such entities); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">corporations that accumulate earnings to avoid U.S. federal income tax; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons subject to the alternative minimum tax or the Medicare contribution tax on net investment income; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax-exempt organizations or tax-qualified retirement plans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">controlled foreign corporations or passive foreign investment companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who acquired our common stock as compensation for services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">dealers in securities or currencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">traders in securities that elect to use a mark-to-market method of accounting for their securities holdings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain former citizens or long-term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who hold our common stock as a position in a hedging transaction, &#147;straddle,&#148; &#147;conversion transaction&#148; or other risk reduction transaction; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who do not hold our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code (generally, for investment purposes); or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our common stock under the constructive sale provisions of the Code. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if a partnership or entity classified as a partnership or other pass-through entity for U.S. federal income tax purposes is a
beneficial owner of our common stock, the tax treatment of a partner in the partnership or an owner of the entity will depend upon the status of the partner or other owner and the activities of the partnership or other entity. Accordingly, this
summary does not address tax considerations applicable to partnerships that hold our common stock, and partners in such partnerships should consult their tax advisors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">INVESTORS CONSIDERING THE PURCHASE OF OUR COMMON STOCK SHOULD CONSULT THEIR OWN TAX ADVISORS
REGARDING THE APPLICATION OF THE U.S. FEDERAL INCOME AND ESTATE TAX LAWS TO THEIR PARTICULAR SITUATIONS AND THE CONSEQUENCES OF FOREIGN, STATE OR LOCAL LAWS, AND TAX TREATIES. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-U.S. Holder Defined </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of
this summary, a &#147;non-U.S. holder&#148; is any holder of our common stock, other than a partnership, that is not: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized under the laws of the United States, any state therein or the District of Columbia; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust if it (i)&nbsp;is subject to the primary supervision of a U.S. court and one of more U.S. persons have authority to control all substantial decisions of the trust or (ii)&nbsp;has a valid election in effect
under the applicable Treasury regulations to be treated as a U.S. person; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate whose income is subject to U.S. income tax regardless of source. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a
non-U.S. citizen who is an individual, you may, in many cases, be deemed to be a resident alien, as opposed to a nonresident alien, by virtue of being present in the United States for at least 31 days in the calendar year and for an aggregate of at
least 183 days during a three-year period ending in the current calendar year. For these purposes, all the days present in the current year, one-third of the days present in the immediately preceding year, and one-sixth of the days present in the
second preceding year are counted. Resident aliens are subject to U.S. federal income tax as if they were U.S. citizens. Such an individual is urged to consult his or her own tax advisor regarding the U.S. federal income tax consequences of the
ownership or disposition of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect to declare or make any distributions on our common stock in the foreseeable future. If we do pay dividends on shares of our
common stock, however, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions
in excess of our current and accumulated earnings and profits will constitute a return of capital that is applied against and reduces, but not below zero, a non-U.S. holder&#146;s adjusted tax basis in shares of our common stock. Any remaining
excess will be treated as gain realized on the sale or other disposition of our common stock. See &#147;&#151;Sale of Common Stock.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any dividend paid to a non-U.S. holder on our common stock that is not effectively connected with a non-U.S. holder&#146;s conduct of a trade
or business in the United States will generally be subject to U.S. withholding tax at a 30% rate. The withholding tax might apply at a reduced rate, however, under the terms of an applicable income tax treaty between the United States and the
non-U.S. holder&#146;s country of residence. You should consult your tax advisors regarding your entitlement to benefits under a relevant income tax treaty. Generally, in order for us or our paying agent to withhold tax at a lower treaty rate, a
non-U.S. holder must certify its entitlement to treaty benefits. A non-U.S. holder generally can meet this certification requirement by providing a Form W-8BEN or Form W-8BEN-E (or any successor of such forms) or appropriate substitute form to us or
our paying agent. If the non-U.S. holder holds the stock through a financial institution or other agent acting on the holder&#146;s behalf, the holder will be required to provide appropriate documentation to the agent. The holder&#146;s agent will
then be required to provide certification to us or our paying agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty, you may obtain a refund or
credit of any excess amounts withheld by filing an appropriate claim for a refund with the IRS in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends received by
a non-U.S. holder that are effectively connected with a U.S. trade or business conducted by the non-U.S. holder, and if required by an applicable income tax treaty between the United States </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the non-U.S. holder&#146;s country of residence, are attributable to a permanent establishment maintained by the non-U.S. holder in the United States, are not subject to U.S. withholding tax.
To obtain this exemption, a non-U.S. holder must provide us or our paying agent with an IRS Form W-8ECI properly certifying such exemption. Such effectively connected dividends, although not subject to withholding tax, are taxed at the same
graduated rates applicable to U.S. persons, net of certain deductions and credits. In addition to being taxed at graduated tax rates, dividends received by corporate non-U.S. holders that are effectively connected with a U.S. trade or business of
the corporate non-U.S. holder may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable tax treaty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale of Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the
discussions below regarding Backup Withholding and Information Reporting and the Foreign Account Tax Compliance Act, non-U.S. holders will generally not be subject to U.S. federal income tax on any gains realized on the sale, exchange or other
disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the gain (i)&nbsp;is effectively connected with the conduct by the non-U.S. holder of a U.S. trade or business and (ii)&nbsp;if required by an applicable income tax treaty between the United States and the non-U.S.
holder&#146;s country of residence, is attributable to a permanent establishment maintained by the non-U.S. holder in the United States (in which case the special rules described below apply); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the non-U.S. holder is an individual who is present in the United States for 183 days or more in the taxable year of the sale, exchange or other disposition of our common stock, and certain other requirements are met
(in which case the gain would be subject to a flat 30% tax, or such reduced rate as may be specified by an applicable income tax treaty, which may be offset by U.S. source capital losses, even though the individual is not considered a resident of
the United States); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rules of the Foreign Investment in Real Property Tax Act, or FIRPTA, treat the gain as effectively connected with a U.S. trade or business. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FIRPTA rules may apply to a sale, exchange or other disposition of our common stock if we are, or were within the shorter of the five-year
period preceding the disposition and the non-U.S. holder&#146;s holding period, a &#147;U.S. real property holding corporation,&#148; or USRPHC. In general, we would be a USRPHC if interests in U.S. real estate comprised at least half of the value
of our business assets. We do not believe that we are a USRPHC and we do not anticipate becoming one in the future. Even if we become a USRPHC, as long as our common stock is regularly traded on an established securities market, such common stock
will be treated as U.S. real property interests only if beneficially owned by a non-U.S. holder that actually or constructively owned more than 5% of our outstanding common stock at some time within the five-year period preceding the disposition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any gain from the sale, exchange or other disposition of our common stock, (i)&nbsp;is effectively connected with a U.S. trade or
business conducted by a non-U.S. holder and (ii)&nbsp;if required by an applicable income tax treaty between the United States and the non-U.S. holder&#146;s country of residence, is attributable to a permanent establishment maintained by such
non-U.S. holder in the United States, then the gain generally will be subject to U.S. federal income tax at the same graduated rates applicable to U.S. persons, net of certain deductions and credits. If the non-U.S. holder is a corporation, under
certain circumstances, that portion of its earnings and profits that is effectively connected with its U.S. trade or business, subject to certain adjustments, generally would be subject also to a &#147;branch profits tax.&#148; The branch profits
tax rate is 30%, although an applicable income tax treaty between the United States and the non-U.S. holder&#146;s country of residence might provide for a lower rate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Estate Tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estates of
nonresident alien individuals generally are subject to U.S. federal estate tax on property with a U.S. situs. Because we are a U.S. corporation, our common stock will be U.S. situs property and therefore will be included in the taxable estate of a
nonresident alien decedent, unless an applicable estate tax treaty between the United States and the decedent&#146;s country of residence provides otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Code and the Treasury regulations require those who make specified payments to report the payments to the IRS. Among the specified payments
are dividends and proceeds paid by brokers to their customers. The required information returns enable the IRS to determine whether the recipient properly included the payments in income. This reporting regime is reinforced by &#147;backup
withholding&#148; rules. These rules require the payors to withhold tax from payments subject to information reporting if the recipient fails to cooperate with the reporting regime by failing to provide his taxpayer identification number to the
payor, furnishing an incorrect identification number, or failing to report interest or dividends on his returns. The backup withholding tax rate is currently 28%. The backup withholding rules do not apply to payments to corporations, whether
domestic or foreign, provided they establish such exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments to non-U.S. holders of dividends on common stock generally will not
be subject to backup withholding, and payments of proceeds made to non-U.S. holders by a broker upon a sale of common stock will not be subject to information reporting or backup withholding, in each case so long as the non-U.S. holder certifies its
nonresident status (and we or our paying agent do not have actual knowledge or reason to know the holder is a U.S. person or that the conditions of any other exemption are not, in fact, satisfied) or otherwise establishes an exemption. The
certification procedures to claim treaty benefits described under &#147;&#151;Dividends&#148; will generally satisfy the certification requirements necessary to avoid the backup withholding tax. We must report annually to the IRS any dividends paid
to each non-U.S. holder and the tax withheld, if any, with respect to these dividends. Copies of these reports may be made available to tax authorities in the country where the non-U.S. holder resides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Treasury regulations, the payment of proceeds from the disposition of shares of our common stock by a non-U.S. holder made to or
through a U.S. office of a broker generally will be subject to information reporting and backup withholding unless the beneficial owner certifies, under penalties of perjury, among other things, its status as a non-U.S. holder (and the broker does
not have actual knowledge or reason to know the holder is a U.S. person) or otherwise establishes an exemption. The payment of proceeds from the disposition of shares of our common stock by a non-U.S. holder made to or through a non-U.S. office of a
broker generally will not be subject to backup withholding and information reporting, except as noted below. Information reporting, but not backup withholding, will apply to a payment of proceeds, even if that payment is made outside of the United
States, if you sell our common stock through a non-U.S. office of a broker that is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a U.S. person (including a foreign branch or office of such person); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;controlled foreign corporation&#148; for U.S. federal income tax purposes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a foreign person 50% or more of whose gross income from certain periods is effectively connected with a U.S. trade or business; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a foreign partnership if at any time during its tax year (a)&nbsp;one or more of its partners are U.S. persons who, in the aggregate, hold more than 50% of the income or capital interests of the partnership or
(b)&nbsp;the foreign partnership is engaged in a U.S. trade or business; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">unless the broker has documentary evidence that the beneficial
owner is a non-U.S. holder and certain other conditions are satisfied, or the beneficial owner otherwise establishes an exemption (and the broker has no actual knowledge or reason to know to the contrary). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld from a payment to a holder of common stock under the backup withholding
rules can be credited against any U.S. federal income tax liability of the holder and may entitle the holder to a refund, provided that the required information is furnished to the IRS in a timely manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Account Tax Compliance Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. federal withholding tax of 30% may apply to dividends and the gross proceeds of a disposition of our common stock paid to a foreign
financial institution (as specifically defined by the applicable rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial
information regarding U.S. account holders of such institution (which includes certain equity holders of such institution, as well as certain account holders that are foreign entities with U.S. owners). This U.S. federal withholding tax of 30% will
also apply to dividends and the gross proceeds of a disposition of our common stock paid to a non-financial foreign entity unless such entity provides the withholding agent with either a certification that it does not have any substantial direct or
indirect U.S. owners or provides information regarding direct and indirect U.S. owners of the entity. The 30% federal withholding tax described in this paragraph cannot be reduced under an income tax treaty with the United States or by providing an
IRS Form W-8BEN or similar documentation. The withholding tax described above will not apply if the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from the rules. Under certain circumstances, a
non-U.S. holder might be eligible for refunds or credits of such taxes. Holders should consult with their own tax advisors regarding the possible implications of the withholding described herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The withholding provisions described above generally apply to proceeds from a sale or other disposition of common stock if such sale or other
disposition occurs on or after January&nbsp;1, 2017 and to payments of dividends on our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THE PRECEDING DISCUSSION OF U.S.
FEDERAL TAX CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY. IT IS NOT TAX ADVICE. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, STATE, LOCAL AND FOREIGN TAX CONSEQUENCES OF PURCHASING, HOLDING
AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters named below have entered into an underwriting agreement, dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015, with respect to the shares being offered. Subject to certain conditions, each underwriter has severally agreed to
purchase the number of shares indicated in the following table. BMO Capital Markets Corp. and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, are the representatives of the underwriters. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:46.20pt; font-size:8pt; font-family:Times New Roman"><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BMO Capital Markets Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JMP Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wedbush Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other
than the shares covered by the option described below unless and until that option is exercised. If an underwriter fails or refuses to purchase any of its committed shares, the purchase commitments of the non-defaulting underwriters may be increased
or the offering may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have an option to buy up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares from us to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above. They may exercise this option for 30 days. If
any shares are purchased pursuant to this option, the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above, and the underwriters will offer the additional shares on the same terms as those
on which the shares are being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters propose to offer the shares of our common stock directly to the public at the
initial public offering price set forth on the cover of this prospectus and to certain dealers at such offering price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. After the initial public offering
of the shares, the offering price and the selling concession may be changed by the underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per share
and total underwriting discounts and commissions to be paid by us to the underwriters assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the total expenses of the offering, including registration, filing and listing fees, printing
fees and legal and accounting expenses, but excluding underwriting discounts and commissions, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, all of which will be paid by us. We have agreed to reimburse the underwriters for
certain of their expenses incurred in connection with the clearance of this offering with the Financial Industry Regulatory Authority, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our officers and directors and the holders of substantially all of our capital stock and options have agreed with the underwriters
that, for a period of 180 days after the date of this prospectus, subject to certain exceptions, we and they will not (1)&nbsp;offer, sell, pledge, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition), directly or indirectly, including the
filing (or participation in the filing) with the SEC of a registration statement under the Securities Act to register, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock or warrants
or other rights to acquire </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of our common stock of which such officer, director or holder is now, or may in the future become, the beneficial owner (within the meaning of Rule 13d-3 under the Exchange Act), or
(2)&nbsp;enter into any swap or other derivatives transaction that transfers to another, in whole or in part, directly or indirectly, any of the economic benefits or risks of ownership of such common stock, securities, warrants or other rights to
acquire common stock, whether any such transaction described in clause (1)&nbsp;or (2)&nbsp;above is to be settled by delivery of common stock or other securities, in cash or otherwise, or (3)&nbsp;publicly disclose the intention to enter into any
transaction described in clause (1)&nbsp;or (2)&nbsp;above, except with the prior written consent of BMO Capital Markets Corp. and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated; provided that BMO Capital Markets Corp. and Stifel,
Nicolaus&nbsp;&amp; Company, Incorporated, on behalf of the underwriters, have agreed to notify us at least three business days before the effective date of any release or waiver granted to one of our officers or directors, and we have agreed to
announce the impending release or waiver by issuing a press release through a major news service at least two business days before the effective date of the release or waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions above do not apply to the following, subject to certain limitations set forth in the lock-up agreements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of securities as a bona fide gift; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers or dispositions of securities to any trust for the direct or indirect benefit of the lock-up signatory or any member of the immediate family of the lock-up signatory; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of securities to affiliates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of securities by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the lock-up signatory; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers or dispositions of shares of our common stock or securities convertible or exchangeable into shares of our common stock acquired in open market purchases after the closing of this offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entry into any trading plan established pursuant to Rule 10b5-1 under the Exchange Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exercise of options, warrants or other rights to acquire shares of common stock in accordance with their terms pursuant to an employee benefit plan, option, warrant or other right; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers pursuant to a court order or settlement agreement related to the distribution of assets in connection with the dissolution of a marriage or civil union; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers to us pursuant to agreements under which we have the option to repurchase such shares or a right of first refusal with respect to transfers of such shares upon termination of service of the lock-up signatory;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers by certain stockholders of shares purchased in this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conversion of outstanding shares of preferred stock into shares of common stock; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of shares of our common stock or any security convertible into or exercisable or exchangeable for common stock pursuant to a liquidation, tender offer, merger, consolidation or similar transaction that results
in all of our stockholders having the right to exchange their securities for cash, securities or other property. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See
&#147;Shares Eligible for Future Sale&#148; for a discussion of certain transfer restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the offering, there has been no
public market for our common stock. The initial public offering price will be negotiated among us and the representatives. Among the factors to be considered in determining the initial public offering price of the shares, in addition to prevailing
market conditions, will be our historical performance, estimates of our business potential and earnings prospects, an assessment of our management and the consideration of the above factors in relation to market valuation of companies in related
businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to have our common stock listed on the NASDAQ Capital Market under the symbol &#147;ANAB.&#148; In connection
with the offering, the underwriters may purchase and sell shares of our common stock in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the open market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of
a greater number of shares than they are required to purchase in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A &#147;covered short position&#148; is a short position that
is not greater than the amount of additional shares for which the underwriters&#146; option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or
purchasing shares in the open market. In determining the source of shares to cover the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price
at which they may purchase additional shares pursuant to the option described above. &#147;Naked&#148; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may
be exercised. The underwriters must cover any such naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price
of the common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock made by the underwriters in the open market
prior to the closing of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to
the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may
have the effect of preventing or retarding a decline in the market price of our stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the common stock. As a result, the price of
our common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected on the
NASDAQ Capital Market, in the over-the- counter market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriters may engage in
passive market making transactions in the common stock on the NASDAQ Capital Market in accordance with Rule 103 of Regulation M under the Exchange Act during a period before the commencement of offers or sales of common stock and extending through
the completion of distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid
must then be lowered when specified purchase limits are exceeded. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market in the absence of those transactions. The
underwriters are not required to engage in passive market making and may end passive market making activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
underwriters do not expect sales to discretionary accounts to exceed five percent of the total number of shares offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed
to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act and to contribute to payments that the underwriters may be required to make for these liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any,
participating in this offering. The representatives may agree to allocate a number of shares of our common stock to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to
underwriters that may make Internet distributions on the same basis as other allocations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged
in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non- financial
activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to persons and entities with relationships with the issuer, for which
they received or will receive customary fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of their various business activities, the underwriters
and their respective affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial
instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of the issuer (directly, as collateral securing other obligations or
otherwise) and/or persons and entities with relationships with the issuer. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express
independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Offer Restrictions Outside the United States </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities
offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or
advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction.
Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a
solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in the European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each, a &#147;Relevant Member State&#148;), no offer of the securities offered
by this prospectus may be made to the public in that Relevant Member State other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall require us or the representatives to publish a prospectus pursuant to Article 3 of the
Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person in a
Relevant Member State who initially acquires any of the securities or to whom any offer is made will be deemed to have represented, acknowledged and agreed that it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant
Member State implementing Article 2(1)(e) of the Prospectus Directive. In the case of any of the securities being offered to a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive, each such financial intermediary
will be deemed to have represented, acknowledged and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreed that the securities acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to,
persons in circumstances which may give rise to an offer of any securities to the public other than their offer or resale in a Relevant Member State to qualified investors as so defined or in circumstances in which the prior consent of the
representatives has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the representatives and their affiliates will rely upon
the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has been prepared on the basis
that any offer of securities in any Relevant Member State will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of securities. Accordingly any person making or intending to make
an offer in that Relevant Member State of securities which are the subject of the offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for us or any of the underwriters to publish a prospectus
pursuant to Article 3 of the Prospectus Directive in relation to such offer. Neither we nor the underwriters have authorized, nor do they authorize, the making of any offer of securities in circumstances in which an obligation arises for us or the
underwriters to publish a prospectus for such offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purpose of the above provisions, the expression &#147;an offer to the
public&#148; in relation to any securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide
to purchase or subscribe the securities, as the same may be varied in the Relevant Member State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression &#147;Prospectus Directive&#148; means Directive
2003/71/EC (including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member States) and includes any relevant implementing measure in the Relevant Member State and the expression &#147;2010 PD Amending Directive&#148;
means Directive 2010/73/EU. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in the United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">who have professional experience in matters relating to investments falling within Article 19 (5)&nbsp;of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order; and/or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as relevant persons).
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this
document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. Any person in the United Kingdom that is not a
relevant person should not act or rely on this document or any of its contents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX
or on any other stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art.
652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the securities or the offering may be
publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing
material relating to the offering, us, the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the
Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of
interests in collective investment schemes under the CISA does not extend to acquirers of securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in the Dubai
International Financial Centre </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document relates to an Exempt Offer in accordance with the Markets Rules 2012 of the Dubai
Financial Services Authority, or DFSA. This document is intended for distribution only to persons of a type specified in the Markets Rules 2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no
responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this document.
The securities to which this document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the
contents of this document you should consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to its use in the Dubai International Financial
Centre, or DIFC, this document is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other
purpose. The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective
investors in the United Arab Emirates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus have not been, and are not being, publicly
offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the
issue, offering and sale of securities. Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This
prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Australia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">does not constitute a disclosure document under Chapter 6D.2 of the Corporations Act 2001 (Cth), or the Corporations Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, as a disclosure document for the purposes of the Corporations Act and does not purport to include the information
required of a disclosure document under Chapter 6D.2 of the Corporations Act; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, or Exempt Investors, available under section 708 of the Corporations
Act. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus may not be directly or indirectly offered for subscription or purchased or
sold, and no invitations to subscribe for or buy the securities may be issued, and no draft or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
definitive offering memorandum, advertisement or other offering material relating to any securities may be distributed in Australia, except where disclosure to investors is not required under
Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the securities, you represent and warrant to us that you are an Exempt Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As any offer of securities under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations Act, the
offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for
the securities you undertake to us that you will not, for a period of 12 months from the date of issue of the securities, offer, transfer, assign or otherwise alienate those securities to investors in Australia except in circumstances where
disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus have not been and will not be registered under the Financial Instruments and Exchange Act.
Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity
organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in
compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice
to prospective investors in Hong Kong </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus have not been offered or sold and will not be
offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in
other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No
advertisement, invitation or document relating to the securities has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of
which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong
Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warning </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The contents of this
document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of this document, you should obtain independent professional
advice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of securities may not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to persons in Singapore other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities (as defined in
Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities
pursuant to an offer made under Section&nbsp;275 of the SFA except: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Bermuda </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities offered by this prospectus may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business
Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, non-Bermudian persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under
applicable Bermuda legislation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Saudi Arabia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities
Regulations as issued by the board of the Saudi Arabian Capital Market Authority, or CMA pursuant to resolution number 2-11-2004 dated 4&nbsp;October 2004 as amended by resolution number 1-28-2008, as amended, or the CMA Regulations. The CMA does
not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the
securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an authorized financial adviser. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in the British Virgin Islands </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription
by us or on our behalf. The securities may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands) (each a BVI Company), but only where the offer will be made to, and received by, the relevant BVI
Company entirely outside of the British Virgin Islands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been, and will not be, registered with the Financial Services Commission
of the British Virgin Islands. No registered prospectus has been or will be prepared in respect of the securities for the purposes of the Securities and Investment Business Act, 2010, or SIBA or the Public Issuers Code of the British Virgin Islands.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be offered to persons located in the British Virgin Islands who are &#147;qualified investors&#148; for the purposes
of SIBA. Qualified investors include (i)&nbsp;certain entities which are regulated by the Financial Services Commission in the British Virgin Islands, including banks, insurance companies, licensees under SIBA and public, professional and private
mutual funds; (ii)&nbsp;a company, any securities of which are listed on a recognised exchange; and (iii)&nbsp;persons defined as &#147;professional investors&#148; under SIBA, which is any person (a)&nbsp;whose ordinary business involves, whether
for that person&#146;s own account or the account of others, the acquisition or disposal of property of the same kind as the property, or a substantial part of our property; or (b)&nbsp;who has signed a declaration that he, whether individually or
jointly with his spouse, has net worth in excess of US$1,000,000 and that he consents to being treated as a professional investor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to
prospective investors in China </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute a public offer of the securities offered by this prospectus,
whether by sale or subscription, in the People&#146;s Republic of China, or the PRC. The securities are not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the securities without obtaining all prior
PRC&#146;s governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Korea </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the
decrees and regulations thereunder, or the FSCMA, and the securities have been and will be offered in Korea as a private placement under the FSCMA. None of the securities may be offered, sold or delivered directly or indirectly, or offered or sold
to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea and the
decrees and regulations thereunder, or the FETL. The securities have not been listed on any of securities exchanges in the world including, without limitation, the Korea Exchange in Korea. Furthermore, the purchaser of the securities shall comply
with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the securities. By the purchase of the securities, the relevant holder thereof will be deemed to represent and
warrant that if it is in Korea or is a resident of Korea, it purchased the securities pursuant to the applicable laws and regulations of Korea. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Malaysia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No prospectus or other offering material or document in connection with the offer and sale of the Securities has been or will be registered
with the Securities Commission of Malaysia, or the Commission for the Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with the offer or
sale, or invitation for subscription or purchase, of the securities may not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or
indirectly, to persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services Licence; (iii)&nbsp;a person who acquires the securities, as principal, if the offer is on terms
that the securities may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3 million (or its equivalent in foreign currencies), excluding the
value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding twelve months; (vi)&nbsp;an individual who, jointly with
his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a corporation with total net assets exceeding RM10 million (or its equivalent in a foreign
currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets exceeding RM10 million (or its equivalent in foreign currencies); (ix)&nbsp;a bank licensee or insurance licensee as defined in the Labuan Financial
Services and Securities Act 2010; (x)&nbsp;an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be specified by the Commission; provided that, in the
each of the preceding categories (i)&nbsp;to (xi), the distribution of the securities is made by a holder of a Capital Markets Services Licence who carries on the business of dealing in securities. The distribution in Malaysia of this prospectus is
subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration
of a prospectus with the Commission under the Capital Markets and Services Act 2007. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in Taiwan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities
laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or
approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the securities in Taiwan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to prospective investors in South Africa </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to restrictions under the securities laws of South Africa, the securities are not offered, and the Offer shall not be transferred, sold,
renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions applies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the offer, transfer, sale, renunciation or delivery is to duly registered banks, mutual banks, financial services provider, financial institution, the Public Investment Corporation (in each case registered as such in
South Africa), a person who deals with securities in their ordinary course of business, or a wholly owned subsidiary of a bank, mutual bank, authorised services provider or financial institution, acting as agent in the capacity of an authorised
portfolio manager for a pension fund (duly registered in South Africa), or as manager for a collective investment scheme(registered in South Africa); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than R1,000,000. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document does not, nor is it intended to, constitute an &#147;offer to the public&#148; (as that term is defined in the South African
Companies Act, 2008, or the SA Companies Act and does not, nor is it intended to, constitute a prospectus prepared and registered under the SA Companies Act. This document is not an &#147;offer to the public&#148; and must not be acted on or relied
on by persons who do not fall within Section&nbsp;96(1)(a) of the SA Companies Act (such persons being referred to as &#147;relevant persons&#148;). Any investment or investment activity to which this document relates is available only to relevant
persons and will be engaged in only with relevant persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A South African resident person or company or any non-South African company
which is a subsidiary of a South African company is not permitted to acquire the securities unless such person has obtained exchange control approval to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Fenwick&nbsp;&amp; West LLP, San
Francisco, California. Certain legal matters relating to the offering will be passed upon for the underwriters by Cooley LLP, San Diego, California. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of AnaptysBio, Inc. as of December&nbsp;31, 2013 and 2014, and for each of the years in the two-year period ended
December&nbsp;31, 2014, have been included herein and in the registration statement in reliance upon the report of KPMG LLP, an independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts
in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc942137_22"></A>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered
hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits filed therewith. For further information about us and the common stock
offered hereby, reference is made to the registration statement and the exhibits filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration
statement are not necessarily complete, and in each instance we refer you to the copy of such contract or other document filed as an exhibit to the registration statement. We currently do not file periodic reports with the SEC. Upon the closing of
our initial public offering, we will be required to file periodic reports, proxy statements and other information with the SEC pursuant to the Exchange Act. A copy of the registration statement and the exhibits filed therewith may be inspected
without charge at the public reference room maintained by the SEC, located at 100 F Street, NE, Washington, DC 20549, and copies of all or any part of the registration statement may be obtained from that office. Please call the SEC at 1-800-SEC-0330
for further information about the public reference room. The SEC also maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the
website is www.sec.gov. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="toc942137_23"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AnaptysBio, Inc. Audited Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin942137_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin942137_2">Balance Sheets as of December&nbsp;31, 2013 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin942137_3">Statements of Operations for the Years ended December&nbsp;31, 2013 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin942137_4">Statements of Convertible Preferred Stock and Stockholders&#146; Deficit for the Years ended December&nbsp;
31, 2013 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin942137_5">Statements of Cash Flows for the Years ended December&nbsp;31, 2013 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin942137_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AnaptysBio, Inc. Unaudited Consolidated Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin942137_7">Consolidated Balance Sheets as of December&nbsp;31, 2014 and June 30, 2015 (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin942137_8">Unaudited Consolidated Statements of Operations for the Six Months Ended June 30, 2014 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin942137_9">Unaudited Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2014 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin942137_10">Notes to Unaudited Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin942137_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors and Stockholders </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AnaptysBio, Inc.: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheets of AnaptysBio, Inc. as of December&nbsp;31, 2013 and 2014, and the related statements of operations,
convertible preferred stock and stockholders&#146; deficit, and cash flows for each of the years in the <FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2014. These financial statements are the responsibility of the
Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in
accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as
well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion,
the financial statements referred to above present fairly, in all material respects, the financial position of AnaptysBio, Inc. as of December&nbsp;31, 2013 and 2014, and the results of its operations and its cash flows for each of the years in the <FONT
STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2014, in conformity with U.S.&nbsp;generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego,
California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;5, 2015, except for earnings per share information and Note 12, which are dated July&nbsp;13, 2015 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin942137_2"></A>BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except par value data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivable from collaborative partner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIABILITIES, CONVERTIBLE PREFERRED STOCK AND</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS&#146; DEFICIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory notes payable to related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred stock, $0.001 par value, 3,015 shares authorized, no shares issued or outstanding at December&nbsp;31,
2013 or 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, $0.001 par value, 27,743 shares authorized, 27,743 shares issued and outstanding at
December&nbsp;31, 2013 and 2014; aggregate liquidation preference at December&nbsp;31, 2014 of $24,991</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C convertible preferred stock, $0.001 par value, 17,982 shares authorized, 11,147 shares issued and outstanding at
December&nbsp;31, 2013 and 2014; aggregate liquidation preference at December&nbsp;31, 2014 of $7,246</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C-1 convertible preferred stock, $0.001 par value, 10,500 shares authorized, no shares and 3,318 shares issued and outstanding
at December&nbsp;31, 2013 and 2014, respectively; aggregate liquidation preference at December&nbsp;31, 2014 of $6,470</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value, 79,000 shares authorized, 17,368 shares issued and outstanding at December&nbsp;31, 2013 and
2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,527</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin942137_3"></A>STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,287</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of liability for preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributed to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributed to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares outstanding:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income per common share (unaudited):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average number of shares outstanding (unaudited):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:150pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin942137_4"></A>STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and unit data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C-1<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-in<BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, January&nbsp;1, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(42,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beneficial conversion feature of convertible promissory notes payable to related parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares converted to common shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,688</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,013</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants for Series C Preferred Stock converted to warrants for common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued under employee stock plans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(48,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,527</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of promissory notes payable to related parties into shares of Series C-1 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(45,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:85pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin942137_5"></A>STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OPERATING ACTIVITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income (loss) to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of liability for preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(627</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivable from collaborative partners</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(489</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,796</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTING ACTIVITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FINANCING ACTIVITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from notes payable, net of costs to issue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible promissory notes payable to related parties, net of costs to issue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,869</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash investing and financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible promissory notes payable to related parties into shares of Series C-1 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beneficial conversion feature of convertible promissory notes payable to related parties allocated to additional paid-in
capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants for Series C Preferred Stock converted to warrants for common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:75pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin942137_6"></A>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Organization and Basis of Presentation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AnaptysBio, Inc. (&#147;we,&#148;
&#147;us,&#148; &#147;our,&#148; or the &#147;Company&#148;) was incorporated in the state of Delaware in November 2005. We are a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in
inflammation and immuno-oncology. We develop our product candidates using our proprietary, antibody discovery technology platform (&#147;SHM-XEL&#148;), which is designed to replicate, <I>in vitro,</I> the natural process of antibody generation. We
currently generate revenue from our collaborative research and development arrangements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have devoted our primary effort to raising capital and research and development activities, and have incurred losses
and negative cash flows from operations through the year ended December&nbsp;31, 2013 and have an accumulated deficit at December&nbsp;31, 2014 of $45.3 million. Through 2013, all of our financial support has been provided primarily from the sale of
our common and preferred stock and proceeds from the issuance of convertible debt. As of December&nbsp;31, 2014, however, following the execution of a significant strategic collaboration, we have positive working capital. Going forward, as we
continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or
circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business
objectives. The accompanying financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Significant Accounting Policies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#147;GAAP&#148;).
The preparation of financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in our financial statements and accompanying notes. Significant estimates in the
financial statements have been made for preferred stock warrant liabilities and stock-based compensation. Actual results could differ materially from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
consider all highly liquid investments with a maturity at date of purchase of three months or less to be cash equivalents. Cash equivalents consist primarily of money market and mutual funds with original maturities of 90 days or less. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
December&nbsp;31, 2013 and 2014, we held restricted cash of $110,000 and $85,000, respectively, used to secure a letter of credit provided as security for our operating leases for our facility. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property
and equipment is carried at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation and amortization are calculated
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
using the straight-line method over the estimated useful lives of the assets, which range from three to seven years. Leasehold improvements are amortized using the straight line method over the
shorter of the lease term or the estimated useful life of the asset. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Long Lived Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived
assets, consisting of property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable based on undiscounted cash flows. If long-lived assets are
impaired, an impairment loss is recognized and is measured as the amount by which the carrying value exceeds the estimated fair value of the assets. No impairment charges were recorded during the years ended December&nbsp;31, 2013 or 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Rent and Operating Lease Incentives </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When an operating lease includes lease incentives, such as a rent abatements or leasehold improvement allowances, or requires fixed escalations
of the minimum lease payments, the aggregate rental expense, including such incentives or increases, is recognized on a straight-line basis over the term of the lease. The cumulative difference between the actual rental payments and rent charged to
expense is recorded as deferred rent in the accompanying balance sheets. For leasehold improvement allowances, the costs are capitalized as leasehold improvement assets and amortized to expense over the appropriate recognition period for such
assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt Issuance Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt issuance costs incurred to obtain debt financing are deferred and are amortized over the term of the debt using the effective interest
method. The costs are recorded as a reduction to the carrying value of the debt and the amortization expense is included in interest expense in the statements of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is
recognized in accordance with revenue recognition accounting guidance, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence that an arrangement exists; (ii) delivery has occurred and title and the
risks and rewards of ownership have been transferred to the client or services have been rendered; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple-Element Revenue Arrangements.</I> We evaluate deliverables in a multiple-element arrangement to determine whether each deliverable
represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value to the customer. If the delivered element does not have standalone value without one of the undelivered elements in the
arrangement, we combine such elements and account for them as a single unit of accounting. We allocate the consideration to each unit of accounting at the inception of the arrangement based on the relative selling price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize consideration allocated to an individual element when all other revenue recognition criteria are met for that element. Our
multiple-element revenue arrangements may include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>License arrangements</B>. The deliverables under our collaboration and license agreements generally include exclusive or nonexclusive licenses to one or more products generated using our technologies. As the
delivered licenses have not historically had standalone value apart from the undelivered elements, these have been recognized as revenue as a combined unit of accounting. Accordingly, we recognize revenue from nonrefundable upfront fees in the same
manner as the undelivered item(s), which is generally the period over which we provide research and developments services. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Research and Development Services. </B>The deliverables under our collaboration and license arrangements may include research and development
services we perform on behalf of or with our </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
collaborators. As the provision of research and development services is an integral part of our operations and we may be principally responsible for the performance of these services under the
agreements, we recognize revenue on a gross basis for research and development services as we perform those services. Additionally, we recognize research related funding under collaboration research and development efforts as revenue as we perform
or deliver the related services in accordance with contract terms. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Milestone Revenue.</I> Our collaboration and
license agreements generally include contingent contractual payments related to achievement of specific research, development and regulatory milestones and sales-based milestones that are dependent upon the performance of the licensor or
collaborator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which
the milestone is achieved. A milestone is defined as an event that can only be achieved based in whole or in part either on our performance, or the performance of our collaborators, or the occurrence of a specific outcome resulting from our past
performance for which there is a substantive uncertainty at the date the arrangement is entered into that the event will be achieved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and
Development </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs associated with research and development activities are expensed as incurred. Research and development costs
primarily include salaries and personnel-related costs, supplies and materials, contract manufacturing, in-licensing fees, outside services, and an allocation of information technology, fringe benefits, and facility overhead costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upfront and milestone payments incurred under our in-licensing agreements are expensed as acquired in-process research and development in the
period in which they are incurred, provided that the technology or method has no alternative future use. Royalties incurred on fees received under our sublicensing arrangements are expensed in the period in which we recognize the related
collaborative revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize stock-based compensation expense using a fair-value-based method for costs related to all share-based payments, including stock
options. Stock-based compensation cost for stock options granted to our employees and directors is measured at the grant date based on the fair-value of the award which is estimated using the Black-Scholes option-pricing model, and is recognized as
expense over the requisite service period on a straight-line basis. We estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. We use historical data to estimate
prevesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options
granted to individual service providers who are not employees or directors are accounted for at estimated fair values using the Black-Scholes option pricing model and are subject to periodic remeasurement over the period during which the services
are rendered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No tax benefits for stock-based compensation have been recognized in the statements of changes in stockholders&#146; equity
or cash flows. We have not recognized, and do not expect to recognize in the near future, any tax benefit related to stock-based compensation cost as a result of our full valuation allowance on net deferred tax assets and net operating loss
carryforwards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrants for Shares of Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for warrants for shares of preferred stock with conversion features that provide for reductions in the warrant price as derivative
liabilities in the accompanying balance sheets at their fair value on the date of issuance. The derivative liabilities are revalued at each balance sheet date until such instruments are exercised or expire, with changes in the fair value between
reporting periods recorded as other income or expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial instruments consist principally of cash, cash equivalents, restricted cash, receivables from collaborative partners, accounts
payable, notes payable and preferred stock warrant liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received to sell an
asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and
minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Includes other inputs that are directly or indirectly observable in the marketplace. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own
assumptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our policy is to place our cash and cash equivalents with high quality financial institutions in order to limit our credit risk exposure, and,
at times, balances may exceed federally insured limits. To date, we have not experienced any credit losses associated with these financial instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for
income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using enacted tax
rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than
not that some portion or all of a deferred tax asset will not be realized based on the weight of available evidence, including expected future earnings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize an uncertain tax position in our financial statements when we concludes that a tax position is more likely than not to be
sustained upon examination based solely on our technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is measured as the largest amount of benefit
that is more likely than not to be realized upon effective settlement. This is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. We have
elected to accrue any interest or penalties related to income taxes as part of our income tax expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) Per Common Share and Pro
Forma Net Income Per Common Share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net income (loss) per share of common stock is determined using the two-class method for
participating securities as this method is more dilutive than the if-converted method. All series of our convertible preferred stock are considered to be participating securities. In accordance with the two-class method, earnings allocated to these
participating securities, which include participation rights in undistributed earnings, are subtracted from net income to determine total earnings to be attributed to common stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per common share is computed by dividing net income (loss) attributed to common stockholders by the weighted-average
number of common shares outstanding during the period. All participating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities are excluded from basic weighted-average common shares outstanding. In computing diluted net income (loss) attributed to common stockholders, undistributed earnings are re-allocated to
reflect the potential impact of dilutive securities, including stock options and warrants that reduce the preferred stockholders participation in earnings to be attributed to common stockholders. Diluted net income (loss) per share attributed to
common stockholders is computed by dividing net income (loss) attributed to common stockholders by the weighted-average number of common equivalent shares outstanding for the period. Diluted net income (loss) per share attributed to common
stockholders includes any dilutive effect from outstanding stock options and warrants using the treasury stock method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Computations for
basic and diluted net income (loss) per common share are below. The unaudited pro forma basic and diluted net income (loss) per common share calculation assumes the conversion of all outstanding shares of convertible preferred stock into common
stock as if such conversion had occurred on January&nbsp;1, 2014 or the original issuance date, if later. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net Income<BR>(Loss)</B><br><B>(Numerator)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>(Denominator)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year Ended December&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributed to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.71</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year Ended December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributed to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributed to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reallocation of net income attributed to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilutive effect of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributed to common stockholders plus assumed conversions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro Forma for the Year Ended December&nbsp;31, 2014 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment to reflect the assumed conversion of convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma basic net income per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilutive effect of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributed to common stockholders plus assumed conversions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Common stock equivalents issuable upon the conversion or exercise of dilutive securities that
could potentially reduce net income per common share in the future that were excluded from the determination of diluted net income (loss) per common share as their effects were antidilutive are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting Pronouncements Recently Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2014, the Financial Accounting Standards Board, (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;)
No.&nbsp;2014-10, <I>Development Stage Entities (Topic 915)</I>, which eliminated the distinction of a Development Stage Entity along with the inception to date reporting requirements. As permitted by this ASU, we elected to early adopt the
amendment beginning with our annual reporting period ending December&nbsp;31, 2014, with retrospective application of the amended guidance. Upon adoption, there was no effect to our financial statements, other than the elimination of inception to
date disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2015, the FASB issued ASU No.&nbsp;2015-03, <I>Simplifying the Presentation of Debt Issuance Costs</I>. This
update requires the presentation of debt issuance costs in financial statements as a direct reduction of related debt liabilities rather than as an asset. Amortization of debt issuance costs continue to be reported as interest expense. As permitted
by the ASU, we elected to early adopt the amendment beginning with our annual reporting period ending December&nbsp;31, 2014, with retrospective application of the amended guidance. The adoption of this ASU resulted in the reclassification $37,000
and $85,000 in deferred debt issuance costs from prepaid expenses and other current assets to a direct reduction to the carrying values of notes payable and convertible promissory notes reported in the balance sheets at December&nbsp;31, 2013 and
2014, respectively. The adoption of this guidance did not have any effect on the statement of operations during the years ended December&nbsp;31, 2013 or 2014. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU 2014-09, <I>Revenue from Contracts with Customers</I>, which outlines a single comprehensive model for
entities to use in accounting for revenue from contracts with customers and supersedes most current revenue recognition guidance in FASB ASC 605, Revenue Recognition, including industry-specific guidance. This standard is based on the principle that
an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard also requires
additional disclosure about the nature, amount, timing and uncertainty of assets recognized from costs incurred to fulfill a contract and becomes effective for our annual reporting period beginning January&nbsp;1, 2018, including interim periods
within that reporting period; early adoption is not permitted. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. We are currently assessing the impact that this
standard will have on our financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU 2014-15, <I>Presentation of Financial
Statements&#151;Going Concern</I>, which provides guidance on management&#146;s responsibility in evaluating whether there is substantial doubt about a company&#146;s ability to continue as a going concern and the related footnote disclosure. For
each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company&#146;s ability to continue as a going concern within one year from the date the financials are issued.
When management identifies conditions or events that raise substantial doubt about the entity&#146;s ability to continue as a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
going concern, this standard also outlines disclosures that are required in our footnotes based on whether or not there are any plans intended to mitigate the relevant conditions or events to
alleviate the substantial doubt. This standard becomes effective for our annual reporting period ending December&nbsp;31, 2016, and for annual and interim periods thereafter. Early application is permitted. We do not expect the adoption of this
standard to have a material impact on our consolidated financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Balance Sheet Accounts and Supplemental Disclosures </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and contract manufacturing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued royalties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Collaborative Research and Development Agreements </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TESARO Collaboration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2014, we entered into a Collaboration and Exclusive License Agreement with TESARO, Inc. and TESARO Development, Inc. (collectively,
&#147;TESARO&#148;), an oncology-focused biopharmaceutical company. Under the terms of the agreement, we agreed to perform certain discovery and early preclinical development of therapeutic antibodies with the goal of generating immunotherapy
antibodies for subsequent preclinical, clinical, regulatory and commercial development to be performed by TESARO. Under the terms of the agreement, TESARO paid an upfront license fee of $17.0 million in March 2014 and agreed to provide funding to us
for research and development services related to antibody discovery programs for three specific targets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2014, we and TESARO
entered into an Amendment No.&nbsp;1 to the Agreement to add an antibody discovery program against a fourth target for an upfront license fee of $2.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each development program, we are eligible to receive milestone payments of up to $18.0 million if certain clinical trial events are
achieved by TESARO, up to an additional $90.0 million if certain U.S. and European regulatory submissions and approvals in multiple indications are achieved, and up to an additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$165.0 million upon the achievement of specified levels of annual worldwide net sales. We will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products
developed under the collaboration and certain commercial milestone payments if specified levels of annual worldwide net sales are attained. Unless earlier terminated by either party upon specified circumstances, the agreement will terminate, with
respect to each specific developed product, upon the later of the 12th anniversary of the first commercial sale of the product or the expiration of the last to expire of any patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We determined that the upfront license fees and research funding under the agreement, as amended, should be accounted for as a single unit of
accounting and that the upfront license fees should be deferred and recognized as revenue over the same period that the research and development services are performed. As a result, the $17.0 million and $2.0 million license fees have been deferred
and are being recognized as revenue ratably over the research periods specified in the contract of 24 and 16 months, respectively. Revenue from the contingent milestone payments will be recognized if and when such payments become due, subject to
satisfaction of all of the criteria necessary to recognize revenue at that time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue recognized under this agreement aggregated $11.5
million during the year ended December&nbsp;31, 2014, which includes $7.0 million for the amortization of the upfront fee and $4.5 million in funding for research and development services, of which $1.5 million was receivable at December&nbsp;31,
2014. Deferred revenue for this agreement was $12.0 million at December&nbsp;31, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Celgene Antibody Generation Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2011, we entered into an Antibody Generation Agreement with Celgene Corporation (&#147;Celgene&#148;), under which we agreed to
develop human therapeutic agents against multiple targets. We successfully delivered three antibodies against three targets under this agreement. The final deliverable under this agreement was completed in 2014. Under the terms of the agreement,
Celgene agreed to pay an initial fee of $6.0 million, followed by a success fee of $0.5 million upon successful delivery of therapeutic antibodies against each of the targets involved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The upfront payment was recognized as revenue ratably over the estimated time to project completion through February 2014. Revenue recognized
under this agreement aggregated $3.7 million during the year ended December&nbsp;31, 2013, which includes $2.0 million for the amortization of the upfront fee, $1.0 million in success fees and $746,000 in funding for research and development costs.
Revenue recognized under this agreement aggregated $592,000 during the year ended December&nbsp;31, 2014, which includes $500,000 in success fees and $92,000 in funding for research and development costs. Deferred revenue for this agreement was
$92,000 at December&nbsp;31, 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Momenta Antibody Generation Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2013, we entered into an Antibody Generation Agreement, with Momenta Pharmaceuticals, Inc. (&#147;Momenta&#148;) under which we
agreed to generate certain antibodies with enhanced affinity specific for a particular target for use in the development of human therapeutic agents by Momenta. Under the terms of the agreement, Momenta agreed to pay an upfront fee of $1.1 million,
followed by a $2.0 million success fee in the event of a successful outcome, which occurred in 2014. This agreement expired in accordance with its terms in 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The upfront payment was recognized as revenue ratably over the estimated time to project completion, or nine months, beginning January 2014
when the project commenced. Revenue recognized under this agreement aggregated $3.1 million during the year ended December&nbsp;31, 2014, which includes $2.0 million in success fees and $1.1 million for the amortization of the upfront fee. Deferred
revenue for this agreement was $1.1 million at December&nbsp;31, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Collaborative Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2013 and 2014, we recognized revenue from other collaborative partners aggregating $1.7 million and $0.6 million, respectively, for the
development of antibodies for specified targets. Revenue from these agreements consisted primarily of the amortization of upfront payments and funding for research and development services that were recognized as the related services were provided.
Our obligations under these collaborative agreements were completed by the end of 2014. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Notes Payable and Convertible Promissory Notes </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notes Payable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;24, 2014, we entered into a Loan and Security Agreement with a bank and a financial institution whereby we may borrow up to
$15.0 million in three separate draws of $5.0 million each. The Term A Loans, for an aggregate of $5.0 million, were drawn on December&nbsp;24, 2014. The Term B Loans for an aggregate of $5.0 million are available for draw through December&nbsp;31,
2015, contingent upon our first multi-dose PK/toxicology studies on at least two development programs and the Term C Loans for an aggregate of $5.0 million are available for draw through December&nbsp;31, 2016, contingent upon receiving FDA approval
on IND submission on at least two development programs. The Term A Loans each bear a fixed rate of interest of 6.97% and are due in 12 monthly interest-only payments through January 2016, followed by 36 equal monthly principal and interest payments,
with final maturity in January 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the issuance of the Term B Loans, the interest-only periods for both the Term A and B Loans are
extended by six months through July 2016, followed by 30 equal monthly principal and interest payments, with final maturity of all Loans in January 2019. Upon the issuance of the Term C Loans, the interest-only periods for all Loans are further
extended by six months through January 2017, followed by 24 equal monthly principal and interest payments, with final maturity of Loans in January 2019. If the Term B and C Loans are issued, they will bear interest at the greater of 6.95% or the
3-month LIBOR plus 6.72%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The costs incurred to issue the Term A Loans of $85,000 were deferred and are included in the discount to the
carrying value of the Term A Loans in the accompanying balance sheet. The Term A Loans also include a final payment fee of $250,000 due at the earlier of prepayment or the maturity date of the Term A Loans. The deferred costs and the final payment
fee will be amortized to interest expense over the expected term of the Term A Loans using the effective interest method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection
with the issuance of the Term A Loans, we issued detachable, fully vested warrants to purchase an aggregate of 288,462 shares of Series C Preferred Stock at an exercise price of $0.65 per share to the lenders, which are subject to change under
anti-dilution provisions. The warrants are exercisable at any time through December 2024. The grant-date fair value of the warrants of $124,000 was recorded a liability, with a reduction to the carrying value of the Term A Loans, and which is
recognized as additional interest expense over the remaining term of the Loans. The initial fair value of the warrants was determined using the Black-Scholes option pricing model with the following assumptions: a stock price volatility of 70.2%, an
expected life equal to the contractual term of the warrants of ten years and a risk-free interest rate of 1.97%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31,
2014, the carrying amount of the Term A Loans was $4.8 million, which is net of discounts of $209,000. The effective interest rate on the Term A Loans at December&nbsp;31, 2014 was 9.25%. As of December&nbsp;31, 2014, future maturities of the Term A
Loans were $1.4 million, $1.7 million, $1.8 million and $153,000 in 2016, 2017, 2018 and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term A Loans are secured
by a first priority interest in most of our assets, excluding intellectual property, with a net book value of $6.0 million at December&nbsp;31, 2014. We are also required to maintain a minimum of 50% of our operating and investment account balances
at all times with one of the lenders. At December&nbsp;31, 2014, we were in compliance with the covenants contained in the Loan and Security Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Promissory Notes Payable to Related Parties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2013, pursuant to a Purchase Agreement, we issued convertible promissory notes to existing investors aggregating $2.0 million. The
notes, which bear interest at 10%&nbsp;per annum, were unsecured and subordinated to all current and future indebtedness and were convertible at any time at the option of the holders into shares of Series C-1 Preferred Stock at a conversion price of
$0.65 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Authoritative accounting guidance requires that a portion of the note proceeds be allocated to additional paid-in
capital for the intrinsic value, if any, of the conversion option (the &#147;beneficial conversion feature&#148;) based upon the difference between the fair value of the underlying preferred stock at the date of issuance of the notes and the
effective conversion price embedded in the notes. The resulting discount on the notes is amortized over the term of the related notes to the stated date of redemption. At August&nbsp;30, 2013, the date of issuance of the notes, the intrinsic value
of the conversion option exceeded the net proceeds of the notes, and therefore the resulting discount attributed to the notes was limited to $2.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, the principal and accrued interest on the notes, which aggregated $2.2 million, were converted into 3.3&nbsp;million shares of
Series C-1 Preferred Stock. The unamortized discount of $405,000 at the date of conversion was recognized as interest expense. Total interest expense resulting from the amortization and write-off of the discount totaled $818,000 and $1.2 million
during the years ended December&nbsp;31, 2013 and 2014, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Fair Value Measurements </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assets and Liabilities Measured at Fair Value on a Recurring Basis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input
levels based on the fair value hierarchy: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value&nbsp;Measurements&nbsp;at&nbsp;End&nbsp;of&nbsp;Period&nbsp;Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Market<BR>Prices for<BR>Identical&nbsp;Assets</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Other<BR>Observable<BR>Inputs</B><br><B>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs</B><br><B>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>At December&nbsp;31, 2013</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury security<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>At December&nbsp;31, 2014</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual funds<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury security<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Included in cash and cash equivalents in the accompanying balance sheets. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Included in cash and cash equivalents, and restricted cash in the accompanying balance sheets. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Marketable Securities.</I> For fair values determined by Level 1 inputs, which utilize quoted prices in active markets for identical
assets, the level of judgment required to estimate fair value is relatively low. The fair values of investments in money market funds, mutual funds and U.S. treasury securities were determined using Level 1 inputs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Warrant Liabilities.</I> Our preferred stock warrants are accounted for as derivative liabilities and measured at fair value on a recurring
basis as they contain features that are either not afforded equity classification or embody risks that are not clearly and closely related to host contracts. We estimate fair values of these derivatives utilizing the Black-Scholes option-pricing
model, which requires Level 3 inputs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimating fair values of derivative financial instruments, including Level 3 instruments,
require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors, including changes in the estimated fair value of our equity
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following weighted-average assumptions were employed in estimating the value of the liabilities for Series C preferred
stock warrants using the Black Scholes option-pricing model: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2013&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2014&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.26</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend Yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average measurement date fair value per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A 10% increase in the fair values of preferred stock at December&nbsp;31, 2013 and 2014 would result in
increases in the estimated fair values of the preferred stock warrant liabilities of $58,000 and $89,000, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table summarizes the activity in liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 Inputs): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Warrant<BR>Liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January&nbsp;1, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stock warrants converted to Common Stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized net gains included in other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized net losses included in other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Other Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of certain of our financial instruments, including cash and cash equivalents, receivable from collaborative partner,
accounts payable, accrued expenses and convertible promissory notes payable, approximate fair value due to their short-term nature. The carrying amount of our notes payable of $4.8 million at December&nbsp;31, 2014 approximated fair value due to the
close proximity of their issuance in December 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Stockholders&#146; Equity </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Amended and Restated Certificate of Incorporation, dated July&nbsp;15, 2013, authorizes 59.2&nbsp;million shares of preferred stock, which
are designated as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B-2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total designated Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series B, B-1, and B-2 Preferred Stock (collectively, the &#147;Series B Preferred Stock&#148;) generally
have consistent rights and preferences discussed below, except that the conversion price of the Series B-2 Preferred Stock shall not be subject to adjustment in the event that we issue additional equity securities at a purchase price less than the
Series B-2 conversion price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The convertible preferred stock has been classified as temporary equity in the accompanying balance sheets
as the shares include provisions allowing the holder to cause redemption of the shares upon certain change in control events that are outside of our control. We have elected not to adjust the carrying values of the convertible preferred stock to the
respective liquidation preferences of such shares as we are uncertain whether or when an event would occur that would obligate us to pay the liquidation preference to the holders of such shares, as discussed below. Adjustments to increase the
carrying values to the respective liquidation preferences will be made if and when it becomes probable that an event would occur obligating us to pay such amounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Dividend Rights.</B> The holders of the Series A, B, C, and C-1 Preferred Stock are entitled to receive noncumulative dividends at a rate
of 8% of the respective Series issue price per annum. The Series C-1 Preferred Stock dividends are payable in preference and in priority to any Series C Preferred Stock. The Series C Preferred Stock dividends are payable in preference and in
priority to any Series B Preferred Stock. The Series B and Series A Preferred Stock dividends are payable in preference and in priority to any dividends on common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock dividends are payable when, as and if declared by our board of directors. As of December&nbsp;31, 2014, the board of
directors has not declared any dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Voting Rights. </B>The holders of Series Preferred Stock are entitled to one vote for each
share of common stock into which such Series Preferred Stock could then be converted; and with respect to such vote, such holder shall have full voting rights and powers equal to the voting rights and powers of the holders of common stock, except
that the holders of the Series B Preferred shares, voting as a separate class, are entitled to elect two members of the board of directors, the holders of the Series A Preferred and common stock shares, each voting as a separate class, are each
entitled to elect one member of the board of directors, and the holders of the Preferred and common shares, voting as a single class, are entitled to elect all remaining members of the board of the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Liquidation Rights. </B>Upon liquidation, dissolution or winding up of the Company, the holders of Preferred Stock are entitled to receive
distributions to be paid out of the assets of the Company, before any distributions are made to the holders of common stock. The holders of the Series C-1 are entitled to receive liquidation preference at three (3)&nbsp;times the original issue
price of $0.65 per share plus all declared and unpaid dividends. Liquidation payments to the holders of Series C-1 Preferred Stock have priority and are made in preference to any payments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the holders of Series C Preferred Stock. The holders of the Series C Preferred Stock are entitled to receive liquidation preferences at the rate of $0.65 per share plus all declared and unpaid
dividends. Liquidation payments to the holders of Series C Preferred Stock have priority and are made in preference to any payments to the holders of Series B Preferred Stock. The holders of the Series B and Series B-1 Preferred Stock are entitled
to receive liquidation preferences at the rate of $0.90 per share plus all declared and unpaid dividends and the holders of Series A and Series B-2 Preferred Stock are entitled to receive liquidation preferences at the rate of $1.00 per share plus
all declared and unpaid dividends. Liquidation payments to the holders of Series B and Series A Preferred Stock have priority and are made in preference to any payments to the holders of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Conversion Rights. </B>The shares of Series A Preferred Stock are convertible into shares of common stock at a conversion price of $0.90
per share and the shares of Series B, C and C-1 Preferred Stock are convertible into an equal number of shares of common stock. The shares of Series Preferred Stock are convertible at any time, at the option of the holder, subject to certain
antidilutive adjustments. Each share of Series Preferred Stock is automatically converted into common stock (i)&nbsp;upon the affirmative election of the holders of at least a majority of the outstanding shares of the Series Preferred Stock, voting
together as a single class on an as if converted basis, or (ii)&nbsp;immediately upon the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, in which the per
share price is at least $1.63 (as adjusted), and the gross cash proceeds are at least $30.0 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion of Preferred Shares and Warrants
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conjunction with the issuance of the convertible promissory notes in August 2013, and pursuant to the Purchase Agreement which
required the parties to the Purchase Agreement to &#147;pay to play,&#148; one of the existing investors, and a related party, was not a participant in the debt financing and, as a result, the investor&#146;s existing preferred shares and warrants
to purchase shares of Series C Preferred Stock converted into common shares and warrants to purchase shares of common stock, respectively. The investor&#146;s 3,000,000 shares of Series A Preferred Stock were converted at a price of $0.90 per share
into 3,333,333 shares of common stock, and 10,925,197 shares of Series B and Series C Preferred Stock were converted into the same number of shares of common stock. The investor&#146;s warrants to purchase 822,386 shares of Series C Preferred Stock
at an exercise price of $0.65 per share were converted into the same number of warrants to purchase shares of common stock at the same warrant price per share, which resulted in an increase to additional paid-in capital of $14,000 at the time of the
conversion. The fair value of the warrants for shares of common stock was determined using the Black-Scholes option pricing model with the following assumptions: a stock price volatility of 67.4%, an expected life equal to the remaining contractual
term of the warrants of five years and a risk-free interest rate of 1.46%. The warrants are exercisable at any time through November 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common
Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have authorized 79.0&nbsp;million shares of common stock, of which 17.4&nbsp;million shares were issued and outstanding
at December&nbsp;31, 2014. Common shares reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at December&nbsp;31, 2014 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued and Outstanding:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants for shares of convertible preferred stock and common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares reserved for future award grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrants for Shares of Preferred and Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the activity related to our warrants during the year ended December&nbsp;31, 2014 is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Subject to<BR>Warrants</B><br><B>(in<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Warrant<BR>Price per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B><br><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B><br><B>(in<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Warrants to Purchase Shares of Series C Preferred Stock</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding and exercisable at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Warrants to Purchase Shares of Common Stock</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding and exercisable at December&nbsp;31, 2013 and 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Equity Incentive Plan </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2006 Equity Incentive Plan (the &#147;Plan&#148;) provides
for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, and rights to purchase restricted stock to our employees, nonemployee directors and consultants. Recipients of incentive stock options shall be eligible
to purchase shares of our common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the Plan is ten years. As of December&nbsp;31, 2014,
awards for up to 9.1&nbsp;million shares of common stock are reserved for issuance under the Plan, of which 8.7&nbsp;million are reserved for issuance upon exercise of granted and outstanding options and 0.4&nbsp;million shares are available for
future grants. In April 2015, we increased the number of shares reserved and available for issuance under the Plan by 3.8 million shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock
Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options granted to employees and nonemployees generally vest over a four-year period and have a maximum term of ten
years from the date of grant, subject to earlier cancellation prior to vesting upon cessation of service to the Company. A summary of the activity related to stock option awards during the year ended December&nbsp;31, 2014 is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Subject to<BR>Options</B><br><B>(in<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B><br><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B><br><B>(in<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeitures and cancellations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding and exercisable at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options vested or expected to vest at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total cash received from the exercise of stock options was $4,000 during the year ended December&nbsp;31,
2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All stock option grants under the Plan provide for exercise of the stock option prior to vesting. Shares of common stock issued
upon exercise of unvested options are subject to repurchase by us at the respective original exercise price until vested. Consideration received for the exercise of unvested stock options is recorded as a liability and reclassified into equity as
the related award vests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of each stock option award was determined on the date of grant using the Black-Scholes option valuation model with the
following assumptions for options granted to employees during the years ended December&nbsp;31, 2013 and 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">1.5%-1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">71.0%-72.5</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend Yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1-9.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average grant date fair value per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We determine the appropriate, risk free interest rate, expected term for employee stock based awards,
contractual term for nonemployee stock based awards, and volatility assumptions. The weighted-average expected option term for employee stock based awards reflects the application of the simplified method, which defines the life as the average of
the contractual term of the options and the weighted average vesting period for all option tranches. The weighted average expected term for nonemployee stock based awards is the remaining contractual life of the award. Estimated volatility
incorporates historical volatility of similar entities whose share prices are publicly available. The risk free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected or contractual term of the share based
payment awards. The assumed dividend yield is based on our expectation of not paying dividends in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total non-cash
stock-based compensation expense for all stock awards that was recognized in the statements of operations is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2013&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2014&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2014, there was $478,000 of unrecognized compensation cost related to unvested stock
option awards, which is expected to be recognized over a remaining weighted average vesting period of 2.9 years. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Employee Benefit Plan </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a defined-contribution 401(k) plan for our employees.
Employees are eligible to participate in the plan beginning on the first day of the month following date of hire. Under the terms of the plan, employees may make voluntary contributions as a percentage of compensation and we have the option to make
a discretionary match as determined by the board of directors, within prescribed limits. There were no employer contributions to the plan during the years ended December&nbsp;31, 2013 or 2014. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Commitments and Contingencies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lease our facility under a non-cancellable operating lease, which expires in August 2016. The lease contains one option to renew for an
additional five-year period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rent expense during each of the years ended December&nbsp;31, 2013 and 2014 was $368,000. At
December&nbsp;31, 2014, deferred rent aggregated $222,000, of which $128,000 is included in other current liabilities and $94,000 is included in noncurrent liabilities in the accompanying balance sheet. At December&nbsp;31, 2014, the future minimum
annual obligations under non-cancellable operating lease commitments are $496,000 and $346,000, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into collaborative license agreements that provide us with rights to use certain know-how, technology and patent rights
maintained by the licensors in our research and development efforts. Terms of the license agreements may require us to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and royalty
payments on fees received under our sublicensing arrangements and/or future sales, if any, of commercial products resulting from the collaboration. Certain of the licensing agreements require guaranteed minimum annual payments. Terms of the
licensing agreements generally range from the remaining life of the patent up to 17 years and, in some cases, may be subject to earlier termination by either party upon specified circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total expense incurred under all collaborative licensing agreements for upfront, milestone and royalty payments during the years ended
December&nbsp;31, 2013 and 2014 was $239,000 and $162,000 and, respectively. Total cash paid under these agreements during the years ended December&nbsp;31, 2013 and 2014 was $98,000 and $227,000, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future minimum guaranteed payment obligations for annual royalty payments under all such agreements at December&nbsp;31, 2014 aggregated
$208,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Letter of Credit </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2013 and 2014, we were contingently liable for a standby letter of credit issued by a commercial bank for $110,000 and
$85,000, respectively, for security on our lease. A restricted cash account with these amounts was held as cash collateral for the letter of credit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are, from time to
time, involved in legal proceedings, regulatory actions, claims and litigation arising in the ordinary course of business. Currently, we are not a defendant in any lawsuit. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income Taxes </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of our deferred tax assets and liabilities are as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Tax Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Tax Liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible promissory note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,071</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets, net of valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have recorded a full valuation allowance against our net deferred tax assets due to the
uncertainty surrounding the realization of such assets. Management has determined it more likely than not that the deferred tax assets are not realizable due to our historical loss position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2014, we have federal and state net operating loss carryforwards (&#147;NOL&#148;) of $41.4 million each. The federal and
state NOLs will begin to expire in 2027 and 2017, respectively, unless previously utilized. At December&nbsp;31, 2014 we had federal and California research tax credit carryforwards of $1.6 million and $1.4 million, respectively. The federal
research tax credit carryforward will begin to expire in 2026 and the California state credits carryforward indefinitely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above NOL
carryforward and the research tax credit carryforwards may be subject to an annual limitation under Section&nbsp;382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if we experience one or more ownership changes which
would limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change as defined by Section&nbsp;382 and 383, results from transactions increasing
ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. We have not completed an IRC Section&nbsp;382/382 analysis. If a change in ownership were to have
occurred, NOL and tax credits carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of
the valuation allowance, limitations created by future ownership changes, if any, will not impact our effective tax rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The differences
between the United States federal statutory tax rate and our effective tax rate are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2013&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2014&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory United States federal income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income tax, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize a tax benefit from an uncertain tax position when it is more likely than not that the position
will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized. At
December&nbsp;31, 2013 and 2014, we had no unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate due to the valuation allowance against deferred tax assets. The following table summarizes the activity
related to our unrecognized tax benefits: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2013&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2014&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase related to current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not anticipate there will be a significant change in unrecognized tax benefits within the next 12
months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our policy is to recognize interest and penalties related to income tax matters in the provision
for income taxes. As of December&nbsp;31, 2013 and 2014, there were no interest or penalties on uncertain tax benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file income
tax returns in the United States and California. Due to our losses incurred, we are essentially subject to income tax examination by tax authorities from inception to date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Subsequent Event </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated subsequent events from the balance sheet date
through June&nbsp;5, 2015, the date at which the financial statements were originally issued, except for the split of Series B and Series B-1 Preferred Stock described in the following paragraph. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;13, 2015, we amended and restated our certificate of incorporation to effect the split of Series B and Series B-1 Preferred Stock
into ten shares for every nine shares outstanding. The financial statements and accompanying footnotes have been retroactively restated to reflect the Series B and Series B-1 Preferred Stock splits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

    <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin942137_7"></A>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except par value data) </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Stockholders&#146;<BR>Equity at<BR>June 30,</B><br><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Receivable from collaborative partner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; EQUITY (DEFICIT)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Notes payable, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Notes payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series A convertible preferred stock, $0.001 par value, 3,015 shares authorized, no shares issued or outstanding at December&nbsp;31,
2014 or June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series B convertible preferred stock, $0.001 par value, 27,743 shares authorized, 27,743 shares issued and outstanding at
December&nbsp;31, 2014 and June&nbsp;30, 2015; aggregate liquidation preference of $24,991 at June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series C convertible preferred stock, $0.001 par value, 17,982 shares authorized, 11,147 shares issued and outstanding at
December&nbsp;31, 2014 and June&nbsp;30, 2015; aggregate liquidation preference of $7,246 at June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Series C-1 convertible preferred stock, $0.001 par value, 10,500 shares authorized, 3,318 shares issued and outstanding at
December&nbsp;31, 2014 and June&nbsp;30, 2015; aggregate liquidation preference of $6,470 at June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Common stock, $0.001 par value, 79,000 shares authorized, 17,368 and 17,811 shares issued and outstanding at December&nbsp;31, 2014 and
June&nbsp;30, 2015, respectively; 60,019 issued and outstanding, pro forma at June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin942137_8"></A>UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except per share data) </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of liability for preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average number of shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:285pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin942137_9"></A>UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OPERATING ACTIVITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of liability for preferred stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivable from collaborative partners</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTING ACTIVITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of investment securities available for sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FINANCING ACTIVITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amounts accrued for property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amounts accrued for deferred financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:162pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin942137_10"></A>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Organization and basis of Presentation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AnaptysBio, Inc. (&#147;we,&#148;
&#147;us,&#148; &#147;our,&#148; or the &#147;Company&#148;) was incorporated in the state of Delaware in November 2005. We are a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in
inflammation and immuno-oncology. We develop our product candidates using our proprietary, antibody discovery technology platform (&#147;SHM-XEL&#148;), which is designed to replicate, <I>in vitro,</I> the natural process of antibody generation. We
currently generate revenue from our collaborative research and development arrangements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the Company and its wholly-owned subsidiary. All intercompany accounts and
transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have devoted our primary effort to raising capital and
research and development activities, and have incurred losses and negative cash flows from operations and have an accumulated deficit at June&nbsp;30, 2015 of $45.7 million. All of our financial support has been provided primarily from the sale of
our common and preferred stock and proceeds from the issuance of convertible debt and notes payable. As of June&nbsp;30, 2015, however, following the execution of a significant strategic collaboration in 2014, we have positive working capital. Going
forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all.
If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our
intended business objectives. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and
Exchange Commission (&#147;SEC&#148;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (&#147;GAAP&#148;) have been omitted. The
accompanying unaudited consolidated financial statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by GAAP. These adjustments consist primarily of normal recurring accruals and
estimates that impact the carrying value of assets and liabilities. Actual results may materially differ from these estimates. Operating results for the six months ended June&nbsp;30, 2015 are not necessarily indicative of the results that may be
expected for the year ending December&nbsp;31, 2015. The financial statements should be read in conjunction with our audited financial statements for the year ended December&nbsp;31, 2014, included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Stockholders&#146; Equity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the closing of the offering contemplated by this prospectus, we expect all of our convertible preferred stock outstanding to convert
into shares of common stock at the then applicable conversion rate. The unaudited pro forma stockholders&#146; equity is based on the assumed conversion of shares of convertible preferred stock outstanding at June&nbsp;30, 2015. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Significant Accounting Policies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared in accordance with GAAP. The preparation of financial statements in
conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in our consolidated financial statements and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accompanying notes. Significant estimates in the consolidated financial statements have been made for preferred stock warrant liabilities and stock-based compensation. Actual results could differ
materially from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We consider all highly liquid investments with a maturity at date of purchase of three months or less to be cash equivalents. Cash equivalents
consist primarily of money market and mutual funds with original maturities of 90 days or less. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2014 and June&nbsp;30, 2015, we held restricted cash of $85,000, used to secure a letter of credit provided as security
for our operating lease for our facility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2015, we incurred an aggregate of $0.5 million in direct costs related to our July 2015 Series D
Convertible Preferred Stock financing and anticipated public offering of common stock. These costs were deferred and recorded as a long-term asset at June&nbsp;30, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is
recognized in accordance with revenue recognition accounting guidance, which requires that four basic criteria be met before revenue can be recognized: 1) persuasive evidence that an arrangement exists; 2) delivery has occurred and title and the
risks and rewards of ownership have been transferred to the client or services have been rendered; 3) the price is fixed or determinable; and 4) collectability is reasonably assured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple-Element Revenue Arrangements.</I> We evaluate deliverables in a multiple-element arrangement to determine whether each deliverable
represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value to the customer. If the delivered element does not have standalone value without one of the undelivered elements in the
arrangement, we combine such elements and account for them as a single unit of accounting. We allocate the consideration to each unit of accounting at the inception of the arrangement based on the relative selling price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize consideration allocated to an individual element when all other revenue recognition criteria are met for that element. Our
multiple-element revenue arrangements may include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>License arrangements</B>. The deliverables under our collaboration and license agreements generally include exclusive or nonexclusive licenses to one or more products generated using our technologies. As the
delivered licenses have not historically had standalone value apart from the undelivered elements, these have been recognized as revenue as a combined unit of accounting. Accordingly, we recognize revenue from nonrefundable upfront fees in the same
manner as the undelivered item(s), which is generally the period over which we provide research and development services. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Research and Development Services. </B>The deliverables under our collaboration and license arrangements may include research and development services we perform on behalf of or with our collaborators. As the
provision of research and development services is an integral part of our operations and we may be principally responsible for the performance of these services under the agreements, we recognize revenue on a gross basis for research and development
services as we perform those services. Additionally, we recognize research related funding under collaboration research and development efforts as revenue as we perform or deliver the related services in accordance with contract terms.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Milestone Revenue.</I> Our collaboration and license agreements generally include
contingent contractual payments related to achievement of specific research, development and regulatory milestones and sales-based milestones that are dependent upon the performance of the licensor or collaborator. A milestone is defined as an event
(i)&nbsp;that can only be achieved based in whole or in part on either the entity&#146;s performance or on the occurrence of a specific outcome resulting from the entity&#146;s performance, (ii)&nbsp;for which there is substantive uncertainty at the
date the arrangement is entered into that the event will be achieved and (iii)&nbsp;that would result in additional payments being due to us. Contingent consideration for which payment is either contingent solely upon the passage of time or the
result of a counterparty&#146;s performance is not considered substantive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize consideration that is contingent upon the
achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consideration is commensurate with either the entity&#146;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the
entity&#146;s performance to achieve the milestone; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consideration relates solely to past performance; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Milestones that are not considered substantive are generally recognized in the same manner as the undelivered item(s), which is generally the
period over which we provide research and developments services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize stock-based compensation expense using a fair-value-based method for costs related to all share-based payments, including stock
options. Stock-based compensation cost for stock options granted to our employees and directors is measured at the grant date based on the fair-value of the award which is estimated using the Black-Scholes option-pricing model, and is recognized as
expense over the requisite service period on a straight-line basis. We estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. We use historical data to estimate
option forfeitures prior to vesting and record stock-based compensation expense only for those awards that are expected to vest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options
granted to individual service providers who are not employees or directors are accounted for at estimated fair values using the Black-Scholes option-pricing model and are subject to periodic remeasurement over the period during which the services
are rendered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No tax benefits for stock-based compensation have been recognized in the statements of cash flows. We have not recognized,
and do not expect to recognize in the near future, any tax benefit related to stock-based compensation cost as a result of our full valuation allowance on our net deferred tax assets and net operating loss carryforwards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrants for Shares of Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for warrants for shares of preferred stock with conversion features that provide for reductions in the warrant price as derivative
liabilities in the accompanying balance sheets at their fair value on the date of issuance. The derivative liabilities are revalued at each balance sheet date until such instruments are exercised or expire, with changes in the fair value between
reporting periods recorded as other income or expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial instruments consist principally of cash, cash equivalents, restricted cash, receivables from collaborative partners, accounts
payable, notes payable and preferred stock warrant liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received to sell an asset or paid to
transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of
unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level
1&#151;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level
2&#151;Includes other inputs that are directly or indirectly observable in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Unobservable inputs that are
supported by little or no market activities, therefore requiring an entity to develop its own assumptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Functional Currency of Foreign
Operations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our international subsidiary operates in a United States dollar (&#147;U.S. dollar&#148;) functional currency
environment. Assets and liabilities of our foreign subsidiary that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets
and capital accounts, which are remeasured at historical foreign currency exchange rates in effect at the date of transaction. Expenses are generally remeasured at monthly foreign currency exchange rates which approximate average rates in effect
during each period. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income (expense), net, in the consolidated statements of operations and totaled $17,000 during the six months
ended June&nbsp;30, 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Common Share and Pro Forma Net Loss Per Common Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during
the period without consideration of common stock equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Computations for basic and diluted net loss per common share are below. The
unaudited pro forma basic and diluted net loss per common share calculation assumes the conversion of all outstanding shares of convertible preferred stock into common stock as if such conversion had occurred on January&nbsp;1, 2015 or the original
issuance date, if later. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net Loss<BR>(Numerator)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>(Denominator)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Six Months Ended June&nbsp;30, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Six Months Ended June&nbsp;30, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro Forma for the Six Months Ended June&nbsp;30, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment to reflect the assumed conversion of convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma basic and diluted net loss per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Common stock equivalents issuable upon the conversion or exercise of dilutive securities that
could potentially reduce net income per common share in the future that were excluded from the determination of diluted net loss per common share as their effects were antidilutive are as follows:</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months</B><br><B>Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) 2014-09,
<I>Revenue from Contracts with Customers</I>, which outlines a single comprehensive model for entities to use in accounting for revenue from contracts with customers and supersedes most current revenue recognition guidance in FASB ASC 605, Revenue
Recognition, including industry-specific guidance. This standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the
entity expects to be entitled in exchange for those goods or services. This standard also requires additional disclosure about the nature, amount, timing and uncertainty of assets recognized from costs incurred to fulfill a contract and was
originally effective for our annual reporting period beginning January&nbsp;1, 2018, including interim periods within that reporting period, with adoption permitted as early as January 1, 2017. Entities have the option of using either a full
retrospective or a modified retrospective approach for the adoption of the new standard. We are currently assessing the impact that this standard will have on our consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU 2014-15, <I>Presentation of Financial Statements&#151;Going Concern</I>, which provides guidance on
management&#146;s responsibility in evaluating whether there is substantial doubt about a company&#146;s ability to continue as a going concern and the related footnote disclosure. For each reporting period, management will be required to evaluate
whether there are conditions or events that raise substantial doubt about a company&#146;s ability to continue as a going concern within one year from the date financial statements are issued. When management identifies conditions or events that
raise substantial doubt about the entity&#146;s ability to continue as a going concern, this standard also outlines disclosures that are required in the footnotes to the financial statements based on whether or not there are any plans intended to
mitigate the relevant conditions or events to alleviate the substantial doubt. This standard becomes effective for our annual reporting period ending December&nbsp;31, 2016, and for annual and interim periods thereafter. Early application is
permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Balance Sheet Accounts and Supplemental Disclosures </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and contract manufacturing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Collaborative Research and Development Agreements </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TESARO Collaboration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2014, we entered into a Collaboration and Exclusive License Agreement with TESARO, Inc. and TESARO Development, Inc. (collectively,
&#147;TESARO&#148;), an oncology-focused biopharmaceutical company. Under the terms of the agreement, we agreed to perform certain discovery and early preclinical development of therapeutic antibodies with the goal of generating immunotherapy
antibodies for subsequent preclinical, clinical, regulatory and commercial development to be performed by TESARO. Under the terms of the agreement, TESARO paid an upfront license fee of $17.0 million in March 2014 and agreed to provide funding to us
for research and development services related to antibody discovery programs for three specific targets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2014, we and TESARO
entered into Amendment No.&nbsp;1 to the Agreement to add an antibody discovery program against a fourth target for an upfront license fee of $2.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each development program, we are eligible to receive milestone payments of up to $18.0 million if certain clinical trial events are
achieved by TESARO, up to an additional $90.0 million if certain U.S. and European regulatory submissions and approvals in multiple indications are achieved, and up to an additional $165.0 million upon the achievement of specified levels of annual
worldwide net sales. We will also be eligible to receive tiered single-digit royalties related to worldwide net sales of products developed under the collaboration and certain commercial milestone payments if specified levels of annual worldwide net
sales are attained. Unless earlier terminated by either party upon specified circumstances, the agreement will terminate, with respect to each specific developed product, upon the later of the 12th anniversary of the first commercial sale of the
product or the expiration of the last to expire of any patent. In June 2015, TESARO notified us that they had initiated <I>in vivo</I> toxicology studies using good laboratory practices for our anti-PD-1 antagonist antibody (TSR-042), resulting in a
$1.0 million milestone payment, which we received in July 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We determined that the upfront license fees, milestone payments that are not considered
substantive and research funding under the agreement, as amended, should be accounted for as a single unit of accounting, and that the upfront license fees and such milestone payments should be deferred and recognized as revenue over the same period
that the research and development services are performed. As a result, the $17.0 million and $2.0 million license fees have been deferred and are being recognized as revenue ratably over the research periods specified in the contract of 24 and 16
months, respectively. In addition, we recognized revenue of $0.6 million during the six months ended June&nbsp;30, 2015 for the achievement of the $1.0 million milestone, with the remaining $0.4 million of the milestone to be recognized ratably
through the end of the specified contract, in March 2016. Revenue from the remaining contingent milestone payments will be recognized if and when such payments become due, subject to satisfaction of all of the criteria necessary to recognize revenue
at that time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue recognized during the six months ended June&nbsp;30, 2014 under the TESARO agreement aggregated $4.1 million, which
includes $2.6 million for the amortization of the upfront fee and $1.5 million in funding for research and development services. Revenue recognized under this agreement aggregated $9.0 million during the six months ended June&nbsp;30, 2015, which
includes $5.6 million for the amortization of the upfront fees and milestone payment, and $3.4 million in funding for research and development services. Amounts receivable from TESARO at December&nbsp;31, 2014 and June&nbsp;30, 2015 were $1.5
million and $2.8 million, respectively. Deferred revenue for this agreement was $12.0 million and $7.4 million at December&nbsp;31, 2014 and June&nbsp;30, 2015, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Celgene Antibody Generation Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2011, we entered into an Antibody Generation Agreement with Celgene Corporation (&#147;Celgene&#148;), under which we agreed to develop
human therapeutic agents against multiple targets. We successfully delivered three antibodies against three targets under this agreement. The final deliverable under this agreement was completed in 2014. Under the terms of the agreement, Celgene
agreed to pay an upfront fee of $6.0 million, followed by a success fee of $0.5 million upon successful delivery of therapeutic antibodies against each of the targets involved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The upfront payment was recognized as revenue ratably over the estimated time to project completion through February 2014. Revenue recognized
under this agreement during the six months ended June&nbsp;30, 2014 aggregated $0.6 million and includes $0.5 million for a success fee and $92,000 for funding of research and development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Momenta Antibody Generation Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2013, we entered into an Antibody Generation Agreement, which expired in 2014, with Momenta Pharmaceuticals, Inc.
(&#147;Momenta&#148;) under which we agreed to generate certain antibodies with enhanced affinity specific for a particular target for use in the development of human therapeutic agents by Momenta. Under the terms of the agreement, Momenta agreed to
pay an upfront fee of $1.1 million, followed by a $2.0 million success fee, which occurred in the third quarter of 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The upfront
payment was recognized as revenue ratably over the estimated time to project completion, or nine months, beginning January 2014 when the project commenced. Revenue recognized during the six months ended June&nbsp;30, 2014 aggregated $0.7 million,
which represents amortization of the upfront fee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Collaborative Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2014, we recognized revenue from other collaborative partners aggregating $0.6 million, for the
development of antibodies for specified targets. Revenue from these agreements consisted of a final payment and the amortization of upfront payments that were recognized as the related services were provided. Our obligations under these
collaborative agreements were completed by the end of 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Notes Payable </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notes Payable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2014, we entered into a Loan and Security Agreement with a bank and a financial institution whereby we may borrow up to $15.0
million in three separate draws of $5.0 million each. The Term A Loans, for an aggregate of $5.0 million, were drawn on December&nbsp;24, 2014. The Term B Loans for an aggregate of $5.0 million are available for draw through December&nbsp;31, 2015,
contingent upon our first multi-dose PK/toxicology studies on at least two development programs and the Term C Loans for an aggregate of $5.0 million are available for draw through December&nbsp;31, 2016, contingent upon receiving FDA approval on
IND submission on at least two development programs. The Term A Loans each bear a fixed rate of interest of 6.97% and are due in 12 monthly interest-only payments through January 2016, followed by 36 equal monthly principal and interest payments,
with final maturity in January 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the issuance of the Term B Loans, the interest-only periods for both the Term A and B Loans are
extended by six months through July 2016, followed by 30 equal monthly principal and interest payments, with final maturity of all Loans in January 2019. Upon the issuance of the Term C Loans, the interest-only periods for all Loans are further
extended by six months through January 2017, followed by 24 equal monthly principal and interest payments, with final maturity of Loans in January 2019. If the Term B and C Loans are issued, they will bear interest at the greater of 6.95% or the
3-month LIBOR plus 6.72%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The costs incurred to issue the Term A Loans of $85,000 were deferred and are included in the discount to the
carrying value of the Term A Loans in the accompanying balance sheet. The Term A Loans also include a final payment fee of $250,000 due at the earlier of prepayment or the maturity date of the Term A Loans. The deferred costs and the final payment
fee will be amortized to interest expense over the expected term of the Term A Loans using the effective interest method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection
with the Loan and Security Agreement, we issued detachable, fully vested warrants to purchase an aggregate of 288,462 shares of Series C Preferred Stock at an exercise price of $0.65 per share to the lenders, which are subject to change under
anti-dilution provisions. The warrants are exercisable at any time through December 2024. The grant-date fair value of the warrants of $124,000 was recorded as a liability, and presented as an offset to the carrying value of the Term A Loans. The
offset will be recognized as additional interest expense over the remaining term of the Loans. The initial fair value of the warrants was determined using the Black-Scholes option pricing model with the following assumptions: a stock price
volatility of 70.2%, an expected life equal to the contractual term of the warrants of ten years and a risk-free interest rate of 1.97%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2014 and June&nbsp;30, 2015, the carrying amounts of the Term A Loans were both $4.8 million, net of discounts of
$209,000 and $153,000, respectively. The effective interest rate on the Term A Loans at June&nbsp;30, 2015 was 9.25%. As of June&nbsp;30, 2015, future maturities of the Term A Loans were $1.4 million, $1.7 million, $1.8 million, and $153,000 in
2016, 2017, 2018 and 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term A Loans are secured by a first priority interest in most of our assets, excluding
intellectual property, with a net book value of $5.9 million at June&nbsp;30, 2015. We are also required to maintain a minimum of 50% of our operating and investment account balances at all times with one of the lenders. At June&nbsp;30, 2015, we
were in compliance with the covenants contained in the Loan and Security Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Fair Value Measurements </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assets and Liabilities Measured at Fair Value on a Recurring Basis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our assets and liabilities that require fair value measurements on a recurring basis and their respective input
levels based on the fair value hierarchy: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value&nbsp;Measurements&nbsp;at&nbsp;End&nbsp;of&nbsp;Period&nbsp;Using:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Market<BR>Prices for<BR>Identical&nbsp;Assets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs</B><br><B>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs</B><br><B>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>At December&nbsp;31, 2014</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual funds<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury security<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>At June&nbsp;30, 2015</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mutual funds<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury security<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Included in cash and cash equivalents in the accompanying balance sheets. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Included in cash and cash equivalents and restricted cash in the accompanying balance sheets. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Marketable Securities.</I> For fair values determined by Level 1 inputs, which utilize quoted prices in active markets for identical
assets, the level of judgment required to estimate fair value is relatively low. The fair values of investments in money market funds, mutual funds and U.S. treasury securities were determined using Level 1 inputs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Warrant Liabilities.</I> Our preferred stock warrants are accounted for as derivative liabilities and measured at fair value on a recurring
basis as they contain features that are either not afforded equity classification or embody risks that are not clearly and closely related to host contracts. We estimate fair values of these derivatives utilizing the Black-Scholes option-pricing
model, which requires Level 3 inputs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimating fair values of derivative financial instruments, including Level 3 instruments, require
the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors, including changes in the estimated fair value of our equity
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following weighted-average assumptions were employed in estimating the value of the liabilities for Series C Preferred
Stock warrants using the Black-Scholes option-pricing model as of the following dates: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.26</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.37</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend Yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average measurement date fair value per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to 2015, we determined the fair value of our preferred stock warrants on an annual
basis. In accordance with accounting guidance for interim reporting, we have recognized $30,000 as a ratable portion of the annual expense for the change in fair value in the statement of operations for the six months ended June&nbsp;30, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A 10% increase in the fair values of preferred stock at December&nbsp;31, 2014 and June&nbsp;30, 2015 would result in increases in the
estimated fair values of the preferred stock warrant liabilities of $89,000 and $226,000, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes
the activity in liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 Inputs): </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock Warrant Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized net losses included in other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Other Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of certain of our financial instruments, including cash and cash equivalents, receivable from collaborative partner,
accounts payable and accrued expenses approximate fair value due to their short-term nature. The carrying amount of our notes payable of $4.8 million at June&nbsp;30, 2015 approximates fair value due to the close proximity of their issuance in
December 2014. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Equity Incentive Plan </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2006 Equity Incentive Plan (the &#147;Plan&#148;) provides
for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, and rights to purchase restricted stock to our employees, nonemployee directors and consultants. Recipients of incentive stock options shall be eligible
to purchase shares of our common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the Plan is ten years. On April&nbsp;29, 2015, our
stockholders approved an amendment to the Plan which provided for an increase in the number of shares of common stock available for issuance under the plan by 3.8 million. As of June&nbsp;30, 2015, awards for up to 12.5&nbsp;million shares of common
stock are reserved for issuance under the Plan, of which 8.7&nbsp;million are reserved for issuance upon exercise of granted and outstanding options and 3.8&nbsp;million shares are available for future grants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options granted to employees and nonemployees generally vest over a four-year period and have a maximum term of ten years from the date
of grant, subject to earlier cancellation prior to vesting upon cessation of service to the Company. A summary of the activity related to stock option awards during the six months ended June&nbsp;30, 2015 is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Subject to</B><br><B>Options</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average</B><br><B>Exercise</B><br><B>Price per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B><br><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeitures and cancellations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding and exercisable at June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options vested or expected to vest at June&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total cash received from the exercise of stock options was $69,000 during the six months ended
June&nbsp;30, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All stock option grants under the Plan provide for exercise of the stock option prior to vesting. Shares of common
stock issued upon exercise of unvested options are subject to repurchase by us at the respective original exercise price until vested. Consideration received for the exercise of unvested stock options is recorded as a liability and reclassified into
equity as the related award vests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair values of stock option awards granted to employees were determined on the date of grant using the Black-Scholes option
valuation model with the following assumptions: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend Yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average grant date fair value per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We determine the appropriate, risk free interest rate, expected term for employee stock based awards,
contractual term for nonemployee stock based awards, and volatility assumptions. The weighted-average expected option term for employee stock based awards reflects the application of the simplified method, which defines the life as the average of
the contractual term of the options and the weighted average vesting period for all option tranches. The weighted average expected term for nonemployee stock based awards is the remaining contractual life of the award. Estimated volatility
incorporates historical volatility of similar entities whose share prices are publicly available. The risk free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected or contractual term of the share based
payment awards. The assumed dividend yield is based on our expectation of not paying dividends in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total non-cash stock-based compensation expense for all stock awards that was recognized in
the statements of operations is as follows: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At June&nbsp;30, 2015, there was $0.5 million of unrecognized compensation cost related to unvested
stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 3.3 years. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Subsequent Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated subsequent events from the balance sheet date
through August 17, 2015, the date at which the financial statements were issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendments to Certificate of Incorporation and 2006 Equity
Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;13, 2015, we amended our amended and restated certificate of incorporation to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increase the total number of shares authorized for issuance from 141,506,903 shares to 203,208,537 shares, of which 120,500,000 shares are designated as common stock and 82,708,537 shares are designated as preferred
stock, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminate the designation of Series A Preferred Stock, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the number of shares designated as Series B Preferred Stock from 28,991,125 shares to 25,524,510 shares, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the number of shares designated as Series C Preferred Stock from 17,982,024 to 13,210,753 shares, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the number of shares designated as Series C-1 Preferred stock from 10,500,000 shares to 3,318,054 shares, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize the issuance of 38,436,851 shares Series D Convertible Preferred stock, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide for the split of Series B and Series B-1 Preferred Stock into ten shares for every nine shares outstanding. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements and accompanying footnotes have been retroactively restated to reflect the Series B and Series B-1
Preferred stock splits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Series D Preferred Stock are entitled to: 1) one vote for each share of common stock into
which the Series D Convertible Preferred Stock could then be converted, 2) receive noncumulative dividends at a rate of 8%&nbsp;per annum, which are in priority and preference to all other series of preferred stock and common stock, 3) in preference
to all other series of preferred stock and common stock, distributions upon liquidation of $1.06&nbsp;per share plus all declared and unpaid dividends, and 4) convert into an equal number of shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;9, 2015, we amended our 2006 Equity Incentive Plan to increase the number of shares reserved for issuance under the plan by
4,766,852 shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuance of Series D Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;13, 2015, we issued and sold 38,436,851 shares of Series D Convertible Preferred Stock at $1.06 per share for net proceeds of
$40.6 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grant of Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to June&nbsp;30, 2015, we granted options to purchase 5,496,050 shares of common stock at an exercise price of $0.99 per share. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:6.00pt solid #0079c1">&nbsp;</P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:40pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g942137g92n73.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>AnaptysBio, Inc. </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:60%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">PRELIMINARY PROSPECTUS
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:60%">&nbsp;</P></center>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>BMO Capital Markets </B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>Stifel </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>JMP Securities </B></P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>Wedbush PacGrow </B></P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 </P>
<P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #0079c1">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth all costs
and expenses, other than underwriting discounts and commissions, paid or payable by the Registrant in connection with the sale of the common stock being registered. All amounts shown are estimates except for the SEC registration fee and the FINRA
filing fee: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount<BR>Paid or<BR>to&nbsp;be&nbsp;Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue sky qualification fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be completed by amendment. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INDEMNIFICATION OF DIRECTORS AND OFFICERS. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General
Corporation Law authorizes a court to award, or a corporation&#146;s board of directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section&nbsp;145 of the Delaware
General Corporation Law are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by the Delaware General Corporation Law, the Registrant&#146;s restated certificate of incorporation to be effective in
connection with the closing of this offering contains provisions that eliminate the personal liability of its directors for monetary damages for any breach of fiduciary duties as a director, except liability for the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any breach of the director&#146;s duty of loyalty to the Registrant or its stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">under Section&nbsp;174 of the Delaware General Corporation Law (regarding unlawful dividends and stock purchases); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction from which the director derived an improper personal benefit. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by
the Delaware General Corporation Law, the Registrant&#146;s restated bylaws to be effective upon the closing of this offering, provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Registrant is required to indemnify its directors and executive officers to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Registrant may indemnify its other employees and agents as set forth in the Delaware General Corporation Law; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Registrant is required to advance expenses, as incurred, to its directors and executive officers in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject
to limited exceptions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rights conferred in the restated bylaws are not exclusive. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the closing of this
offering, the Registrant has entered into indemnification agreements with each of its current directors and executive officers to provide these directors and executive officers additional contractual assurances regarding the scope of the
indemnification set forth in the Registrant&#146;s restated certificate of incorporation and restated bylaws and to provide additional procedural protections. There is no pending litigation or proceeding involving a director or executive officer of
the Registrant for which indemnification is sought. Reference is also made to Section&nbsp;9 of the underwriting agreement to be filed as Exhibit 1.1 to this registration statement, which provides for the indemnification of executive officers,
directors and controlling persons of the Registrant against certain liabilities. The indemnification provisions in the Registrant&#146;s restated certificate of incorporation, restated bylaws and the indemnification agreements entered into or to be
entered into between the Registrant and each of its directors and executive officers may be sufficiently broad to permit indemnification of the Registrant&#146;s directors and executive officers for liabilities arising under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant currently carries liability insurance for its directors and officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to the following documents filed as exhibits to this Registration Statement regarding relevant indemnification provisions
described above and elsewhere herein: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:62.40pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit Document</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Underwriting Agreement.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Restated Certificate of Incorporation to be effective upon the closing of this offering.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Restated Bylaws to be effective upon the closing of this offering.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amended and Restated Investors&#146; Rights Agreement dated July&nbsp;13, 2015 among the Registrant and certain of its stockholders, as
amended.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Indemnification Agreement.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RECENT SALES OF UNREGISTERED SECURITIES. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following lists set forth information
regarding all securities sold or granted by us within the past three years that were not registered under the Securities Act, and the consideration, if any, received by us for such securities: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(a) Stock Option Grants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Between August 17, 2012 and August 17, 2015, the Registrant granted options to purchase 9,451,991 shares of common stock under our 2006
Equity Incentive Plan to our directors, officers, employees, consultants, and other service providers with per share exercise prices ranging from $0.10 to $0.99. In this same period, the Registrant issued 535,076 shares of common stock upon exercise
of stock options previously issued under the 2006 Equity Incentive Plan to our directors, officers, employees, consultants, and other service providers for cash consideration in the aggregate amount of $88,235.26. The stock options and the common
stock issuable upon the exercise of such options as described in this section (a)&nbsp;of Item&nbsp;15 were issued pursuant to written compensatory plans or arrangements with the Company&#146;s employees and directors in reliance on the exemption
provided by Rule 701 promulgated under the Securities Act. All recipients either received adequate information about the Company or had access, through employment or other relationships, to such information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(b) Warrants to Purchase Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. In August 2013, the Registrant issued a warrant to an accredited investor to purchase 822,386 shares of Registrant&#146;s common stock upon
the conversion of warrant to purchase 822,386 shares of the Registrant&#146;s Series </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
C convertible preferred stock The common stock warrant has a per share exercise price of $0.65. The securities issued in this transaction were exempt from the registration requirements of the
Securities Act in reliance upon Section&nbsp;4(2) under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(c) Sales and Conversion of Preferred Stock
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. In August 2013, the Registrant issued an aggregate of 14,258,530 shares of Registrant&#146;s common stock to an accredited
investor upon the conversion of 3,000,000 previously-held shares of Series A convertible preferred stock and 6,019,065 previously-held shares of Series B convertible preferred stock. The securities issued in this transaction were exempt from the
registration requirements of the Securities Act in reliance upon on Rule 506 promulgated under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. In August 2013, the
Registrant issued a warrant to purchase 822,386 shares of Registrant&#146;s common stock upon the conversion of warrant to purchase 822,386 shares of the Registrant&#146;s Series C convertible preferred stock The warrant has a per share exercise
price of $0.65. The securities issued in this transaction were exempt from the registration requirements of the Securities Act in reliance upon on Rule 506 promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. In April 2014, the Registrant issued an aggregate of 3,318,054 shares of the Registrant&#146;s Series C-1 convertible preferred stock at a
purchase price of $0.65 per share for an aggregate purchase price of $2.2 million to 12 purchasers that represented to us that they are each a sophisticated accredited investor and qualified institutional buyer. The securities issued in this
transaction were exempt from registration requirements of the Securities Act in reliance on Rule 506 promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. In July 2015, the Registrant issued an aggregate of 38,436,851 shares of the Registrant&#146;s Series D convertible preferred stock at a
purchase price of $1.06 per share for an aggregate purchase price of $40.8 million to 19 purchasers that represented to us that they are each a sophisticated accredited investor and qualified institutional buyer. The securities issued in this
transaction were exempt from registration requirements of the Securities Act in reliance on Rule 506 promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions or any public offering, and the Registrant
believes each transaction was exempt from the registration requirements of the Securities Act as stated above. All recipients of the foregoing transactions either received adequate information about the Registrant or had access, through their
relationships with the Registrant, to such information. Furthermore, the Registrant affixed appropriate legends to the share certificates and instruments issued in each foregoing transaction setting forth that the securities had not been registered
and the applicable restrictions on transfer. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Exhibits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See Exhibit Index immediately following signature page. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Financial Statement Schedules. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No financial statement schedules are provided because the
information called for is not required or is shown either in the financial statements or notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;17.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>UNDERTAKINGS. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes to provide to the
underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit
or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to
a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this
registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of
the time it was declared effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) For the purpose of determining any liability under the Securities Act, each post-effective
amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the Registrant has duly caused this registration statement on Form S-1 to be signed on its
behalf by the undersigned, thereunto duly authorized, in San Diego, California, on the &nbsp;&nbsp;&nbsp;&nbsp; day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ANAPTYSBIO, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Hamza Suria</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Chief Executive Officer</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>KNOW ALL PERSONS BY THESE PRESENTS,</I> that each person whose signature appears below hereby constitutes and appoints Hamza Suria and
Robert E. Hoffman, and each of them, as his or her true and lawful attorneys-in-fact, proxies and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement
(including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought), and to file the same, with all exhibits
thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, proxies and agents full power and authority to do and perform each and every act and thing requisite and
necessary to be done in connection therewith, as fully for all intents and purposes as he or her might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, proxies and agents, or their or his or her substitute or
substitutes, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this
registration statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hamza Suria</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">President, Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Executive Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Robert E. Hoffman</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Accounting and Financial Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tiba Aynechi, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Carol G. Gallagher, Pharm.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Nicholas B. Lydon, Ph.D., FRS</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hollings Renton</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">John Schmid</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">James N. Topper, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:85.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Document</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement, including Form of Lock-Up Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation, as amended to date, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Restated Certificate of Incorporation to be effective upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Restated Bylaws to be effective upon the closing of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Common Stock Certificate.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amended and Restated Investors&#146; Rights Agreement, dated July 13, 2015, by and among the Registrant and certain of its stockholders.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Fenwick &amp; West LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2006 Equity Incentive Plan and forms of award agreements.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2015 Equity Incentive Plan, to become effective on the date the registration statement is declared effective, and forms of award agreements.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2015 Employee Stock Purchase Plan, to become effective on the date the registration statement is declared effective, and forms of award agreements.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, effective as of January 1, 2012, by and between the Registrant and Hamza Suria, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, effective as of January 1, 2012, by and between the Registrant and David King, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consulting Agreement, dated as of May 1, 2015, by and between the Registrant and David King.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, effective as of October&nbsp;20, 2014, by and between the Registrant and Marco Londei.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Office Lease, dated April 19, 2011, by and between the Registrant and Kilroy Realty, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Antibody Generation Agreement, dated December 22, 2011, by and between the Registrant and Celgene Corporation, as modified.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Collaboration and Exclusive License Agreement, dated March 10, 2014, by and among the Registrant, TESARO, Inc. and TESARO Development, Ltd., as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement, dated August 30, 2006, by and between the Registrant and Medical Research Council, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Non-Exclusive Research and Commercial License Agreement, dated May 15, 2009, by and between the Registrant and Millipore Corporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Loan and Security Agreement, dated December 24, 2014, by and among the Registrant, Oxford Finance LLC and Silicon Valley Bank.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subsidiaries of the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of KPMG LLP, an independent registered public accounting firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Fenwick &amp; West LLP (included in Exhibit 5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney. Reference is made to the signature page hereto.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Filed previously. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top">Registrant has omitted and filed separately with the SEC portions of the exhibit pursuant to a confidential treatment request under Rule&nbsp;406 promulgated under the Securities Act. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 10.10 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="62%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">[*]</TD>
<TD ALIGN="left" VALIGN="top">Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANTIBODY GENERATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This ANTIBODY GENERATION AGREEMENT is entered into and effective as of December 2011 (the &#147;<B><I>Effective Date</I></B>&#148;), by and
between <B>ANAPTYSBIO, INC.</B>, a Delaware corporation (&#147;<B><I>AnaptysBio</I></B>&#148;), having its principal place of business at 10421 Pacific Center Court, Suite 200, San Diego, CA 92121, and CELGENE CORPORATION, a Delaware corporation
(together with its subsidiaries and affiliates hereinafter collectively referred to as &#147;<B><I>Client</I></B>&#148;), having its principal place of business at 86 Morris Avenue, Summit, NJ 07901. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, AnaptysBio possesses proprietary technology useful for the discovery, modification, optimization
and humanization of antibodies; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, Client wishes to have AnaptysBio apply such technology
to one or more biological targets and/or antibodies selected by Client for the purpose of generating antibodies for use in the development of human therapeutic agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL> T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the foregoing premises and the mutual covenants
contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, agree as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>D<SMALL>EFINED</SMALL> T<SMALL>ERMS</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1 </B>&#147;<B>Accounting
Standards</B>&#148; shall mean (a)&nbsp;GAAP (United States Generally Accepted Accounting Principles); or (b)&nbsp;IFRS (International Financial Reporting Standards), in either case, consistently applied.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2 </B>&#147;<B>Affiliate</B>&#148; shall mean any entity that, directly or indirectly through one or more intermediaries, is controlled
by, controlling, or under common control with a party hereto, for so long as such control exists, and shall include any entity more than 50% of whose voting stock or participating profit interest is owned or controlled, directly or indirectly, by a
party, and any entity which owns or controls, directly or indirectly, more than 50% (or such lesser percentage that is the maximum allowed to be owned by a foreign entity in a particular jurisdiction) of the voting stock of a party. As used in this
Section&nbsp;1.1, &#147;control&#148; means to possess, directly or indirectly, the power to direct the management and policies of an entity, whether through ownership of voting securities or by contract relating to voting rights or corporate
governance.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> &#147;<B>AnaptysBio Platform</B>&#146;&#146; shall mean AnaptysBio&#146;s proprietary technology that is
generally applicable to the discovery, modification, optimization and/or humanization of antibodies and/or other proteins, and/or nucleic acids relating thereto (including, without </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitation, the expression, manufacture and formulation of any of the foregoing), such as, but not limited to, software, nucleic acids, vectors, cell lines, libraries, screening systems,
reagents, methods, databases and instrumentation that, in each case, is Controlled by AnaptysBio on or after the Effective Date. The AnaptysBio Platform shall exclude Client Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4 </B>&#147;<B>AnaptysBio Technology</B>&#148; shall mean: (a)&nbsp;to the extent Controlled by AnaptysBio on the Effective Date or
during the Research Period, all Information relating to the AnaptysBio Platform; and (b)&nbsp;all patent and other intellectual property rights in any of the foregoing. Without limiting the generality of the foregoing, AnaptysBio Technology shall
include any such Information generated, discovered or developed in whole or in part by employees or agents of AnaptysBio in performing any Project, or otherwise generated, discovered or developed in whole or in part by employees or agents of
AnaptysBio during the term of this Agreement; in each case, to the extent any of the foregoing: (i)&nbsp;relate or apply to the AnaptysBio Platform, improvements to the AnaptysBio Platform, or the use of the AnaptysBio Platform or any such
AnaptysBio Platform improvements; or (ii)&nbsp;are generally applicable to the discovery, modification, optimization or humanization of proteins and nucleic acids (including, without limitation, the expression and manufacture thereof). AnaptysBio
Technology shall exclude Client Technology.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5 </B>&#147;<B>Antibody</B>&#148; shall mean any immunoglobulin molecule, or
fragment thereof, whether in monospecific or other form, and shall include any immunoglobulin fragment (such as Fv, Fab, F(ab&#146;)2) containing one or more complementarity determining regions (CDRs) or framework regions (FRs)), any fusion protein
comprising an immunoglobulin molecule or immunoglobulin molecule fragment and any single chain antibody (such as scFv), any truncation of any of the foregoing, or any derivative or modification of any of the foregoing.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6 </B>&#147;<B>BLA</B>&#148; shall mean a biologics license application, as defined in the United States Federal Food, Drug and Cosmetic
Act of 1938, as amended from time to time, and all rules, regulations and guidance promulgated thereunder, or any successor application thereto, or any foreign equivalent application, registration, certification or approval that is required prior to
the marketing, distribution, sale and/or other commercial exploitation of a biological product for human use in a regulatory jurisdiction.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7 </B>&#147;<B>Client Antibody</B>&#148; shall mean, with respect to a particular Project, the starting Antibody (if any) identified in
the applicable Research Plan.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8 </B>&#147;<B>Client Assay</B>&#148; shall mean, with respect to a particular Project, any
assay identified in the applicable Research Plan that is to be transferred by Client to AnaptysBio (if any).<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9
</B>&#147;<B>Client Information</B>&#148; shall mean, with respect to a particular Project: (a)&nbsp;the Information (other than chemical or biological materials) identified in the applicable Research Plan that is to be provided by Client to
AnaptysBio in connection with such Project, and (b)&nbsp;any additional Information disclosed by Client to AnaptysBio in connection with Client&#146;s transfer to AnaptysBio of the Client Materials for such Project.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10 </B>&#147;<B>Client Materials</B>&#148; shall mean, with respect to a particular Project,
collectively, the chemical or biological samples of Client Antibody and Client Target to be provided, and the Client Assay(s) to be transferred, by Client to AnaptysBio for use in the performance of such Project, each as set forth in the applicable
Research Plan.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11 </B>&#147;<B>Client Results</B>&#148; shall mean, with respect to a particular Project, effective only upon
and from such time as Client has made full and timely payment of the Success Fee for such Project to AnaptysBio:<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> any
and all data and results generated, discovered or developed by or on behalf of Client as a result of performing the Evaluation (but excluding AnaptysBio Technology); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> any and all data and results generated, discovered or developed by or on behalf of Client after payment of the Success Fee using
any Delivered Antibody(ies) and/or Delivered Antibody Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12 </B>&#147;<B>Client Target</B>&#148; shall mean, with respect
to a particular Project, the biological target identified in the applicable Research Plan.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13 </B>&#147;<B>Client
Technology</B>&#148; shall mean: (a)&nbsp;Client Materials and Client Information; (b)&nbsp;if applicable, Client Results; and (c)&nbsp;all patent and other intellectual property rights in any of the foregoing.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14 </B>&#147;<B>Confidential Information</B>&#148; shall mean all Information, tangible or intangible, whether in written, graphic, oral,
visual or electronic form, that is disclosed or made available by one party to the other party under this Agreement and is not subject to the exceptions set forth in Section&nbsp;5.2. Confidential Information provided by a party to the other party
in written, graphic or electronic form shall be marked &#147;Confidential.&#148; Confidential Information initially provided by a party to the other party orally or visually shall be summarized in a writing marked &#147;Confidential&#148; which
shall be delivered to the other party within 30 days after the initial oral or visual disclosure.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15
</B>&#147;<B>Controlled</B>&#148; shall mean, with respect to any Information or intellectual property rights, possession by a party of the ability (whether by ownership, license or otherwise) to grant a license or a sublicense of or under such
Information or intellectual property rights without violating the terms of any agreement or other arrangement with any Third Party.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16 </B>&#147;<B>Delivered Antibody</B>&#148; shall mean, with respect to a particular Project, any Antibody resulting from
AnaptysBio&#146;s performance of such Project that is delivered to Client pursuant to Section 2.3(a).<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17 &#147;Delivered
Antibody Information</B>&#148; shall mean, with respect to a particular Project: [*], as more fully described in the applicable Research Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18</B> &#147;<B>Delivered Antibody Inventions</B>&#148; shall have the meaning provided in Section&nbsp;4.4(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19 </B>&#147;<B>Delivered Antibody Patents</B>&#148; shall mean all patents and patent
applications claiming or disclosing any Delivered Antibody Invention(s).<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20</B> &#147;<B>Evaluation</B>&#148; shall have the
meaning provided in Section 2.4(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21</B> &#147;<B>Evaluation Period</B>&#148; shall have the meaning provided in Section 2.4(a).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22 </B>&#147;<B>Excluded Costs</B>&#148; shall mean, with respect to a particular Project: (a)&nbsp;the reasonable out-of-pocket
costs of specialized reagents, supplies or equipment, or specialized services performed by Third Party subcontractors of AnaptysBio, that, in each case, are needed specifically for such Project but are not generally required for other similar
projects AnaptysBio performs on behalf of Third Parties; and (b)&nbsp;all reasonable out-of-pocket travel costs <FONT STYLE="white-space:nowrap">pre-approved</FONT> by Client, that are in compliance with Client&#146;s travel policy, and incurred by
AnaptysBio in the event that Client requests, and AnaptysBio agrees, that any AnaptysBio personnel provide technical assistance at any location other than AnaptysBio&#146;s facilities in connection with such Project.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23 </B>&#147;<B>First Commercial Sale</B>&#148; shall mean the first sale of a Product by Client or any of its Affiliates, licensees or
sublicensees to a Third Party for end use or consumption in a country after the governing health regulatory authority of such country has granted marketing approval (<B></B><I>e.g</I><B></B>., BLA approval) with respect to such Product. Sale to an
Affiliate or to a licensee or sublicensee of Client or any of its Affiliates shall not constitute a First Commercial Sale.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24
</B>&#147;<B>Information</B>&#148; shall mean know-how, trade secrets, data, inventions, proprietary software, works of authorship, designs, techniques, methods, processes, formulations, structure and other information relating to compounds,
compositions, specifications, reagents, ideas and information.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25 </B>&#147;<B>Joint Invention</B>&#148; shall mean any
invention, whether or not patentable, that is made jointly (as determined in accordance with U.S. laws of inventorship) by one or more employees, consultants or contractors of Client and one or more employees, consultants or contractors of
AnaptysBio, in the course of activities undertaken pursuant to this Agreement; but, in each case, excluding AnaptysBio Technology and Client Technology.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26</B> &#147;<B>Joint Patents</B>&#148; shall have the meaning provided in Section 4.4(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.27</B> &#147;<B>Materials</B>&#148; shall have the meaning provided in Section 2.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.28 </B>&#147;<B>Net Sales</B>&#148; shall mean [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.29 </B>&#147;<B>Phase 1 Trial</B>&#148; shall mean a human clinical trial that would satisfy the requirements for a Phase 1 study as
defined in 21 CFR &#167; 312.21(a) (or its successor regulation) or any foreign equivalent thereof.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.30 </B>&#147;<B>Phase 2
Trial</B>&#148; shall mean a human clinical trial that would satisfy the requirements for a Phase 2 study as defined in 21 CFR &#167; 312.21(b) (or its successor regulation) or any foreign equivalent thereof.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.31 </B>&#147;<B>Phase 3 Trial</B>&#148; shall mean a human clinical trial that would satisfy
the requirements for a Phase 3 study as defined in 21 CFR &#167; 312.2l(c) (or its successor regulation) or any foreign equivalent thereof.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.32 </B>&#147;<B>Product</B>&#148; shall mean any product, composition, method, device, or service (a)&nbsp;that comprises, contains or
uses any Delivered Antibody (or any derivative or modification of a Delivered Antibody), in whole or in part, or (b)&nbsp;the manufacture, use, sale, offer for sale or import of which is covered by any Delivered Antibody Patent.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.33 </B>&#147;<B>Project</B>&#148; shall mean a project directed to either [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.34 </B>&#147;<B>Project Goals</B>&#148; shall mean, with respect to a particular Project, the specific design goals with respect to
binding affinity and specificity of the Antibodies to be generated and characterized by AnaptysBio in such Project, as set forth in the applicable Research Plan.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.35 </B>&#147;<B>Remaining Materials</B>&#148; shall mean any and all biological or chemical materials derived from the Client Materials
in the course and as a result of performance of a Project by or on behalf of AnaptysBio. Notwithstanding the foregoing, Remaining Materials shall exclude the Delivered Antibodies.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.36 </B>&#147;<B>Research Period</B>&#148; shall mean the period commencing on the Effective Date and, subject to earlier termination of
this Agreement in accordance with Article 7, [*]<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.37</B> &#147;<B>Research Plan</B>&#148; shall have the meaning provided in
Section 2.1(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.38 </B>&#147;<B>Results</B>&#148; shall mean, with respect to a particular Project: (a)&nbsp;any and all data and
results generated, discovered or developed by or on behalf of AnaptysBio in the course and as a result of performance of such Project, which data and results relate specifically and solely to the applicable Client Materials, Client Information
and/or Delivered Antibodies; and (b)&nbsp;any and all data and results generated is covered or developed by or on behalf of Client as a result of performing the Evaluation of Delivered Antibodies from such Project (it being understood that upon
payment of the Success Fee for such Project to AnaptysBio, the data and results described in this clause (b)&nbsp;shall be deemed Client Results). Notwithstanding the foregoing, the Results shall exclude the AnaptysBio Technology and the Client
Technology.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.39</B> &#147;<B>Subject AnaptysBio Patent</B>&#148; shall mean any patent application or patent within the
AnaptysBio Technology that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> claims any invention that AnaptysBio either (i)&nbsp;used in generating a particular Delivered
Antibody assigned to Client hereunder, or (ii)&nbsp;incorporated into a particular Delivered Antibody assigned to Client hereunder; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> would, in the absence of a license thereunder, be infringed by the manufacture, use, sale, offer for sale or import of such
Delivered Antibody. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.40</B> &#147;<B>Success Fee</B>&#148; shall have the meaning provided in Section 3.3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.41 </B>&#147;<B>Success Fee Due Date</B>&#148; shall mean, with respect to a particular
Project, the date that is [*] after expiration of the Evaluation Period and receipt of invoice for such Project. Notwithstanding the foregoing, if, prior to expiration of the Evaluation Period for a Project, Client exercises its rights under
Section&nbsp;2.4(b) with respect to such Project, then the &#147;Success Fee Due Date&#148; shall be the date that is [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.42</B>
&#147;<B>Third Party</B>&#148; shall mean any entity other than AnaptysBio or Client or an Affiliate of AnaptysBio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.43
</B>&#147;<B>Valid Claim</B>&#148; means a claim of an issued patent that has not expired or been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable
judgment (or judgment from which no appeal was taken within the allowable time period), or a claim within a patent application that has not been revoked, cancelled, withdrawn, held invalid or abandoned and which has not been pending for more than
[*] years from its first priority filing date.<B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>S<SMALL>TEERING</SMALL> C<SMALL>OMMITTEE</SMALL>, P<SMALL>ROJECTS</SMALL> <SMALL>AND</SMALL> D<SMALL>ELIVERABLES</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1 Steering Committee and Projects</B>.<B></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Steering Committee</B>. A steering committee (hereinafter the &#147;<B><I>Steering&nbsp;Committee</I></B>&#148;) shall be formed within
[*] after the Effective Date, as further described at Exhibit&nbsp;B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Approval of Projects</B>. During the Research Period,
AnaptysBio shall perform the [*] Projects for Client attached hereto as Exhibit A (the &#147;<B><I>Research Plan</I></B>&#148;) and the Projects described therein (the &#147;<B><I>Projects</I></B>&#148;). During the performance of a Project, [*]. If
AnaptysBio disputes in good faith that a proposed substitute Project is feasible, AnaptysBio shall so notify Client within [*] after receipt of the Project Notice, and the parties shall confer in good faith regarding the matter, [*]. In addition, in
the event AnaptysBio [*]. Unless AnaptysBio provides notice as set forth above that [*], which shall be in a form acceptable to the parties and shall specify the following information for such substitute Project: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">[*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) Research
Plans</B>. Each Research Plan shall be subject to all of the terms and conditions of this Agreement, in addition to the specific details set forth in such Research Plan. To the extent any terms of a Research Plan conflict with the terms of this
Agreement, the terms of this Agreement shall control, unless and only to the extent that such Research Plan expressly states the intent of the parties that the Research Plan supersede this Agreement with respect to a specific matter. Each
fully-executed Research Plan shall be deemed incorporated herein by reference, and a copy thereof shall be attached to this Agreement. Any changes to a Research Plan shall be in writing, executed by an authorized representative of each party,
attached to the original Research Plan, and incorporated herein and therein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) Exclusivity</B>. On a Project-by-Project
basis, commencing on acceptance of the Research Plan for each Project and expiring on, as applicable, [*]; except for the activities under this Agreement, AnaptysBio shall not [*]. Notwithstanding the preceding sentence or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other provision of this Agreement to the contrary, AnaptysBio shall at all times be free to conduct, participate in, or fund, directly or indirectly, alone or with any Third Party, any activities
directed to the discovery, research or commercialization of Antibodies that: [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2 Transfer and Use of Client Materials and
Information</B>. As promptly as practicable after mutual written approval of the Research Plan for each substitute Project (or after the Effective Date in the case of the Projects), Client shall deliver to AnaptysBio the Client Materials and the
Client Information for such Project as specified in the applicable Research Plan.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3 Performance of Projects; Substitution of
Projects; Deliverables</B>. On a Project-by-Project basis, promptly following receipt of the Client Materials and Client Information for a Project, AnaptysBio shall use commercially reasonable efforts to perform such Project, as described in the
applicable Research Plan. In the event that the research term of the Project exceeds [*] or a substitute Project is agreed to by the parties under Section&nbsp;2.l(b), and the combined research term of the Project and substitute Project exceed [*],
the parties agree to negotiate in good faith additional funding payments for the time period that is in excess of [*]. In addition, such substitute Project shall not be counted as an additional Project. AnaptysBio may perform some Project activities
through one or more subcontractors, provided that AnaptysBio shall at all times be fully responsible for the compliance of its subcontractors with this Agreement. Promptly following AnaptysBio&#146;s completion of its responsibilities under each
Research Plan, AnaptysBio shall:<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> deliver to Client the Antibodies generated and characterized in the course of the
performance of the applicable Project that meet the Project Goals; [*]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> provide a written report to Client setting forth,
for each Delivered Antibody from such Project, [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, AnaptysBio shall have no obligation: (A)&nbsp;to generate
or characterize Antibodies other than as expressly set forth in the Research Plans; (B)&nbsp;to deliver to Client any Antibodies other than as expressly set forth in Section&nbsp;2.3(a); (C)&nbsp;to disclose to Client any Results with respect to any
Antibody other than the Delivered Antibody Information with respect to the Delivered Antibodies; or (D)&nbsp;to disclose to Client any Information regarding the AnaptysBio Platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4 Client Evaluation of Delivered Antibodies</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Evaluation</B>. Commencing upon Client&#146;s receipt of the Delivered Antibodies and Delivered Antibody Information from each Project
and for a period of [*] thereafter, or such extended time period as may mutually agreed by the parties (the &#147;<B><I>Evaluation Period</I></B>&#148;), Client will [*]. Client may conduct the Evaluation either directly or indirectly through its
Affiliate(s), agent(s), consultant(s) and/or subcontractor(s), provided that Client shall at all times be fully responsible for the compliance of its Affiliate(s), agent(s), consultant(s) and/or subcontractor(s) with this Agreement and, prior to
providing any Delivered Antibody or Delivered Antibody Information to any agent, consultant or subcontractor, shall obtain the written agreement of such agent, consultant or subcontractor to be bound by clauses (ii)&nbsp;and (iii) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Section&nbsp;2.5(a). Unless Client notifies AnaptysBio in writing on or before the end of the Evaluation Period for a Project that Client in good faith believes that [*]. In addition,
regardless of whether or not Client has completed any or all Evaluation activities by the end of the Evaluation Period for a Project, Client shall not have the right to deliver a notice to AnaptysBio that the Project Goals for such Project have not
been met unless Client has generated data during such Evaluation Period, through performance of Evaluation activities, to support its contention that none of such Delivered Antibodies meets the Project Goals. If Client notifies AnaptysBio in writing
by the end of the Evaluation Period for a Project that Client in good faith believes that [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Independent Laboratory
Determination</B>. If Client notifies AnaptysBio in writing by the end of the Evaluation Period for a Project that Client in good faith believes that [*] of the Delivered Antibodies] from such Project do not meet the Project Goals, and AnaptysBio in
good faith does not agree that [*] of the Delivered Antibodies from such Project do not meet the Project Goals, then [*]. The parties will initially share the costs of the independent laboratory&#146;s analysis on an equal basis in accordance with a
pre-agreed budget and maximum cost for such activities, but the party in whose favor the independent laboratory rules shall be entitled to have its share of such costs reimbursed by the other party promptly following such determination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5 Use of Delivered Antibodies, Information and Results</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Prior to Success Fee Due Date. On a Project-by-Project basis, until the Success Fee Due Date for a Project (or, if this Agreement
is earlier terminated in accordance with Article 7, until such termination), except as expressly set forth in Sections 2.5(b) and 2.5(c): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> AnaptysBio shall solely own all rights in the Delivered Antibodies and Delivered Antibody Information resulting from such Project
and associated Results; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> each party shall treat such Delivered Antibodies and Delivered Antibody Information as Confidential
Information of the other party in accordance with Article&nbsp;5; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> Client covenants that: (1)&nbsp;except as expressly
permitted by Section&nbsp;2.4, it will not conduct or have conducted on its behalf, nor cause or allow any Affiliate or Third Party to conduct, any study of any such Delivered Antibody or related Product; (2)&nbsp;Client will not use any such
Delivered Antibody or Delivered Antibody Information for any purpose other than the Evaluation; and (3)&nbsp;except as expressly permitted by Section&nbsp;2.4, Client will not transfer or disclose, or cause to be transferred or disclosed, any such
Delivered Antibody, Delivered Antibody Information, or Results to any Affiliate or to any Third Party; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> AnaptysBio shall
not use any such Delivered Antibody, Delivered Antibody Information or Results for any purpose other than performance of such Project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Success Fee Timely Paid</B>. On a Project-by-Project basis, if Client pays the Success Fee for a Project in full on or before the
applicable Success Fee Due Date (or, if this Agreement is earlier terminated in accordance with Article 7, prior to such termination), then effective upon such payment: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> ownership of the Delivered Antibodies and Delivered Antibody Information from such
Project and all associated Results shall be assigned solely to Client pursuant to, and subject to the terms and conditions of, Section 4.1; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> AnaptysBio shall treat such Delivered Antibodies, Delivered Antibody Information and Results as Confidential Information of
Client in accordance with Article&nbsp;5; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> AnaptysBio shall destroy all Results of such Project (other than the
Delivered Antibodies and Delivered Antibody Information) and all Remaining Client Materials from such Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Success Fee Not
Timely Paid</B>. On a Project-by-Project basis, if Client fails to pay the Success Fee for a Project in full on or before the applicable Success Fee Due Date (or, if this Agreement is earlier terminated in accordance with Article 7, prior to such
termination), then effective as of such Success Fee Due Date (or such earlier termination, as applicable):<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> neither
party shall file, or cause to be filed, any Delivered Antibody Patent with respect to any Delivered Antibody Invention from such Project; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Client and AnaptysBio shall immediately destroy all Delivered Antibodies from such Project and, except as expressly set forth in
Section&nbsp;7.4(b), all associated Delivered Antibody Information and Results, and AnaptysBio shall destroy all Remaining Client Materials from such Project, and, in each case, certify such destruction in writing to the other party; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> the Delivered Antibodies and Delivered Antibody Information from such Project and all associated Results shall be considered
Confidential Information of both parties; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> each of Client and AnaptysBio hereby covenants that it will not (either
directly or through any Affiliate or Third Party) develop, make, have made, use, sell, have sold, offer for sale or import any such Delivered Antibody or any Product based thereon, or otherwise exploit the associated Delivered Antibody Information
or Results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6 Materials Transfer</B>. In connection with a Project, a party may provide to the other party certain biological or
chemical materials, including, but not limited to, Client Materials and Delivered Antibodies (collectively, &#147;<B><I>Materials</I></B>&#148;). Except as otherwise expressly set forth in this Agreement , all such Materials will remain the sole
property of the providing party, will be used only in furtherance of the activities expressly contemplated by this Agreement, will not be used or delivered to or for the benefit of any Third Party (except, in the case of AnaptysBio, in connection
with the subcontracting of Project activities in accordance with Section&nbsp;2.3) without the prior written consent of the providing party, and will be used in compliance with all applicable laws, rules and regulations. The Materials supplied under
this Agreement must be used with prudence and appropriate caution in any experimental work because not all of their characteristics may be known. Except as expressly set forth herein, THE MATERIALS ARE PROVIDED &#147;AS IS&#148; AND WITHOUT ANY
REPRESENTATION OR </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT
INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>P<SMALL>AYMENTS</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1 Initial Fee</B>. Client shall pay to AnaptysBio a
one-time, non-refundable, non-creditable initial fee of [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2 Reimbursement for Excluded Costs</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> On a Project-by-Project basis Client shall reimburse AnaptysBio for [*] Except as expressly set forth in such Research Plan,
AnaptysBio shall issue written, reasonably detailed invoices to Client for such Excluded Costs on a monthly basis, and Client shall pay each such invoice in full within [*] of receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3 Success Fee</B>. On a Project-by-Project basis, Client shall pay to AnaptysBio [*]: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4 Milestone
Payments</B>. Subject to the limitations set forth below, within [*] following the first occurrence of each of the events set forth below with respect to each Product arising from a Project, Client shall provide written notice to AnaptysBio of the
occurrence of such event and shall pay to AnaptysBio the corresponding milestone payment set forth below (whether such milestone is achieved by Client, its Affiliate or any of their respective licensees or sublicensees):<B> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.25pt; font-size:8pt; font-family:Times New Roman"><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone<BR>Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;[*]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[*]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[*]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[*]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[*]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">[*]</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-size:4pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total per Product</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>[*]</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On a Project-by-Project basis, each of the milestone payments set forth above shall be payable: (a)&nbsp;only
once per Product, regardless of the number of times a particular Product achieves any milestone set forth above; and (b)&nbsp;only two times per Project, for the first two Products to achieve any milestone set forth above, regardless of the number
of Products from such Project that achieve the milestones set forth above; such that the maximum amount payable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under this Section&nbsp;3.4 for each Project shall be [*]. With respect to any particular milestone event set forth above, from and after such time as the corresponding milestone payment has been
paid for two Products arising from a Project, Client shall have no further obligation to notify AnaptysBio of the achievement of such milestone event by any other Product arising from such Project or to pay any additional milestone payment for any
such achievement. For purposes of the foregoing milestones, &#147;initiation&#148; of a clinical trial shall mean [*]. Each of the foregoing milestone payments shall be payable only one time for the first and second Product arising from a Project
and shall not be payable on any additional Products arising from the Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>3.5 Royalties</B><B><I></I></B>. Client
shall pay to AnaptysBio a royalty equal to [*] percent [*]% of Net Sales of Products. Royalties under this Section&nbsp;3.5 shall be payable on a Product-by-Product and country-by-country basis from the First Commercial Sale of a Product in a
country until the later of [*] (the &#147;<B><I>Royalty Term</I></B>&#148;). In the event Client obtains a license under any issued patent of a Third Party in a country for which license Client is obligated to pay such Third Party a royalty on sales
of a Product in such country, then Client may offset [*] percent ([*]%) of the royalties actually paid to such Third Party under such patent license with respect to sales of such Product in such country against the royalties due AnaptysBio under
this Agreement with respect to Net Sales of such Product in such country, provided that in no event shall the effective royalty rate applicable to Net Sales of such Product in such country hereunder be reduced below [*]% as a result of all such
offsets in the aggregate. For the avoidance of doubt, royalties shall be payable only once with respect to the same unit of Product. On a <FONT STYLE="white-space:nowrap">Product-by-Product</FONT> and country-by-country basis, upon expiration of the
Royalty Term for a Product in a country, Client&#146;s licenses and rights hereunder with respect to such Product in such country shall continue in effect, but become fully paid-up, royalty-free, transferable, perpetual and irrevocable.<B><I>
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6 Applicability of Payment Obligations</B>. Client acknowledges and agrees that all milestone and royalty payment
obligations as set forth in Sections 3.4 and 3.5 shall apply notwithstanding the sale, license, transfer or other disposition by Client of any of its rights with respect to any Delivered Antibody, Product, Delivered Antibody Information or Delivered
Antibody Patent. Moreover, Client shall at all times be and remain liable for any and all fees and payments that may become due hereunder with respect to any Delivered Antibody or Product, regardless of whether Client has sold, licensed, transferred
or otherwise disposed of any of its rights with respect to such Delivered Antibody or Product or any Delivered Antibody Information or Delivered Antibody Patent to any Affiliate or Third Party. Prior to selling, licensing, transferring or otherwise
disposing of any of Client&#146;s rights with respect to any Delivered Antibody, Product, Delivered Antibody Information or Delivered Antibody Patent to any Affiliate or Third Party, Client shall obtain the written agreement of such Affiliate or
Third Party, for the benefit of AnaptysBio, to be bound by Sections 3.4 through 3.12 of this Agreement to the same extent as Client, and Client shall provide prompt written notice of any such sale, license, transfer or other disposition to
AnaptysBio, including the identity of the applicable Delivered Antibody(ies), Product(s), Delivered Antibody Information and/or Delivered Antibody Patent and the identity of the purchaser, licensee, transferee or other recipient thereof. Client
shall ensure that any such transfer arrangement is consistent with the terms of this Agreement.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.7 Third Party Patents</B>.
Except as expressly set forth in Section&nbsp;4.3(b), Client shall be solely responsible for obtaining such licenses under Third Party patent or other intellectual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property rights as Client determines are necessary or desirable for the manufacture, use, sale, offer for sale or import of Delivered Antibodies or Products, at Client&#146;s sole expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.8 Payment; Reports</B>. Royalties shall be calculated and reported for each calendar quarter and shall be paid within [*] after the end
of each calendar quarter. Each payment shall be accompanied by a report of [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.9 Exchange Rate; Manner and Place of Payment</B>.
All payments hereunder shall be payable in U.S. dollars and shall be made by electronic funds transfer in immediately available funds to a bank and account designated in writing by AnaptysBio, unless otherwise specified in writing by AnaptysBio.
When conversion of payments from any foreign currency is required, such conversion shall be made at the rate of exchange used by Client throughout its accounting system for the applicable calendar quarter.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.10 Income Tax Withholding</B>. AnaptysBio will pay any and all taxes levied on account of any payments made to it under this Agreement.
If any taxes are required to be withheld by Client, Client will (a)&nbsp;deduct such taxes from the payment made to AnaptysBio, (b)&nbsp;timely pay the taxes to the proper taxing authority, (c)&nbsp;send proof of payment to AnaptysBio (and, if such
tax authority provides a receipt for such payment to Client, a copy of such receipt), and (d)&nbsp;reasonably assist AnaptysBio in its efforts to obtain a credit for or refund of such tax payment.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.11 Records and Audit Rights</B>. During the Term and for a period of [*] years thereafter, Client shall keep (and shall cause its
Affiliates, licensees and sublicensees to keep) complete and accurate records pertaining to the sale or other disposition of Products in sufficient detail to permit AnaptysBio to confirm the accuracy of all royalty payments due hereunder. AnaptysBio
shall have the right to cause an independent, certified public accountant reasonably acceptable to Client to audit such records to confirm Net Sales and royalty payments for a period covering not more than the preceding [*] full calendar years. Such
audits may be exercised during normal business hours upon reasonable prior written notice to Client. All information received or learned in connection with such audit shall be Confidential Information of Client and shall be subject to Article 5,
provided that AnaptysBio may use and disclose such information to the extent necessary to prepare its financial statements. Prompt adjustments shall be made by the parties to reflect the results of such audit. AnaptysBio shall bear the full cost of
such audit unless such audit discloses an underpayment by Client of more than [*]% of the amount due under this Agreement, in which case, Client shall bear the full cost of such audit and shall promptly remit to AnaptysBio the amount of any
underpayment.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.12 Late Payments</B>. In the event that any payment due under this Agreement is not made when due, the payment
shall accrue interest from the date due at the rate of [*]% per month (or, if lower, the maximum legal annual interest rate). The payment of such interest shall not limit AnaptysBio from exercising any other rights it may have as a consequence of
the lateness of any payment.<B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>I<SMALL>NTELLECTUAL</SMALL> P<SMALL>ROPERTY</SMALL> R<SMALL>IGHTS</SMALL>. </B></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1 Delivered Antibodies</B>. Subject to the terms and conditions of this Agreement, on a
Project-by-Project basis, and effective only upon payment in full of the Success Fee for a Project on or before the applicable Success Fee Due Date (or, if this Agreement is earlier terminated in accordance with Article 7, prior to such
termination), AnaptysBio hereby assigns to Client all right, title and interest of AnaptysBio in and to the Delivered Antibodies and Delivered Antibody Information from such Project, and the Results of the Evaluation thereof, including all
intellectual property rights in any of the foregoing. Client acknowledges and agrees that, notwithstanding any assignment by AnaptysBio to Client of any Delivered Antibody, Delivered Antibody Information and/or any Results of the Evaluation, or any
further assignment, license or transfer by Client to any Affiliate or Third Party of any rights in any Delivered Antibody, Product, Delivered Antibody Information and/or Results of the Evaluation, all Delivered Antibodies and Products shall be and
remain subject to the milestone and royalty payment obligations set forth in Sections 3.4 and 3.5, respectively.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2 AnaptysBio
Technology</B>. AnaptysBio shall at all times be and remain the sole and exclusive owner of the AnaptysBio Technology and shall have no obligation to deliver, make available or disclose to Client any AnaptysBio Technology. AnaptysBio shall be free,
in its sole discretion, to seek patent or other intellectual property protection of AnaptysBio Technology. Except as expressly set forth in Section&nbsp;4.3, nothing in this Agreement shall be construed as granting to Client any right or license in
any AnaptysBio Technology or any other intellectual property rights of AnaptysBio.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3 Freedom to Operate</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Subject AnaptysBio Patents</B>. Subject to the terms and conditions of this Agreement (including Sections 3.4 and 3.5 above and
Section&nbsp;4.3(b) below), on a <FONT STYLE="white-space:nowrap">Project-by-Project</FONT> basis, to the extent necessary, and effective only upon the effectiveness of the assignment set forth in Section&nbsp;4.1 for a Project, AnaptysBio shall,
and it hereby does, grant to Client a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, royalty-bearing license under the Subject AnaptysBio Patents associated with a particular Delivered Antibody from such Project, solely to make,
have made, use, sell, have sold, offer for sale, and import such Delivered Antibody and related Products for all uses and purposes. The foregoing license will include the right to sublicense solely in conjunction with the grant by Client to a Third
Party of a license to make, have made, use, sell, have sold, offer for sale, or import a Product based on such Delivered Antibody. For the avoidance of doubt, the license granted pursuant to this Section&nbsp;4.3(a) excludes (i)&nbsp;the right to
use any AnaptysBio Technology for the purpose of modifying any Antibody (including, without limitation, any Delivered Antibody), and (ii)&nbsp;the right to make, have made, use, sell, have sold, offer for sale, or import any Antibody other than a
Delivered Antibody that has been assigned to Client pursuant to Section&nbsp;4.1 and its related Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) In-Licensed
Patents</B>. With regard to any Subject AnaptysBio Patent licensed to Client pursuant to Section&nbsp;4.3(a) that is licensed to AnaptysBio by [*]. Subject to mutual execution by the parties of a sublicense agreement with respect to an In-Licensed
Patent, AnaptysBio shall be responsible for any payments that may be due to Licensor(s) as a result of Client&#146;s practice of the invention(s) claimed by such In-Licensed Patent within the scope of such sublicense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4 Patents</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Delivered Antibody Patents</B>. Subject to the terms and conditions of this Agreement, on a Project-by-Project basis and effective only
upon effectiveness of the assignment set forth in Section&nbsp;4.1 for a Project, Client shall have the exclusive right, in its sole discretion and at its own expense, to file and prosecute any patent applications, and to maintain, defend and
enforce any resulting patents, claiming or disclosing any Delivered Antibody or Delivered Antibody Information from such Project, any associated Product, or any method of making or using any of the foregoing (collectively, &#147;<B><I>Delivered
Antibody Inventions</I></B>&#148;). [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Joint Patents</B>. For the avoidance of doubt, the parties do not anticipate that there
will be any Joint Inventions, as they anticipate that inventions and information resulting from activities under this Agreement are most likely to fall within the scope of AnaptysBio Technology, Client Technology or Delivered Antibody Inventions.
However, in the event that any Joint Invention is made, the parties shall mutually agree, on a case-by-case basis, [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5
Cooperation</B>. The parties shall cooperate in good faith to accomplish the intent of Sections 4.1 and 4.4 and to enable each party to exercise its rights and perform its responsibilities under such Sections, including the execution of all such
documents and instruments and the performance of such acts (and causing its relevant employees to execute such documents and instruments and to perform such acts) as may be reasonably necessary in order to permit each party to exercise such rights
and perform such obligations.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6 No Implied Licenses</B>. No right or license under any Information or intellectual property
right of either party is granted or shall be granted by implication hereunder. All such rights or licenses are or shall be granted only as expressly provided in this Agreement.<B> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>P<SMALL>ROTECTION</SMALL> <SMALL>OF</SMALL> C<SMALL>ONFIDENTIAL</SMALL> I<SMALL>NFORMATION</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1 Confidentiality</B>. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the parties, the
parties agree that a party (referred to as the &#147;receiving party&#146; shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement any Confidential
Information of the other party. Each party may use the other party&#146;s Confidential Information only to the extent required to accomplish the purposes of this Agreement. Each party may disclose Confidential Information of the other party to those
of such party&#146;s employees, directors, contractors and consultants who have a need for such information, provided that such party shall advise such employees, directors, contractors and consultants of the confidential nature thereof, shall
insure that each such employee, director, contractor or consultant is bound by obligations of confidentiality at least as stringent as those contained in this Agreement and shall be responsible for the compliance of its employees, directors,
contractors and consultants with the terms of this Agreement. Each party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to ensure that
its employees, directors, contractors and consultants do not disclose or make any unauthorized use of the other party&#146;s Confidential Information. Each party will promptly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
notify the other upon discovery of any unauthorized use or disclosure of the other party&#146;s Confidential Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2 Exceptions</B>. Confidential Information shall not include any information that the receiving party can prove by competent evidence:
(a)&nbsp;was already known to the receiving party prior to receipt from the other party other than as a result of performance of a Project; (b)&nbsp;was generally available to the public or otherwise part of the public domain at the time of its
disclosure to the receiving party; (c)&nbsp;became generally available to the public or otherwise part of the public domain after its disclosure, other than through any act or omission of the receiving party in breach of this Agreement; (d)&nbsp;was
disclosed to the receiving party, other than under an obligation of confidentiality, by a Third Party with the lawful right to make such disclosure; or (e)&nbsp;was independently discovered or developed by the receiving party without access to and
without the aid, use or application of any Confidential Information disclosed or made available to the receiving party by the other party.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3 Authorized Disclosure</B>. Notwithstanding Section&nbsp;5.1, a party may disclose Confidential Information of the other party, without
violating its obligations under this Agreement, to the extent the disclosure is necessary in the following instances:<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>
filing or prosecuting patent applications as permitted by this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> prosecuting or defending litigation as permitted by
this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> exercising rights expressly granted to such party hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> enforcing the provisions of this Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> complying with a valid order of a court or other governmental body having jurisdiction or with applicable law; provided that, if
legally permissible and to the extent practicable under the circumstances, such party gives reasonable prior written notice to the other party of such required disclosure and, at the other party&#146;s request and expense, cooperates with the other
party&#146;s efforts to contest such required disclosure, and/or to obtain a protective order preventing or limiting the disclosure and/or requiring that the Confidential Information so disclosed be used only for the purposes for which the law or
regulation requires, or for which the order was issued, and/or to obtain other confidential treatment of such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4 Use of
Names; Blinded Data</B>. Neither party shall use the other party&#146;s name or trademarks in any advertising, sales, or promotional material or in any publication without the prior written consent of the other party. Notwithstanding the preceding
sentence or any other provision of this Article 5, the parties agree that for the purposes of promoting or otherwise highlighting the advantages of the AnaptysBio Technology, AnaptysBio may publish (or cause to be published) or otherwise disclose
(or cause to be disclosed) to Third Parties, blinded data relating to Results, Delivered Antibodies and/or Delivered Antibody Information (such data to be limited to the number of projects, the types of projects, number and diversity of Antibodies
generated or matured, binding affinity of Antibodies generated or matured, functional assay data, and number and types of mutations observed), at any time during or subsequent to the Term, provided that neither Client nor any Client Target, Client
Antibody or Delivered Antibody shall be identified, directly or indirectly, in connection therewith.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5 Confidentiality of this Agreement</B>. This Agreement and its terms are considered
Confidential Information of both parties, and each party shall keep confidential and shall not publish or otherwise disclose this Agreement or its terms without the prior written consent of the other party, except as expressly permitted by
Section&nbsp;5.3, Section&nbsp;5.4 or Section&nbsp;5.6, and except that AnaptysBio may disclose this Agreement and its terms to actual or potential investors, strategic partners, acquirers and merger candidates on a confidential basis.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6 Publicity</B>. Except as required by judicial order or applicable law, neither party shall make any public announcement concerning this
Agreement without the prior written consent of the other party. Notwithstanding the foregoing, from and after such time as Client begins publicly disclosing or discussing Client&#146;s interest and/or efforts in the development of antibodies,
AnaptysBio may issue one or more press releases concerning, or otherwise publicly disclose or discuss, the existence of this Agreement and/or the achievement of significant development and regulatory milestones by Products arising from this
Agreement, after good faith consultation between the parties with respect to the text and timing of any such press release (or content and timing of any such other public disclosure or discussion) and subject to Client&#146;s prior approval, which
shall not be unreasonably withheld.<B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL>; D<SMALL>ISCLAIMER</SMALL>; L<SMALL>IMITATION</SMALL> <SMALL>OF</SMALL> L<SMALL>IABILITY</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1 Mutual Representations and Warranties</B>. Each party represents and warrants to the other that: (a)&nbsp;it is duly organized and
validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof; (b)&nbsp;it is duly authorized to execute and
deliver this Agreement and to perform its obligations hereunder; and (c)&nbsp;this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or
written, to which it is a party or by which it may be bound.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2 Limited Services Warranty</B>. AnaptysBio&#146;s sole warranty
with respect to each Project is that AnaptysBio will perform such Project with due care and in accordance with applicable laws and regulations (including, without limitation, laws and regulations relating to health, safety and the environment, fair
labor practices, unlawful discrimination and animal welfare), (b)&nbsp;the terms and conditions contained herein and (c)&nbsp;generally prevailing industry standards.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3 Disclaimer</B>. Except as expressly set forth herein, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE
PRACTICES. Without limiting the generality of the foregoing, Client acknowledges and&#149; agrees that AnaptysBio does not make, and that AnaptysBio hereby disclaims, any representation or warranty (a)&nbsp;that the Project Goals will be achieved by
any Antibody generated in the course of any Project, (b)&nbsp;as to the safety or usefulness for any purpose of the AnaptysBio Technology or any Delivered Antibody, Delivered Antibody Information or other Results, or (c)&nbsp;that any Delivered
Antibody, Product, Delivered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Antibody Information or other Results will be acceptable to any regulatory governmental agency to which they are presented or that Client will be able to market or otherwise exploit any Delivered
Antibody or Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4 Limitation of Liability</B>. EXCEPT FOR LIABILITY FOR BREACH OF SECTION 4.1, 4.3 OR 4.4, OR ARTICLE 5 HEREOF,
IN NO EVENT SHALL EITHER PARTY BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING, WITHOUT LIMITATION, LOST PROFITS AND THE COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR
SERVICES, IN CONNECTION WITH THIS AGREEMENT, EVEN IF THE OTHER PARTY HAD NOTICE OF THE POSSIBILITY OF SUCH DAMAGES; provided, however, that the foregoing shall not be construed to limit either party&#146;s indemnification obligations under Article
8. [*] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>T<SMALL>ERMINATION</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1 Term</B>. The term of this Agreement (the
&#147;<B></B><B><I>Term</I></B><B></B>&#148;) shall commence on the Effective Date and, subject to earlier termination of this Agreement in accordance with this Article 7, shall continue until:<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> the Success Fee Due Date for the last Project initiated during the Research Period, unless Client has timely paid the Success Fee
for at least one Project on or before the Success Fee Due Date for such last Project; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> if Client pays the Success Fee for at
least one Project on or before the applicable Success Fee Due Date, the expiration of the last-to-expire of all Royalty Terms with respect to all Products associated with any Project for which Client obtained the assignment set forth in Section 4.1.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2 Termination of Agreement for Material Breach</B>. Each party shall have the right to terminate this Agreement upon 60 days&#146;
prior written notice to the other party upon or after the material breach of any provision of this Agreement by the other party if the breaching party has not cured such breach by the end of such 60-day period.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3 Termination by Client At Will</B>. Client shall have the right, at any time prior to delivery to Client of the Delivered Antibodies and
Delivered Antibody Information pursuant to Section&nbsp;2.3 and in its sole discretion, to terminate this Agreement upon 30 days&#146; prior written notice to AnaptysBio.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4 Disposal of Materials and Information</B>. In the event of expiration or any termination of this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> each party shall return to the other party all Materials of the other party remaining in such party&#146;s possession promptly
following such expiration or termination, except as expressly provided in Section&nbsp;7.5 (including any surviving sections of this Agreement referenced therein); provided that AnaptysBio shall destroy all Remaining Materials; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> each party shall return to the other party all Confidential Information of the other
party (including all copies thereof) in such party&#146;s possession; provided, however, that each party may retain one copy of the other party&#146;s Confidential Information in such party&#146;s secure archives for the sole purpose of monitoring
compliance with its obligations hereunder; and provided, further, that a party may retain such Confidential Information of the other party as is necessary or useful for the exercise or enforcement of any of its rights under this Agreement that
survive such expiration or termination pursuant to the applicable provisions of Section&nbsp;7.5; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> each party covenants
that, from and after such expiration or termination, it will not use any Confidential Information of the other party for any purpose whatsoever, except as expressly set forth in Section&nbsp;7.5 (including any surviving sections of this Agreement
referenced therein). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5 Consequences of Termination or Expiration</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Project Goals Not Achieved; Success Fee Not Paid</B>. On a Project-by-Project basis, in the event of any termination or expiration of
this Agreement, if the Project Goals for a Project were not met prior to such termination or expiration, and Client did not pay the Success Fee for such Project in full to AnaptysBio on or before the applicable Success Fee Due Date (or, if earlier,
prior to termination or expiration of this Agreement), then: (i)&nbsp;Sections 4.1, 4.3 and 4.4(a) shall terminate with respect to such Project and be of no further force or effect; and (ii)&nbsp;clauses (i)&nbsp;through (iv)&nbsp;of
Section&nbsp;2.5(c) shall become effective with respect to such Project and survive such termination or expiration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Success Fee
Paid</B>. On a Project-by-Project basis, in the event of any termination or expiration of this Agreement, if Client paid the Success Fee for a Project in full on or before the Success Fee Due Date and prior to such termination or expiration,
Sections 2.5(b), 4.1, 4.3 and 4.4(a) shall survive such termination or expiration with respect to such Project in accordance with their respective terms, subject to Client&#146;s continued compliance with all applicable terms and conditions of this
Agreement, including, without limitation, Sections 3.4 through 3.12 (which shall survive such termination). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c) General</B>. Except as
expressly set forth in Section&nbsp;7.4, 7.5(a) or 7.5(b), or below in this Section&nbsp;7.5(c), upon expiration or any termination of this Agreement, all rights and obligations of the parties under this Agreement shall terminate and be of no
further force or effect. The expiration or termination of this Agreement for any reason shall not release either party from any liability or obligation that, at the time of such expiration or termination, has already accrued to the other party or
that is attributable to a period prior to such expiration or termination, nor will expiration or any termination of this Agreement preclude either party from pursuing all rights and remedies it may have under this Agreement , or at law or in equity,
with respect to breach of this Agreement. In the event of expiration or any termination of this Agreement (and in addition to any provisions of this Agreement that survive pursuant to the preceding provisions of this Section&nbsp;7.5), the following
provisions of this Agreement shall survive such expiration or termination in accordance with their respective terms and conditions: Sections 2.6 (last sentence only), 3.11, 3.12, 4.2, 4.4(b), 4.5 (solely as it applies to Joint Patents), 4.6, 6.3,
6.4, 7.4 and 7.5, and Articles 5, 8 and 9. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>I<SMALL>NDEMNIFICATION</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>8.1 By Client</B><B><I></I></B>.
Client hereby agrees to save, defend, indemnify and hold harmless AnaptysBio and its officers, directors, employees, consultants and agents (each, an &#147;<B><I>AnaptysBio Indemnitee</I></B>&#148;) from and against any and all losses, damages,
liabilities, expenses and costs, including reasonable legal expense and attorneys&#146; fees (collectively, &#147;<B><I>Losses</I></B>&#148;), to which any AnaptysBio Indemnitee may become subject as a result of any claim, demand, action or other
proceeding by any Third Party to the extent such Losses arise directly or indirectly out of (a)&nbsp;the use of Client Materials or Client Information in performance of a Project, (b)&nbsp;the development , manufacture, use, handling, storage, sale
or other disposition of any Delivered Antibody or Product or use of any Delivered Antibody Information by or on behalf of Client or any Affiliate or Third Party to whom Client sells, licenses, transfers or disposes of its rights therein,
(c)&nbsp;the negligence or willful misconduct of any Client Indemnitee, or (d)&nbsp;the breach by Client of any warranty, representation , covenant or agreement made by Client in this Agreement; except, in each case, to the extent such Losses result
from the negligence or willful misconduct of any AnaptysBio Indemnitee or the breach by AnaptysBio of any warranty, representation, covenant or agreement made by AnaptysBio in this Agreement.<B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2 By AnaptysBio</B>. AnaptysBio hereby agrees to save, defend, indemnify and hold harmless Client and its officers, directors, employees,
consultants and agents (each, a &#147;<B></B><B><I>Client Indemnitee</I></B><B></B>&#148;) from and against any and all Losses to which any Client Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any
Third Party to the extent such Losses arise directly or indirectly out of (a)&nbsp;the negligence or willful misconduct of any AnaptysBio Indemnitee, or (b)&nbsp;the breach by AnaptysBio of any warranty, representation, covenant or agreement made by
AnaptysBio in this Agreement; except, in each case, to the extent such Losses result from the negligence or willful misconduct of any Client Indemnitee or the breach by Client of any warranty, representation, covenant or agreement made by Client in
this Agreement.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3 Control of Defense</B>. In the event a party seeks indemnification under Section&nbsp;8.1 or
Section&nbsp;8.2, it shall inform the other party (the &#147;<B></B><B><I>Indemnifying Party</I></B><B></B>&#148;) of a claim as soon as reasonably practicable after it receives notice of the claim, shall permit the Indemnifying Party to assume
direction and control of the defense of the claim (including the right to settle the claim solely for monetary consideration with no admission of fault) at the Indemnifying Party&#146;s expense, and shall cooperate as requested (at the expense of
the Indemnifying Party) in the defense of the claim.<B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>M<SMALL>ISCELLANEOUS</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1 Independent Contractor Relationship</B>.
AnaptysBio&#146;s relationship with Client is that of an independent contractor, and nothing in this Agreement should be construed to create a partnership, joint venture, or employer-employee relationship. Neither party is an agent of the other
party or authorized to make any representation, contract, or commitment on behalf of the other party.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2 Entire Agreement;
Amendment</B>. This Agreement, together with all Exhibits attached hereto, constitutes the final, complete and exclusive agreement of the parties with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respect to the subject matter hereof and supersedes all prior and contemporaneous understandings and agreements relating to its subject matter, including, without limitation, that certain Mutual
Confidentiality Agreement between the parties dated May&nbsp;11, 2011 (the &#147;<B><I>CDA</I></B>&#148;); provided, however, that all &#147;Confidential Information,&#148; as such term is defined in the CDA, that was disclosed by a party to the
other party pursuant to the CDA shall be deemed Confidential Information of such party for purposes of this Agreement. This Agreement (including its Exhibits) may not be changed, modified, amended or supplemented except by a written instrument
signed by both parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3 Non-Waiver</B>. The failure of a party to insist upon strict performance of any provision of this
Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a party
of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such party.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.4 Severability</B>. If any provision of this Agreement should be held invalid or unenforceable, the remaining provisions shall be
unaffected and shall remain in full force and effect, to the extent consistent with the intent of the parties as evidenced by this Agreement as a whole.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.5 Assignment</B>. Neither this Agreement nor any rights or obligations hereunder may be assigned by either party without the prior
written consent of the other party (which consent shall not be unreasonably withheld); provided, however, that either party may assign this Agreement and its rights and obligations hereunder without the other party&#146;s consent to an Affiliate of
the assigning party or in connection with the transfer or sale of all or substantially all of the business of such party to which this Agreement relates to a Third Party, whether by merger, sale of stock, sale of assets or otherwise, provided that
in the event of any such transaction involving AnaptysBio (whether this Agreement is actually assigned or is assumed by the acquiring party by operation of law (e.g., in the context of a reverse triangular merger)), intellectual property rights of
the acquiring party to such transaction (if other than AnaptysBio) shall not be included in the technology subject to this Agreement. The rights and obligations of the parties under this Agreement shall be binding upon and inure to the benefit of
the successors and permitted assigns of the parties, and the name of a party appearing herein will be deemed to include the name of such party&#146;s successors and permitted assigns to the extent necessary to carry out the intent of this section.
Any assignment not in accordance with this Agreement shall be void.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.6 Governing Law</B>. This Agreement shall be governed by
the laws of the State of California, excluding its conflict of laws principles.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.7 Force Majeure</B>. Except for the
obligation to make payment when due, each party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such party&#146;s reasonable control including but not
limited to Acts of God, fire, flood, explosion, earthquake, or other natural forces, war, civil unrest, acts of terrorism, accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of
raw materials, any strike or labor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disturbance, or any other event similar to those enumerated above. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in
performance and provided that the party has not caused such event(s) to occur. All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such force majeure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.8 Notices</B>. Any notice to be given under this Agreement must be in writing and delivered either in person, by any method of mail
(postage prepaid) requiring return receipt, by overnight courier, or by facsimile, to the party to be notified at its address(es) given below, or at any address such party has previously designated by prior written notice to the other. Notice shall
be deemed sufficiently given for all purposes upon the earlier of: (a)&nbsp;the date of actual receipt; or (b)&nbsp;if mailed, three calendar days after the date of postmark.<B> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If&nbsp;to&nbsp;AnaptysBio:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AnaptysBio, Inc.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10421 Pacific Center Court, Suite 200</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Chief Executive Officer</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fax: (858)&nbsp;228-9642</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If to Client:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Celgene Corporation</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">86 Morris Avenue</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Summit, NJ 07901</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: George S. Golumbeski</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fax: (908)&nbsp;673-2769</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">with&nbsp;a&nbsp;copy&nbsp;to:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Celgene Corporation</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">86 Morris Avenue</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Summit, NJ 07901</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Legal Department</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fax: (908)&nbsp;673-2771</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.9 Interpretation</B>. The headings of clauses contained in this Agreement preceding the text of the
sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. All references in this
Agreement to the singular shall include the plural where applicable. Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections and paragraphs in such Article, references to any Section shall
include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection. Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against
either party, irrespective of which party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the English language shall control its interpretation. In addition, all
notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the parties regarding this Agreement, shall be in the English language.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.10 Counterparts</B>. This Agreement may be executed in counterparts, including by
transmission of facsimile or PDF copies of signature pages, each of which shall be deemed an original and all of which together shall constitute one and the same instrument.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Signature page follows.] </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have executed this ANTIBODY GENERATION AGREEMENT on
the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>A<SMALL>NAPTYS</SMALL>B<SMALL>IO</SMALL>, I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>C<SMALL>ELGENE</SMALL> C<SMALL>ORPORATION</SMALL></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Hamza Suria</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ G.S. Golumberski</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hamza Suria</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">G.S. Golumberski</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Acting CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">SVP Business Development</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>C<SMALL>ELGENE</SMALL> C<SMALL>ORPORATION</SMALL></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Robert J. Hugin</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Robert J. Hugin</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Research Plan </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[*]
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>*Confidential
Treatment Requested. </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Steering Committee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(a) <B><U>Steering Committee</U></B>. A steering committee (hereinafter the &#147;Steering Committee&#148;) shall be formed within [*]
after the Effective Date. The duties of the Steering Committee shall include:<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[*] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(b) <B><U>Steering Committee Composition</U></B>. The Steering Committee shall be comprised of [*] representatives from each Party. The
Steering Committee representatives from each party shall be designated by such party upon written notice to the other party, and each party can change its designated representatives from time to time upon written notice to the other party.<B>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(c) <B><U>Steering Committee Meetings</U></B>. The Steering Committee shall meet [*] and meetings may be conducted by
telephone, electronic mail, facsimile, video conference or in person. Up to [*] additional employees of each party may attend the Steering Committee meetings as non-voting observers. The Steering Committee shall be chaired by one of the
representatives [*] (the &#147;Chairperson&#148;). The Chairperson shall prepare written minutes of each Steering Committee meeting and a written record of all Steering Committee decisions made during such meetings.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(d) <B><U>Quorum; Required Vote</U></B>. No Steering Committee meeting may be conducted unless at least [*] Steering Committee member
from each party is participating. For the purposes of any approval or action taken by the Steering Committee, all decisions of the Steering Committee initially will be taken [*].<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">B-1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 10.11 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="60%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[*]</TD>
<TD ALIGN="left" VALIGN="top">Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (the &#147;<B>Agreement</B>&#148;), effective as of March&nbsp;10 , 2014 (the
&#147;<B>Effective Date</B>&#148;), is made by and between (i)&nbsp;<B>AnaptysBio, Inc.</B>, a Delaware corporation, having a place of business at 10421 Pacific Center Court, Suite 200, San Diego, California 92121 (&#147;<B>AnaptysBio</B>&#148;),
and (ii)&nbsp;<B>TESARO, Inc.</B>, a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (&#147;<B>TESARO US</B>&#148;) and <B>TESARO Development, Ltd.</B>, a Bermuda corporation, having
its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, &#147;TESARO&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BACKGROUND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. AnaptysBio
has skills, expertise and proprietary technology for the discovery, generation and optimization of immunotherapy antibodies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.
AnaptysBio is developing therapeutic antibodies against immune checkpoint proteins for use in the treatment of cancer and related conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. TESARO possesses expertise in the research, development, manufacturing and commercialization of treatments for cancer and related
conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. TESARO and AnaptysBio desire to enter a collaboration wherein AnaptysBio will perform certain discovery and early
development of therapeutic antibodies against immune checkpoint proteins, with the goal of generating immunotherapy antibodies to such targets for subsequent preclinical, clinical, regulatory and commercial development by TESARO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, for and in consideration of the covenants, conditions and undertakings hereinafter set forth, it is agreed by and
between the Parties as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DEFINITIONS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used herein, the following terms will have the meanings set forth
below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1.</B> &#147;<B>Affiliate</B>&#148; shall mean any corporation or other entity, whether de jure or de facto, which is
directly or indirectly controlling, controlled by or under common control of a Party hereto for so long as such control exists. For the purposes of this Section&nbsp;1.1, &#147;control&#148; shall mean the direct or indirect ownership of at least
fifty percent (50%)&nbsp;of the outstanding shares or other voting rights of the subject entity having the power to vote, or if not meeting the preceding, </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the maximum voting right that may be held by the particular Party under the laws of the country where such entity exists, or the power to otherwise direct the affairs of the entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2.</B> &#147;<B>AnaptysBio IP Rights</B>&#148; shall mean, collectively, the AnaptysBio Patents and the AnaptysBio Know-How. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3.</B> &#147;<B>AnaptysBio Know-How</B>&#148; shall mean all trade secret and other proprietary know- how rights in and to all data,
information, compositions and other technology (including, but not limited to, formulae, procedures, protocols, techniques and results of experimentation and testing) which are necessary or useful for TESARO to make, use, develop, sell or seek
regulatory approval to market a Product, or to practice any method or process, and which (a)&nbsp;AnaptysBio discloses or makes available to TESARO under this Agreement, or (b)&nbsp;are within the Control of AnaptysBio. AnaptysBio Know-How shall
exclude the AnaptysBio Platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4.</B> &#147;<B>AnaptysBio Patents</B>&#148; shall mean all Patents owned or Controlled by
AnaptysBio to the extent claiming the manufacture, composition or use of the Development Antibodies. AnaptysBio Patents shall exclude Patents included within the AnaptysBio Platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5.</B> &#147;<B>AnaptysBio Platform</B>&#148; shall mean: (a)&nbsp;all know-how, trade secrets, data, inventions, proprietary software,
works of authorship, designs, techniques, methods, processes, formulations, structure and other information relating to compounds, compositions, specifications, reagents, ideas and information relating to AnaptysBio&#146;s proprietary technology
that is, in each case, generally applicable to the discovery, modification, optimization and/or humanization of antibodies and/or other proteins, and/or nucleic acids relating thereto (including, without limitation, the expression, manufacture and
formulation of any of the foregoing); and (b)&nbsp;all patent and other intellectual property rights in any of the foregoing; provided, that the AnaptysBio Platform shall not include any Patents covering the composition of matter, in whole or in
part, of any Development Antibody or the Patents set forth on Schedule 12.2(i). Without limiting the generality of the foregoing, AnaptysBio Platform shall include any such information generated, discovered or developed in whole or in part by
employees or agents of AnaptysBio in performing any Discovery Program, or otherwise generated, discovered or developed in whole or in part by employees or agents of AnaptysBio during the term of this Agreement; in each case, to the extent any of the
foregoing: (i)&nbsp;relate to the AnaptysBio Platform, improvements to the AnaptysBio Platform, or the use of the AnaptysBio Platform or any such AnaptysBio Platform improvements; or (ii)&nbsp;are generally applicable to the discovery, modification,
optimization or humanization of proteins and nucleic acids (including, without limitation, the expression and manufacture thereof); provided, that the AnaptysBio Platform shall not include any Patents covering the composition of matter, in whole or
in part, of any Development Antibody or the Patents set forth on Schedule 12.2(i). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6.</B> &#147;<B>Collaboration IP Rights</B>&#148;
shall mean all Collaboration Patents and Collaboration Know-How. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7.</B> &#147;<B>Collaboration Know-How</B>&#148; shall mean all
proprietary ideas, inventions, data, instructions, processes, formulas, expert opinions and information, including, without limitation, biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety,
manufacturing and quality control data and information developed solely or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jointly by AnaptysBio and/or TESARO during and in connection with the Discovery Program, or by or for TESARO, its Affiliate or sublicensees in connection with the further development of a Product
during and in connection with the Discovery Program. Collaboration Know-How shall exclude the AnaptysBio Platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8.</B>
&#147;<B>Collaboration Patents</B>&#148; shall mean all Patents the subject of which are inventions conceived and reduced to practice solely or jointly by AnaptysBio and/or TESARO during and in connection with the Discovery Program, or by or for
TESARO, its Affiliate or sublicensees in connection with the further development of a Product during and in connection with the Discovery Program. Collaboration Patents shall exclude the AnaptysBio Platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9.</B> &#147;<B>Combination Product</B>&#148; means a Product that contains a Development Antibody and at least one other therapeutically
active product or pharmaceutical ingredient which is not a Development Antibody. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10.</B> &#147;<B>Commercially Reasonable
Efforts</B>&#148; means, with respect to a Party, such efforts that are consistent with the efforts and resources normally used by such Party in the exercise of its reasonable business discretion relating to the research, development and
commercialization of a pharmaceutical or biologic product owned by it or to which it has exclusive rights, with similar product characteristics, which is of similar market potential at a similar stage in its development or product life, taking into
account issues of patent coverage, safety and efficacy, product profile, the competitiveness of the marketplace, the proprietary position of the compound or product, the regulatory structure involved, the potential or actual profitability of the
applicable products (including pricing and reimbursement status achieved or to be achieved), and other relevant factors, including technical, legal, scientific and/or medical factors. For purposes of clarity, Commercially Reasonable Efforts would be
determined on a market-by-market and indication- by-indication basis for a particular product and it is anticipated that the level of effort may be different for different markets and may change over time, reflecting changes in the status of the
product and the market(s) involved. [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11.</B> &#147;<B>Confidential Information</B>&#148; shall have the meaning set forth in
Section 10.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12.</B> &#147;<B>Control,</B>&#148; &#147;<B>Controls,</B>&#148; &#147;<B>Controlled</B>&#148; or
&#147;<B>Controlling</B>&#148; shall mean possession of the ability to grant the licenses or sublicenses as provided herein without violating the terms of any agreement or other arrangements with any Third Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13.</B> &#147;<B>Development Antibody</B>&#148; shall mean any antibody that is developed using the AnaptysBio Platform antibody
technology under one of the Discovery Programs and is a Target Antagonist. In addition, the antibodies existing as of the Effective Date and identified on Exhibit C attached to the Supplmental Information Package, which Exhibit also sets forth the
sequence of such antibodies, shall each be a &#147;Development Antibody&#148; under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14.</B> &#147;<B>Development
Programs</B>&#148; shall mean, collectively, the PD-1 Development Program, TIM-3 Development Program and LAG-3 Development Program, and &#147;<B>Development Program</B>&#148; shall mean any of such programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15.</B> &#147;<B>Discovery Plan</B>&#148; shall mean the written research plan governing the joint effort of the Parties in conducting
the applicable Discovery Program, which may be amended from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time to time, in accordance with this Agreement. The initial Discovery Plan for each Discovery Program is attached to the Supplemental Information Package as Exhibits A-1 &#150; A-3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16.</B> &#147;<B>Discovery Programs</B>&#148; shall mean, collectively, the PD-1 Discovery Program, TIM-3 Discovery Program and LAG-3
Discovery Program, and &#147;<B>Discovery Program</B>&#148; shall mean any of such programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17.</B> &#147;<B>Discovery Program
Term</B>&#148; shall mean, with respect to a Discovery Program, the term of such Discovery Program, as provided in Section&nbsp;2.7 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18.</B> &#147;<B>EMA</B>&#148; shall mean the European Agency for the Evaluation of Medicinal Products of the European Union, or the
successor thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19.</B> &#147;<B>FDA</B>&#148; shall mean the Food and Drug Administration of the United States, or the successor
thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20.</B> &#147;<B>Field</B>&#148; shall mean all uses of Products for any purpose, including the [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21.</B> &#147;<B>FTE</B>&#148; shall mean a full-time person working on the Discovery Program, or in the case of less than a full-time,
dedicated person, a full-time, equivalent person year, based upon a total of [*] hours per year of work in connection with a Discovery Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22.</B> &#147;<B>GLP Study</B>&#148; shall mean any in vitro or in vivo study that (i)&nbsp;is required under 21 C.F.R. &#167; 58 to be
governed under the principles of good laboratory practice, or (ii)&nbsp;is performed by a GLP vendor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23.</B> &#147;<B>IND</B>&#148;
shall mean an investigational new drug application filed with the FDA as more fully defined in 21 C.F.R. &#167; 312.3 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24.</B>
&#147;<B>JSC</B>&#148; or &#147;<B>Joint Steering Committee</B>&#148; shall have the meaning set forth in Section 4.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25.</B>
&#147;<B>LAG-3</B>&#148; shall mean lymphocyte-activation gene 3, encoded by the LAG3 gene, also known as CD223. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26.</B>
&#147;<B>LAG-3 Development Program</B>&#148; shall mean the development program to be conducted in accordance with Section&nbsp;3 for the development of Development Antibodies generated under the LAG-3 Discovery Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.27.</B> &#147;<B>LAG-3 Discovery Program</B>&#148; shall mean the discovery program to be conducted in accordance with Section&nbsp;2 for
the development of antibodies directed to antagonize LAG-3, including dual-reactive antibodies that are directed to antagonize both PD-1 and LAG-3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.28.</B> &#147;<B>MAA</B>&#148; means a Marketing Authorization Application, or similar application for marketing approval of a Product
for use in the Field submitted to the EMA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.29.</B> &#147;<B>NDA</B>&#148; shall mean a New Drug Application or Biologics License
Application, or similar application for marketing approval of a Product for use in the Field submitted to the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.30.</B>
&#147;<B>Net Sales</B>&#148; means, with respect to any Product, the gross invoiced sales price of such Product sold by TESARO, its Affiliates or sublicensees (the &#147;Selling Party&#148;), in arm&#146;s- length sales to Third Parties, less
deductions allowed to the Third Party customer by the Selling Party, to the extent actually taken by the Third Party customer, on such sales for: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">[*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maximum allowed for deductions
resulting from clauses [*], collectively, shall not exceed [*] percent ([*]) of the total Net Sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a Product is sold as part of a Combination
Product, for purposes of determining payments due hereunder, Net Sales of such Product shall be deemed to be an amount equal to the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(X divided by Y) multiplied by Z, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">where &#147;X&#148; is the average sales price during the applicable reporting period achieved for the relevant Product in the country in
which such sale occurred when the Product contains only the Product and no other active pharmaceutical ingredient; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; is the
sum of the average sales price during the applicable reporting period achieved in that country (as applicable) of each active pharmaceutical ingredient included in the Combination Product when such compound is sold as a separate product and not as
part of a Combination Product; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Z&#148; is the single price at which the relevant Combination Product was actually sold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that no separate sale of either (i)&nbsp;the Product and no other active pharmaceutical ingredient or (ii)&nbsp;the other active
pharmaceutical ingredient(s) of the Combination Product are made during the accounting period in which the sale was made or if the price for a particular therapeutically active ingredient or relevant product cannot otherwise be determined for an
accounting period, Net Sales allocable to the Product shall be determined by mutual agreement reached in good faith by the Parties prior to the end of the accounting period in question based on an equitable method of determining the same that takes
into account, variations in potency, the relative contribution of each therapeutically active ingredient in the Combination Product, and relative value to the end user of each therapeutically active ingredient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales among TESARO and its Affiliates or sublicensees shall be excluded from the computation of Net Sales, and no royalties will be payable on
such sales except where such Affiliates or sublicensees are end users; provided, however, in that any subsequent resale to a Third Party shall be included within Net Sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Net Sales shall be calculated and accounted for in accordance with United States generally accepted accounting
principles (&#147;GAAP&#148;); provided, that if TESARO should change accounting standards during the term of this Agreement due to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
merger, acquisition or requirement of applicable laws, then Net Sales hereunder may be calculated and accounted for in accordance with such different set of accounting standards, consistently
applied, following such change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.31.</B> &#147;<B>Party</B>&#148; or &#147;<B>Parties</B>&#148; shall mean, respectively, AnaptysBio
or TESARO, individually, or AnaptysBio and TESARO, collectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.32.</B> &#147;<B>Patents</B>&#148; shall mean (a)&nbsp;all patents
and patent applications in any country or supranational jurisdiction in the Territory, and (b)&nbsp;any substitutions, divisions, continuations, continuations-in-part, provisional applications, reissues, renewals, registrations, confirmations,
re-examinations, extensions, supplementary protection certificates and the like of any such patents or patent applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.33.</B>
&#147;<B>PD-1</B>&#148; shall mean programmed cell death protein 1, encoded by the PDCD1 gene, also known as CD279. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.34.</B>
&#147;<B>PD-1 Development Program</B>&#148; shall mean the development program to be conducted in accordance with Section&nbsp;3 for the development of Development Antibodies generated under the PD-1 Discovery Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.35. </B>&#147;<B>PD-1 Discovery Program</B>&#148; shall mean the discovery program to be conducted in accordance with Section&nbsp;2 for
the development of antibodies directed to antagonize PD-1, including the antibody identified on Exhibit C to the Supplemental Information Package. [*] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.36.</B> &#147;<B>Phase II Clinical Trial</B>&#148; shall mean a human clinical trial in any country that is intended to initially
evaluate the effectiveness of a Product for a particular indication or indications in patients with the disease or indication under study and would satisfy requirements of 21 CFR 312.21(b) or its foreign equivalent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.37.</B> &#147;<B>Phase III Clinical Trial</B>&#148; shall mean a human clinical trial in any country, the results of which could be used
to establish safety and efficacy of a Product as a basis for an NDA, and would satisfy requirements of 21 CFR 312.21(c) or its foreign equivalent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.38.</B> &#147;<B>Product</B>&#148; shall mean any pharmaceutical or biologic product or therapy including one or more Development
Antibodies, in whole or in part, as an active ingredient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.39.</B> &#147;<B>Subcontractor</B>&#148; means a Third Party which a Party
has engaged to perform services in connection with such Party fulfilling its obligations and exercising its rights under and pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.40.</B> &#147;<B>Supplemental Information Package</B>&#148; means the Supplemental Information Package delivered in connection with the
execution of this Agreement by the Parties on the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.41.</B> &#147;<B>Target(s)</B>&#148; shall mean LAG-3, PD-1 and
TIM-3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.42.</B> &#147;<B>Target Antagonist</B>&#148; shall mean an antibody that is created against and selected in order to
antagonize Target(s), and does anatagonize that Target. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.43.</B> &#147;<B>Territory</B>&#148; shall mean worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.44.</B> &#147;<B>TESARO Know-How</B>&#148; shall mean all proprietary ideas, inventions, data, instructions, processes, formulas, expert
opinions and information, including, without limitation, biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and quality control data and information developed by or for
TESARO, its Affiliate or sublicensees in connection with the further development of a Product and Controlled by TESARO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.45.</B>
&#147;<B>TESARO Patents</B>&#148; shall mean all Patents Controlled by TESARO the subject of which are inventions conceived and reduced to practice by or for TESARO, its Affiliate or sublicensees in connection with the further development of a
Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.46.</B> &#147;<B>TIM-3</B>&#148; shall mean the T cell immunoglobulin and mucin protein 3 protein, encoded by the TIM3
gene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.47.</B> &#147;<B>TIM-3 Development Program</B>&#148; shall mean the development program to be conducted in accordance with
Section&nbsp;3 for the development of Development Antibodies generated under the TIM-3 Discovery Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.48.</B> &#147;<B>TIM-3
Discovery Program</B>&#148; shall mean the discovery program to be conducted in accordance with Section&nbsp;2 for the development of antibodies directed to antagonize TIM-3, including dual-reactive antibodies that are directed to antagonize both
PD-1 and TIM-3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.49.</B> &#147;<B>Third Party</B>&#148; shall mean any person or entity other than AnaptysBio and TESARO, and their
respective Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.50.</B> &#147;<B>Third Party In-License</B>&#148; shall mean any agreement between AnaptysBio or any
Affiliate thereof and any Third Party under which AnaptysBio or such Affiliate is or has been granted a license or other rights under the AnaptysBio IP Rights or with respect to the AnaptysBio Platform. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DISCOVERY PROGRAMS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1. Goals</B>. The goals of the Discovery Programs are the
discovery of Development Antibodies directed to the applicable Targets, and characterization and certain testing, including certain efficacy, pharmacology and toxicology studies, provided that none shall be a GLP Study, all as set forth in the
applicable Discovery Plan for such Discovery Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2. Responsibility</B>. AnaptysBio shall hold the primary responsibility for
executing each of the Discovery Programs in accordance with each Discovery Plan. AnaptysBio shall utilize resources and methodologies as needed with respect to the AnaptysBio Platform to generate Development Antibodies with respect to each Target.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3. Conduct of the Discovery Program</B>. Subject to the terms and conditions set forth herein, AnaptysBio agrees to conduct research
under the Discovery Programs, which shall be funded as set forth in Section&nbsp;6. During each Discovery Program Term, AnaptysBio shall use Commercially Reasonable Efforts to conduct each Discovery Program in accordance with the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable Discovery Plan within the time schedules contemplated therein and to keep TESARO informed as to the progress and results of the Discovery Programs hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4. Discovery Plans</B>. Each Discovery Program shall be carried out in accordance with a mutually agreed upon written Discovery Plan,
which shall establish specific research objectives and the research tasks to be performed and resources to be provided by AnaptysBio. The initial Discovery Plans, attached to the Supplemental Information Package as Exhibits A-1 &#150; A-3,
establish: (i)&nbsp;the scope of the research activities which will be performed under the applicable Discovery Program; (ii)&nbsp;the research objectives and work plan activities with respect to such Discovery Program; and (iii)&nbsp;the criteria
for determining when a Development Antibody shall be advanced into its respective Development Program. The Discovery Plans may be amended or modified from time to time by approval of the JSC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5. Discovery Budgets</B>. Each Discovery Plan includes a budget covering the activities to be conducted by AnaptysBio under such
Discovery Plan, as approved by the Parties (each, a &#147;<B>Discovery Budget</B>&#148;). The Discovery Budgets may be amended from time to time by approval of the JSC, but, unless otherwise decided by the JSC, only following a JSC-approved
modification to the applicable Discovery Plan which necessitates a change in the applicable Discovery Budget. At all times the Discovery Budgets shall reflect the Parties&#146; good faith estimate of the costs reasonably necessary in order for
AnaptysBio to complete its activities set forth in the Discovery Plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6. Discovery Program Costs</B>. During the applicable
Discovery Program Term and subject to TESARO funding the costs of each Discovery Program pursuant to Section&nbsp;6.1, AnaptysBio shall [*]. At the beginning of each calendar quarter, [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.7. Term of Discovery Program</B>. Each Discovery Program Term shall commence on the Effective Date and shall end upon the earlier of [*].
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.8. Third Party Licenses.</B> In the event that the Parties agree to acquire additional technologies, equipment or other fixed assets
from a Third Party specifically for use in the conduct of a Discovery Program, TESARO will be responsible for the payment of any amounts due to Third Parties for the license of intellectual property which directly applies to any Target, and the
costs of negotiating, preparing and executing any such license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.9. Records; Inspection</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Records</B>. AnaptysBio and TESARO shall maintain records of each Discovery Program (or cause such records to be maintained) in
sufficient detail and in good scientific manner as will properly reflect all work done and results achieved in the performance of the Discovery Program (including all data in the form required under any applicable governmental regulations or as
directed by the JSC). All such records shall be owned by AnaptysBio, and licensed to TESARO on a Discovery Program-by-Discovery Program basis in accordance with Section&nbsp;5.1 and AnaptysBio shall deliver copies of any such records to TESARO upon
TESARO&#146;s written request. AnaptysBio shall maintain any such records, to the extent not delivered to TESARO, during the applicable Discovery Program Term and for a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period of at least five (5)&nbsp;years thereafter, and shall provide TESARO access to such records at AnaptysBio&#146;s place of business upon reasonable advance notice by TESARO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Reports and Information Exchange</B>. During each Discovery Program Term, each of TESARO and AnaptysBio shall use their respective
Commercially Reasonable Efforts to disclose to the other Party all material information relating to the applicable Discovery Program promptly after it is learned or its materiality is appreciated. Each Party shall also keep the other Party,
including the Joint Steering Committee, informed as to its progress under each Discovery Plan. [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.10. Technology Transfer</B>. At
any time after cessation, termination or completion of the applicable Discovery Program, or as reasonably requested by TESARO at any time after the Effective Date, TESARO shall have the right to request that AnaptysBio commence a technology transfer
to TESARO, or its designee, of any tangible embodiments of AnaptysBio Know-How or other information and technology reasonably necessary for the GLP manufacture, clinical and/or commercial manufacture of Products or any Development Antibodies with
respect to such Discovery Program. The cost of a technology transfer shall be borne by TESARO and shall be based on the FTE rates set forth herein. [*] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.11. Subcontracting</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) AnaptysBio Right to Subcontract</B>. Subject to the terms of this Agreement, AnaptysBio shall have the right to engage Affiliates or
Subcontractors to perform certain of its obligations under the Discovery Plans; provided, that with respect to each subcontract: (i)&nbsp;AnaptysBio shall notify TESARO in writing (on a confidential basis) in advance (including a description of the
activity(ies) to be subcontracted, the identity of the Subcontractor and the countries involved); (ii)&nbsp;AnaptysBio shall ensure that each of its Subcontractors accepts and complies with all applicable terms and conditions of this Agreement, and
AnaptysBio shall remain responsible for the performance of its Subcontractors hereunder; (iii)&nbsp;no subcontract shall contain any royalty bearing licenses or any milestone payment obligations, in each case, payable by AnaptysBio, without the
prior written consent of TESARO; and (iv)&nbsp;any such subcontract shall (A)&nbsp;be in writing, (B)&nbsp;be subject and subordinate to the terms and conditions of this Agreement, (C)&nbsp;contain terms and conditions which are consistent with the
terms and conditions of this Agreement, (D)&nbsp;not in any way diminish, reduce or eliminate any of AnaptysBio&#146;s obligations under this Agreement, (E)&nbsp;impose on the Subcontractor all applicable obligations under the terms of this
Agreement, including the reporting, audit, inspection and confidentiality provisions hereunder, as well as a provision prohibiting such Subcontractor from further sublicensing or subcontracting, and (F)&nbsp;use reasonable efforts to cause such
subcontract to be assignable to TESARO without consent of the Subcontractor. Notwithstanding the foregoing, approval of the JSC will be required if AnaptysBio desires to engage a Subcontractor to perform work related to chemistry, manufacturing and
controls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) TESARO Right to Subcontract</B>. Subject to the terms of this Agreement, TESARO shall have the right to engage
Affiliates or Subcontractors to perform certain of its obligations and exercise its rights under this Agreement (including any activities under the Development Programs); provided, that with respect to each subcontract: (i)&nbsp;TESARO shall ensure
that each of its Subcontractors accepts and complies with all applicable terms and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions of this Agreement, and TESARO shall remain responsible for the performance of its Subcontractors hereunder; and (ii)&nbsp;any such subcontract shall (A)&nbsp;be in writing, (B)&nbsp;be
subject and subordinate to the terms and conditions of this Agreement, (C)&nbsp;contain terms and conditions which are consistent with the terms and conditions of this Agreement, (D)&nbsp;not in any way diminish, reduce or eliminate any of
TESARO&#146;s obligations under this Agreement, (E)&nbsp;impose on the Subcontractor all applicable obligations under the terms of this Agreement, including the reporting, audit, inspection and confidentiality provisions hereunder, and (F)&nbsp;use
reasonable efforts to cause such subcontract to be assignable to AnaptysBio without consent of the Subcontractor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.12.</B> [*] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DEVELOPMENT PROGRAMS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1. Development Program Activities</B>. Following completion
of each Discovery Program, TESARO shall be responsible, at its sole expense, for conducting the Development Program, which shall include without limitation all pre-IND activities, including cross-reactivity studies and pilot studies to enable GLP
pharmacology/toxicology studies, GMP manufacturing, regulatory filings, clinical trials and commercialization activities with respect to one or more Development Antibodies under each Development Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2. Records; Inspection</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Records</B>. TESARO shall maintain records of each Development Program (or cause such records to be maintained) in sufficient detail
and in good scientific manner as will properly reflect all work done and results achieved in the performance of the Development Program (including all data in the form required under any applicable governmental regulations). TESARO shall maintain
such records for a period of [*], and shall provide AnaptysBio access to such records at TESARO&#146;s place of business upon reasonable advance notice by AnaptysBio in accordance with Section 7.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Reports and Information Exchange</B>. During the performance of each Development Program, TESARO shall use Commercially Reasonable
Efforts to disclose to AnaptysBio all material information relating to the applicable Development Program promptly after it is learned or its materiality is appreciated. TESARO shall also keep AnaptysBio informed as to its progress under each
Development Program. Within sixty (60)&nbsp;days following the end of each calendar quarter of the Development Program, [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)
Assistance by AnaptysBio</B>. Upon reasonable request by TESARO, AnaptysBio will in good faith make available key personnel to assist TESARO in the planning, monitoring and strategy of preclinical development, manufacturing and early clinical
development under each Development Program, provided that any material expenses incurred by AnaptysBio (including FTEs utilized, reasonable travel expenses and specialized supplies or equipment required) shall be reimbursed by TESARO in accordance
with Section&nbsp;2.6 above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MANAGEMENT </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1. Joint Steering Committee</B>. Promptly after the Effective Date,
TESARO and AnaptysBio will establish a committee (the &#147;<B>Joint Steering Committee</B>&#148; or &#147;JSC&#148;) to oversee, review and recommend direction of each Discovery Program. The responsibilities of the Joint Steering Committee shall
include, monitoring, reporting progress, developing strategies and ensuring open and frequent exchange between the Parties regarding each Discovery Program and the activities of the Parties and their Affiliates, Subcontractors and agents thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2. Membership</B>. The JSC shall include [*] of each of TESARO and AnaptysBio, each Party&#146;s members selected by that Party.
AnaptysBio and TESARO may each replace its JSC representatives at any time, upon written notice to the other Party. From time to time, the JSC may establish subcommittees to oversee particular projects or activities, and such subcommittees will be
constituted as the JSC agrees. Each Party&#146;s JSC members shall be senior individuals empowered to provide timely feedback regarding their Party&#146;s decisions on key matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3. Meetings</B>. During each Discovery Program Term, the JSC shall meet at least quarterly, or as agreed by the Parties, at such
locations as the Parties agree, and will otherwise communicate regularly by telephone, electronic mail, facsimile and/or video conference. With the consent of the Parties, other representatives of AnaptysBio or TESARO may attend JSC meetings as
nonvoting observers. Each Party shall be responsible for all of its own expenses associated with attendance of such meetings. [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4.
Minutes</B>. The JSC shall keep accurate minutes of its deliberations which shall record all proposed decisions and all actions recommended or taken. The Secretary of the JSC (as appointed by the members of the JSC) shall be responsible for the
preparation of draft minutes. [*] All records of the JSC shall at all times be available to both AnaptysBio and TESARO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5. Decision
Making</B>. [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6. Development Program Meetings</B>. During each [*] calendar period commencing with the completion of the
applicable Discovery Program and continuing for a period of [*] thereafter, and then annually after such [*] period, upon the written request of either Party, TESARO and AnaptysBio shall meet to discuss the progress of each Development Program and
review future activities planned by TESARO with respect thereto, including strategic plans for preclinical, clinical and commercial advancement of Products under each Development Program. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LICENSES; EXCLUSIVITY </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1. Grant</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Subject to the terms and conditions of this Agreement, AnaptysBio hereby grants to TESARO and its Affiliates an exclusive license
(with the right to grant sublicenses through multiple tiers) under the AnaptysBio IP Rights and Collaboration IP Rights to research, develop, make, have made, use, sell, offer for sale, import and export Products for use in the Field and in the
Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Subject to the terms and conditions of this Agreement, AnaptysBio hereby grants to
TESARO and its Affiliates a non-exclusive license (with the right to grant sublicenses through multiple tiers) under the Patents and other intellectual property constituting the AnaptysBio Platform to research, develop, make, have made, use, sell,
offer for sale, import and export Products for use in the Field and in the Territory and as necessary for TESARO to practice the licenses granted to it under Section&nbsp;5.1(a); provided, however that the foregoing license grant to TESARO is
limited to researching, developing, making, having made, selling, offering for sale, importing, exporting and using Development Antibodies previously generated by AnaptysBio, and expressly excludes any license of rights to TESARO to utilize,
practice or operate the AnaptysBio Platform to develop or generate new or materially different antibodies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2. No Implied
Licenses</B>. Only the licenses granted pursuant to the express terms of this Agreement shall be of any legal force or effect. No other license or rights shall be created by implication, estoppel or otherwise. Without limiting the foregoing, if a
Product contains an active pharmaceutcial ingredient or biologic in addition to the Development Antibody, then the licenses granted to TESARO under AnaptysBio IP Rights and the AnaptysBioPlatform shall not include the right to research, develop,
make, have made, use, sell, offer for sale, import and export such other active pharmaceutical ingredient or biologic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3.
Exclusivity</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Except to the extent required for AnaptysBio to fulfill its obligations under this Agreement and as permitted
under this Agreement, with respect to each Target (or combination of Targets), [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> During the Exclusivity Period, and except
with respect to a Product pursuant to this Agreement, TESARO shall not [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> The exclusivity described in Sections 5.3(a) and
5.3(b) will apply on a Discovery Program/Development Program basis, such that if a Discovery Program or Development Program is terminated for any reason, then the Targets that are subject of that Discovery Program or Development Program shall no
longer be subject to the exclusivity. By way of example, if the TIM-3 Discovery Program is terminated, then the exclusivity shall no longer apply to TIM-3 alone or dual-reactivity to TIM-3 and PD-1, but the exclusivity for the other non-terminated
Discovery Programs (or Development Programs) shall continue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> Notwithstanding the foregoing provision of this Section&nbsp;5.3,
in the event of a Change of Control (as defined below) of AnaptysBio, or if AnaptysBio or an Affiliate acquires any Third Party, business or assets, or any interest therein (an &#147;<B>AnaptysBio Business Acquisition</B>&#148;), the provisions of
this Section&nbsp;5.3 shall not apply to any active research or development program that a portion of the surviving entity or Affiliate that was not AnaptysBio (prior to the Change of Control or AnaptysBio Business Acquisition) had ongoing as of
immediately prior to the date of such Change of Control or AnaptysBio Business Acquisition. For purposes of this Section&nbsp;5.3, a &#147;<B>Change of Control</B>&#148; shall mean, with respect to a Party, the merger, consolidation, sale of
substantially all of such Party&#146;s assets or similar transaction or series of transactions, as a result of which such Party&#146;s shareholders before such transaction or series of transactions own less than fifty percent (50%)&nbsp;of the total
number of voting securities of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the surviving entity immediately after such transaction or series of transactions. For clarity, if as a result of any such Change of Control, a Party exists as a wholly owned subsidiary of a
parent, then the provisions of this Section&nbsp;5.3 shall continue to apply to such Party as the surviving entity, but not to such parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> Notwithstanding the foregoing provision of this Section&nbsp;5.3, in the event of a Change of Control of TESARO or if TESARO or an
Affiliate acquires any Third Party, business or assets, or any interest therein (a &#147;<B>TESARO Business Acquisition</B>&#148;), the provisions of this Section&nbsp;5.3 shall not apply to any active research or development program that a portion
of the surviving entity or Affiliate that was not TESARO (prior to the Change of Control or TESARO Business Acquisition) had ongoing as of immediately prior to the date of such Change of Control or TESARO Business Acquisition. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PAYMENTS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1. Upfront Payment</B>. Within ten (10)&nbsp;business days following the
Effective Date, TESARO shall pay to AnaptysBio a non-creditable, non-refundable license fee of seventeen million dollars (USD $17,000,000.00). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2. Discovery Program Funding.</B> TESARO shall reimburse AnaptysBio on a quarterly basis for all [*]. All payments are non-creditable
(against amounts in Secction 6.3 or 6.4) and non-refundable (except pursuant to Section&nbsp;7.4 or Section&nbsp;13.2). Within ten (10)&nbsp;days of the end of each calendar quarter, AnaptysBio shall provide TESARO with an invoice for all amounts
owed by TESARO under this Section&nbsp;6.2 for that calendar quarter and TESARO shall pay such amounts within thirty (30)&nbsp;days after receipt of AnaptysBio&#146;s quarterly invoice. All amounts paid by TESARO to AnaptysBio pursuant to this
Section&nbsp;6.2 shall be made in accordance with Section&nbsp;7.2 with respect to withholding for taxes or any other charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3.
Upfront Payment</B>. On a Development Program-by-Development Program basis, TESARO shall pay AnaptysBio the following payments [*]: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:55.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:65.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone&nbsp;Payment<BR>(USD)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initiation of first GLP PK/tox Study</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[*]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First IND clearance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[*]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initiation of the first Phase II Clinical Trial</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[*]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initiation of the first Phase III Clinical Trial for first indication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[*]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initiation of the first Phase III Clinical Trial for second indication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[*]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Filing of the first NDA for the first indication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[*]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Filing of the first NDA for the second indication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[*]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Filing of the first MAA for the first indication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[*]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Filing of the first MAA for the second indication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[*]</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:55.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:65.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Milestone&nbsp;Payment<BR>(USD)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First NDA approval for the first indication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[*]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First NDA approval for the second indication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[*]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First MAA approval for the first indication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[*]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First MAA approval for the second indication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[*]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Achievement of annual worldwide Net Sales in a calendar year equal to or greater than $[*]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[*]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Achievement of annual worldwide Net Sales in a calendar year equal to or greater than $[*]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[*]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Achievement of annual worldwide Net Sales in a calendar year equal to or greater than $[*]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[*]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Achievement of annual worldwide Net Sales in a calendar year equal to or greater than $[*]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$[*]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;6.3, the following terms have the meanings set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>initiation</B>&#148; means, with respect to a study or clinical trial, the administration of the first dose of Product to the first
patient enrolled in such study or trial; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>IND clearance</B>&#148; means filing and clearance by FDA without rejection or being
placed on clinical hold; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>indication</B>&#148; means a specific disease or condition; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>filing</B>&#148; means acceptance for filing with the applicable regulatory or governmental authority; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>approval</B>&#148; means, with respect to a Product in any country or jurisdiction, any approval, registration, license or
authorization from a regulatory or governmental authority in a country or other jurisdiction that is necessary to market and sell such Product in such country or jurisdiction; &#147;approval&#148; shall specifically include FDA approvals of BLAs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4. Earned Royalties</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> With respect to Net Sales of a Product resulting from a Development Antibody, on a Product-by-Product basis, TESARO shall pay
AnaptysBio a royalty on Net Sales as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Worldwide Annual Net Sales of a Product (on a</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Product-by-Product basis) during the applicable</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:153.15pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">calendar year during the Royalty Term:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:43.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Royalty&nbsp;Rate<BR>Applicable&nbsp;to<BR>a Product:</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Portion less than or equal to $[*]:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[*]%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Portion greater than $[*], but less than or equal to $[*]:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[*]%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Portion greater than $[*], but less than or equal to $[*]:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[*]%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Portion greater than $[*], but less than or equal to $[*]:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[*]%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Portion greater than $[*]:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[*]%</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Royalties payable under this Section&nbsp;6.4 shall be paid on a country-by- country
basis from the date of the first commercial sale of each Product with respect to which royalty payments are due until the later of (i)&nbsp;the [*] ([*]) anniversary of the first commercial sale of the Product in such country, and (ii)&nbsp;the
expiration date in such country of the last to expire of any Patent within the AnaptysBio Patents or the Collaboration Patents covering the manufacture, use or sale of such Product in such country (the &#147;<B>Royalty Term</B>&#148;). For the
avoidance of doubt, TESARO&#146;s obligation to pay royalties under this Section&nbsp;6.4 is imposed only once with respect to the same unit of Product, notwithstanding such Product may be covered by more than one valid claim of an AnaptysBio Patent
or Collaboration Patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If TESARO pays royalties to any Third Party in a country in order to make, use, sell, offer for sale
or import the Development Antibody component of a Product in such country, then TESARO shall have the right to credit [*] percent ([*]%) of such Third Party royalty payments against the royalties owing to AnaptysBio under Section&nbsp;6.4(a) with
respect to sales of such Product in such country; provided, however, that TESARO shall not reduce the amount of the royalties owing to AnaptysBio under Section&nbsp;6.4(a) with respect to such Product in such country to less than [*] percent ([*]%)
of the royalties that would otherwise be due under Section&nbsp;6.4(a) with respect to such Product in such country. Notwithstanding the foregoing, if TESARO pays any such royalties to a Third Party that [*]. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PAYMENTS; RECORDS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1. Payment Method</B>. All payments due under this Agreement
shall be made from a bank located in the United States by bank wire transfer in immediately available funds to a bank account designated by AnaptysBio. All payments hereunder shall be made in U.S. dollars. In the event that the due date of any
payment subject to Section&nbsp;6 is a Saturday, Sunday or national holiday, such payment may be paid on the following business day. Any payments that are not paid on the date such payments are due under this Agreement shall bear interest to the
extent permitted by applicable law at the rate of [*] percent ([*]%) per annum, calculated on the number of days such payment is delinquent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2. Taxes</B>. All payments required to be paid to AnaptysBio pursuant to this Agreement shall be paid with deduction for withholding for
or on account of any taxes (other than taxes imposed on or measured by net income) or similar governmental charge. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3. Royalty Payments and Reports</B>. Royalty payments under this Agreement with respect to
Net Sales of Product in a given calendar quarter shall be made to AnaptysBio or its designee quarterly within [*] ([*]) days following the applicable calendar quarter. Each royalty payment shall be accompanied by a report [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4. Books and Records; Accounting and Audits</B>. Each Party shall maintain complete and accurate books and records, in accordance with
GAAP, which are relevant to, as applicable, costs or expenses to be reimbursed by TESARO, or payments to made to AnaptysBio, under this Agreement, which books and records shall be sufficient in detail to verify all payment amounts due to a Party
hereunder. The Party requesting an audit (the &#147;<B>Auditing Party</B>&#148;) shall have the right, at its own expense and not more than once in any calendar year during the term of this Agreement, to have an independent, certified public
accountant, selected by the Auditing Party, and under an obligation of confidence, audit the books and records of the other Party (the &#147;<B>Audited Party</B>&#148;) in the location(s) where such books and records are maintained upon reasonable
notice (which shall be no less than fifteen (15)&nbsp;business days prior written notice) and during regular business hours, and for the sole purpose of verifying the basis and accuracy of payments required and made under this Agreement. The report
and communication of such accountant with respect to such an audit shall be limited to a certificate stating whether any, as applicable, report made or reimbursement or other payment submitted during such period is accurate or inaccurate and, if a
discrepancy is identified, shall also indicate the amount and if applicable, with respect to any report, the nature, of any discrepancy, and the correct information (with respect to the applicable period). Such accountant shall provide AnaptysBio
and TESARO with a copy of each such report simultaneously. Should the audit lead to the discovery of a discrepancy: (i)&nbsp;to the Auditing Party&#146;s detriment, the Audited Party shall pay to the Auditing Party the amount of the discrepancy
within thirty (30)&nbsp;days of the Audited Party&#146;s receipt of the report; or (ii)&nbsp;to the Audited Party&#146;s detriment, the Audited Party may, as applicable, credit the amount of the discrepancy against future payments payable to the
Auditing Party under this Agreement, and if there are no such payments payable, then the Auditing Party shall pay to the Audited Party the amount of the discrepancy within thirty (30)&nbsp;days of the Auditing Party&#146;s receipt of the report.
Additionally, in the event that the discrepancy is to the Auditing Party&#146;s detriment and is greater than five percent (5%)&nbsp;of the amount due for such audited period, then the Audited Party shall pay or reimburse the reasonable cost charged
by such accountant for such audit. Once the Auditing Party has conducted an audit permitted by this Section&nbsp;7.4 in respect of any period, it may not re-inspect the Audited Party&#146;s books and records in respect of such period, unless a
subsequent audit of a separate reporting period uncovers fraud on the part of the Audited Party that is reasonably expected to have been occurring during the prior audited period. For clarity, however, if a discrepancy is identified by the
accountant during the course of an audit and the Parties do not agree upon a resolution of such discrepancy, then the Auditing Party&#146;s accountant may re-inspect the books and records to the extent reasonably relevant to resolving such
discrepancy. Notwithstanding anything herein to the contrary, upon the expiration of three (3)&nbsp;years following the end of any calendar year, the right to audit, the books and records for such calendar year shall expire and such Party shall be
released from any liability or accountability with respect to payments or FTE work performed as reflected in such books of such Party for such calendar year (including, for clarity, with respect to the calculation of royalties payable with respect
to each such calendar year). The Parties shall no longer be required to retain such books and records for any calendar year after the expiration of the third (3rd)&nbsp;calendar year following such calendar year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5. Blocked Currency</B>. If at any time legal restrictions in the Territory prevent the
prompt remittance of any payments with respect to sales therein, TESARO shall have the right and option to make such payments by depositing the amount thereof in local currency to AnaptysBio account in a bank or depository in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6. Confidentiality</B>. Each Party shall treat all financial information of the other Party that is subject to review under this
Section&nbsp;7 of this Agreement (including all royalty reports) as such other Party&#146;s Confidential Information. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DILIGENCE; REVERSION </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1. Products</B>. TESARO shall use Commercially Reasonable
Efforts to (a)&nbsp;fund the development of each Discovery Program as set forth in the applicable Discovery Plan and until each Discovery Program has reached the applicable key program decision point set forth in the applicable Discovery Plan,
(b)&nbsp;advance at least one Development Antibody with respect to each Development Program, (c)&nbsp;research, test and develop Products, (d)&nbsp;obtain regulatory approval for preclinical, clinical and commercial use of at least one Product with
respect to each Development Program, and (e)&nbsp;commercialize Products and attempt to obtain the optimum commercial return for each Product in all major markets throughout the world. [*] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2. Reversion</B>. If TESARO fails to satisfy its obligations under Section&nbsp;8.1 with respect to a Discovery Program or Development
Program, or discontinues development of all Products within a Discovery Program or Development Program, then all rights to that Discovery Program and/or Development Program, including Development Antibody, Products, data, result, materials and
Collaboration IP Rights resulting from such Discovery Program or Development Program shall revert to AnaptysBio in accordance with Sections 14.4(b), 14.4(d) or 14.4(e) without any further obligation to TESARO. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INTELLECTUAL PROPERTY </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1. Ownership of Inventions; Disclosure</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Ownership</B>. Title to all inventions and other intellectual property made by employees of AnaptysBio in the course of performing, or
in connection with, the Discovery Programs shall be owned by AnaptysBio; title to all inventions and other intellectual property made by employees of TESARO in the course of performing, or in connection with, the Discovery Programs or the further
development of a Product shall be owned by TESARO; title to all inventions and other intellectual property made jointly by employees of TESARO and AnaptysBio in the course of performing, or in connection with, the Discovery Programs shall be owned
jointly by TESARO and AnaptysBio. Inventorship of inventions and other intellectual property made pursuant to this Agreement shall be determined in accordance with the patent laws of the United States. Except as expressly provided in this Agreement,
neither Party shall have any obligation to account to the other for profits, or to obtain any approval of the other Party to license or exploit patented jointly-owned subject matter, by reason of joint ownership thereof, and each Party hereby waives
any right it may have under the laws of any jurisdiction to require any such consent or accounting. Notwithstanding the foregoing, AnaptysBio is and shall be the sole owner of the AnaptysBio Platform. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b) Disclosure of Inventions</B>. Each Party shall promptly disclose to the other any
inventions made in connection with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2. Patent Prosecution</B>. Prior to the IND clearance for a Product resulting
from a Discovery Program, AnaptysBio shall be responsible, at TESARO&#146;s expense, for (i)&nbsp;preparing, filing, prosecuting and maintaining Patent applications and Patents directed to Collaboration Patents claiming the manufacture, composition
or use of such Product, and (ii)&nbsp;for conducting any interferences, re-examinations, reissues and oppositions relating thereto (&#147;<B>Prosecute and Maintain</B>&#148;); provided, that TESARO&#146;s financial obligations with respect to any
such interference or opposition shall be subject to AnaptysBio obtaining TESARO&#146;s prior written consent with respect to any such action and the associated costs. After IND clearance for a Product resulting from a Discovery Program, TESARO shall
be responsible at TESARO&#146;s expense to Prosecute and Maintain the applicable Collaboration Patents. The Party that is tasked to Prosecute and Maintain shall keep the other Party informed with respect to the prosecution and issuance of the
Collaboration Patents and provide prompt notice of all material matters related thereto (including upon such Party&#146;s request), and the other Party shall reasonably cooperate with and assist the Party tasked to Prosecute and Maintain in
connection with such activities, including without limitation by making scientists and scientific records reasonably available and the execution of all such documents and instruments and the performance of such acts as may be reasonably necessary in
order to continue any filing, prosecution, maintenance or extension thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3. Enforcement and Defense</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Each Party shall promptly notify the other of any knowledge it acquires of any potential infringement of the Collaboration Patents
by a Third Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If any Patent within the Collaboration Patents is infringed by a Third Party in any country in the Territory
in connection with the manufacture, use and sale of a product the same as or substantially similar to a Product in the Field in such country, TESARO shall have the primary right, but not the obligation, to institute, prosecute, and control any
action or proceeding with respect to such infringement of such Patent, by counsel of its own choice, and AnaptysBio shall have the right, at its own expense, to be represented in that action by counsel of its own choice. If TESARO fails to bring an
action or proceeding within a period of one hundred twenty (120)&nbsp;days after a request by AnaptysBio to do so, AnaptysBio shall have the right to bring and control any such action by counsel of its own choice, and TESARO shall have the right to
be represented in any such action by counsel of its own choice at its own expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If one Party brings an action or proceeding
in accordance with Section&nbsp;9.3(b), the second Party agrees to be joined as a party plaintiff if necessary and to give the first Party reasonable assistance and authority to file and prosecute the suit. The costs and expenses of the Party
bringing suit under this Section shall be borne by such Party, and any damages or other monetary awards recovered shall be shared as follows: The amount of such recovery actually received by the Party controlling such action shall first be applied
to the out-of- pocket costs of such action, and then (i)&nbsp;if TESARO is the Party that brings such action or proceeding, then AnaptysBio shall be paid an amount equal to the royalties, if any, that would have been due upon sales of the infringing
product as if such infringing sales had been Net Sales of a Product sold by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or under the authority of TESARO, and the remaining portion of such recovery shall be paid to TESARO, or (ii)&nbsp;if AnaptysBio is the Party that brings such action or proceeding, then the
remaining portion of such recovery shall be retained by AnaptysBio. A settlement or consent judgment or other voluntary final disposition of a suit under this Section&nbsp;9.3 may be entered into without the consent of the Party not bringing the
suit. Neither Party shall, however, have the right to enter into any settlement or consent to any claim to the effect that the patent protection offered under any part of the Collaboration Patents would be materially negatively affected, without the
consent of the other Party, such consent not to be unreasonably withheld. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONFIDENTIALITY </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1. Confidential Information</B>. Except as otherwise expressly
provided herein, the Parties agree that, for the term of this Agreement and for ten (10)&nbsp;years thereafter, the receiving Party shall not, except as expressly provided in this Section&nbsp;10, disclose to any Third Party any Confidential
Information furnished to it by the disclosing Party hereto pursuant to this Agreement, or any results of the Discovery Programs (&#147;<B>Results</B>&#148;). For purposes of this Section&nbsp;10, &#147;<B>Confidential Information</B>&#148; shall
mean any information, samples or other materials, which if disclosed in tangible form is marked &#147;confidential&#148; or with other similar designation to indicate its confidential or proprietary nature, or, if disclosed orally, is indicated
orally to be confidential or proprietary at the time of such disclosure and is confirmed in writing as confidential or proprietary within forty-five (45)&nbsp;days after such disclosure. Notwithstanding the foregoing, Confidential Information shall
not include any information that can be established by the receiving Party by competent proof that such information: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> was
already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> was
generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
became generally available to the public or otherwise part of the public domain after its disclosure and other than through any breach of this Agreement by the receiving Party; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> was independently developed by the receiving Party as demonstrated by documented evidence prepared contemporaneously with such
independent development; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> was disclosed to the receiving Party, other than under an obligation of confidentiality, by a
Third Party who had no obligation to the disclosing Party not to disclose such information to others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2. Permitted Use and
Disclosures</B>. Each Party hereto may use or disclose Confidential Information disclosed to it by the other Party or Results to the extent such use or disclosure is reasonably necessary and permitted in the exercise of the rights granted hereunder
in filing or prosecuting Patent applications, prosecuting or defending litigation, complying with applicable governmental laws, rules, regulations or court order or otherwise submitting information to tax or other governmental authorities,
conducting clinical trials, or making a permitted sublicense or otherwise exercising license rights expressly granted by the other Party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to it pursuant to the terms of this Agreement; provided, that if a Party is required to make any such disclosure, other than pursuant to a confidentiality agreement, it will give reasonable
advance notice to the other Party of such disclosure and, save to the extent inappropriate in the case of Patent applications, will use its reasonable efforts to secure confidential treatment of such information in consultation with the other Party
prior to its disclosure (whether through protective orders or otherwise) and disclose only the minimum necessary to comply with such requirements. Nothing in this Article 10 shall restrict TESARO from providing Development Antibodies (and associated
related information) to academic and other collaborators to conduct pre-clinical and clinical studies to further the research, development and commercialization of the Development Antibodies. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PUBLICITY </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.1. Nondisclosure of Terms</B>. Each of the Parties hereto agrees not
to disclose the terms of this Agreement to any Third Party without the prior written consent of the other Party hereto, which consent shall not be unreasonably withheld, except to such Party&#146;s attorneys, advisors, investors, potential investors
and other similarly situated Third Parties on a need to know basis under circumstances that reasonably ensure the confidentiality thereof, or to the extent required by law. Notwithstanding the foregoing, the press release attached to the
Supplemental Information Package as Exhibit B-1 shall be jointly released by both Parties promptly following the Effective Date, and the press release attached to the Supplemental Information Package as Exhibit B-2 shall be released by AnaptysBio
promptly following the Effective Date. Furthermore, it is understood that either Party may be required to issue subsequent press releases or make disclosures required by law (pursuant to filings with the Securities and Exchange Commission or
otherwise) relating to the terms of this Agreement or activities hereunder. The Parties agree to consult with each other reasonably and in good faith with respect to the text and timing of all such press releases or other disclosures required by law
prior to the issuance thereof, provided that a Party may not unreasonably withhold or delay consent to such releases or disclosures, and that either Party may issue such press releases or make such disclosures as it determines, based on advice of
counsel, are reasonably necessary to comply with laws or regulations or for appropriate stock market disclosure. Furthermore, AnaptysBio shall have the right to publicly announce, by press release or otherwise, the occurrence of each significant
event under the terms of this Agreement, including the receipt of each milestone payment reference above, provided that AnaptysBio consults with TESARO reasonably and in good faith with respect to the text and timing of such public announcement
prior to the issuance thereof, provided that no Confidential Information shall be disclosed without permission of TESARO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.2.
Publications</B>. With respect to any Discovery Program, each Party shall submit any proposed scientific publication to the other Party that relates directly to one or more Development Antibodies or Products, discloses the results of a Discovery
Program or includes Confidential Information of the other Party at least thirty (30)&nbsp;days in advance to allow that Party to review such planned public disclosure. The reviewing Party will promptly review such proposed scientific publication and
make any objections that it may have to the publication of such results or the Confidential Information of the reviewing Party contained therein. Should the reviewing Party make an objection to the publication of any such results or Confidential
Information, then the Parties shall discuss the advantages and disadvantages of publishing such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
results or Confidential Information. If the Parties are unable to agree on whether to publish the same, the respective Chief Executive Officers of AnaptysBio and TESARO (or, with respect to
TESARO, the President) shall reasonably agree on the extent to which the publication of such results or Confidential Information shall be made. AnaptysBio acknowledges that TESARO may enter into agreements with academic and other collaborators to
conduct studies with Development Antibodies, including in combination with other compounds, in all cases consistent with the license rights granted hereunder. Notwithstanding the provisions of this Section&nbsp;11.2 to the contrary, TESARO shall be
required only to request such collaborators comply with the provisions of this Section&nbsp;11.2 with regard to their scientific publications, but TESARO shall not be in violation of this Section&nbsp;11.2 as a result of the actions of such
collaborators with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.3. Blinded Data</B>. For the purposes of promoting or otherwise highlighting the advantages of
the AnaptysBio Platform, AnaptysBio may disclose (or cause to be disclosed) to Third Parties, blinded data relating to each of the Discovery Programs at any time during or subsequent to the term of the Agreement, provided that (a)&nbsp;neither
TESARO, the Targets or therapeutic area shall be identified, directly or indirectly, in connection therewith, (b)&nbsp;TESARO shall have an opportunity to review each such disclosure at least thirty (30)&nbsp;days prior to the release thereof, and
(c)&nbsp;no such disclosure shall include any Confidential Information of TESARO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.4. Permitted Disclosures</B>. Notwithstanding
anything to the contrary contained in this Agreement or any confidentiality agreement between the Parties, nothing herein or therein shall prevent a Party from disclosing the terms of this Agreement or such other information a Party reasonably
determines, based on advice from its counsel, is necessary or desirable to disclose under applicable law, regulation or legal process (whether in connection with its ongoing disclosure obligations, in connection with a corporate activity or
otherwise), including as required by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States or of any stock exchange or NASDAQ, or in connection with a
presentation or disclosure to investors or potential investors subject to customary and appropriate confidentiality restrictions. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>REPRESENTATIONS AND WARRANTIES </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.1.</B> TESARO. TESARO represents and warrants
that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> it has the legal power, authority and right to enter into this Agreement and to fully perform all of its obligations
hereunder, and has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms, except as such
enforcement may be limited by bankruptcy, insolvency, or other similar laws affecting creditors, generally, or general principles of equity; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> the performance of its obligations hereunder do not conflict with, violate or breach
or constitute a default or require any consent under, any agreement, instrument or understanding, or other contractual obligations of TESARO; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> no government authorization, consent, approval, license, exemption of or filing or registration with any court or governmental
authority, is necessary for the transactions contemplated by this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations under this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> TESARO has not and shall not employ (or use any Subcontractor or consultant that employs) any individual or entity debarred by the
FDA (or subject to a similar sanction of the EMA), or any individual who or entity which is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMA), or is convicted of a crime for which an individual or entity
could be debarred under 21 U.S.C. Section&nbsp;335a or its foreign equivalent or has been under indictment for a crime for which a person or entity could be debarred under such provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.2. AnaptysBio</B>. AnaptysBio represents and warrants that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> it has the legal power, authority and right to enter into this Agreement and to fully perform all of its obligations hereunder, and
has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> this Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms, except as such
enforcement may be limited by bankruptcy, insolvency, or other similar laws affecting creditors, generally, or general principles of equity; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> the performance of its obligations hereunder do not conflict with, violate or breach or constitute a default or require any consent
under, any agreement, instrument or understanding, or other contractual obligations of AnaptysBio; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> no government
authorization, consent, approval, license, exemption of or filing or registration with any court or governmental authority, is necessary for the transactions contemplated by this Agreement or any other agreement or instrument executed in connection
herewith, or for the performance by it of its obligations under this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> AnaptysBio Controls the AnaptysBio Know-How
and AnaptysBio Patents existing as of the Effective Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> AnaptysBio has the right to grant all rights and licenses it
purports to grant to TESARO with respect to the AnaptysBio Know-How, AnaptysBio Patents and AnaptysBio Platform under this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> AnaptysBio has no present knowledge that any settled, pending or threatened claim or lawsuit or legal proceeding of a Third Party
against AnaptysBio or any other person alleging that the AnaptysBio Know-How, AnaptysBio Patents or AnaptysBio Platform </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
misappropriates or infringes, in part or in whole, the intellectual property or intellectual property rights of such Third Party; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> AnaptysBio has not granted any right or license to any Third Party relating to any of the AnaptysBio Know-How, AnaptysBio Patents
or AnaptysBio Platform that would conflict or interfere with any of the rights or licenses granted or purported to be granted to TESARO hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Schedule 12.2(i) attached hereto sets forth a complete and accurate list of the AnaptysBio Patents as of the Effective Date,
indicating the owner or co-owners thereof if such AnaptysBio Patent is not solely owned by AnaptysBio. AnaptysBio has disclosed to TESARO all material information received by AnaptysBio as of the Effective Date concerning the institution of any
interference, opposition, reexamination, reissue, revocation, nullification or any official proceeding involving any AnaptysBio Patent or Patent included in the AnaptysBio Platform anywhere in the Territory; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> To the best of AnaptysBio&#146;s knowledge as of the Effective Date, Exhibit C attached to the Supplemental Information Package
sets forth a complete and accurate list of all Target Antagonists owned or Controlled by AnaptysBio as of the Effective Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(k)</B>
To the best of AnaptysBio&#146;s knowledge as of the Effective Date, TESARO will not be required to obtain a license or sublicense under any Third Party In-License for TESARO to research, develop, make, have made, use, sell, offer for sale, import
and export Products for use in the Field and in the Territory pursuant to the rights and licenses granted to it under this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> AnaptysBio has not and shall not employ (or use any Subcontractor or consultant that employs) any individual or entity debarred by
the FDA (or subject to a similar sanction of the EMA), or any individual who or entity which is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMA), or is convicted of a crime for which an individual or entity
could be debarred under 21 U.S.C. Section&nbsp;335a or its foreign equivalent or has been under indictment for a crime for which a person or entity could be debarred under such provision; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> AnaptysBio acknowledges that, in entering into this Agreement, TESARO has relied upon information supplied by AnaptysBio and
information which AnaptysBio has caused to be supplied to TESARO by AnaptysBio&#146;s agents and/or representatives (all of such information being hereinafter referred to collectively as &#147;<B>Product Information</B>&#148;). To the knowledge of
AnaptysBio as of the Effective Date, the Product Information is accurate in all material respects. AnaptysBio has not, as of the Effective Date, intentionally omitted to furnish TESARO with any material information known to AnaptysBio concerning the
AnaptysBio IP Rights, AnaptysBio Platform or Development Antibodies, or the transactions contemplated by this Agreement, which would reasonably be considered to be material to TESARO&#146;s decision to enter into this Agreement and to undertake the
commitments and obligations set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.3. Disclaimer</B>. TESARO and AnaptysBio specifically disclaim any guarantee that the
Discovery Programs will be successful, in whole or in part. The failure of the Parties to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
successfully develop Products will not constitute a breach of any representation or warranty or other obligation under this Agreement. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT,
ANAPTYSBIO AND TESARO MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE ANAPTYSBIO IP RIGHTS, INFORMATION DISCLOSED HEREUNDER OR PRODUCTS INCLUDING, BUT NOT LIMITED TO,
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INDEMNIFICATION </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.1. TESARO</B>. TESARO agrees to indemnify, defend and hold
AnaptysBio and its Affiliates and their respective directors, officers, employees, agents and their respective successors, heirs and assigns (the &#147;<B>AnaptysBio Indemnitees</B>&#148;) harmless from and against any losses, costs, claims,
damages, liabilities or expense (including reasonable attorneys&#146; and professional fees and other expenses of litigation) (collectively, &#147;<B>Liabilities</B>&#148;) arising, directly or indirectly out of or in connection with Third Party
claims, suits, actions, demands or judgments, relating to (i)&nbsp;any breach by TESARO of the representations and warranties made in this Agreement, or (ii)&nbsp;the development or commercialization of a Product, except, in each case, to the extent
such Liabilities result from the gross negligence or intentional misconduct of AnaptysBio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.2. AnaptysBio</B>. AnaptysBio agrees to
indemnify, defend and hold TESARO and its Affiliates and their respective directors, officers, employees, agents and their respective successors, heirs and assigns (the &#147;<B>TESARO Indemnitees</B>&#148;) harmless from and against any Liabilities
arising, directly or indirectly out of or in connection with Third Party claims, suits, actions, demands or judgments, relating to any breach by AnaptysBio of its representations and warranties made in this Agreement, except to the extent such
Liabilities result from the gross negligence or intentional misconduct of TESARO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.3. Indemnification Procedure</B>. A Party that
intends to claim indemnification (the &#147;Indemnitee&#148;) under this Section&nbsp;13 shall promptly notify the other Party (the &#147;<B>Indemnitor</B>&#148;) in writing of any claim, complaint, suit, proceeding or cause of action with respect
to which the Indemnitee intends to claim such indemnification (for purposes of this Section&nbsp;13.3, each a &#147;<B>Claim</B>&#148;), and the Indemnitor shall have sole control of the defense and/or settlement thereof; provided that the
Indemnitee shall have the right to participate, at its own expense, with counsel of its own choosing in the defense and/or settlement of such Claim. The indemnification obligations of the Parties under this Section&nbsp;13 shall not apply to amounts
paid in settlement of any Claim if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after
the commencement of any such Claim, if prejudicial to its ability to defend such action, shall relieve such Indemnitor of any liability to the Indemnitee under this Section&nbsp;13, but the omission so to deliver written notice to the Indemnitor
shall not relieve the Indemnitor of any liability to any Indemnitee otherwise than under this Section&nbsp;13. The Indemnitee under this Section&nbsp;13, and its employees, at the Indemnitor&#146;s request and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expense, shall provide full information and reasonable assistance to Indemnitor and its legal representatives with respect to such Claims covered by this indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.4. LIMITATION OF LIABILITY</B>. EXCEPT FOR A BREACH OF ARTICLES 10 OR 11, OR FOR ACTS OF GROSS NEGLIGENCE OR WRONGFUL INTENTIONAL ACTS
OR OMISSIONS, NEITHER TESARO NOR ANAPTYSBIO, NOR ANY OF THEIR RESPECTIVE AFFILIATES OR SUBLICENSEES, SHALL BE LIABLE TO THE OTHER PARTY, ITS AFFILIATES OR ANY OF THEIR SUBLICENSEES FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, RELIANCE OR
PUNITIVE DAMAGES OR LOST OR IMPUTED PROFITS, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY
HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE; PROVIDED, THAT THIS LIMITATION WILL NOT LIMIT THE INDEMNIFICATION OBLIGATION OF A PARTY UNDER THE PROVISIONS OF ARTICLE 13 FOR SUCH DAMAGES CLAIMED
BY A THIRD PARTY. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>TERM AND TERMINATION </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.1. Term</B>. Unless earlier terminated, the Agreement will
continue in full force and effect, on a Product-by-Product, Discovery Program-by-Discovery Program, Development Program-by-Development Program and country-by-country basis until the date no further payments are due under Section&nbsp;6 above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.2. Termination for Breach</B>. Either Party to this Agreement may terminate one or more Discovery Program(s), Development Program(s)
and/or this Agreement in the event the other Party hereto shall have materially breached or defaulted in any of its representations or warranties or the performance of any of its obligations hereunder, and such default shall have continued for [*]
after written notice thereof was provided to the breaching Party by the non-breaching Party. Any termination shall become effective at the end of such [*] period unless the breaching Party (or any other Party on its behalf) has cured any such breach
or default prior to the expiration of the [*] period; provided, however, in the case of a failure to pay any amount due hereunder, such default may be the basis of termination [*] following the date that notice of such default was provided to the
breaching Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.3. Termination without cause by TESARO</B>. TESARO may terminate this Agreement in its entirety or on a Discovery
Program-by-Discovery Program or Development Program-by-Development Program basis without cause upon [*] prior written notice to AnaptysBio.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.4. Effect of Breach or Termination</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a) Accrued Rights and Obligations</B>. Termination of this Agreement, or any portion hereof, for any reason shall not release either Party
hereto from any liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period prior to such termination nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Return of Materials. Upon a termination of this Agreement, in its entirety, TESARO and AnaptysBio shall promptly return to the
other all Confidential Information of the other Party, except one copy of which may be retained for archival purposes. Upon termination of this Agreement, a Discovery Program or a Development Program by TESARO pursuant to Section&nbsp;14.3, or by
AnaptysBio pursuant to Section&nbsp;14.2, TESARO shall return to AnaptysBio copies of records received by TESARO pursuant to Section&nbsp;2.9 or, if only a Discovery Program or a Development Program is terminated, then those records received by
TESARO pursuant to Section&nbsp;2.9, with respect to the terminated program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Effect of Termination of Agreement by TESARO
Without Cause or by AnaptysBio for Breach by TESARO. If TESARO terminates this Agreement in its entirety without cause pursuant to Section&nbsp;14.3 or if AnaptysBio terminates this Agreement in its entirety pursuant to Section&nbsp;14.2 for breach
by TESARO, then: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> all licenses and rights to TESARO under Section&nbsp;5.1 shall concurrently terminate, and TESARO and its
Affiliates and sublicensees shall immediately cease all manufacture, development and commercialization of Products; provided, that TESARO and its Affiliates, sublicensees and distributors shall be entitled, during the twelve (12)&nbsp;month period
immediately following the effective date of termination, to finish any work-in-progress and to sell any Products remaining in inventory, in accordance with the terms of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> TESARO hereby grants to AnaptysBio an irrevocable, non- exclusive, worldwide license, with the right to grant and authorize
sublicenses, under TESARO&#146;s interest in the Collaboration IP Rights, TESARO Patents and TESARO Know-How, to make, have made, use, sell, offer to sell and import Products; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To the extent permitted by applicable regulatory authorities, TESARO shall and hereby does transfer to AnaptysBio all regulatory
filings and regulatory approvals for the Products held by TESARO, its Affiliates or sublicensees, or if the foregoing transfer is not permitted by the applicable regulatory authority, TESARO hereby permit AnaptysBio to cross-reference and rely upon
any such regulatory approvals and regulatory filings; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> AnaptysBio shall have the sole right to Prosecute and Maintain, and to
solely enforce, all Collaboration IP Rights; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> Upon AnaptysBio&#146;s request, TESARO shall continue all on-going
development for the Products for a mutually agreed upon migration period after termination of this Agreement (&#147;<B>Migration Period</B>&#148;). During such Migration Period, TESARO shall provide such knowledge transfer and other training to
AnaptysBio as reasonably necessary for AnaptysBio to continue such activities. In connection with such transfer, TESARO shall, subject to subsection (i)&nbsp;above: (A)&nbsp;transfer to AnaptysBio all quantities of Products manufactured by TESARO in
TESARO&#146;s control as of the effective date of termination, (B)&nbsp;assign to AnaptysBio any agreements with Third Parties with respect to the development or commercialization of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Product (to the extent assignable) and (C)&nbsp;continue funding FTEs (equivalent to the number of FTEs being funded upon the date of notice of termination) for a mutually agreed period not to
exceed [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(d) Effect of Termination of Discovery Program</B>. If AnaptysBio terminates a Discovery Program pursuant to
Section&nbsp;14.2 for breach by TESARO, or TESARO discontinues a Discovery Program in accordance with Section&nbsp;8.2, then: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>
AnaptysBio&#146;s obligations to conduct further activities under the applicable Discovery Program shall terminate as of the effective date of such termination; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> all licenses and rights to TESARO under Section&nbsp;5.1 for the Products resulting from such Discovery Program shall
concurrently terminate, and TESARO and its Affiliates and sublicensees shall immediately cease all manufacture, development and commercialization of such Products; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> TESARO hereby grants to AnaptysBio an irrevocable, non- exclusive, worldwide license, with the right to grant and authorize
sublicenses, under TESARO&#146;s interest in the Collaboration IP Rights, TESARO Patents and TESARO Know-How, to make, have made, use, sell, offer to sell and import Products resulting from such Discovery Program; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> To the extent permitted by applicable regulatory authorities, TESARO shall and hereby does transfer to AnaptysBio all regulatory
filings and regulatory approvals for the Product resulting from such Discovery Program held by TESARO, its Affiliates or sublicensees, or if the foregoing transfer is not permitted by the applicable regulatory authority, TESARO hereby permit
AnaptysBio to cross-reference and rely upon any such regulatory approvals and regulatory filings; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> AnaptysBio shall have the
sole right to Prosecute and Maintain, and to solely enforce, all Collaboration IP Rights that are the subject of such Discovery Program; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> Upon AnaptysBio&#146;s request, TESARO shall continue all on-going development for the Products resulting from such Discovery
Program for a mutually agreed upon Migration Period after termination of this Agreement. During such Migration Period, TESARO shall provide such knowledge transfer and other training to AnaptysBio as reasonably necessary for AnaptysBio to continue
such activities. In connection with such transfer, TESARO shall: (A)&nbsp;transfer to AnaptysBio all quantities of Product resulting from such Discovery Program generated by TESARO in TESARO&#146;s control as of the effective date of termination,
(B)&nbsp;assign to AnaptysBio any agreements with Third Parties with respect to the development or commercialization of such Products (to the extent assignable), and (C)&nbsp;continue funding FTEs (equivalent to the number of FTEs being funded upon
the date of notice of termination) for a mutually agreed period not to exceed [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(e) Effect of Termination of Development
Program</B>. If AnaptysBio terminates a Development Program pursuant to Section&nbsp;14.2 for breach by TESARO, or TESARO discontinues a Development Program in accordance with Section&nbsp;8.2, then: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">27</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> all licenses and rights to TESARO under Section&nbsp;5.1 for the Products resulting
from such Development Program shall concurrently terminate, and TESARO and its Affiliates and sublicensees shall immediately cease all manufacture, development and commercialization of such Products; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> TESARO hereby grants to AnaptysBio an irrevocable, non- exclusive, worldwide license, with the right to grant and authorize
sublicenses, under TESARO&#146;s interest in the Collaboration IP Rights, TESARO Patents and TESARO Know-How, to make, have made, use, sell, offer to sell and import Products resulting from such Development Program; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To the extent permitted by applicable regulatory authorities, TESARO shall and hereby does transfer to AnaptysBio all regulatory
filings and regulatory approvals for the Product resulting from such Development Program held by TESARO, its Affiliates or sublicensees, or if the foregoing transfer is not permitted by the applicable regulatory authority, TESARO hereby permit
AnaptysBio to cross-reference and rely upon any such regulatory approvals and regulatory filings; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> AnaptysBio shall have the
sole right to Prosecute and Maintain, and to solely enforce, all Collaboration IP Rights that are the subject of such Development Program; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> Upon AnaptysBio&#146;s request, TESARO shall continue all on-going development for the Products resulting from such Development
Program for a mutually agreed upon Migration Period after termination of this Agreement. During such Migration Period, TESARO shall provide such knowledge transfer and other training to AnaptysBio as reasonably necessary for AnaptysBio to continue
such activities. In connection with such transfer, TESARO shall: (A)&nbsp;transfer to AnaptysBio all quantities of Product resulting from such Discovery Program manufactured by TESARO in TESARO&#146;s control as of the effective date of termination,
(B)&nbsp;assign to AnaptysBio any agreements with Third Parties with respect to the development or commercialization of such Products (to the extent assignable), and (C)&nbsp;continue funding FTEs (equivalent to the number of FTEs being funded upon
the date of notice of termination) for a mutually agreed period not to exceed the remaining portion of the then-current calendar quarter and one (1)&nbsp;full calendar quarter following the effective date of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(f) Effect of Termination by TESARO With Cause or by TESARO for Breach by AnaptysBio</B>. If TESARO terminates one or more Discovery
Programs or this Agreement pursuant to Section&nbsp;14.2 for breach by AnaptysBio, then: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> all licenses and rights to TESARO
under Section&nbsp;5.1 with respect to the applicable Discovery Program(s), Development Program(s) and Products shall automatically become perpetual and irrevocable; provided, that the payment obligations under Sections 6.3 and 6.4 shall continue;
provided, however, that if TESARO terminated this Agreement pursuant to AnaptysBio&#146;s uncured material breach of Article 5, then without limiting any other rights or remedies available to TESARO, TESARO shall continue to make payments to
AnaptysBio under Sections 6.3 and 6.4 but at [*] percent ([*]%) of the amounts set forth therein when and if they become due; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">28</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> AnaptysBio and its Affiliates and sublicensees shall immediately cease all research,
development or other activities with respect to applicable Development Antibodies and Products resulting from such Discovery Program; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To the extent permitted by applicable regulatory authorities, AnaptysBio shall and hereby does transfer to TESARO all regulatory
filings and regulatory approvals for the applicable Products resulting from such Discovery Program held by AnaptysBio, its Affiliates or sublicensees, or if the foregoing transfer is not permitted by the applicable regulatory authority, AnaptysBio
shall, and hereby does, permit TESARO to cross- reference and rely upon any such regulatory approvals and regulatory filings; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> TESARO shall have the sole right to Prosecute and Maintain, and to solely enforce, all Collaboration IP Rights specific to such
Discovery Program; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> Upon TESARO&#146;s request, AnaptysBio shall continue all on-going development under such Discovery
Program and for applicable Products for a mutually agreed upon Migration Period after termination of this Agreement. During such Migration Period, AnaptysBio shall provide such knowledge transfer and other training to TESARO or its designees as
reasonably necessary for TESARO to continue such activities. In connection with such transfer, AnaptysBio shall transfer to TESARO all quantities of applicable Development Antibodies and Products manufactured by or on behalf of AnaptysBio and in the
possession or control of AnaptysBio or its affiliates or contractors as of the effective date of termination, and assign to TESARO any agreements with Third Parties with respect to the research, development or commercialization of applicable
Development Antibodies or Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.5. Expiration</B>. Upon the expiration of the last to expire Royalty Term for Products
resulting from a Discovery Program and Development Program, all licenses and rights to TESARO under Section&nbsp;5.1 with respect to such Discovery Program and Development Program and Products shall automatically become fully paid up, perpetual and
irrevocable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.6. Survival Sections</B>. Sections 7, 9, 10, 13, 14.4, 14.5, 14.6, 14.7 and 15 shall survive the expiration or
termination of this Agreement for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.7. Termination Not Sole Remedy</B>. Termination is not the sole remedy under this
Agreement and, whether or not termination is effected, all other remedies will remain available except as agreed to otherwise herein. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MISCELLANEOUS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.1. Governing Laws</B>. This Agreement and any dispute arising from
the construction, performance or breach hereof shall be governed by and construed, and enforced in accordance with, the laws of the State of Delaware, without reference to conflicts of laws principles thereof that would result in the application of
any other law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.2. Waiver</B>. It is agreed that no waiver by either Party hereto of any breach or default of any of the covenants
or agreements herein set forth shall be deemed a waiver as to any subsequent and/or similar breach or default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.3. Assignment</B>. This Agreement shall not be assignable by either Party to any Third
Party hereto without the written consent of the other Party hereto, and any attempted assignment shall be null and void. Notwithstanding the foregoing, either Party may assign this Agreement, without such consent, to an entity that acquires all or
substantially all of the business or assets of such Party to which this Agreement pertains, whether by merger, reorganization, acquisition, sale, or otherwise. This Agreement shall be binding upon and accrue to the benefit any permitted assignee,
and any such assignee shall agree to perform the obligations of the assignor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.4. Independent Contractors</B>. The relationship of
the Parties hereto is that of independent contractors. The Parties hereto are not deemed to be agents, partners or joint venturers of the others for any purpose as a result of this Agreement or the transactions contemplated thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.5. Compliance with Laws</B>. In exercising their rights under this license, the Parties shall fully comply in all material respects with
the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this license including, without limitation, those applicable to the discovery, development,
manufacture, distribution, import and export and sale of Products pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.6. Notices</B>. All notices, requests
and other communications hereunder shall be in writing and shall be personally delivered or by registered or certified mail, return receipt requested, postage prepaid, in each case to the respective address specified below, or such other address as
may be specified in writing to the other Parties hereto and shall be deemed to have been given upon receipt: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="68%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>If to TESARO:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">TESARO, Inc.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">1000 Winter Street, Suite 3300</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Waltham, Massachusetts 02541</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Leon O. Moulder, Jr.,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">339-230-3961</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">and</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">TESARO Development Ltd.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Clarendon House</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">2 Church Street</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Hamilton HM 11</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Bermuda</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Corporate Secretary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with&nbsp;a&nbsp;copy&nbsp;(which&nbsp;shall</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">not&nbsp;constitute&nbsp;notice)&nbsp;to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Hogan Lovells US LLP</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">100 International Drive, Suite 2000</TD></TR></TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="68%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Baltimore, MD 21202</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Asher M. Rubin</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">410-659 2701</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>If to AnaptysBio:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">AnaptysBio, Inc.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">10421 Pacific Center Court, Suite 200</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">San Diego, CA 92121</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hamza Suria, Chief Executive Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">858-366-9055</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy (which shall</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">not constitute
notice) to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Fenwick&nbsp;&amp; West</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">1191 Second Avenue, 10th Floor</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Seattle, WA 98101</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Effie Toshav</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">206-389-4511</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.7. Severability</B>. Each Party hereby agrees that it does not intend to violate any public
policy, statutory or common laws, rules, regulations, treaty or decision of any government agency or executive body thereof of any country or community or association of countries. Should one or more provisions of this Agreement be or become
invalid, the Parties hereto shall substitute, by mutual consent, valid provisions for such invalid provisions which valid provisions in their economic effect are sufficiently similar to the invalid provisions that it can be reasonably assumed that
the Parties would have entered into this Agreement with such valid provisions. In the event a Party seeks to avoid a material provision of this Agreement upon an assertion that such provision is invalid, illegal or otherwise unenforceable, the other
Party shall have the right to terminate this Agreement upon sixty (60)&nbsp;days prior written notice to the asserting Party, unless such assertion is eliminated and cured within such sixty (60)&nbsp;day period. Such a termination shall be deemed a
termination by such Party for breach pursuant to Section 14.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.8. Force Majeure</B>. Neither Party shall lose any rights hereunder
or be liable to the other Party for damages or losses (except for payment obligations) on account of failure of performance by the defaulting Party if the failure is occasioned by war, strike, fire, Act of God, earthquake, flood, lockout, embargo,
governmental acts or orders or restrictions, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or misconduct of the non-performing Party and such
Party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a Party be required to settle any labor dispute or disturbance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.9. Complete Agreement</B>. This Agreement and the Supplemental Information Package, constitute the entire agreement, both written and
oral, between the Parties with respect to the subject matter hereof, and all prior agreements respecting the subject matter hereof, either written or oral, express or implied, shall be abrogated, canceled, and are null and void and of no effect. No
amendment or change hereof or addition hereto shall be effective or binding on either of the Parties hereto unless reduced to writing and executed by the respective duly authorized representatives of AnaptysBio and TESARO. TESARO, Inc., and TESARO
Development, Ltd shall be jointly and severally liable for all obligations of TESARO under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.10. Headings</B>. The captions to the several Sections hereof are not a part of this
Agreement, but are included merely for convenience of reference and shall not affect its meaning or interpretation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.11.
Counterparts</B>. This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[signature page follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties hereto have caused this Collaboration and Exclusive
License Agreement to be duly executed by their authorized representatives and delivered in duplicate originals effective as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TESARO, INC.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">ANAPTYSBIO, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Leon O. Moulder, Jr.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Hamza Suria</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Leon O. Moulder, Jr.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Hamza Suria</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">President&nbsp;&amp; CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TESARO DEVELOPMENT, LTD.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Leon O. Moulder, Jr.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Leon O. Moulder, Jr.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>Signature page to Collaboration and Exclusive License Agreement</I></B><B> </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule 12.2(i) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AnaptysBio Patents </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>*Confidential
Treatment Requested. </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDMENT NO. 1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TO COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No.&nbsp;1 to the Collaboration and Exclusive License Agreement (this &#147;<B>Amendment</B>&#148;) effective as of
November&nbsp;<U>28</U>, 2014 (the &#147;<B>Amendment Date</B>&#148;), is entered into is made by and between (i)&nbsp;<B>AnaptysBio, Inc.</B>, a Delaware corporation, having a place of business at 10421 Pacific Center Court, Suite 200, San Diego,
California 92121 (&#147;<B>AnaptysBio</B>&#148;), and (ii)&nbsp;<B>TESARO, Inc.</B>, a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (&#147;<B>TESARO US</B>&#148;) and <B>TESARO
Development, Ltd.</B>, a Bermuda corporation, having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, &#147;<B>TESARO</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties previously entered into that certain Collaboration and Exclusive License Agreement dated as of March&nbsp;10, 2014 (the
&#147;Agreement&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties wish to amend the Agreement in certain respects on the terms and conditions set forth
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, capitalized terms not defined in this Amendment shall have the meaning ascribed in the Agreement, and the parties
hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <U>Amendment License Fee</U>. Within ten (10)&nbsp;business days following the Amendment Date, TESARO
shall pay to AnaptysBio a non-creditable, non-refundable license fee of two million dollars (USD $2,000,000.00). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.
</B><U>Amendment</U>. The following Sections of the Agreement are hereby amended and replaced in their entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.1.</B>
Section&nbsp;1 of the Agreement is amended to add the following new definitions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>1.51 &#147;<B>[*]</B>&#148; shall mean [*].
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> 1.52 &#147;<B>[*]</B>&#148; shall mean both [*] and shall be used with respect to a Development Antibody that is specifically
designed to cross-react and antagonize both [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> 1.53 &#147;<B>[*] Development Program</B>&#148; shall mean the development
program to be conducted in accordance with Section&nbsp;3 for the development of Development Antibodies generated under the [*] Discovery Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> 1.54 &#147;<B>[*] Discovery Program</B>&#148; shall mean the discovery program to be conducted in accordance with Section&nbsp;2
for the development of antibodies directed to antagonize both [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.2.</B> Section&nbsp;1.14, the definition of &#147;Development
Programs&#148;, is amended to add the [*] Development Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>*Confidential
Treatment Requested. </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.3.</B> Section&nbsp;1.15, the definition of &#147;Discovery Plan&#148;, is amended to add
Exhibit A-4 to the Supplemental Information Package. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.4.</B> Section&nbsp;1.16, the definition of &#147;Discovery Programs&#148;, is
amended to add the [*] Discovery Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.5.</B> Section&nbsp;1.41, the definition of &#147;Target(s)&#148;, is amended to include
[*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.6.</B> Section&nbsp;2.4 is hereby amended by adding the following new sentence immediately following the end of
Section&nbsp;2.4: &#147;Exhibit A-4 to the Supplemental Information Package is hereby added as an additional Discovery Program to be carried out in accordance with this Agreement.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>2.7.</B> Section&nbsp;5.3(a) of the Agreement is hereby amended by adding the following new sentence immediately following the end of
Section 5.3(a): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.
</B>TESARO shall pay AnaptysBio each of the milestone payments set forth in Section&nbsp;6.3 of the License Agreement [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.
</B><U>Discovery Plan</U>. The Discovery Plan for the [*] Discovery Program shall be added to the Supplemental Information Package as Exhibit A-4, thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5. </B><U>Press Release</U>. Disclosure of the terms of this Amendment are subject to Section&nbsp;11.1 of the Agreement, provided that the
press release attached to this Amendment as Appendix A shall be jointly released by both Parties promptly following the Amendment Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6. </B><U>Miscellaneous</U>. This Amendment shall be effective for all purposes as of the Amendment Date. Except as expressly modified
herein, the Agreement shall continue to remain in full force and effect in accordance with its terms. This Amendment may be executed in counterparts, each of which shall be deemed to be an original and together shall be deemed to be one and the same
document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>*Confidential
Treatment Requested. </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their respective
duly authorized representatives effective as of the Amendment Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TESARO, INC.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">ANAPTYSBIO, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Leon O. Moulder, Jr.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Hamza Suria</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Leon O. Moulder, Jr.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Hamza Suria</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">President&nbsp;&amp; CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TESARO DEVELOPMENT, LTD.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Leon O. Moulder, Jr.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Leon O. Moulder, Jr.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Press Release </U></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR RELEASE ON DECEMBER 2, 2014 AT 5:15 AM ET </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TESARO AND ANAPTYSBIO EXPAND IMMUNO-ONCOLOGY COLLABORATION TO INCLUDE NOVEL BISPECIFIC ANTIBODY CANDIDATE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#151;Candidate Will Target Two Undisclosed Immune Checkpoints </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#151;Anti-TIM-3 Antibody Data to be Presented Today at the AACR Conference in Orlando </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WALTHAM, MA, and SAN DIEGO, CA &#150; December&nbsp;2, 2014 &#150; TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, and AnaptysBio,
Inc., a privately-held therapeutic antibody company, today announced an expansion of their immuno-oncology collaboration and exclusive license agreement to include development of a novel bispecific antibody candidate designed to target two
undisclosed immune checkpoints. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AnaptysBio and TESARO first initiated their collaboration in March of 2014, and have together focused on the development
of monospecific antibody drug candidates targeting TIM-3, LAG-3 and PD-1 and dual reactive antibody drug candidates targeting PD-1/TIM-3 and PD-1/LAG-3. Since the beginning of this partnership, Investigational New Drug (IND) enabling preclinical
studies of TSR-042 (anti-PD-1 antibody candidate) have been initiated, and additional clinical candidates have been identified, including lead candidates targeting TIM-3 and LAG-3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Through our collaboration with AnaptysBio, we are employing a variety of approaches, including monospecific, bispecific and dual specific antibodies, to
address some of the most validated and promising immune checkpoint targets,&#148; said Mary Lynne Hedley, president and COO of TESARO. &#147;We are committed to advancing the science of immuno-oncology in order to potentially transform the care of
patients with cancer. Our team looks forward to continued collaboration with AnaptysBio on these programs and to the presentation of data describing our anti-TIM-3 antibody candidate at the AACR conference later today in Orlando.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;AnaptysBio continues to focus on the development of therapeutic antibodies for unmet medical needs in immuno-oncology, inflammation and fibrosis. Our
strategic advantage is the ability to rapidly discover and develop therapeutic antibodies against emerging biological targets using the natural somatic hypermutation mechanism encoded within the human immune system,&#148; said Hamza Suria, president
and CEO of AnaptysBio. &#147;We are pleased to expand our collaboration with TESARO, and look forward to advancing multiple immuno-oncology antibodies into the clinic.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of this expansion, TESARO will pay AnaptysBio an undisclosed upfront fee and will provide funding for all costs incurred by AnaptysBio related
to the development of a clinical antibody candidate. For each program within the collaboration, AnaptysBio is eligible to receive milestone payments if certain research and development events are achieved and additional payments for achievement of
certain U.S. and ex-U.S. regulatory submissions and approvals in multiple indications. AnaptysBio will also be eligible to receive royalties related to worldwide net sales of products developed under the collaboration, and may earn certain
commercial milestone payments if specified levels of annual worldwide net sales are attained. AnaptysBio and TESARO will together complete preclinical development of the antibody candidates, with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
TESARO being solely responsible for all clinical development, manufacturing, regulatory and commercial activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AACR Poster Presentation Details </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AACR Conference: Tumor
Immunology and Immunotherapy: A New Chapter (Orlando) Tuesday, December&nbsp;2, 2014, 1:15 PM to 3:30 PM, Poster Session A </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abstract title:
<I>Identification and characterization of a potent anti-human TIM-3 antagonist</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This poster will be available following its presentation at:
<U>http://www.tesarobio.com/documents/AACRDec2014.pdf</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About AnaptysBio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AnaptysBio is a privately-held antibody development company advancing first-in-class programs in immuno-oncology, inflammation and fibrosis. AnaptysBio&#146;s
proprietary SHM-XEL&#153; platform, which couples fully human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies. replicates key features of the human immune system and overcomes
limitations of prior antibody technologies. Multiple antibodies emanating from the AnaptysBio pipeline are currently undergoing IND-enabling studies with potentially transformative clinical read-outs during the 2016-2017 timeframe. For more
information, visit <U>www.anaptysbio.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About TESARO </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer
and more effective therapeutics. For more information, visit <U>www.tesarobio.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TESARO Contact: </B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer Davis Sr. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, Corporate Development&nbsp;&amp;
Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1.781.325.1116 or<U> jdavis@tesarobio.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AnaptysBio Contact: </B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Julie Rathbun </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1.206.769.9219 or <U>julie@rathbuncomm.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>To the
extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Words such as &#147;may,&#148; &#147;will,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;intend,&#148; and similar expressions (as well as other
words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward looking statements contained in this press release include, among others, statements regarding our
expectations regarding the timing of both the selection of clinical candidates from the programs and the commencement of clinical testing, our development plans for any antibody therapeutic candidates individually and in combination
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
other products and product candidates, and our ability to form partnerships in the future in support of our overall oncology strategy. Forward-looking statements in this release involve
substantial risks and uncertainties that could cause our research and pre-clinical development programs, clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among others. the uncertainties inherent in the research and development of therapeutic antibodies, including the selection, pre-clinical testing and manufacturing of antibodies,
initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of our drug candidates. TESARO undertakes no
obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to
the business of the Company in general, see TESARO&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2013, and Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2014. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>### </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 10.12 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="62%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">[*]</TD>
<TD ALIGN="left" VALIGN="top">Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Between </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYS
BIOSCIENCES, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(ANAPTYS) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDICAL RESEARCH
COUNCIL </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(MRC) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Exclusive License Agreement (&#147;Agreement&#148;), is entered into as of the 30th day of August 2006 (hereinafter called
&#147;Effective Date&#148;), by and between the MEDICAL RESEARCH COUNCIL (&#147;MRC&#148;), a UK government funded non-departmental body with principal offices at, 20 Park Crescent, London, W1B 1AL, United Kingdom and ANAPTYS BIOSCIENCES,
INCORPORATED (&#147;ANAPTYS&#148;), a corporation organized under the laws of Delaware and having a principal place of business at 10931 North Torrey Pines Road, Suite 101, La Jolla, California 92037, United States of America. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
MRC is the owner of certain Patent Rights (as defined below); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the MRC is willing to grant a royalty bearing, exclusive license
to the Patent Rights to ANAPTYS on the terms and subject to the conditions set forth herein; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, ANAPTYS desires to obtain said
exclusive license under the Patent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for and in consideration of the premises and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto hereby expressly agree as set forth below. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DEFINITIONS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>1.1 &#147;<B>Affiliates</B>&#148; means any corporation,
partnership, joint venture or other entity of which more than fifty percent (50%)&nbsp;of the voting stock or other equity ownership thereof is owned or controlled by, or under common control with ANAPTYS, or which owns or controls more than fifty
percent (50%)&nbsp;of the voting stock or other equity ownership of ANAPTYS.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>1.2 &#147;<B>Confidential
Information</B>&#148; means any confidential information of a Party relating to any use, process, method, compound, research project, work in process, future development, scientific, engineering, manufacturing, marketing, business plan, financial or
personnel matter relating to the disclosing Party, its present or future products, sales, suppliers, customers, employees, investors or business, whether in oral, written, graphic or electronic form, which is marked confidential or designated by the
disclosing party as being confidential prior to disclosure or which is marked confidential and provided to the other Party within thirty (30)&nbsp;days of such oral disclosure.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>1.3 &#147;<B>Control</B>&#148; means possession of the ability to grant a license or sublicense as provided for herein without
violating the terms of any agreement or other arrangement with any third party.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>1.4 &#147;<B>Covered</B>&#148;,
&#147;<B>Cover</B>&#148; or &#147;<B>Covering</B>&#148; means with respect to Patent Rights, that the making, using, importation, offer for sale, or sale, or the conducting of an activity, in the absence of a license under such Patent Rights would
infringe at least one claim of such Patent Rights.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 &#147;<B>Developing Countries</B>&#148; shall mean those countries as may
be defined from time to time as low income or low middle income by the World Bank &#150; see <U>www.worldbank.org/data/countryclass/class groups.htm</U> at the time of the case by case analysis under Section&nbsp;2.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6 &#147;<B>FDA</B>&#148; means the United States Food and Drug Administration and any equivalent agency thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7 &#147;<B>Field</B>&#148; means all fields of use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>1.8 &#147;<B>First Commercial Sale</B>&#148; means, with respect to any Product, the first sale of such Product by ANAPTYS, its
Affiliates or Sublicenses to customers who are not Affiliates in any country after all applicable marketing and pricing approvals (if any) have been granted by the applicable governing health authority of such country.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>1.9 &#147;<B>First Commercial Service Activity</B>&#148; means, with respect to any Licensed Method, the date first payment is received
by ANAPTYS, its Affiliates or Sublicensees for completion of services provided to customers using Licensed Methods.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10
&#147;<B>IND</B>&#148; means an Investigational New Drug Application or equivalent application filed to commence human clinical testing of a Licensed Product with the FDA or its foreign equivalent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>1.11 &#147;<B>Licensed Product(s)</B>&#148; means a composition, product or device, the
manufacture, use, sale, offer for sale or import of which, but for the License, would infringe any Patent Rights in any country were they issued at the time of such manufacture, use, sale, offer for sale or import in that country or a product that
is identified and / or developed through the use of methods Covered by Licensed Methods.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>1.12 &#147;<B>Licensed
Method(s)</B>&#148; means any process, art or method the use or practice of which, but for the License, would infringe, induce to infringe or contribute to infringement of, any Patent Rights in any country were they issued at the time of the
infringing activity in that country.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>1.13 &#147;<B>Materials</B>&#148; means relevant cell lines and other materials
relating to or necessary to enable ANAPTYS to use the Licensed Products and implement the Licensed Methods at their facilities as specified in Exhibit C attached hereto and to which MRC has the right to transfer.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.14 &#147;<B>MRC Specific Method[s]</B>&#148; means [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.15 &#147;<B>NDA</B>&#148; means a New Drug Application, Biological License Application, or Product License Application, as appropriate,
filed pursuant to the requirements of the FDA or its foreign equivalent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.16 &#147;<B>Net Sales</B>&#148; means, with respect to any
Licensed Product, [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[*] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">&#147;<B>Net Sales</B>&#148; means, with respect to any Licensed Method, [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.17 &#147;<B>Parties</B>&#148; means ANAPTYS and the MRC, each of which, individually, is a &#147;Party.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>1.18 &#147;<B>Patent Rights</B>&#148; means: (a)&nbsp;the patent applications listed in Exhibit&nbsp;A attached hereto, (b)&nbsp;any
corresponding foreign patents and patent applications, (c)&nbsp;any provisionals, substitutions, divisionals, reissues, continuations, continuations-in-part (but only to the extent the claims thereof are enabled by disclosure of the parent
application), and (d)&nbsp;any patents issuing from any of the foregoing patent applications.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>1.19 &#147;<B>Phase II
Clinical Trial</B>&#148; shall mean a human clinical trial in any country that is intended to initially evaluate the effectiveness of a product for a particular indication or indications in patients with the disease or indication under study, or
that would otherwise satisfy requirements of 21&nbsp;CFR 312.21(b), or its foreign equivalent.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.20 &#147;<B>Phase III Clinical
Trial</B>&#148; means that portion of the clinical development program which provides for the continued trials of a Licensed Product on sufficient numbers of patients to establish its safety and efficacy for the desired claims and indications, as
more specifically defined by the rules of the FDA or its equivalent and corresponding rules and regulations in other countries and jurisdictions, and the results of which are intended to be used as the basis for the filing of an NDA or equivalent
application to obtain approval to market Licensed Products. For the purposes of this Agreement, &#147;initiation of Phase&nbsp;3 Trial&#148; for a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">-3-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Licensed Product means the first dosing of such Licensed Product in a human patient in a Phase&nbsp;3 Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>1.21 &#147;<B>Sublicensee</B>&#148; means any third party licensed by licensee to make, or sell any Licensed Product or use any
Licensed Methods in accordance with the terms of this Agreement.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.22 &#147;<B>Territory</B>&#148; means all countries of the
world where Patent Rights exist. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.23 &#147;<B>Third Party</B>&#148; shall mean any person other than ANAPTYS and MRC and their
respective Affiliates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>GRANT </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>2.1 <B>License.</B> MRC hereby grants ANAPTYS an exclusive,
royalty-bearing license, including the right to grant sublicenses, under the Patent Rights to make, have made, use, sell, have sold, offer for sale and import Licensed Products and to practice Licensed Methods in the Territory (the
&#147;License&#148;).<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>2.2 <B>Technology Transfer. </B>Within fifteen (15)&nbsp;calendar days after the Effective Date, MRC
will transfer sufficient quantities of relevant cell lines and other Materials listed on Exhibit&nbsp;C (attached hereto) relating to or necessary to enable Anaptys to use the Licensed Products and implement the Licensed Methods at their
facilities.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>2.3 <B>Retention of Rights.</B> MRC retains the right under the Patent Rights to use the Licensed Methods
solely for academic research including with academic collaborators. Provided however, that the any such use is:<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) not supported
by a commercial entity or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) not in support of any commercial activity and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) MRC or its academic collaborators shall disclose to ANAPTYS&#146; all protein products directly generated using the Licensed Methods. MRC,
and where appropriate its academic collaborators (if any), and ANAPTYS shall jointly determine whether or not to commercialize each such identified protein product on a case-by-case basis. Notwithstanding such decision, ANAPTYS shall have the first
right of refusal to negotiate an exclusive license to commercialize the identified protein products. ANAPTYS shall have one hundred and eighty (180)&nbsp;days after the disclosure of each identified protein product to ANAPTYS to exercise its option
and to begin good faith negotiations. If ANAPTYS does not notify MRC, in writing, of its intention to enter into such discussions before such one hundred and eighty (180)&nbsp;day period has expired, MRC and/or its academic collaborators may proceed
to commercialize the corresponding identified protein product. To avoid doubt, apart from any delay that may be reasonably required to obtain appropriate intellectual property protection with respect to the results arising from the research
conducted under this Section&nbsp;2.3, any decision to commercialize and/or license an identified protein product shall not prevent or delay the timely publication of such results by the MRC and/or their academic collaborators. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>2.4 <B>Limited use of antibodies for HIV Project by Global HIV Vaccine Enterprise.
</B>Notwithstanding the above, ANAPTYS hereby agrees that, in support of and pursuant to MRC&#146;s participation in the collaborative HIV project funded by the Bill and Melinda Gates Foundation, and subject to prior notification to ANAPTYS by the
MRC, the MRC may grant certain and limited rights solely to the use of the Licensed Methods for future development of HIV antigen-based vaccines. Unless otherwise agreed to by the Parties, these rights will be strictly limited to the use of
antibodies generated by MRC or other members of said HIV project consortium, to identify HIV epitopes which will then be used to develop and/or use, but not be incorporated into, as said HIV vaccines. For clarification, any rights granted hereunder
or in any subsequent agreement contemplated below will not extend to any other use of the antibodies generated through this program, including but not limited to use as a vaccine or use as a therapeutic or prophylactic agent. ANAPTYS recognises that
the Bill and Melinda Gates Foundation is providing said funding in furtherance of their charitable objective to ensure access to affordable health solutions resulting from said project for the benefit of people most in need within Developing
Countries. Therefore, in recognition of such charitable objective, ANAPTYS agrees that the rights to such anti-HIV antibodies, solely for the limited purpose of identifying epitopes for HIV vaccines and as reasonably needed to use such epitope(s) as
vaccine(s), will be granted free of consideration where such vaccines are for use in people most in need within Developing Countries. If necessary to ensure development of vaccines for such use in Developing Countries, with ANAPTYS&#146; prior
written consent on a case-by-case basis, such rights may be extended on royalty free or minimal royalty basis where it is necessary for such vaccines to be made in other than Developing Countries for eventual use in Developing Countries. To avoid
doubt, ANAPTYS shall be free to set other terms and conditions in respect of such rights, provided such terms and conditions are consistent with achieving said charitable objective. Any request made to the MRC to use such HIV antibodies for the
development and/or use of said HIV vaccines outside of said HIV Project shall be referred to ANAPTYS. To avoid doubt, the MRC shall not be involved in negotiations between ANAPTYS and any third party wishing to use such anti-HIV antibodies for any
purpose related to, but outside of, the collaborative HIV project. Notwithstanding the above, no rights are extended or reserved for the use of any antibodies, as quid pro quo or otherwise, for any developer to make vaccines available without
ANAPTYS&#146; prior written approval on a case-by-case basis.<B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DEVELOPMENT EFFORTS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>3.1 <B>Diligence. </B>ANAPTYS will work to identify,
research and/or develop Licensed Methods and Licensed Products for purposes of commercializing such products and methods at least as diligently as ANAPTYS researches and/or develops its products and methods of similar probability of technical
success, market / commercial potential and stages of development. Failure by the ANAPTYS to meets its diligence obligation above due to reasons beyond ANAPTYS&#146; control, (including, without limitation, force majeure and/or lack of technical
success of Licensed Products, or Licensed Methods if applicable) will not constitute lack of due diligence for purposes of this Agreement (&#147;Commercially Reasonable Efforts&#148;).<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>3.2 <B>Reporting. </B>Within sixty (60)&nbsp;days following the first anniversary of the Effective Date, ANAPTYS will provide MRC with
annual progress reports which will include a budget and a summary plan for the development of Licensed Products and/or Licensed Methods.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>3.3 <B>Milestones. </B>ANAPTYS will obtain financing of at least $[*] by [*]. ANAPTYS will
enter into at least [*] with another entity by [*].<B> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PAYMENTS AND REPORTS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>4.1 <B>License Issue Fee.</B> Within [*] days following
the Effective Date, ANAPTYS will issue to MRC [*] shares of common ANAPTYS stock, and will pay to MRC $[*] as a one time License Issue Fee.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <B>License Maintenance Fee.</B> Following the [*] anniversary of the Effective Date and thereafter on the anniversary of the Effective
Date and until the First Commercial Sale of Licensed Products, ANAPTYS will pay MRC an annual License Maintenance fee of $[*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3
<B>Royalties.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) ANAPTYS will pay MRC royalties as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <B>Licensed Methods</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">[*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <B>Licensed
Products</B> for therapeutic or prophylactic uses in humans or animals </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">[*] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <B>Licensed Products</B> for non-therapeutic uses: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">[*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) All royalties payable
under this Section&nbsp;4.3 shall be subject to the following conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) No multiple royalties shall be owed because the use or
sale of any Licensed Product or Licensed Methods is covered by more than one valid and unexpired claim contained in the Patent Rights. For clarification, royalties shall only be owed either for a Licensed Product or Licensed Method and solely based
upon one of the following sections: 4.3(a)(i) or 4.3(a)(ii) or 4.3(a)(iii) above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If ANAPTYS, its affiliate or its Sublicensee is
required to obtain a license or patent rights from one or more independent third parties in order to make, have made, use, have used, sell, have sold, offer for sale, import or have imported Licensed Products or Licensed Methods without infringement
of such patents, and if the total royalty burden (including royalties payable to MRC) for such Licensed Products or Licensed Methods exceeds, [*], then the royalty rate applicable to Net Sales of such Licensed Product or Licensed Method by ANAPTYS,
its affiliates and its Sublicensees payable to MRC shall be adjusted as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">-6-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(1) For Licensed Products for therapeutic or prophylactic uses in humans or animals, the royalty
rate applicable to Net Sales of such Licensed Product shall be adjusted to the rate determined by [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(2) For Licensed Products for
non-therapeutic uses, the royalty rate applicable to Net Sales of such Licensed Product shall be adjusted to the rate determined by [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(3) For Licensed Methods, the royalty rate applicable to Net Sales of such Licensed Method for the first [*] years following the First
Commercial Service Activity shall be adjusted to the rate determined by [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(4) For Licensed Methods, the royalty rate applicable to
Net Sales of such Licensed Method after the end of the [*] year of First Commercial Service Activity as below shall be adjusted to the rate determined by [*]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that (i)&nbsp;in the case of any royalty due on services using Licensed Methods [*], and (ii)&nbsp;any royalty due on services using Licensed
Methods, [*]. In no event, however, shall the royalty rate payable to MRC for any Licensed Product, or Licensed Method be reduced by greater than [*]% of the royalty rate otherwise due to the MRC under this provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) In the case of any combination product, Net Sales for such Combination Product shall be calculated by multiplying actual Net Sales of
such combination product by the fraction A/(A+B) where A is the invoice price of the Licensed Product if sold separately, and B is the total invoice price of the other active ingredient or ingredients in the combination product, if sold separately.
If neither the Licensed Product nor the other active ingredient(s) are sold separately, the Parties shall determine Net Sales for such combination product by mutual agreement based on the relative contribution of the Licensed Product and each other
active ingredient to the combination product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) In the event that any patent or claim thereof included within the Patent Rights is
held invalid in a final decision by a court of competent jurisdiction and last resort and from which no appeal has or can be taken, or has been pending for more than [*] years without issuance, then all obligation to pay royalties based on that
patent or claim or any claim patentably indistinct there from will cease as of the date of final decision or [*] year anniversary. ANAPTYS will not, however, be relieved from paying any royalties that accrued before such final decision or
anniversary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <B>Minimum Annual Royalties</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) On the [*] anniversary of the First Commercial Sale of Licensed Products, and annually thereafter, ANAPTYS shall pay $[*] to the MRC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) All minimum annual royalty payments shall be creditable against future royalties due to MRC as follows: where actual royalty owed is less
than $[*], then the difference ($[*] minus the actual amount owed) may be credited against any future royalty payments owed in excess of the minimum royalty in any one year for a period of [*] years. That is, such amount </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">-7-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may not be credited against minimum royalty payments such that the minimum royalty payment of $[*] will be payable for any year actual royalties are less than $[*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 <B>Milestone Payments.</B> ANAPTYS will pay to MRC the following milestone payments on Licensed Products upon achievement of the
milestones by the ANAPTYS, its affiliates, or their respective Sublicensees. Each of the milestone payments below shall be payable one time per Licensed Product that achieves any such milestone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) $[*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) $[*] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) $[*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) $[*] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) $[*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) $[*] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>4.6 <B>Sublicense Fee. </B>ANAPTYS will initially pay to MRC a sub-licensing fee of $[*] upon execution of a sub-license to another
party of the Patent Rights under this Agreement for any sub-license executed prior to [*]. Subsequent to [*] the sub-licensing fee payable upon execution of a sub-license to another party of the Patent Rights under this Agreement will be $[*].<B>
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PAYMENTS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 Payment of the royalties and other payments specified in Section&nbsp;4,
will be made by ANAPTYS to the MRC within [*] days after [*] of each year during the term of this Agreement (&#147;Payment Period&#148;) covering the quantity of Licensed Products sold by ANAPTYS, its Affiliates and/or Sublicensees, as appropriate,
during the preceding Payment Period or Licensed Methods. After termination or expiration of this Agreement, a final payment will be made by ANAPTYS covering the whole or partial Payment Period. Each annual payment will be accompanied by a written
statement of Net Sales of Licensed Products by ANAPTYS, its Affiliates and/or Sublicensees, as appropriate. Such written statements will be duly signed by an authorized officer of ANAPTYS on behalf of ANAPTYS and will show the Net Sales of Licensed
Products by ANAPTYS, its Affiliates and/or Sublicensees, as appropriate, during such Payment Period and the amount of royalties payable under this Agreement based thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 Such amount shall be determined from the books and records of ANAPTYS, maintained in accordance with U.S. Generally Accepted Accounting
Principles. ANAPTYS shall be entitled to deduct the amount of any withholding taxes, value-added taxes or other taxes, levies or charges with respect to such amounts, other than United States taxes, payable by ANAPTYS, or any taxes required to be
withheld by ANAPTYS, to the extent ANAPTYS pays to the appropriate governmental authority on behalf of MRC such taxes, levies or charges. ANAPTYS shall use reasonable efforts to minimize any such taxes, levies or charges required to be withheld on
behalf of MRC by ANAPTYS. ANAPTYS promptly shall deliver to MRC proof </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">-8-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of payment of all such taxes, levies and other charges, together with copies of all communications from or with such governmental authority with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>5.3 <B>Form of Payment. </B>All payments due hereunder are expressed in and will be paid by wire transfer or check payable in United
States Dollars, without deduction of exchange, collection or other charges, to the MRC, or to the account of the MRC at such other bank as the MRC may from time to time designate by written notice to ANAPTYS.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <B>Exchange Rate.</B> With respect to each quarter, for countries other than the United States, whenever conversion of payments from any
foreign currency is required, such conversion will be made at the rate of exchange reported in <U>The Wall Street Journal</U> on the last business day of the applicable calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <B>Records and Inspection.</B> ANAPTYS will maintain or cause to be maintained a true and correct set of records pertaining to the Net
Sales of Licensed Products and Licensed Methods by ANAPTYS. During the term of this Agreement and for a period of [*] years thereafter, ANAPTYS agrees to permit an independent certified public accountant selected and paid by the MRC and reasonably
accepted to ANAPTYS to have reasonable access during ordinary business hours to such records as are maintained by ANAPTYS as may be necessary, in the opinion of such accountant, to determine the correctness of any report and/or payment made under
this Agreement. Such audits may be exercised no more than once in any [*] month period upon at least [*] days prior written notice to ANAPTYS. Should an audit show that payments are [*] percent ([*]%) or more below that reported then ANAPTYS shall
reimburse MRC for reasonable direct costs of the audit reimbursed to the auditor. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>PATENTS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>6.1 <B>Prior Patent Costs.</B> ANAPTYS will reimburse MRC for all past
patent costs (prior to the Effective Date); <B></B><I>provided, however,</I><B></B> that reimbursement for costs incurred prior to the Effective Date shall be payable in installments of $[*] a year, the first payment being due within [*] days of
signing, and the subsequent payments being made on each anniversary of the Effective Date over the first [*] years of the license granted under this Agreement, with any outstanding balance paid on the [*] anniversary of the Effective Date. ANAPTYS
will also pay all future patent costs incurred from and after the Effective Date for the prosecution and maintenance of the Patent Rights (to the extent such costs have not been previously reimbursed).<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <B>Patent Prosecution.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Within a reasonably practical time following the Effective Date, but in no event not longer than sixty (60)&nbsp;days after such date
(&#147;Prosecution Transfer Period&#148;), ANAPTYS shall at its own expense be solely responsible for maintaining and prosecuting the Patent Rights including for the avoidance of doubt all annuity and renewal fees and for the conduct of any claims
or proceedings relating to the Patent Rights including any interference, opposition, infringement or revocation proceedings. ANAPTYS shall have sole responsibility for the appointment or otherwise of a patent agent and in deciding upon the scope and
geographical extent to which any patent may be filed after written agreement from MRC. During the Prosecution Transfer Period, MRC will be solely responsible for (i)&nbsp;making all payments and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">-9-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maintaining all prosecution such that there are no losses of Patent Rights, (ii)&nbsp;timely transfer all files related to the Patent Rights, and (iii)&nbsp;timely file all documents necessary to
affect the transfer to ANAPTYS and enable ANAPTYS to assume its responsibilities under this Section&nbsp;6.2. For avoidance of doubt, ANAPTYS will pay all costs incurred by MRC during the Prosecution Transfer Period for the prosecution and
maintenance of the Patent Rights (to the extent such costs have not been previously reimbursed). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) Should ANAPTYS decide that it does
not wish to prosecute, maintain or defend the Patent Rights or any part thereof it shall give MRC not less than sixty (60)&nbsp;days notice of that decision before any critical time period and thereafter MRC may in its sole discretion and at its own
costs and expense prosecute, maintain or defend the Patent Rights or any part thereof. If MRC so decides to prosecute, maintain or defend the Patent Rights or any part thereof ANAPTYS shall promptly arrange for its patent attorneys to transfer to
MRC all relevant papers, files and other documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) ANAPTYS agrees to keep MRC informed on major or key prosecution issues of the
Patent Rights and arrange for MRC to be sent copies of any patent correspondence upon request of MRC. Any action relating to the prosecution of the continuing applications must be notified to MRC at least thirty (30)&nbsp;days (or the maximum
possible if at least thirty 30 days notice are not available to ANAPTYS) prior to any submission to any patent office for MRC&#146;s review. In the event that MRC has a concern regarding the submission, the Parties will discuss to mutually resolve
any potential conflict or material impact to the parent patent applications in the Patent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <B>Patent Enforcement.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) Each of MRC and ANAPTYS shall as soon as practicable after it becomes aware thereof give to the other in writing reasonable particulars of
any use or proposed use or threat of the same by another person in any country which in that Party&#146;s view amounts to or might amount to an infringement of the Patent Rights in such country. ANAPTYS shall at its own expense and with legal
counsel of its own choice, bring suit (or take other appropriate legal action) against any actual, alleged or threatened infringement of the Patent Rights. MRC will cooperate with ANAPTYS and name ANAPTYS as a party if required for ANAPTYS to bring
the suit. MRC shall cooperate fully with ANAPTYS and shall endeavor to cause the appropriate MRC scientists to cooperate with ANAPTYS at the request of ANAPTYS, including by giving testimony and producing documents lawfully requested in the
prosecution of any suit by ANAPTYS for infringement of the MRC Patents; provided, that ANAPTYS shall pay all reasonable expenses (including attorneys&#146; fees) incurred by MRC in connection with such cooperation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) If ANAPTYS does not wish to undertake such action MRC shall have the right (but not the obligation) to undertake proceedings at its own
expense and with legal counsel of its own choice. Any damages, monetary awards or other amount recovered, whether by judgment or settlement, pursuant to any suit, proceeding or other legal action taken under this section shall be to the account of
the Party bringing and prosecuting the same. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONFIDENTIALITY </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>7.1 <B>Treatment of Confidential Information.</B> During the
term of this Agreement, and for a period of five (5)&nbsp;years after this Agreement expires or terminates, a Party receiving Confidential Information of the other Party will (i)&nbsp;maintain in confidence such Confidential Information to the same
extent such receiving Party maintains its own proprietary information (but at a minimum each Party shall use reasonable efforts); (ii)&nbsp;not disclose such Confidential Information to any Third Party without prior written consent of the other
Party; and (iii)&nbsp;not use such Confidential Information for any purpose except those permitted by this Agreement. A Party shall have no such obligation with respect to any portion of such Confidential Information which:<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) is publicly disclosed by the disclosing Party, or is otherwise publicly disclosed without the fault of the receiving Party, either before
or after it becomes known to the receiving Party; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) was known to the receiving Party prior to when it was received from the
disclosing Party, as evidence by contemporaneous written records; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) is subsequently disclosed to the receiving Party in good faith
by a Third Party who has a right to make such a disclosure; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) has been published by a third party which had a right to do so; or
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) has been independently developed by the receiving Party without the aid, application or use of Confidential Information from the
disclosing Party; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) is required by law to be disclosed, but then only to the limited extent of such legally required disclosure;
provided, however, that the other Party shall be given prompt notice of any such legally required disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>7.2
<B>Publicity.</B> Any publication, news release or other public announcement that discloses or refers to this Agreement or to the performance thereof, shall first be reviewed and approved by both Parties, which approval shall not be unreasonably
withheld. Either Party shall be entitled to disclose the substance of this Agreement to its shareholders, potential investors, sublicensees, or research collaboration partners (and to prospective shareholders to whom its stock is offered for
purchase) under a confidentiality agreement consistent with this Agreement. Each Party shall also be entitled to provide a copy of this Agreement to the Securities and Exchange Commission (if required).<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>7.3 <B>Terms of this Agreement.</B> Except as otherwise provided in Section&nbsp;7.1 above, neither Party shall disclose any terms or
conditions of this Agreement to any Third Party without the prior written consent of the other Party. Notwithstanding the foregoing, prior to execution of this Agreement, the Parties shall agree upon the substance of information that can be used to
describe the terms of this transaction, and each Party may disclose such information, s modified by mutual agreement from time to time, without the other Party&#146;s consent.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>TERM AND TERMINATION </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>8.1 <B>Term.</B> Unless earlier terminated as hereinafter
provided, this Agreement shall expire upon the later of (i)&nbsp;ten (10)&nbsp;years from the First Commercial Sale of a Licensed Product by ANAPTYS, or First Commercial Service Activity or (ii)&nbsp;the expiration of the last to expire patent
within the Patent Rights.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 <B>Termination.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) ANAPTYS may terminate this Agreement for any reason following sixty (60)&nbsp;day written notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) A Party may terminate this Agreement upon or after the breach of any material provision of this Agreement by the other Party, if the
breaching Party has not cured such breach within sixty (60)&nbsp;days after notice thereof from the other Party; provided, however, that if the breach is due to ANAPTYS&#146; failure to pay under Section&nbsp;4 or complete a milestone in
Section&nbsp;3.3, MRC shall provide an additional notice of failure to pay or meet milestone and allow ANAPTYS a second sixty (60)&nbsp;day period to cure such breach. If ANAPTYS fails to cure such breach during the second sixty (60)&nbsp;day
period, MRC shall provide a third and final notice of failure to pay and allow ANAPTYS a third and final sixty (60)&nbsp;day period to cure such breach prior to any termination hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>8.3 <B>Default for Bankruptcy.</B> Each Party will have the right, at its option, to terminate this Agreement in the event that the
other Party (i)&nbsp;shall file in court or agency pursuant to any applicable state or federal petition in bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation) or if such Party is served with an
involuntary petition in bankruptcy, or (ii)&nbsp;makes an assignment of all or substantially all of its assets for the benefit of creditors, or (iii)&nbsp;in the event that a receiver or trustee is appointed for the other Party and such Party will,
after the expiration of thirty (30)&nbsp;days following any of the events enumerated above, be unable to secure a dismissal, stay or other suspension of such proceedings.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4 In the event of termination of this Agreement, all Patent Rights licensed to ANAPTYS will revert to the MRC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>8.5 <B>Survival of Certain Sublicenses.</B> Sublicenses granted by a defaulting Party to a Third Party will survive termination of the
defaulting Party&#146;s license under Section&nbsp;8.1(b), provided however, that (i)&nbsp;such Third Party is not the cause of the default, (ii)&nbsp;such Third Party is not in breach of, and continues to fully perform all obligations under its
sublicense agreement and any surviving provisions in this Agreement applicable to such sublicensee and (iii)&nbsp;the terminating Party continues to receive from such Third Party all royalty payments set forth in Section 4.3.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.6 <B>Survival.</B> Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such
expiration or termination. No termination or expiration of this Agreement will constitute a termination or a waiver of any rights of either Party against the other Party accruing at or prior to the time of such termination. The obligations
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and rights of the Parties under Sections 5.5, 7, 8.5, 13, and 15 shall survive termination or expiration of this Agreement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INDEMNITY </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1 ANAPTYS hereby agrees to indemnify and hold harmless the MRC and its
directors, officers, researchers, scientists, employees and agents (collectively, the &#147;MRC Indemnities&#148;) from and against any losses, claims, damages, costs, and expenses (collectively, &#147;Losses&#148;) incurred in connection with or
arising from (i)&nbsp;any product liability or similar claim asserted by any party as to any Licensed Products; (ii)&nbsp;any claims arising from ANAPTYS&#146; or ANAPTYS&#146; Sublicensee&#146;s use of any Licensed Methods; (iii)&nbsp;any claims
for death, personal injury or related property damage arising from the manufacture, sale, marketing, distribution or use of any Licensed Products; but excluding Losses arising from or relating to the breach of this Agreement by the MRC or the gross
negligence or willful misconduct of the MRC Indemnities. Without limiting the generality of the foregoing, such indemnity obligation shall apply to any product liability or other claims, including without limitation, personal injury, death or
property damage, made by employees, subcontractors, or agents of ANAPTYS, as well as by any customer, patient, hospital, doctor, or member of the general public who buys or uses a Licensed Product. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>REPRESENTATIONS AND WARRANTIES </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>10.1 <B>Due Authorization.</B> Each Party hereby
represents and warrants that such Party is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>10.2 <B>Binding Obligation.</B> Each Party hereby represents and warrants that this Agreement is a legal and valid obligation binding
upon it and is enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by such Party does not conflict with any agreement, instrument, or understanding, oral or written, to which it is a party or by which
it may be bound, nor violate any law or regulation or any court, government body or administrative or other agency having authority over it.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>10.3 <B>Consents.</B> Each Party hereby represents all necessary consents, approvals and authorizations of all governmental authorities
and other persons required to be obtained by such Party in connection with this Agreement have been obtained.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>10.4 <B>No
Conflict.</B> Each Party hereby represents the execution and delivery of this Agreement and the performance of such Party&#146;s obligations hereunder (a)&nbsp;do not conflict with or violate any requirement of applicable laws or regulations and
(b)&nbsp;do not conflict with, or constitute a default under, any contractual obligation of such Party.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>10.5
<B>Disclosure.</B> MRC represents that it has provided ANAPTYS with all documents and information under its custody or control regarding the Patent Rights necessary for ANAPTYS to determine the scope, ownership, validity and enforcement of the
Patent Rights. MRC further represents that the Patent Rights include all rights owned or controlled by MRC that are necessary for ANAPTYS to commercialize Licensed Products and Licensed Methods.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DISCLAIMER OF WARRANTIES </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THE MRC
MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE OR MERCHANTABILITY, REGARDING OR WITH RESPECT TO THE LICENSED METHODS OR LICENSED PRODUCTS. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LIMITATION OF LIABILITY </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NEITHER PARTY WILL BE ENTITLED TO RECOVER FROM THE OTHER PARTY
ANY SPECIAL, INCIDENTAL, EXEMPLARY, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ASSIGNABILITY </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1 Except as provided in Section&nbsp;13.2 below, ANAPTYS may assign
this Agreement to another entity only with the prior written consent of the MRC, which consent shall not be unreasonably withheld or delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.2 Notwithstanding anything herein to the contrary, in the event ANAPTYS merges with another entity or is acquired by another entity,
ANAPTYS may assign its rights and obligations hereunder to the surviving entity without the MRC&#146;s consent so long as ANAPTYS is not then in material breach of this Agreement and ANAPTYS provides written notice of the assignment to the MRC, at
least fifteen (15)&nbsp;days prior to the effective date of the assignment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>GOVERNMENTAL COMPLIANCE </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>14.1 <B>Compliance with Laws.</B> ANAPTYS will at all
times during the term of this Agreement and for so long as it sells imports, exports, manufactures, uses, distributes, markets or otherwise commercially exploits Licensed Products comply with all laws that control the import, export, manufacture,
use, sale, marketing, distribution and other commercial exploitation of Licensed Products or any other activity undertaken pursuant to this Agreement.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>14.2 <B>Governmental Approval or Registration.</B> If this Agreement or any associated transaction is required by the law of any nation
to be either approved or registered with any governmental agency, ANAPTYS shall assume all legal obligations to do so. ANAPTYS shall notify the MRC if it becomes aware that this Agreement is subject to a United States of America or other government
reporting or approval requirement. ANAPTYS shall make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated with such reporting or approval process.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>GOVERNING LAW </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.1 <B>Law.</B> This Agreement will be governed by, and will be
construed and enforced in accordance with, the laws of England. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.2 <B>Jurisdiction.</B> This Agreement is performable in part in San
Diego County, California, and the Parties mutually agree that personal jurisdiction and venue will be proper in the state and federal courts situated in San Diego County, California, and hereby consent to such exclusive jurisdiction and venue. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>NOTICES </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any payment, notice or other communication pursuant to this Agreement will be
mailed by first class, certified or registered mail, postage prepaid, or delivered by overnight delivery service addressed as follows or to such other address designated by written notice given to the other Party: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of the MRC: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Graham
Wagner </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Associate Director, Licensing and Agreements </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medical Research Council Technology </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20 Park Crescent </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">London, W1B 1AL
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">United Kingdom </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case
of ANAPTYS: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">William James Boyle </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">President and Chief Science Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANAPTYS Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10931
North Torrey Pines Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">La Jolla, CA 92037 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any such payment, notice or other communication will be effective upon receipt. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>GENERAL PROVISIONS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>17.1 <B>Independent Contractors.</B> The Parties hereby
acknowledge and agree that each is an independent contractor and that neither Party will be considered to be the agent, representative, master or servant of the other Party for any purpose whatsoever, and that neither Party has any authority to
enter into a contract, to assume any obligation or to give warranties or representations on behalf of the other Party without the prior written consent of the other Party. Nothing in this relationship will be construed to create a joint venture,
agency, partnership, fiduciary or other similar relationship between the Parties.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.2 <B>Non-Waiver.</B> The Parties covenant and
agree that if a Party fails or neglects for any reason to take advantage of any of the terms provided for the termination of this Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or if a Party, having the right to declare this Agreement terminated, will fail to do so, any such failure or neglect by such Party will not be a waiver or be deemed or be construed to be a
waiver of any cause for the termination of this Agreement subsequently arising, or as a waiver of any of the terms, covenants or conditions of this Agreement or of the performance thereof. None of the terms, covenants and conditions of this
Agreement may be waived by a Party except by its written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>17.3 <B>Reformation.</B> Any provision of this Agreement which
is prohibited or unenforceable in any jurisdiction will, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability
will not invalidate or render unenforceable such provision in any other jurisdiction. Should any provision of this Agreement be so held to be unenforceable, such provision, if permitted by law, will be considered to have been superseded by a legally
permissible and enforceable clause which corresponds most closely to the intent of the Parties as evidenced by the provision held to be unenforceable.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>17.4 <B>Force Majeure.</B> Except for the payment of any amounts due under this Agreement, no liability hereunder will result to a
Party by reason of delay in performance caused by force majeure, that is circumstances beyond the reasonable control of the Party, including, without limitation, acts of God, fire, flood, war, civil unrest, labor unrest, or shortage of or inability
to obtain material as equipment.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>17.5 <B>Entire Agreement.</B> The terms and conditions herein constitute the entire
agreement between the Parties and will supersede all previous agreements, either oral or written, between the Parties hereto with respect to the subject matter hereof. No agreement or understanding bearing on this Agreement will be binding upon
either Party hereto unless it is in writing and signed by the duly authorized officer or representative of each of the Parties and it expressly refers to this Agreement.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>17.6 <B>Headings.</B> The headings for each Section in this Agreement have been inserted for convenience of reference only and are not
intended to limit or expand on the meaning of the language contained in the particular Section.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>17.7 <B>Counterparts.</B>
This Agreement may be signed in two (2)&nbsp;or more counterparts, each of which will be deemed an original, but all of which together will constitute one (1)&nbsp;and the same instrument. Signatures may be transmitted by facsimile, thereby
constituting the valid signature and delivery of this Agreement.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties hereto have executed and delivered this Agreement by their duly
authorized officers and representatives effective as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>M<SMALL>EDICAL</SMALL> R<SMALL>ESEARCH</SMALL> C<SMALL>OUNCIL</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>A<SMALL>NAPTYS</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Graham L Wagner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Bill Boyle</TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Graham L Wagner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Bill Boyle</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Associate Director Licensing and Agreements</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">President</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Medical Research Council Technology</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;September 2006</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">23-Aug-2006</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE MRC / ANAPTYS LICENSE AGREEMENT] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Patent&nbsp;Rights</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[*]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[*]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">-18-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Competing Technology </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">-19-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Technology Transfer Materials </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">-20-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT TO LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> F<SMALL>IRST</SMALL> A<SMALL>MENDMENT</SMALL> <SMALL>TO</SMALL> L<SMALL>ICENSE</SMALL>
A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (the &#147;<B><I>Amendment</I></B>&#148;) is entered into and effective as of March&nbsp;31, 2008 (the &#147;<B><I>Amendment Date</I></B>&#148;) for the purpose of amending that certain License Agreement
dated August&nbsp;30, 2006 (the &#147;<B><I>Agreement</I></B>&#148;) by and between the <B>M<SMALL>EDICAL</SMALL> R<SMALL>ESEARCH</SMALL> C<SMALL>OUNCIL</SMALL></B><SMALL></SMALL>, a UK government funded non-departmental body with principal offices
at 20 Park Crescent, London, W1B 1AL, United Kingdom (the &#147;<B><I>MRC</I></B>&#148;); and <B>A<SMALL>NAPTYS</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation having a principal place of business at 10931 North
Torrey Pines Road, Suite 101, La Jolla, California 92037, United States of America (&#147;<B><I>Anaptys</I></B>&#148;). Capitalized terms used but not otherwise defined herein shall have the meanings provided in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the MRC and Anaptys agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. New Defined Terms</B>. The following terms shall have the respective meanings set forth
below for purposes of this Amendment: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>&#147;<B><I>Antibody Services</I></B>&#148; shall mean [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>&#147;<B><I>Modified Third Party Antibody</I></B>&#148; shall mean [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>&#147;<B><I>Third Party Antibody</I></B>&#148; shall mean [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>&#147;<B><I>Anaptys-Controlled Antibody</I></B>&#148; shall mean [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Amendment of &#147;Licensed Product(s)&#148; Definition</B>. Section&nbsp;1.11 of the Agreement is hereby amended and restated to read in its entirety
as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;1.11 &#147;<B>Licensed Product(s)</B>&#148; means a composition, product or device (i)&nbsp;the manufacture, use, sale,
offer for sale or import of which, but for the License, would infringe any Patent Rights in any country were they issued at the time of such manufacture, use, sale, offer for sale or import in that country or (ii)&nbsp;which is an antibody initially
discovered using Licensed Methods (whether Anaptys or a third party controls such antibody) or (iii)&nbsp;is an Anaptys-Controlled Antibody resulting from Licensed Method-based affinity maturation of antibodies initially discovered without using
Licensed Methods.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Amendment of &#147;Net Sales&#148; Definition</B>. Section&nbsp;1.16 of the Agreement is hereby amended and restated to
read in its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;1.16 &#147;<B>Net Sales</B>&#148; means, [*] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">[*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Amendment of &#147;Sublicensee&#148;
Definition</B>. Section&nbsp;1.21 of the Agreement is hereby amended and restated to read in its entirety as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>*Confidential
Treatment Requested. </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;1.21 &#147;<B>Sublicensee</B>&#148; means any Third Party to which Anaptys grants a
sublicense under the Patent Rights to make or sell any Licensed Product in the Territory or use Licensed Methods in the Territory in accordance with the terms of this Agreement.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Amendment of Section&nbsp;3.2</B>. Section&nbsp;3.2 is hereby amended and restated to read in its entirety as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;3.2 <B>Reporting</B>. Within sixty (60)&nbsp;days following the first anniversary of the Effective Date and each subsequent anniversary
thereof during the term of this Agreement, Anaptys will provide MRC with annual progress reports which will include a summary budget and a summary plan for the development of Licensed Products and/or Licensed Methods; <I>provided</I>,
<I>however</I>, that, in lieu of the summary budget specified in this clause, Anaptys may provide to MRC a written certification by an Anaptys officer that Anaptys&#146; budget for the twelve (12)&nbsp;months after such anniversary allocates at
least $[*] to the development and/or commercialization of Licensed Products and/or Licensed Methods.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Elimination of Section&nbsp;4.2</B>.
Section&nbsp;4.2 of the Agreement is hereby deleted in its entirety and shall be of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Amendment of
Section&nbsp;4.3(a)</B>. Paragraph (a)&nbsp;of Section&nbsp;4.3 is hereby amended and restated to read in its entirety as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;(a) Anaptys will pay MRC royalties as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) <B>Licensed Products &#150; Therapeutic,</B> <B><I>In Vivo</I></B> <B>Diagnostic or Prophylactic Uses</B>. For Licensed Products for
therapeutic, prophylactic and/or in vivo diagnostic uses in humans or animals, Anaptys will pay MRC: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) [*] of that
portion of annual Net Sales of Licensed Products up to $[*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) [*] of that portion of annual Net Sales of Licensed
Products from over $[*]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) [*] of that portion of annual Net Sales of Licensed Products over $[*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) <B>Licensed Products &#150; Other Uses</B>. For Licensed Products for non-therapeutic, non-prophylactic and non-in vivo diagnostic uses:
[*] of worldwide annual Net Sales of such Licensed Products for non-therapeutic, non-prophylactic and non-in vivo diagnostic uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii)
<B>Modified Third Party Antibodies; Antibody Services</B>. Notwithstanding the preceding provisions of this Section&nbsp;4.3(a) or any other provision of this Agreement to the contrary, the only amounts payable to MRC with respect to Modified Third
Party Antibodies and/or Antibody Services are those set forth in this Section&nbsp;4.3(a)(iv). Beginning </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
on the second anniversary of the Effective Date and on each anniversary thereof during the term of this Agreement, Anaptys shall pay to the MRC a flat annual fee of $[*] (each, an &#147;Annual
Fee&#148;), which shall be payable regardless of whether Anaptys actually (A)&nbsp;performs any Antibody Services during the applicable year and/or (B)&nbsp;receives any consideration with respect to any Modified Third Party Antibody or Antibody
Services during such year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, no royalties or consideration other than the Annual Fee shall be payable to the
MRC with respect to Antibody Services, or with respect to any Modified Third Party Antibody.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Amendment of Section&nbsp;4.3(b)</B>. The second
sentence of subparagraph (i)&nbsp;of paragraph (b)&nbsp;of Section&nbsp;4.3 is hereby deleted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Amendment of Section&nbsp;4.5</B>. Section&nbsp;4.5
of the Agreement is hereby amended and restated to read in its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;4.5 <B>Milestone Payments</B>. Anaptys will pay
to MRC the following non-refundable milestone payments on Licensed Products on achievement of the milestones by Anaptys, its Affiliates or their respective Sublicensees. Each of the milestone payments below shall be payable one time per Licensed
Product that achieves any such milestone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(a) $[*]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(b) $[*]; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(c) $[*]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(d) $[*]; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(e) $[*].&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Amendment of Section&nbsp;4.6</B>. Section&nbsp;4.6 of the Agreement is hereby amended and restated to read in its entirety as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;4.6 <B>Sublicense Fee</B>. Anaptys will pay to MRC a sublicense fee of $[*] for each sublicense it grants to a Sublicensee under the
Patent Rights to make or sell Licensed Products for therapeutic, prophylactic and/or in vivo diagnostic uses in humans or animals. For purposes of clarification, the foregoing sublicense fee shall be payable on a Sublicensee-by-Sublicensee basis and
shall be due within thirty (30)&nbsp;days after the grant of a sublicense to the applicable Sublicensee.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Amendment of Section&nbsp;5.1</B>.
The first sentence of Section&nbsp;5.1 is hereby amended and restated to read in its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Payment of royalties
under the applicable provisions of Section&nbsp;4.3(a) will be made by Anaptys to the MRC on an annual basis within ninety (90)&nbsp;days after the end of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
twelve-month period ending December&nbsp;31 (each, a &#147;Payment Period&#148;) covering the quantity of Licensed Products and Licensed Methods sold by Anaptys, its Affiliates and/or
Sublicensees, as appropriate, during the applicable Payment Period. Payment of any other amount due under Section&nbsp;4 will be made by Anaptys to the MRC within forty-five (45)&nbsp;days after such amount becomes due.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Amendment of Section&nbsp;6.3(a)</B>. The second sentence of paragraph (a)&nbsp;of Section&nbsp;6.3 of the Agreement is hereby amended and restated to
read in its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Anaptys shall have the first right (but not the obligation) to bring suit (or take other
appropriate legal action) against any actual, alleged or threatened infringement of the Patent Rights, at its own expense and with legal counsel of its own choice.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Amendment of Section&nbsp;7.1</B>. Paragraphs (b)&nbsp;through (f)&nbsp;of Section&nbsp;7.1 of the Agreement are hereby deleted and replaced in their
entirety with the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;(b) was known to the receiving Party (other than under an obligation of
confidentiality) prior to when it was received from the disclosing Party, as evidenced by contemporaneous written records; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) is subsequently disclosed to the receiving Party on a non-confidential basis in good faith by a Third Party who has a
right to make such a disclosure; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) has been published by a Third Party which had a right to do so; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) has been independently developed by the receiving Party without the aid, application or use of Confidential Information
from the disclosing Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, and notwithstanding the preceding provisions of this Section&nbsp;7.1, the receiving Party may,
without breaching its obligations hereunder, disclose such Confidential Information as is required by law to be disclosed, but then only to the limited extent of such legally required disclosure; provided, however, that the receiving Party shall
give prompt written notice to the disclosing Party of such legally required disclosure and, at the disclosing Party&#146;s request and expense, shall cooperate, as far as it is reasonably able to do so, with the disclosing Party&#146;s lawful
efforts to contest such required disclosure or to obtain a protective order or other confidential treatment of the information required to be disclosed.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Amendment of Section&nbsp;7.2</B>. A new sentence is hereby added to the end of Section&nbsp;7.2, reading in its entirety as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;In addition, and notwithstanding the preceding provisions of this Section&nbsp;7.2, each Party shall be free to disclose via any medium,
without the other Party&#146;s prior written consent, the existence of this Agreement, the identity of the other Party, and those terms of, or other matters relating to, this Agreement which have already been publicly disclosed with the other
Party&#146;s approval.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Amendment of Section&nbsp;8.1</B>. Section&nbsp;8.1 of the Agreement is hereby amended and restated to
read in its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;8.1 <B>Term</B>. Royalties under Section&nbsp;4.3 of the Agreement shall be payable on a Licensed
Product-by-Licensed Product or Licensed Method-by-Licensed Method and country-by-country basis in the Territory until the later of [*]. Unless earlier terminated as hereinafter provided, this Agreement shall expire upon [*].&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Amendment of Section&nbsp;8.5</B>. Section&nbsp;8.5 of the Agreement is hereby amended and restated to read in its entirety as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;8.5 <B>Survival of Certain Sublicenses</B>. Sublicenses granted by Anaptys to a Third Party will survive termination of Anaptys&#146;
license as a result of termination of this Agreement by the MRC for breach by Anaptys pursuant to Section&nbsp;8.2(b); <I>provided</I>, however, that (i)&nbsp;such Third Party is not the cause of such breach, (ii)&nbsp;such Third Party agrees in
writing to assume all applicable obligations of Anaptys under this Agreement, and (iii)&nbsp;the MRC continues to receive from such Third Party all payments under Section&nbsp;4.3 that MRC would have received from Anaptys with respect to such Third
Party&#146;s activities had this Agreement remained in effect.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Amendment of Section&nbsp;13.2</B>. Section&nbsp;13.2 of the Agreement is
hereby amended and restated to read in its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;13.2 Notwithstanding anything herein to the contrary, Anaptys may
assign this Agreement and its rights and obligations hereunder without the MRC&#146;s consent in connection with the transfer or sale of all or substantially all of Anaptys&#146; business to which this Agreement relates to a Third Party, whether by
merger, sale of stock, sale of assets or otherwise, so long as Anaptys is not in material breach of this Agreement and Anaptys provides prompt written notice of the assignment to the MRC.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Entire Agreement</B>. The Agreement, as amended by this Amendment, embodies the entire understanding of the Parties and shall supersede all previous
communications, representations and understandings, whether oral, written or otherwise, between the Parties relating to the subject matter hereof. Except as specifically amended by this Amendment, the terms and conditions of the Agreement shall
remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. Counterparts</B>. This Amendment may be executed in counterparts, each of which shall be deemed an original
document, and all of which, together with this writing, shall be deemed one instrument. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
Parties hereto have duly executed this Amendment as of the Amendment Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>M<SMALL>EDICAL</SMALL> R<SMALL>ESEARCH</SMALL> C<SMALL>OUNCIL</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>A<SMALL>NAPTYS</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Graham L Wagner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Tom Smart</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Graham L Wagner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Tom Smart</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Associate Director Licensing and Agreements</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Chairman and CEO</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Medical Research Council Technology</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDMENT TO LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> S<SMALL>ECOND</SMALL> A<SMALL>MENDMENT</SMALL> T<SMALL>O</SMALL> L<SMALL>ICENSE</SMALL>
A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (the &#147;<B><I>Amendment</I></B>&#148;) is entered into and effective as of October&nbsp;27, 2009 (the &#147;<B><I>Amendment Date</I></B>&#148;) for the purpose of amending that certain License Agreement
dated August&nbsp;30, 2006, as amended by that certain First Amendment to License Agreement dated March&nbsp;31, 2009 (collectively, the &#147;<B><I>Agreement</I></B>&#148;), by and between the <B>M<SMALL>EDICAL</SMALL> R<SMALL>ESEARCH</SMALL>
C<SMALL>OUNCIL</SMALL></B><SMALL></SMALL>, a UK government funded non-departmental body with principal offices at 20 Park Crescent, London, W1B 1AL, United Kingdom (the &#147;<B><I>MRC</I></B>&#148;); and <B>A<SMALL>NAPTYS</SMALL>B<SMALL>IO</SMALL>,
I<SMALL>NC</SMALL>.</B> (formerly known as Anaptys Biosciences, Inc.), a Delaware corporation having a principal place of business at 10835 Road to the Cure, Suite 100, San Diego, California 92121, United States of America
(&#147;<B><I>AnaptysBio</I></B>&#148;). Capitalized terms used but not otherwise defined herein shall have the meanings provided in the Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the MRC and AnaptysBio agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Patent Rights</B>. Exhibit A to the Agreement is hereby amended and restated to read
in its entirety as set forth in Appendix 1 attached to this Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Addition of New Section&nbsp;2.5</B>. A new Section&nbsp;2.5 is hereby added
to the Agreement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;2.5 Limited Use of Specified Patent Rights</B>. Notwithstanding the above, the license to use
Patent No. [*] set forth on Exhibit A (the &#147;Specified Patent Rights&#148;) shall not include [*].&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fee</B>. Within thirty (30)&nbsp;days
following the Amendment Date, AnaptysBio shall pay MRC a one-time fee of $[*]. For purposes of clarification, this fee is in addition to the amounts payable by AnaptysBio to MRC pursuant to the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Materials</B>. MRC agrees to provide AnaptysBio materials, as listed on Appendix 2 attached hereto, promptly following the Amendment Date, which shall
be included under the definition of Materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Entire Agreement</B>. The Agreement, as amended by this Amendment, embodies the entire understanding
of the Parties and shall supersede all previous communications, representations and understandings, whether oral, written or otherwise, between the Parties relating to the subject matter hereof. Except as specifically amended by this Amendment, the
terms and conditions of the Agreement shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Counterparts</B>. This Amendment may be executed in counterparts, each
of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>*Confidential
Treatment Requested. </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
Parties have caused this Amendment to be executed by their duly authorized representatives or officers as of the Amendment Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>M<SMALL>EDICAL</SMALL> R<SMALL>ESEARCH</SMALL> C<SMALL>OUNCIL</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>A<SMALL>NAPTYS</SMALL>B<SMALL>IO</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Graham L Wagner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Tom Smart</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Graham L Wagner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Tom Smart</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Associate Director Licensing and Agreements</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Chairman and CEO</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Medical Research Council Technology</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDMENT</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATEMENT</SMALL> <SMALL>OF</SMALL> E<SMALL>XHIBIT</SMALL> A <SMALL>TO</SMALL>
L<SMALL>ICENSE</SMALL> A<SMALL>GREEMENT</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Patent Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[*] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>*Confidential
Treatment Requested. </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>M<SMALL>ATERIALS</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>*Confidential
Treatment Requested. </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDMENT TO LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> T<SMALL>HIRD</SMALL> A<SMALL>MENDMENT</SMALL> T<SMALL>O</SMALL> L<SMALL>ICENSE</SMALL>
A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (the &#147;<B><I>Amendment</I></B>&#148;) is entered into and effective as of October&nbsp;7<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2010 (the &#147;<B><I>Amendment Date</I></B>&#148;) for
the purpose of amending that certain Lease Agreement dated August&nbsp;30, 2006, as amended by that certain First Amendment to License Agreement dated March&nbsp;31, 2008, and that certain Second Amendment to License Agreement dated October&nbsp;27,
2009 (collectively, the &#147;<B><I>Agreement</I></B>&#148;), by and between the <B>M<SMALL>EDICAL</SMALL> R<SMALL>ESEARCH</SMALL> C<SMALL>OUNCIL</SMALL></B><SMALL></SMALL>, a UK government funded non-departmental body with principal offices at 20
Park Crescent, London, W1B 1AL, United Kingdom (the &#147;<B><I>MRC</I></B>&#148;); and <B>A<SMALL>NAPTYS</SMALL>B<SMALL>IO</SMALL>, I<SMALL>NC</SMALL>.</B> (formerly known as Anaptys Biosciences, Inc.), a Delaware corporation having a principal
place of business at 10835 Road to the Cure, Suite 100, San Diego, California 92121, United States of America (&#147;<B><I>AnaptysBio</I></B>&#148;). Capitalized terms used but not otherwise defined herein shall have the meanings provided in the
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the MRC and AnaptysBio agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Amendment of &#147;Antibody Services&#148; Definition</B>.
The definition of &#147;Antibody services&#148; is hereby amended and restated to read in its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Antibody
Services</B>&#148; shall mean any use of Licensed Methods in the Territory to perform services on behalf of a Third Party with respect to a Third Party Molecule, including, but not limited to, services directed to discovery, generation, affinity
maturation, or modification of such Third Party Molecule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Amendment of &#147;Licensed Method(s)&#148; Definition</B>. The definition of
&#147;Licensed Method(s)&#148; is hereby amended and restated to read in its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Licensed Method(s)</B>&#148;
shall mean any process, art or method the use or practice of which is within the scope of the Patent Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Amendment of &#147;Licensed
Product(s)&#148; Definition</B>. The definition of &#147;Licensed Product(s)&#148; is hereby amended and restated to read in its entirety as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Licensed Product(s)</B>&#148; shall mean a composition, product or device that is within the scope of the Patent Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Amendment of &#147;Modified Third Party Antibody&#148; Definition</B>. The definition of &#147;Modified Third Party Antibody&#148; is hereby amended and
restated to read in its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Modified Third Party Antibody</B>&#148; shall mean an antibody, or other protein or
nucleic acid, resulting from use of Licensed methods as applied to a Third Party Molecule through the performance of Antibody Services. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Replacement of &#147;Third Party Antibody&#148; Definition</B>. The definition of &#147;Third Party
Antibody&#148; is hereby eliminated, and all references to such term in the Agreement shall be deemed to refer to the term &#147;Third Party Molecule&#148; as defined below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Third Party Molecule</B>&#148; shall mean an antibody, or other protein or nucleic acid, that: (i)&nbsp;is not an Anaptys-Controlled
Antibody (defined below); and (ii)&nbsp;is either (A)&nbsp;provided by a Third Party to Anaptys for the purpose of having Anaptys provide research and development services with respect to such molecule on a fee-for-service basis, or
(B)&nbsp;discovered or generated by Anaptys on behalf of a Third Party on a fee-for-service basis (which, in each case, may include compensation post-provision of the service); in each case, without granting the Third Party a sublicense under the
Patent Right to practice Licensed Methods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Amendment of Section&nbsp;4.3(a)(i)</B>. Section&nbsp;4.3(a)(i) shall be amended and restated to read in
its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;(i) <B>Licensed Products &#150; All Uses</B>. Royalties will be payable with respect to a Licensed Product
sold by Anaptys, its Affiliates and its Sublicensees if such Licensed Product is Covered by Patent Rights at the time of such sale in the country where such Licensed Product is sold, and such royalties shall be payable on a Licensed
Product-by-Licensed Product and country-by-country basis from the First Commercial Sale of a Licensed Product in a country until expiration of the last-to-expire Patent Rights Covering such Licensed Product in such country, subject to earlier
termination in accordance with Section&nbsp;4.3(b)(iv). Subject to the foregoing, Anaptys will pay MRC royalties on worldwide annual Net Sales of a Licensed Product for any and all uses, on a Licensed Product-by-Licensed Product basis, as follows:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top">[*] of that portion of worldwide annual Net Sales of such Licensed Product from $[*]; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top">[*] of that portion of worldwide annual Net Sales of such Licensed product over $[*]&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Deletion of
Section&nbsp;4.3(a)(ii)</B>. Section&nbsp;4.3(a)(ii) is hereby deleted in its entirety from the Agreement and of no further force or effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.
Amendment of Section&nbsp;4.3(a)(iii)</B>. Section&nbsp;4.3(a)(iii) is hereby amended and restated to read in its entirety as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;(iii) <B>Modified Third Party Antibodies; Antibody Services</B>. Notwithstanding the preceding provisions of this Section&nbsp;4.3(a) or
any other provision of this Agreement to the contrary, the only amounts payable to MRC with respect to Modified Third Party Antibodies and/or Antibody Services are those set forth in this Section&nbsp;4.3(a)(iii). Anaptys shall pay to MRC a flat
annual fee of $[*] upon each of the [*] and [*] anniversaries of the Effective Date, and a flat annual fee of $[*] upon the [*] and each subsequent anniversary of the Effective Date (each an &#147;Annual Fee&#148;), [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, no royalties or consideration other than the Annual Fee shall be payable to the MRC with respect to Antibody
Service, or with respect to any Modified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>*Confidential
Treatment Requested. </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Third Party Antibody.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Amendment of Section&nbsp;4.3(b)(ii)</B>. Section&nbsp;4.3(b)(ii)
shall be amended and restated to read in its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;(ii) If ANAPTYS, its affiliate or its Sublicensee is required to
obtain a license of patent rights from one or more independent third parties in order to make, have made, use, have used, sell, have sold, offer for sale, import or have imported a Licensed Product without infringement of such patents, and if the
total royalty burden (including royalties payable to MRC) for such Licensed Product exceeds, [*], then the royalty rate applicable to Net Sales of such Licensed Product by ANAPTYS, its Affiliates and its Sublicensees payable to MRC shall be adjusted
as follows]: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) For Licensed Products for therapeutic or prophylactic uses in humans or animals, the royalty rate
applicable to Net Sales of such Licensed Product shall be adjusted to the rate determined by [*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) For Licensed
Products for non-therapeutic uses, the royalty rate applicable to Net Sales of such Licensed Product shall be adjusted to the rate determined by [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In no event, however, shall the royalty rate payable to MRC for any Licensed Product be reduced by greater than [*]% of the royalty rate
otherwise due to the MRC under Section&nbsp;4.3(a)(i).&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Amendment of Section&nbsp;4.5</B>. Section&nbsp;4.5 of the Agreement is hereby
amended and restated to read in its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;4.5 Milestone Payments. </B>Anaptys will pay to MRC the following
non-refundable milestone payments on each Licensed Product upon the first achievement of each of the milestones set forth below (whether achieved by Anaptys, its Affiliate, or a Sublicensee), provided that such Licensed Product is Covered by Patent
Rights in the country where the applicable milestone is achieved at the time of such achievement. Each of the milestone payments below shall be payable one time per Licensed Product that achieves any such milestone and only for the first achievement
of such milestone by such Licensed Product. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(i)</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>$[*]; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(ii)</B></TD>
<TD ALIGN="left" VALIGN="top">$[*]; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(iii)</B></TD>
<TD ALIGN="left" VALIGN="top">$[*]; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(iv)</B></TD>
<TD ALIGN="left" VALIGN="top">$[*]; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(v)</B></TD>
<TD ALIGN="left" VALIGN="top">$[*].&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Amendment of Section&nbsp;8.1</B>. Section&nbsp;8.1 of the Agreement is hereby amended and
restated to read in its entirety as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>*Confidential
Treatment Requested. </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;8.1 Term</B>. Unless earlier terminated as hereinafter provided, this Agreement shall
expire upon the expiration of all royalty payment obligations under Section&nbsp;4.3 hereof.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Additional Consideration</B>. Within sixty
(60)&nbsp;days after the Amendment Date, AnaptsBio shall: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> pay to MRC the sum of [*] dollars ($[*]); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> subject to MRC&#146;s execution and delivery to AnaptsBio of a stock issuance agreement in the form attached to this Amendment as
<B>Annex I</B>, issue to MRC [*] shares of the common stock of AnaptysBio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Entire Agreement</B>. The Agreement, as amended by this Amendment,
embodies the entire understanding of the Parties and shall supersede all previous communications, representations and understandings, whether oral, written or otherwise, between the Parties relating to the subject matter hereof. Except as
specifically amended by this Amendment, the terms and conditions of the Agreement shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Counterparts</B>. This
Amendment may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have caused this Amendment to be executed by their duly authorized representatives or officers as of
the Amendment Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>M<SMALL>EDICAL</SMALL> R<SMALL>ESEARCH</SMALL> C<SMALL>OUNCIL</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>A<SMALL>NAPTYS</SMALL>B<SMALL>IO</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Graham L Wagner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Tom Smart</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Graham L Wagner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Tom Smart</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Associate Director Licensing and Agreements</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Chairman and CEO</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Medical Research Council Technology</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>*Confidential
Treatment Requested. </B></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 10.13 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="60%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">[*]</TD>
<TD ALIGN="left" VALIGN="top">Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as
amended. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NON-EXCLUSIVE RESEARCH AND COMMERCIAL LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Non-Exclusive Research and Commercial License Agreement (this &#147;AGREEMENT&#148;) is made by and between AnaptysBio, Inc.
(&#147;ANAPTYSBIO&#148;), a Delaware corporation, with a principal business address at 10835 Road To The Cure, Suite 100, San Diego, CA 92121, and MILLIPORE CORPORATION (&#147;MILLIPORE&#148;), a Massachusetts corporation with offices at 290 Concord
Road, Billerica, MA 91821, and is effective as of May&nbsp;15, 2009 (the &#147;EFFECTIVE DATE&#148;). MILLIPORE and ANAPTYSBIO are sometimes each referred to herein individually as a &#147;PARTY&#148; and together as the &#147;PARTIES&#148;. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1. BACKGROUND RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MILLIPORE owns intellectual property covering or claiming the use of proprietary ubiquitous chromatin opening elements (UCOE<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> elements) and related gene expression technologies and is the owner of the MATERIALS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ANAPTYSBIO desires to use the MATERIALS and the MILLIPORE INTELLECTUAL PROPERTY to enable ANAPTYSBIO to perform research, develop and/or
commercialize recombinant therapeutic proteins. MILLIPORE is willing to grant ANAPTYSBIO a license to enable such uses under the terms and conditions defined herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2. DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of
this AGREEMENT, the following definitions shall apply: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;AFFILIATE&#148; means with respect to a referenced entity, any entity that CONTROLS, is
CONTROLLED by, or is under common CONTROL with such referenced entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;ANAPTYSBIO CELL LINES&#148; means cells (and any replicates, progeny or
derivatives thereof) owned or controlled by ANAPTYSBIO transfected with MATERIALS and/or various control vectors. For clarity, ANAPTYSBIO CELL LINES includes pools of transfected cells as well as individual clones and cell lines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;ANAPTYSBIO PROTEINS&#148; means any proteins expressed by any cells (including ANAPTYSBIO CELL LINES) that are derived using or improved by ANAPTYSBIO
TECHNOLOGY, whether by ANAPTYSBIO or its AFFILIATE or a THIRD PARTY on behalf of ANAPTYSBIO (i.e. service provider), and/or are related to one or more product development programs of ANAPTYSBIO. This definition expressly excludes any proteins made
with use of </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the MATERIALS to generate new cell or cell lines solely for the benefit of any THIRD PARTY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;ANAPTYSBIO TECHNOLOGY&#148; means any and all data, technology, information, documents, know-how and other intellectual or other property now or
hereafter owned or controlled by ANAPTYSBIO, including, without limitation, ANAPTYSBIO&#146;s proprietary somatic hypermutation technology and any genes, CHO cells, cell lines (including any ANAPTYSBIO CELL LINES), expressed proteins and antibodies,
in each case including all improvements or modifications to any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;COMMERCIAL MILESTONES&#148; means the specific milestones listed
in Clause 4.4 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;COMMERCIAL PURPOSES&#148; means use of the MILLIPORE INTELLECTUAL PROPERTY and/or MATERIALS in one or more steps in the
expression, scale-up or production, or any related steps in the preclinical and/or clinical development, of a COMMERCIALIZED PRODUCT where such a COMMERCIALIZED PRODUCT requires the submission of an investigational new drug application or equivalent
filing with a United States or foreign REGULATORY AUTHORITY. For purposes of clarity, COMMERCIAL PURPOSES excludes CONTRACT MANUFACTURING. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;COMMERCIALIZED PRODUCT&#148; means a pharmaceutical product, whether or not actually commercialized, made by or on behalf of ANAPTYSBIO incorporating
ANAPTYSBIO PROTEINS expressed using the MATERIALS and/or MILLIPORE INTELLECTUAL PROPERTY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;CONTRACT MANUFACTURING&#148; means MANUFACTURING on a
contract or fee-for- service basis by ANAPTYSBIO for a THIRD PARTY other than: (i)&nbsp;SUBLICENSEES of ANAPTYSBIO, (ii)&nbsp;entities who have entered into a collaboration, co-development, partnership, cooperation, strategic alliance, or similar
agreement with ANAPTYSBIO relating to ANAPTYSBIO TECHNOLOGY and/or ANAPTYSBIO PROTEINS (collectively &#147;ANAPTYSBIO PARTNERS&#148;), and/or (iii)&nbsp;otherwise in connection with the research, development, manufacture and/or commercialization of
an ANAPTYSBIO PROTEIN. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;CONTRACT RESEARCH&#148; means research and/or development on a contract or fee-for-service basis by ANAPTYSBIO for a THIRD
PARTY other than: (i)&nbsp;for SUBLICENSEES of ANAPTYSBIO, (ii)&nbsp;for ANAPTYSBIO PARTNERS, and/or (iii)&nbsp;otherwise in connection with the research, development, manufacture and/or commercialization of an ANAPTYSBIO PROTEIN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;CONTROL&#148; means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of an entity,
whether through the ownership of voting securities, by contract, or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;CONFIDENTIAL INFORMATION&#148; means: (i)&nbsp;in the case of
ANAPTYSBIO, the terms of this AGREEMENT, any commercial, technical or other data, documents, materials, procedures and information of ANAPTYSBIO that are not generally known to the public and are maintained in a confidential manner by ANAPTYSBIO,
and that are (A)&nbsp;disclosed by or on behalf of ANAPTYSBIO under this AGREEMENT, whether in oral or tangible form, or (B)&nbsp;observed at ANAPTYSBIO&#146;s facilities during the term of this AGREEMENT; and (ii)&nbsp;in the case of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
MILLIPORE, the MILLIPORE INTELLECTUAL PROPERTY, the terms of this AGREEMENT and the MATERIALS. MILLIPORE acknowledges that ANAPTYSBIO is unwilling to receive or have access to any confidential or
proprietary data, documents, materials, procedures and information of MILLIPORE other than the MILLIPORE INTELLECTUAL PROPERTY and the MATERIALS, and MILLIPORE agrees not to disclose or make available to ANAPTYSBIO any such confidential or
proprietary data, documents, materials, procedures or information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;FIELD OF USE&#148; means the use of the MILLIPORE INTELLECTUAL PROPERTY and/or
MATERIALS for RESEARCH PURPOSES and/or COMMERCIAL PURPOSES by or on behalf of ANAPTYSBIO, including, without limitation, by (i)&nbsp;ANAPTYSBIO&#146;s AFFILIATES or authorized SUBLICENSEES, and (ii)&nbsp;ANAPTYSBIO PARTNERS. The FIELD OF USE
specifically excludes: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[*] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;MAJOR
MARKET&#148; means [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;MANUFACTURING&#148; means the use of the MATERIALS and/or MILLIPORE INTELLECTUAL PROPERTY in one or more steps in the
making or production of COMMERCIALIZED PRODUCT that: (i)&nbsp;is intended for a commercial purpose (including, without limitation, pre-clinical and clinical development of COMMERCIALIZED PRODUCT intended for a commercial purpose); and (ii)&nbsp;does
not contain the MATERIALS itself. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;MATERIALS&#148; means the materials set out in Exhibit B as updated from time to time (and any replicates,
progeny and derivatives thereof) to the extent covered by a valid claim of the MILLIPORE INTELLECTUAL PROPERTY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;MILLIPORE INTELLECTUAL
PROPERTY&#148; means the patents and patent applications listed in Exhibit A, and all patents issuing from said patents and patent applications, including any divisionals, continuations and continuations-in-part (to the extent that they cover the
same subject matter of the original application), and reissues and reexaminations of any such patents, together with all non-US counterparts of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;NET SALES&#148; means the gross selling price actually invoiced by ANAPTYSBIO and/or its AFFILIATES or SUBLICENSEES to an arm&#146;s-length third-party
purchaser of a COMMERCIALIZED PRODUCT less the following discounts: [*]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;REGULATORY AGENCY&#148; means, with respect to any particular country or,
where applicable, a multinational jurisdiction governmental authority, body, commission, agency or other instrumentality of such country or multinational jurisdiction (e.g., the EMEA with respect to the European Union), with the primary
responsibility for the evaluation or approval of pharmaceutical products before a COMMERCIAL PRODUCT can be tested, marketed, promoted, distributed or sold in such country or multinational jurisdiction, including such governmental bodies, if any,
that have jurisdiction over the pricing of such pharmaceutical product. The term &#147;REGULATORY AGENCY&#148; includes, without limitation, the FDA and the EMEA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;RESEARCH PURPOSES&#148; means for purposes of using the MATERIALS and/or MILLIPORE INTELLECTUAL PROPERTY to
express ANAPTYSBIO PROTEINS for pharmaceutical research and preclinical development programs conducted by or on behalf of ANAPTYSBIO (including, without limitation, by or for (i)&nbsp;ANAPTYSBIO&#146;s AFFILIATES or SUBLICENSEES, and
(ii)&nbsp;ANAPTYSBIO PARTNERS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;SALE&#148; means the sale, transfer, exchange, or other disposition of COMMERCIALIZED PRODUCTS for consideration to
an arm&#146;s-length THIRD PARTY, other than an AFFILIATE or SUBLICENSEE. Sales of COMMERCIALIZED PRODUCTS shall be deemed consummated upon the first to occur of: (a)&nbsp;receipt of payment from the purchaser; (b)&nbsp;delivery of COMMERCIALIZED
PRODUCTS to the purchaser or common carrier; or (c)&nbsp;release of COMMERCIALIZED PRODUCTS from consignment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;SUBLICENSEE&#148; means a sublicensee
of intellectual property rights owned or controlled by ANAPTYSBIO concerning ANAPTYSBIO TECHNOLOGY necessary or useful for developing and/or commercializing one or more COMMERCIALIZED PRODUCTS. The SUBLICENSEE will have no rights to use MILLIPORE
INTELLECTUAL PROPERTY to generate new cells or cell lines, but may use ANAPTYSBIO CELL LINES generated by ANAPTYSBIO which express ANAPTYSBIO PROTEINS. For purposes of clarification, ANAPTYSBIO has the right to grant a sublicense to use ANAPTYSBIO
CELL LINES for the purpose of development and/or commercialization of COMMERCIALIZED PRODUCTS, but no rights to grant a sublicense of the MILLIPORE INTELLECTUAL PROPERTY to generate cells or cell lines other than ANAPTYSBIO CELL LINES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;TERM&#148; means the time period which commences on the EFFECTIVE DATE and terminates on the last-to&#150;expire Valid Claim (defined below) of the US
patents listed in Exhibit A. For avoidance of doubt, any COMMERCIALIZED PRODUCTS manufactured prior to the last-to&#150; expire Valid Claim of the US patents listed in Exhibit A shall be subject to payments due as provided in Article 4. For purposes
hereof, &#147;Valid Claim&#148; means a claim contained in (a)&nbsp;an issued and unexpired patent which has not been held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction,
unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through abandonment, reissue, disclaimer or otherwise, or (b)&nbsp;a pending patent application; provided, however, that if
a claim of a pending patent application shall not have issued within ten (10)&nbsp;years after the earliest filing date from which such claim takes priority, such claim shall not constitute a Valid Claim for the purposes of this Agreement unless and
until a patent issues with such claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;TERRITORY&#148; means worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;THIRD PARTY&#148; means any person or entity that is not a signor of this AGREEMENT or an AFFILIATE. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3. GRANT OF NON-EXCLUSIVE LICENSE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1. <B>Research Rights</B>. MILLIPORE hereby grants ANAPTYSBIO, solely within the FIELD OF USE and TERRITORY, the non-exclusive right and
license, under the MILLIPORE </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
INTELLECTUAL PROPERTY and to use and modify the MATERIALS, with the right to grant sublicenses as expressly provided in this AGREEMENT, to use the MATERIALS and MILLIPORE INTELLECTUAL PROPERTY
for RESEARCH PURPOSES in ANAPTYSBIO&#146;s research facilities worldwide or the worldwide research facilities of a SUBLICENSEE or of a THIRD PARTY retained by ANAPTYSBIO or a SUBLICENSEE to perform contract research and/or contract development on
behalf of ANAPTYSBIO (a &#147;CRO&#148;) and specifically related to ANAPTYSBIO TECHNOLOGY and/or ANAPTYSBIO PROTEINS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2. <B>Commercial
Rights</B>. MILLIPORE hereby grants ANAPTYSBIO, solely within the FIELD OF USE and TERRITORY, the non-exclusive right and license, under the MILLIPORE INTELLECTUAL PROPERTY, with the right to grant sublicenses as expressly provided in this
Agreement, to make, have made, use, have used, sell, have sold and import COMMERCIALIZED PRODUCTS for COMMERCIAL PURPOSES. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3.
ANAPTYSBIO&#146;s authorized SUBLICENSEES are expressly prohibited from using the MILLIPORE INTELLECTUAL PROPERTY to [*]. ANAPTYSBIO may conduct activities pursuant to the rights granted hereunder, including, without limiting, cell line development,
through use of AFFILIATES and/or service providers. A service provider that is engaged by ANAPTYSBIO or a SUBLICENSEE of ANAPTYSBIO shall not itself be considered a SUBLICENSEE. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4. LICENSE FEES AND ROYALTY OBLIGATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In partial consideration of the rights granted to ANAPTYSBIO herein, ANAPTYSBIO shall: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1. Pay MILLIPORE a non-refundable first research license fee in the sum of [*] Dollars ($[*]) upon execution of this AGREEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2. Pay MILLIPORE a non-refundable second research license fee in the sum of [*] Dollars ($[*]) on [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3. Pay MILLIPORE subsequent non-refundable annual research license fees in the sums of [*] Dollars ($[*]) on the [*], subject to clause
4.3.1 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3.1 In the event that the majority of stock or substantially all the assets of ANAPTYSBIO is transferred [*]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All annual research license fees shall be paid within thirty (30)&nbsp;days following annual anniversaries of the EFFECTIVE DATE of this AGREEMENT and shall
be adjusted upward only, on a year-to-year basis, beginning after the third anniversary of the EFFECTIVE DATE, in accordance with increases in the United States Consumer Price Index &#150; All Urban Consumers &#150; US City Average (CPI). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4. Pay MILLIPORE the applicable milestone payment below within thirty (30)&nbsp;days following the first achievement of each of the
milestone events below (or, in the case of each of the clinical COMMERCIAL MILESTONES below, the first achievement of such clinical COMMERCIAL MILESTONE in the first MAJOR MARKET in which such clinical COMMERCIAL MILESTONE was first achieved) by
ANAPTYSBIO or its AFFILIATES </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and/or SUBLICENSEES for each and every COMMERCIALIZED PRODUCT, on a product- by-product basis, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3">COMMERCIAL MILESTONE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Milestone&nbsp;Payment</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">4.4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Enrollment of first patient in the first Phase I clinical trial of each COMMERCIALIZED PRODUCT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$[*]</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">4.4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Enrollment of first patient in the first Phase II clinical trial of each COMMERCIALIZED PRODUCT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$[*]</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">4.4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Enrollment of first patient in the first Phase III clinical trial of each COMMERCIALIZED PRODUCT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$[*]</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">4.4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First commercial SALE of each COMMERCIALIZED PRODUCT in a MAJOR MARKET</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$[*]</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">4.4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">When each COMMERCIALIZED PRODUCT first reaches SALES of over $[*] in the first applicable calendar year</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$[*]</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">4.4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">When each COMMERCIALIZED PRODUCT first reaches SALES of over $[*] in the first applicable calendar year</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$[*]</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">4.4.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">When each COMMERCIALIZED PRODUCT first reaches SALES of over $[*] in the first applicable calendar year</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$[*]</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">For purposes of clarification, subject to clause 4.5 below, each of the milestone payments specified in this
clause 4.4 shall be payable only one time per COMMERCIALIZED PRODUCT regardless of the number of indications for which a COMMERCIALIZED PRODUCT is developed or approved, and, in the case of the milestone payments for COMMERCIAL MILESTONES [*],
regardless of the number of MAJOR MARKETS in which a COMMERCIALIZED PRODUCT achieves the same COMMERCIAL MILESTONE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">In the event
ANAPTYSBIO sells all or substantially all of its rights to one or more COMMERCIALIZED PRODUCTS to a THIRD PARTY, whether by merger, sale of stock, sale of assets or otherwise, [*]% of the milestone payment for the next-to-occur clinical COMMERCIAL
MILESTONE for the MOST-ADVANCED COMMERCIALIZED PRODUCT (defined below) to which such THIRD PARTY acquires rights will be due, which amount shall be fully creditable against future payments due hereunder. All remaining COMMERCIAL MILESTONES shall
continue in full force and effect. &#147;MOST ADVANCED COMMERCIALIZED PRODUCT&#148; means, of all of the COMMERCIALIZED </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
PRODUCTS to which a THIRD PARTY acquires rights in a transaction or series of transactions of the type described in the first sentence of this Section&nbsp;4.3.1, the COMMERCIALIZED PRODUCT that
is at the most advanced stage of development but has not yet achieved all of the clinical COMMERCIAL MILESTONES (i.e., COMMERCIAL MILESTONES 1, 2 and 3) at the time of consummation of such transaction(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5. ANAPTYSBIO shall notify MILLIPORE, in writing, of the achievement of each COMMERCIAL MILESTONE for which a milestone payment is due under
clause 4.4(a) or 4.4(b) within thirty (30)&nbsp;calendar days after such achievement. For purposes of this AGREEMENT, a COMMERCIALIZED PRODUCT that contains a particular ANAPTYSBIO PROTEIN or particular ANAPTYSBIO PROTEINS and any and all other
COMMERCIALIZED PRODUCTS (such as modified, improved or &#147;next generation&#148; COMMERCIALIZED PRODUCTS) that contains the same ANAPTYSBIO PROTEIN(S) shall collectively be considered one and the same COMMERCIALIZED PRODUCT, regardless of whether
such COMMERCIALIZED PRODUCTS are sold under different product names or trademarks. Without limiting the generality of the foregoing, and solely by way of example, if (i)&nbsp;development of a COMMERCIALIZED PRODUCT containing a particular ANAPTYSBIO
PROTEIN or particular ANAPTYSBIO PROTEINS is abandoned after one or more of the COMMERCIAL MILESTONES has been achieved, and (ii)&nbsp;any COMMERCIALIZED PRODUCT containing the same ANAPTYSBIO PROTEIN(S) is developed as a replacement for the
abandoned COMMERCIALIZED PRODUCT, then no milestone payment shall be due upon achievement of any COMMERCIAL MILESTONE by the replacement COMMERCIALIZED PRODUCT that was previously achieved by the abandoned COMMERCIALIZED PRODUCT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6. All payments due pursuant to this AGREEMENT shall be paid in United States dollars. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5. SUBLICENSING RIGHTS AND OBLIGATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ANAPTYSBIO may sub-license only the rights granted to it under clause 3.1 and/or clause 3.2 to any CRO(s) and to THIRD PARTY(IES), in each case, solely for
the use of cells, cell lines or clones containing the MATERIALS which express ANAPTYSBIO PROTEINS so long as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All terms and conditions of any sublicense shall contain terms and conditions that are consistent with the terms and conditions of this AGREEMENT. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">ANAPTYSBIO shall pay continuing applicable Milestone Payments to MILLIPORE on the achievement of COMMERCIAL MILESTONES by any SUBLICENSEE in accordance with Clause 4.4 above. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">The sublicense does not permit any SUBLICENSEE or CRO to transfer or assign its sublicense to use the MILLIPORE INTELLECTUAL PROPERTY; provided,
however, that a sublicense may permit such SUBLICENSEE or CRO to assign such sublicense to an AFFILIATE or to any successor-in-interest by way of merger, acquisition, or sale of all or substantially all of its assets related to such sublicense, in
which event such SUBLICENSEE or CRO shall be obligated to notify ANAPTYSBIO and in such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
instances, ANAPTYSBIO shall be obligated to notify MILLIPORE in writing of such assignment; and provided, further, that a sublicense may permit a SUBLICENSEE to sublicense its rights to a CRO so
long as ANAPTYSBIO complies with clause (e)&nbsp;below. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">The sublicense shall contain provisions that any sublicense to use the MILLIPORE INTELLECTUAL PROPERTY that was granted to the SUBLICENSEE or CRO shall terminate upon the termination of this AGREEMENT; provided,
however, that the sublicense may permit the SUBLICENSEE or CRO to retain and continue using any already-existing ANAPTYSBIO CELL LINES as permitted by Article 9. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top">ANAPTYSBIO shall notify MILLIPORE in writing of the sublicense and its applicable terms concerning the MILLIPORE INTELLECTUAL PROPERTY promptly following the signing of such sublicense; provided, however, that
ANAPTYSBIO shall not be required to disclose to MILLIPORE the financial terms of any sublicense. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6. REPORTING
OBLIGATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1. ANAPTYSBIO and its SUBLICENSEES and AFFILIATES will keep accurate books and records showing all COMMERCIALIZED
PRODUCTS offered for sale, imported, sold and or otherwise exploited and all NET SALES and any other amounts payable herein. Such books and records will be preserved for at least three (3)&nbsp;years after the date of the payment to which they
pertain and will be open to inspection by an independent certified public accountant retained by MILLIPORE at reasonable times (but no more frequently than annually) on prior written notice to ANAPTYSBIO solely to determine the accuracy of reports
and payments made by ANAPTYSBIO under this AGREEMENT and to assess ANAPTYSBIO&#146;s compliance with the payment terms of this AGREEMENT. Such independent certified public accountant shall execute and deliver a confidentiality agreement reasonably
requested by ANAPTYSBIO and shall not disclose to MILLIPORE any information other than information relating to accuracy of reports and payments made by ANAPTYSBIO under this AGREEMENT and the compliance by ANAPTYSBIO of the terms of this AGREEMENT.
MILLIPORE shall bear the fees and expenses of such examination. If, however, an error in payments due of more than [*] percent ([*]%) or $[*] (whichever is greater) for any year is discovered in any examination, then ANAPTYSBIO shall reimburse
MILLIPORE the reasonable fees and expenses of such examination and shall remit the underpayment to MILLIPORE along with applicable simple interest due at the rate of [*] per annum within [*] days of delivery of the examination result to ANAPTYSBIO.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2. For each COMMERCIALIZED PRODUCT, ANAPTYSBIO shall identify to MILLIPORE the reference number for all applicable Biological Master
Files (or equivalent) for such COMMERCIALIZED PRODUCT filed by ANAPTYSBIO or its SUBLICENSEES or ANAPTYSBIO PARTNERS with the relevant REGULATORY AGENCIES. MILLIPORE shall have the right to identify to any REGULATORY AGENCY such reference number for
any such Biological Master File (or equivalent) with regard to COMMERCIALIZED PRODUCTS developed by THIRD PARTIES with the use of MILLIPORE INTELLECTUAL PROPERTY, for the sole purpose of notifying the REGULATORY AGENCY of the existence of such prior
Biological Master File. Any such identification shall be made solely to the REGULATORY AGENCY and shall not constitute authorization to or by MILLIPORE or any THIRD PARTY </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(except the REGULATORY AGENCY) to access, reference or use any such filing or any data therein or to disclose or use any confidential or proprietary information in any such filing or in any IND
(or equivalent) or Biological Master File (or equivalent) or other filing submitted by ANAPTYSBIO or any AFFILIATE or SUBLICENSEE with any REGULATORY AGENCY. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7. OWNERSHIP OF THE INTELLECTUAL PROPERTY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1. The MILLIPORE INTELLECTUAL PROPERTY and MATERIALS shall at all times remain the property of MILLIPORE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2. ANAPTYSBIO shall at all times be the sole owner of ANAPTYSBIO&#146;s technology made prior to or outside the scope of the license
(&#147;ANAPTYSBIO&#146;s BACKGROUND TECHNOLOGY&#148;), all ANAPTYSBIO CELL LINES, all ANAPTYSBIO TECHNOLOGY and all ANAPTYSBIO PROTEINS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3. ANAPTYSBIO agrees that the MILLIPORE INTELLECTUAL PROPERTY and MATERIALS will be used solely within the FIELD OF USE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4. ANAPTYSBIO agrees that it shall hold and use the MILLIPORE INTELLECTUAL PROPERTY and MATERIALS in a confidential and secure manner, to
the extent provided in Article 10 below. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8. INTELLECTUAL PROPERTY IMPROVEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any and all results, discoveries, improvements and/or inventions (whether or not patentable) (a)&nbsp;made solely by or on behalf of ANAPTYSBIO shall be the
sole and exclusive property of ANAPTYSBIO, except that any made by ANAPTYSBIO that [*]; (b)&nbsp;made solely by MILLIPORE shall be the sole and exclusive property of MILLIPORE, except that any made by MILLIPORE which relate to or are enabled by
ANAPTYSBIO&#146;s BACKGROUND TECHNOLOGY, the ANAPTYSBIO CELL LINES, the ANAPTYSBIO PROTEINS and/or the ANAPTYSBIO TECHNOLOGY shall be the sole and exclusive property of ANAPTYSBIO (it being understood, however, that ANAPTYSBIO is not granting to
MILLIPORE any license or other right to use, or any access to, ANAPTYSBIO&#146;s BACKGROUND TECHNOLOGY, the ANAPTYSBIO CELL LINES, the ANAPTYSBIO PROTEINS and/or the ANAPTYSBIO TECHNOLOGY); and (c)&nbsp;made jointly by MILLIPORE and ANAPTYSBIO shall
be the joint property of MILLIPORE and ANAPTYSBIO; provided that any jointly made results, discoveries, improvements and/or inventions [*]. Each PARTY, upon the request and cost of the other PARTY, shall promptly perform all necessary acts to
execute any patent applications, assignments and/or other documents which the other PARTY deems necessary or useful for the prosecution of results, discoveries, improvement and/or inventions owned by such other PARTY. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9. TERM AND TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1. This AGREEMENT shall commence on the EFFECTIVE DATE and shall, unless terminated earlier as provided herein, continue in full force and
effect. The term during which ANAPTYSBIO shall pay to MILLIPORE research license fees and milestone payments pursuant to this AGREEMENT shall end upon the expiration of the TERM. Upon the expiration of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
TERM, the licenses and other rights granted by MILLIPORE to ANAPTYSBIO pursuant to this AGREEMENT shall be fully paid-up. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2. ANAPTYSBIO shall have the right to voluntarily terminate this AGREEMENT, for any or no reason, on not less than ninety (90)&nbsp;days
written notice to MILLIPORE. However, the obligation to pay the first year research license fee (clause 4.1) is non-terminable in the event ANAPTYSBIO exercises its rights pursuant this paragraph. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3. Either PARTY may terminate this AGREEMENT upon material breach of this AGREEMENT by the other PARTY (including, in the case of
termination by MILLIPORE, a breach resulting from ANAPTYSBIO&#146;s failure to pay any sums due hereunder) where such breach shall not have been remedied within sixty (60)&nbsp;days of the receipt of a written notification from the other PARTY
identifying the breach and requiring its remedy. Upon termination of this AGREEMENT by ANAPTYSBIO on account of the material breach by MILLIPORE, MILLIPORE shall promptly refund to ANAPTYSBIO the pro rata portion of any research license fees
attributable to the period of time following such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4. In the event of termination of this AGREEMENT, ANAPTYSBIO&#146;s
licenses under clauses 3.1 and 3.2 with respect to any ANAPTYSBIO CELL LINES generated before such termination (including, without limitation, ANAPTYSBIO&#146;s right to sublicense such ANAPTYSBIO CELL LINES in accordance with clause (d)&nbsp;of
Article 5) and ANAPTYSBIO&#146;s rights with respect to ANAPTYSBIO PROTEINS expressed by such ANAPTYSBIO CELL LINES, shall survive such termination and continue in full force and effect, subject to the terms and conditions of this AGREEMENT
(including, without limitation, Article 4 hereof); provided, however, that if MILLIPORE terminates this AGREEMENT for ANAPTYSBIO&#146;s uncured material breach of any of its payment obligations under Article 4, then ANAPTYSBIO&#146;s licenses with
respect to such existing ANAPTYSBIO CELL LINES shall terminate, and ANAPTYSBIO shall destroy such existing ANAPTYSBIO CELL LINES as specified below in this Article 9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5. Upon termination of this AGREEMENT by MILLIPORE pursuant to the terms hereof, each sublicense by ANAPTYSBIO to a SUBLICENSEE to use the
MILLIPORE INTELLECTUAL PROPERTY for COMMERCIAL PURPOSES that was in effect before such termination will survive such termination; provided, however, that (i)&nbsp;such sublicense was granted in accordance with the terms of this AGREEMENT;
(ii)&nbsp;such SUBLICENSEE is not the cause of such breach; (iii)&nbsp;such SUBLICENSEE agrees in writing to assume all applicable obligations of ANAPTYSBIO under this AGREEMENT; and (iv)&nbsp;MILLIPORE continues to receive from such SUBLICENSEE all
payments under Article 4 that MILLIPORE would have received from ANAPTYSBIO with respect to such SUBLICENSEE&#146;s activities had this AGREEMENT remained in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6. ANAPTYSBIO agrees that, upon termination of this AGREEMENT, all MATERIALS and other MATERIALS incorporated in mixtures or combinations
with ANAPTYSBIO TECHNOLOGY and/or ANAPTYSBIO PROTEINS in its possession or control, including any in the possession of its CROs or SUBLICENSEES or ANAPTYSBIO PARTNERS, shall be destroyed within thirty (30)&nbsp;days following such termination,
unless otherwise agreed in writing by the PARTIES; provided, however, that neither ANAPTYSBIO nor any of its CROs or SUBLICENSEES or ANAPTYSBIO PARTNERS shall be required to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
destroy or to cease using any existing ANAPTYSBIO CELL LINES to which ANAPTYSBIO retains its license as set forth above in this Article 9 or any ANAPTYSBIO PROTEINS expressed by such ANAPTYSBIO
CELL LINES; and provided, further, that notwithstanding anything contained in this AGREEMENT to the contrary, ANAPTYSBIO shall have the right following such termination to sell any inventory of COMMERCIALIZED PRODUCTS and finish and sell any work in
progress. ANAPTYSBIO&#146;s obligation pursuant to this paragraph shall not apply if this AGREEMENT is terminated by ANAPTYSBIO on account of the breach of this AGREEMENT by MILLIPORE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.7. Articles 6, 7, 8, 9 (including any other provisions specified herein as surviving), 10, 12, 13, 14&nbsp;&amp; 15 shall survive
termination of this AGREEMENT or expiration of TERM and continue in full force and effect. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10. CONFIDENTIALITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1. Each PARTY agrees to maintain, and require its employees, agents, representatives and AFFILIATES and their employees, agents and
representatives to maintain, CONFIDENTIAL INFORMATION of the other PARTY with the same degree of care it uses to protect its own CONFIDENTIAL INFORMATION of a similar nature, and each PARTY represents that it exercises reasonable care to protect its
own CONFIDENTIAL INFORMATION. Each PARTY agrees not to use, and require its employees, agents, representatives and AFFILIATES and their employees, agents and representatives not to use, the CONFIDENTIAL INFORMATION of the other PARTY for any purpose
other than performing its obligations and exercising its rights under this AGREEMENT, except as otherwise explicitly set forth in this Article. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2. Each PARTY agrees to maintain in confidence and not to disclose to any THIRD PARTY, other than its employees, agents, representatives
and AFFILIATES and their employees, agents and representatives, any CONFIDENTIAL INFORMATION of the other PARTY, either during or for five years after expiration of the TERM or earlier termination of this AGREEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3. Without granting any right or license to the use of its CONFIDENTIAL INFORMATION, except as specifically provided hereunder, each PARTY
agrees that the limitations of non-use and non-disclosure of CONFIDENTIAL INFORMATION it provides to the other PARTY under this AGREEMENT shall not apply to such information, to the extent and only to the extent, that the receiving PARTY can
credibly document that such information: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">is now or hereafter becomes generally known or available to the public without the receiving PARTY&#146;s breach of any obligation owed to the providing PARTY; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">is independently developed by the receiving PARTY without use of or reference to CONFIDENTIAL INFORMATION of the providing PARTY, or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">was acquired by the receiving PARTY before receiving such information from the providing PARTY under this AGREEMENT, without restriction as to use or disclosure; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">is hereafter rightfully furnished to the receiving PARTY by an AFFILIATE or THIRD PARTY without any breach of an obligation of confidentiality to the providing PARTY and without restriction on use or disclosure; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">is disclosed or used by the receiving PARTY with the prior written consent of the providing PARTY, on a case-by-case basis. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.4. For purposes of clarifying clause 10.3 (confidentiality and non-use exclusions), information that is combined, synthesized or used by
the providing PARTY in a particular manner, as provided to the receiving PARTY under this AGREEMENT, shall not be deemed &#147;known&#148;, &#147;available&#148;, &#147;developed&#148;, &#147;acquired&#148;, or &#147;furnished&#148; separately to
the receiving PARTY merely because the various pieces of information were previously known, available, developed, acquired, or furnished without being so combined, synthesized or used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.5. A receiving PARTY may disclose CONFIDENTIAL INFORMATION to the extent required to do so by applicable law, an administrative or court
order, or governmental regulation; provided that the receiving PARTY promptly notifies the providing PARTY when it learns that disclosure may be required, and the receiving PARTY shall, at the providing PARTY&#146;s expense, take reasonable action
to avoid the disclosure or limit its scope. Any information disclosed pursuant to this clause 10.5 will remain the CONFIDENTIAL INFORMATION of the providing PARTY and subject to this AGREEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6. Either PARTY may, without the prior written consent of the other PARTY, disclose the terms of this AGREEMENT to such PARTY&#146;s
lawyers or other paid consultants or advisors, under substantially the same terms as clauses 10.1 through 10.5 (confidentiality and non-use requirements), solely for the purpose of discussions related to business decisions of such PARTY. Any
information disclosed pursuant to this clause 10.6 will remain the CONFIDENTIAL INFORMATION of the providing PARTY and subject to this AGREEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.7. The terms of this AGREEMENT are deemed confidential, but (a)&nbsp;either PARTY may disclose the existence of this AGREEMENT, without
disclosing the terms, in a media release or similar public announcement provided that such PARTY allows the other PARTY a reasonable opportunity to review and comment on the content of such release or announcement prior to its release which approval
shall not be unreasonably withheld or delayed, and (b)&nbsp;ANAPTYSBIO may disclose the existence of this AGREEMENT to its current or prospective banks or other financial institutions or current or prospective investors for the purpose of raising
capital or borrowing money. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.8. Notwithstanding anything contained in this AGREEMENT to the contrary, ANAPTYSBIO shall be permitted to
disclose CONFIDENTIAL INFORMATION of MILLIPORE and the existence and terms of this AGREEMENT to (a)&nbsp;ANAPTYSBIO&#146;s current or prospective banks or other financial institutions or investors for the purpose of raising capital or borrowing
money or maintaining compliance with agreements, arrangements and understandings relating thereto, and (b)&nbsp;to any person or entity who proposes to be a SUBLICENSEE or to purchase or otherwise succeed (by merger, operation of law or otherwise)
to all of ANAPTYSBIO&#146;s right, title and interest in, to and under this Agreement, if such person </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or entity agrees to maintain the confidentiality of such CONFIDENTIAL INFORMATION pursuant to written confidentiality agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11. REPRESENTATIONS AND WARRANTIES; INSURANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1. Each PARTY hereby represents and warrants to the other PARTY that (a)&nbsp;it has all requisite power and authority to enter into this
AGREEMENT and to consummate the transactions contemplated hereby, and (b)&nbsp;this AGREEMENT has been duly and validly executed and delivered by such PARTY and constitutes its valid, legal and binding obligation, enforceable against it in
accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium and similar laws affecting the enforcement of creditors&#146; rights generally and by general principles of equity, regardless of whether such enforceability is
considered in a proceeding in equity or at law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2. MILLIPORE hereby represents and warrants to ANAPTYSBIO that as of the EFFECTIVE
DATE (a)&nbsp;to its knowledge, neither the grant of the licenses pursuant to this AGREEMENT nor the practice of the MILLIPORE INTELLECTUAL PROPERTY or use of the MATERIALS by ANAPTYSBIO, its AFFILIATES and/or its SUBLICENSEES shall infringe or
misappropriate any patent or other intellectual property rights of any THIRD PARTY and it does not know of any claim of a THIRD PARTY with respect to any such infringement or misappropriation; and (b)&nbsp;MILLIPORE owns or controls the entire
right, title, and interest in and to the MILLIPORE INTELLECTUAL PROPERTY and the MATERIALS as of the EFFECTIVE DATE; and (c)&nbsp;the MATERIALS have been manufactured by or on behalf of MILLIPORE in accordance with all applicable laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3. ANAPTYSBIO warrants that it will not MANUFACTURE, use, sublicense or sell COMMERCIALIZED PRODUCT for any purpose other than those
purposes for which it is authorized under Articles 3 and 5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.4. ANAPTYSBIO shall take out, maintain and keep current in respect of the
manufacture, sale and use of COMMERCIALIZED PRODUCT all appropriate insurances, as determined by ANAPTYSBIO in good faith, including, commencing upon the first commercial SALE by ANAPTYSBIO of a COMMERCIALIZED PRODUCT, adequate product liability
insurance and appropriate THIRD PARTY and other insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.5. EXCEPT AS PROVIDED HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS AND
EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12. INDEMNITY&nbsp;&amp; LIMITATION OF LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.1. ANAPTYSBIO shall indemnify, defend and hold MILLIPORE and its directors, officers, employees and agents harmless from and against any
and all THIRD PARTY claims, demands, or causes of action (each, a &#147;Liability&#148;) arising out of or relating in any way to (i)&nbsp;the possession, manufacture, use, sale or other disposition of COMMERCIALIZED PRODUCT hereunder, whether based
on breach of warranty, negligence, product liability or otherwise, (ii)&nbsp;the exercise of any right granted to ANAPTYSBIO pursuant to this Agreement, or (iii)&nbsp;any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breach of this Agreement by ANAPTYSBIO, except to the extent, in each case, that such Liability is caused by the negligence or willful misconduct of MILLIPORE, its directors, officers, employees
and/or agents as determined by a court of competent jurisdiction or by MILLIPORE&#146;s breach of this AGREEMENT; provided, however, that upon receiving notice of any such Liability, MILLIPORE shall promptly notify ANAPTYSBIO and permit ANAPTYSBIO
to handle and control the defense (including litigation and settlement) of such Liability, at ANAPTYSBIO&#146;s sole expense, and MILLIPORE shall reasonably cooperate with ANAPTYSBIO in the defense of such Liability, at ANAPTYSBIO&#146;s sole
expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2. LIMITATION OF LIABILITY. NEITHER PARTY OR ITS AFFILIATES SHALL BE LIABLE TO THE OTHER PARTY OR THE OTHER PARTY&#146;S
AFFILIATES FOR ANY CONSEQUENTIAL, SPECIAL, INDIRECT OR EXEMPLARY DAMAGES OR FOR THE LOSS OF PROFITS ARISING FROM THE PERFORMANCE OR NONPERFORMANCE OF THIS AGREEMENT OR ANY ACTS OR OMISSIONS ASSOCIATED HEREWITH. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 13. NOTICE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1.
Any notices required or permitted to be given under this AGREEMENT shall be deemed given on the date received in writing: personally; or by a letter delivered to a reputable courier guaranteeing next day service; or by facsimile, with confirmation
by prepaid first class letter sent the same day. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to MILLIPORE:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attn. Business Development Department 290 Concord Road Billerica, MA 01821</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">with a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellectual Property Department</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">28820 Single
Oak Drive</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Temecula, CA 92590</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If&nbsp;to&nbsp;ANAPTYSBIO:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AnaptysBio, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10835 Road to the Cure, Suite
100</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California 92121</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Chief Executive
Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">with a copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AnaptysBio, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10835 Road to the Cure, Suite
100</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California 92121</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Vice President,
Corporate Development</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.2. Any PARTY may change its designated address and facsimile number by notice to the other PARTY in the
manner provided in this Article 13. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 14. DISPUTE RESOLUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.1. In the event any PARTY claims breach of this AGREEMENT, the PARTIES shall consult with each other in good faith on the most effective
means to cure the breach and to achieve any necessary restitution of its consequences. This consultation shall be undertaken </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
within a period of [*] days following the receipt of a written request to consult, and the consultation period shall not exceed [*] days. During the consultation period, neither litigation nor
arbitration may be pursued until attempts at consultative dispute resolution have been exhausted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.2. Any dispute between the PARTIES
arising out of or related to this AGREEMENT and not resolved by consultation as provided in clause 14.1 shall be finally settled by binding, expedited arbitration in accordance with the applicable rules of the American Arbitration Association
regarding commercial or business disputes (&#147;Rules&#148;) then in effect. The arbitration proceeding shall be conducted in Denver, CO, and carried out by a single arbitrator, selected according to such Rules. Each PARTY shall be responsible for
any costs or expenses incurred in presenting such PARTY&#146;s case to the arbitrators, such as attorneys&#146; fees or expert witness fees, and all other fees and expenses of the arbitrator shall initially be paid equally by the PARTIES, provided
that the arbitrator shall have the authority, but not the obligation, to require a PARTY to reimburse all or any portion of such costs, expenses and/or fees in the final award. The decision of the arbitrator shall be final and binding on the
PARTIES, provided however that the arbitrator shall not have the authority to alter any explicit provision of this AGREEMENT. Judgment upon the arbitrator&#146;s decision may be entered in any court of competent jurisdiction. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.3. Notwithstanding clauses 14.1 and 14.2 or any other provision of this
Agreement to the contrary, either PARTY shall at all times have the right to seek injunctive or other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action
may be filed and maintained notwithstanding any consultation or ongoing arbitration proceeding. Further, in the event ANAPTYSBIO or its AFFILIATE thereof files an action seeking a declaration of patent invalidity and/or unenforceability of any
MILLIPORE INTELLECTUAL PROPERTY, ANAPTYSBIO shall bear all of MILLIPORE&#146;s fees, costs and expenses associated with litigating such action, including the fees, costs and expenses associated with any appeals. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 15. MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.1. <B>Amendments</B>. No change, modification, extension, termination, or waiver of this AGREEMENT, or any of the provisions herein
contained, shall be valid unless made in writing and signed by duly authorized representatives of the PARTIES hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.2.
<B>Assignment</B>. Neither this AGREEMENT nor any rights or benefits hereunder shall be assignable or transferable by either PARTY without the written consent of the other PARTY; provided, however, that either PARTY shall have the right to assign
this AGREEMENT to an AFFILIATE or to any successor-in-interest by way of merger, acquisition, or sale of all or substantially all of its assets related to the performance of this AGREEMENT. Should a merger, acquisition or sale occur, the affected
PARTY shall notify the other PARTY. Any purported assignment by a PARTY not in accordance with this clause shall be void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.3.
<B>Binding Effect</B>. This AGREEMENT shall be binding upon and inure to the benefit of the successors and permitted assigns of the PARTIES. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>*Confidential&nbsp;Treatment&nbsp;Requested.</B></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.4. <B>Counterparts</B>. This AGREEMENT may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.5. <B>Exhibit
Incorporation</B>. All Exhibits cited herein are incorporated by reference and made a part of this AGREEMENT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.6. <B>Headings</B>. The
Article, paragraph and clause headings, and paragraph parenthetical cross-references contained herein are for the purposes of convenience of reference only and are not intended to define or limit the contents of said Articles, paragraphs or clauses.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.7. <B>Independent Contractors</B>. Nothing in this AGREEMENT is intended nor is to be construed as to constitute the PARTIES as
partners, joint venturers, or principal and agent with respect to this AGREEMENT. No PARTY shall have any express or implied authority to bind the other PARTY to any other agreement, contract, obligation or undertaking with any THIRD PARTY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.8. <B>Interpretation</B>. Whenever required by the context, the singular term shall include the plural, the plural term shall include the
singular, and the gender of any pronoun shall include all genders. Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder shall fall on a Saturday, Sunday, or national or local holiday, the PARTY having such
privilege or duty shall have until 5:00 pm on the next succeeding business day to exercise such privilege or to discharge such duty. It is further agreed that no usage of trade or other regular practice between the PARTIES hereto shall be used to
interpret or alter the terms of this AGREEMENT. Since the PARTIES have participated jointly in the negotiation and drafting of this AGREEMENT, in the event an ambiguity or question of interpretation arises, no presumption or burden of proof shall
arise favoring or disfavoring any PARTY by virtue of authorship of any provision of this AGREEMENT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.9. <B>Prior Agreements</B>. This
AGREEMENT together with the Exhibits hereto, sets forth the entire understanding between the PARTIES with respect to the mattes dealt with herein and supersedes any and all prior agreements, written or oral, previously entered into by the PARTIES
covering the matters dealt with herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.10. <B>Severability</B>. If any provision of this AGREEMENET is in violation of any law or is
found to be otherwise unenforceable by a court or competent administrative body from which there is no appeal, or no appeal is taken, such provision shall be deleted and the PARTIES shall negotiate in good faith to substitute for any such invalid or
unenforceable provision, a valid and enforceable provision that achieves to the greatest extent possible the economic, legal and commercial objectives of the invalid or unenforceable provision, a valid and enforceable provision that achieves to the
greatest extent possible the economic, legal and commercial objectives of the invalid or unenforceable provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.11. <B>Waiver</B>.
No delay on the part of any PARTY hereto in exercising any power or right hereunder shall operate as a waiver thereof, nor shall nay single or partial exercise of any power or right hereunder operate as a waiver thereof, nor shall any single or
partial exercise of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any power or right hereunder preclude other or further exercise thereof or the exercise of any other power or right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes hereof, a facsimile of a signed copy shall have the same force and effect as an original signed AGREEMENT. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MILLIPORE CORPORATION</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">ANAPTYSBIO, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Andrew Bulpin</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Tom Smart</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name/Title: A Bulpin VP</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name/Title: Tom Smart, CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: 18&nbsp;May 2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Date: May&nbsp;14, 2009</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>*Confidential
Treatment Requested. </B></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[*] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>*Confidential
Treatment Requested. </B></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g942137g07x01.jpg
<TEXT>
begin 644 g942137g07x01.jpg
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M 0$! 0$! ?_  !$( 3("7P,!$0 "$0$#$0'_Q  ?  $  @(# 0$! 0
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MF<6- YE#8]5E/5>[GZCL00J^4E&JXX&9T(Q]@\-939CF2[C"K%+&P-S:Y[@
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MJ/5S^3"43B*.UVX4Z$CA@T5CI9TW0E T&EJ^78O^<O\ WY5 4[=P-M_%?O\
M'6VU46;$+JJZN;AK\AL5@MJP6)V+#B6Z?H57T8F@)C(@;E9#S]\MW"HTBVV<
M-MM]MVZV5$=\^>GMQ53ML>8J?\4IQ2G%*<4IQ2M.>WO;%WUI2IF)PBJREYWG
MV+LS>K*6J@?*A4#9'# V*'YY+9#*YT:9%6<2AD,AD8+F3I5 )(2F=_4&0X$]
MW=J*M565;WWL +D_Z?S)K#5?W6$OF(&/=EJWD_5.[C3R\$FM42Y1Y-V$C"=?
M14>D=A3^NK#BP%,%,ZY1C4LCY4/(73&-$2ZS@@(:1_8J'?MDU"OB.0VWY<^0
M/BY5#2OBP>'V#;NW93L2+:L1U7UM=!8AF!VLJ.!U=< J)FZSF4@((015D &3
M ;.(TN*T,KL7OGO735RU;NPYI <IBWB[R/Q',5(X]XF/2.4SJ+UN'NORRZ8(
M M@S0E7%M 121241!U/XQ$#\H.P,;%HC8LEA3-:4Q^LI8:"6&:";-GXV,.47
MK/9=3%MS;E]W<;$^D7VN-JHB=>-/T3C]/S.WH#.Y9<+6&@*LF&\8AU5VL*/2
M&$6U/1=>1^;13:8P>/#Y)%&!X@X'G3@5T^'AI /4A9-PTF;T8!>*D(U[6MS&
MY'<+F_X58O=SQ"Q74=7KD&$0:+RR1=F'TP2A9&Y+B!]6JL!-87&1$F=M)G95
MA1HU]'IE(TSPP;"8,]C&A@^33+MG&XG8.Z\JH5;WWL!SL+]]MK5#8]XM%$MI
M8-A-U0NSJ#-I]40':J:.I;&"DJC,.$')FO!TX6G*:]'R81+S#PLDVWBI6*+$
MA,UV+!@4>W<3%[M&4%,3S&XRQ^\VOR._NK*D?%RZ?H3FFXF(-6 =#VQIV#U*
M3#2HK9"-:G(]; #&06&"M*+22#")Q%#[%J\SL\"D8XW)@VFC0N?:#@QD(_(*
M8-OZ+=XWORL>1O5V2;Q#.GL1&I$S-P:YU=P6C+'$BP\#LV32:1Q7LL1-B:+4
MB41C4++2J7GK'(1LXW"PV,!RTR1R-<*% #!'&BFRHQ/B\8]&W/?EM<5L94ML
MU_>=>1JU:M/_ $G@DM;O5P9C84:!.%<C"CX(49OP4D&AY"$*B30PB(+AC@H<
M6%$V+M@09-G;=5+54$6-CW58O%*<4JI+[NJ$]<*3M>_+'6>H02G8!*;%E61;
M;1X57#Q00Z+NF0AFHLW3>%R&K;# 4T5<MTG)!RV04<(:;[*Z*D"Y ',FW\Z\
MVC'B87Q6532^W.P70&P*ECS&"5;8T#)#[?BUA1B1B[,MF 5=K#)M)PT4'Z5G
M;8-.Q!<M5A*PR4"RP<:<0&R_=T-6QQ5L1>P:_CVMX^6^XVYU:;SQ5^J$&9RI
M2[9PVKHD#M;M+7H@-&H[;-NOSH3J=8J%?V9,%VL%JEP_$8C^S\4:EXO+%^PB
M@Y<D^3DAZ/@2TB;JC$GEZ.=AS%QS/\O'6<(>)KUDBQRUDIU-PHJ(P>64E$8*
M=AB$^M>46P1O*DQMZ1A.,UM *Z+2EZY4AKUT::MXCI.DUXL/7E)5T!;Z.F#-
M3$[;<P3_ "-OZU*Q/B4=))!,JM@L?O49(#5SM*X<UZ0 P^Q3,*)+V^W?.:M"
M&K(&0]U7D*E<^2&/\16&S>41V5F%FJC9H&4<^8ELIBV^W*_>+[<]N?X\JK%O
MXDH-QT>I3NMBIRVHJYK4JBL&M?\ TM9Y( '%I=@6-"-S"\A]A8;$$0SQ]B2K
M,TQ37=XV3R,T<-U=L/,*8[D>($_R!-38%XI'0N0DI@,8]A [/:"0^U9W(R<B
MAME1*-:1JCCFT<MQR&ELJA@:+RDC7YCT3:21Z+&#,B9)NQ[WV5NQ(L'+A3%O
M%XN6_/E_/NJCH-XO-)6A;C^OX"#56B#2\Z I1M84\=36K7!1S>E'W!=F"J-?
MS:KQLM"OHN-J-ZT]C3%&,,) ')XEC62,F" YH<5)0@7]!/<=@0.X^G?Q5<P'
MQ4^A<HBTFF$=O78R*B[R"LU6;"KKF<2J4XL\N5!5R1K"#:5WF;7"!G)8&991
M6251'YG'SFXHAN/)KHM%U-%1@VVW/[N[G?Q6[[VM5%6%XSO6 $K*TZW2/60P
M"=5"7:L-.'H&P(16!>/!['>UH6B1F5.JZ.&H?(!!L84;F,EH@MH*-CW,->H)
M3%)8(DJ0A[]M[=U^5_'RL?'6U+[Q$^F@RV9-23^[!K:PH@\EX@ZVWB=@;11.
M3U_$G$ZG$&&V3I$]JV/V/%(BS>'3U; ):3G@UDS=Y<QW15JX235&+6O;;\._
M8&W.U]K\KU"8]XJW0F5Q:33&/WOL1#Q9G51!=OK5MSMY))&-XEU(_4;JM88[
MKM"8VVC/SZ#@#'=ZM!3##LTV="L^C?MEVZ:F+>+Q]XVMSOOM;OO:MP:AM^O+
MXKT#:=5G]Y+"))L52&$W 4_&W^CL$9(1XX,+1N5BP<GCQH*=%$@Y<)( XPN,
M(L7+1ZR062VTPJ""#8\ZLKBHK0KLMW(G577?7G6+KYUZ==E;_G%:3&[2<6=V
M@ IF'P>H86>!Q%S*)%.CX&4^D*R*82(=&XE'1D=>;D'B1%V7) 1K'UQ95@+B
MY-A>U[7W^[[JQ3CQ-.LD%"U:EV)+2GK39UAPH!-9!45EPF8OY'3H\_)7,(:/
M+F/PN/R6%U=%WTS8OP,>G=@2"+1&49;9>B":J/I=4%,3O:Q -K@C?OV',[>*
ML=-?%IZ 5]+)=!Y3>C]K*(,9LV.2(:-IJ^9'JG(J8*ZB;9 ""$;K L,DYNNL
M[ZFI>*C#PP_!P_SIT^02A>NQ[$7']?\ 3G3%CW?ZCW]_=XSL-Z[\M\5CH-"9
M.TAYN^M5SI#6"8'IQNLKCFHT@ZM2MA]N5:)'R"&UZ>C[X_9U?DV9NN8ZT*+'
M9TXV7 Q8<5D;-X);S0(Q[O\ 4=W,\^0[SR%=WZTGH7EO5;U/L&(787(#"R:'
M$VL+LQV*'QZ13Q]5H0S911K"EA]+#2=E"RL!:N[C<P-'>8"2T>\[!46_:MU,
M6WVY?=]^WCVWVOMO76?>*CT-8CI63_+HH12AED.*@,L@%67/)CKBS6+F=H%H
M7&HW'J[*2&:FH^E6DS*2="&BSR<8CPQK)I J-CIR/E"BF+>+NOW<MO>/YUCV
M'B>]7E'UBE'\Y#NJSC+7K@M 9G7[2PK8D=K.^S$,D\W@PN-UA :W+RQV4=AX
ML2>#AD7Q,RCP<S+D#+&,ZAG:&5,3XM]^>UK<][_\_$5/J&[SU;V3N\W5]1:Z
M2R$MNME0=DXS;C%^Y1%2L#;<\MJ!MP"<8)AAIL(2CSZIR"A7VNHB^2=$-A+P
M0-?"W6%%"I N?&1;[@#_ .]:-TSXRN+0LBJHN8ZXLX["[HO2W>OT)D<<[$5[
M8-B,);4SRU&;P_.Z+8 PT_B$!(9J20.G4NWU)L +!^"?/M56Q9DHNJ2E@=]P
M >6V]N1[^=7W&?%XZ6:U_3THM2U@M>2>V*HKBVE(T!"VE9P") [5)J H*G()
M]'*N:" 69<>0<BH<E-6,+,RM5NLH)!*)Z;YU5&#;V'(D=PW'/8G\3XJA<;\9
MOJR_BU[N94E+(O95'D^VZ'Y*6L5GDC(V *ZCRV21V6.(1-&L&8P Q(B@L(/E
MSZ%L9"]/0B-GVAR5)M8XV='M5,#<#QX__P! 6]U7W6GB8]1[+(T]%VDWD@*>
M7-%JJD0>(&ZNM='6+/[G$.C%=0^P9DG!]X! IA,$1Q+Z( )A* 9&9MV>A.)M
MC H@,>/%"I%^6WI'=XA>Y'I%;^<56G%*<4IQ2G%*<4IQ2JLO.KF5XTG<-*DB
MSH".M^K+!JY^<8MTG;T*RL")%XFZ+-&B^Z:#IT.0+*/&[=91-)95'1-3?73;
M.V%!L0?%6E,O\-R(RX;"!KBSI$STA/AWV[X>K95(",5V?1:VPE:A']D+:[N]
M<)2 .E6S1=H$3SL.<[E'.BSO35!+.X;;5;+GZ6#?RO[ZUIBO@B55#[.6FPJU
M-W$<?9&R(E'3E+53)I9^4D=1(RC?I( M*2C"\HB$:=(!V$ZWC$;18'F4K]?;
MB)X-C)8F!=*DN2+'[K@D;7ORY'F1]WIKA?7@J1N\ZEH6EGW8Z8"X+1W42 ]4
MF8<G (Y,!KE2NL@5!%SQ4(9+)A():)KV T$2HZT'&23N*81"Q\I&'S9,YE0/
MN3;FQ/\ .]P?1O5?Q?P?9A=SB]0O;6V)&SI.3=N_$!N> 49#!D%2RHGVH;6I
M7$<LM6S629"2M,M:QM(\;%U^3;K*B)L[T>G"#X6U1C*2I+VL5&X503]UCR^\
M<ZL6$^#*RKZ'Q_6)]BD(S<$(O"DKJ@]IQ/K;2\68L'5%P"RZUCP271 .T0?V
M+DY&[@L!R<)RF;.$F!\HV?PL3$AR1$,65&?HV((()/>;_AR'(=V]ZZ;GP3(U
MM5FU6-NR\\RQ,]6NQ_5:<&R4"B#TK+(MV$OV1=B595HFR<B6(&316;G_ $/F
M#FV1)P8R3;^H!\+J8PH7WO8<U(Y_N@#_ -JV_H_HM(:'O:9V#$^R<\VI286]
M:U_.^N^\/A2(UQ;=S"&K"9$#MC^IKRTS#6I74A*HK#VR0=4,??I^O2 T(8-A
M7%06N!L+@ 7] ]'C]-:_W_X-M0]B[#[$W;-+CN8;>ER3JJ)I7T\BLTF4;CU)
M:42.C"50BV%3AIDQK6R5(:="G)2T+V& *ODC<R//!. SI7UK=4AR !86%P18
M;W.^_,7&VQ[A62M3PD('9L#,Q]:T7368*]V[1[PQN3&ZZCDQBXR9VV&,QN40
M21UV8(Z,)="\@CY!!FIN:#GVA)N'*-2K?<>JW>J9[\OW0IW[A;O[N0JI=O!"
MB.LIILTGV'/+A*9*]<)9&HP^INKFPT'-: MA[;A%[7 Z)-8C$Z@C%OR J25L
M<!7\0%&R[W+-ZZF+UK@P+.*G/8BW.XYGD1;?QV[J]TN*SIQ2O@ZT<*-G";1?
M1LZW05T;.54/64V[C9/;5%=1MZ5#UC1)3.JFZ'ID?2ZZY3]*GYWGX4KP\BO@
M6TI QU>E(A>-W-K7!1;L5$K0L:23"7S05;H_M)!Y?&[=66JJ131W7%<.SLJD
MPZR%%:["A/791%0JQS!A33+K56AD)O<"VUA;E8[;\^6V_CJR)GX1T:D8@0D$
MO>5QB2Q:E^@E4Q&0_0P :;BBGA_V:8L^ S(@#=D$$#'TR+%\LY)'MGC)LU:M
M4\LB&^5%-,JC/T#FYMR\,6(_#NK 27PAR693+IM5W;*95;)YNZ[S-I ]2JN#
M3%L[BO?&X@5M6+'-6,A>;)ME(FX!MQT1-M%&[W5ZBQ+$DW;)!^ *JG/8 CEC
M;?[(M78C_@UU[#BD;AL/O2PQ/5H?8_6FY)3UU>1N'EEY;9W52!5O *W*9MI9
MHA+@<:+L:AKHM.HPR9K*&2X1YD*:C0TP['85!>_,"]B+^AB2=N7>=_359N/!
M_<UQ4TNCFUHSGM)%H5TC["]+*'H K':NK=T/K"YS\,D(E@\LY59D@3G$4<0L
M0Q:3@_J/9JMAXLBB(&FF+QV<5.=^ZQR#$\]Q?N_&]OY5Z,^'YURDO5CJ34M3
MV":UE-OY'F)_>TQ]:]HK3"]K3D!2Q;<D"Q;9)%4PFO.)*89C2*R*.ZP5D,TU
M;M44DFJ*JL;DD;#N'B Y5K*:\*\6[ZRU-UI"WQ)QH"L>Q=LWZ24+PL+)HG9J
M%NSBX9N6KZQZY=%F8*4QZ/$+=7=QE(P[?B$C\4CITW'3FJ*@O*ISW)(Y@#[K
M "X\7+_6J5;^#G&JHZF=E:8A\MD]S%K3ZBTMURCX1\2CU1/]G'7.06O,*_.C
MYG@'.A 20DS=DME'&2<5(1C5]&!^KMBB*)O=&*F9)!V':+>,;V'+[A6N]=>$
M-?G8N36YV [>SQQ"KX/WC#9_7)*;0ZC[84=@ /6L30LJ;V96->[LZ@U9F-$M
M'$)91>3KF0&8F .'"ST@0,C7:I+@  <K$'F/WK['G[]]JV#L_P (DA#HR\E?
M7JP\&IE"H'TB<P^K3D-KJ!1:8V=T&NY:YX"6T(P4/$XI!$K$8';"A).-AXB-
MAHHK,!<BTV8,(]JP44#]Q_ZM_0PM;>YV-CWFI@4\,:2UE=_8+N53]@E)#;D\
MB'8,G$J:'16OJ<%3>P+JCZ[,&#OV:0MR+B]G1BOS2Z+N/G3D.VG;-1#!^03*
MPS[1-0FJ,K@*>6WIM;Q<R"?Y>@5Z3]4Z,:=8^LU ]=V)3)U&DJ?KVL=SN4]D
M?;KN&1<8#?F\(;YSLWU+OF;DCJV\OD;:N<(:^35/&.*J3<D^,D_SJ_N*BG%*
M<4IQ2G%*T^[<]3<]F6U/R2*6C(*.NWKS97Y5*5MR/  4OVC9Y]%ST'DX210V
M2:X$RR&S&'28N$D 3=X)>*^<R=LC#-1IMHX5(-K]X(L1^(/]0*U0F?AAV#-Q
MU6'S?>.Z2]XP@QV27E-ORB)0R6-Y#%NU$6CL/L>"0>N#/I8I446CX>'QK\F(
MB->T!$0?-2I$@+DKV0%%UE6SYV46VV](Y&_?S-__ (K&1_P@X" H:W:(TN*5
M.AEN5;T0JTC(%8N%U?"A_14!#0,:)-V>'VS=VO/DH>DX.-5U=$0ZA!QHPV<Z
MZ:YV>/T__5,][V[V/K5EY?X2M;2?N!*^U"$^08M)W8\6N250,M3U734SI9L.
MKX;7X@A#K2F DO)(-&W"0"/24F)!#])*C)1SES%YM%V)=^/45&9QMZ".9&Q-
MSL.??SV]%0@SX,\%*4[$JE0O29#L0OI15G38-)4XD <.O5*DO.&7S';&=C5W
MV6JY%U(X2.%%(YA5-DL*<N_0$F[G9-5-Z?\ G=[J9FY-N;%OYUN3VJZI6!V.
MC-:#PG8!2 &H0@9:2L9(:A@UQ4M<#61AAPTIBR*/FZV@,F\%OANAF$$&AUFZ
MB3E^8:Z;$V11RAE4 V[K_B01^(K0]+P3(_&*YCM=U7VEM&N6PSK)OUN.E1T6
MC?K<A'*=F"/:=R3;) 'D4TBT8+3@](H8<KF/;M CNHR^T"'/Q"2&"2KT_P#.
M_P!]6S)-R =[_P"EO]!:Q\8O6<@W@PPN$-(NS8WB8;-1%C=M9B='1RKX7% 9
M:,=RJIAU76C! 0,8YW81!L&:Q!$C!S;/0@[%Z/-VAIK(7B:AAU%M[_\ .0'_
M +"F?H\7?XC<?_/C]%1M/P5]BD"DT3L'M.^M D8J/JU2@IQ-^NU.FH</@/4P
MQ/'E?@RL&?).O:FA4=.%=#Y\1(XO/V\A88D$8F\=;N= ;.:9^(6W8[$_O  _
MT^ZVQKT\Z@]<4>IG7F 4$WL.7VBC!M9'G28S9TNX+.=9'*C<IP(8(N7Q1<3%
M(Q@U]&H6 5*%% ,3$AA"A,BHSW>+JJ3<WM;[O^?S]-;+<5%.*55%ZTS".Q5,
M6G0UDM7;R!7! I17<L1'.=61/4)+!#H.]="GNR3C5B69)NO713W9!?#,@W;.
M<HJX2]'LJ0;$$<P;_P J\W"/AA6I8=73"KK_ .^MU7(%(P*KJR@@_:&Q*"1"
M(QNLK7@=J(2:30:+O- EE6\>6KP+&'MFG=F+L9'W)IN###\F2>'2IRWV4#>_
M>>?=]WHK-,O"EA#*9S>9:VY*5'$U;^(Z@X9;1P1A%ACQ&)]')[+-D%</<[JY
MK1S'$AT>QOKK[<;NE5B7JBFFNN5,O1]C_P#@6_UJ C_!]80T_%K(JGLK,(#<
M]<G:%/5M/W%>1*6BX^K373EOTM,L#,(-/=1<F'V%7>'IUYC=Z+>QR2+M=Q;U
M=DT6;OE3GM:VVXM][9<_0:'O"!Q*[VJ>\9IVMLFQBM3S3J[8HK%D0>&RB29E
MO6Y5DJ_2C\F;J!F-?1*WG:#V0SR.02+ G"LN?[%-3;D*FI&7"F6Q%K7ORV&^
M_+?EW>C^=7NW\-Z)-^D],]+,6=(]H]3=H599P^<Y!#,&3;RKK\8WRR%/!7K?
MJ+5J6)L=8\Z<(.%%6[!39XEINXQA+*HRW)MS!'\UM5%S#P8*DG]/5[2TJMJ<
M.(U HEW\BR;X:'##BY';OC:K:VRIC5;=9XV9/JJD#%BE&T=VSYG($6VOMM#1
M-11#94AR.X?N\_\ I%O]>^NYGPDMYK-R5DW]V>F%QS63W-2MO30BA6L-KH>;
MUI?KY>771A$AHF+O-T@0T_%;N(&"!+5<@2;'0NBC93+0AZLP4SMR%MB/'S(/
M_M_SOZNGA0V"O0D/Z_GN\EG2>%U7M0D<JJ.E:Q@K"!LJEZ_LSXL'6EHPV+O(
MZXN!O+Q1@8C.29R2BF)E["X<]1CC+1D6:&U,][XC>]_O/.WB]'BN=ZKYOX',
M/'5*I3H?L9+1\:)=7+<ZJ2%32M88FJ3AEE=CI5V5%&Q[,8[%"XX9B,KE;D-J
MS$,D018(R9HH# >-=T]E"Y)O;O!_D,:MR3^$F"E4WE&2'8:=_D'+7_=7;*.T
M3K#89C$9[(7G!9Y#9/,%;*322E9N'"7EFS66QVOUTF2;8Z50;D9 3"#VHK53
M/EMO8*3XP.[_ $&]8F;^#O!IA!X_#<V^YW1CG3CJ1T^20EU15S8T5/Q_J7,)
M/+@DEE,1F"#]NZ4FJ\G6;%V<<(Q:11Q5@Q*P^;ABB6'.% ]N[]YFV)%B1;:W
MB_UK?/IOUG0ZA]?HA0[>Q);:",5?RLBG)Y>LXRNEK*I27D^L=CP]T1,K@(5%
MM2V(_#8XJ9,*A8\/8,EBI!9-1TJJI-S?E_\  M_]UM#Q45H=V7Z9RRVKGK[L
MK1/8:1=9.P$&KB84N]F@VOX?:L>F=134X#E;V)R6$33+=EL_ RZ.C9-$9 P)
M,U19#<@B38G1SWU)%5@;"Q%QS\6_WUJU8OA MIP+.1MOV\OI./W)0E:==.V[
MR<MXS:M@]CH16,FETF&&U;%E[=4Q7,X+?E FD?*%P+8D#;1DHP' 8R&< AKY
M-4A_^D;$E>8L3;NORV!_K>YJ?)^%7!4)#[>;VM)D==;1[]V:BPUCPO***_?6
M,K1F1A=5=GV5-FE<ME<+@'6WE7-;Z8T(ZMM<YVX_^?\ 7>HRY;>+_0WK!UYX
M24&KW:#;-;BEA+Z#VUT4MAMZQ&@Z'K[[HQUX!]>HV'7]&^W]"TGPH(G)#;E/
MSE@Y!=1DPT<MM=5<O'Z?_JF7H[F_U-ZHS3P':C:FH659V^N[28BW<;L=K,J2
MJ:RL32-^\=:?8D6G%4["'20374A;O;;DD%*G,!I6S*QIL'(MP0F4#6QM-4Y^
MCT\R-[ =WW7M_6MCE_#"P A%+M*D[#2FM+=H'L1V@[ UM;.T B<Q;MG/;$W:
M[RR8@>@!USJ&-C6P2UGP<"4]HLR3%V"$E\^DUW>C7"HRY[7!"@C_  VMO^%0
MR?\ A()S9Q)"BG:2R79V9'>JYJ<NIG$HS*@UG:=9ZOL2M-Q5L148ZB(&<AK#
M4L1Q.BH#=J*C0B9QR,NT01(4.]E**D/L!;EE;<[9$<ONM:KDZ-^&]$ND!ID9
MCEFGYWEAUT@'7)NV+1H)'TO8->6Y=UK"Y!LF$6]42*/%;I> WC%DS9BDT0#5
MXQ;--7N[%JJ&8L+6[\OQL!_[575?^$/2-9I=>C$2-LQ-H45V*NV]B%P#JYB8
MNP[1$7B]NI>055-9(-V:G7<2&-+@0'CO62Y!'=&#1WU@9NECT#=4ER;^(@"W
M,"UM_OV_U->;=S>$/V7@XZ/]<>KA"3$:>G5/=):GN>RS4QIUC%)CCJ9:6Y\)
M)9U#)#&5;5@I"/155XHW94V:F+*Q'FX8<8Q#4QY-R658..;>-R!OMD/Y'?QV
MMSN>[TH?^$U "@,/'WEMR_U$9,/$1EBJC8 &1=.OK#QDY%3!AHHHX72;XKI"
M<.MXVZR@XR758-LDVZ.BBFF'B]'_ -53+T?9_P#Y '^MJ@0OP>6K>Z>MEU%>
MRAY>1]>P]!AO:\5J2#5W/I:*Z^LD186(KV7#GHZ1[UK/13)B/LN#3S6S$BC3
M<PSBI:'#B^6+14Y[$6YWY[VOZ.5QW$6]->TW%4IQ2O-CZT6F_L\>(C_]N;N1
M_)[BK8GQKZZ?%3ZT6F_L\>(C_P#;F[D?R>XIB?&OKI\5/K1:;^SQXB/_ -N;
MN1_)[BF)\:^NGQ4^M%IO[/'B(_\ VYNY'\GN*8GQKZZ?%3ZT6F_L\>(C_P#;
MF[D?R>XIB?&OKI\58@CXLO7T0KH@6I/OT+653]*FB1\/GMXR542\[;3TFB;F
MI4M]T_/UVU\_7&=?.UVU\OEQG'.B'1ZO4*6T^EU$ZJ<2T,$LJAK XDHK &Q!
ML=[$'OK"6?3P$+-J-/$Q&0$D\2$B]K@,XN+@B]8_ZWOK1\)>]7[@O;/^5/-O
MFSI+^'Z[V34?IUEU[0^>Z/VJ#]2GUO?6CX2]ZOW!>V?\J>/FSI+^'Z[V34?I
MTZ]H?/='[5!^I3ZWOK1\)>]7[@O;/^5/'S9TE_#]=[)J/TZ=>T/GNC]J@_4I
M];WUH^$O>K]P7MG_ "IX^;.DOX?KO9-1^G3KVA\]T?M4'ZE/K>^M'PE[U?N"
M]L_Y4\?-G27\/UWLFH_3IU[0^>Z/VJ#]2GUO?6CX2]ZOW!>V?\J>/FSI+^'Z
M[V34?ITZ]H?/='[5!^I3ZWOK1\)>]7[@O;/^5/'S9TE_#]=[)J/TZ=>T/GNC
M]J@_4I];WUH^$O>K]P7MG_*GCYLZ2_A^N]DU'Z=.O:'SW1^U0?J4^M[ZT?"7
MO5^X+VS_ )4\?-G27\/UWLFH_3IU[0^>Z/VJ#]2GUO?6CX2]ZOW!>V?\J>/F
MSI+^'Z[V34?ITZ]H?/='[5!^I3ZWOK1\)>]7[@O;/^5/'S9TE_#]=[)J/TZ=
M>T/GNC]J@_4I];WUH^$O>K]P7MG_ "IX^;.DOX?KO9-1^G3KVA\]T?M4'ZE/
MK>^M'PE[U?N"]L_Y4\?-G27\/UWLFH_3IU[0^>Z/VJ#]2GUO?6CX2]ZOW!>V
M?\J>/FSI+^'Z[V34?ITZ]H?/='[5!^I3ZWOK1\)>]7[@O;/^5/'S9TE_#]=[
M)J/TZ=>T/GNC]J@_4I];WUH^$O>K]P7MG_*GCYLZ2_A^N]DU'Z=.O:'SW1^U
M0?J4^M[ZT?"7O5^X+VS_ )4\?-G27\/UWLFH_3IU[0^>Z/VJ#]2GUO?6CX2]
MZOW!>V?\J>/FSI+^'Z[V34?ITZ]H?/='[5!^I3ZWOK1\)>]7[@O;/^5/'S9T
ME_#]=[)J/TZ=>T/GNC]J@_4I];WUH^$O>K]P7MG_ "IX^;.DOX?KO9-1^G3K
MVA\]T?M4'ZE/K>^M'PE[U?N"]L_Y4\?-G27\/UWLFH_3IU[0^>Z/VJ#]2GUO
M?6CX2]ZOW!>V?\J>/FSI+^'Z[V34?ITZ]H?/='[5!^I3ZWOK1\)>]7[@O;/^
M5/'S9TE_#]=[)J/TZ=>T/GNC]J@_4I];WUH^$O>K]P7MG_*GCYLZ2_A^N]DU
M'Z=.O:'SW1^U0?J4^M[ZT?"7O5^X+VS_ )4\?-G27\/UWLFH_3IU[0^>Z/VJ
M#]2GUO?6CX2]ZOW!>V?\J>/FSI+^'Z[V34?ITZ]H?/='[5!^I3ZWOK1\)>]7
M[@O;/^5/'S9TE_#]=[)J/TZ=>T/GNC]J@_4I];WUH^$O>K]P7MG_ "IX^;.D
MOX?KO9-1^G3KVA\]T?M4'ZE/K>^M'PE[U?N"]L_Y4\?-G27\/UWLFH_3IU[0
M^>Z/VJ#]2GUO?6CX2]ZOW!>V?\J>/FSI+^'Z[V34?ITZ]H?/='[5!^I3ZWOK
M1\)>]7[@O;/^5/'S9TE_#]=[)J/TZ=>T/GNC]J@_4I];WUH^$O>K]P7MG_*G
MCYLZ2_A^N]DU'Z=.O:'SW1^U0?J4^M[ZT?"7O5^X+VS_ )4\?-G27\/UWLFH
M_3IU[0^>Z/VJ#]2GUO?6CX2]ZOW!>V?\J>/FSI+^'Z[V34?ITZ]H?/='[5!^
MI3ZWOK1\)>]7[@O;/^5/'S9TE_#]=[)J/TZ=>T/GNC]J@_4I];WUH^$O>K]P
M7MG_ "IX^;.DOX?KO9-1^G3KVA\]T?M4'ZE/K>^M'PE[U?N"]L_Y4\?-G27\
M/UWLFH_3IU[0^>Z/VJ#]2GUO?6CX2]ZOW!>V?\J>/FSI+^'Z[V34?ITZ]H?/
M='[5!^I3ZWOK1\)>]7[@O;/^5/'S9TE_#]=[)J/TZ=>T/GNC]J@_4I];WUH^
M$O>K]P7MG_*GCYLZ2_A^N]DU'Z=.O:'SW1^U0?J4^M[ZT?"7O5^X+VS_ )4\
M?-G27\/UWLFH_3IU[0^>Z/VJ#]2GUO?6CX2]ZOW!>V?\J>/FSI+^'Z[V34?I
MTZ]H?/='[5!^I3ZWOK1\)>]7[@O;/^5/'S9TE_#]=[)J/TZ=>T/GNC]J@_4I
M];WUH^$O>K]P7MG_ "IX^;.DOX?KO9-1^G3KVA\]T?M4'ZE/K>^M'PE[U?N"
M]L_Y4\?-G27\/UWLFH_3IU[0^>Z/VJ#]2GUO?6CX2]ZOW!>V?\J>/FSI+^'Z
M[V34?ITZ]H?/='[5!^I3ZWOK1\)>]7[@O;/^5/'S9TE_#]=[)J/TZ=>T/GNC
M]J@_4I];WUH^$O>K]P7MG_*GCYLZ2_A^N]DU'Z=.O:'SW1^U0?J4^M[ZT?"7
MO5^X+VS_ )4\?-G27\/UWLFH_3IU[0^>Z/VJ#]2GUO?6CX2]ZOW!>V?\J>/F
MSI+^'Z[V34?ITZ]H?/='[5!^I3ZWOK1\)>]7[@O;/^5/'S9TE_#]=[)J/TZ=
M>T/GNC]J@_4I];WUH^$O>K]P7MG_ "IX^;.DOX?KO9-1^G3KVA\]T?M4'ZE/
MK>^M'PE[U?N"]L_Y4\?-G27\/UWLFH_3IU[0^>Z/VJ#]2GUO?6CX2]ZOW!>V
M?\J>/FSI+^'Z[V34?ITZ]H?/='[5!^I3ZWOK1\)>]7[@O;/^5/'S9TE_#]=[
M)J/TZ=>T/GNC]J@_4I];WUH^$O>K]P7MG_*GCYLZ2_A^N]DU'Z=.O:'SW1^U
M0?J4^M[ZT?"7O5^X+VS_ )4\?-G27\/UWLFH_3IU[0^>Z/VJ#]2GUO?6CX2]
MZOW!>V?\J>/FSI+^'Z[V34?ITZ]H?/='[5!^I3ZWOK1\)>]7[@O;/^5/'S9T
ME_#]=[)J/TZ=>T/GNC]J@_4I];WUH^$O>K]P7MG_ "IX^;.DOX?KO9-1^G3K
MVA\]T?M4'ZE/K>^M'PE[U?N"]L_Y4\?-G27\/UWLFH_3IU[0^>Z/VJ#]2GUO
M?6CX2]ZOW!>V?\J>/FSI+^'Z[V34?ITZ]H?/='[5!^I3ZWOK1\)>]7[@O;/^
M5/'S9TE_#]=[)J/TZ=>T/GNC]J@_4I];WUH^$O>K]P7MG_*GCYLZ2_A^N]DU
M'Z=.O:'SW1^U0?J4^M[ZT?"7O5^X+VS_ )4\?-G27\/UWLFH_3IU[0^>Z/VJ
M#]2GUO?6CX2]ZOW!>V?\J>/FSI+^'Z[V34?ITZ]H?/='[5!^I3ZWOK1\)>]7
M[@O;/^5/'S9TE_#]=[)J/TZ=>T/GNC]J@_4I];WUH^$O>K]P7MG_ "IX^;.D
MOX?KO9-1^G3KVA\]T?M4'ZE/K>^M'PE[U?N"]L_Y4\?-G27\/UWLFH_3IU[0
M^>Z/VJ#]2N6GB\]:=]L:XJ;O1C.?+^?;H/VSUQ^;&<_GSFJO)C^[_P#[^;CY
MLZ2_A^N]DU'Z=.O:'S[1^U0?J5ZF<X:ZJ<4IQ2G%*<4K3SL9_P":0?\ D&O_
M +B]Y^D?(S_P_5?YP_\ HPUX;Y4_WS3_ .6_W9*UZY["O,4XI3BE.*4XI3BE
M.*4XI3BE.*4XI5 PSLA7T[L1*L0B$CTD:WY>?,4?#6B S_\ 3I8E?UE/_.=)
MDEUL>GD=DQY2.^1KGVB,3).G7LY9LDU<\L>LBEFX*A\SUK<@!?['-%!+OD3X
M<RX;;@,3:P!ZI-)+%%QF*8?V;D26_M<4LT6Q4#9(FSWV-@+WN)A9UIB*N9QU
M1Z E\M,R^0;1F+16"@_;LA-%409F3/-4TUW0X4.9#P$>,$GA0X5%C=,-4AZ3
MI8L1%CWNDTZP!+K)(TCX(D2Y.S8LYYD* $1F+,RKL!?)E!SA@:8O9HXUC7-W
ME;%%7)4'(%B2S*H"JQWN0%!(IP7W-ITXO"5@J$])1B;9JUJG/$H.8;PZ-'+J
M(-0]8Q>6/2&K,D+D4F,D10A1@@)?:1P@8#H2QP!P39;K<R](Z9C'CQ623@ 2
M\)A&C:E@L".38J[L57$*<"RB3&XKH;H_4*),C$KQ\8\+B*9'73@M,Z 7#(B@
MM<L,PK% UC5\R"SJUB4CCD/E5A0>,RZ8*Z(1&+2"6  TCE*ZCC1IHC' A(@V
M)FU=W:B;71,8U=;[.-]$<8RIMC7/4\T,;I&\L222;1QO(BO)W=A20S;[=D&N
M5(9I$>1(I'2/PW2-F1-K]M@"%VWW(VJLYAVPZV0<-+3AV[ZO]5@:H%*9MALX
MC)<I&,R8\RC07<Z*'%'#\4B],OV[719\@@GCR+;YV\Q!7.N,FOT<2R,^I@M%
MCQ LJ,R9L$7)0Q*W8VW [_$:WCT.LE9%7337ERX9,3JKX(7;%BH#64$V%^[Q
MBIXUN.HGQR21AE:E;O)+#1"\@E\>:SB,.#D5 M46[AT;D@E(IN_!B&S=VT77
M)%&[5FBBZ;JJ+:Z+)[;:C4Z<LZ">$O&I>1!*A9$ !+.N5U4 @EF %B#?>LCI
MYPJ.8)@DC!8W,;A78D@*C8V9B00 I)N#6!]XWKU]%D9S^7BF?H2X+(@$)A^5
M"$?19<ZY;;/6X5&0>W/9*A9PSTW=HCM'>SQ5MKLOHCLEKG?%>N:3#B]:T_#+
M!1)QXL"Q%PN>6.1&X%[D;U;JFJSX?5M1Q,<N'P9,\0;%L,<L;[7M:]9<G=-2
M"I(O"7%EP#:?),'Q%&OM)M%$IP];C@"4I<^IQIV9;$M_,CKAJ;V5412;(B73
M8HX71'+:NN2VITZN8S-%Q;%A%Q8^*0%#FR%@? (:^P"D,2 ;U5=-.R<00R\*
MX4R\.0Q@EL!=PI'A K;GD"H!.U0N2]J: AD8/R26VI!@"\4K+>W9-$7,OBSZ
M=!8.F";R'8HO% QHF2>:*,7;1-DJ*T(,RSMXR0#NR'K[+=QF^NTD:,\D\2E(
M>L/&9(S*L6(?(HK,3L18K<,2 I-Q?1-%JI'5$@D8/-P$D$;B-I,BN.;* -P;
MY6*@$L!8VGIBU(<+%UV6;$,2)I;$AC<=KW:-*LBNLI6DHMY)$B8ESJ[28/ H
MR%"3\\*$$':FN(E'BS\<F1=:-&+O5YXU6%@<Q.Z)#A9N(74N"IN 5$:O*3?P
M$8BYL#FL$C-*I&!@5WESNN&!"D,+7#-(5B4$>&ZAL1<BE#7<VG F_:))3$M?
M+]28EI-+(1'@DE<G@F A\L]VKM5P1;-I8X$/XN?B1I+"X_05,!C@(]52VRDN
MIS-TEIEZ]?B$Z"/BS )X:XLQX-R!(5*/&VXM(I4^.NA>C]0W4O  US\.$ECV
M6R51Q;*2F0=778Y1D,*ZLJ[K4[&XO&)8P;3"9,)I6XJS8LUBHD7[1+"C-CUU
M5+$'LA)#L<1$RKZ:6?'!K\.=<"]0^R!I,R[8.Q:K7<_2.G2-) ))!)"LR!%7
M)E::*!4L[)C)Q)D4JY7&S!RI4BI3H[4,[QDQQF.9H'+L;*RQ2S%KHKY)PX7(
M9<LKKB"#>N27<:$:*$0):N[?!6@PF0J#)TPZC4>+V,4+FH45L9@[$YB4ND<'
M>A-H2 /GG)?$UT:#] SH:0V:FG(L80#I"+=6AU"3B18NK%$:8LT;3*1PY'B*
M\)'<MQ; *0UF*JSYODV99M.T)C:3K =UA55D6(AN)&D@;B,JA>&2<@PNH9A]
MF?=*DRKJ*;A%9D;C,GVJILYGHZ'%?H=#S%WD6 :K8Y-GKW5F3 R&4&"P<4N*
M]D.EXH\,"=9O]&DR+154.D=,QCQ,C(_ '%$;<.-M2P6!)";%7D9E7'$E"R\3
M $&H/1^H4/EPU=..1$9%XDBZ8%IGC NK*BAF!R&85N'G8U^1_NC3<B1T?-DI
MJP"OFT./QV0&HNL("2ZNYS,F4!!6Q%WCQTGL2KK62% VA8OLDW)! AP'+"H=
MK$S \VX)TEIW%QQ I$;H[IBLD,L@B6="3VH<V7)MBJLLA41L&)NCM0AL>&6!
MD5T5PS1RQQF5H' &TV :R[AF5D#%U*C;3G?7#3BE:F6AV]B-4R2S Y>M[:/1
MZEHF#G5NV'%A<)?P^OHD<'&3.#99H0GHJ=%FPH+'RY<PG$X5(G35BS4V10<K
M9U1SP3](1P/,K0ZATTT:RZB:-8S'#&RLV3 RK*V*HS-PXW( Y$[5W0Z!YDA9
M9H%;4.T<$3M())75E7%2(FC!9F"KG(H)/=5KF^P%#1I(VO([LJ./HQE^.%21
M4Y9$.$IQ\H8<FV0D:<W?F6^HD@4>1F2-![)_ENY>N8^<;MDE%1+_ $;[MJ]*
MF1?4Z= A"N6FC7!F+!5:[#$L4< &Q)1K>";8+I=2^.&GG;,%DQAD;( *25LI
MR #H21< ,I/A"_6GW8*G:X1/)2*PHCF2 J^D=GX@+&41Q>PC<,BX(I(R9>.Q
M!8LV+%VN18<@LW=H(X8*>KJ;;O$DDU54TNKT\.0>:/-8GFX0=.*T:*7+)&6#
M,+*;$;>FIBTNHF*X128-*D/%*/PED=E15>0*54Y,+@[[\JZ6G9"EV;!$C+;$
MA5=)/3KJ/"4; G$&C;DT_:[,$\Z"TE9,MZ9118FS;ZCU=D#"+E9-!X-;*JH:
MJUZYI@+R31PW8HHEEB0L18=GMF^[ 6\*YL0#:IZIJ";)%)+V0QX4<CA0;\[)
M_P!)-Q=2!L3O68<WG50C9NG+IU#X&X)3@U7D?:S69PP&XE4H!D4QC@;&TMY"
MMDH^7=+M]4 ^F=) EER@B0#L72NK?ECJH%MQ)8XB9&B0221J7=2%*IVS<W([
M/ABXNH)JHTT[7X<4DH$:RN8XY&"(PN"_8%A_U>!XF-8B3]CZ8C3.9*I3^+2H
MK7Q0 (FL3A<DCDDF$7?226#84P2/QUF7P_#>C/%$6[O4IHS41PBZUUT4<(^@
MVA]9ID$EI8Y&A95ECC='DC+N(P'0-=>T;'*W?WBU632:AS&#$Z+*&:-Y$=(W
M"(TAQ<K9NRI(QOW5V+M[!U'U[BAB56C-8_'\C8K+I<,C+D\ 93&9,80%7.G6
M$&CQ<J,=2@PBR1UU38#]ML^L.&J:ZK?5?53C4ZO3Z2-I)Y$2R22!"R"201KD
MPB1F4NUNX=Y'*]1I]+/JG5(8V:[I&7"L8XS(P53(Z@A%N>9[@;7J0J7)4*4D
M/0Q6U:W2F$62'+2>**3F,:22.(EWHT:)5/ MBF"@A(H1,AQXY0@U;Z/7I4:U
M;957?-4U;]8TX=HS/")$ +Q\5,T#$!2R99*&+*!<"Y8 ;D57J\Y19!!-PWN$
MDX;X-B"6Q;'%L0K$V)L%).P-?LFN.HH4MHWF5J5Q$EU)&A#DT)-.(R!6WESH
M8,-MHKHF5*--]I&X#&@Y= 'KKDFJ,+#'Z;79H_:JJGU&GBVEGAC.8CL\J)]8
M5#!.TP[95E8+S*L#:Q%$T\\F\<$S]@R=B-V^K!92_94]@,K*6\&ZL+W!J,->
MQ=.>8[WD,\C,#RE9<IJ4:E8$BCL16DLUB)+044&Q=,J72V.[*NU4?4467GOU
MTUDL[LDME--,T&LT^^<J1?72:=>*Z1YRQMBRIDPRWY6W/BJYTFHVPB>6\*3G
MA(\F$<@R4OBO9VYWV'CJ08NRF<G)#&,6Y6.9)$1)H_*X]B>Q7)R, HXX59R$
MU(1/M;U\*) NT%VIHD2;MF8MPBJ@^6053WUQ?K.GR=./#G&K/(G%3)%0V=G7
M*ZJI!#%@ IYD53JVHQ1^!-A(RJC\)\79Q=51L;,S#=0"21N+UTXW?M$S(V/C
M40NJI95(RWMC L!&['AQPV2^CV%,G_9XH69=/GGL/"*V3'JZ"GLS"2GKOH/,
MV\D)JM+(P2/4P2.V6*)-&S-AX=E5B3A^]8=GOM4OI=3&I=]/.B+CD[PR*HS\
M&[%0!E^[<[]UZZZ/8?K^XCCZ8H7G3J\1&&G,;)2E&S84I'!\B9C'1IV!?'-#
M>PQH::AF3TLY%N'2;Y 8T=/U4-6K=572!J](4,@U6G,:L49Q-'@'"EBI;*P8
M*"Q4FX4$VL*=5U68CZM/FRAPG!DS*$A0P7&Y4L0H8"UR!>]?:(WO4,^GIRLX
M58$7E,PC\$A%EOQP R/+)[PFQ%CB,4/,7C!PX:D6;_0$H\4W9JK8:CBT9(N<
MILY,#6?(]5IY96ACE1Y$BBF*JP;ZJ8L(W!!(8' G:]@R$[.MSZ:>*)9I(G2-
MI)(064K]9%CFI! ((RMO:Y5P-T:UN<Z*PJCS78.NP%\Q#KH07+XL*:Q%]+Q2
MB0WTD=;-T,2!88%*&/3Z^IR.3C878)J,B\-E?:0BNIH\V7;^R=$W7*VKA351
MZ,EN-+&9%V[  R(5FOL[K'*R+;M+#(;C'?I72ROI9-6,>%%((VW[=SC=@MMT
M0R1*YOLTL8L<MNC(^U'72+([+$KIK5;"%CQ2I"*0J:1PNX"V'-"KD. BYYN.
M).%@9-PZ8$U%VQ31JJS9!S#YSHFU%/U4(?7:-.>IA-IHX&"RHQ661BJ(X#$J
M20;AK6"L3LIM*:+5OX.GFWA><$QNH:*,!G=20 R@%=Q>Y90-V%^O7W:SK[9$
M+5G06UX$.%CA0$O*&$@FD1&&X(WD[C#0 C/!WMUQ]$W1=WMHU'(EUD/7G.^B
M#39=7;&N46NTDT?%6>)5"HSAY(U:(2;()1D>&6.RACN>5ZF70ZJ*3AM!*Q+,
MJ%(Y&64H+MPCB,PHW.-[#G:I2#[ T+)DRRT;NZHI B C&)L=5!V3#2R86&9Q
MC;$N+;L#3C4;&,ZYQM@\\RB*\F<9];\F<<NNKTKY%-3IW")Q7*S1MC'Y1K,<
M4_ZS9?36;Z751XYZ:=,GX:YPR+E)]A;J+O\ ]([7HJ61^Q*_ED4WGD5G4.DL
M&30).5)G'Y.$,Q1-L&V7T+N-Y$.?.0^B K9JYU)*[/,)L=FZ^'6R64E,:Z)-
M#)'Q8Y8WBW/$1U:.RWR.:DKV;&^^UC>J/#+&_">*1)=APW1E>[6Q&! ;M7%M
MM[BU0Q3L7U\1B:4]6O:FTH*N]>#4)HI9\)TB:Q$?LWU?L$I'L<P'4>L=GC35
MXUT>97;;.F^%D],KI>=EUS2",2G5:81$E1+QXN&2+7 ?+&XN+B]Q<>.M.J:H
MR&(:;4&4 $Q\&3B &]B4QRL;&QMO8^*NG,NQU,PF01&($I]%W\RFYF#BH_#
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M-"9IJDW:9XUZ.U 32PM)"R:9]/)'+]8LNGX3*SQ1* 1+'(J<)6ED#(C')9+
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M>=JO6%:65&JDD1O6;=>))VCDD??2B-QQ]":HA[>-+'TLO"6VS"03?&TG;(#
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M2%&5<IY1*IC2[ LPC?!06.PJYW_;Z@A[P\.^E$F*$XW*R<')"HS5-N2\HK+
M6#>\E!A1L5@IE[)GD1;Q]\]FF8V@60AHUR")RA42.E$:=%^@](:52XS<LCF-
ME2#42-FN6:J(XF+F,(3+AD(U*-(55T+<XT&J(4X(JN@D!>>",8-C@S%Y5"!\
MP(\\>(V2IDR.%P,][JT1#P,B)"93],R(J $9P&3!!Y4O#3Z^E7/[ACD3WM5G
M&R-<@I5,($S1DT?CI:0)20A'B0TXP!/6)!AL[K+TEI8U<K)Q&6(R+BLAC8\
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MC E]ZL^0?JD0NC?<W$)J/CUX-;#J)GBBS;&"&?B&-U1EG:50 646=3$<E:S
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M0&D*K>R:US<LTHIA6T3J1+,7#!50]?UM(Q,C;!Y.NS=+:RF4R)2-Q5B>EB*
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MF",) &MD,LU*D'+8J0".HRZ/;1Z+3.L85<9R*5%8482%R^'#X/#$")$XUZ^
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M4*K)*5I2Z0J2H4+/'PIY1>,1-L@!F!L9D.D]1&=9<1@(LT\<DQ=XI62*!C%
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M@!ID_>;ME<&^A%H%:?6'4))%%#F\:!9(N)>=(@%9=/.51!("2L3?NKV0V0K
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MA#\?Z&O4;GX37Z]7CSXO<8LO%>02VXS*'4(K:H6,[*6K+\^('?O100%1/O8
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M*LUZ.K1\Q3MW,0TD#2?D&48=@%"31TY2=+L]N*LOA=W(WO>UK&_+?E?E4/\
M#$@%TQ^-7W8W9.'WD#O^Y+4"R2PI1=X[KY&W<S;Q>N(E X@I"H5UNFDYA,5B
M<=C4=9!/0E3#B5%3:18J3=.FSEAANHQ&P%K ;6O^-\@#?_3E7A7TJ[2=?;+[
M5!+'[\0J"7=8-[U_')D0D,U\*,JPF?7;M**L@+$X)349N.-=:W,HF<4$UMN&
M3&V1.9-)V<=4@8Q9.PQFCC9CE6K @64D 7_?YBW.U[#>^PK^Q;BL*T\[&?\
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MFN\B\,&,0C1$G1,@68L-/G(FGX5LB-.8^D-7K7CC8QW6-%U$443*%+&($I&
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MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O'.T-RS41W"Z[YAEBN;1NGMC
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M)PA8O8Q><#UH;%#Z9"OYJKK#W[51):',':T9!SI@6E#MY(5<11%V)=@V\$^
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MMRVW.2F^U7;63 *P$1XN6"V:\6.HCA^M.7:OQ-[*F#C&S7O6^77JQ)U.6-I
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MY!PIKHHNBR4([-DEE---U=$M=]M==MLXQFPQ9E^RQ'\C:NR)^)%%(18R1HY
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M)B=U<.F[LC/=/I''C0 JT"L-=E\K9NJBV-]QR-S:QMS*I?\ EM71II9).()
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M(U,NIJL638-&#1NW9Z%%M-%2.K=-/5ZIIJHYPKMKC.!)/,D_?0(J@!550+V
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MT9I0^4R".(NTHS(Y7$DQPQ.+2@\')'X[H*$ZAB++46/PVL.*!B UMQ;$\CS
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M%*Y:?XL?Z_[9XI6\W/05^3TXI3BE.*4XI6NUQ_\ 6Q?^5?\ =N.?,UW[1/\
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MLV3.NI;:4L:EDGF%<K*N"2UH.V2[7='5)ND);*IJJ;N5=$ZW[(7Q%CZP4?\
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M#],+3Q38<[C#>YM9+8]G\!>Y(VV J@T489R<2C\8X\,9WG+%[R$FX&38@*I
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M"*68V W)W/\ 2YJD(/VYZX60LBA"K7CYW=Q)&T.;[)(&&B+B5NBQ$"E'$')
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M,^C:L6+9=RX4\F?,22WV\F?)P 20!N3L!Z34$A068V"@DD\@ +DG[A7PC\G
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M2T;ZWDS\T'O1QAZOQ4@+:Y.YOWC8[\QSY ?>38<J][N*I6NUQ_\ 6Q?^5?\
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M#UL3N.F2QJRZ3C[PR-:MI'-R,-K=8J78CXA$VT@6EK**',U4AC8!B+W 4L5
M8 G%K!MN0NUAN;6N.EY<XTSXD*M@5<R+&LK-&SA#+$3)$,@ SE([D!5!R"F
MP;L=-89T'K>PGTKP2GY:R7E1CY0=<#K'8$UFU]RBO$G$>FLQGE7@)\ <Q4"X
MTJ^X;'GD/:V"'^BE@RM)<S(UHD1DH#*1:P"Y$>#^X&W #6-_"4 V-P-A<42=
MDT:/E=S(8@Q^L!M,R;.SQAUQ4\.5W0.,7;=L33(3O;V+FE4S*RHP9IMLWIJD
M[SMF6-EH:O)5; >TEV+N&JQX)J1BEODXS$V<Y@U9LCI D"-3QB/-'6Y*+E#4
M:V;:O+<- P!R[3*HL; 9*IONMS8M;>VPW -9KJYWC9U,7U44LC=@MF8IY(PH
MQE*J'2.Y*EQ<W4E;5";%[W7714 N-9.RX3.9K IYWPFOLDY%8TWRVC],VJV#
MUO711[,NP$"51$N$"FC?85 F4XL_<')8&C'H<FW:I$)A(B5BNQ *Q"XO^\.T
M=D-SZ38<]^5J/JY8DE[:.Z/K& 95'9B<"-"6F38WY('DLR60  O:MM=^;;@<
MG.$8P;IF59;V9V.@PCK:F#+N;=<QFE^I5SWU"9\E(1,Y=/GP^QSL!AQ7?=I6
MZ@[> 6%&6,?77D64W\AJL0(Y,.RAS_=NSJI'(<LCWWN#?;EI)K)$9L3$;23H
M(+$RE8M-+,CY![VD**=H[8.H!RW::">T%\RJT(C2,!MZA+!;2BQ(L!4[%Q"N
MB1J&I#I%UZO&X#,.%189;Y$4[G48?U;$R>CY2;+L6\$M2+;E03\HR4('X**
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MBW&4[FC:T7\6MIE$!]913*L^1,C7#)HZ:9D;2#B9(0;O9K"$8- &:":@(W7
M6!LS7P!QL,01>YV[^XFW(W/>+=9<,ZAXX@K3.&ES<2%9 HC7M@CF,L QNZ!$
M[C5TM[TV-/C<P@+*6!&\?D DY-8@4C:,>ATM"-JV[B4-5P\0STCMU3B=9:26
M(3LZA*D[+A%62!Z4CI903&FX-P7"!+",  GGR(.XWC9K^"!S&V):PYF]9G5R
M.S(&&+ LA4*C )J88P!C,[V97;+B+&Q(-E"W47IXC?86QH!%NPD%B]HP2E&8
M'I])+&CAF2M2:<VM.72=W/X8\C%3R)C-XDO&I17*06-$$R(EA)2R<KLVO7*C
M=F/:+LSM8E!*$@M=[&UK"UCV@0;AKG;;96M<\M=;.Z+.BR)$%TK.I8'.1F+I
M:-@ZXLEE-P&.4B;6%C#<]W^T!R>VT%A$-A1)Y$S79\<#K DW@GTI1'=;963:
M!7B:(;L$3M0J1MD-'4F.N9+2<!C@<C:U?&0QLM'Q;=W8\\-++<D7P[6]B7%R
M-UQ&-][,20IV^S7K<Y>141"5.H C.&5H&..RSF0\4+;M0H 9$()4?68:SO$,
MN?1B*F-:M( .K2?QZ^;6IN7R1A"FPV95]4AF$PB'M"I*SNP%),,C9^57D]F/
M#L.4D<H0K66UVB&AGK;0R8(R(EY'(D%58"^Q8$G8*QVV&_[P/<0*A];+8-&$
M".)I(F8* R1LB)<R30BSG*0LMV$;1V0[D_)3M];D&:W!IO.(%6ZD==]J;?%:
MW:@5F&9V:@4X&L!/7Z$.DYK%/9R(%%\DS+)@4CYK3,GB/T7 I))/6I-@IQV)
MO@O9L+7'A'8\_38;&Y[PZS*@E[2ICUB0<6[YE' $"=I;8C8VN>TN*\P?G+O$
M%O"/P^UIT+.4F:D,9>=W@FE!:1LM]/JC;=;JKN&Q(//+0(M+$<O7PQQ((#"X
M)-&B<7C(Q^K:</<!"H8AY6QH(E)4'( X=O:QR95(7:U[$D;GD;W[H;63!9'!
MA)4ZM>#BV<8@CE='D(<[9(J/V5!XBV(.S6/,.T7:VHY'9"TB?U?;0FL+H?5#
M]"8;54FB$IGSQ_TM5[2C5@Y=>SYBF*(-96Z$P4*-U!%]B0'5ZJ066-OFCT?7
M%#C;)<E!N2"!]9@=L1?;?F-_16C:C41F0MPY!'*8L$C96?\ LO6!8F1[$,0@
M&.XN3N1:,57W*[,VD7KJ#"S=1(.[)LFKXZG9/T:@\F8AQDYZ^=H+?E0<?#JD
M[06P.U>@UZ0A[Z&%Y7.A11Z$FZC610IQJ,:GS\M&JW)#; FVXO9D4&[(NQR-
M[#8CGO85CU4\A1 8KO)&,\48 -#J)6 6+42#;@K@6<&S=I#;)KHZ<7A;=NW?
M.ORD3F,.&6_6&@I,RKT"#>A6+>5_EA[3UU-IM'VQ&7'7;9B<=UN.<%V^R#W+
M5L4AP%<NHK&L$9+$BJJBP/AL+^C&,@<N[+Q^/;>M=--)+*V;K;J\+! +=KBZ
MB-W +,;$QB_/8J+]F[>EG,:[J<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2N6G^+'^O\ MGBE;S<]!7Y/7DSX
MS<WK4)TX=P.=7/3%3%K.M2CQD7%7G<,KI6!VDTCUVUN>FM=R>6U^$D,^9P>1
MQ-%^&GY./#FK2/QDHZ-2B21.,M2DA8*NE\N1-@;V%R+@CE_2H[X.9>F7=87@
M%IJ.]38^QCEK#&LD]SKL!;/92L7Y@C XX5;.'MEV;#8HQ<2)(6[9MWPF%.3X
MD6DF@@5>LSWKPULH_,>%R_> !YGN%>-_B"%QJ?B5WP0CL<Z7,.P ^[.G4+J:
M V]#^ZQ'LG?#64P^FV"%F0L55/:&OZMG4&K,F;/IM\CHJ%8ZI5_,14O3&OFF
M\CE:KKX(OE:S7(MB.>VXVOMW]_X5_3YTRNZ3]D.K5(WE,P0J.R:R80RD)5C'
MT3;:-/%=W+MHC(XHWDJ:<A0B,N:M4)7$T3>-RJ4<-#$WR[ESJHX55D18D#<5
MD[C_ .MB_P#*O^[<<^9KOVB?X/\ N->S^3/]UU'^8_VTJH.<5>DIQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4KJO&+(BWV:$&;5^UWSKMNV>-TG3??.FV-],[(
MKZ;I[9TWQC;7.=<YUVQC;'DSC&>*$ [$7'B.]?%@)%BM=]!8T>-T4\W"FK!F
MW9ZJ>9G?;3S]6Z:>-O,V55SKYV,^;E3?./)G?;RKD\S>H  Y #[A:NJO'(\Y
M7$NG($*X= <J9!.5Q;%5<+E5/"2N1*RB&R@[*J6NJ:F6>R/GIZXTV\NN,8XN
M?'SY^FE@;&PN.1L-ON\7X5V7X@25&K!B@L<2$.4=6S@4_9-G@U=OIYN=$%F+
MA)1JJCKG33.J6Z6VFOF:^37'FX\BA (L0"#M8BX_ERK\<AQ#T9D*\%#78;9!
M)KL)<L6JXS9LW\ST#?+!5+=KE!'T27HD<I>C3]'IYFN/,U\BE@18@$<K6V_E
MRKDF(%):N=4A@]/5YA75WJFR;::NM5ML[+8<XU3QA?"NVVVRN%?.PIMG.=O+
MG.>*6'B%==>.Q]TOJZ<@@[ESHY</='"XQDLOJ\=L]!SIWJJHALIJY<CTTV#A
M?&V%5F>FC53?9#7&F%+ \P#W\ASM:_\ +;[MJIAKUJK)O;;.YE,2HA)PY)V<
MC0LK+SI&(Q(^_B1&!O#,8C;IVHS$K;Q U( C0:EML #HR63.@8<81D1EX]MF
MV..UN1V%SO?<_?OX]A67 CXHE[19;E068JI*E+JM[#LD@#P1DV(!)-7:R#B!
MJ*3<<*&CT$'#AV@@R8M6J*+MWE;+MTDF@DGHFX=9<+Y<+::X47RLME3;;TF_
MG5K4 #8  <]A:OB\CT?(-<L7X,.^994:K99O!C)RURJQSC+)7+=9#='*C3.N
MN6N_F><WSKC*6=/)CB]N5" 18@$>(@6VY5D4VK5)=PZ2;()N7>$<.G":*>B[
MG#?7;1##A;77"BV$--MM$?2;;>CUVVUT\W&<XXJ:^_%*<4IQ2G%*^>J*.BJJ
MVB2>BRV$\+*ZIZZJJX2QMA+"JF,8V4PGC;;">-LYQIC;;&OD\N>*5T'P0,3:
M;L"0D808J.=7BC)\P:NVF[O1?#K1UNV<)*([.=7.,.-5]M,JZKXPMC;"F/.X
MJ" 18@$<[$7%<E@XAP^]IN!8Y<EABL+P068ME7WLQQOA5<=ZWNELOZBNIC"B
MS3TGJZF^,;[I[;8\O%+"]["]K7MO;Q7\5?7V</\ (ICU!GY%DUT5L>JH>15%
MUYGK*2G]C^VFX]&GZ?3;RZJ^CT])C;S=?(J;?\^_G7P<! SK9INZ$C'.X]][
M48;N&#5;9D3QC?7!%ILHEMEL^\U3?7UM'.CCR;[X])Y-L^546'B&QOR[_']_
MIKXIQV/HK+.$@09)PX=N'[A=,8RT67?N_08=/5E=4,;JNW.&K;UASOMLLMZN
MAZ3?;T2?FJ6'B'._(<_']^W.NP_$"2FS;<F+'$=V6ZRC/=^R;/-FBCANHT<*
M-MG"2F4-UVJRK9;9+.FRK=51'?.R>^VN5" ;7 -N5Q>WW5R2%"T"#LL@-8(E
M7Z3=!\329MTR#U!KC;#5%V]T3PY<I-L;;8;IK*;Z(XVVPGC7RYXI87)L+GF;
M;FWC-?)R$"O$6#=V(%NFXIPV>"T'+!HNB-=LL9U9NF"2J6VC-PTUSG5LNWU3
M50QG.$MM,9XI8&UP#:Q&W(CD1]W=7)R&$/,MLO!0UUEF0U+-,N6+5?+4KIY^
M=";;TJ6WH"&F5-\ZO$O-<Z^?OY%,>=GRJ6!M< V-QMR/C'I]-0^&57!("C(D
M8V :-]I9))G*3[EUKA^])$Y[*C,SDB2[QWA5SN+<R ^5=MA.5,CV.CK9NU;I
M(XQKR22>_E:WX"PJJQHE\5':9V-]R2[%VW/<68[<A4ZRT:Y4RKELWRKE?5UE
M3**?I,N=$,-='.=_-\[*^K;&&^JWE])JAC".-L)XQKR*O749! PW3*8X0,8)
MY?."F=&3!JUTR3=ZJ:.R.=4$D]?7G6BRNCAWY/6%M55-5%-L;[8RJ  .0 WO
ML!S/,_?Z:["0]@@MJX09-$7&B&S75=)LBFMJVW6RXW;ZJZ:8WU0V<9ROLCC;
M">RV<JYUSO\ VN*FPYVW_P"&NWQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KEI_BQ_K_MGBE;S<]!7Y/7F
M7XN(>.O.F$D.E)/$X/)(=9] R:N)9*JGEEWY;6&*O:N'\0CH2KH&W=32:F9P
M>9CHBSCP%!11ZL636>:ILVBSENJR>$-K[&^X&Q!ON=AMS-83PHNRYWLS3]A2
M,PO4SE !.@S06O3O5^ZNJ\96'R>OHG-Q;QQ$+ODTD/21V9CTB R(?+0RC4 3
MC)J/[LL/-<X=J*. #8 C[R#O<C]W;\.=:-]A@/;JPN_5M9IPEV:F$W@UU]<!
MM'3.FNRE;">H/7>J,1.GI+=D#[=T9O/FDD5G,F;.;&F"XN25Q,3]@0N85MO!
MG@--BQV1588A03;D;@@W)N;%3_(;$6WO>OZ,^*SK7:X_^MB_\J_[MQSYFN_:
M)_@_[C7M/DS_ '74?YC_ &TJH.<5>DIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
MT<[K6'94*==7H]7$EM*-YM3L&6@\O4I:-5-)[**1<9UM["66B-CC.Z(S*X0U
MQB5U]&"1AZN,T(Z@1Q-LP=)*NMM%=(P#F2%.*7&18"^:+OB0>1/XUR:IW3JX
M1I%XDY1N$L;2%1!/)91*K)X2*2;7Q!L:H:NR?;V>VA7]1V+=]MTMNXJKL%8K
M-R.B'5]S9\H QR\(1$ZB)VTV=579==C))O I-NY/AJS;Q8>LX7:*O&PDIH]%
M,;'  D*K;J.;V!QNV/:4VOX[_CSK%#J7E2)Y9(KQ32"RZ<R,%F18S)>.2,-@
MUV$>(Y<C<#8/KCV,E=TU!'&6$E,7B]A<H(:2QW4=KMJ'DB\3FQJ!,IBPG;03
MI 5&<WR':S0= A%E.I8W FDU&Z2P]HH2Q5U"M_TW&V0+"X!(MSVY7(M<5O!.
MTL:C_P W%CEPY."Q5R@8/;"SV#A ^0!\0O5?5%9-R=@Z<ZCAUK4-5]8UD50_
MN2W[&K2.5]Z_H,!#!T=U!@PEA0RQ8D"^EDYFP<J+R2C1%3<!!I0P:.,/,*/$
M98*K.0MU!LH)/?ON0038#Q\R*I&\LT6F'$*/)'Q9'14O8 +B%=75<G<$74[(
MP!OO525G:78$'775N;R/L-/[)(7?V/LVN96PF40H8>*'16O*H[CF1S..Z5W3
M<"(-%RYVKH"9./29$NYW=1W1J(4#B"AT:4DA26 4"RJ18MS9HQWL>08@??O?
M:LHY9A'IW:9W,L\B,&6( +''JB N$:'<QH6))-UL+ L#1E>=Y>Q\GI3I8#?3
M1GO>+NY>OJ_:*2HQ"*9;R6F[/L3KX(CXI(.W#8#QHS:<%[55H=1)QP8+6;/8
M98;".;LEAJRC6YC4-(;=G%\!<[, Y/?OB48;D\P>^LDU<[1:52PXW%AZPV*V
M:*1X0HM:RM(FHC8%0-TD"VMMMQV@[&64A5LINJ@99,P@JKJ[/S,E6Y:E5XI/
M79!BZ)JMYM<L"O\ CT1M$5UQ#LHN9;FGU31A.SY"HH6=P-<ZO'_9+G-%&05@
M.T0+Y7'=LI6ZEM_WMAL#SKIGFDP:6%F"QH6*&+%R1?M2I,%D$ "FYC7B'<IE
MC:K'[!WS<5=W'7[*J8[$)_#7/67L5<DNC,JFZ=>LGNE92KK_ *!3 >3-:^GQ
MA8UJ(FLB%# JB 2+.O;BA.1F6JHD1HK"*I4Y$@YHH(%SV@]Q:X\0\9\0W-7F
MFE25!&%=3IYI65GP!X;0V(8(YO9V %@N]V(L+TFX\0LH(U?2$=7)8Y7SB7R9
MZ5F\_/E(_'H!$1D6I^0#AK\E7M(2D/"-B R?F2;,A>)^)1!H^CA0>5N-35^W
M;QVW"'>;, .R!<DW8<BPO:W[H)W\'QY==(!81LT>37=R55%QB8 E(F"7$A-Y
MBJ@J09=^SEY7XA\CK\"4G$SHMFG!RLK[#5[5N\2LDK,)M*IS0]N%*C;,Y9#V
M-6-L1(%/B@IR18E(V7L4K'T?5A[^//BC]LTX$0-@&WLC-<64!ERV.6Y'+<"Y
M[[5+:UD!=H1B6F2/&0L[/#*8K.O#&(<C8J9"NP*DFU9F.]W[9F)': 1OKDR;
M6^R;6Y(WH>PYM9E/5Z5@=1 Z.+$I#$I9:/7F+S<B]-$NP$+BC-G(JJB@,<9#
M3AZ_E&084*0E$<-1N7[.PN &()RY@.0+8D[,3N-N=I75R/V%@^M'$)$C21(5
MC6$DJTD"N23,B@-&H!#DM8*7I"2]O[L6M-BH(?&!-5!5+?T.CD);5Z\L*G1'
M:NE:5"L]=_R 2D'M$HP(GF<"T14IP8+LSAK8O+C!&/QX^3N(UQN?"[-MC;=&
M;[8-S;>XMRL!O63:F4R#&XC!D![4>98:B*)?_)=<%#[6:Y#&[$A2=[*!OZ:W
M6X''GU:QN+5A.(Y)995TE:6@W/S,L&C<L9QO76<5T\B<:=15\98DQQ]I]&#E
MA"0V-W(&5F )K8(@?R90NV5R" 1:PW%]C<WMRW"GQ [VZX9FELQC58W5FC;B
M9,0K!>TA5<200W99P.3$&V6U'*5T4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE85A)(Z4)E HP^%(F >R>AH2P*L7A,/NMC.4="C
M!NNHZ'[*XQG*>KM)'.^,9SKC/DXL?%4!E)(# D<P""1]XYC\:S7%37YG.,8S
MG.<8QC'ESG/YL8QC^_.<_P#IC'%*^:"Z+E%%RV62<-W"2:Z"Z"FBJ*Z*NF%$
MED54\[:*I*Z;:[IJ:;;:;Z;8VUSG&<9XI7UXI3BE.*4XI3BE.*4XI3BE.*5B
M2IX$!T15.&A(9-QOLF@H5(LQVB^^F,;;Z([O%D=5=]=<XVVUTSMG7&<9SC&,
M\6ORJ"RKX1"_>0/ZUBE)W!TDD%U9E%$T76JF[9921"-$G&J2FR*NR"FSS&BV
MJ:NNR2F4\[8T4UVTVSC;&<<FQ\1_E49IL<UL>1R&]O%O7=WE,83*"PBDC IF
MC;39^%$;EQ^I0NQTTRIN]%L-G&';]IHGKMOLY:)*HZZ:YVSOC&,YY%N_NJ<E
MN!<7.X%Q<CQ@<S65]=9X6<-\NVWK#1!)T[0].EZ9JV<97P@Y<)>?YZ*"V6KK
M"2RFNJ:F6R^--MLHJ>:J:Z F11\]Z;V&=#FO5O,]8]DDV1'U?TGG>C]-ZFNM
MZ+TGF;^9Y_F^=YNWF^7S<^1:W.H#*W@L&MXB#_2N(>21V0[$-0!\*<V$O-QQ
M74.58D]AI!+R^D8D,,EU\LWB?DSY[5SZ-?3R9\[3'%J!E-[$&VQL0;'Q&W*L
MUQ4TXI3BE.*5RT_Q8_U_VSQ2MYN>@K\GKPX\:7LL_K&/T_1C1IUK:M['CEP=
MB7<F[,V;.JK#-7W3(O35APZ*57)*ZDD1D[.[I7/)=&'D!?MCNS=AO&"6KT#(
MFKQ8?E6B"]SOM8; 'PKC>^UK7_F/OK:'PPHGT^%43O-NH<G:2 +:2$#E\W")
MWN[OEU5)16NXVC&:2P5>2(\I"P=417V?%8S =-!*4>%-=44AJ*>VFNJJM>^_
M=MR VN=]OZUX?=0KQZL=P>Z3R[NT\THNJYUV1KB"7[7#FC?$ [!5P3!%:[F@
M.IX%U^[!5KM=H"MS]N9C'T8-MH]'(J%8FL:2]-]#'^Y)X0=JT8%187-B5-U4
MW[R0;7MO;?\ ^*_KGXK&O,?Q(#)@(+HI<,5)"%GW9KJJ&>K#'SI@J\#F+^B8
M\N*=*-%4MW TJP778D6*N=VKYFLJV<I*HJ;Z9^?J@#*+B_U+G?Q@-8_A7K.@
MB1HI+$B_2&G!L;7!:$$&W<1L1WUY3 .V';A6%@+)+SRIW(USUYI;L<1BS&I"
M;/9=.<VFY@Q6 MCBMC.E6HYU&$L$%#F[!R5:R[S7K+&D=QM&E.<H@.-F\-DO
MD.X;&UO']VVW/<?874:G!9"\9!ABG*B,CPY"A3+,V%M\K$Y[CL]D_LL[7]N!
M,3FEALIY4Z(T/1O?B_AL74J,FYV29]*KC#P.,P98YFQT%5TK,"R-!>:2++#1
MT(="M-(L/9>MK.=02.]K-X4:WR'_ )@))MCW6L!_.C:G4@,X:, 0ZR8+PR=M
M+*$5+\2_U@8%FYBW9 WJ26]X@<WA\3G;"*G*M<V[#3'?K5]"GR*KXF"!=>FE
MADJ8)2:/,SR)@8UD(L1#29!V[PSTE8LFJ_ X:MG2:J$"*Y!(;$\*Q[B7QR%[
M=US]UMZF36LJN%,9D0ZRZ\RH@#F*ZY C(!22?"!N+5)9)V;NJ$6A):3L2[J>
MKD3'YU(&CKLK+J^0 Q1NBTHVJK2CU;N(\8L9K'F<C/%YO,R0\D[E'K+RNJX,
M"&[/>4;[S!& @*Y!6)MX -SX1!.PO8 "_B)&]MJLT\J2&)Y8D"NU]0Z8J+11
MR+'B7"AF+L02W@1D6R[5?2T;]M:P.N]%RFSZ^GE U;.B?6V0=BK0#2]A%V(>
MO+ C#4_.A+!Z$E"5N5A&1L^>QN$3V524;#B$=@KV3$W!H4V;N"[8JJ'8 AB
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M;#@KDCHP:,W4G!L(83/J/G;-BHVEG<XW)  7'_\ 08@@\]K'[C>U4CT^G'%
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M'J;]D3++D-MG!IJ]9[82QZ'*JFJ-=#<DG+RHC-K#[7/_ -JY9XE74"T:+'P
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M>T&L1?([$V%MO2;<[&W7&(VGB;3Q-$J1R+,3"\(*D+A&0R)DP;M"U\ &N1D
MWIQS&N^G%*<4IQ2N6G^+'^O^V>*5O-ST%?D]5E8U*4U</L?-MU)65I9CWM#
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MOJ'2)2JMNKQ.=%XK#Y3.8M*"L8;6)"!0B:V(0:3V/^G][;); E8KE<CB=\[
MD*0#B=A5#UBQ)XP%HP#PY,FC$NMQ#F)>,K</@%RJLZL5XB!7<CO5K9O8Z73K
M Y-_V>:W-&)[TW'LH!*!14Q4H. 2"LZ8D'91*YIC'JTB->(R]Y#2D]D7F2P;
M!I,TFBL1S7\,CQ@N=CRAE0#]P@K)<BUR<F"%023:X V)&-R;[41YV?8Z@2JV
ME 1KF((R1F?BLL:QY%"[=H(V6."*25J-5G).[JT=$N+(?=C&XA\C3F.U.@6!
MVVYF\8//#I/-D*4C@C  Y%=#=]AN E _K(*L"&B:]T0D\ D0\]JB;.2PC_=P
MOVL-UM:PMEN?O!DL;W#"VU5C;5E1GQK'A=8LLF:DD\3A713X@PTX=0G:1@UB
M985K2W['M*G#3D/V0*P>&6%6LNBQFRHOM'YDL."5)WZT&$K#2&C4EG:S5ZO2
MX11"::(2MLUEX-A.!(*<2\\,VK=0K@8W*D&VXOE'L+^B_+;;8D"K%)7DB-IR
MBO&RF1<6L(M9N]AOOP1VNU9@' =F%6IU>?WEK,JO&7'CL\$FK!K6 T1& T$?
MC^OB51I]3H>YD2]B$W0$?7XN0)7CO,FQ1FF:3NX3.F,= AXZE4V76SB'QLV.
M%NUN3VK\0VQW)\#'>V-KGPJUTYERC$G'## !0A$/"ZLI.>P16XN7?Q0X50O#
M)KUAYC7T*<4IQ2G%*<4J.3"4B8-$I3-C^ZZ8*'QPW*32C9#9RY3$Q\8Z+$=V
M[;3.-G"^C-HMLDAKG&RJF-4\9QG;') N0!S)M_.JLP168\E4L;>("Y_T%8O>
MR(0T@HRR3<F#1:%%0X4ZC()8381L:V82!NU<"\D'I9RU9L5G.'K9'5)=QKME
MPIJAKYRF<8RL;VMON+#?ESY5'$0()"P5" <F(4 'E<G8<Z[2L_@B!\'%%YK$
MD93)Q^Q>-1I62!TS\A$Z)J*[DP8;=Y@B6'Z)(JJ;/6#9PVU324WRKC73;.%C
MN;&PYFW+[ZG-,@N2Y,+JN0R8>,"]R/2*BPF[*SD-DJ51'96*D4Q;1^32(DU
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M4XI3BE.*4XI7+3_%C_7_ &SQ2MYN>@K\GIQ2G%*<4IQ2M=KC_P"MB_\ *O\
MNW'/F:[]HG^#_N->T^3/]UU'^8_VTJH.<5>DIQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*AD_G(JN8N\E9AA(BS5J[$#D1<3CY.3R D2/%V((4R8"!*"
M[C?TY(BUU=D'.6H@*Q]9,GB(L(P($6L@7-MOQ-A_K_P\AO578(I8AC:PLJEF
M)8A0 !Z2+G8 ;L0 2-7''?WKTW%-#.'%A.V&H"3RJ3K#ZTEY!.O8U!+(DE26
M ;GKEF.69@6,&G\2D 0]Y'+M=5$:Y-@T# !!8HG?A/RMX@-QN2N0 ^]2"/\
M7>N?KD-@W;(LS-:-S@J2&)R]A8!'5@=R=B5!&]='7OE6PJ*3V93:$6I%@E>V
M!>,3/OD(+(S[$?%J%.,Q$PL@H09"T&@\#JF28.4!.BCR1OUO:C&.#)$H ,JL
MW#-P 020IYCFU[+SY[<^7*]KU'7$"LSI(H1YE)P8@+"0&D)L %W&V[$W"ABI
MM+I!W;H&*RAY'I$:DPD2Q.3F,+V,ZA$HQ5?TCK&KI=<MBA-)^F-4!;/897\&
MDY0QGT^&V[T,5!#7#\X$.CQ<"-B+@#D#:XO9F"C:]]R1W>D[$7LVJA5B&+
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MZZM"L3#ASO78MV(CUN6-/K4E2T<:1>NP$?&/TI?9<I7"I>PU@8D:JP$M@N&
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MB0%PB!1()D$&:778\IPLP',#C^9R1V0?EUPJ;./M:9G$J H4]POXP;[DF_9
M^X>/>NA=.H=9&DDDD4@Y-@"0J2(JD(BK8"61M@"6:Y-K**K>>')4RD&U@#&<
M6 D#4:0P<19R$/3MA!S0Z$0'\G8I$S$;$JF4PQ\\U%X3,-RV\>U*BI&CJZ#N
MV(AT5"$K<5KY6%[D_O"UV+&Q# ]]N?*LSHH\, [V[-PPB<'%,!=7C9#L+WQN
M&Y$ D'9*DZ C5#J39.)R69EQ<X<5X_=BI<2&F\#2E=U! *1:%69K =I)G[Z0
MPNL(7O)%9$:.:N3@YT5':#-RI%)Q1F+6N +7Y;<V+>.VQ)M:VU;10K#EBS$-
M@2&(-BD:1 @V#798URR)W%Q:YO>W*UM3BE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE<M/\6/]?\ ;/%*WFYZ"OR>G%*<
M4IQ2G%*UVN/_ *V+_P J_P"[<<^9KOVB?X/^XU[3Y,_W74?YC_;2J@YQ5Z2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2N.^<XTVSC^_&NV<?_ %QC.>*5X1U'WM[!(5Q2
MU@6B=EKD7<G5C>VG3V2T?'X0,2LK4?5<@9!*6DPPFL&F YV"E$Y*N LR8($'
M$7 -)$++:JCR@]YTO$N3*MNS)CLQ/9N?"'=:P%QWFUN\?(BU<W#B>0L1+IC+
M=HE0<2T; 1,#9A9G-G )50P.Q!W((^( DP-V+&]*<*+R6)3Z*P".PMS/(U'K
M$//)=V,A?6X(=/025M@)R-Q \?G0::QB:@TYS"2D&VU<E)+'Y$1#1PGGPO!.
M6Q4L38V'9+6N+W-E((V(/($;UU'66+KPCDKJBH757.4Z0*S(P#*K,X=77-"G
M-E8A3&9CXE@.$/RD2+U&64LR!ISEY;$'93 <ZV",8,1&-=6U<E4@NVUH22<#
MRR!J @=AD.3?-D'0^5%(<=]2%/9$)-C?8VL;>._A"_9M:QY\P1<;U5M<%)4Q
MDR)F94##LA"!]6;7D9P<D6RW&S%&V-@2+N)(7H$],(O5\C:U*SM-S5 6W4#,
M8?/7LNA?8&/49-V1:NRNK0@#CS^4_3 ''3V'Y4B\TC;\@\"1_5['ER5<!L">
MT1?$@BP*Y#?QVL2+=_,U<ZEB"RQMPQ(8Q+=3=DG$+@H=PI;(*UR2%)(6ZWI6
MI^[MIX=O!UDQC,CL";SZ=12L*[!$(T,C?K2'9FTZ:C QU-,BFY >PCL>K4L7
ME1@D/.O7C(*2+AF! H5$Q-*QC&Q!V"@D[W\!6Y>DMMRY@'E>LH]7)N)%N[NZ
MQH"H%^/)$HSML%6,EB0Q-B0"2%K<J<]A"]=TH+LV85XUB4L(R9G"U8),+%BH
M 6/D+F4/(SZ?>;ZX(Z%H^ZT'KR$#M&8T=FL@!.1N&<"T-.'88?0*"ULMK7N
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MA<V"QLI);AK^7R31@=T9GJEU^A@$CJ,%%MCDBL$ B@W'!&9P\-DQ8WR;8<B
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M1C9S&!5.[M^-#Y17R9]EU19861(0^SI$$B^TF.P2XY/'QT/F19M&=7;TTL]
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MZX\N<8QC.V?.V\F,8\[;R8QY<^3^_/DQC'ES^?R8QC^[&.*5^>9I_;_L:_\
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5LR3CAQ^33U5]U.L:CR\WYK_%7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g942137g14k10.jpg
<TEXT>
begin 644 g942137g14k10.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1E:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      %U    $     $       MP<FEN=$]U
M='!U=     <     0VQR4V5N=6T     0VQR4P    !21T)#     $YM("!4
M15A4    $0!! &0 ;P!B &4 ( !2 $< 0@ @ "@ ,0 Y #D .  I
M26YT965N=6T     26YT90    !#;')M     $UP0FQB;V]L 0    ]P<FEN
M=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    B %P 7 !0
M $@ 6 !& $( 50 M $T 5P!% "T 1@!0 #$ , !< $$ 6@ P #$ -0 Q "T
M6 !% %( 3P!8 "T ,0 X       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'=B
M).         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE- _(       H
M /_______P  .$))300-       $    'CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M    !"D   .$          $                          0
M   #A   !"D                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P  !"D     4F=H=&QO;F<   .$    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   0I     %)G
M:'1L;VYG   #A     -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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MM5O:L#XN_N:AWYYHK-MQKJK;$N<3R>!HU.L[KM++L !Q+7-L::R!(W0YOO\
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MW(5*C'RF]6R\FS9]FMJH93$[YK-WJ>IK^;ZO^NQ)3'"P1Z55N77^M,)=](N
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MI,DG@I0@I9)/JDDI_]D .$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      7Y-30 J    "  ,
M 0   P    $#A    0$  P    $$L    0(  P    ,   "> 08  P    $
M @   1(  P    $  0   14  P    $  P   1H !0    $   "D 1L !0
M  $   "L 2@  P    $  @   3$  @   !X   "T 3(  @   !0   #2AVD
M!     $   #H   !(  (  @ "  Y%IP  "<0 #D6G   )Q!!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$U.C X.C$T(#$P.C4T.C0R      20
M   '    !# R,C&@ 0 #     ?__  "@ @ $     0   X2@ P $     0
M!"D         !@$#  ,    !  8   $:  4    !   !;@$;  4    !   !
M=@$H  ,    !  (   (!  0    !   !?@("  0    !              !(
M     0   $@    !.$))30/]       (          #_X0& 34T *@    @
M# $   ,    ! X0   $!  ,    !!+    $"  ,    #    G@$&  ,    !
M  (   $2  ,    !      $5  ,    !  ,   $:  4    !    I $;  4
M   !    K $H  ,    !  (   $Q  (    >    M $R  (    4    TH=I
M  0    !    Z    2  "  (  @   /      0   \     !061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP.#HQ-" Q,#HU-#HT,@     $
MD   !P    0P,C(QH $  P    '__P  H ( !     $   .$H , !     $
M  0I          8! P #     0 &   !&@ %     0   6X!&P %     0
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M 0$! 0$! 0'_P  1" $1 .<# 1$  A$! Q$!_\0 '@ !  $$ P$!
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MPVT^T%*JI*703<4=Y0:I23C= 4<23&4)*?DI9C&,'JQE4HT3'3,<1.=98#J
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M/:C22I<C,4&)*6^TH./9WB..0&_A>A1*8"G*8#$,&T!BB E,40N!@$-! =!
M0'6XCNQN22%I2M"[R5 *2I)24J214$$"A!&((C'8Y&M<J4QJ,*:^7AY.=]/T
MXZ_K;OOB:'4^GM#PQK]=V'1TI 0TW]][?*WH'/A;"AU/I[0'O37'#K/3?#OO
MZ<^P.[UW84.I]/:'IUUARAOOW[M.Z_I<![-.6%#J?3VAD1T,JT]:$?*)UY;]
M^N[A<--=-=<*'4^GM##KKRB-1[KWOIW@ ::\_2^%#\1Y#VA[?IY1.HAOMO[>
M/N_;B**^+T$1$"':%K;MU@TONU]0#"BOB]!$\\\\<\:=9Y^$ #D/+3EV<;:;
MK<?#"BOB]!#]=P'#A7'HXPUO>]^0!:UK<AUW_B';A17Q>@AU4_*OKD(:]F[E
MI<.WM$?(/'"BOB]!#SW_ #WTKP_6 #J(7\.(;K=H^6_CA17Q>@A3"NOZUZP\
M-.S8.0>08JNJT/KIY?/]/-"P<@\@P(.A]1O'Z\.!A$['W?3],1UX9;Z_+Z0A
MLV_P^G9\AUQ!\]=0,N>..N'&A8\?WAL_=[]/'$^77#U%<(0V/N_^'#R_3KA"
M&Q]WT_3$PAL_=[=WGB,??7/ ;O7W,/E#8^[KV![[-W/#Y>&[#@?.M"!SA#8#
M[/I^G'AKAC[YY8TIQUPQRAUU^T6W5[F484Q.O(5$595O&NE6)"I]8?KB)B.V
MFELFZU1(NTJFELFZTY"IB4VU8<!M7,VG);-VW-V,TIZU)>SIER20E':K[5*#
MWVVJ*#KC2;SC;5U7:+0E%U5ZZ?;9K;#L_*-S*KLNM]M+I*KHNE5**5A=2HT2
MI510$FHI4>/-02^=*]32,@@D>89K+O4FOQ[N*!-=TX)6Q8US)&/'K2HQZ:Z=
M'"^>MY0KIF@<PDAY';?=5\1+=L>T4&9M2=F';2?*'YV;>5.S$TLA5F&82AQR
M8[-3ZD&T@TTZR4+4 G[PR$M ]8")I@W&&D)81>0RTGLD-C"8#9*0B\$ ]A?*
M5A0&-Q=513V\KG*R9O5WT:W.O&(NFS S5)I*KS,M',X]%%XLT:_0@H0DXJWD
MWS-RU7;OV4G),TWL<VBXU9J[M&7V<4\SV#[J.U6T\X5K=EA*,.NNK+;;RS-7
MIN3"V&UI6E;3C##JFGES#J5MU!4\$+OH22E*DIH$N=HM*4 %2!V8[)VBU @I
M4E:TA2 A!"MO*0Z.,1F+#2-92KFH&;]V\D%FS9-9L1O-*E;)JE<**.VBSA'K
MI$RZ3IP58W6F*IL=4<ICF^M?LDVJVNG?L]>5.C[W.2BIZ4V?G)V^IV;89ED?
M=2\XM7^8::G"Y+)?6>^VR4+)+96?F3;[[$]B+5VR5:R7I^0;GWFIRV;/L]<N
MB5<F'7BJ96U?8<<EG)E/\Y]+:C_,<4ML-J7AJW49LUXBIY)!I&/%8*#D(ULU
MB]N(0=K132/IM)U'$1?L%GBYP<IS;%+K9:&/' 8'@&D&[1NP6^4YQ<K.O3#F
MT,Q,_P#U',+F_P")S$^F=5,,S_WB> 4^.V0&2VC[JH-)EIA*@@,)0Q>+J/I&
M1E4V=*2LG9,NTS9$DQ+2\A+RQ92TF39980VVS@I2DA*5(2I3B"#59+A 2:3&
MR.=#%R8LY"M)A&+8HE<A"/8E+^8IA0*C=H!%+R36+*UB126IV+F%WJ#)TT?M
M3+,$5X_XY\OY'V-FG4),K,NRZWWE%'WIF94)*63]Q;7]X2RY,%R8O(G7Y9#2
MG6W&7+KJD/=DTCUH7/I)[5M+@0D5[)2!VKA[4]R^$!**%I"RH)*5 E(*;RCZ
M)=$^0K>7R\2=UDR<L3'18&1:KMSM2MY$4URS"#) [V2%!B14K<Z* /WA$5%%
M2?$**@N./IC[%C:0D+=84[,3.SDO/,M[//S"UNA:+KWWUN6<6VS?EFR):MQI
MMD3"G^S0E1=2-#VJ+/;2:PE+<ZME2IU#8":'N=D5I"ET</\ ,_$I2[ER\2+L
M;2=7V&]^&.V=$ZQJE5:GF8=6 WT'Y>^W$4I3R&[+EEOPA56JH=6'WN/IX?MA
MXX]=>>D*JU/,PZL!W7]^_3 ;O.O6M?+QPA56IYF&P7$;_P!J#$<!F>.M#41-
M5:J]=V?*(V [?,,3@>M#]/3QB*JU5NU\?6&P';[\,1E[4WX;^-<SPXPJK4\S
MU^T-@.W$_7PS]^>43WOS>&,-@.WWX88:9TW9_MGX8B(JK56[7K&&P';Z?+"O
M7I]:?N*JJU/K$[ >QPPKAINX^7+7'#"%5:J'.(V [??AAQW9?N?2FIA56JO6
M/O%5=]<:XT\LZ$?0U\:B_#$D\:\-PW##7/4<3C"&&&HW;Q7+CECAGG7 TH$,
M,!G3#Y<3B/3S$(8C TR&==P \?>N6,(88>-3AX9CCCPQH,\80Q-1I]-:8"F6
MORRA#$8?L=]?"F7@/E"&&%/I@?6GR\:[@AA@=V'B-?+7]<(0Q-/>F^GCAN-3
MX5A&/9[*NA:B<'>/H-))XJ83*NH]5>/45,(B)CJD:J)MUE#B-SJJHG5,.\^-
M!MO[,=B[??7-3EC-M3;BBIR8D'7Y%QQ1Q4MU$LXAAUQ1_$MQE;A.:B3&6E;<
MM230&VIE1;3@EMU*70D# !)6"M*0,DI4$C2*;&Y,9>QJQ7 0IGRA# 8@2+QR
M[1 0^TV,H5LJ7F5=)4O9CP6?]C^P5GO(?%DKG5I(4D6A-S,TR"*"AERM$NZ-
M4O-.).&=8OO;26N\DH^\AH$4)9;;0KR7=*TGBA23&+ND+,2T!5_1.804F_AF
M,STBV$'+LXIVO'M92%_LFS5=_1$@W:G22>1GQ;)DZ^ <$4:_$,VJ_5=:W1,3
MJ,JRTTRXTVTVVTU+)2RVA"4(:0EQM*$MH2D)0$I%U(2D )P2*81KSREE;2BI
M1*GN^222HE*R2HYFIQ-3B<ZQGV=HJE*F-UDW!,7RU@+\4)#(/-D+6+\8U.@Z
M$H6T(*HE#@&-5MO8W9?:-7:6S8TG./70G[RI"F)RX, G[W+*9F2E*:$([4I
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MI*UK-PT:N!:@E:DA2$I4O:/([I&3CRH(V"<?2CZ/>BQ$T?,*I.52MWZK5/\
MS4Y46^/,_A_CV2$ZR324C8V455ASN5')".!Z/L9MWM7LS:UF2$W:#MNV+.6@
MQ9SLH^MV8F)=3[W8(?E'G MQD*4%O23"G^SG95(=$NUVB5MX*U+(LZ?EGWFF
M$R<TTPM]+B EM#@0B^I#B!1*BD%*7EA%67#=*U4*5>D E#D'D'OPQ]AQS2%@
MY!WVX^GCZ80ALAR#RT][OVUPA#9 =Q0OW>_GVX0B+%Y!Y>_?HA$[(<B^E\(0
ML7[-O(?EW>N$([O5D^R&$*PZLGV0PA#JR?9#"$.K)]D,(0ZLGV0PA#JR?9#"
M$.K)]D,(5!R,4>8IN J!$K>;B(^42((BF5ZV37%(1WBB<Y141,/$R1B"//&)
MM6PK&MQD,6Q9<E:3222A,Y+MO%LD4):6M)6T2-[:DG 8X1Z)>;F9117*ONL*
M/XBTM2;W!0!HH<% B*/$Y>41!N"O(NF(EJ[(;:3<_#@NNB;?M(JN!6.B/(4C
M$$-P:8Q-E["['V,^F:LW9ZS):9;-YN8[ //-*^)IR8+JVE88%LI.X&D>F8M:
MTII!;F)U]Q!%%(OW4*&BTHNI7_N!C"O1\K&HJ_E>DU'5@_+.,:)Z255T%339
MRR8)HQU)1] Y:RS2'$C=LB#Q)*0G)5R*[[XEVH9X8BC@Z2:)$]MFY:7>9;9>
M9;>9?ED]LT\@.M.!96%)6AP*0I)  *"+N&48MEQ:5K4E:DJ0X;BDDI4F@!!2
MH4(-:X@U$9<7RJRZ<*]<I2$.![[5DD#-TQ$=XBBW421&_$!3$!QHSWV;;"/N
M]LO9>R@NMZC3*F&R<\66%MLD<"W3A&93;MKH3<%H3!'YE!:M/QK"E_\ =%UQ
M<%"PB M8>*81C<1 3),6J+8AS!N,H"1"]8;7^HXF-VXV:S;'LJQF?N]DV;)6
M<P34MR4LU+I4H?U+[)"2M6)[RRI6)QQC'OS,Q-+OS+[KZQDIU:ED#1-XF@X"
M@BI]63[(8R468=63[(80AU9/LAA"'5D^R&$(=63[(80AU9/LAA"+"KG+2E\P
M&J:,TU,1TW*)6DDU$A'C<NWU@)W4(JDN@"O]YU*Z:A"G$QTNJ5,*F-+VOV#L
M#;1AM-J-.M3C"%(E;2DUAJ=ET*));O*2MMYA2B267FUI!*BWV:U%492S;7G+
M+6HRZDJ:<(+K#@O-.$4HH@$%*P *+20< #4"D:XRO17>"HX&,G8=XDZV 6"5
MC5&JBI$A'J".#M_I KGJ@&Q#'(0"B(B0A ''#Y[_  _6LVL?PK:63?;25%L3
MTO,R;C057 *EE3B23DI:4-7L[HRC;&=LY<@_>9!Q*B!>++C;H41O(<#) &-
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M]OI^N%?;,\./"%Q&D-CM]_MA7A\_?]87$Z>6L:7?P\B7Z'>38W'_ -7K;_\
MI%8ACT31_GN#_H_\$X=>6^++"$EM)(J>]_Y$8>,;H[ <_P!\6+W :;]*:Q=N
M(T^?C$[ <QPKP'K[]#"%Q.GJ?KS\<8; <QPO<!Z[\]\+B-/GNRAL!S'"]PUW
MG?GOA<1\(_;*&P' 1Q%> ]?#6)N)T]3XZPV YCB;W >OOKCXXQ%Q&GSZRP\,
M(; <Q]^&(KP'-7O$W$Z?.&P',<3>X>JO>([-&G77SCDV?O#KV!ROR\-W;N$+
MQ=5054,Z?A.F_'70<<L[?:JT&'O37SSX9@TD"#>VT/D&^U^7KNQ%Q1-+U/\
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M,O<X85I7.E(=HK05I7?T<<,-1$[.G]0[M= Y7Y:_EOW7PNJ^+RNG#"NN_?O
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M/+\@WVN'XQ0TY[DTTUS]1XQ-,<O.IK\O2M( 4.0:6MOO[_'EIA=(UW;DX?\
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MC;O:1#=CR>S$]*2;G9H7-VJS,2;300J64I]Z9>;DY-QQ ET$JEY%<ZI"GO\
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MG%F93F=TH+JK,MX0C)4'K=RW*X=/U7362@I2EGIW?7]0V<.UJ;FI2'45209
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MRM81 E > =W;?G?GH&FG#D,7CJ><(;(<0"W'?YZ\-]P'UPO*U/7753")L7B
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ML+\YO*U^4("!>7Y=G9?SN/#"^K7T'M"*1/NY&-@YF1AXGZ=EF$4_>QL&#LC
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M(KANDL"3I%1LY2*LF50$W#=8"JH+$ VRJ@H4%$E ,F<"F*8,47!QZ\H1V
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#C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g942137g15o09.jpg
<TEXT>
begin 644 g942137g15o09.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1=X4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @   #A"24T$)0
M    $-/)GTL]C>HHA4@U:H05G"LX0DE-!#H      74    0     0
M"W!R:6YT3W5T<'5T    !P    !#;')396YU;0    !#;')3     %)'0D,
M    3FT@(%1%6%0    1 $$ 9 !O &( 90 @ %( 1P!" "  *  Q #D .0 X
M "D       !);G1E96YU;0    !);G1E     $-L<FT     37!";&)O;VP!
M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585
M "( 7 !< %  2 !8 $8 0@!5 "T 30!7 $4 +0!& %  ,0 P %P 00!: #
M,0 U #$ +0!8 $4 4@!/ %@ +0 Q #@       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q =>            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              +N   %90
M   !                          $             !64   +N
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   +N     %)G
M:'1L;VYG   %90    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "[@    !29VAT;&]N9P  !64    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M  %^34T *@    @ # $   ,    !#.0   $!  ,    !"?8   $"  ,    #
M    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !  ,   $:  4
M   !    I $;  4    !    K $H  ,    !  (   $Q  (    >    M $R
M  (    4    TH=I  0    !    Z    2  "  (  @ -6?@   G$  U9^
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP.#HQ-" Q
M,#HU-CHR.      $D   !P    0P,C(QH $  P    '__P  H ( !     $
M  5EH , !     $   +N          8! P #     0 &   !&@ %     0
M 6X!&P %     0   78!*  #     0 "   " 0 $     0   7X" @ $
M 0              2     $   !(     3A"24T#_0      "
M_^$!@$U- "H    (  P!   #     0SD   ! 0 #     0GV   ! @ #
M P   )X!!@ #     0 "   !$@ #     0     !%0 #     0 #   !&@ %
M     0   *0!&P %     0   *P!*  #     0 "   !,0 "    '@   +0!
M,@ "    %    -*':0 $     0   .@   $@  @ "  (   #P     $   /
M     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,34Z,#@Z,30@
M,3 Z-38Z,C@     !)    <    $,#(R,: !  ,    !__\  * "  0    !
M   %9: #  0    !   "[@         & 0,  P    $ !@   1H !0    $
M  %N 1L !0    $   %V 2@  P    $  @   @$ !     $   %^ @( !
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ S@%[ P$1  (1 0,1 ?_$ !X
M 0 " @(# 0             '" 8)! 4! @H#_\0 2Q    8" 0,# @,$ PL)
M"0   0(#! 4&  <($1(3"10A%3$6(D$*%S)1&2.!&"0S0EAA<7*7P? F-$-2
MF*&QU-<E-41B<W2"LK/_Q  > 0$  00# 0$             !@$$!0<" P@)
M"O_$ %(1  (!! $" P0&!P,&"@D%  $" P $!1$2!B$'$S$4(D%1"!4C,F%Q
M%H&1H;'1\"1"P1<S4E6"X24T4V)D<Y.RU/$U1%2#DI25PM-#<G2STO_:  P#
M 0 "$0,1 #\ ^_C%*8I3%*8I3%*8I3%*8I3%*8I3%*^>[FCPKY9:PJVT=\5O
MU1N6#9BYN@2<3KYL]>Q<1!1MPN"39K!LG4/<F#%)G -)0C9H#& C6JB;-,B3
M%DF<$D\)XF^*]KX:]"7W5$71>'S,^,;%V_LUQ<-:K<&\O;:Q>5YQ:74BE1,9
M=<7+,.);N6K-=/XE<UE(,<\[6ZS+,WFJ@D*^5"\N@A9-\N&OO=M[K69KZ&YL
M7:X1%86]2;E='IR?O^YXG;[$X.E[*+>2 =$37%$#>0S4J0]5"]H'$X=1+VCY
MBQ7TX),C?06;>$'340E$GV@S<SD<(GD'NG"J#O@!Z^AV-^AV!-X:VT<;.,M,
M2NNWLL>N[!?^6_&L@Y/4SFMQ_P!#[#W$P]2[E=9GE(8P[Q&"=VJQ1C:0&4L\
M)7S)JOD;J\4;@BG+G<E$C943G0*D(% _>7=/AG](B'K[KKI[I"?PZP6-BS<]
MY"]]#?O<R6XM<9?9 ,L#XV)).9M!$=R+H2%]DKHX'+=&Q8S'75\M_),;=8V$
M9@5 W.:.+182L1KS.7H?37QW6H_7G/KGS=KE!U9?FMR4CTI==PB=XEM:X+J(
M BR<NP,5(\RF4_<+<"" G*  81^X!GM?'=,86^O;>T..L8Q._ N+2%BONLV^
M)"@^FO4?X5KN[G]FMI9PO,QKRX[UON!ZZ/SK8=8Y3G15IF$@9'U*N0SZ:?*$
M;ST-$7K8YWU5>J1,;+ILY!Q).XV&?J"C)D:G4@I24;D?LI!,5!:%8/9&+>*,
M>&\/_#'K;Q#LNG[?)_HKB9,G9VEY!96=OE@EXMH5$]O+>75JN^4@::T5_+:+
M2<S(D5,#.V8S>-Q$G" 7UP())(R[O!]F9?N.B(YUI3I];Y=] %LPJ37FU9;-
M!P"OJ1<K&B<O)-F!G)+C8UC(E<' GD*G^," H) ^>T3D ?YA^OSCL/IR27EY
M;VI\'^FHQ/*L9<9R=BN_B!]2 '7Q&QNMR2>&=NB.PRTQXJ6U[)'\/0'[?X]_
MA^RK 7O1O,^G4FVVQ'U0.6;Y:M5R9G4V2E@GT4W9XJ/</2MSKEO:ID2+"CXS
M*@DH8A3=W8;IVYN+H'Z2476G7'2'2,WAO@<?%U/U)AL%)?19!YY+1,K?P637
M*0-C8EF:$3>8L321ARO$NN]U@,OT;%C,7D<BM_)*UC975VL30*@D-O"\H0N)
M6*ABO$D*2-]@:H[3-C<X[7<:G5U?4*Y2LD[)9H&OJ/$[[9UCM"3,JTCCNB(F
MM"95CMRN15*D91,%!(!!.0![@]V];]'83I'HOJ_JN*QL;Z7ICIC/=0QV4EE#
M EY)A<5=9%+5YU\UH4N&MA$TJQR% Y<(Q&CJG%98Y')X['F)8A?7]I9F0,6,
M8N;B.$R!2JAB@?D%) 8C6Q5VMD:3YGT77=^O"'J?\LY%:F4FU6Q&/4L4^V2?
MJUR!?S";)5P2]+&03='9 @=<J2IDBJ"<J9Q*!1^?W3GTHTSO4.!P;^&73]LF
M:S6*Q+W"9*21[=<E?V]FTR1MBT#M$)C(J%T#%0O)=[&W[OH:&VM;FY^L97-O
M;SSA3;(.1BC:0+OSNP/'6]'0[Z-:3M8\]N?6P-E:\H3CFOR4C$+O>:E3UI)'
M:EP<JQZ5EGX^%4?)-CS*1'"K0CT5R(F52*J9,"&4(!A,'N2XP^&A@FF&)L&,
M,,LH4V\0#&-&?1/#L#K6]'0^%:ZK[A.'_#+=W&R[6:U;/YU;ZY21$[5_H#"E
M[2 PP,%(C*L) +,S,^L=F>%EDFS->+1!FK'(&:23WWI'IRLQ::DR>5M+^*..
M#$66/9).9EMNSNO$KY;:1 5)(8\@QVHUKOM6PO,+2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2JW\L:_6[1I"RPEMCW\G!O)"N&=,XR5"&>'4;3T>Z;&2D!8R()
M FY12.H46A_*0#)]R?=WEU#XYQ8R?PXR\.7LILA827>($MK;WIQ\KL,G;/$R
MW0M[HH$D579?);F 4VN^0DW2'GC.VIMI5@F$=R5D>+SU']GD# Q^9'ODI(WS
M&M[[ZU6GR:JNDM,QSC9,'KNU2,K711!JS?[* K5?ZPX2@E_**5,$_5-M*+*)
M]H?X0A.OQUSP9..@<!$^6M^CLK)-:@<$?J]^)\]A;MO>!;T64D=O4#\ZW$JY
MBX(A?*6X5_4C&#8U[P_]<'Q W59]_P"_M6[7T_=M>7/1\PM6+,SBV\LG$[=7
MC9$R;&P1,LW!L^/07A6Y@>Q[85#"U6[T052Z%[^\NZOHN]3X'JKQZ\/<#C^F
M[O!WM_=YP0963/G+1VC6_2N=NW+X]L38"Y$L<#P!3=P^6THE!<QB-XWUM;9#
M'=+9>\EOXKI(8[8M;BQ\@R<[ZUC $PN93'HN'WY;;X\=#EL:G):O\.=.1SO9
MD)QSV4_E:FE[UFS>\D3%:KG='+&G*L)-/&,!01>J'#M*(]Y2_IUS[/7'2^4P
M<3Y6#/PRRV?&1(Y,.H1BSK%[VLAO0$A/;Y5YWBR@R3K926X2.?:LR3$L.*EQ
MK<8&]J/QU\*NG5=O1EJV+Q[HFRM(6A2%LUK_  2B+7D9?;$&LK#^[^%L7X?E
M%9[CW7*9,V)O54Z_%.T*A;[1](:0K: DW[ D)'L"^=?&[./?>$?B3:W\-C<8
MZ_P9^L[>SLHL5=9&U;)Q[\B]CN[V:U4W+RS!Y;,AWEEE6-FFDD,NZ9QB19_$
MRP3RI-#<!H'E^VCC81L 3$?+Y^Z NN8[!0#I0*V826N=%:Z8NKW&:_MSR1JB
M)IMFV=;)*#==PQ#RII+"2FB8$SF#\_8'=TZ]/Y9\@Y;;P_Q,<F2AZ/RS2V2M
M<(K=7OQ9D&P#_P !$:/Y&M_+]<RD1'*6P63W"?JP; /;M_;/XFJZ[FYE4EIJ
M/9SI_HAX_9-J':UWC%+;+EBL\;)0;TZS9-[^ W7M%%TRF3*X]LN*(F _A4[0
M(:=>"OB!@;KQ>\,[;'](76/OYNN>F$L[Z;J9KZ*TN6RUJ8+B6R^I;;VJ.*3B
M[V_M$'FJ"GFQ\N0QG46)OOJ',^=DXY83C;U98UQXB9T,#JZ+)[4_ED@D!^#<
M?O<3K5:@-3<\='NMJ:S;,N*%B9/7&PJ6@T>K<C7+Q)FY6LL8F@Z4:?N?;>[(
MW5,18[;W"'G*04O,EW>0OU[\6.JNH(O"OQ+EO[BQO;*+P^ZSEO;.*Q:SEN[6
M/IO)/<6L=Y[5<>RR7$0>)+GV>;R&<2^3+Q\MM"X+!VJYO#F%I(Y1E<>8I"1(
M$D]KB*,T>DYJKZ8IS4-KCR7>QN@O7*6B6>CW.M3&DGYXFQ5.QP,H1KM5PW=&
MCI>&>Q[XC=P-&6*W<&:N%017%)4$E!*H*:@%[!^-?AKUUTUD_$;P_P ;!T=>
M6<^0ZWZ3LH;QNJ6NEM);O/X^WCN6M3@X!<K \BRF#SX1,%\OSH^7-?0.9QV1
MM\/E9WR<,BPXV^E:/ZN">8L=K*Y0.+MBG,*5Y<25WOB=:.L326EN&:.Y]0JQ
M6B=GL91/:.OSQKYQR$!^@SD"VV(,R=KL/W3M?>HMG()K*M/=-O<D(9#SH]_E
M+]W<KT/>V^,R5P>H%D6"PO)BGU.B<Q%;R.4Y?6#<>077+3<=[XG6J\NQY]Y)
M(D]E0"22--B8DKS8#9'EC?8[ _#UK[K\\H5)J8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3
M%*8I3%*8I6C;=E!]<N_2MWKM?F>!"6M7MKDW%2(Z_>:WGB5AI-K.JR225/%.
MP"1+&ILBR7052&<@OXS]@E'+CJ+IOP]ZMP3X/.+U%[/<>R2W/L4UK!)Y]M(D
MP\N1DD 3SD!(*>\G;L3VOL=D+C%W27EMY9FC5U7S%+KJ12C>Z&7OHG7?0/<[
MJIMHX0^M5;X-[7IB<X-#'2 MA< UE]CH..K1VW>H^-4:PH!.B[9(3?D'N)W%
M_P ;KFJKSZ.?@-?V\EI<#KSRI>/+AE;!6]QU==-[$VO>4?W3VV.WK4D3KO.1
ML' LMC>MV[:^(WVF^7_D*A63]*7U;)9BYCG4WPV*W= 0JAD;3L(B@>-4BP"0
MQJ6H ")DR@(B0WP(_ =0$,UX<>"/@IX6=:X+K_I8=;'/]/27LN/&3R-E>6)>
M_P ;>XJ?VBVCM+9Y1[+?SE )X^,O!R6"\6M,SU=EL[C+K$WPM?9+Q8UE$$+1
MRZBGCG7BYE8#WXDW[IV-@>H(BVT>B/ZH%N@9*N2M@XGA'2J*:#H6MVO2+@")
MKI+@*2A]>JE*;R(DZB*9P$HB !\]0]7W?B[!>V\MK/'-Y4H ?A91JVE97'%C
M>-KWE'J/38[5!(,1:6TR3QB7G'LKR?:[*E?30^![?#M62UKT?/5VK4YKR>+L
MKBY,KZRF(^P5YK,6.6!)_,Q%7_!41(V^1AM0PUANS^)J@$@(J0M4Y*R$;%)D
M8,G:#/O0/KCJ2YZ+ZIP>7Z?R4&72PS=J;2]:T*13K"UPERRVS2S316_*>-9'
M"0\6.R5+:(SMG=S6-U#=PA#+ _./FNTWHK[RA@3V)WW%6BG.%WK86&(D821G
M.#'L91JJS= A*;'26\*Q>TX)J#63@0_3^$PE, #^@YH"Y^COX$74$MM*.O/+
MF0QN5RE@K<6['B39'1U^!_(U*5ZZSBL&"V6U((_L[:[?^_W_  ]/VUZM/I)^
MK'<*U/U26F^'18JR0TE!R(L[7L%%T5E*,U63D6RQZ2L1)<$%C@DH9%4I#@!A
M(8H=HTZ5^CIX#='=2X+JO#CKSZUZ=RUCF<=[7E;">U]LQ]PES;^T0I8Q-+#Y
ML:F2-9(RR;4,I/:EYUSG+ZTN;*?V+R;J&2"7A;NK^7*I1N+&8Z;B3HD'OW(/
MI59*W^SP>HA5;% 6B+L7&89.MS<3/QP.MAW59J+^&?-Y%F#E(FLTCJMQ<-T_
M,F15,RB?<4%""(&#TAU%G>F.I^G\[TUDTRHQO46&RF"R!MD@BN18Y>QGQ]W[
M/*TLBQ3^SW$GE2-'(J2<6*, 145M;B2SN;>[B ,MK/%<1<QR0R0R+*@9=C:\
MD&QL=NP(JVCGTKO5O=MG#56;X: DY06;J]EHV(4_8NF9,XE$:88 ,!3#VB)3
M !N@]!#X'S/T]]&SP"Z9S^#ZDQ@Z^.1Z>S&,SN/%SEL?+;^W8B]@O[07$2V$
M;2P^?;Q^;&LB%X^:JZ%N52N[ZZSE[:75G.++R;NVGM9>%NROY5Q&T3\&,Y"O
MP<Z.B.0!(T-5CU:](GU8*I9*_:HJ?X@?5*S.1%AC =6V^K-1D(60;R3+W"):
M(F95#W+5+S) JF*B8F("A!'N#VA=>+\-Y;7%I,DODW4$UM+PLD5_+GC:-RK&
M\.FXL='1T>^C6MDPEDCHX$W)'#KN0:Y AMZX^FQW'YUOSX=M_4W1N5J'G"_X
MKNZ":LIA42Z,3NI;22W_ %1H/62-/M6L9] ^C?40< 'D?#(_31;=K<'O73F3
M. ,4?U2,B)O,/F>V>5Y9BXG[O EN?/CKX<>6^_&LO6PK,+2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2N#(.P9-3N!^Q3$#[=?XS@7[?V_P#'VSN@
MB\Z0)\PQ[?@":Z9Y/*C+DZT5'?MZD"L?+92"8H=0^1 /X/YC_IR^./(WV/8$
M^ORJP]N78'(=_P 6K+LQ=96F*5X$P%#J80* ?<1$ #Y'H'R/Q\C\?Z<4KSBE
M> $#!U*("'40Z@("'4HB4P?'ZE, E$/N @(#\ABE><4KQU#J!>H=1 1 .OR(
M!T 1 /N( )B@(_IU#K]PQ2O.*5XZAU$O4.X  1+U#J &$0*(A]P 1*8 '[")
M1Z?8<4KSBE>GD3ZE#O)U.'4@=Q>IPZ";J4.O4P= $>H=?@!'[!BE>^*4Q2F*
M5X 0,'4H@(=1#J @(=2B("'4/U 0$!#]! 0'Y#%*\XI7J!BF$P 8HB00*< $
M!$IA*!@ P!_"(E,4P /0>TP#]A#%*\B8I>G<(%ZB!0ZB =3&'H !U^XB/P ?
M<1^ Q2O.*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2L+O[OV59=N -VB5=F #_KN4R_R'[]<RN&C\V_C3YI*?
MV1L?\*Q>8D\JPD?Y-%^^11^K\Z@5&QB*J0>0?E5,.G7^9R__ "@/V'^S)BUD
MO!CQ_NM\OE4/6^/)1^('J?G^_P#=\-?"K79KFMB57KD7J"X;IK$!6JK?$-??
M1;$2Y&E#PQYU5S9*Y'/G&O1,P%]'H"UK-[5@M@%4.N94)JG02::*B2CD25!U
M_7S]?VC8_75"-_'^OA^P]ZKM:.).VKA8XZPSNT_=.V4I?S*K*7+:3ALK&7:Q
M0M@:JLZVYFU:Q"%KL= 1=/8U:&C64"8K<+RDY:3P-XMKR##TUVU\A\C\?7OZ
M[]1Z>E4XGXG?Y]_B"?P_#T_'\N#<N)'(*W0BM>D.1DY(,)"E6^K3A7%EO\>U
MGS2&OKQKZNC)Q#&759#U,OJZ]3,FP/'R!+G7+\L=.=9; 0)6@8 [U\1\ ?CL
M_P ORUZ:[M'Y_/\ W=QH_P!'UWL=\PXM[S0FWZG[_)J*K4KL"9M3J,K]GO\
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M>H'HRI<CM\M=A5_>55K[!'7]<K@L+'4MAJ2 N(R3L+I5<!BZ[(M?;*%DDRI
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M+P@M%6L7$OWB;Y.4*P:%14;E(^4G(7Z4K( \$4J\3\OWC^/I0D"K(UV>B[5
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M?PDD\_Y7VV,G*U19H7,758U,SANB=@D_FW+R.;-FB(_4 8<OKW-?ZUO/3?\
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M,4IBE,4IBE,4IBE,4IBE,4IBE,4K![Y18R]0YV#OHV?H =2+E"$ RS%P8/U
M>GF:+"!2NFQC 50H <@IKIHJIY;#Y>XQ%R)H_M(7T+BW)TLR _ ]^$B]S'(!
MM3L$,C,K8G+XFWRUL8I/LYD!-O<*/?B<CX_Z4;: DC)TP (XNJLM5J7I2U2=
MI>L+0W5BX.%<E*]>D$.V8Z@"B*,.L*8 LDX3$JBSOH'M$SBDH0CT!1+L+*=5
M8Z#'QS8]Q/=W2$Q1$][;X,]TH/N,C;"1[^U8<E)B]\Z]Q?2^3GR$L%^CV]K:
MN!+,-ZN?[RK:N>SJZD%I-?9@\6 EV@NNQ8LXQFW8,&Z31FT2*BW;HE B:29
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MM:_01'9E"M33/'[?,85R9$""L5N9[KI %C) HF*@)B82 H03=.XO6^L\%?9
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M/G^C]X+7$IF;!]4)(UK<63M'U2R\[:Z4I/$0<>P^T4E2R\7 ^ZP/>I".N,Z
M%Y6A =)!NV'9XSM#V8>A[Z.Q\Q5,!_9P-KCL?]Z7]V32/Q1^+2W7K^XB7^G?
M6BR@2X#[3]Z?=[3W@ /M_-\I_D\G^-F\.?3/^3__ "9_5%_^B_Z*?H9Y7UI_
M;?J3ZK^J.'MGLO+VGV+W?:.'+S/M..^U1_ZRN3D_K?:>V>V^W\N \OVCSO/W
MY?IQ\S^[\NU3K.>B3R<L"**#_F;JXI$%A7)[?CI+IF$XD,F/<)]MJ (=IA^
M /GI\_ID6\'NDN@/ S+Y;-]!83+V]]FL<F*OFR>;.2C:TCN8[M1%'):((W\Z
M)27!)*[77>N_J+-7W5%O;VV6:-XK:8SQ"",0GS&C:,\BI/)>+'MZ;J_?#'AS
MS'XKJU"F37*[55ZT="S%AE[!1F/'EU 6B;4G&;TQ4V-U5V9)*1!F\RJQ?@H:
M+?)BW:*-!;G*N)B["ZGZFM>I[J;(W./FCR4D4,*S+=+Y*K#I5W ( &]SD#[P
M))!WVK!6]O':QB*($("2 3R.V[GN:VGY#J[Z8I3%*8I3%*U.<F^?'+/C7.2Z
MLEP :636QKG)56C[#+RSU]#JW1HV*^=1DR>GDH,Q,UH96+8J/S1LFLJHP$?:
M+.5%@#OP_5_6/A[T!B;'+]8]5S8B"_N4LHQ%T[ELF5O&@EN# ?J])W($<,I\
MXQK&2H&P64')XO#Y#-326^.A6>6*+SG5IH8=1\U3ERF>-3[SJ- D]]ZT#4,5
MKU5^6%OBTYFO^G"S?1RJRK=-<W,O7+03*H'\:I!1>:T06#M-\ 84^TW^*(Y#
MK/QQ\#[Z 7%MU_>/"2R\CT7U,G="0?=>U5NQ'R'S&Q67?HOJ*-N+V2*?_P"7
M:'_NS&J:5_\ :49*T6U&CPG!9\]LSAX]CT(\G)!@45GD>FX4<H)K'TH5$YP!
MJL"8%./F.!2(]YCD WI*P\.WR7D>QY99/:8A/$7LQ$#$8O.YL9;Q @$0+'F5
MUK1T:B,\B6R.\QXK&P5B 6T2X0:"AB=L0.P/K4_?TVV] ?2$8MZ>AFS^+,V*
M];.>6%2141%VC[A >IM3>-0%$?S@*9S@'\)^TWQFK_%+/]!>#3X)/$'JZ3$-
MU)#D)\/[-T]E<P+F+%R6L5ZS-B1>" Q27ENH6X\MI.9,8<*VLK@L3?\ 48NF
MQ$(N19M$EQSEBM^#3J[1:%P\7,,L;G:<@NM-HD R4EZK7*Y>LJ7!+TX6AZ\E
M%.IH[W^[*UR4X1S)!9PY7!H;6@.Q,FB@J8$01\QQ*!2)F,8H#$,#XL^#W4M]
MB,=A^N;NYN\Y?66.QL;](=0VZSW>0N8[2TC:2XMXDA$EQ+&A>8HB EW95!(R
M=UTGG;.&XN+BUC2*UBDGG(NK9BD<,9DD;BLI9N* G2!B2- $ZJ/M?>M5OO:,
MTYK]+]/1*4E6D8M,+MUN7%+C2DCV[IFS66!>2U4T0,8KA^U("15#*F!03E()
M"',7;_B+@L5X582VZBZWSKXO$W>3AP\%Q#B;C).V0N+6]O883;XV>[G56M\?
M=.96C$2F,(6#NBM'<,IS]T]GB]7%Q' URZ,1"!"DD43-SF\M#IYHQQ#$]R0-
M*Q$5[M_:$KSQWN:5 VOP*4@+0M"L+"FP:<HJ_/)#%23AZU:./>P>GY!D!E%H
MYX44!< NF"93*)D*HF)L?T7;].^(.';/=*]1O?XQ+V?'M/+A;VQ875M'#++'
MY-[)!,0J7$)YB/@>1"L2K 7=_CKO&3BVO(Q%,8UEXATD'!BP4\HV9=DJ>V]_
M'5;G.)F^^1&^HA6T;BXJ-^/%1EJM5;7KV<2WQ3]O*75G9FQY $U8JMUR ?5D
M648I'O!-+%,=P9\+8$45FJP9U9*SL;-Q':Y$WTBR21S+['+;"(QGCV9Y'$FV
MY#W>PUO9!%656%N&LJG=?*K*LU$7ZJ0)#),E/"Y,4I0(0%TSE5:.RE(4I !T
MV6,5,H$(8@ '3LQV=R&-41PNDEN"2;:=!)$=G;:]'3D22>#J">Y!K#Y'!8_)
MDR3(\=QH 7,#>7+V&EY=F1]#0'-&(  ! J$FNF;)4K9#2S8L;=:XE($+(,'2
M*#=^BR7ZHJ.!9/#*,G9V!5/=IB@Z!=95L4$VI1.!0ELG5%CDL=<VTAGQ5\T)
M,$T;N\+2K[XC$L066(3$&,ATX*KG<AUNHG'TQ?8W(VMS&L&4L5F FB=5298G
M]POY4S-%(80WF@K('9D'&/9U5K"E*0I2$*4I2@!2E* %*4H!T "@'0   ^
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M?<Q+(%9!(L<ULZ!PCNH<#D%=E!TQ!ZTDDB/*.1XV(T61F0D;!UM2#K8!UZ;
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MM2SZNZ?M?#3$]"'(*]SCND\+TZ^0$%V()9<5C[.R>Y6'V<R+',UL76,N756
M8DC9U7/C7ES-SE!*H2>_N;P1$$NJW$TDHC+!M$KST>W?1.ANOIHUMMC<=OI4
M+8KIQANNL;+(A(#)4>5V#JFP/X/VLJ^9,_/+P=K4BW?U)@V:RZ7MCB+=%^FU
M7 KE!8H:;GMK6.5DBR$-Q&O'C*L-R@?:@G2O%R'%B5[^I&QV(K+58C+&E,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4K#=@UR;MM.G*[6[?)4*=DFZ)(VVQ#=N[?PSA!VW=
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@C&A-J2<F]H=?#?Q]?W57O\?P_K^OPJ>\I5:8I3%*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g942137g24a08.jpg
<TEXT>
begin 644 g942137g24a08.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1Q84&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   *\_0 X0DE-!"4      ! 2!6%E
MW/,D8T,$P10T#O'6.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M      !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG
M8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE
M9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E
M8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/      0 !.$))
M300F       .             #^    X0DE- _(       H  /_______P
M.$))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))300*       !   X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           "OP   ^@          0                         !
M          /H   "OP                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   "OP    !29VAT;&]N9P   ^@    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   K\
M    4F=H=&QO;F<   /H     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,     !&U     0   *    !P   !X
MT@   !&9 !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M746M_/\ YNQ0Z5U;#ZKC?:<4G:'%CV.$.:X?28[Z3?\ ,=L0.JNQ\".I.O\
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %^34T *@    @
M# $   ,    !#.0   $!  ,    !"A<   $"  ,    #    G@$&  ,    !
M  (   $2  ,    !  $   $5  ,    !  ,   $:  4    !    I $;  4
M   !    K $H  ,    !  (   $Q  (    >    M $R  (    4    TH=I
M  0    !    Z    2  "  (  @ +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP.#HQ-" Q,#HU,SHU.      $
MD   !P    0P,C(QH $  P    '__P  H ( !     $   /HH , !     $
M  *_          8! P #     0 &   !&@ %     0   6X!&P %     0
M 78!*  #     0 "   " 0 $     0   7X" @ $     0
M2     $   !(     3A"24T#_0      "           _^$!@$U- "H    (
M  P!   #     0SD   ! 0 #     0H7   ! @ #     P   )X!!@ #
M 0 "   !$@ #     0     !%0 #     0 #   !&@ %     0   *0!&P %
M     0   *P!*  #     0 "   !,0 "    '@   +0!,@ "    %    -*'
M:0 $     0   .@   $@  @ "  (   #P     $   /      4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,34Z,#@Z,30@,3 Z-3,Z-3@
M!)    <    $,#(R,: !  ,    !__\  * "  0    !   #Z* #  0    !
M   "OP         & 0,  P    $ !@   1H !0    $   %N 1L !0    $
M  %V 2@  P    $  @   @$ !     $   %^ @( !     $
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M31:^['!2L26WCWFTF9(Z"U((7>.:KRW"279 BR^H!'7^_'"',T4D/ZI\E_\
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M@]*;>'4I*>+J_%L6%M_V2+M%)&4_YP5$D<=(V/IDNS11627'54<)[,ISI)_
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MK14PY&"I_P O60-CG(YQO_#_ +RG2&VE/K$(;'^ ^)ZJ#;7*&KM;*IIXMGM
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M5YFF#0OTKK*\<;H\B+']_.ZM>3:'6>1Z[0W=G7@V^^L6UT]!ED>:ZU2$SVF
MCC9(5C$<H[V&B21T9(F>3E!B7I @$%($D@O.G!5.2LXKX@?H;)MA()W]%'U6
M?]9]Q:8@D1MWXVT$E"[2G?S.:1NTT^NM[B2I7XCI?;5W71P["^9*VK%FPD?S
M327&1XTC@DNUY)E0R/##,C,A7@G2W.UIZ>&_:YEO-IJ-VU/KM>$M[5JL#2-
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M(N#S_P 1_+T\!H-OGTNSWB26:,,E75HKS1+8CFB^9E+<K'"GRBQ=FX#3SP1
MJ9>XN7H_9:9 ATURQRS5;AP1X\DXJ80\.Z/)VH>/?B8@D5#2R&36 ]-NE-^W
M:6ON>CJF_J.^FEH_!/)-UL=MIM%0^V]E!-;9QKIZ[U6J:JQ-3GNP7)98:\M>
M>RQ2LPD#3!$,2/ZR+F[N_/?&M%JM5O-]?^P];<CI^F=A6M):2SLZ\5R*G/3A
MBGL0SUZRF2TI1DK_ +3UF00LPKO97JO1(^&ZG+DZ!CFXH]5C+9860E8L0W'[
M%/TV*E;Q#^V#=BJ_Q<VXP."VCVH:5ZUWB^GVOD^QB\7UT*R;*Q<6M1BGE6N
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M.?S&7]CXC;J<,#5UJ=OQ2.SR/Y<VC^9X_+V/OQF)IC\,%!F+B7=%]ON0)1D
M/7'(./@W6JFT"-Z);=%KK]M)CQ"]C^X1UX=#>GF'2/E;6\42Z]V$/B<$'CU7
MQQ;U@UZ6R?:5ME\EIEWD=AV>0Q_:J:U9WA]5_4 ?M,.D40F%>**%.,EM1S>2
M7/)GKLUB_K1JK>K:]LI-#-75$B#MJI+;0"7THQ&0I%<EI9S7^:FFG>3OC5^/
M&D^-O6/[M1G0K1<)?5,-JR 9N,AP6$&2KL2]*3*78M+.O1>XXAD"/^#VB"GJ
M007($,(*7YT'A>J\<NS7:$MUI)JWRK1V)8I8U5GAD=UXA27N[PJQ+2,H[,%4
M#J%L=IY%>V]>.M:2NJQS>L&AC=&)"NBJ09&3JJN0 J@GA223R3L-SKLH<8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QD<?32?+GU_V4]XXZ
MU_\ G0W3=_\ ^=E__P!_^O\ T?A^O[O]<9([&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,C:7_I^7T#_/\%>-MN]-?_K]#I])]=__ +?V6O\ ^7_GO)_
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M^SJ=N@S1INH6V*VKTUJ2K%DCXR;#2K?Q/.A:'?TL=YUM;&4SBO1"^E4,*6G
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MBL111B:660=Z\D<@D>:->\3,B&)@68;!KNK*'ZJ&ECC1B_[_ '5F/50K$,"
M &X#>_N/;)=^ OY29SR$OB>&=]H<;0^JK T1'SU4(5)4,^3=(DOIU$B7:,DH
M_P#J@B,C')'3X9S0#YCNX%((4HVPT;I;/51TU$]6W';J/(T:,>(K(ZI"QDDJ
MEFDCA9IO3BD;VD:-R/89A*,O[R,I !8<AU'8D "1?NL?;W' XY'U]^-SN4V>
M<8QFO_S.\YZ'XPF0-' B8*^]SL$-+6BF464G@8%L0$ *0&W.&G/LE&MH>V@P
M1 \8+LA8*9%TTR, UHA_<JT9K0>15=:\+(L]@1L\<1D)"!B.%#/PW4,R]NIX
M)(XSVB&1NH*@D'@$@%B!SPH/UX_'_P#B/<^V::5?E^\Y$V69;)IO !3Z]$<]
MFIWG"7SAGJX+:RB&YEV;GY&=^F8+&"):?"U#6+99Z]M*0C6BVA4] ^AUZQI(
M+EWT99MC%#<-,""R:D4;UQ#%ZAF$D[.JRJX KB13VDZ.,R"!^64JO=5B9D]4
M!E]3GL6)7IU4#E>&Y;^'(XWB^#WF=4?-/D[5\AX"5I=FCEH'M-*G6EL'Q_SD
M'#QLT$EY*'W8*=_6FN1SC[;9#2QB1G=/-M#G&\_>I24++UGDAFZ<$2UY4FA<
M$ _<D0E6*\]7 )ZMRO/(S#Q[ \, PY'92IXY(]P?I]/Z<'\<FCFGD8QC/AQM
MMYMQIUM#K3J%-NM.)2MMQM:=I6VXA6MI6A:=[2I*M;2I.]ZWK>MXQFOXBB^.
M7B3UZV=> N-SK\Y<(#;,QR>MN583FP-99+(+!=350Z[#0E0%$F")67CIF4L4
M07(S$C9'$R$CJ2FA7MRM2M7.?0B[*A'>5BL<:D_16ED*IV/X("7('LIRKV.Y
MUVJ]-;MD)+-SZ%>-)+%J;CZF.M DDS*#[&3H(P?8L#P,RM0O,GCE_+%8!)DX
ML$\Y,8%8#WJU(UQV36I"6XXF8JMDL8T82I3C:=N2FPP4..L,*-T^0PVYLSZ:
M]!$\Q2.5(QVE,$@D:(<<EF3V?JH]V95*JOWF(7WRNJ>6:>W<CH%[-.W,0((K
M]2:IZ['Z+$[CTRS'VC1F1Y&X5%9O;)7959TN,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&?SF/SM]:Z3)^09W.; =("Q\A:>C7*TB)==2++S\=T:T46#C"5Z7O1\
M?2*Y5 (J 9=<?;%!(9=0I?JP[GUKP.I \<]QE5IH%KP0^P/H^K%ZUB1/;V>:
M1BA?]X)$R*>K,#\D\$UZS^2?$/R*_P#M]P_ENPT<,TOWI:FCUB0#5UH.W_(A
MFJR0SND859I/VK!F8L82?C/Z#?H+R6J?.J^8<92>EIG8N^51;CKL*9&AUJ6D
MM3S@>][8&E(-<>T0/*M);+^KHF,V_L0]YE=QYC6K-JWONJBY4DK"M-["1Q+9
MCB>LQ^LD3I([>FW*JR]P!PW.7XN:?5[+PC<6KZ+'9U5<7M;?4B.U3N12QF$U
MYQPZ-))U0!6'$ACE'$D:,O\ 3C\>YR<LW!>)V.S/D%6*?Y+SJ9G2RO?HHR6D
MZC$&R!A*7?\ 50064\Z2^V[ZNMNNJ;<WM:5;SXA( LDBK^Z'<+[\_=#$#W_E
MGT32V+-O3ZFU='6Y9UFOL6U"A>MJ>I#+83J. .LS.O  'M[#C,OYXRRQC&,8
MQC&,8S^>);69>K7SH$%:;S&5=Z*Z6?.VV39FC)Q=:L4?=X@BQG5V%DP9VVA]
M]##^1LMF!B_Z9BX$J4;6B.=T>\U]3I 25*#)4DF=Z$5>&*6 U#81JTT,*6+$
M<E.E)HS;4 R6)OM*:W$@=Y$14/H<*6 D")ZGJ%E;N%^^I)1&#R"T$^@1?36,
ML.![\1T\R.KU=RO%>/'0H.=KULH]S3;J[7.:1%7@N6\Y%GX?[*H-@=: 9'HB
MIL*1#L;DR6Q6WX&8DI0, DT9\YAVXT]:9Y%VE*1+"30&O+:V,T[W;S1OP97"
MFP*?I=$JK&)9Q)# LC1JTB]-F1N$,4@"%7+(L2J(X@WU4<!3)V'WN6X(Y8>_
M.69X\4>LU^'7>*)?>ACR%C#K(4B6[';J!*8?71(Z,L4/!PE2F;G/V&1;D!(E
MH.=6EFM(%.D8XYL:6=9:R-I8GG9J]RK3<5A>"0JQF3UFU<LU>6:U;CJ58X2D
MCR?+AQ<,M99(XW58^VLW55]FD7D(68?=)0R ,JJA=SSPHY("<$@G/Z<D%J13
M"0^IC?K+:BH_4IO>V]^LCH1G1N_5KU:WZD_+_+>]M[_^C_'TSXKGG*KC&,8S
M2?\ F_CYR2X5RB.CQ98B-L?3MTP@B/J49>@H6:L47MZ'GYRKS3K<2=$QD;$6
M311!B7- M$./MZ2K^<O/'FCCO^M(8^(()9^CVI:33"'K(8(+$(,J6)0O6'T^
MK%^ &'/.>T';E.&)D 0$1B4+V8 LR,0I4?5N?H/?/-1Y!=]YKQCGO8(AFBJN
M5#[58++279NA&62C6J ZS$P(<5TB7L-DM,1-P,64\V>#NI1U2@WXJ5#9F$.;
M2.T?LGM-?KK-^77J\G6S2K0V8UM^C-6>@\@GHI7KPD2LO=YVLB>17021J.A/
M&;[R1H)PB!HY)&4E/463UU'64L6Y7\BO0=2.>??ZXR_$URD<'R,X1TWGLG9'
M9.T7*&A@@I@Z!K;L;)Q72Z/H<UNO"R$E)WNM*4ZSI=E;'C(6*.'DQI +[(+>
MU9O+KDTU*S5LB -5EA*&&*:8,TU>=OO6G"I5="%)J,KRRAEE60QQMVU%4 $_
M4&.3GEE5E(('[G/9QR?WO8 @ CZ9_14SY3F#&,9Y+OR< Q;?G3U\_K;,B+S"
M"YP#/29\I14S,#.5*X\_JM(3"PMTC]JN%>D 9N/E2#XZJMMO'C[?402VA"EZ
M['0B<TD6D4:_/LH$JHEPQ3Q6*K"=)9*K=:TD<AE189K#'TY(I%0#EB=F'TB.
M9>1%''*928NRLL@Z=5D'[16 ]R$^H^I&:'O./N51ML;SOQQO-"GZ_<N1:BAC
MK=SDMYNF3<>9%"(@1J_SZV#HG;2#'UMZ-:@IB8M4,>B2=FT"L["DW%.=KHZ,
MD;3[>C-"T-KU0JWV_M**KDN;%FNGIUW9U+.$CD0Q,C,O/4K[GDY2.*1 &B 4
MM'V"<<?="AQV("\<%C^)/MGHF_[/CRY_DMJ[+38T\Z6@82/M@Y<F_.1$F@HI
MZT4ENONDPT.Z2BDF.!QT_MVG2!A<O%'IF'CW]N&I0WPWEEOYVQ5M.%62>K%(
MRK!)!T[*>5[R$FV..O6VH2.5>H1 J9@<!4Z^WW99%!#JW*CJ 3UYZ?QC8]E/
M//USU&9R68L8QC&,\%W_ &@KL?1%=8@.1.R4D%5IJ>Z5>[.PT\\TQ9)N(Z)/
M4:N1\B]KV?L@J77ZR&+#,O>YID4L1[XM;8"VU]J\'K0&G'.%4M#7@]/V!Z2S
M^H]F4'ZEV<>DKG[RI&T:D*2N<;I:_J[GR38V>)+B[-]?"S>[04*\43UHX@?^
M6LT<BRR!> [DN>69B=?7XF^K=+I_EWSWGE2D#S*3U<R3KW1J8[M94!,03%>E
MY%R:,CG-+%;D*X@)4D-)MMME($:,C%/JCI(\4B_\A@A:DUME LUWA$,G [,)
M9TC>%O;EXV65V*'E0WW^/8\Y/+J56WH[LEA5#U(C8K3_ +LD$RE>AC?V*]VZ
MH0#P25/[RH1_2!X9*RLYQGEDO-O/%2LC0:J48<2M3A,DMV&$4B4(6K>U*(E&
MOCD'M[_^Z2K_ &_VS\^651+-A(_^6EB9(_\ Z+(RI_\ Y SHM=++/KZ$TXXG
MFI5)9QQUXFD@C>4=?^GAV8<?A],RKF'-S&,8QC&,8QC&,8QC&,8QC&,8QC*;
M)3$1#-MNR\K&Q33R]MM.R1PH+;KB4[7M#:RG6DK7I&MJVE.]JTG6U;UZ:]<8
MS2;^1[\-W*_.TMV^P4D)&VI\DN3]K4JJ'UJ9(:8%E#Z]9Q(NQC (F5Q["Y^!
MEJW,Q4A,-KF!RH*3<D"#KS4;^]IG+5G7AEZ.CKWC=0Q95DC[)VZ,S%&1XY4[
MNHD]-F0\/L?&=G7V]SR'Q78UJ-_9) NWUFT@EL:;;2U8A!6ML:\D=O7WXZZI
M7:U7]>.:"*)9:CNGJ&&G@U^ \OQ^N)TO9R$QP\NVB,L=OD[3&V"ZO551+),A
M5J,!7(@&(K?[S3#8\G9I ]V4%TAIT0(IMO8>]_;^46=ND0GZ\0DO%#%$88$F
M*E1.X:>Q)++&I81@NL:=CP/=PW)[3Q#S?S6Y2J>7V?']7XG3M16K>HT,^PO6
M]Z]<]DKW+5RK22M1D;_FB-993$7C6-)FCMU_3_'(BPQV(B*T".-%BL!CQP6V
M$-@!BI^F..V,SO6AV!TC[&:;TA*&_AVTG6OCVG7*9]DRH8QC&,8QC&,^''6V
M4;<=<0TVGT]SCBTH0GUWI.O52MZ3KU5O6M>N_P"=[UK7\[QC-!_Y"OQ%S/:+
MK=>[^,E@C8GJEB$;,/H$W,N5:&:M<G88V2LO0:O8X49$I%7"UQD:]$R:CCP&
M9!APMAV:;CGOUK/2:??"BL=6Y")J0E9Y2D<<T\D8BE$55X[):K-5CL2?,K%+
M$WIS_MHSZ@3A^9'L_7JAY("DNI9ON\-V*CKV# E>%/(S2UU3\</DDQ(2E+E/
M$:Z22*15KZYR:4J5.#O\4E$Y8VI.'J-E-M$/>-2UDV4[/'-3P%EU7(UN35J.
M:9>]=)Z"MOZ7,,SWNKV;-!=DDZVX7XABECFL0OJS35:0C]%'JCO<F>,,'90>
M<S%.&50 $CF] H1_U.&5)!,'+2<ESWYZ 'V _'91^/'\4EX#ZY =\[;70N7<
MXH\@;/TGFC$W'3$K9ES+<=+2E7O +31,9 5"HW4$@L6O1KT5&N."$!JKB!Y(
MT]=+M-ZD](48&,YD6%;5B2%85[U#/%#+5$;1L\EBK(HMV+L4EJ1AU]3JJ\8V
M([LR_=!+< ,6^[( 71B1]%<'H$X0 _3DDYZ:V7V2$?*.\T^W[EH^1EQ#J/>V
MM3;B?>C:D^YMQ*D+3Z^J5I4E6M*UO6<KGG.7&,8QF(NK\VYYWVD63F-K(9D
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MYFT]#+5;PZ^#*SP\A6HJPMM5R!Z'7PE@'Q=7$9#6\+TF:(+;;$^D^4*!KZ:
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MG Y]E+N>%5F&DWFWDFGRII'9?%HGQ_@>8PMABG)$RV@2Y,2]5#8N?A7V";
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MQAD-& QL*.HAL2( C(P0,$=C,V4JJ 42GU>DQ)!Y<54:_$5J+?E'6'Y!<;"
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A8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g942137g35u60.jpg
<TEXT>
begin 644 g942137g35u60.jpg
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ME!IN0G9/*S'"^PJ+Q*)Q<:9D\G//DVKIQH.""7JR#%H\)//1AS)V[05: +'
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MQ3Q')CCMV19& 4!5!W"XVD]E9&9E3:"#O*!9"I.T,.]*OHD94,1R&,Y$F#S
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M82X(R./I.4>N,3D#'2'.]7+)ZX]M6RSTDCPKYQNAOR-WN3*ZQ\U0CM!F#-N
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MN_\ TP=-O7>G](_N9ZE+ZJ:S,MSIG&;U(1(AK-ND(. V-/TQ<=Y3U8B^J?\
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M;1*W.UT[T1FIBDQU_=,YC8=0!8'J\?W+ X+&JI?R,Q!Y6D)=R=4A79@4SE1
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MVXE:+4(6+"SY[H#U<.(P84WR-M7)R58QLYC)%>>SWXRI'?[//QD]W^OBJ<3
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M/8&?O/:DM3G6E"/;RN322T ,C:#;"<W5QV)=BD+.KJ; $RKNL'KQD[V#L&*
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ML?GK]-/17/\ 9U_JE/W<<"?\S+\F_P!%.-%^=C\]?IIZ*Y_LZ_U2G[N.!/\
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M>! .U=W4UTX[2.>32D=^#CDJC"B5??;9_P Y^?R/'_\ 2LC/0SH?D7_J;O\
MB*S_  YJGE7_ )%O]C3WVV?\Y^?R/'_]*QZ&=#\B_P#4W?\ $4\.:IY5_P"1
M;_8T]]MG_.?G\CQ__2L>AG0_(O\ U-W_ !%/#FJ>5?\ D6_V-/?;9_SGY_(\
M?_TK'H9T/R+_ -3=_P 13PYJGE7_ )%O]C3WVV?\Y^?R/'_]*QZ&=#\B_P#4
MW?\ $4\.:IY5_P"1;_8T]]MG_.?G\CQ__2L>AG0_(O\ U-W_ !%/#FJ>5?\
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M_.DW]^S6.N7?E,_RK_37;?0_H7M+I7^7VGV5/>I9OXPYO^=)O[]CKEWY3/\
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MK8RR[=_6+N/LC VPW4T2<O9V(N3XSDU+F1M9]0%(NS-0Q>S]JA)F) I,T!1
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MCR8_+#[.GI8/[=+_ )>?XVGPT4OQ<*?G;K_MO'AT>3'Y8?9T]+!_;I?\O/\
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M.6SN;<.7JOCI):Q2-!E(^%"9/O1C4H=ZX&%QM&T\^ZI*[+=?1M]=:+(ZY"'
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MOI[T.L;FXL[OI#IUO=6LTD%Q!)*P>*:)BDD;C8<,C J1GO%>>\>]?4*0U!)
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M@&EPZ)2DG%YJ# E3)!B5UU]GEFKY9!%/*2UB=XRJMMGM)Y4C=@621%=5.X!
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M$0CTIL#U;PJ?C<0K C=D<L<=%8 .JVNK) E#D985M$B$4WCR$[:UR5C+,J4
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M^5F^FGP-8S\\SOV ?^]CP'%^?D\U:>F9J'M99_*S?33X&L9^>9W[ /\ WL>
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MH,X=P?[CPR+!E'E?4O>,HX,G$SZ<+F!ZFT]8XDV#>S;H4RF;&>,W9YRZV/\
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MXL?@9OGK6X=&/P5W\)%\UJRG:3^A\Q]* OUDCG-M7]9/^G'\X5UOH#_:6U^
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MT-QU;\$S);13QB<GB(',:]EVJ-:XLAJ\=J81X1;39KA+CA)N%DEU;QRP\?\
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M_8F\Q?KTXR>[\5/;L'_4]^SZ_P"=CPS9^Q-YB_7IQD]WXJ>W8/\ J>_9]?\
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MM@AK+>'>LAWU0YV4([J*K[J5]8FW!^*^X*5!R>2G)*^QMYGL]WN5[O?.=S9
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M:+O3*.^AEP6""9&="#B:A#9\V E7@+1QP(6Y997UB8D,97) (&3D ,02 #R
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MGV0#R/B/.H]J?P=%$0T-+AMAPZL+$3E<Y%SYM%8_448JRHX&9%0[6#;J5M6
M!T4:19S)@.[]&P"*IPJ^G?!)RR/*K!=&HI"I[J1BI5G7:I3<9&=V!.[MN<9
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MA34?+)_/-/>A8/SN-?:N?V8\!Z1[7VWF?SIX4U'RR?SS3WH6#\[C7VKG]F/
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MGGEK"NL\]A'&Z6[M35EQI/U4E--$N2JH=?9RW:9UQ?2PW'!5;<KV.;M=A^T
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M&)[M3CAN)%4KV" QQ4L[9H8QF8SRV-U>!PR"%>JO=]G88R["5+8CU:%&.[M
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M0)!'<02",'%:4CU>Z^(5^0JY*IHAQ!RTC;S(F(V8[J."$S9J,E&4S>'%%MY
MXF#'D:.T8RI4KL?9H#V+=J12;M&Z2=H6-F(F@ZO'PF<2,N"29!C$A<G?Q%VC
M:^[<,#!&*N&\NC*)C,_$53&&SR$9SE N-H0Y.4V[223C)K:XK2M3P?B%<1"O
MXO'.*Z&RL3"?5 Q%GS'6,[?#BDUT8\I<:\\KRPJ)8%)$]7Y6?&2:')%^X7>+
M+KJW([:WBX7#A1."LBQ;5QL$I5I<>[(RAG)R689)R35#W$TG$WRN_%*-)N8G
M<8P5CS^@K$(.Y0<  5]8#3E758N2=5W!H]#W!<>-$$50C+5KNY$AB\H/"!7/
M/'.WFA8HS-981'#T>$V;)S("F[9%+AUOQGL5M! 6,,21E@JL5&,JK.RK^BK2
M.0!R!8X[Z2SS3 "61G"DL QSAF5%+>^5C0$]Y"C-?U&GZP;P1&L$(/'TJ^;%
M43;:(:,N. ;<HWE^L^;.T&7&WFT=FTQT3/MDT_)1;ODT^44]$D]$M0MX!$(!
M$G!#!A'CLAA)Q00/%B3MCQ ]W*O#/,9#,9&XI!4OGM$%.&03X\IV3[([Z^C^
MI*T*+R%R1A0%XXEDX@]ER19=GKNH9GM:;1#>!2M]MX_&L8BFT AG(=SSXO1>
M8X,\6O/F/X1K>!MY:)29)8IGR/52P\/A2'_JCX4>T^+8OL4$\J[,2,-D<D28
M/J8Y>)Q$'_2_%DW#Q[S[-:B,ZRT &LCWO"ZDA+&S-9(9F",S;ATDS+.420*5
MCTG.CEN.?-C",I$G"C>4.!Z3;:2+.O3CGI[]%NZ2MBRM%FZPMO&)][2"3;V@
M[JR.P]@NK,'(QNSELGG59N[EHN TTABVJG#+=DHC*R*?9",J[,YV@87 Y5KZ
MW3WK"X%,@2U)P7<*..RB1,!7JS?@>T?39$:WF+-NUU7X13CLI0#"$3\1UTXB
MA9(6.3?!E]6;?A.@Z=8E0IMHMH9W"XY RA1( ,^H<*H>/\&P4 KR%5B^O 2P
MN),E44G/,B,DH<X]4A9BK^K4DX:LZ3ZQT 8X:ZDJHB+K1G4RU$I)[,-DTU*>
M7$% /N[=IHK)IOXP@'.G![$>^U<:CD#9C@?LVV*/]G%;6-HV,P1G%N;7N_\
M\Y4IP2 >:!68 '.T,V,;CF@7=RN<32#,PN.__P <,&XH]ARRJ21C)5<YP,>H
MQUOHB06 PM,U54-)3\:O'W;>2.1*6[E4A$>.-8B6(-N.>!Y8U$N-4^(L:*M'
MA6.>9;^I7C'T=#S9K*U>43M!&TJE"'*\\Q_@V([F:/ V,P+)@;2*+=W*Q&%9
MG$9##:#R ?U:@]ZJ^3O52%?\8&MH1J2M&_J[S,* I^J;$,VV-\EGKQZ%9<A]
M>^NYJA_"_@'B?M/(/2GGX=E/6SS^#QYS\%SJ\(QB)>S,UP.7=,^[=*/^IM[Y
M/_4:HX\IS]\;M1+ >??$NW;&?^D;%P/^D5(F7JM4Q2OUI_X]?_=K_P ^,\/<
M?>/^U>CO'OC_ 'KJMG"*ZO3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I7->POY]S'_$QO\ 6+C.SZ1_
M56G?W*V_8I7,]0]?WO\ >I_VK5Q!HA.\)QV )2.(*=AN6T4[L=G!%LSN;7(9
M-=?"5%1TW9T= 5G$:FD-FG6;:3#9!S!FT>>0VK(K[/I@R;DA*N1^W(P_'6HN
M9;LO'UO$>I7JW$LEPS6AM4:9%@C@>9P'#\((8X$V;#E]O)I"XZO':A9.JY>P
MM&@CC@5;H7#+$S2R3)"I*%.(6$DS[RRX3(RM8JX.=C>.D<QOB-GNSD6!(>#0
M[ 2BRK#MN]))-M)[?*U>"#U7V#1;$U:<[EU=O(SJ-G9=^?"LJT#[)&(VT9@R
M)5EJM&\"%[SP9)=(U[&HT:[>::>Z>02W1B5H);4-/+)"4Q*Q=1"O:4!6;!3-
MF6U\();.MH['5K5(HX+=8S';<4K-%<E88TE#[HU"L96[+$L%/:Z=]0HU:0J8
MV@9(";PB-&&8C52->P_L3:CZV[!VL9CS-EK1EX<R;LBUI-'H*=%OZ]&C8Y()
MALIN> R L+CP$<]36-3FG).LD[%;J.U:.W$,=Y.9YN,O$X\BEIIW2)U,0"/)
MZI&944'+1%\\)2)0;=[A7FXKVL(ABX1V<%&58H4:12)"65/4LH+L1V<A7':N
M6S:[DJK?1VE&@E0U+!?)".VE=AJ:<)1U@:=ME-(O(NJ,(A6[Q;<6EJ5;;6JD
MS'H*/%A121+M63,I5#?R27(@*VH4LZY2>Y:3LAB.P]C''GD-PXP &2&8@ TR
MV<<=OQ@UP6VH</#;K'ERH/;6\DDQS.W[SD\MP4$D:UV"[9RNJ+:#1N*/8E*8
M^,L;KO7]B0Y&J;:-G0>E_67%Z^9F"]WB"C6IJ[*CFTM824)")"#/F)2P;H)[
MO0/$B".-[=YJ$EO<(D9C=!-:131\"X9EZU,D09KI6%O"P$@=8G5V< <UWJ:K
MM;))X69Q(C-%=212<:!5;JT32$"W8&>524*-(K*J-XFVL!!G78R8<]BZB;.2
MI)PV6M7PR**S==\Z5051"]R82R#)*)**[)[I"6>^[08GMKSHP;;[(->$DMN=
M><6R9C>0 LQ!N.D8()."$U&(*/\ ]1R7V!R%9%TJBUF( !X.A<\#/:L)"WG'
MF?9/?4I75VNO&OY;V7)QH+4KBL.K+NGG\F%&VTN=6)882Q 4>,GA,>(,#HX!
M$#8=N0(+1HH]#S!O)R'+..+@ O**I]W?N;^ZADO61;<P6)MBZL)#-*LRHSJA
M#A(V4,2C%9 YPA1<;S:@LK>2.T#M.)KQ;@(5V"*)HF=59@06=6VC>H*%!EP[
M>I&]?"KEO'+378#%^-W'>QWU4YTY]9\;>R2&A!70]IKR1\?M1L@TT6V_!R,Y
M2YW4X'<:>+G6]U^3EV(_ZT-A^-^#&>WZK\)R_1_Z:M]2CY]M_P"K1>^+\(<=
MCN]1S]_W:K3,^S?:.00=J+1D]>TU> CLIU.C<PJ\W35A(%H5";@OAO7Z(UV>
M*67J N*%R=5HLT3M6MU@@&4B!DUC0]A$).DD1"8,E]?/&J[X;>Z6]L$D@-O,
M&CCN+GA;69IMMQ$^"./#M5U610L;C*Y<=G9K(3LEGMS:7KI,)XBKR06_%R%6
M+=!(H.>#+N9&,;DR)D-8N3=J)[$V%[I/1$+?&*>[:=1^NC-5%J98LCH6_&_4
M;F72%9@J=>.FQ,<O?TQ4C""3Y5HW0!@4B>A;=N46(9CW\L8N@5C9K>_T^S!&
MX!ENQ8<1\;B0RFZDV#. %7=NPV<-+.-S;<Y )[.\N3S4E6MS>\-0=H&TBVCW
M\LG<VTKE<5H$]D9S45/SS6$2:-O)SIV&\)3-48G)*JM^ZCIZ+5;VRLELDW:M
M*P-A>:]A['<L- E+"EKYR C2K^/#QT?-+.=FB&$M[);V\HB>,R]<UF7AO!<7
M+ND%_.!@0,O"C&0C32$HF4 5LXK+-HD\Z<1&$?5M*CWK/!;JLDUE">?&5N*Y
MPS") &;#,74#)M;2G8&X+NN<D(&"*XC%/Q2L:2G\@T?H28U8YM]=U=&)2P A
M7[<L)C01M%2K%HH^,OQ)M0Z.76&MA =UIJ8R0MKNYN;@@+"END%M*^0[3,;F
M%G"*0P10C 98JVY25"J1NK#N+:"W@!+2O.\UQ$N"BQ*+>54+,"K.V]2<*&7:
MPR68=FH[OWM;>-;2?M 2B 6I'-<=3H56-CRL;(VTN=SVQ0LO%ES,@C$;>##H
ML'$#+48 ([QD\0&2] P979 7$9;:<JFN+%WJ%U#)?F-;<PZ?'!,X<2&699%9
MF1"K*D; *=C$2;F(4H/55=MK.WE2T#M.);V26)"A011,A55=P5+.I9EWJ"A5
M<L'/J:^5@=R['J0SV-UL2.QH*\K^.3$_2U7DX?-0#ZR(^%DL,BT<L5O>RA\U
M7<GBKU],A#BQ(Q'X>+FM2(%1VIQJ73V2=OTNI36[7G&1%,22/;0-'*C3(KQH
MDPN2S0O&3(IF1(UE@##<&&"?8K"*=;7A.["5XUN)A)&RQ,R2.T1M]JRHX$9$
M3NYCF*G:1W#'6/VH[*5&=EU2'!5(3FV&Y#J&O"Y.$#SJ%5XJ+[27T:HE<3,(
M\]ELYD@LG#BD<(F6!L=(GC:5"W.BND=$.13Q@YIFO[VW>2W9;66X!T\QNJRQ
MP[;ZZ:U*R(9)75HV1F#!R'4CL J0?8K.TG5)E:XC@(O@Z,T;RYL[9;G<C!(U
M(D#!2I3*$>J;(Q["E[3BO)W>,>.R:#![-9O.L\/;R-&$7W:,=F$PFD(FQI^Q
MK[KM'+&+FDGG+6.D7K<%$#P#?D.U*26>R<LE'=R&E37,L,MTKO$L^;*,/P[J
M=)))(I6(AM$F9LD(3MC9.R&>5V"9KP6\<L5NRI(8L7;E>);Q,B1R1J#+=-$J
MXRP!9U;M$+&@+8K"@^Z=PEZ\H^RCT?BM=U^>D]UPRY;0*U=9LLB\=EM27NYI
M8(#(1@7*PDMI$39"0.2R/B>6%I+X[6KUJUC$R0474X*KTKJ5RT-K,R1Q1/)<
MQ7,[0S.B26]T;95*+(LELLVQWXLW$2$@1R#/:-36$ EN8D9Y9%2W>WA6:%'=
M)K?CLP<HR7!BW(O#BX;2@ET('(>1?LU8U?@3$D%B0\0J@?V4[<@K;MZ6 [=O
M ! &]=VSP'BVIP,PL-O)J^BTX9*2DB4GS59W4M+(QA%JM"!<9+M.1-)O9H5=
MU58X!>Z@MQ<2)<7*0B&<*FY5E#Q1RCB,TH)@MM@'"",-OHM(I656+/,;2R:&
M"-H+=I3)#N?:QB*2O&0@$9 FGWYXC.IW6S['6M9<!/==X153:!<R2^+B+UBH
M:L1N>? 8N-%TC;UL.3Z8N.% S\T0;[UHBV: N2HI YL[V%;F@&SO0Z-D+V>>
M)[.*W$.^ZN&@W3!RB!;:><OM1E+$<' 3<N[.W<N=PPK6&*5+J28R;+:%9=L6
MT,Y:XAAV[G#!1]]R6VMMQG:V-IIG,^]]J Z@.'V*M8IV]6'/:32=0D54EU6H
M+GB?62P2T">R&..(/(&G-,P*5.1''+J9604E#>*&2?,?1'RQ4$4?*1LFJW"6
M[,.!UB'KW%B6WN9UE%E,T1=#$XZM#(5YR3-)PV;9M?:QK/CTV%IU4B;@S=3X
M<C3V\)CZW&L@1Q(IZQ*@;\'$$WJ-Q*;@!I=LW9V5=H=S)0G,:]>5'!8E04M'
M5R[C]G1^6,8]/XJT/N \=LVNKBA)J/&E-U?*+GTFCI(@Z2U]#%C!^[D>O1/<
MWI\(OQ(3;Q1VLBQ%9TD594#E4FAGC96Y]IN88CU*J2M5PV]HIL4V2B>22YC,
MH:%D+12% S0RP2*R_DKD$#O8G!%A@/;2Z)A?)R+Q&L5S56Q;L&^H60M6U86.
MJ:9#0K-NSD-MN;FX*I5D.'A9,ZXVWKM6*.R3R(I:&DYFB6>H1]/*34+F2[:.
M. M!'=FU?$$VX!<![@W&X0@*Y_!<,DQ]KB!CLK&:RMTME=Y@LSVPN5)FBVDL
M25@%OMXQ+(/PN\ .<</:-QC:&]M.SDUAL!+F6U*QOCL'U[ONP:V6C8*<$"-<
MRJGDHSNS<2E8K+F[28BY6,/NB>HT4TBKF'E&345N7FC554KQ9CU"]DBB9A;)
MUNTNYH2BREH7MPA!DW2 2!PQ.U0A1@!ND'.KCV5I&\@!N'ZK<V\<NYHP)4GW
M9" (2C(5 RQ<."3MC/9K.0_L9V*AE3]/)+:)N"<PRR:OA$EL^^%:CL"1@&YR
M3I5XE%H7)6L6L3SM7E90QD9AR_NR2-RU::21J@S<Q6-MWS9'FN.\O(H-.>=H
MN%-#$\UUP)74/)PA'$X27,+2!V)N7#0AQ@H@(KQ[6UDFODA63B132+%;\>)&
MVIQ2\B;XL3!"@ MT*R[#D.Q&:L#VM[-E^LKJ(&W@ 67@\IA=X-D%5/3$S;BY
M817ZEFU?#!ZJ;K1BHUGP"'V:)Y:J-?6#B0-(T@.>)^?<MG.7?WK61C8JK1O'
M<@=^\W$47&AC7!QB58YEQC)<(%/,BL6SM%NPZABLB26Y\6T022\&:1N61PFD
MA;.<!2Y([B*G/>YLVM"N4MR,+!L7$$>]. -ULPLFGD>4CO8N?=TPM)SVO@)^
M)R@":]3UTYA,F,OQ)!VX1D3$Y$!,I2+QDI(@1:/;499X><2CA'3EN0KRH5O)
M=26VEA5HW5MD1B<E22'#1J^Y&=6S18)#+RD8B07[6Y9(VW6L5@T\<C(ZLNZ4
M2(H(P5*NR[6",-,D,X[12""OG,@G]>R8Z'\)Q$JWKC1.,RJ(L!#,#;ST4J.E
M+II+Y"Y.0]%HH.]6 &;0<4Y;LWC G(W^Q%N0%VWEOGB)>6%W76XX81LD15"3
MD8<B1RT8&W:@"MR(9SD%;B1V:R +%*BMI$DLN720L6A!!0%$"R9!RQ)',$(,
M$-82/]I+YE!Z-T:R;5 *NU[=EZU@;L9[&ID_JS2/TE&8Y,%9*&K5.>#94N?E
M Z=1(<C$7-IZH"%4)4;YDA9H*;#GN6M]=NZ6H%NMR;FZ@:8K(8-EK&DF]8>*
M)"SB6->&9\+AVWL% .*UG;*KW&9VMUM[>58@R";=<.T>UI>$R!4,;DOP>UE%
MV@DL,O4?<6;SLR-CTBB\/%$1]3=NCTM="7)9P)>3[JIV$#4*]>11T\=)[\P&
M5+J%I(@D^3<EAR+@8.5+**LW:[RJVU&69E5TC4BWOVDVEB#+8W:VI*$G\$_:
M< @L,@;C@D^36,<8+*[L&GLE3(4$17EL;@!P ?OB<DR#M)#$#!&,-UCNKL'<
ME_CR\AE4!955*.D/3Z]G%;CX<=X?AI)<R=Y>NM@$F<35;1!US)(IIZQ=DPI1
ML]A[&+ V@\6<&&93(J;&YN[F[5G>(02:9I]V85C?*O<]:W;',AP=\?,E6!C"
M* KAW?V\@M8+<JB2F9-0OK;BEUPR0&WV[D$8SV7Y ,"'+L692J+HW8VQ+ "6
M1VE9!IS,!#*/R;P52 %H,DQI@U"(6!VQ=QZ>HB&[5ZDD-2FP#74'+DV>B.DD
M#Z\##/#UEQPAEF]FE6;4 LLBA&T((%=@%XM^R2[0#A>*G9DQC>O9;(Y5=M(H
MFBLBT<;%UUG<2BDMPK)6CW$CGPV[29SL;FN#71F0SIDVF(RM%(_9.SR5!W*Z
M,PCT-D#N' ]%42R?DDYVU9+ @!A/U:INV;OG&B^BSH3OYOGT]MPI-/*!((=L
MV74XD2-C&N=PYR@%$88R 3XUY<Q46D9*&;=#A&'WMY%#MC:>49.YEY\R!CDW
ML&N.TTL.X: ^&!'@G%T5N5)5;UR5J>$V'>!.^37&LSNLA3]E7S%;'G,NGS""
M%_-3>.L.883?(B1Q.'CIR]'+-B[Y-OKDLUS:>$$7K$!:"S-O'-=-=L.)=&WF
MNDFEDE$3'BJ.&2%4QB4K@FIR.*"ZZBQX$H$UV)I(K<6R_>[<3PV[Q1I&9%^]
ML=Z@L5D:/=E1G+V5+C@*/#Z,#PWL)&YW'.VE A[$B48[F6W,9!8L4LR 3,T*
M81*^998L*E$:1-<1M7F4QODO"!Z!@7R1W]8IF$";VJ:1U06JQ7<<J:A9I-&F
MHSR--'-%(ZB.ZDFCD0/L^^+NC7<N>><FF-%9C<M):O&]G<M$[V$*+$\,L:DO
M;)%(C;=W8;$AVMCEMP/AS=$FVZ@06MY%:UM0Z37SV?LZK]2(HY8<_P"P77>H
MJ]L25G;#A1^9A6)FPSM@P.+0Q2J7,[UW/*,I#.HT^8RJ4A$1TN+.LOX.BA:>
MXC>[OIH-RM--=VEO#*[S1O(H,KRQI$8#*-^&E0J\B@2-[U=>O22K!"ZVUG%-
MAEBCMKJ>2)%BD6,E8ECD=^,(^SE8F!1#E%NA1?90_*.ACN\7O*)JSJLJFR!\
M[;&6)89H0MBC!D@!R=8N'?:##XIE*)!%=Y$@/>IL2J8$\QWVY355T5R2M;UY
M-*-T<-/!!,LH8,N;BU#J^Y3AU#NF_!PVUAW5'W-JJ:CU<96*6:(Q[2IQ#<%6
M3:PRI*J^W(RNY35>I9W [?PZ/VI("0#K>Z1J[J+&N[!%!D/LWE1Y#"*%@N"M
M*,^5Y*GJO*.&]>%%6%QK<L!"2KE@U<4XXU7</&6')J.H1I.S)9'@Z?'J; "?
MG$W%W6PRXS)]Z.+@X7F ;<Y)&6EA92-"H:ZS->OIX),/*0</%P>SR0&49@YL
M1DB<$ -86;=LI5&FO8ERQ 1E;BH.RG5&F(XF^]9:J%8WV TZQ;GBAC5(EIY1
ML5[[Y-J#V8^C,.-@HGAZT?>:(>EYDFH.@NR$3^CWEA;IG/:2[%D6+<QVEZRX
M3&!V5R#SSB1V2,;7+/B>TO;AL8Y-;=<VJO(]ENKINSD]IL$<L1'!KZO^-1.Z
M25A6W5[DHX[=3NDZD3TH>V)X9T7#.3I)2,A:]KVPEI/8"FH$0H]"AV+V.*1L
M('E,FE$J(BV&VK3'CN[N..Y,L\!8ZA+;0?T:XE8$%FX:PQ2EY>PN54%-BJ[N
MY4<K\EM;.\ BAF"BQBN)_P"D0QKV@@WM)+'LC[3$,2&WLR(B GGKL&[$=J[S
ML'JJ]A$KJVN6E@53W'3FL3E56SLX'(S?KW>]<52ZD2HC>R(7*0J;Y!YR^B\:
M?OTR<-Y*2D9)WDM=.Q:T?HBO+^YEL#&\$/&@U'BQR0RLIEM+J& N5XL<BYSE
M$)W1[I%<R$J4KDM;*WBO!(DTICFL>&Z31JPCN;>68+NX4B-C&'<#$F$*; &#
MXVG^T]WR*F K>J!E6 %J@Z<5UV.G_O6?6K.]IFM.GMMM1$%BTD,V,I+8\S;H
M4U(US-ES<Y9SD>L<",-8X6] (+\>6]]=/;*+=8$-OIT-Y+U@SR\3BM<!8HW:
M82* +=]TTC3%2RC8V":]GM+=;AC,9F$]]+:Q<$0Q;.&("TCHL6QC]_3;#&L(
M.UNTN16YE>Z]V/MYO8<5B=9,*>K8IU,7-QZ3M)<XM"2 NRH:L"15@Q*,3(Z-
MQ,W D[ 4>M'ST)*&TG4;:@7(B-<M]I"]N-J5TW%FCC@%O"UAO202<=TO$@9@
M&#!(VB$Q()5PY&PJF-YMBPMQPXG>8SRK>[60H(4:T:8*2I4NZR<+! 9"N=P9
MO4CJCI_X]?\ W:_\^,G#W'WC_M40.\>^/]ZZK9PBNKTQ2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5S7
ML+^?<Q_Q,;_6+C.SZ1_56G?W*V_8I7,]0]?WO]ZG_:M44Q>&Q>%-BS.*A68-
ML>DTCF1A%EKOKH0E$N+.3DD-./+WWYV>&"SMR^=[:\ZZ;+K;<Z:::^+7C.2-
M(@PC4*'=Y& \;R,6=C[K,23[M8SN\A4NQ8JBHN?$B *BCW%4 "M=3J"LTJG5
MHM.&B-*C7@[NM58'PFMZC4@C\.M'WD9V3\]Z1ZM<!G"P]37S_G>4%-N.%>-N
M?*RCJ\ M^J\->KF(P\+\7A%2I3V<%21WU5QYN-UGB-QQ()N)^-Q V\/[&0P!
M[JD1))-!))!'3A-)%/1))/7_ ,.B:>O&FFFO_EKKQQQQ_P"7&7ARY#N%6CSY
MGO-?3%*@R6=:*)G4Y0LF65I'S<T0(0\QP9=>GZ>?.5\31+P8^^'-WB(DC(8D
M]03]GS[]@Y,"FGEC6CU(:JJTWQ9+*UEEXTD*-)F-MQSS:%MT3E00I>,CL.06
M [(.TXK(2[N8X^$DK+'AUVC')9 1(H)&X*X)W*"%8\R,\ZVD)3M8QLV-D@*&
M!QAT.0M L,)MDUN'+(E=,I:36TWB.VRVVO"TVE3%H;,[;:[<*/$-.4.$$_&G
MS<6V@1E=(E5U:=E8=X:Y<23GWY7 9O='+%4-/,RE&D8JPA!!Q@B!#'".[_PT
M)5?<//-0BKTRIXY>=BWM/(^&G4BFARLSH9H6%+(I1A>L(^+&!$7FR)3=E,&[
M8X*;RX*A(!6[6-'M=7XEMH1T]8[8O@ZW:ZFNI565Y6A90RD!# BJH/:Q)AE$
MB[UPC<U&1FLGK\ZVT5M&S1K&LRL00=XF=F8C*YC.UBC%3EUY$XY5OSKJ]U^>
MV1O;KNJHLO8NTD'S+63*-W/+A"8#![00VEC1EZ5P+9R=02P8BGY]HQ1+%1K)
MHP*.WC1LBCI=-C:&;K!@C,V\2;\'\( %$@&=H?: I<#<R@!B15H7ET(N )G$
M6TILY>H))*$XW%,DD*3M4DE0#6,;=2.N;2,RN()U8#4!3;>)[2-%V\./G[K2
M E]I! 6S(X]*N#H1C SRBQJ$#P9(:QB)5=R0CK<:[<KJJ>#3[,(\8@79)P]^
M2Y)X3;X@'+%U$3DM&%8"-B2F"37IO;HLCF9MT>_;@* .(NR0E0 K&1>S(6!+
M@ ,2!7W,]3^NDBEPV=G*EBY66B5X*]8F7FCY9=,M63A@X@$@51V>^B.Y/$]1
MC)B'E#QNO(6P=+<'ZSV#+N&"IM/LWD$KVZ-(IB(8Y)W08X3GG@O'M 5R"X7L
MYVDBBWMTJ&-9W"-Q,J,8Q+GB+W9"/DED!"[NUC=SK]2;JEUVF*#9K)*HC)-!
ML6L@SYO?@@WX=N;ADN\RM-H5Y9OF^QD%8$IWX.RN,E^7L<,D4&CAX*4V9,_,
M)+"SE #VZ, TS>,9-P_$G#8(W+-)VI$;*,0,KR&"7EU'G9,RY6)?$<"!-D)&
M0=K1IV4=<,HR >9J2XC6D#@;M^^A\8& '90-$H\0<,-%=5'86""U0L0'+<J*
MJ>-N %+K,6''''&VJ"FW"FRFWBVR_'#%$28T"%EC0XSS6)=L8[^Y%Y"K+RR2
M "1RP#.PSXFD.YS[[-S-0"3Z9T]++TGUYV''PT\,2[2K. XHP)53;QS:KDGJ
MC!-ZJB4Y:2\>Z,K#Y"U$2 4J,#F1+0@U;+/M=':.(VFVTEU+=3(LK2<#:K @
M)P <9(;$@+8<*ZE590P&>8R1?SI;QV\3-&J<;<5(R_&QG&5RA"Y4LK996()Q
MRJ1?@TT1N<FTB>5E'"Y2Q0TLCDPV/INY$P*1Z>O4"4Z!(ASKHB'$AYL1:M2,
MO&!6 YE)G[1H\-H/G+5NJG>ZE:[I7,",TRR))ORX992#*H5RRJLI ,@4*'(!
M8$@5:ZW<[8U$SJ(F1H]N$(:,8C8LH#,T8)",Q)0$A2 37GC'6"A(<)<!8_6@
M-JS=RR#SAXL[7*F"SZ45F7'GJ[)OCYD@0.O=805%L7<68.B*HT'YG9$>S0;K
MN$526-K&I5(5 ,D4IR69B\#!H6+,2QX3*"@)PN,  9%>O>7,C!FE8D))&,!5
M4),I64!5 4<120Y RW>2366FG7VFK"<'7LO@0DL2D96)G2I?5<D--[&X*S(#
MHB98'!+YB6#%@(XN5',2(9Z/><#R9!BHLHU>N45/9;2VF+&2)6+M&Y;+!M\0
M98V5E(960,P#*0<,1G!-4QW4\041R,H174+R*[9""ZE2"&#%5)# C*J>\#&K
M_!(ZX:B(G'DJEC+:.0E\6?QV-,N2;&-(+')@ZGY- C'FA! -(!KB:O74FT$2
M%B4$M2RZCIFR0VYRCP?9[8TZN@2(L40;@@+2&5LH"%<&4E]KAE#<P <57UVZ
MW._&<O( &<X+=E!&,,1N4[%"$J02HP2:]\EZN4#+T=&TCK,&39>T4PE+L<HX
M+(##!BP#B,EFVTC&-2* ^3C90>;H%#(&0MB8%ZZ2TW5&\\:\:YZ]C:2##P(P
MWR2$=H!FE8/)O (#AV 9E<,I/BKQ+RYC.4E8':B X4E5B7;'M)!*%%.%92&
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ME414Y-&[F(/TS;UNZY4V*P!ZB^A)Q9DFZ3&N9#%E$$VP21.6:IL>+Y6"H/\
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?M/\ QZ_^[7_GQGA[C[Q_VKT=X]\?[UU6SA%=7K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g942137g58e15.jpg
<TEXT>
begin 644 g942137g58e15.jpg
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M^0^CF$9GQ.3QNY(5.:YE]1P0U2$JK4BRN0A)[^,XCU(,HS&63LB)D3.SS:9
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MF5R!8W7,_KD.? DB]8R*)0PJZL6 R4,>;#2$/FD6@I)9:-H%4I&PUD! 2Q*
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MA#E*.Z)?F/N;'5$7F^@C5/\ )N_KV(;-\:?E7'U9Q]A7Z28/9SY=Z^2MAP!
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ML^BYPZ+(%9ITG/RYCOY'JSCOW5,%0_&CW7$-.889-H3 2S9]!_B'3LRS8Y-
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M%M.AZN+2@S%:P%T]3-/AX8>D3K9^3.O(AG(^O"JYAP\**.7L;#@]UG9$IN^
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M\E/0G$-Q<@0N"5'6<B'F@-V-;]@Z+Z$4S+ Y6/4<9D</4R_5L,]?=A1QJF!
MQDA&Y)7Z4^&QZ4QT@YCJI4N4EK0T.#LD]6.L<]^K /O^5W7BQIXB>(GB)XB>
M(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB^*C=NJJ@NJ@BHNURILV
M642TW5;[*Z925V04VUSNEE1/.4U,IYUSOIG.FWXZY_#Q%\LL&.R;M'9FTV2(
M;;[/TLMT<IO=E4M$%-G>F=/I<[*(IZ([Y6QOG=+31/;\=-<8P1?3+5MLH@ML
MW0RLUU4T:JY23RHVT5UUT5T0WSK]2.JNNFFJFJ>=<;ZZ:XVQG&N,8(JWC_\
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MF%?=XL:>(GB*M<__ +X.I_\ EK]"?]4',GBL/R._B;\GJRCQ53Q$\1/$75G
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MQH>V0:#$4M"QGF?'Q^*V]XH3Q%HGJ3^S+T7_ .Q-N_Y?R'Q2.8\1\UA_#/\
M8FX\_P"%GGW_ "EB/B'F?$_-2F\4)XB>(GB+\Z;X4TUWUQMC7?7&V,;Z;I[X
MQG'XX^I-37133;_^.N^NNV,_U9QC/H!R 1G!&=P6GWAP!![B 1UJ <@$9P1G
M<%I]X< 0>X@$=:_7I4J/'3D3-G:SWE<-:[N[$J V.MR -T?Q^^1-P[5PL4C6
MOX:[;*)S6).I'#%4?]G7;![&^<XV2TVUUOBFDGGM9JZ)A?<K-/%>+<UOYI)Z
M(.,M*.T5U&^IHB-A_:,\P%HGI$ME96</&YVF,RW[A:LI^*+)&W\]15VH2.J;
M>, DMN]LEK[2]O(BMSL6@C<<.E@2>1*,S:-.\/H]+@(F2!7>,8Q^8%FF*!!D
MIOI^.<IJ9;N$_NI;9^M)7&Z6^,;Z;8Q[5%607"CI:ZE?TE-64\-3 \?XHIXV
MR,)[#I<,CF#D'<+:[5<Z.]6RWW>WR]-0W2BIJ^DEY:Z>KA9/"XC)TNT/;J:=
MVNRT[@K)/?4O03Q$\1>?#F>QK<>_-YUI,#?&/8<(JBY:VA="Q6[)G4'Z-4B!
MCFW%CORTT)3+)U=EK ;*PU9M:J+L-'Y"0NS@5,F(!ZO?K3+(<:&^T"1DD=?M
M8[NK&ZN/O%I>J1JE)33DMB@B,Q2U&3J_HG-$A[81,Z/+ 38:4.ADC5$ORD>E
MM?$7@:PH[ED]%#3_ .WB$:/N?R);19J5!C?/N\5OM!=!T@BZ:K).6SE)-=NX
M04T60706TPHBLBLGG9-5)5/;7=-33;;3?3;&VN<ZYQGQ0OKXB>(GB)XB>(GB
M)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(O/[\7%R=5W7-Z^L&YYG\BDQ S:%
MRJ0NC=B4KR77W$T@5=ZKJ!3E=O8@S&=%#@)%O]A[78V6C&I7\NLBWEVFR^BJ
MNY9'  ;:.S8N+O?GV?O9>@+Q8T\1/$5:Y_\ WP=3_P#+7Z$_ZH.9/%8?D=_$
MWY/5E'BJN/ETGAUHSSJX^]NANXUWPT=[-<)I[Z)[:[OM4<LDU\[;ZYT:J.-7
M*NF-U4TMTTU-]::VB01X?J+2\'HY#'@$ @RAO1!V3LPO#W#+@T@$BG2-$@CP
M_46EX/1R&/ (!!E#>B:[)&&%X>X9<UI:TD<CUU=?!TX3:-G#M75?=)J@JX4T
M:M7+USLFBGLIOJW9,DG#QVOMKKG"35H@LY<*9U20245WTTVJ]XC8^1P<6L:Y
M[@QCY7D-!<0R.-KY)'$#V61M<]YPUK2X@&KWB-CY'!Q:QKGN#&/E>0T%Q#(H
MFODD<0/99&QSWG#6-<X@']I*:K))JZ84QJJGHIKA5)5!7&N^N-L8416T3614
MQC.,;I*IZ*I[?CHIIKMC.,2TAS0X9PX C4US78(R,M< YI[6N <#L0#LI:0Y
MH<,X< 1J:YKL$9&6N <T]K7 .!V(!V6 VG6L<MV"GH%)]%]6!E!/9J28J[-B
M\?-L5DWP*3 GNF=56!V/%F[0L*>);8V1>-4_KQNCLHGOY]VME->*"HM]4'='
M,T%DL9TS4\\;@^"JIWC>.HIIFLFA>-VO8,Y&0?#XDX?H.*+-6V6XAX@JV-,5
M1"XQU5#60/;-17&BF&'05M!51Q55-*TY;+$W.6ES3K?GRRY#)1\@K2S<I-[I
MJ-TU 3K5-#\JUE8MQA?]HVB!2QOOIN GXIIDCLFEG'Z1($3@!=)!09KKOYG#
MMSJ:F.HMET+6WRSN93W##=#*N)VKU.ZT[>1I[C$PRX;_ '-0V>G<UIB&? X&
MX@KKA!7</\0Z6<6\+R1T-Y#6=''<Z9^O\+XCHFY(-%>Z6+IR&D>JUS*VB>UC
MJ<9D5[9%OB>(GB)XB>(GB)XBP:#6?6MH-2SVM+#@UAL@)=S'SKR"RT#+6H4\
MS_#\X$+.(^0()#2[3ZM?S(UYNB]0^K7[J.GXX\3&.:C<4LZO^%:K*/ND;S<Z
MU1&53C^+V58JDF.'(U @$>!K:!+*G98Q*)#/IDX-[%T0TA713,RYP3 Q9L-?
M2;=G@P4@%Q  R3]^Y9ERCV)S;V_5V;EY=M 7:E?(GR,5?EF0N0Q]^'DHI!FZ
M? SL;EH@#)09%-D1'$$D"HAI^<&$&!-EEPP>-G*I'-+3@C!^^Q28\4)XB>(G
MB)XB>(GB)XB>(GB)XB>(GB)XB\V7RMO*YKJ]H=->J[8I8WMI$9XYIB(L[:[\
MXJL@+4JAX,_F(LE:?,)>\8)/=QY1H!V?%Y#6->Z.,-@B1+\DW11)X+(W<8 [
M,[-=OOCF!CS/6IY"^@1EZ\'UK(.(.@FD(.BL1&M![$00@=OV\7F<'K_!8IS1
M#Y'U+((C%2-Z&6K,9HA.;A9FMR\?T(S,@%43.MY2+*N,'<?R'/&=NKP\%6+5
MORA]>V04Y^FV;1A>0<6&_%9#K<K6.UH)2&7[.NXKIM.EKS+M2DF%(3>)OJE)
M0/",49P9T*CB\J#2%8FD=C+T6U;%?0-]N>LC?D&C([M^OW8PL1BOR@]O%@,-
M2>VJ#R1Z_BG/$RB1[%7P1)'CC:Y?D9>\C' H9KJ*PSFK$-7;I!<*K;V)20TL
MB,E'Q)X_!K+1E A:W/+\N<[_ )L,U?$CJQMW[J?HWNK=3XR;/EG39>:2R<D"
MG<7-#&=UK0UESAK8C^EIW<=31^>G05(0.7!J\:24)$QSZ0&B;>-0)K(,ELL'
M MAA$>T*NGV@!M^4[D#F <;XSS\59!PS_8FX\_X6>??\I8CXJGF?$_-2F\4)
MXB>(GB)XB>(GB**O.7_ZA2&WN>U]LI-JVE>)A7:"F/I^NI+54?20$V9YWQJH
MNTBLP2G,+3SC[F&C$$+0V4_#='ZM2X:_[OJ;SPX[V6VRK]=MK3MFSW8R5-.U
MF=W,I*P5]".>AE/$W.X7-> L62NXHX%?[,?#]R%UL+';9X7XE=-<**.+.'/B
MMMU;>;0T^T(H:*F83@LS*KVVKI2>(GB)XBJH^9KFWKKJ_AB;4UQ=/-83:AR3
M1MR?88E:T&6L2M4$RC66UPC+DMD= VIY1Z*?/='KQB+.# [Z,EG>HTVZ35*[
M"T.RX9'GOX??:NN^'W-F5'S.%X=Z0FCR5=4\?1R&!;.1=;*/F#* V:T*S&DD
M8C*%=L9G$2B\-35JC,D3;MD&\OK*6QEIA\. #S9<C\%Q<.1)QXCG]?>K:/%1
M/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\1/$3Q$\18'9L;F,NA)D! +'(U-
M+WN1R@:?"XW&)>Y"JL2K%^Y2WCDP8$011B89-7(,FBLB@]3'$G3@.2$F$F)1
MH3XKRL\.7GPCRYTK"SJ0^,)#Y6C.!PV]V7+WR64,^:)%C[.*FS9..V>1O>B3
M4?6GDA#1V=V(K,J\C<7)'T"CC4:JNF/5C[YGY+*=1'?MMJ8?#88/+JP>7EZX
MO2L2>(GB*M<__O@ZG_Y:_0G_ %0<R>*P_([^)OR>K*/%5/$3Q$\1/$3Q%%3H
MP&6A[Z,]+0EBY?2>HV[II.P8Y'=5Y/:1)N47$WC^$$MM-WI:*?:TGT03WRIG
M4N&>#4$ML'W.-]2XE@FHGTO$]#&Y]59VO97P1M)?<+%*X.KJ?2,%\U)@7"C!
MSB:%\31_:'9YKQ[1U5JFMWI!M$,DUQX79)%>J.!A=+>N#ZB1K[Q0AC2TRU5L
MTB]VMI+L55)+3L:?79 9*@3P:4!!$ECI)H8 GQK(P&+,%=5V1(62;)NV+UJM
MK_4H@Y;*IK)[?U?CKOC\<8S^.,;/3U$%7!#54TK)J>HBCF@FC.IDL4K0^.1A
M'-KFD$'L*Z!15M)<J.EN%!4155%74\-725,+@^*HIJB-LL,T;A^9DD;FO:>P
MKMO9E]2>(GB)XB>(L(LR#,K/K>P*U)$S 0=8<(E<&?F8\[PP/B&4M OP#HF#
M?9T5PR,,$""CH8[RFIAN]206SIO]'TY(-MU3A\-_PQM/B<6Z ([]!E;O)W<[
MAS)%%.%?R?1^/QR"+2=8.HY#_NN7;%Y.^WE+O\X3R\:-6#9+#%@TWPX=NERR
M22:\;8QGKSSQW#L5I73_ #54_7]$V+SK=H9R;KFS FP<TD.=X'&AJR2Z+T6>
MCQ3*+G],/@R;9J3%/-F[E#5RWU2>M'K!9TR<%0$M((YA0S^*G@VM_C6HLSS9
M&DW?[I+V%*9L9F,BD@1^=NS\H(A@I6QPT>'.U'$6C IHY!Q/,55:I+1\BSW=
M/EB&\C:'396>XO.H]F/#GM_/_16D>*B>(GB)XB>(GB)XB>(GB)XB>(GB)XB>
M(J$OE9:W 0ON"#N64^CL74]Y=MC2YMJF-\O H>ZY-Q,8TC+&B[KJ865"ZV)^
MZ'+?$<=5\FS-CV;A5:3OD1ZH';0LC,8WTXSL#J.^.QO5]/%2HY+XFY(EW( H
M>ZBDBO"E^F_Y(>DQH+I,4'-2D$Q1HBH*^IL8X:)CVJH,_7U1UM7\>W(X<+R3
M)IF=?O#;A8JXTPY^]5+G9[",C;ES)/N))[E+!/C;D]&65'.F_.E-M9=0D?'1
M6F#S2OXXT?5I&PV'GZ$$B&S9@DF('1[<B2<1QLW3PG'W9(D]#88NR#Q9<HU'
M<9._/?GV^?7VKK&W#O';,9<@9KS/2K<3T(Z2>W6/1K^/)M;(=-S+R2M%Y,EJ
MRQJ[W8R@B1E0_.F$L,)60?2=GA \[<$%":G;;GV>6_+P7SMVMX!4'%MSUK5L
M.CL @$0YYMP7&8A$Q30* "L?V+)G*B+$<R3202RX=N'+UXM].5WKYRY?.U5G
M;E=90@_,/$+[<,_V)N//^%GGW_*6(^(>9\3\UKNV>@UHI?@4>VL*/!8971BO
M8O8<)>$@*):6/+C4(#LD6[-WO^N91K--W7LH5<#,804%GI!J\25T9_<0U6X7
M<T]VB8VLABIJ.2D@K*9SXA)4.N)>S6UKCTN*(.HYRYFVB64.!#<CB_$_'3[9
MQO201WVAH[18*JQ6V_6B:HHF5-SFXL=/3FH9%([US3P\V6PW)TE. PTU;7"5
MKA%J9TLGNFR(7:/1&"\A45K?)%S7<#WV9#M/Y.K'8<_06RHWG#K1IJJZ83U\
M?D[7.Y=1XFVDHJ-BV>NN#V4<XZBYUM+7W@23$T6HTE(=+/['6MM%+6P^UIRY
ME6^6=O[34&S1PL;_ 'N%\-RXOX@L_$G'WK5>YW#_ $\EALAZ& ?@'$$' MEX
M@M_[01:I(+W/77&/-4Z5L=QIJ"GB ]=T'!Y];ULM=3I(+)[.P2C/,]%6&(_:
M4;CIR'-97*%+(5DY^SFB\?)EMXV[1CHU<FF!3_44 PXTH$;Z$=&V,_+5W&X#
MI7Q3UVN&R6JLC]7@@EIVU$YK#/+7-="^3H'"%AD$7MB-DAC < O(OG%/%$;:
MVHH[EQ&*BW>CO@N_4OX7;[?66F*YW(\0.N-=Q'%)0U%2;?*V@IWU#:)OK#*2
MGK'4<8G;&MCSBR)P0%7Y;L7L(J/%4E+(B)A\3$H@5XG+ J4)K6>R%S(=78AX
M5*;31O/'@@6NS+,?TEDS$/A/V7^[Q9W]E56U3X[M<8*R1D=LJ*>.FIXQ"ZGJ
M(A2T55,Z;,;I)/615NC86R-,;6QOBPXN+M@O/$%YGIN-N*;;?JF"EX/NEKIK
M5;*5E%):[I1ML_#UZKY*\24LM34F[QWN6EIWQ54/JL45+-2Z)S*^7=34M/&/
M2KR-OY?N8BQ>GSTI#1/02.%"0CX;,HV(8J?F]-7ADB16;/G>A%^\)99J?=T_
M(!QNJ>VBOIMDJVWMT+ZCI()+=+/'3B-D<<3F5,$;#J]J1[RUSM;W/TG/L1L
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MI^1(#=$GT[1:S@?"">P)@\LJ0OY%HP;E? (;@8)..>?/L/<<>"^DP[=LJO\
MEWH^7YZ3?2?H&OP?.LC(1N=\:63SXC6 6U+@&UX?F]>US:\<C4XM"KRB3N0,
M(@2>J2]RT-1%5D2DC\F_W&HOO['-,#(V[>3@<X&>8Y?YK/:J[PLA+G'MNWR$
MC!W_ !BB)@G77-MHL*V+4V0O*TC48BP1A5)NO31'=TT/".@I8(J9.2LV$<%2
M!4FBDT$:N0[XD1(6[@<LY)&<X SOGP^2F!PW<%GV=5TPB=^/HZ0Z*Y^MV>T5
M=KV*"M@$=-GHXZ9R6#38(!5677$";)IR75M8;0>HIOJQVDZ[!)171G]S8H<
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M143"-T3)*F8RF*)[FO?'$,-:T/<QA>[29']&P/>0T 9;;PQ16ZO-T?5W2Z7
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M7/\ ^^#J?_EK]"?]4',GBD?D=_$WY/4IC/,=2R,/88^0 431>R2<F+%YL18
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ME2M\54\1/$3Q$\1>8WO&"_(O#KWF<R+6+>+SG^S[\"5S649ION09SF\FI&U
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MIF$%8OF(F9QP]*(:2F]>Z*SJ&"[%B0H[7Q260]%>21L?)W)D.W7?LD$=REI
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M9^K&=,Z*Z:;ZJ:[)[:XWUVUQVVBO%IN0!M]SM]=D XI*RGJ" >UL4CB-]B"
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M 80QHND:?JE&I)XD/=LO$K>&^'[B=5;9;74OW/22T5.9<D8)$HC$@]SNH'F
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MKS=EO:EYE3;B_C]#?(UD8E++04<(5^F$-FCE(JJ9$:I/)P39C$5A=EH[M8Z
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MU.^*-(_6WR?_ $I_/([-_A+=/?XA.#O]3OB:1^MOD_\ I3^>1V;_  ENGO\
M$)P=_J=\32/UM\G_ -*?SR.S?X2W3W^(3@[_ %.^)I'ZV^3_ .E/YY'9O\);
MI[_$)P=_J=\32/UM\G_TI_/([-_A+=/?XA.#O]3OB:1^MOD_^E/YY'9O\);I
M[_$)P=_J=\32/UM\G_TK6T-^2;HJP)E;-?1'XM^G2TNHV41^&6D(_EPXH8_M
M>22F"1BS 0W+XET8S&F?ST(F4;-_FX^\*L6V"7Z<[<MRK1\Q;$T@8]MN^X_-
MVD?I[05LG^>1V;_"6Z>_Q"<'?ZG?$TC];?)_]*?SR.S?X2W3W^(3@[_4[XFD
M?K;Y/_I3^>1V;_"6Z>_Q"<'?ZG?$TC];?)_]*?SR.S?X2W3W^(3@[_4[XFD?
MK;Y/_I3^>1V;_"6Z>_Q"<'?ZG?$TC];?)_\ 2G\\CLW^$MT]_B$X._U.^)I'
MZV^3_P"E/YY'9O\ "6Z>_P 0G!W^IWQ-(_6WR?\ TK6U1?)-T5>]>@;5JGXM
M^G95 I/N93!GL7AQ0%P^WCQ\I%R^/TV0]&"2[?\ *' I-C^+L>AA?\M^9;96
M:+(+JD+0-B]O_-_2MD_SR.S?X2W3W^(3@[_4[XFD?K;Y/_I3^>1V;_"6Z>_Q
M"<'?ZG?$TC];?)_]*?SR.S?X2W3W^(3@[_4[XFD?K;Y/_I3^>1V;_"6Z>_Q"
M<'?ZG?$TC];?)_\ 2G\\CLW^$MT]_B$X._U.^)I'ZV^3_P"E/YY'9O\ "6Z>
M_P 0G!W^IWQ-(_6WR?\ TK75N_)!T=1-83VYK5^+7IV*UM6,5,S6<23-X\3F
ML!(S'V:I N3R)CW1I8X1_*-$5%?R8D8^?K_3]#9JLIG73) T$@!S220!^;K_
M /2K96CC5VU;.]-=M='3=%QKKM^'U:ZK)ZJ:Z[?AG./JQC;&,_AG./Q_^&?%
M5<CQ$\1/$3Q$\1/$3Q$\1<$F,&FAI ,9'L2P@LQ=C"HHFT0?C28U^@HU?#R#
M%TFJU>L7K555L[:.4E$'""BB*R>Z>^VN2+#W-4U<].0N3/*V@+N25NR5&UW(
M',.CJYR!#EVNC%<?"RRH[=_%F2S%--FJU!N&*"C731ONGE'7&F"*!T@Z9X_A
M75$MY07H'?4S<TSAM;75:@RK:PTJ"1W+:E83>U(%5=PD%#C2<S*832M8J>+-
MB+N 2F'M=#(8&=E8TK(VXY0K8.,YY<ADYP,#(\//KY!=38_>G'E'3R8\A2NM
MY+$:F@@8O6<TFH.$0X9SC$I"MSE*.EW5%J,@\F9RUO(2//($U-&[<'6ZT+W;
MN6D=_<Z4I?I!<D#21JSWXSOSQGSVY\UJR._+AS+ *E!AXSSQTE'34%0;Q<9S
M,.B53IV?$ZDAG-@?I)I8J376Y]Z[UK<3SZZ#'&3-I8CN=*DU$8&WABTW27 I
M%.@D_F;C]63@DG&.6<Y[N6_)3,K3N^AK@Z.;<S5PO,I)+''/S;H[,Q3B1$;6
M>(60=UEJ+"LY68R/R<E[X/;<*DRHN.CS# *%))Z2(L(,+LQ+HHTD#5U9QWYW
M^BF9XJIXBTOT/>\*YFIJ<7?8*!U]%X.S&J+"8LP;E)/(3$@.BXK%8M&V#U\+
M8.9!*I4<"QP*F2*BAGZD4;;$B@YAJX>H%(!)P%$B=]@<UVGQ=8MUVQ5,]*P&
M)V?K3M@\^2D#$2%I-[]A=\@JK 5(J*$3@A7Q"7.+MTB32,E6%C.(.ZR0"2)2
M6H =UR"!3@YP#WYWQC&<]N,<]L\U_ 'RB\[GUN<@VL=M\;.>C;IF- LZ^?PE
MFN=J6QZ[E$]@\Z%W,=#'RU?1;4!,ZYD<>;:!YK)7\M42U+P=C)HZU+&!A-)W
MY8: ?$.QC'7U]FW7NK(/%5/$3Q$\10CZRO\ YPJ:PN2X==4/D,XGUB=#PX71
M#8!#7LB3@=BG]7U9,[//'U%1\=A88,TL=Y&UR)(KDR13E+AA&0)]U^;2:E8
MD.QRQOX9SCX?!3<\54\1/$3Q%'7JOI^L^/*.F]^VRG+'L3A @F34"P2+DIA,
M)"Y&AR9S8. "#M,)Y=*#A!%XY*FGH:+@!K)\=E,@ Q\<1*M"D#40!S.V^WW]
MXW4-IK\@/(,>Z9@*DSKJ>MI6"@P.#J=(.HW%U('3RW1]=.^A0],2@GI-<S=$
M]8<,HX=)WJD7@<HA[,@+APLQ+!I,T.:+%(:2-O'&>>-L]FV?'?92)Y [<KGL
MH;+W4-A-H5L9AC"M9(^B-MB8F)DCZ W1"6MAU%8@Y.%S.="/VU/HHX5=CV9
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M-!+F,A[!;3::6+"-U8"$)LT"I>(#2M=%&S*>;[H"92[T?[1UL]!-!\A-%!&
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M[*POI3XSX-U,00(V/>5VMUEAUO5U(M8]_):.3D_-MU2JOY=+.:2&-ZU<;-8
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M2^K71!UP>8\MK\^$X=AA((K4V) Q#Q$::EZ,)C&[%Z]#L#9$M*9B<:"%=O%
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MDJPJWI^S*9GD77:[C$B3X??8CGV;,RF2"^SQ',T1)A=AK]F.70G[^_OW*Q8
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M0R'%Y+L[+,6+W#626 :CT2&X%#G+LTOL5+M?S+<<JS98<$'#5NJ3X*B+Y?\
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AB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(GB)XB>(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g942137g65f78.jpg
<TEXT>
begin 644 g942137g65f78.jpg
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M;KZ]OGYTN>BW<#KC5ON4,=MNOK[$5A R/:B_K, =:^M@;N%I1/82VI X,5@
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MJXM\9 'RP._U.-CZC\1C<>L?&(]JXM\9 'RP._U.-CZC\1C<>L?&(]JXM\9
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MMYLAOJ-I% 7N5W:L\N^"NZH[J%9>\]J2S J$!;8=#-B%P*]BB[E3OSV+!68
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M@4D&NV_'.FNPEJ[XYWXYUXY\OO9RIB95E=MU>-D64T?9[4IL:NG^=L52M?\
M]Y$Z7R<:NRNJS(H2V[[#4]M:V6^CZVC,&?KT\T&>H)95=2:1F(=')]"I!+H\
MBNX/Q8)*@161@V[4R0CKE<P#8/UR8Q%O(!)4$NJ]:HZ(F1I 6IMJ]9N4$\7Q
MLBJM+K,>ZNFP@5VO58E;DHM@".RA6)K=; %)W1E8>:03ZF1198]5=]+VU@EZ
MTL1K$ =JR716+* Z,AW V=67Q!$WUI_&FW]H1_Q-<8_VQ1_/5?XUGM_V"[^:
ML_P&=",_64_*DTNQ?Y"RK\"O?\/G(_5?N;F_T>S]$VT?9J_PU_3.6=DU_M8*
M$+0U*\"?9&R(98'.W+'E]ZPUB1+DAR*XXX=M/"\O_P#LN'WE<<-?]_PCC_<R
MJ]F>T([.V:VYQ#E^S'9G6^SP O[CR<ZQC>3C+)[F[O1C^W[C:OO?:]]7[:>Z
MWI!U=-,49 Q_8[6M-U<DU=[WPT^XVG'^R5\#;OQ[WS^'CW;^$DC*S)J,1&(C
M$1B(Q$8B:VVF40>CRA9G*HV[% VZSLV3;'!C@>':MT57+AR4>).MVX]N@W06
M<++.U$DTT455=]M=$]]N,BC@J"C MT4%3NQ/0!1MN>I'AZYYN/6)E!!<5(!(
MP\!)CS0,V/9%PQD2\;D11842;)/!Q,809J+-'X]^S61=,GC595NZ;*IKH*;I
M;Z[<^$%258%64D,I!!!!V((/4$'H0>H,]F0SR(Q$_G//'''////'''''////
M//DXXXX]_GGGGGWN.../]O.(F("2$!)6BC^.' Y]BBY69*O A-D5:)/&_F\.
M&BCABNNCHY0YVUX60VWX52\[7S]-?+QF3*R'9E92>NS @[>OKM&^_A,QF,31
MM:VA6ME*V_ZDUVL96#-ZV]I%'Q-7="%-S[F4>I&8Q5[N&8:NCKGQY-\R'-R9
M;EF);E'KQH%#H,=G>V=UW/+ZUWAMX[#[(5"<B=N1V4; $D#<[ %FW\V&^_IV
MV_%XS><USV,1&(C$32[#@$:M&&FX%,&J[V-R%%L@4:MG;A@NJFT?-2*'";MK
MNFNCSJZ9H;\\I[Z\[:Z\Z<^77;;CF;[.=H=3[*ZU@=H-&MKHU/37MLQ;;::\
MBM&NHMQG+4VJU;[U76* P.Q(8=0)&ZQI.%KNFY6DZC6UN%F*B7UI8]3,M=M=
MR@65D.NUE:'=2-P"/ R$ZL]S%ZBRF5IBC$,DB[+9@]7Y33G,G;[>D1UTY3Y]
M(D_UW\G'G<^7CR^3G_CGW31?_P!1'[J&;FBG(U;3VK[JQ]ET;3U.Z[;=13OZ
M9\WR?W'>PM=19-/RP>0'W2S3X_#;+,?^A[Z,?$"6?_Z/,/G/+=^_C^Z'_*6%
M_P#B\']E(_\ >E[$^X,K_P#(9?[6<9>V_4B UQ8KZL*+HF62<J3*&FP^3$)1
M)%XM%V;%_NSTU(O5'R+;<@FGYJ_')8BQ:IZ[-]^=2>RVS3CZ5V&_=+U;4Z,W
M6.UW;72]*T[3+*U;3*=/P!JNHED[P=Q7W3V]PQ^MDXU%]K$6#?&"BTT/M;V#
MTW NQ=,[-=E=0U#.STL89]F=F>Q^"%?@>]?O4K[T AP+[JJU!0[7EC6-EH7H
MQ&X Z&2VQR/$JES%9!\Q%C57+2-!'B.VJB2GI./#OS;INIKQMHJXX9C^.>=M
M-QKCS=%^:OVY_=MU'7JLG2NSV/[%Z5>KTWY62M=NHYE+@JR\3WE&%58IV*UF
MZ_P(R*]V26#LC^Y3A:/91J.M7>R&HU,MM6/2SUX.+:IW4[^9;E6(1N&?NZ?$
M&E]@\O[GPB?7HQ$8B,1&(C$1B(Q$U^62J/P6*R:;2PFB%BL.CYF524PXT75;
MB8_'ASDN9)KIM4EW*B+ <T<NE=&Z"R^^B6VJ22BG.NG* -R /$]!^.0'!>X_
M7*R])+I![%1,%(K"7MC$HX]CTJBDH<0=@CRJXE 6.S0)'"QT'KMZ)OR7$-7@
MU-VZ9MEG:2KMOJIX"#X3(HPVW'0G;?H1OZMP>A]XR;*]G *SH!![*BV[I2,V
M%#XS.(XH^;<LWNX*6!61X1N\:;;;[-76P\@WV<-N=]^4%>=TN=MN=?+S[/"-
MB0?$';XIN&)Y&(C$2O5Q=JJ&H,EH(M6<J1TAZA3E3YNQB4WEO &**O7PY*52
MQ:&1N0MX=%UGPPFU2D4J5#AE5AA+1-[MRP=^A\) _3,@K-X#?T>(&Y]0W\3[
MPW,G<83'&AH\R'?LR@@LQ:$Q9,>X2>,"(Y^W3=,7[%VWW40=,WC95)PV<([[
MI+HJ:*I[[:;<<\^S&>[$1B(Q$8B,1&(C$1B(Q$8B=N,YYT1B)CC'V)*?@Y[^
MC*YSY?VKD_T>[]6TQ?VC?@M^@RG]S*&D:?M9:-RT9 )$E6TZ4 SLT[9, T*-
M:1<IL+EI9\2;/!S(9&WW"!E^[?M'3)NU9*K.FRZ&BB6U)3;FFZEQR7=1N2PW
M&Z@ @DGP&Q!]^<2[<EW&XW&X'I&_A^/PE,.@%@A)RC9J(Z0LSQ00V@OKSEGW
M$NWM?HB[<.)R-65T3N"$PI& (*%P1IEKS%F:B4E=#'C4JW'*11BWVZ,E2O#=
M=@>6WUBNC?VI_@,W+H0?.\-^A/(S9:-MO$;[[;UK7ZOXI._CZ3T_'-2[!2WW
M/HFSM^C;3D9EP1D]L:,YHA$ =F/9+ +3LN'QN+N/9^81"..U8D0D$3*,N3;!
MH65;F ,K-B#+ C&9&0!N<JURAW=B ;!/-Y%-F1&+#=6/G %3MN/%1MU ,]06
MCBR[=%Z;E0"H)/4$]>OXP=CT(WEVK_A,QL&OFD:@C7=Y(M[(ILSHAH2:"MN1
M$8MN%261J^,>NF;?CA".B2B^S?E?A5[JGRS;I+KKIH*6K]SS4M/TGM3C9FJ.
M*\3V,[0XO(TV7_[3G]G]4P<%>[K2QMWS<BA _'C46[UV1$9A7>T6%EZAIHQL
M%"^1[(:/=Q%B5?6<75L+)R3S=D7S<:JTE>6[@<%#,P4Y^SOY=2'^T-OU>TS\
M]=M?^U&K?SM'^4QY^M>QG_9G2OYJ[_-7RD/;JCW_ &$K&,5XT:C7S!*]>N\V
ME3$H2>B47L&KJZX/-YNU;/1_'C-"3B+ BJ0Q)NJU47?;((ZO6?._#A.*TC.7
M3\FW(8LK' U&BIE4.1?D85U%!*MYO$6NI8D$!=SL? RVJ8;9V/70 I S<&ZP
M,Q4&FC+INN *]>1K1N(!&YV&X\92ZQO<_)(S,7BZI%J'C,;DDRZ;6-$8SS-S
M#-U*"?7R7S.134(1D$@#3KB,O'B1D*2A1-V)D8I*5B!:[\<P:H+/4IG&[05E
M<'RUGLMKIUC'NL[A&%2ZA3370ZUUO1WJ@HZW*'K8U.P#,2%,3D:)8'S#B!:Z
M[+=*R*Z^^=3:V#;;9:C.Z7=V2&1J6*V*+%4D* 2/K*^KW9'B H :T%:1QK9!
M3L&8N4&>MZ&EYN4EMI H,$B9M]81*AI$'$P-UK'Y,[M.$U[&V9DP3(1HPU/G
M=DI&,?JM4T[R@V9+=X<=-/3#>O$O2E:<9[WM1<=<^MGR!WE2XM^18R(JV*43
MZVR^V:=J'<!,=>[&0V<^6CY537-;D)2E3M>V%8BTGA8V3536'9FK<.Y%B-Y]
M>F5X#:Z,-DF$'D4K&L/<PS@0&^DR[1E(SW2V:Q&86='W)Q8"^U#^TS6.OPT8
M-+L'K=VX(I*%4&+/9SMI[[,X+9"$M?74S=IJW=:P6KKUJFVG&L"!QS[LV*]J
M!@0%(4L=IC[$YBT. M+V*.SKHAL(6QM(MJMR*RY0\.\%;+6Q4@DCD%&\D4SU
M)GI\]<\WVCD!$RVR>]'2SL4*=ID$G1496M$Q+J6%G %>0: FSO8@.5K*XA\:
M&I:Z,B3$]Y_GC-)02;H\Z:OCI7AT=YD/5C:'K6G."NRODYUNJO18*^\(XL,G
M$:QCYRLG\+NE)Z7TRY[,N[NZ%MR-8TG.4[[NN/A5:8ER&S@#R4X^4*U]JRO_
M  >\83Q='J;/Q:Y>PI,ONFYKFAY-*^MG6+^#/6W(VN9'+][YL5NSU>H(^D'!
M#LO@%%LE67&S/=AUV8[:+.U-E'&_NMYB6X>GJG3(SZJ=2U/J#RR*Z1@XY.Q/
MG.E5^<P/7EJ!Z  "8:/B/5EYS-L<?"LLT_3NC#C19;Y;>!R\51[:,($=-L >
M)ZG>I#U8GI+N6SLAB^CR77,Z8A5\SV.J/'.LC(]E:M@LKJ.*.M!6K'9@[CA6
M(&:VE3E^H]1>#9;148Y]"[0*;<-]%>J8ZZ,V,RV'442_ HLV'=KIN5?3EV@O
MRY"Q+4R:@H4AJLZSJ"G7=9IMS:L,@&OR!VIS;JR3WC:AC4VXM1"[;&MJFQ["
MQ8%;,.KH0W2N<7Z77^I6M6U0>C=81OGKMUS[#TZ(LL+,WA4Q?4CM>O5($(+E
MQ/,.%.HB(DS[GBT+0Y,EC#WZ(R W08VD#9NK).)&S6M/&3DY:6Y5OLAJ.G9C
MXUE(5<"K$R!D.B/WSBUZQ_LV+P1!Y.6YFLD5S@KTG../CXKUX]?D.!GXJ9"6
MEFS;,J@T*SIW2FI;#MD9/-G;R@+QY@&PYJ6=4NRJ3*8P.*QRM3,8M-QTCD9^
M8E;!)AGT,>];7=:-YV!:Q=&%D^9,N99URR=Q8CJ<#,E-"I/UIRR<"&#,_A3J
MNF[TWVV9*6XHUNJNE,=76Y=2&2:+#:;E[L(<EA:O!VW1>.X=BF=NF:AM;177
MCO5DG1['N:]D-1T\XXN05]TW>%QCJ:FYH//;EL4 >48IU#EX"1U=(^!$';$X
M][H9V:[-3$JS42T*%*OM^#=G(D 05>:"DW)60.&]F5P/,AW:WAD1@K=#E\Y2
M!LD=^6W5Z;*\JOG>5L[/:;IE*,#Q7*Q+],ML('(A*QY-DLC@;EGWX@NTZ:M+
MM2S&?C2&KUW4=1M8'SFQLNG4:D&X7=K",BA70] J[<B$603'NG?8V.0CJ:V<
M1\3N0ZWTU:77&11>"VT& [S0/+4:?1%VT$-2BK#X9!$TWK0H$E,),"69O0%(
M6RS>1//!D8\8[[-9TZR_5B+&XZEF8NHUVWXCV=R]7E9;$L2O*K<E#D(]5R.R
M<T(-8W6Q.*O2L^NG3 44G Q,G LKIRE0W+:,7CE(]F.Z -Y.R64N@?A8#WAV
M*-E]>ATW R]$$V!E9'3,EKWJ?$.0+&_?4[NN_I;Q(P6S!R R;J4K*)^' OP[
M*:1"4 'T;-%94]D.Q*.Q=5[H:7P]GJ+*3872K,JR-5NYG3^8R?9%V8O6B9:5
M8[NKM3=58+$6I:^-ENW 9^PMR6A C/BV4:95P&<5./Y BJ$=WQ6LO5&46U6(
M4=K2Y:NKES-Z.L-)NZ:$6[Z[$QMI(+&['=@K95)@DT5'94%8]H'I%$UC;_AF
MU<N"Z,35 ,'B"VSGACP/;CTG*R#)#;B"U/-&8^'P>PUXVFZ?B!;-P$LQL9*[
M0B[D!#;WC*1MRY%B 6,F-.Q#B)E<UK#WZAG919-MV3(R7LJ+G8$L*BBD'?;B
M%!( EI&G\:;?VA'_ !-<XL?[8H_GJO\ &L[+_L%W\U9_@,Z$9^LI^5)I=B_R
M%E7X%>_X?.1^J_<W-_H]GZ)MH^S5_AK^F<F+EBTEE36MTXRWV<* ;CKB4F^-
M7K=CZ&- C/+HTXVY<N&_#K5%M]5RR1Y6<.O]Q%NKM]3D'V*U;3-)M[3-JE@K
M74.Q?:72<$FBR_GJ>?A=U@U@55V&HO;T%[\*ZO;/8@ZSF[28&;GUZ*,%"YQ.
MTFC9^5M:E7'"Q<DV9+GFZ=X%3J:EY._@J,>DF/*7+)&(C$1B(Q$8B>5]_$GG
M]E<?X6^>CQ'PC],3\Z/3CK]*R?5[KM? FFZZHJ*P+W/^R \MFL8,A5I_V=6L
M"H0J4>]L T5CPU%*. 7@IW.=GDWD!N2(R==@U&C&B:QHDO9,S(09>3CM=9D/
M9J-91'5N[Q>[O);@SL?.8$5[5JJ\022?- T(OF@@  (=R/%MQZ?>'O\ 7?\
M'+'4);EJ=>(=UY&6I?7!^I9E[FE/[]=KO*PB[1G13OK[%Z#41>Q)K&&:$JF$
M<TAMG/%#0.9G94=+FHPW>""XEL55!H<V135DODFG'XW)JE>/L+7)R!D/D;\R
MWFHW.H<614558A@Q'*9*2H7=NAK)\!TXA?#U]#Z=_"9"&WKW$.FNP]3P@U8I
MR:I=>*0N>FW78@'U;BD_1>3^R)I&),WCR5+/'-<-F,@B<>16JX3<HME( T[U
M2:SS5]&W7*G.+T82KC7.M:UG(OHO\F;+>LBNNMD+=^.\\UV/>F@E6KZU[.)Y
MN_4 GVJD$\0>IV.VW3J/#?KOXS_!+M7<,H?=>Z8JR0]FCQ^7$.SS>U)%Q">G
MD>[- );0!2O1N]5NF%EN8?U<W=LM[&V+2 ]# LD7-QF-LG$2:*HO)#)@WHQ*
M4&3?<F*JH,7NE[S-;%9,@6'O@:@^5L>[V5;&3BS>>?:JWO(^:!RZ\M^BANGH
MZ[+Z?'WNGC.@56K2Z6=74$^Y ",!C3V&S8+=8J1.8?Q&7,38O9"%>%)AS'9%
M)(*,1D<%:-3TR&"Y(2CH)T4+"DGW@F/U$=;P3*_V)G(#HU!7GR#D*P"<E5SQ
ML)5"5#, "1N9F-ROG#KL=_\ K?TCWY O2BMXQS95^=CJMKL13M%W,'J6(U%"
M0$7:01I. -6(3;=S?S^%,&0U %]$E2;-PD.U=CV1PG7<'B\A*MT$SH]BPZ,Z
MQNZQ\6VQKLBAKGNL9BYK:WAMCASN6[OAR?J5%EC*-^))\0=2P&RG;8;;;[?P
MMO1OZ/>V)G17(V9QB(Q$8B,1&(C$28Z+_EZC^"B7_P!*63_9O[I#^8M_Y9RY
MGV$_A++JY]!D3.1=N?;/GO\ S49_35<WCP'P#]$T'Q/PG],CO/9Y&(C$1B(Q
M$8B,1&(C$2M'='_['7;+_P#C1>__ /RV59X? _ ?T3)/;K^$OZ1*41BDKEF<
M#@-^W64K ..IOIG9,0JN'U=S*"S\K]%.MHMH9D<^E,H8 _)X,'$!C0;$PH-5
MD@4?/RBY]UX9FVY\ WXD^@=/QCT_]?CF9902J[^<X))]XGH /A\3\4T/J]&C
MU.J>Y7D@=J6\=:]@:/=Q^SHS,+"D,C@ST8(ZPM[-AR,9@#MSS#H.I!R,?:A0
M3J& PA%Z"7>I25X?)/GI)R'3C[XV\?>W\/#T?_,];9A=T4<2""!L1Y_$]?$[
M[[]2>OAM-;I:ZG1_LOTSG%>'+3$UKV7-7TF22M3M3)+0/69#HS4UARX2=+T$
M1?EX33_L_*8J'68+PAP(6!MGBD5."VB[Y=FW>D$'H=_3OOX^CT;?_,]8;*X/
M'DO'P0#8DC^%XMT]?PB8Y&V[7Z^5CV9!K2*96/V?']4;5OB%W,#OF47A35HQ
M@)(V;!*RPM6GS#P'2\JBG$F"N6,+CD/;PPD+9$&8<Y)A@I1%MYN1OZ]MP=^A
M]_;KM^@QL'*^ 3FJD<0K#??IN/$'8]2=_>$L_P!2XU;PBWHP<;S,6ZJ&54L:
M?R0(9[FSWM8>L"5:F(4O$K<B3.<0X)[%-/ OI -ENL0>#X40XD,;2;QP>Y'#
M^=_1OZ^FWKWW]_P_1[TP8J0>GG!A_ " #KN#L3[VV_7H>O62OW9]JIE6MC5_
M7W9:E:77UJ^5\V<%G@$:;DKZ'R$:Y9MUV\@7G8KBL!KX<UDHW25DZ^GR6JKK
M<@.'<N0V[=T/4$;@=/S?^WPPG0ABK-U&VW3J#\!W^ $?#)CZD203+^K?7:2@
M(>1K\"7I:M70.$E7BI%]%PWLB)2%!E"3A%LX*),F";=)J4<-6JY)IP@^6:ME
M7&R"?H\!\ F+C9V!()Y'J/ ]98;/9C&(C$1B(Q$8B,1&(C$1B)VXSGG1&(F.
M,?8DI^#GOZ,KG/E_:N3_ $>[]6TQ?VC?@M^@R@79\ZB)J4X)?Q4O,P4[0+U]
M)(^%K^W;&=/@$JBDC9OD50]*1V23,<Q<<ZI,WI[AJR8,&[G='4FV+O!&B],I
M&[@A@I79E)9$ *L".MA"GWAZ?5MO.-/;#8[$=0=U7J"/2Q _%*\](ASUS+KV
MFIF)R",FY8M#EG.I>$]J(,,YX<'+,E1-O'!/9&,QH>DV=RZ72F6&$J^1<?\
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M_P#F^:/I4JP^_P I^5FGS7CF?>_/\\<![_YOFCZ5*L/O\I^5FGS7CF?>_/\
M/' >_P#F^:/I4JP^_P I^5FGS7CF?>_/\\<![_YOFCZ5*L/O\I^5FGS7CF?>
M_/\ /' >_P#F^:/I4JP^_P I^5FGS7CF?>_/\\<![_YOFCZ5*L/O\I^5FGS7
MCF?>_/\ /' >_P#F^:/I4JP^_P I^5FGS7CF?>_/\\<![_YOFCZ5*L/O\I^5
MFGS7CF?>_/\ /' >_P#F^:/I4JP^_P I^5FGS7CF?>_/\\<![_YOFCZ5*L/O
M\I^5FGS7CF?>_/\ /' >_P#F^:/I4JP^_P I^5FGS7CF?>_/\\<![_YOFCZ5
M*L/O\I^5FGS7CF?>_/\ /' >_P#F^:/I4JP^_P I^5FGS7CF?>_/\\<![_YO
MFCZ5*L/O\I^5FGS7CF?>_/\ /' >_P#F^:/I4JP^_P I^5FGS7CF?>_/\\<!
M[_YOFCZ5*L/O\I^5FGS7CF?>_/\ /' >_P#F^:/I4JP^_P I^5FGS7CF?>_/
M\\<![_YOFCZ5*L/O\I^5FGS7CF?>_/\ /' >_P#F^:/I4JP^_P I^5FGS7CF
M?>_/\\<![_YOFCZ5*L/O\I^5FGS7CF?>_/\ /' >_P#F^:/I4JP^_P I^5FG
MS7CF?>_/\\<![_YOFCZ5*L/O\I^5FGS7CF?>_/\ /' >_P#F^:/I4JP^_P I
M^5FGS7CF?>_/\\<![_YOFEE\PF<8B8XQ]B2GX.>_HRN<^7]JY/\ 1[OU;3%_
M:-^"WZ#*)=H(J6F_7.[XL"?3YB9,5A,D1FU6OQXNPGSU$&\=-P<3(E Y]DS+
M2-1#@ BNH)=JZ:$E/"\(._0.4:72P6VMB%(#J3SW*^(ZL 02!X^/HG&AV92=
MO$>/A^/P\/&5_P"GV\P>3NX3,J!WYRP,1ZO5('-[VD!;8Y)X&,F%T Q*#NN'
M515*PJN1<D1A>9KQM=&2S9>#SRO7<^5BA/EE$!>V_CPK ->X+\EK V#%:R?.
M[Q^8V(7EYJ\E8)R&[')]MEV*^G<+MT.RGQW.XZ[;]!N&VW\3?;.::Y'MFE*T
M#QMB^MMBF1A?$UKELHU58NB.G,C?3^-L80OX5G]?YV:S1P =:+?]DUW1U=./
MK"*F6CL;1K.1V@QJ] M-.H^2:K9S6VNH^0TZ3FVZJG.SS=K-,3,K*^VL#&M/
M/99&ZK;IM.('U5!9A^6:>I4HU@\ILS\9,%N*=?-S6QV#>"$!V\T&>6SOY=2'
M^T-OU>TSX1VU_P"U&K?SM'^4QY^J^QG_ &9TK^:N_P U?-#RK2SQB(Q$8B,1
M&(C$1B(Q$8B,1&(C$3PDC0F.,'1XZ38A0PA'8@2+$W2#(>/9MOKBSIV[<[IH
M(():Z\[;J*[ZZ\<?[><[]+PLW4M1P<#3L7(SL_+RJ:,3$Q*;,C)R+WL45U4T
MU*UEEC'P55)/JG#J>9BZ?IV=FYV31AXF+BWW9&5DVI3114E;%K+;;"J(BCQ9
MB!*2SSM-V([XR4U2O48B7@M*,W&XFS.PQ!JY%JD&2G'FNA<7YTT:$&:;QMOS
MLW',EFTG-)*H;$%HL#W?*NOZ(Z7V:T#]R/3<?M/^Z9>FL=J,BOOM#[$X]E%P
MIL_@7Z@P#U.:W&UE[A\#%97%"ZCEBI4_G?G=I->[=Y5VB]D6MP=%1C5J?:&Q
M7K-B'H]6+[5U#KOQK0KDW*5[PXM!<MTUZ;=7:IZPP%W&Z\#Z[%7R[?F4S4FF
M@O*I8[10TVU5*$-$].4F""FZNPX*SX1&#N%5=T4-GCAX\=?,]=[?=H.W^9=J
M.MY %-5[KI^FX_),'3J65#W=%9)+V-T[[)M+WW$ ,PK6NNOZ-V5[+Z5V8P3C
M:=3O:Y'E6;:%;*RW4#SK; !LBDGNZ4VKKW)"EV=VEFW5*?#*P(M9H(<\=F+5
MK:/0XAL&4>OM+$6-J_0^4W=,D_$HIC3*Z[AJX=J;#QZJRJRFNO"F_/.>B#7+
MQJ5.D9%J)1HVJY.=5WXKK.EKCK[)@)8>#&VA55U0"VT*%!.PDAJITFDX-NI4
MUNUNIZ=CXEAI+N-0-Q\@)9!R KN8LK.>[K)+';<R:L@),1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B8XQ]B2GX.>_HRN<^7]JY/]'N
M_5M,7]HWX+?H,IM=,N@D,K&8$['E=?PV+O@K^/KEK1>-&L(6?2!HN)'"3B#L
MD)Y,-C#MTF/VC[)^W)G=5]A@[;AXY2YXI5:LSJ$#,VX.R>VZ==QT.VWCOX#Q
M,XU!)&P)]/F^/3TCU;>OT2B/N>4>B_$K[ 3>$!(L#C!5&LX)QK7772>=>*[)
M'X ^LUV:?BA=IRXQ-Y,>3UF+%@9+:16*Q/4:UCJ@ E+EGI-R(Z,HGC4K$DCF
MWG6K:P#!-@2BA0/-W Y,>IW"[#?9;_!!WW&Y.[*QZ[?Q1L/#PW)WWWVVG4#.
M2:9'MFP"-V9&V,3EA]2-!E)K7)[8JDY8-=]2,1GT;E85CZ8EKNU\TL9"L!6Z
M?.OIUM'FR+3G5THCMQ:.QNJYFB]H,;.P,09N1Y)JV'W!2UQW&I:3FZ=E7<:2
M'_V;&RK<@-[1#4&L!K#"1NK8&-J6(,7*O.-3Y7I^1WH:M3WF)GXV717O9NNU
MM]-=1'MF#E4V<J9:1]#8L3=K/GX-@Z=N.==EG"J7.RBFVNFJ>O.W/G<>7GC3
M377CWO\ 9QQF.5V<T/-OLRLK3,:_(M(-EMBL7<JH0$GD/!5 'O 2]XW:'6\.
MBO&Q=2R:**@174C@(@9BY &Q\68GX3/)]#Z%?%L9^1Y_:SG^I+LW_(^'^0WT
MIO\ JJ[1?ROF?ECZ,CJV(E&PT".$A09DQ?-]A?H'3=/G55/TQ=@@KYNWG<^3
MST55$]O>_P!W;G)KL_V+[*Y.K8M-^AX-M3B_E6];%6XX]K+N.7H901[XD9K'
M;#M/1I]]M.M9U=BFKBZV#<<KJU.WF^D$CX#*;^-=_?U/QY])_>V["?\ A?2O
MD6^G*5]7_;/_ ,1ZE\JOT(\:[^_J?CQ^]MV$_P#"^E?(M]./J_[9_P#B/4OE
M5^A'C7?W]3\>/WMNPG_A?2OD6^G'U?\ ;/\ \1ZE\JOT(\:[^_J?CQ^]MV$_
M\+Z5\BWTX^K_ +9_^(]2^57Z$>-=_?U/QX_>V["?^%]*^1;Z<?5_VS_\1ZE\
MJOT(\:[^_J?CQ^]MV$_\+Z5\BWTX^K_MG_XCU+Y5?H2PU"A14C]J_7K%N4\'
MZB\+XK7G?T'B/7'I_1^3GCR>E] CYWW?1Z_<RG=K>PG9#"]C_)>S^GT=YY7W
MG=U,O/AY-QW\_KQYMM\)ED[/=M>U>5Y7Y1KN?;P\GX<[ >/+ON6WF^GBN_P"
M3T2@4-2'$%4XZ-T439.E$]]4N>-M-]$%-M=N.?.][G7;CCGCG[O&4?)[*=G4
MQ[W72,,,M-K*0C=&5&(/MO01O+$W:OM&%8C5\S<*?X8]7X,ASV>"?T:V_P#A
MY_:RH^P6D?R?C_DGYYR?5=VE_EG-^4'T8]G@G]&MO_AY_:Q[!:1_)^/^2?GC
MZKNTO\LYOR@^C'L\$_HUM_\ #S^UCV"TC^3\?\D_/'U7=I?Y9S?E!]&:-95+
MUO;4)/5].8VW*1J1-=&[]OHJLU<I[H+I.F;UD\0WU7:/F+Q!!VT<);>5-9'7
MS]5$^=T]Y_LQE6=CM<P.T?9U:M/U;3K'?&R$0,.-M3T7TVUONEM-]%EE-M;@
MAD<[;-LPANT&?G]J-)R]#US-R<_3,Y46_'M?H358EU-B,H#)93=6EM;J0591
MXC<'9H/!8A6L6$0J!QX9%HL";<-1882WX0:MT_+SLHIOSY=EG3MRKSLX>OG:
MB[U\Z45=/'"[A517;HU;5]3UW4,G5=8S<C4-0S+#9D962Y>QV\ H\%KKK79*
MJ:U2JFM5KJ1*U51%8.#AZ;BU86!CU8N+0O&JFE>**/23Z6=CNSNY9W8EG9F)
M)GR"_8]Y_;/^BGDKHGVO;_/?\B25H]H?PC^@36;@KV,6(UKM"42%2/)P^WJ\
ML('NFY'MO7$GAYCUB#CV_)#7;5=,PZ_@^[9GYI!?CZEGMJI[^770]3R]+?5&
MP\491SM$U33,@%+7[C$SJ.ZR,H=T05-"><'?>I?%P1.#5L#&U!<!<F\XXQ-5
MT_/I(:M>]R<2[O*:#W@/(6MYI5-K&\$.\E[(22L8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(F.,?8DI^#GOZ,KG/E_:N3_1[OU;3%_:
M-^"WZ#*L3JOH+9T=<Q&Q8?&YQ&':S5TN!E09@<%\O&*VKD>_3:$4'"2!$<ZT
M3=C2*&J;T<\32=LET'"2:NM)5F0\D9E;UJ2#U\>H]?I]<X@2#N"0?>F@TW0<
M-HC:7MH"8GVT=EY9$^I%)?.I#/A0 ]OL]V,%(X4FCLY,&7,BY<M."8MY*" %
MGH'&)QT2"TX?:OLK+&LXE@NZC;DJA21Z 0NRG;T'B"=SR)Z;>LQ;;?;<>D #
M?X=NGYOADW9KF,B"\:TD%MP=G"XRN+;%E+#J21ZJF7#EJQ\!"+3A\T+I\K-&
M;];Q2HD ]28)^'Y36?;MT5UFR.ZCA*Y=@=:Q- [38VHYJWO1['Z]@\<=$>SO
MM5T'4M+QCQLLJ7NUR,RIKFY\EJ#LJNP"-#:]IN1JVGC#QFJ6TY^DY.]S,J=W
M@ZIAYMPW5'/(U8[BL<=F<J&902PO/G=+3&(D5W7]K21?U@_Z]&9/]F/NWA_!
MD_Y6Z1&N_<O)^&G]?7*%Y]9GSZ>$F3'!1I P7?-1@D2Q=DR9)\NFU8CQS!!1
MT]?/'*VVB+=JT;)*KN%U=]4T44]U-]M==>>>/&8*"S$*J@LQ)V  &Y))\ !U
M)GH!8A5!))   W))Z  #J23T 'C(4K3LQ3EN<">(7(3.ZQTZ>C@9G)H)/H(1
M(E8Y&@4S?I(#9Q&(Z_T1<P^2A)4#=N&R+:21U[P9CZI,>@Z<(\U&;CY''NG;
MSV=%#U75$LB+81M:B$;UNKJ2 '0\DY $C?;B7T\N\5?,568I978 &9D'6MV'
M1U9&&^ZN.+;$C>><ZISQB(Q$M)UJ_GI_=S_/LH?;;_AG]=_TDMG9?_?OZM_J
M)90M]BB?X/>_HRF?.\O[5R?Z/=^K:6I_:-^"WZ#('RCSAC$1B)C3!@1'A;\X
M?*#@@44U6?%"Y=ZV'#!S)OIRHN[?/WBB+5HV1TXYW5775323UXYVWVXX]_-^
M-BY.;D4XF'CWY>5D6+3CXV-59?D7VN=DJIIJ5K++&/14169CT ,UW758]5E]
M]M=--2E[;K76NJM%&[.[N0J*HZEF( 'B9ZFKIJ^;-WK)RW>,W:*;AJ[:K)N&
MSENMIPHBNW71VW2615TVUW353WVTWTYXVUVYXYXYS797958]5J/5;6S)978K
M)96ZDJR.C ,K*00RL 0001O,E97571E='4,KJ0RLK#<,K#<%2.H()!'420X^
M_4&1TJ]2TT441>(^;HIYWF<^DY;)<^7S>==O>UWYYX\G/'O\<>7WO>R6Q,E\
M/2\O)159J[J]E??B>;4UG?8@] VXZ^(DSI&,F9DU8SLRK8UN[)MR'"EK!MN"
M.I4 ]/#>0'?0F5VDRJAN$U MMX+?%4V@3Y(KOF^JX2"GN2A-LSY00>\K$5D/
MJ6;=7AL@LI]2J\;:_5Y-]ENWM>D6:ZV?BLPU'LOKND8ODJ<R,[4,7N<5K^\O
MKXXHL^SNG.Q5ZI6YZ3M[0]AVU*O2%PLG8X7:#2-2R?*'" X>%D=[DBGNZ+.6
M04^PHX6MFZ.Z#K)X]NB/P1E^)?\ ?95_JFRO<^/_ 'GTY8/J9Q?=&1_=_0CV
MZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0CVZ(_!&7XE_P!]CZILKW/C
M_P!Y]./J9Q?=&1_=_0CVZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0CV
MZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0CVZ(_!&7XE_P!]CZILKW/C
M_P!Y]./J9Q?=&1_=_0CVZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0CV
MZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0CVZ(_!&7XE_P!]CZILKW/C
M_P!Y]./J9Q?=&1_=_0CVZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0CV
MZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0CVZ(_!&7XE_P!]CZILKW/C
M_P!Y]./J9Q?=&1_=_0CVZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0CV
MZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0CVZ(_!&7XE_P!]CZILKW/C
M_P!Y]./J9Q?=&1_=_0CVZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0CV
MZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0CVZ(_!&7XE_P!]CZILKW/C
M_P!Y]./J9Q?=&1_=_0CVZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0CV
MZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0CVZ(_!&7XE_P!]CZILKW/C
M_P!Y]./J9Q?=&1_=_0CVZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0CV
MZ(_!&7XE_P!]CZILKW/C_P!Y]./J9Q?=&1_=_0GT1FY!15)/EHSXX44TTYYX
MX7\O'&VW&O//'U[_ &^_F2=I,IG131C[,RJ=N\]) _CS%^S>*J.POR-U5F&_
M=^@$_P 2>&YK*<U9%F4B:B4#"CHZU#\M5W2C3331RP)O.5^%4T5]N=M>6&NG
M&GF<<<\*<[>=QSKQQS9<[+.'2MH06<K!7L6X[;J[;[['^+MM[\XNRV@IVBU"
MW!LR7Q17AV90L2L6DE+L>KAQ9D !%Q.^_P#! VZRLGTY1CXBC?EMU\WY%>SC
M^YE^4/T)?OWKL;^6+_[)7^WCZ<HQ\11ORVZ^;\>SC^YE^4/T(_>NQOY8O_LE
M?[>/IRC'Q%&_+;KYOQ[./[F7Y0_0C]Z[&_EB_P#LE?[>/IRC'Q%&_+;KYOQ[
M./[F7Y0_0C]Z[&_EB_\ LE?[>/IRC'Q%&_+;KYOQ[./[F7Y0_0C]Z[&_EB_^
MR5_MX^G*,?$4;\MNOF_'LX_N9?E#]"/WKL;^6+_[)7^WCZ<HQ\11ORVZ^;\>
MSC^YE^4/T(_>NQOY8O\ [)7^WCZ<HQ\11ORVZ^;\>SC^YE^4/T(_>NQOY8O_
M +)7^WCZ<HQ\11ORVZ^;\>SC^YE^4/T(_>NQOY8O_LE?[>/IRC'Q%&_+;KYO
MQ[./[F7Y0_0C]Z[&_EB_^R5_MX^G*,?$4;\MNOF_'LX_N9?E#]"/WKL;^6+_
M .R5_MX^G*,?$4;\MNOF_'LX_N9?E#]"/WKL;^6+_P"R5_MX^G*,?$4;\MNO
MF_'LX_N9?E#]"/WKL;^6+_[)7^WCZ<HQ\11ORVZ^;\>SC^YE^4/T(_>NQOY8
MO_LE?[>/IRC'Q%&_+;KYOQ[./[F7Y0_0C]Z[&_EB_P#LE?[>/IRC'Q%&_+;K
MYOQ[./[F7Y0_0C]Z[&_EB_\ LE?[>/IRC'Q%&_+;KYOQ[./[F7Y0_0C]Z[&_
MEB_^R5_MX^G*,?$4;\MNOF_'LX_N9?E#]"/WKL;^6+_[)7^WCZ<HQ\11ORVZ
M^;\>SC^YE^4/T(_>NQOY8O\ [)7^WCZ<HQ\11ORVZ^;\>SC^YE^4/T(_>NQO
MY8O_ +)7^WCZ<HQ\11ORVZ^;\>SC^YE^4/T(_>NQOY8O_LE?[>/IRC'Q%&_+
M;KYOQ[./[F7Y0_0C]Z[&_EB_^R5_MX^G*,?$4;\MNOF_'LX_N9?E#]"/WKL;
M^6+_ .R5_MX^G*,?$4;\MNOF_'LX_N9?E#]"/WKL;^6+_P"R5_MYE O;DL6)
MMA^\)'HZN/3>534RYWYU]$W56X\FO+#7CGR\I^;_ +>/)QSY?^'DS)-;=F"^
M3J-]^O>$^ )_B3FR_P!S7'QL>R\:M<Y3AYIQ:QOR=4\>^.VW+?P]$O%E@GR6
M,1,>6XYV%$]=>.=MMA[WC77CCGGGGGELIQQQQQQ[_////O<<<>_SSG/E G%R
M0!N3CW  =22:VV $Q?VK?@G]!D'^$=?!G'Y%3]G*7W-OWJS\AOFG%L?4?B,>
M$=?!G'Y%3]G'<V_>K/R&^:-CZC\1CPCKX,X_(J?LX[FW[U9^0WS1L?4?B,A/
ML#I936O6JU9-I9[5ZV13>NO,39D5S' !2VX4G,.>$QZ*CGU;Q$MS?)Q3S?0(
MA>""KK;1KHMOK=OW/:--/:C']G$Q5T\:9VA8G4.%>,,Q>SVJ-IOG7<:^_P#9
M$8OD@WYME=RM8-A4&#[1>R"Z:#IHRO*O9#1Q_LBV-=Y.=6PAF=*P6[OR3O\
MOSML*>\+;+O+V9NEKC$2*[K^UI(OZP?]>C,G^S'W;P_@R?\ *W2(UW[EY/PT
M_KZY0O/K,^?31+24B:-8V,M/&"Y6#)027J3,8U;N73DE$](^0VD3!NU9[INW
M*[P/P\;HMVJFCE9135-#?57;7;C5>:Q1<;1RJ%5AL4 DFO@>8 &Q.Z[C8=?5
M-E//O:N[/&SO$[MB0-GY#B=ST&S;'<])S:Z=U'/D+0%6=,8AVB?1,P/?3:"&
M+PM'JO( D5?R*O8?!F1A8'1K ?+3LN)5O%@,11+R<M+4!K#DLZ57W.'CA\G#
M:=CW"];K*\XUL#94V5?@NM9>FNH,4QE%C6&E%K#.S\5W)\YG9I3-NK[IJD?#
M#@K78N/5F*SA;'L*\L@E%06NS\46O<A1MQ55'6#)Z0\8B,1+2=:OYZ?W<_S[
M*'VV_P"&?UW_ $DMG9?_ '[^K?ZB64+?8HG^#WOZ,IGSO+^U<G^CW?JVEJ?V
MC?@M^@R!\H\X8Q$8B:/9-<Q"VX/(:ZG@U0Q$I0T39&1R1 B+4<(HND'J'.CX
M4Z9OD=D'C5NXU]$XUUWV2XT6U51V42WEM"US4^S>K86MZ/D+BZEI]C6XM[4T
M9 1GK>I]ZLBNVEP]5CH>2$@,2I5@&'#J6G8>K8.1IV?4;L3*0)=6++*BRAE=
M=K*G2Q=G56Z,-]MB"I(/,)WT\[3]5W+@]TNN%U+X8FLJ\<4/:KANZ8+Z;;\J
MJ-@KU?=D#W7<[\\<;N&^\&*>A3UU6.D%.?-V^_5_NF_N>_NA(F'^ZGV9KTS5
M&45)VP[.H]=R$ *KY5*"[+"(N_%+!J^/R8E<2D=1\Q?L=VI[+,V1V+UALO#!
M+MH.JLKUL/$K382E!9CXLOD-G$ &^P^,OU/[IU!$.2%2]HX/)NM5J[.&?G<2
M@>_4@Y'?A=OIPY;F%6R3\*V=<HJKH."K-4!HV\S;24N_+QOM']H/W$-1/9_-
MU+]S_5L/MWHV0Z74>QUE(U.M4LI=ZGQUL:K(NJ52'KH=,MG\WR"MO-%I[(?N
MI:9C:OC8/:[$O[+9Z-8KOFI9Y Q>AZU<7E ]".Y!5[4..JD,<IE\Z>OMYVCT
MK$YU?:A7SEI7ME6W$",@N$)($.88UB84^*V-1]\[')O$2;&0AR#EVYVV>M6G
MJT:Y62\?HD[X95/]S#]SL]H</]T.S+IKMUS0.S.IT879;,P7]E;-2R\+)&)G
M4UY#5-CW8.51756!59;Y1D5JW<%JN^OG[H?;H:'E=ATQK7KTC6NT&G79?:/&
MS$]C:]/QLN@Y6);92MJWU9F-;8[DV5U]S2[+WH6SNNA.NVN^NN^FVNVFVO&V
MNVO/&VNVNW'EUVUVX\O'.O/'/'/'/'/DYX]_C/B!!!((((.Q!Z$$>((]!$^O
M@@@$'<'J".H(/@09_K/(C$1B(Q$8B<F.OGNA%K3=]U<,W55M40NL>W[.WE:Y
MD\*M"0%I# 7=0Q&6V 4YM./2J#1T4VC+^)0HYLK, ,I=M 1W@.+)C?0'6[]K
M)7X-:#)%-EKV8IJ[Q7K4*XM=:QW;*['D'==D*[LO(@^;L8^K,L8T&Q*UKR!9
MP97)9#6K.>:L@''BI\X-T.P(Z]+=P3NUUJLAM*7<6G1K9&)0%2UG?$AK"V84
MXD%7)J<H_1'KIG-(-'W=K059QZ%JTEE8H2X$]=OA;1H^7<%Q:;SF?$R*^(=%
M\Y^[\VRIPMGWNPH["I_25LXL "2.AVZ$RJ'Y<7/FIWG6NQ>5?\= R V)Z U?
M($D '<C?QM^]75SF!V39)BQ2<(BU.FH0"M/Z*%:6M4\E@+NR2PD) WDH@UEP
M>*3@4 E9 X/X#RES'=8RY:;/"7K;4<**NF3R/(YUUA [6AS7W=E5JN*P2_%Z
MW9"5"G=0W+?IMN0"\JHX.Y<JM946=XEE90N0$Y*Z*P#$C9MN.W7?8$SW1;NO
MUIE\=.2<7/R+!C&;.K6G9$-EM=6? Y:#L*Y)!%XO58<K!)O#(]-F#"?%YI&=
M(S)G,?2BI)@3X,I&_4S1^_:^-B7J5!0'E79:I5ZW5JZE9K2'1V0E C<E#<@1
MMMN0(7*H92P<[*Z5L&2Q6#V%16"C*&V<LO%MN)!WWVW,T_LOWRICK5'9@4*I
MRN;GJ_M:@JHFL2A<*GQ\E'"M_P EB@Z.OW[J/P\\S\.UBLD5E;5-'97B0OV+
M&OQ"^\\DT>!OL\?"MR&4#B@>J^U&=D 84*Q8#DRGJZ\#_%!+GS%8C&_+JI#$
M\G9+*:W55<E3<RA22%(]JW(?QB @/-@#9$S;,(C]1%[R-/R :N05=D;3+$SX
M(W%R@N&"HXM*R#XQ&I0/"R("]9A6ZR[T,?%BRXY9-1F29-':2J*>@5NUHI #
M6,XK 5E8%RW$ ,I*L"? J2#X@D3<;$6HW$D5A#82P*D*!R)*L P.WH(!]!&\
MYKAO=#;5/=#.RW8,W4L>J?L?UT:OM)33<F(%)2& O344AEGUPN64:*14N_9'
MZQL6)OW_ "T<,$4Y&F>&,GRZ0O??GO.#6,W'H%K6X]^W&Y0%+ ,]=FVX8 K9
M6P&^_F\20-YQ+F6/B77&M:[J?;5G=@-U6Q-_:D[UNN^Q]MOL>DL>P[@AHK8O
M<,7<I('&(#0%MTM6<"= H]*STREC^UZ2JZ>-(^C&H_[3R"=S4K,YR^$1B/P6
M+\EGP_1DT2#D'C=T_7Y_)6=,4U L]U5MC\F5445VV(6Y-Q5$"("S.VP._4 @
M3>,D*^2+2%2JRJM-E8LQLJK<+LO(LQ9B%"KN>@V)FQ%^^O5,! (_91RRWPF.
MR>S"E*B1I"M[5:S[FXA$:/2YU5).JE81K9X*QE@,<(NA4+.Q ;(CKE8(+!CB
M):31MB6\&'DL[5K6"RUBXD65E.Z+*O>BWGW9K#, 7#E5ZDD!6(].7CA Y<@,
MYK X6<^\52QK-?'O%?93LC*&/0 $LH/G)]^^K8F7 8.YF<V7D$CDT,@X_451
M-_' S6?3^.#)A%Z[D$I"U@0B\3L5U%# Z1D8!*3(>8QT(XY)2,():(N%4@PL
M@JSA4XJKN=[J >%;%&L538&:L,"H=049ALI)@YE 95Y/NS*@VJM(YN RH65"
MH?B02I(91[8"2=&NSM%S -3!^-SUL5&]A)&>B50^A"2=-_+)%% <QD4I&;AW
M 5$O'%8R*@$NWD2LK8@VP-\'W$%%FIAV/8N];8]R&U638T*K6]5V56*JIWWV
M;D77B%)+ [C< D9K?4PJ*ON+F9:^C;L5#%AL1NO$(V_(#8C;Q(!GK-,W1B(Q
M$8B,1&(GW:_QEO\ ]^E_B:YLI^RU?SB?XA-=WV*W^;?_  F:QV]^UF'_ .=A
MGZDD67S6_M6O^D)^KMD?^YG]W\K_ .DY'^;P9S?RKS[I&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B;-#OY1CO\ Q?Z ZS95]D7\?^$R
M/U7[0O\ _2_75SM%E\GY7C$1B(Q$8B,1('[)6F=IJK5)Q'&(DB3UGE1Q7AJ;
M2>+,/ S^UH9!"R_.C%ZP<>+:"Y&\=#MO$^A3((MMW*+IOJJV5L?971\?7=7&
MGY5EU5)TW6\SGCE%L[S3=&S]1I7>RNQ>#W8J):./(ULX1D;9A!]H=3OTC3#F
MXZ566#.TK%XW!RG#/U3#P;6V1T;DE60[5^=L+ I8,NZF>,KDG(Q$BNZ_M:2+
M^L'_ %Z,R?[,?=O#^#)_RMTB-=^Y>3\-/Z^N4+SZS/GTCNS=),K&U$0&T+3&
M+:F4ILO."9L./;Q#>*2+5==B2!>8NR>IG?4'+UVY<-&[2.<GG:+E,D@/XVTW
M\^'F=UQ/+O3:S*!7W;[D,O4'GPW)( 3F=^0$V5<>7G=YR\WN^["L2_->A#>(
MX\M@-R7XC;8F<JNC6E/-+A CZY(=55DFD2-MPS:D;&['2A[J(08HII>H6,^5
M5KUQ']&VJ?D<M-]^=&?HE!&^VG/'/,'I@QQD(*3@]*V"C&NS+#Q V\T6GNN&
MWI&_3;C)G43<:&-HS-RZECD4XJ#EN?;&KZZ&W]!]/1IV644313W55WT222TV
M4444VUT333TUYVWWWWVYXUTTTUXYVVVVYXUUUXYYYYXXXRQ2"F-0.A')5R";
M&13@VR9-23P,@0:*E6@Y]NHFR?N1Z:VSM!D\W15T:NE4=$'&Z2FJ2F_.FW'&
M(=2Q0,I8 ,5!!8 ^!(WW .QV.VQ]$]*L &*D*20&(.Q(\0#X;C?J/1,KF4\E
MI.M7\]/[N?Y]E#[;?\,_KO\ I);.R_\ OW]6_P!1+*%OL43_  >]_1E,^=Y?
MVKD_T>[]6TM3^T;\%OT&0/E'G#*J]FKS(THA )&'4%G!(:?C=[?AK&45B$GC
MRNI)!;2:1M>+M[0F<'!*.EK' @B2J'KYD7*Q>*S?2-I%7XMT.WW4U]YR!W!*
MG@VSE>:LA._!6/M"1X;!F7<@'>9HO+<>L>:=F(W!7??B"? GT>)&\VCK)84O
MM2K-)[,4&3-:0S6QWD9'H&80>)BH#[='](&*DY&MI!*H/O)QL5U%LRZ "1F>
M&JB*;<N^6D"9;;/+E5'XKOT5-R0P!;B.1 <!N).^VX'O #:>. K;#T ;^/CL
M-]MP#MOZQ\'3:6"S5,8Q$U"V:OJBSJ=E[2VJ^$V "#).2B;)R&]:'6GAVZ"K
MG>+.&OHS8XTX;I;-VR@)XR(.-]]6R:WUSS>;GV6UWM!H-;Y'9O6+M&S[<["H
M3)7(6C&)NR<:I?+EM#8MF*IL)M&55;2J<F9=A,O8?1-91J->TNK5<*NK,N>A
MJ&NR-JL.VT^2&HKD)D'AM4<>RNUGV56W,_)?;V@=PT<13K:"[-CJME\A'ZKU
MI9D9;DPO$G4<^0(I&%Q! OKN>67VW'#M?5_M*HT7<L-CQ%%XZ:K?OCLNV4EM
M>I=OLS]SV_M'I>#>4[0=G]0?'R_8X)OEKJ"95&*5PE4"_(/?^QXM2NX85#U5
MV)^5.T(QWK? [&8O;>G0M1S*@VBZWA)?C>6FS;%;!;'MR <MF)IJ'=>6E'>H
MY=RV6(W>'W-VQKK-5+Q65Y5O9,3-UPV9LHI*YM#Y& :2N&\\>@',/'FA[1-P
M:C/&F@[;7SN%'H7D8OIPX<-"CC/QI^[UH79+%[3'M!V/U_0-3P]>LMNU+3=(
MU3 S;--U4'GD7=SB7VLF)J'(W@[<:LL9"$HEN/7/U7^XQK/:;)[/C1.U&C:U
M@96C)75@9^IZ=FXE>?IOM*:N^R::U?)PMA21ORLQNX8!WKO>='L^#S[-&(C$
M1B(Q$Y1=?_<P*WKKJ#(*?DT9@8;L#85!6W1\VN^*I$9.8%L[8:R0>47B)J2H
M#"PX;Z$J+(/Q(IK'&94@(:>,05Y:-7.DE=J-EF4MJLYI2ZJY*6V4'NBI4,%)
M!/0@$EB 3MXF1]."B8QK94%STV5-:N[$=YR!XEMB!U&X''?8;^ FD0#I9V2C
M=<3=($!A%2]D _6624;5'8;GNCVG[%^A,'GD'=F.(Y KJA;H124+EKJ! RSE
M]&EI9)(H28 T!PDTV )NB.3Y6.UB;E[*#D+=91Y)C4=!S Y/2X-SH'('+@K
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M\7^@.LV5?9%_'_A,C]5^T+__ $OUU<[19?)^5XQ$8B,1&(C$2(;RG4*KFO\
M>3V!'%)5&]9A6X+D.D+$F-^3<LL.+Q:+DO!&W#5ASJ$DQD29W=<K>+8:,-GP
MY-8@W;(J3?9[3M0U34AB:9E##RO(=5R._:ZZ@>3X6EYF9F5=YCH]F^1B47T!
M./"TV=W:5J9V$5K6;AZ?@')S\<Y6.,O3J.Z%55Q[[*U#&Q<6SA<R)M3DW57%
MM^=80O6&L55,O9"25C$2*[K^UI(OZP?]>C,G^S'W;P_@R?\ *W2(UW[EY/PT
M_KZY0O/K,^?2.K?9K$:EM$>W##I&X?5U-F:$>+M2[X2=6<QHFBD&*,H^FL?>
M#BF^^K)ZU")*EW#9=5(:GN]W1UYTY )Q[P%#DTV@(P8JQ*-YI";N0W@0HY$'
MS>NTVT':ZDEBH%M9+*5#+LX\X%O-!'B"WF[^/24 Z13R6$]ZUBTEOCM!,'C"
MM![8E7MN]'YI2 $:0&1\>@NW(VB7ID")4* UD]VS=OQ9)K<\NGMLD0D&VW+I
M:(TRZQC36^5G6$4@&K(TRS&0%4&X-[8ZKR0] .^;D1[9_$R6?76.]=,?$K!M
M)%M.H5Y#$%CL5I6]FV8=3]:'$>A? 6W[/NW[^K917*=+7+<82VHC-:\DZ-+$
M:>&'XR#D\== GQ%5S;]G5L-37<-"KG42J,VD"B+UMRH_8)(<)\KR&<S&AZ1B
MY.2N1792XQFQU9%="I8G(NI&Y#'CQY;$=0.F_%B "Y+>_HH:EZ[4[\7LKLC!
M@-J*K20"HY;\=P>AW\*E]5*Y64N0?91ZF>PL>GVHFW',_O&V&_4U/Z)9Z8OZ
MQ$LXX6<T)=,V+C1D%CU>"HY#X4RB3>,#V8A%V4)H'AZ:IB/P*B<D7/BY:6\;
MS;E7C ^O/8:%",<7(L95K2I4KK5 @"@LW(>=V9EOU@U+D8SU[TBK'I\M^M*@
MM)=1DT5J6L:UFLL+\B6(4<3LO4')V1,M)UJ_GI_=S_/LH?;;_AG]=_TDMG9?
M_?OZM_J)90M]BB?X/>_HRF?.\O[5R?Z/=^K:6I_:-^"WZ#('RCSAE$.]H4PM
M#($^!1Z5+B2EG AMOR2KJOJ&Q[6$5N'@MJOP;Z/-[JB\N@;)J,L F$8$2AH"
M3="8U*I<E%]&9XVFYYZ<8CDP)7<*2@=[%0L60$'NRK'=02 "-RJ\MP-IMJ\3
MN0/-/'DS*O(E?XI!\-]AOX@;]!,GT8EDU(5B0ADXKBS(:\ALEEFD>/V#64"K
M-::P8C-)-O!3+L95Z8V +3%U%&XHC,.8E&HV&Y>D6[G04S=NG;1OYD*H?DKH
MW(+N$9VXL%7D-WW;B&W"\F)V'C/+0.6X*G<#<!BVQ &_4[G;?PW)/OSUW-WF
MJNF9;*8$^CLWF,T@S)24S*,1'6%^NH_5(N')3:67.X'269QQZZK:)LG3"/.B
M;!NY*2&>$6T'A0B32!$DU'J\9[%# JJMT5FY;%RW%:]PI'-CN>NP"@LQ VW+
M6S '< 'H"=]N6^P7H#LQ\=O5U.PET<YYKFVL?Y(&O[:U_P 5GD@?N'G_ ,]3
M^MQY8.SGW2QOPK_\K9( M291&&-H(K+P"A]*26E!(;'M$QPPEZIETD*^"CQ_
M?4HNAJS3$O/X1N18\JDV?'UQB@JK]3FGLYI6IZM9K*Z7FKA-@=G=9U7.+7Y%
M'E.F8&-WN=A XZ.;6R:O,%%W''M]K<ZKUEKU[4M/TU-*;4<0Y:YNNZ5IN&!3
M1=Y/J&;D=UAY9%[H*QCV>>;JN5]?MJD9NDE+*[)V,1&(C$1B(Q$8B,1&(E7)
MCVWK>)6\ZI-I&+>GTP H0IW/W5853+I[':N9V([>-8:XGYD"Q<)C.3"8]Z54
M9C4C!(/'F_,D/,A8%9L16Z$QK&J[TM56AY\.\L5#84&[A QZ[>&YV!;S02W2
M:&R$6PU<;'90I<I6S+6')"\R/#?8G8;D*.1 '63?%[$A<T-V#'(N?:F#55RM
MI![!'MTW2:L9E;Z'16P&@9YNX;HHK.%H=-XJ<U49*.FW#<P@CLOJ[2=-T-3(
MZ!&92!8I=#_&4.]9(_\ O1AUV/3?P()VJZL753N:VX..OFL55]NHZ^:RGIN.
MOKFZ9A,I#P.ZXO(+TL*@&3$UK+*XJ^J+7,%U41_LT^ 6]);;BT>8BG:1)4DL
M7'OJ<D2YE)T*:,D6I$+LQ?/UE7R+#::F%-=Y*\;++:@.O(-4M3,3TVV(M7;8
MD[@[@=-]8M5K7I /)*Z[">G$BQK%7;KON.[._3;8C8GKM,.:ILC$1B(Q$8B,
M1&(C$1B(Q$^[7^,M_P#OTO\ $US93]EJ_G$_Q":[OL5O\V_^$S6.WOVLP_\
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M PTJ:#ARC^2/%0)WC<2,;JQ[=)=XJT->H:KZ\'K6^NTJF-73T0GSB4"DL 2
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MC$2*[K^UI(OZP?\ 7HS)_LQ]V\/X,G_*W2(UW[EY/PT_KZY0O/K,^?31+20
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M.DQ[QR>;[1_C@U"Z4@-VZO@UI0,@KC8IM%J^4M26%E%U-#XZ+W((0HY9F!+
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M=VG!>)5.*\5*$%2J[;#B0"NPZ$ C8B97/)G&(C$1B(Q$8B;-#OY1CO\ Q?Z
MZS95]D7\?^$R/U7[0O\ _2_75SM%E\GY7C$1B(Q$8B,1(4[!50\NFMMX(Q,-
M@3C:;5;+."#MHJ]1X1KVS8E/G+/T"*J&_I";>-*CD%?2>:W6=)KJ:*:)[)[3
M_9G64T'51J-E#Y"C3]8PNZ1Q6W+4])S=-2SDP8;5/EK:PVW94*@@D$0^O:6^
ML:<<%+EH8YFF97>,I<;:?J6)GLG$%3O8N,:P=]E+AB"!L9KR DQ&(D5W7]K2
M1?U@_P"O1F3_ &8^[>'\&3_E;I$:[]R\GX:?U]<H7GUF?/I#7862$8E2-GG!
M56GKJ>MH<:;IU?&VH5\2F&A!FH/7&*,3QV.,GHKE%THL=:($N2S@*D_2"#BY
M?=D*><V6YKQKG%#Y)%;#N$"EK 1L00S("NQW8 \BNX56;93OQE#WU*URT V+
M]=8L FQWWW57(/3S21Q#;%BJ[L.?_4VKB(:X(A+V/77M=$V+P(?,223]G;AA
M<MC< ($8-$HJT95I' -SV!*2DK*C8O'8BY/3T M(1D("NVCB4#W3\@+/1.!2
M5R:[!AY]:E79WS<BNQ*B:JZP*$3)M=G942LM:G-:E/GJ2RM(YERM197Y5AN0
MRJJXF/96]H%CN3:[8]2"M2S.%K8*;&!"$!2O1.\I:E :4N"=+OY$*1A56V!+
M5BD0;@G<L&I1R)ES"C^+M90P*1ES(F>C/EP%;R(81!+$DVR9=@['[.&ZDQE6
M=UC9%I+J*J+;.5?$V#A6S;H'#(7&VZ\U9=]N0(W$C<=.]R**]E/>75)LY8(>
M;JNSE"KA3OYQ0AMM^)!V,H!U*TA@ZV8J_F\*)F>R,K#7M%RMGRKL#(.PI\7&
MZR.58Z78QDL:B4%! 87,-)J)>ET*W@D$AXZ2"1[!(:?U--"Z,3I_="]#;4S9
MCC*1KWRWRW5*6HW",U=2I59WBEA3556'4 *W(,)'-+FEQ78%Q4;'84KC+BJ7
MM6[8LJO8SO7W;!3;98Y1F.Z\2#U1R=D1+2=:OYZ?W<_S[*'VV_X9_7?])+9V
M7_W[^K?ZB64+?8HG^#WOZ,IGSO+^U<G^CW?JVEJ?VC?@M^@R!\H\X94_MW5]
MSVM"8L$H^<+5U*1<BEII27#U8^R."7'-*6R$A:PHL?BLNV&-E+.-P9M*5 +%
MB>=PIQ)!R)3D8[*AS.ZAT1F-B\P0HXG?8_7$+;@$;^8&VWW ;8[;@$9UE5.[
M#<=!MUZ^<N_@1Z-]O1OMTFR]6 =MQZH& ^ZG$F6F6TIGCYLE-I7'IO-!T2(S
M(T]A@F52>(L1T6*F!4:7&L5%0+?9FFU0:HK.GI!-Z[6\N*&PFL+QXI[4%5+!
M0&(5B2-VW/\ _$\?CR\WPV'@"!OL-]@>NV_KG-+MZ>"1[MM)G)>K'Y&3%:I1
M8UDQ"J]J&<LNZ>QD)P;K$<.DM56+'ZR;Q7VQ-R&O7\4>Q$J=CS]0E84ID "*
MDVJ!GKH!- V<;<_/W[G:M6.SDAT+EN(#!@0"-D4%ATW(/,'G=.74^9LH)V.X
M()WVV;?< ^&V_6=N,CYSS;6/\D#7]M:_XK/) _<//_GJ?UN/+!V<^Z6-^%?_
M )6R5TN"LW5FM:[;M2K<3S"+>KRS%]G#91SP_:P@QZT7%(\)JI>@</\ 3ZRB
MYWYW30V^JW2WX][/.R_:"OL_9KCV8SY(U?LQKG9] EBU]S9J^+Y.F2W)6YI2
M?.:L<6<= P,L_:+1+-;KT=*[TQ_8SM#H^MN71G[VO2\GOWH7BR\7M'FJYW53
MU*F2]E8EAC$1B(Q$8B,1&(C$3599.X1 F;4C.IE%86/>NN&+)]+)"(CC-V]Y
M247X9M7)AXS1<.N44E5N&Z6^ZOHDU%/,\S3;GC)4=R0BLY W(52Q \-SL#TW
M($Q9U38NRJ"=@6(7<^H;D=9\U)_!TC<0C:DMCO!Z?C#1J#B>"['9]+A$<;BW
M9XG'$-%MMS#$0U-B'+]TQX71;($F2RF_";A/;9P?9FXMQ0@.=CLI;< ,?X))
M! WVW(,<UW5>0W<$H-^K!=B2/6 "-]O6)MV8S*,1,')XV%F4:D,0DC+@E'94
M#+1L^.Y<.FG#\*<8.!A5ERZ8KMGK;ATQ=+H<N&;ENZ1])Z1NNDKKHIKDK%&5
MU.S*P93T.Q4[@['<'8CT])XRAE*L-U8%2/#<$;$=.OAZIJ3H_4M(1F'1DI(X
M'5L48LQ$)@HDZ?"1,5JU$,6PP-&H\F6>LDG&S)@BT:,QS/E5;1'1'31/GCS?
M+EM;<SL%>QCN[E5+'J=V9M@?3U),PWKJ55+)6H 5 6"C8  *-R/ ;#:23FN;
M(Q$8B,1&(C$1B(Q$8B?=K_&6_P#WZ7^)KFRG[+5_.)_B$UW?8K?YM_\ "9K'
M;W[68?\ YV&?J219?-;^U:_Z0GZNV1_[F?W?RO\ Z3D?YO!G-S1--/G?G333
M3E3?E13G3777E13GC77G??R<<>=OSKKKKSMMY=N>-=>/+Y..,K+,S<0S,P1>
M*\B3Q7<GBN_@NY)V&PW)/B3/N2HB%BB*I=B[E5"EW( +-L!R8@ %CN=@!OTG
M^\QF48B,1&(C$1B(Q$8B<&JCJ"R[\ 2.#QVH(G' $4]TCNBT7/9HQ* &LH"L
M:Y[;RJ8EAM?QH4.>S#65EDA:T%3=EWH8&F(*DW2CETW]$S6E[+:Z6#M8S,V%
M57Y.%/$\\95!=B>/$;\]@"=]AMXD4'$P\K4*[**\*FJNGM+FY1U1[:^]1<;5
M[KG7'J13=WSA3C@NR5\&<DD; ^[UK=54PWNSV'@5V'8X-K+OA*U6M0-(E!'L
M(F@\G-ZM S9M/2IN/%YL[7-!#BC,$M$I+#4XTLR0?>B*.UU54_"*K&Q*7J!+
MX:_7>3\U(6PIP 8(-B-SR5^6_HV$]Y9V+1KFHX^=94N+K]Q&&*:&HO5K\6N\
M9#O6]Y+I9Q3N;*165#><23):[<=C+%A)^W)Q2]E7Z=VHJ<59'97&P4%HK7K5
M$'QA>O5Y)!+".S,8RMJ7')!'9:D4=D*Z.D%X>YDL>:((#%V+_P 5KQZ49:UM
M2D=ZEA4E[>_8#GQ=%0FM0K+MYX'+@W4[SKU?4LFFS,OPLK4'\@R,2JVNNC ]
MC*2YQS9CY#WJN7=997=S+XSL:396H"\6Y35*[ MF!=N$4;?FELPNEIK.X##>
MOKB#QZK#M'2=X>B;!F2@-R.G45-6_%["D=A\&]8R<0* H<NP]EQXXPW?\FV!
M+4J5OC?6DK:U5=K@YL%R@,2'JV85-6J<>0V9@>1(VV,[KLG,Q]8 S+LRC"OR
M,>G3C15BV8%ILJ57Q\TFI\RK)LR.?=6!ZZ2O=JKAN:M7JFKO[FW&3@UQ1*.7
MH3"2/L,8C,FB+UIU2'=; 5#AK:.UU)DV#E68H=CN;!A,<$JR5R<>H>),3<43
M )17V8>#T$MUM6+4'K9JMUI#*P.0;S<:@Z[CB:.#L>.PVV0ABW($F.PL[6\U
MZ,VFK/9+=1>JVEAI*Z97IZ9=F-:%)O&I>4T5H;38PW>]&K%7=%5G4.W8_(C4
M<:.X1"JJFT^CY5 O#VUNN7PZ.!WVZ+@80,-# B)S(T**IAR+]D@X&".%ET7K
MABN[;M72WG<%;*&V=[$1ALW=[%B/';8LH(W Z$^_+3FUV65*:*,._(K</2,T
MLM2'8JSJZ4W.C\&9043<AB"0"=ZC^YPM=@-;7?"38UJ&LN']H[BTN /'=6_%
M;B["F3D-9"[*I.4-N5-*X1CDRCFH5N528R%N[]9<'AC ANHCG1FGD]3@\D;'
MJ[HM[<HNZ;V?^?DK;[=/#;>1'9H=WBYU%BJF53JN;Y:E6WDR9-Q3)*X>W^["
MJZO@'XV \N\56Z3H;G'+'&(C$1B(Q$8B,1&(FS0[^48[_P 7^@.LV5?9%_'_
M (3(_5?M"_\ ]+]=7.T67R?E>,1&(C$1B(Q$KIVHB\]F%0J!*V;DG,IVL:E2
MFJ0HFB(>>H -QP0Y+E/&KO1Z?#9&*#C2KYKXGSW[+1=BDBZ4<:-E;1V.R]-P
M=;&1JK5)A^Q>OT\KJ6O3RG)T+4<?!'=K78>;9MM"UOQVKL*V%D"EUK_:;&SL
MO233IRV-D^R&C6[56K4_<4:O@WY9YL]8XC%KN+KRWL0,@5BP4V+RKRP1B)%=
MU_:TD7]8/^O1F3_9C[MX?P9/^5ND1KOW+R?AI_7URA>?69\^D$=BK+K>O*U/
M-+%MX-2>D[#R&%QF<%2*8YP)D18 02:$@^^ZJ'*I4-QSR7:IZ+([>>SXYX53
M\GG\<N9=332PNR%QN]5ZTM9N/%V0[%3T\Y?;#KZ)T8U5MMJFJALCNV6QJU!.
MZJPW#; [*WM2=O3.5700K$"=RA(C#9ST]"1B-%9S9\;A_6VVY#/3,Y]H:DK2
ML3J_,<)5K!&X&)/3$6?VK)R[XW,#AB;&PR#UP[=#W\JD$%I35MDK77;IRUHU
MMZ5X>0]KV\Z*:'/ TUA*RR&]V+6,UC*"207:8U$6+0SV5YS,XKI9\NA:EKXW
M6W+YXMLY.%84HH6M5K5M@ 0B]<;:C%O2@>,:5-9<*KA;15[K(5)K4[JUVAM@
MX032;LVS!M8]=ZB^4=N'&SE59<KH]26U1\.WX2VW5G\BO(L51CWUTGKS-F.<
M@,".@ %U/'T[DEM_#82%I>A"3?59:.G$5W"DJ=^I)-5N_O;<=O?]%=NL?4%]
MUUFLBD[-;K&R'RD4NS.,Z4ZCB*'D1-[XUN\8+$98,M28;.PS';5]OQ'M@VC7
M=V\T>(N&JB&^KGCPM/;#M=P<(!U(88VGKBNQW!&]BWV;J.OF<=MSON/3U9>:
M,JM4VS"4;=3D9S9* ;$$!&IKV8]/.Y;[#;8CPO)DI(^6DZU?ST_NY_GV4/MM
M_P ,_KO^DEL[+_[]_5O]1+*%OL43_![W]&4SYWE_:N3_ $>[]6TM3^T;\%OT
M&0/E'G#*"=\;,?P^+U\TCUAOHVFRM&-+VV A=TT;2MB/JWD<%M].-Z,)?=LJ
MBPD*U)S^)L2+9$2092&5-(7)A8IWP)'2O=MTXR!F?=0=T;@6KLL4.&KWZ5@D
M[*Q'4$+R!(W*S;6 2=P#T/$E68;@KOT4'?H?3T&X/CM)OZI24?+:1C!T62F!
M=FZ>R)--].[3KRYI,KLV/D6ZFKVP:LE4TA1=)+=/9-FW&R!VL+::HC2";5^U
M<-DM=RE;&!XC;;VJ.@\!X*ZJP_&.OB.FTQ?HQ\/1X J/#U, 1_T9R1NXDI7_
M &!M6%3B15+71<B0BK+K;]&KW6FX:FU1CBHM(>+F#ZDX]+P\HF@TG-?6A,F#
M?N$2I=VFZA@N2KL&S(HCVU@/4C*+& #=]PPJ[.N^_$6$$*0NP!\![8CT3<H!
M12 3MN7XT*WIZCF1L-AX$;@>.WHG?K(V<TVUC_) U_;6O^*SR0/W#S_YZG];
MCRP=G/NEC?A7_P"5LE6;[CDUD;*J$X2@_76#7S5$CDW \BD.V2A08_XF3+N]
ME7;3AXP28_5.QR?+A5XG];3:..?J,Z^Q>=I.!;VE;5WI1<KL9VEP=/[^AKPV
MK96%W>GI4%JM[JYK>E5[<%J;SC:GC)WM9AZGF5: -,6YFQNU?9_,S>YN6DKI
MF-F!\YK"UE?>4K5ULI'-K%Z"M_"3SE,EKC$1B(Q$8B,1&(C$3E1[H@/+E+[]
MSE8@JGAEWDU[SO/AO6E@G!\<B4@XTZFW*HLH5,%8I-F33U0AJH::<*QHCLN]
M'MVZ/#995-VA)8) HSRUC4@4T_7$4LR_[55X ,AZ^'MAX^J<&8";<,"M;3WM
MOF.0JG_9[?$E6 V\?:GK*M NI]KU3;G02E];82HV3'B'NE%EO]J%&1J2!:AB
MUG2RN+!:4M23BV(.4CC"-0Q"0#8T/D!JKE$=F#,PH#B$85(BE0'0V37;5FV]
MWWRJN!7]>+*;6K5ZS;;W3ABSE2Q46;[[;NVQY<XQ[*[,2KO.Z8G-<]R%85JY
M1^ZJ[Q&4*NX )K\-]E7<;;"S[7W'/NO5$@EKCOI'L(ZAG;Z1R<K0D8ZCQC24
MQ?J_=*U+KW':)?LL,3KB, V#QN *&8?6R+ F=-2M]ND-'PX&YT;8G&J2^X]U
M2:.>*JBYLH\6R*N]%58QSWC,1R"M82 %&Y+,)[W]CTU+WMW?<<@L:ACKR6BT
MU=[8UR\ -P"538DL3MQ$SL5[3=A3,<Z-=E;6G\UCG7RV>O\ TE)SO:AV-%O&
MH;L9?1P:UD#6^X78T5D%G?0?M!S+X%#8(2HPJT/PMVO+"!ABFEP)E8/%L>@-
MFX]:(U]5^8$[XW@G'I!V-+5LM?>U\'=Q>"KCB%.^Z-DN1<1BWV,PILIQN?==
MT=KK6V/>HZFSN["RJAJ.Z^=OZ&'LH2]>[ESVLQLL6K,$J^:=Q;HI2PZ^D!CJ
MZ,I6*5#7-CV'6" H6+0]'VB3N\6UCD:GV[PT7Y'25\0*M642T@Q.,NFBZG$J
MJ-9X\SBTW(X&0;FM>NNPDG[6[DEG3H-U !+<PP*FW*M<..7 9-E3H30*UK1W
M38#[/WHXJ^Y/7<@+Q*D64]T'WI0G%D:S)5)55R=H+T@\ZJ6B8S.8]&BKL6)/
MLDD)A.9*?,#WKN$4S7^[L7*+#.H*-O6#IF BX)$O.CL1#O=&#WP?O!;;5CTN
MEMS5LPW*G=44 @/:^Q6M>NV[,=D5V&_,[HKW9KKMOM5JZE95) /1G)()6M-P
MSD>.P4;L5$NC2D%3JZFZEK)*1NI@G7-9P2!:2U\IZ5[*-8?%Q4=XD+U3T[GS
MW9GU=ZQ<[>(7\Y=SOSRLKS]7MR7/WEMMG'AWECOQ'@O)BW$>'AOMX#PG34G=
MU5U\N7!$3D?%N*A=S[YVW,DW-<V1B(Q$8B,1&(C$1B)]VO\ &6__ 'Z7^)KF
MRG[+5_.)_B$UW?8K?YM_\)FL=O?M9A_^=AGZDD67S6_M6O\ I"?J[9'_ +F?
MW?RO_I.1_F\&<W\J\^Z1B(Q$8B,1&(C$1B(Q$TZ$5_#JX&E \)!MP TU*Y9.
M"C5LL[6T>2J=2!_*988WV>.'*FJYD^4?D5TDM]&J*CC9)H@W;Z)HZ9,[.07/
M(A50$_Q4 51^( #US31CTXRNE""M7NNO< L=[;[&MN?SB3N]C,Q Z GH .DU
M!_0=0$XI/H.^A ]Q%+1F#N?3X-N[*ZMY)+WQ 05=FW:NA#5T@X6( 1#G9%BN
MU:<;LD]=6^NFZNJF8NM#(X<\JU"(=AYJ@$ >&W@Q\=SUFEM/PVIR*&H4U9=S
M9&0G)]K;F9&-A(;<$M6AV4@>;X>,T6<=..M5DRJ0S.;5:..'9:X$OY1PH;E;
M,'(3 !HT'@I&9B@T\SBI*5A6+!BS%2QV%5DHYJS:H-"J*3=+73),F]%54L("
M[A>BDJ&)+*&(+!22=UWXG<[CK.>_1=,R;K+[\1;++BC6[V7"NQZP%KM>E;!2
MUR*JA+BG>J% #C838G766CWUFH6^^@^KZ=-CS>5M7;V12QW'FLM:#>!#27-H
M(X/*0-O+6H[7ANVE",:T/(>3TR1#1?Z[F(OM"=V'V0CB=@H8J3N5Y[<^)/7C
MRX^]-ATO ;*&8U'+(%@N#-9<U8N"\!<*#8<<7!0 +15W@\0V_68]KU1H$?8+
MBSQL"]5RQW*N9T\X%RF:#(J]FVZ^KM68/:]82-O7[R4N'NFI!U(',85+.R7'
MK%R[5?<\N.?3D7%!67W4+P&ZJ6"?Q0Y7F% Z <M@.GA,1I&GKD'*7'XW&[R@
M\;;UJ:_?D;FQUL&.;2WG&PU%RWG$ENLW*UJ1K&[1P<;94;4-IQXBH6 /QYZ2
MQ,^"(+M5&3AR&D\/, )&+V=,U=VSS1B503=H\ZIN=%==-.-<:[7J)*';<;$%
M592-]^JL&4]?#<=)OR\'%SE1<JKO.[8O6RV6TV5L1Q)2VEZ[$W4[-Q< CQWF
M4K&J*[IF*HPFL8H-B,;2?D"RK%AXE=<@8++\N2ILT5(+O"YXX37YX5(&C3]^
M5>[:I^)=J\)I\:^66/:W.QBS=!N?0!X  ;  >@  #U3+%Q,;"J%&+2M-7)G*
MKN2SN=W=W8L]EC'VSNS,W3<G:2%F$Z8Q$8B,1&(C$1B(Q$V:'?RC'?\ B_T!
MUFRK[(OX_P#"9'ZK]H7_ /I?KJYVBR^3\KQB(Q$8B,1&(E=.U%BRJJZA4E\-
M=-V9S6QJ5CG"SID@02]536XX+#I EX9SINEZ1<"=)((K>;Z1JLIHY1YU52TV
MXM'8[2\/6-;&%GHUF/[%Z_E<4L:H]]@:%J.=C'FA#;+DX]3,N^SJ"AZ,97^T
MVH9.F:4<O$94N&H:-C[LBV#NLS5\'#O'%@1N:+[ K>*L0PZB6+RKRP1B)%=U
M_:TD7]8/^O1F3_9C[MX?P9/^5ND1KOW+R?AI_7URA>?69\^FN3",LIK$I3#2
M3DBR'2V.&XR_>"'?+ LT9'ACH4Z<BWVNN^S,B@@Z459.]=-^6[G1);C7;G3R
M<X6(+*[*R2!8C(2IV8!U*D@^@@'H?09DCFMT< $HRN PW!*D$ CTC<=1Z1*I
M53UIM>+3>L))9]Z1B? *1B!Z'5A'832#*I7W#$\(#QY5:>G4;!FK:1IM@P5G
MPD#B0"NHMN9;CS2P'=4,&;L."C"OKMH>_*2U,:MJZ$KQA0=F54/>L+; ^RJ-
MEK2E.0#%"57;LNRJ72Y:<=ZVR'6RUK,@WC=2S;5@U5E-V8^<[6OQW7ELS$V"
MNQF9(TS;8^.35C6TA?5C/68&Q2;_ -5#8"9<Q4J@+FI IY=?5K&+/MT#KM_Y
MVO@T&"CCR\>C\N=F2&./D!+!2YIM"7,>*U,:VXV%O0*SLQ/H WG/CE1?27K-
MJBZLM4!N;%#KO6!Z2XW4#TD[3G'TXXF8F^W-2ETX;5Z-2A;<ECZIDNS@Z[)^
M5"W&6JTC%7#F.)$2$EYBH'8$]-:SV?\ JZ1+N):#1'!FS64EEMX?3N\7*[AN
M[H[A<BPT#-&3:RY#4&O=.3/W:\"_>V[.2Z@* [$R6;P.,+QSN[]J5%WDAQZU
M:A;E<!]@G-N07NZMT\QB6W19UJR>D/+2=:OYZ?W<_P ^RA]MO^&?UW_22V=E
M_P#?OZM_J)90M]BB?X/>_HRF?.\O[5R?Z/=^K:6I_:-^"WZ#('RCSAE->Z=Z
MQCKA7#*?EZSAEBO31A^)39S:1B(."X0A-;V;:KCUA+",7EZG!/U!$98'@@)N
M!?+FYI)AX758(.,&#P[?CUFU^(=DV .Z@L=V9$&RAEZ<F4L=^B@GJ0 =E:EC
ML"1\ )/4A?#<>DC?J.@^ 29:+L6(6;#2IN"# XZ+AK!LF#C5HVY&OHT9]A)L
M;BKD\!?B$&XYTS*.A:RSK5MIOJ/+\$Q"CEZL.4>N,+%*, Q))5&.^X(Y*#L0
M>O3?IZQL?3,6!4['QV4]?$;@'8[_  _%UG+/NRK%^;'NWGD >"1J(H0&7WU)
MQ5X5E K)ED8F->/J]*QFG*PG5.V*K/QTLA#1C']G*4UJZ0N;'B;873DB&3P8
M<<D^O'WX5^<"S<EK4UNR*58.#8ZNG$JV[>UL 4[V H1MNKWV7T[[A/-) (._
MG$,-NOO$;$EAM.T[%\Q)M47PUXU(,7.O.[=XQ<(NVJ^G&VVG.R+A#=1%77C?
M7;7G;3?;CC;7;7R^7CGC."<\W=C_ "0-?VUK_BL\D#]P\_\ GJ?UN/+!V<^Z
M6-^%?_E;)5F^YY)($RJA>-.$&RDKOFJ(&:Y7:(N^%HW+#_J\TW2X7UVX;KK-
MOJ4G:7FK-]OJTMM=O?SK[%Z-@:U;VE34$>Q=-[&=I-9Q.%KU<<_3<+O\1VX$
M<T2SJU3;HXZ,").]K-5S=)JT!L)U1L_M7H&E9/*M;.6%GYG<Y2*&!X,U?M;%
MV9/%2)/.4R6N,1&(C$1B(Q$8B,1,"3BT8-%HV?,QP"6.PUZ_)1 T3$#WY:*D
M2H=]'BA"-D73=5X#>D@!,D#?NA:S5=X'(/AKA11D[<(J9!F 90S . & ) 8
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M1ON)T#?BO1O3S"T*3\&Y&PZ=/4/';K/T%Y&3EDH07['O/[9_T4\LVB?:]O\
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M;EXQ%-7PL\M8]1$>\-'*'Q4+/$O,;2X=6CIB_9'UP#Y-Z[8INC>ZLDT+M94
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MAVZ$'=-W(YN\07>*NVZ/I44=EETN>^X5]RG\+)M-"-L&".:;;0S*2.2@5$$
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EC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g942137g71b55.jpg
<TEXT>
begin 644 g942137g71b55.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1X.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %T< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(Q-CDU.3$< @4
M-$UI8W)O<V]F="!7;W)D("T@.30R,3,W7T%N87!T>7-":6]?1F]R;5]3+3$N
M1$]#+F1O8W@ .$))300E       08K*I>F!F50O%CY-TN19[<SA"24T$.@
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$""P           "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 \     !  (#P     $  CA"24T$)@      #@             _
M@   .$))30/R       *  #_______\  #A"24T$#0      !    '@X0DE-
M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     S4    &              ,^   #[@         !
M          $              ^X   ,^                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   ,^     %)G:'1L;VYG   #[@    9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #/@    !29VAT;&]N9P   ^X    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     LX0DE-! P     $VL    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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MGV3[_P!(YOKV4_X&SU$*ZK9C.OZO<SIV!+GNQ:G[2XOFQ_VK*9L<^RRPO?\
M9\/T_P!)O_29:P\KZ]5X^W'Z+AUMQ:M&NL!K:1_P6/5M]-G]?_ME. )V33VZ
M!B9N/F-<ZAQ)K=LL8]KF/8Z [;95:&6,]KMWN:J/U?Z_1UO%?8UAIOI(;?23
MN@G5CV/]N^M_]53SOU+/IZB-*;MN+F> !/ZI>?\ BK[/1?\ \'D^I_@$VNB'
M26(?K'%UK!0;&[W#%<)8'MK;:[)?ZEGZ-_IV8S_YCU/9?C?OK;6*/K#MO<RZ
MC8P6/KJ+=SG/]-UM)#&OKJ8YVZIG\U9;6SU/TC_YOU$%,!]9@T/<^H$-;99
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MBNI*?__7]57)=7_YN_M"[=]I]7<?6^S[=F_\_P#GOS_W_37@22J\Y\@^3?\
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MW_I?1_FUIKY520*G_]D .$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z !;C8   "<0 %N-@   )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$U.C W.C$U(#$U.C X.C4Q ')R,38Y-3DQ       #
MH $  P    '__P  H ( !     $   /NH , !     $   ,^          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!2$U- "H    (  @!$@ #     0
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H
M   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,34Z,#<Z,34@,34Z,#@Z-3$ <G(Q-CDU.3$       .@ 0 #     ?__
M  "@ @ $     0   ^Z@ P $     0   SX         !@$#  ,    !  8
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( (4
MH0,!$0 "$0$#$0'_Q  ?  $  04  P$!            "@4&!P@) P0+ 0+_
MQ !$$  " @(" 0(#! 0)"@<!   $!0(# 08 !P@1$PD2% H5%B$X476V%R(Q
M-3=!872S&",E,G%WD9*XT4-24WB5H;?5_\0 '0$!  (" P$!
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M^U-UWL32F 2A*DZ]W_3RI]R;-LY3!>=VEJVBZCUE'3Z]H"!4(?PA/:[=0VA
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MV'I;>/J$_P!894L!,71C'-P)M<,X*5M!,RQ6>H9T!LU]WK0:(/=&5>*O+#+
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M=="=.ZXS@1<$,)[AE7AK,0I:%A=/(,UB1&VQ>0!>Y%P&M_$\M;VWT7FJ*F"
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MZ:KO][X$O-M__P!"TO\ YQ1?M52BQ\_55:_4L3[/)^C;YI_MQ%^X6R\JV/\
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3L-Q<^_V[UD&WL]BSAS"PG"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g942137g83r03.jpg
<TEXT>
begin 644 g942137g83r03.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1964&AO=&]S:&]P(#,N,  X0DE-! 0
M     %T< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(Q-CDU.3$< @4
M-$UI8W)O<V]F="!7;W)D("T@.30R,3,W7T%N87!T>7-":6]?1F]R;5]3+3$N
M1$]#+F1O8W@ .$))300E       08K*I>F!F50O%CY-TN19[<SA"24T$.@
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$""P           "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 \     !  $#P     $  3A"24T$)@      #@             _
M@   .$))30/R       *  #_______\  #A"24T$#0      !    '@X0DE-
M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     S4    &              0:   (*0         !
M          $             ""D   0:                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   0:     %)G:'1L;VYG   (*0    9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   $&@    !29VAT;&]N9P  ""D    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     <X0DE-! P     "[,    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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MYKFAC*QN=[OSKO\ B]B2G__9 #A"24T$(0      50    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@
M  @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I
M  0    !    O    .@ 6XV    G$ !;C8   "<0061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q-3HP-SHQ-2 Q-3HQ.#HQ, !R<C$V.34Y,0
M     Z !  ,    !__\  * "  0    !   (*: #  0    !   $&@
M   & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P
M  $  @   @$ !     $   %& @( !     $              $@    !
M2     $X0DE- _T       @          /_A 4A-30 J    "  ( 1(  P
M  $      1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$
M @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
M    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#$U.C W.C$U(#$U.C$X.C$P ')R,38Y-3DQ       #H $  P
M  '__P  H ( !     $   @IH , !     $   0:          8! P #
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M2(DD<JF-XY &1T;AD=6]TJP."&XQUXKD27$E]/91*LUJ8KJWE9EG:WD$\?\
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M/-*NR\*LP:6W-I:K\=N ZNP*J:13H*S\9LQQ)9@*K\2*:X:O_$"F1"?7$M=
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M3QMSM)!Y6]1GJ6[M]+^U.WFNZ4?V9Z08LX(1>[CJ%3[KN+J2W!B+FO\ 0;O
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MZHCD1?X+S<WI( )%5@.A/!'^UAS]">O7-:N'C/N,5^]3ZY'J"?E7J6H%?X=
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MUULXN"4RLL[#'@B'NHR1QEG+*>L9Z5Q;K7[.'*VRM=2<@,04A!\\L S<^"J
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M=QV:5@^M:RUOZS!X:AM8Z0S7T-0>\5UWK+%I4<A@5E85!TSZUT4S QZ^5@)
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M63Q:9H7:72_9K#4((Y+18UTR74[8V>H6<Z26\HNK6=;,C:^VD_1WZ/,/Z?\
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MD]23UR?&M"T.<L0:\X[*V-Y 5% JQTD-B^8&:!K?;,+5CG+,RL(^%$^@:&^
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MD65":I#6C(QZ-B<T^%D,[9F*U?>GMC8Z/PYBM>WSY5%5JU!(!'@<9^G2J@D
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CV.***-J,CCCC8B-9&QJ(UC&HC6M1$1$1$3ER @G(QQ2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g942137g85n14.jpg
<TEXT>
begin 644 g942137g85n14.jpg
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M&2%55WF4EIBXTQ@B(SE86=76UPHQ,C@D025"89?_Q  = 0$  00# 0
M         0(%!@<#! @)_\0 3A$  00! @,$!P8#!00$#P    $" P0%!A$'
M$B$3,4'P%")187&!H0@5,I'!T2.QX18D0E+Q"1=B<C-#@Y(E)C0U-D935EAS
ME9:RU=?_V@ , P$  A$#$0 _ ._C & , 8 P!@# & :UN>:$*VIZU[$$-6;X
MK JUG4T&,B.J^P]V0BT7*'&35_JV6;.=F;ARQ22=:MW""_J&^_B2R2GT[ZB4
MZJB>\H%E'SCEAOQ<\[]<Q\ORZ:ZHM2753'YM1:,H<O6L>:3.QWD4DB[&!,K%
M_>,.7&@FZ))GZ6+/4V*[G1T_T>,_=4-QR=GZZMZ[)NN_P3<N"-=Y\NQ\CV*)
M*V$\;O\ @J,Q67]1(ZPR;+^5^!FD'*V-&W;)5&/J)3-1_$PI)_LUA>Y]RT6;
M^,7B3=ZLB@H./E7IT_%W>_KM_/VFB+F^87@&A/V"0L:X#;0M:7/T+Z@KF.@Z
MIM63R&8TQ/EBVD=E D4!AK]?1?[4 <+&@I#[$O&0@EZ8D3,8/2_/V$HQR]R;
M]=N].]/?O_KX'YT]\R'QV7W<%8TA4]_)RR:7(/W<UP\3@-D"X9)32$>;RI[!
MV\Y-Q,;%F]@"P3INX,PYX4;F@Q%9&-E&[24K)!-P5CD155-D3HO=T\^"]RF1
MB?E;XG+WU'^=4I_-ATUE]CF:<A<CD-*7)&JHFEM1]^^%%ZZB5MGX,-@!^2-R
M@U\-0U'GEAA,BAJQ%$GSMRS1<!RKMOTV1$5=E151%]J(N_T-=S#YMOC9@EFG
M*CD]]O1TPB-T'J!GOOM6VNK'*ZLJ/R9S#7 ^>2Y*%[1F,B'\E9/QH61ORF@,
MNF-*%F+Y4&,?DVPGD=MOMTVW[TZIMOTZ]>GL,U^67LRR^#.-I-T'449@TMGC
M"?U9"@XFQT3[B(_A/YL+C+MX2;QDP!,J^M&KU55MXU*-_-''Y:JNCE-/9LL(
M:G,NWQ^B*OZ%>\E^63L:@R'R%49TE4G-1'H_C_D'3K>!R^C3=E%:.F(%X[$B
M6L6FD?F3@9/ )QJ1/#'6S9(ZT4+C4R2C3QDU2'E"8JY$5&JBKLYW+U[T]Z>T
MS?@SY0.IKNZFIKG6^(OR;.Q=\\HH]0"9QR!*)\77I)LLD.7;0J_(],R$BT F
M"*C[T.U6:&&J>I[UJR0T(^+./60.:B(JHJ]%VV5$3?WH8G\/OS16/W,_M('U
M? :JI,@+IMSTK49>"JR=F#E5$Q6S+!J"T#Q[26GY LD[@4YA"39T^'NDFKMD
M2654',?6'U.F^X>Q&[;*J]=E^*ING=[47\T7O\-6\G?/I8%C1OOFZ.C*5A\#
MI+FJD(AT32H>'_M&TLN;P"SI5*PM4!9J\D)PN UD,_9M85N/(B!(88SWDNK]
M=HHT4U;LQ*Q[*U$7JJJB[^"IMO\ S^A.7E+I3Y0)0'@72_85<<051QG.ZQD-
MORAM"I?;;:^.>Z_3KPM8D5D-D/I9L\KN8([,V0T=,64:1!/X[X6_5=F_N@HJ
M/;"ER,3HBN54Z=R;*N_@G?Y_.:O*?<=!=GM) 1HQS9;P8!%1>1H%)]2UM5.+
ME<0FWA?:(S2!DK*AT78S:*R#0$349E(VN0\12105((LDWX_9T*5:K>_^:+W?
M!5)?8(& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!7#\F/=9GANHZW=U
MO7#:XNA.B;K@W.?.U8D"VP()(+/L%=PB-?RDLEYZX9Q<-HW^I_XUV07?$7@@
M3]^(;D7!L8*FMYE7==D1%55]R?JIKJ']:=6\IC?UOY9EN381"IU/*HK*G[0Y
M.:7T;C?MD68]D#'R$6: G J0%HHQ8JBF:K>S'9$;!O='R+0FN.(N$$,$JB+^
M#F5=E547;P\4V_EW_$W=<WR:<6\_2F[H?;%N[Q@QSBC3"]UJ>0F>%@]?^= $
MVPRJTS1\/&GX75Q(/7:!%9L@_67$A/5#)5-H.;N'"0A&N7;9._?;NZ[=YY?/
MWRG<-=,M;O>UC=*233G:,I3VV%K A\WJOR/5NY'/"[*RTM+%CL:5)0-X+8N"
M"9]BFLB@SW8N7R;1$L(W?@K')MT[^[;KU]G3Q]QX_.WRS<-=16$A5M5V?)=9
MF8AI>QH..GM2VO6"%HU\!16<EYC5K^P(;'6<Z#LF;=P0WT!K.":@UL\)(CE&
M#!^X; K')U5.Y=EZHNR^_95V-'"/GY^*@T[ (MNE7#<=)X^7. Y&1J.YA\8(
MO@0[4L2A+(VZ@*;1[8R3!9GZE!66SF1.B),/'VK):2&!8=V)[-_^7W>'[]WO
M[O>;_AWRM\(37F6Q>NF=W( Z4J28NZ[LHC+H?.(O+HC8+58:W3@[^NBT=0G;
MN5$5#(O40&$1\D[*[N_4F6BR[,@DT$*QR+MMUVW\%Z>W?N(U7A\M]/3SBCNB
MT./Y\3'=!<L4R2G#^"6Q5,S@$XA;T@/]=Q&1EZXM..1]X8CQ1/SQPT?-VA 3
MMZHU1?J(JNFZ"PJ1B\S4<G15\%1?JFYFC_Y?.5*'J*D7G3-B27RT3_+],7[;
MR-;TS:=D#*\"6-%PRJ<PL)Q64-DP2N04BD[EXT MCSU@LO\ 6V\;-?6:[1=8
M1R.55V3INJ)NJ)O[DW7J2GKWO_EJT)>[@42G1Q27#^:P/6Y $;KBR(P_'T3)
M%O4!4J>HR.*"]FQ%13Z?%HDIYK+&^JFFRP;7SW;W44\J^SQY?;U3P-,&/EYX
M8&0VD9L,GU@SEGT)!SUGUH K.B+ML><O*QBIQ>-2:Q#\$AL",2N)1 (<:N!K
MDK)!0WQTNW<_I:1#1JZV1$\CNO3N79=U1.J^&ZKM^1EWR6=A2GC7X_[OZ_J@
M'&)E)*\C4"/Q(/.&IW2,E4YK84(B6BIEB,?Q\_HFB+E:S]-JF^&NM7:""3GU
M/7Q9+T&IS.1/:5SA/E1[,J6R[RH#JVJ.925I1_XX;(^0>F)GSN<LQU '0F$"
M#JK.!6K%9\MI*A+L@5#./%BH@XW:^M4&[9CLY6,Z/!(JY45$<BKMS(U=]M_B
MGA\NNQC_  K\N'6MVW[Q!5]V0[D*<Q7N2F9]; U7E.36*[L?FMO!H6UF.G^D
M-$Y@6E3$*.D#EZSAXE9 H.T7D2C])N\=.!6HTF#F(B.5%=ZJHG5.B^'3\OR,
ML^,WYB;;ZYZ[N;FSH&LZRK@&FC<AKFZ80C>3M?VT&T1;)"NK"BTKWDL@-M'D
MR&"5P4M]]")!6J89,F_68:HN&J30',1J(J*JKTW3V;INGZH8+R1\Z4PN_H?K
M_:T*V@<0XUI;EF\NOJ6L&,(R5S9]@TU3-UDZB0D1A,K(E8ZZ7FGD4EA0.*%!
MA.^CG40Q2?OTEMG2X.CV1O7=RKLJ>Q51%^/BA)#C'K/Y4>E0U/\ 5\[ICBJM
M>(KBU4E^D+WG-K)].U_2I)F0>QVSCDM):^4\?TW'HLI$\"-@X!XYC;UNX3]&
MO]G#)H(<C&[INY7)[DVW\4[]^GGNZSHY9^0#FOLLJ9'4(7L4^R&AE9,(E4EI
M6W:]@L\BS<U^SKF2UQ-IY"X]&9P(;&_=6"Z@$DZ=:;[ZK>M?M?J7U$*U6]^W
MYHJI\41>A-3!2, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!JB^8H:GE&W
M/!HV@DZD4SJBQ8H!;+N$FB#@U(H@8$"T%G2^VB#9)5\\034<+;ZI(Z;>J*;:
MZ:^^^"4[T^*',%)O@R,Z?$_S-6$,Y+H03\@D,FU/&K1G@]K5HR<JC0-H.S4S
MW=V^EZEX=VUB>[+1RB@?=[$D&W@]MXZ4220V'+VGKN7=>5479.NW5/8;:ZYX
MB^1A#H+Y=!_-]#57;51_*32E11YI:TMNX-7[BF2U44F>K0]'"$%=CG9Z72&9
M[&#",/<LE!43$OGL:(R>2(#TC[1H(:YNS-U5%8JKLB;[[KOW^&WC]"05!<!]
M%PGLGFBWY?# "4"K3X+JZX?E!/V4QDBX'=&@)JS)F8NU&(/5W[L5H$]>^>2Q
MDW4C[E+=9IH0WV6_*4$*Y.16^/:*[Y;;$?J#^,?K.O\ F;X.*X.U_'!TRXGZ
MFG=I=&,VLUAZZ<6B,BF%D'&Q(<19D]VDM<NF)T)XY8QY<D]\67U362_!JOLB
M)5R*LB[_ (DZ=_NZ&I"G ?RMVWT?S9+NA D\L)>A_DUK[HZ3VR:[&#/Z%*T)
M$[!>.@3>D.1V?H\3!C$7A[Y3<D5.CQD[_*;N H3P\A*2C80)1S$1VW3=BM1.
M7KNJ)U5WQ\-]OUSFZ?BVZ]F?Q^_,G1,?KV,N;:["^3>;=*T*P5G$-:IR.HB]
MW4M-0YTD?7*:,(R]\CT6EKKP$<=L2[9715IZTU<$44W (]O/&O@UB(OQV5/U
M+.OFFY,M[M?A23T)2$>8R><&[0IL_P"B"$D&1-!6.Q>?B"\F7U-EGPYLW6:!
MD'3E+1-VD\6V3_+8^*._44]AQL7E<B^S?ZHJ)]3#;T^*&C*XX0[>H_AJDPT;
MM[I>G9#%7!J23J52F73Z0Z#%F\;%R6TK:E,ID.@MKNLMH/9OY @ '+.5%]4&
MOYBJV"4>JN:KEZ(J+\.O79$Z$".'?C3Z@BG6?#5UO>/*$^/")\ETW+*_ODS4
M%NQ>;S;MLT>K@5#1SB:QNL8;&8HU9M),/<SE^\F;V0'/"!-RIH6*$F(9XP(5
M.>G*Y.9SN94VW_P[+OXJO?W="(QGX1^^4OC_ ."8!6*<?K'J:NG/6?-_22;2
M<Q)=@KR=UM95@F)"Z>'$2*@F4-(P#*MRC:-A'JYWQU,G^S)JJ4&[I-A5VC>9
MZ]Z+RJG3_$U$VZ$_[&^'.;658GR956'8!*VYUZ$XHY!YYYKEBAD:2T&2CFN/
MC=(\U/QH6MO(!X*/2")1=$HY5'(;$A6[G</XZ7\]3T%"/1.1>]6N<J_/8WGS
M\4^5XI2HOE3I?X^^>24#A7/$[JFP;$(]7!R4=Z;T"TS(8=!HE'()'8@2.UPW
MM.3IQ@78$CF:SQ@!BI*4DQD<\?\ Z8%0!>3?F1R]5WVVZMZ]^^_7;PV_,^CX
MCN7>O>;)W?8VPHI8-#\<.H_7XKG'EBU^DP'4\DJZ1BM'WDP<P:= =':41JG9
MMNU'Q^%O3I BLI])%ZV9KH;>K ]45$[E=XJB;;_'WEY.#C& , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8!4W\M?&%U]65QSU87,)&(MNE>.>E*]Z<J0%/
MW:X^&3Q]"%U524"-DF^NWHO];VU&NVCU?U)DLJ*]#OG8IH75-#!6QR(JHO<Y
M%1?=OX_(T9T-&>N^\N$.WZS[LY;JGBJ$)T*]D%=//](<+>9]&TZZ3)6,SL8\
M=AT=$1R'U_&#<4C#SUKJL]DRK#TUHY<?:J>I^"45&N:K5W7?KNFR=>FW?\?T
M*GZ"XCZH[E^%RY+E<"1]@]=?(=TS4%^R%60E1$5]?5-2MB1&(PX>Y?R%XW8>
M#A\0A<IEX%!P]46?"I4W0;:K+K)(;BISD:]$3HC$5/FJ+U_-2R7L7XRN@.F>
MK/D/DL=UC\-K;IOXVX?SI6\[>R!AH@M<D9L)M+6X61@!:CJ3CHVJV$,AQ<]^
MC.4- [Y=,>D1<(^L-A2UZ(C/:UVZ_ Q*I>3.^^@NB/CXGW2?-E>\J0KXW:#N
MB #WP"[8?:1?H&>VA2X6E6OL5%0QEYK7M>#VL?;2?UA*WWI1!-XX ^)O?K_4
M$ 56HCT1=^=47NVV1%WZ[]Z_!-O>:\H/XONK8-RE\']6RFN8LVFO%77LON#H
M@?I,88]0BT/+V!:,G'EQI%N2592M]LT.QI;9E'ER)!)WLCYLEYLP5W;B5>U5
MDV[G(FW3QZ'E7+\5?8TO#]TRB&1>#;3,I\L55_(%SS"9--@S2-7A$*Q&.6SJ
M(R8B/4(IPU:1>FGRB"$H:M/-RHIKH1]8LG/A1$$>WU4Z]&*U5\4W\4\_4]VU
M^$>\>P2WR3]06904/YWLSH+@IEQE1'.#:ZX799P\[:2-M-BDWL"QX^B)K\:L
M[+L&H6,Z>/MU41+APB7_ $W4<@Y*@CFMY41=T1W,J[>[;9-^OQ*D>MTWU>=%
M]15O8Y1NWAU!_'MP/6/5-, >U*ZXU*72T@%*.9;(ZW:(S>I+D,=+.GNRK4*.
M?U"[KET.;D1D$1.$"$G_ !="IO5&[*NZN<J+RJ[;JGL5-N[N7?V[=Q<!(ZA[
M4F_1D,[LXJY@ADKJ+MSXM:VYWWB5P6T.J MRN0D*C>7@C<Z"*C#IZ;QZ,QPD
M*9KQ^#,W)TP\1(H?> 4VC)T7%"<J>JJ_A>J]$WYNY-D]G=X]"/4@^,SMZ)<8
M<.UY6/,4F"=L4!01V#Q3K.F.THA3!^C):?MB620A!K*CV^KL5<%,.PS\+(7K
M..O)$3=NGDDCK5B&U?.2+\5<[>9RJOJJNZHK=]_V4N1^3;F#HWJ/XH+:YBB_
MZ!9/34VK*F I%RB0$0V.2^>Q.?5E)9X78O#6X@0$'$MHY(2PUN[]8):)[MV*
M:22FZ:7@XVJB/1?!%W^1X 7XI.>Z&Y$ZBAG,E*B8]T7T%R/8M-FYG)9Y,YW*
MI%))'596/BXPM8-GRJ6D@,04E:P[=46)(C(PG]D/?+,/?!C/=N',JJFZ]$7?
M;N1/DA5!Q?\ %9UQ&K6^-XR0XUH#A%WQ7]NYZ Z0K>Y8E++7Z_'MHRR#$HF=
MBM60\*V6;3=\U6VDSFQ91)7#8<5?K,3*KELH./Q]/R_J<CGIL_UG.YNY%3HW
MKOXJO=[D,/L[X>.^?..1+JCQL?@W:=>=R=G3&#O$I_$FJ3GF'L8(9@,]WTE&
MK]48P)O@2D?-)#G#G]8%M6A+[1CJ?W:(9(21O-UWY5:U%^+>J?$F\,^'J2,.
M@;/K<:S8@.4)1\*(GX[0-E-"(98^C:.DV4</I XAFK],TL\^UW4G;TFY13$E
M#*ZK-1]NY<+Z:BGGZ(OCVG/_ "_8SGB,=\N%'5!3O#MM<5<ZRFM*6ANM3$NG
M''38Q:%V/4<.CKX#$P8NF&<.>S]G(C01H#C#DM)OM ^B7KDL2CR?FZ@_0'<B
MJKD<NZKOMMU15]^Z)W_R^9^7Q3\D=?<V=%6DL1K&;\I<(NZ?;BH5R//NIP?5
M8^.7Z[G2!DA,*0,B4%G=<U,WB?ZR+7C1XB@;-G2^AL@/6_\ Q6L:!ZHJ)XNW
MZJB;=/?[5WZ[E_&#C& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M?<PV5;1M2UDR.)MR0UY+6-NI%Z31L25X'S598I'0QN<K&Y!G.6L8 P!@# &
M, 8 P!@# & , 8 P!@# & ?$2?)C!S\DJB\<I#V3I\JW',W!$@X3:(*.-T6(
M]FFJ[?/%=4_4VK-JDJX=+[:(()[J[ZZ^@<KG&,[6,?)O.G6\^G 1E:_3]O6O
M$J]G/=]X<HDR,*DH EN#:.?BOM'GRMVT]D IBQ2\DJ[<R[)EGS;:R),2<GVC
M[9<#JPP!@# *MOET_P#KC2'](O\ &%_CZY[P"Q.R_L_W<S_]0F+FNV'[$RK[
MVP&;ELR=P5I^A/\ [F8M7CS79HT<QE'ZS2#EUKLW059:*KZ^I:[>>][%\_WG
MCNSI-R4GIU3DQSVN>R^_TB/EI/8S9[VVG;0.:Q>9R2*C>JH<-C;L)N:58&]C
M)S3HJ-6%.1V\J*Y%:BQIZZ*Y%1%3=4V* /C%7-=DL+S?O_D>ZVDI^MK4D$>
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MK<17?'*JUF2UY7M:BISY-L+85:G>YL>S72*G<CEY45S51>BC/-QG@P!@# &
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M2NM,A] <VPQCF/:USWN;(CU;!S.<JMW53H+SSL9N, 8 P!@# & , 8 P!@#
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MGB+)HD[6V6\<;*N4T$]%U-G'C9GXO[NKYOMZMXT:^*^^_7]LA]7Y6HD^W &
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M1KSJ/#.MZZF<QFA.TE^N1C$JEL.(E96E7S<:\D[MDS#Z_LB_0=>AY\_ Z&\
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M_BEF7R*.H+M =[%48O3S*:0O:O1\D6EZ*KBM)(-.. ODG2U>N1&^_P"N_O\
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M6>(K8B7*VX[::SR,]//T&5[-9V-MU7TJL-B&[*CFW'9M$\"# & , 8 P!@#
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MU4G3D#T@3J?:LT1FDQ5C.@/P5M(TP[=N 2+?;>/$HXBE'$U=0>FH_P  C/\
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MCH&^YEG=_>O.U]<I?'HR\L:#0R[>H>B/ASZ7AG/)>9!UK23A%E=<<[6&DL@
M^ML3+,@PY,P@[+-AZ;57]")./-$M$%-4P.AW & , 8 P!@# & , 8 P!@# &
M ><8V*:B"FP/1HH;U'/M@Z9#931@H4\;*^C]'NZ7^UU:;._R=7.R7^TU1]W]
MT_UO/,Y(>R6:))U>D':1]LL2(LB1<R=HL:.]57HS?D1W3FVWZ%+N;E=R;*_E
M7E1W<KMO5WVZ[;[;^XY2OCHJ+M^^9=VOY92XN%6%6]YNK:B]@DQT?;NX9W2$
M=LD3 A#2->:^/ZZF5?;NX;: 5K]W'%XB7#[ T_O7*BRWK?B5F="Z?IZ&^ZVR
MWL;D\"S$6\=%+9<R[H*=CW0S*MK?L\G2R2,NXJ=_):;<AF[=>1J-366G:N:N
MRYKTI60SU[[K44ZI&BQ9MBHDC42/\5:6!>QLLZQK%(WL_655.D?F^^!]_P!>
M_M"J%=0R?18P^@MOUF45T4.5G9\?\13DD3([:?AJ[:^;+-RT;-(^?9R.+$PQ
MYE[]N0UTT\RZFT_)I[(^C).R]C[<,=_#92%%2#*8JQS+6MQ;_@?LUT-F!WKU
MK<4]>3UHU5=A4+C;L':*Q89HWNAM5W+N^O99MVD3E3HY.J/C>GJR1.9(WHY#
M?^8\=T8 P!@# & , 8 P!@# & , 8 P"#GR'V39=4<UOYA7&Y$>S1LBH!5MR
MD-5JMV&8-0)NR(X+NV:#:K09%E9?Z#KUT;4(H:@I%X&"*E)-N +Z!-F:H$,?
MBK\Y[1NWLO?AN!UV+X?D+2A93 II7G/*U'AOWTJ"[ C=N5:(DC^.QDG<D>AX
M6.5U.6Q]9D\8P4W:9^""B?V#!$*$ NQP" _R)\<%^VZ5CM7""5)MU0%@(S1<
M3T)1S*_*S.H^P:=0?U)U$U)+#RX:1 ]IOY*8M*H_)&#]@8!H#W2;H25()^!W
MD2JD^)&1U3T)1L^]Z*]FE/5"=Y[M@I%Y/!'J]NSB^><^%9%P/&)04L_2:["4
M8A)*\/ZV#*02D*>'7,_'?2E)?T8BZ;IAY_(\ODKG>%<T_+[U)"())KCE0DY\
M<?($T=O[NO*V[_E#<H3Z>[;$+L14NN683:2AXRDV LUF,4&%&L='D7!8FR&H
M/S)1P[ O!P!@# & , 8 P!@# & , 8 P!@# (A=FQ@Y^[<'=4('K$K&YDEC6
M[XN.::?4\D@,&,)B+0@R7T[:J*^S2KC,M$,6WFWNN\@] NO=-E&:7NN,ZJKR
M^@0Y:HQ9+VG[+<O7C;^*>&&.2+(5$VZKZ5CI;,;&^,_8KWM0WO\ 9^S.-_M=
MD>'FH[4=32?&+!S<.<S;G=M7Q&2R5RG?T9J23=%8Q-/:TQ^"OV9E3=N*3)PH
MY&V'[R=B4I!3F*QJ:Q8@@7C,O !Y/'BK;;S=N2!GA[<J*?H;^>^^;(NV+I!=
M/WSWW\=5/,O]:Q#<K5[==Z2U[4,5B"1OX9(9F-DC>GN<QS7)[E-.9S"Y+3>:
MR^GLS5DHYC!92_ALK2F16RU,CC+4M*[6D:J(J2068)8GHJ?B:ID&<Y:Q@# &
M , 8 P!@# & , 8 P!@'XN7+=DW</'CA%HT:(JN73IRJF@W;-T$]E5W#A=7;
M5)%%%+791553;5--/7;??;S7SWW *_1=R=O/[3NIW#*2JVU^>8X6#H5>6,S,
MA2-DR]N1B<)DN[^N'Z+>Y:RNN O$9(33%S\T>Y\7:G S^*K1LRFSVE2P%A&
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MG_4F]@# & 5;0[_?7=%_T6W%_P#BR[VP"TG & , 8 P!@# & , 8 P!@# &
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M%<^)&QV(Y$5EB&9K41T=B)R(Z*3=%545J([\3%<Q4<LALQP[PP!@# & , 8
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MY3'_ -=;?YF /U85_*8_^NMO\S 'ZL*_E,?_ %UM_F8 _5A7\IC_ .NMO\S
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M\:O$]-F[A)3<#T_X+;XR?^71PE_=%Y__ /'V /X+;XR?^71PE_=%Y_\ _'V
M8Z3^.7XG0IH!&C/"'QX"9'*]WR<7 $^7^;&!J2*#$-7)+0 *=0=)\8W'MM]7
M#[4<@Y]:(;:JK^)I^^;8!I.@OAP^.'G^(E(99/+O%-MGI[?-\3J)R&>\HT0Q
M,H#+:M"?VY$Z;CB!X1)GA$;44)*:P>,-!KY!O[$H3H]&QN-B&O@<:!([^"V^
M,G_ET<)?W1>?_P#Q]@#^"V^,G_ET<)?W1>?_ /Q]@#^"V^,G_ET<)?W1>?\
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M;1/W?1/P=6;[PWZUGC_W=1/3QG%E2KCW??37\O\ ';SST#<F , 8 P!@# &
M, 8 P!@'/[W#Q5T1;?R0UI;\'IW68Q$B\^.9[&>A?)) &7^C*/Y*ZHNNY^D
M+L9(),,L)OI>=:3F,Q,-[6L?D;>6$-GH::_HXD4W>*B.OGV?7]/#V=<!OCDW
MJCH'Y"*YZ''<QRB'BI'87"<M W),I=2^\BYDA/(=F=3/;X@)IL"LH[*4/](:
M,6!$58FQJUO+ LG%S5TWLEQ%WL=(#D0\]?R]O]/S(X<R?%1T.WY1[CJ6X.>W
MT#)2;X\:KYM&1439\6:(]9]>4M[UA(B'1#Q]6]@:H$8Q89FU*T0;JW,Y"&9:
MY1>L[#BS8/'T-70>WSY]WU]ITQ\TQ4_!.<J A$K'[")3#:3JJ*R45NNU=;C#
M\>@@$08'[N6*[EDXV9$6;EMLNS<N&JOJ7JC==5+;138$Z(B>XW9@DY^N_.*.
MB;G^0NK;8KZG-)I%7Z'Q\)1>_?)/ AWO+2W*_95CWST*NY&2&2"IXG^^>II0
M AP?VM <CVE1%@L F/@@.T;/%0^'GSY]IB'8G*'4/2W;-07L YBDC4,=_P!!
MD1&IW,9=3*![D%WR-\@<LO&\Y8308V,5,:-^@J,]",(CK4NLM)R73<?%;':Q
M1-)T@U$>>OY;^>]/CND_> ^53O,-X?)"KK#2T7K&YNIH'9U1%C<Q<S<G. NW
M*]#1><2M^9-2233!5^ZM>/SML_WF+I NZ>-EGC9'<0X'.%0VZK\$^FY9O@D8
M!S]?(%Q1T3<_R"U9;,!IS2P(B1'\ CXI=OLG@8S_ $4B/+O=)3HKH VX'222
M"IQIY<5-O!T/$[5D#D;F3EQ"<9EV@D%LF^]#KX>?/GVI*SH>@)AT!T;\:748
MRDYW&9?1'55DZ6,RF,X [N*[H_\ <!UM724K3BP*Q#\ <)V-.S]6%6[^+H$[
M$<QPY$6DL0$I1PL&CP%K. , 8!6K\KO*Y7K#D<]#8?#2L^LR+SFIIO6T9:3!
MW&ANYV/VS!")<P3'.)''XA(5@,0:2(B*0F&I)N->)_?@FR4AT'KZB%ZHJ>XL
MJP2, 8!\9%BB4'OQCA1VDW(LW3%=5@^>#'R:+M#=NJHR)#UVS\>[TT4VV;/F
M+EN\:+>:+METED]%-0.6^9?&Y>D'H7:&QKE9]=%:5W\JO;%[H\R.IU79DG:]
M#W)0M[U-3$[_ %>W+#:QN0O04ZL>(S,FE8LO1G"#1$S*U$'LL%MF9 4^WWK[
MO<F_7X;I_(Z"N-*RG%*<@<ITU9Q%(O952<VT965A%D'RA1 I.(%6$7BLL(HD
MU?\ :D4GI\40<IOE?]H[T5\<;_ZRGN"HDE@# *@^FN+[!FWR#5YT348@N(<R
M+A7N*BYS<#V<DUF$&GL\TYO8T .%1Q_(W#R-C]%XW8<C]WKN,MF/A=L8-2%7
MT\89N'PA4[O/@I2_7WQH=8QFGH08+\*;+0:N[,Y&UG_$Z4RYX7>W2_I#XX;1
MY3LFY&+7]Y?M+DV1B]9O").&<3"8")Q)8K7WD^,@1\I1$@E@VV\_U_=??T.G
M?ARJ9]1/%W)-)VJ_1*6;4/-=(5G83]N0V+MW4T@U:QJ-291N6W]]W*-_U@:\
MU0([>_B]2UT<_P 7YOX8))2X P!@# & , 8 P!@# ($?(W1=CWW0D0"5?%0U
MB2&N.EN7+Z(58>-#8\.M>*47>L(LR5U[X6.^?LVV)G@<>>>@=91NWC;@\U&-
MS+X<R54(-0*XT>,^LXMQ5Q/0BG/\6L4KRW=E:=4S2OT[1@C>'S5)W;5X&S?+
M\9]DGV8A0E2<:G\*.1V1R-(56Q]W$1HH&19+LD%4 (XT=\2_8-83GCD$>!P,
MHR@<)^/5[+[[%SEBL2H5SR!!.I UC4]$!!%%K,I (FK^Z(V"AQ*,)M8X\$$I
MRZE.@+QB+:R //GRAYE6?#_T [^/WN2A+;I"N1]@2[@GG#F.CX,)L,(3C=D]
M'\JT3?,)9=+DWX]80!&I63.+4BK^+^V)YY)1*L$"RB7C0YH.#W'AY^OGI_,Z
ME(FP<BHM&A;W3Q-X-CX9@[3UWU4U3<LQS9NOIJII[MIOYJJGOKYOIM[KMYY]
M6OOOGOGN 9!@# * ..N,^KN7NG[:N<M2L:DP^+ .Q(J .QZS(>QDW53KK?Y$
M'O5$3FYCTEZ@M%W5(U,27BYY"Q'.A%R?6*!H.H7";MR3D1U]GL]G7VK\C4G/
M7Q3W0W!=70.^ZE@>\4.<IV+S^!V93D<4:]36(7ZTZ0Z9A%J2MF*6'.QP02UL
MB&"WPJT-_P!0(R,Y/A!04[AC=,A)1)>AR!7DIJ/DOEVJ)RR1'36L>=:3KR8#
MVSUJ2;L)3"ZUC,;D#)N18JK,GZ+4L-=H)/6:RK5TGIJNW542WTV] D5@# &
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M7>'H%L<D-6U!U39SVP8FH0D)"P%7<^=T<,=I0<0BZTCNTO BA"CQZ!<M%/'
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M;( PV_+SYV_0Z%, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g942137g92a42.jpg
<TEXT>
begin 644 g942137g92a42.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2%>4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@     !=0   !     !       +<')I;G1/=71P=70    '
M     $-L<E-E;G5M     $-L<E,     4D="0P    !.;2 @5$585    !$
M00!D &\ 8@!E "  4@!' $( (  H #$ .0 Y #@ *0       $EN=&5E;G5M
M     $EN=&4     0VQR;0    !-<$)L8F]O; $    /<')I;G13:7AT965N
M0FET8F]O;      +<')I;G1E<DYA;65415A4    (@!< %P 4 !( %@ 1@!"
M %4 +0!- %< 10 M $8 4  Q #  7 !! %H ,  Q #4 ,0 M %@ 10!2 $\
M6  M #$ .       #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\
M9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M
M$     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#
M;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O
M;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !"
M;" @9&]U8D!OX            $)R9%15;G1&(U)L=                $)L
M9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!UX
M"G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M    3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M        4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN
M9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,
M969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!2
M96-T5&]P;&]N9P      .$))30/M       0 \     !  $#P     $  3A"
M24T$)@      #@             _@   .$))30/R       *  #_______\
M #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M           ! #A"24TG$       "@ !          $X0DE- _4      $@
M+V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@
M  8       $ -0    $ +0    8       $X0DE- _@      '   /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z   .$))300(       0     0   D    )      #A"
M24T$'@      !      X0DE-!!H      S4    &              -4   $
MB          !                          $             !(@   -4
M                      $                         $     $
M  !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   -4
M     %)G:'1L;VYG   $B     9S;&EC97-6;$QS     4]B:F,    !
M   %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N
M9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E
M;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   #5     !29VAT;&]N9P
M!(@    #=7)L5$585     $       !N=6QL5$585     $       !-<V=E
M5$585     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(
M5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N
M=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N
M96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R
M5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/
M=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M
M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M      P    "/_         X0DE-!!$       $! #A"24T$%       !
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M%@<UDS/\XT_GL3(_-(:]]=F29],9&A0KT[U'J4.4;,O%QZJJ7&@?SK1[H<V
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MMGT[:V!^Z'?S;O>L^BS,]4,9=]EWC8+35B!DD2P_HLI]C_=^XH?67)LS:V]
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MZ]P]3[%4Z.\.?8__ +\U:VU<[T9Q/4V@\M8P?V?3=M_ZE=(D1J5 Z ]Q:'(
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MV_26YB_MS[0W[6<4X^T[O2%@?N_-V^H=FU?,B22G_]DX0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$
M(@     !+DU- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %
M     0   &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"'
M:0 $     0   *0   #0 #5GX   )Q  -6?@   G$$%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,34Z,#@Z,30@,3 Z-34Z-#0   .@ 0 #
M ?__  "@ @ $     0  !(B@ P $     0   U0         !@$#  ,    !
M  8   $:  4    !   !'@$;  4    !   !)@$H  ,    !  (   (!  0
M   !   !+@("  0    !              !(     0   $@    !.$))30/]
M       (          #_X0$P34T *@    @ !P$2  ,    !      $:  4
M   !    8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R
M  (    4    D(=I  0    !    I    -    /      0   \     !061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP.#HQ-" Q,#HU-3HT
M-    Z !  ,    !__\  * "  0    !   $B* #  0    !   #5
M   & 0,  P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P
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M 0$! 0$! ?_  !$( .H!/@,!$0 "$0$#$0'_Q  >   " P$  P$!
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MW<"S27E]RE3YG>ZC*:3=\H6G'*<":>JN-.+/IESI&8K:63?Z7B8#&0F43V7
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MUV5'2E'2E'2E9@][_+JG:REX9K"W-K:2.KT^R;#)X2PT-C))+D<\0GH^L-*
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MWZ/KP/J.JLULUMEMP 3;QJ@6% 2-YH0J,TOM27"O.27<L=L,5>C<D<?U]A;
M"N^=UIU/IJGP^8!EH',70:FKC69&O*KF68EB(-.]J(:"D1#?+)FJOTG:W$=W
M;07,7L3Q)*OB Z@Z3_B4Y5O @BOCJZMY+2YGM9?[RWE>)\<B48KJ'^%L:E/>
M"#2T2=FW;/Q\V*S"?9\>A%6M96C.GV\[ZZ2UNK""LIZ@23:2W;4*M;0P:NK
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M4$$\<%K*>+[L,<CH%>U'=:MXHY)A.ZZI0258EMB00<+G3R)[N^MY;QK:P]1
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MLV^<E=;#+=_;._>:]JXS]M'"N*1:(N WML FE8O2;=XT &%17"*=*C !ZL8
MV VK0KBG'7&(SA=7<DU\I!EX?<1!54Q9-;4L/B$4D00LV .<KXRSBL+PJ90
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M<]LC.V!FJX//'E\*SMNOMC,=%J"J7-<"[:UJ@["<&>SOM32YVQ1!Y5A?*RG
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M%-6"T@B .VE<C Y;:0 0 /+D,8XE@2'2^C(6(S9 ]ML$%L#O8G'XY[Z43EW
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MC+^*1%6 8:8AWE(/RF:TGZ0=;$SV4 6&2YD]I%V$1,:$]:VF,R'2L@#,>\;
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MXE <VJ%518S9FJ][/Q3$K.OJD3XE/2YOJ9Z(6_W_ *^IZ>IR18%N>D8$/[E
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MDGF=22KRNRDC!*EB5)'<<8V[J2/:=Q_<'D.1=C2@=KVPVF$^\=73<:Z&K@M
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M5+$G469BS=HLQ(/*MGP/@-AT>L/0.'*ZJTCW$TKGUL]Q(%#RR% H.52-%50
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MM4[9V(.>>P&OF>[S!SC:KA<2$XZIM]ADN,;<SV?'GW#NS74Y(Y8N=WV6Z?F
M7"34ME;Y.2_I,U9V,%M)6L&TL4-!K?F-7[()X8HPP6^K)AID!+K6!N>8T>62
M9LWA-M')QGA]J9"G67<$?6 #.IW "J&8J&+$("W94G+;"M/TDOI+3HUQJ^2
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MXDTAY960(,E4C0 * L<:+]W)M/MEW9W*';_Q#O+&O$J[+0X:DGL0@(&BUK+
M0=*XV6J%9&R."H+*#E+J88V^U'6SC-B=)&C7NUMW&D-Q-'N0LC '.3C.=]\Y
M'(^8-;F-CH7RV[_N[<N0&W+%7GZ'?N_7^'_X_P"'T_PZP=G^$_6_C5^H\]_/
M<X^1_'^5?4$.Z0J-%]*M:Y)')]?[K%1?YKX3^/Y^LT"*\J *=CJ)[NSOSSX[
M5BF<K$YR<D:1[VV\>X;]]2OK;5JJJ?F\3E$[CBT#X:+:!R"3=X>&N-?8T=0@
MU))N\TW;3):Z/)[NIKGLPZZ-8S9<7J2AI/3-5T-G:,"$E?U_I\Z4E&JX1^T1
M-"1]5W1XR2Y%KKHN$Z;.YRGHIK^?167W?#?FJ_AX^TCI*C.$CE$SF[.Z;9%0
MCYPW/DS D;ZZQR)&079-1"D>>.>VX]_=CN-9$>0'2K:03\_@<>'GMGE5H<#\
M>]UF7TT=ISGS+F]WGY,:M>;G*"KKQAOOL^3/3.THI:XBAMXHE^&T0K@([<:B
M0<X.03,!3M<HT%^I881-)SL3^(QL2<$$8V^=3$:0'+MD;Y  Y[8.<#S\!Y5V
MN[V@GLN#[[058<A6AXVM\UR?G)('*V>NLL7="6)5I$Y/JQX-$MQ,KD17-8CG
M-:Y41%G<%*IQ"*(D:+M)[%]SC3>PO;9.1]QI1(/ KD;['2=)D,G![B9,F7AT
MMIQ>+8:B_"+N'B)13XSI;/ 1ME92NP))E'-VJC;VU\L[C/&R0M?PGM])0V47
MJ9+$I&'LK"H.C14]3'L?(-.SRWU-<B?3RG4**(>DQ(PW$RJ5.<C#X(/=G;Q\
M#6]ZQ73*[AU&DC<%6&Q!!WSW<N8KJ=O=0)2<"<(TX;/0+5\1\< #M]/MK[0F
M/IX&N<QJ-:U[D9ZGHB?WU=Y^O5+CUD\KG229'//Q<Y^&>_WC/.KE<:5]PSMW
MXR?G^%6_Z&_J_FO6$(,[:?$<S\//RY^%5UCS_'O^%'H;^K^:_P#'JI0<R0<;
M]_(X[L>8IK'F?P^OP^='H;^K^:_\>J:!XC8XYG&_RQX^ZFL?UQ_7Z^=1R_9F
M/BLO]X/@_BTT<:Y7XITB/72_)KI(T"]*HCB_DJW:HU_EGP_Q#O'K:Q4N52-0
M7;LD,=_9V[\<MQ_E5"Z;:N88:?\ E8(V_#//&U=^5CO:D]I/ROMO]OZ_G?Z5
M]']Y?3_>\?G^GZ_IU0(I*ZB,9&=SG'?[]A\?,T+\\ \CX<^ZLZ:SB_[0NXX_
MIF7O/.:HMA;Y1 =!7Q.PBS9NY-8LLMDFEI>WKX:]M!(R[&M<)1565K IXLK8
M 7%J[*Z.7E63^[*VT9(4YVR<@;C8M@>/:Y[C3O4?,Y']X 3C8@;9&_)1Y[=V
MVYQ4LP'&O?>%HW6O(_.W'-K5,UF?+2KSE.'"/8XP3<5)5W0'"F<9B_ SDX(K
M7BA&TI8=V[1)DXK/3F5E:22^C>CD:5CP<'2? D;<F)&^#X<S5RF8$%G!&1G8
M;KG?[O/&=QOY^#F;#-";'):G)&N] >JSEYG"Y/2DBL&O*PJL(?Z'^6O],13U
M]+D5'>/"IX7K'"[0313QL%DBD25&&<AT;4IV .Q6ES%%=6\]K,NJ&XAE@E0@
M8:.5"CIX;JQ7D:IGM1O2M!V_\<K92QR6N>J2,59QL<JRCD8FQ,R\,)C5\2-,
M<!5!D3K*UDDRSH2K&MF;U-XQ"@XG=LF.KFD])B\!%=J+F,#&V%24#N QW'EJ
M^CDLAX'PZ.=B;BUM_0+AL;M<\.9["=]S]Z:W=\?X@,D#)B79X% _'\N:1CEE
MGVO<SW :,F9RJKI&P<A668K45RJJ^B&DSM7!$WSZ(8HV0Q_@C;YPW:Y>)>Y+
M>!0-]LQASC;O8D[;YWK<(V,^)(8[?Q*I/>.\GQIM?0W]7\U_X]0] Y[?/)SW
M<M^?NJ_6//Z\.?SH]#?U?S7Z]4"#R'XGW]WT.^J:QMS\]AO\_KY@]#?U?S7J
M[0,\USO\<^[Z[J:_?\O'\.[R_+?@6D>=^<9GYK\*ERAUBN72=ST(4Y:6P2Q^
M"1%1KI/DBV"RH]%1!_=5OXD:O5P1L/@]DCM\\$9V[O'PJA=,J2-QG3G;<C?'
M/F,UWT8U?T?S7JWJ\8]Q[VVY?#Q_K5VL9Y_+;\@:0T_CWOJN#]19UG-><R(2
M\A\HNRN;L L-;H["%Z:Q&XR)/LQ.&BI@(:2@@I+=<LL]U>W L=U2:'D(2XUP
M=QQ?(_=UP"F<A<D9Y@;Y[0))R=_'<#;>/F8DG7@9.!MX[?<.-L;'/([[G$-S
MO"?VB  Y@%MW0XDF$#)-J<O:14U6=<K?"Y#X8:RT:V7$S@+-AVR#K"[LHH6Q
M/FIGW$E.ZE,L5#94M;-GU7,@D; #_:VVVV\AORJ@Z[&#)[N_P\1OR[\^1&^=
M)58WZ_3Z?M^OT_-^M45/T?I3J+I&V_(Y'M;>?+ER_D*D!_'XX]V^/C^E*CVD
MQ,SV2W_%2SOD_P!D?+6ZRE;$2CV&_=@ZT=HZ \AKOJL9[+@Q8)&_DE2!\<">
MQ%&J[;C!$\UO>9R;RQM97+?>EBC%M.W?N\]O(Q'BWARY_HXOHEI><-Q@<.XK
MQ&")>Y+6XF/$;*,#;LQ6=];Q+_A3GG-<_@07XSN&[T-',QRDD\@<696&1R^6
MLJLEQ'02B!Q?^)(X[#07)[FJY4]^SG<U&^I4ZB3K^[VB<E$<CD9[VF<%O@JC
MQ[A6^#8+'GJ /P++XG'(>=-[Z&_J_FO430/+^6_X<^7GCRS5^L>?U^-'H;^K
M_#\_UZ:1Y=^Y)/=X_+;\.>[6,<S\/'/Y?7?1Z&_J_FO_ !Z: -\CQYGZ/?R\
MQY4UCZ'/;N_'QQM1Z&_J_FO30/$;[\V[C^HV^5-8Q]?H-_EYU&\A'F&YJG3'
M?!KF$$1*90'R/#^#];_'P[I'*]8_<]?U<JKY\]7LAUDOC7MD]^=\<O(<O# \
MJM1ET@+L,'&!Y_6V_OJ(<T!\F&<>6(G#Q+ =\1>X:$ R2QHZEHU&_>9INWE2
MST>4W52 ]F&72+&7-C=04/)Z9*NCL;5H0TB-4UY?V<'._,XV&Q!YX[_?S-4=
MV*X0X;;?PY9&X/GOCW4H6@X<^T")B<^E[F\DRQ@%TA@1!=)F :CYT:MJ#F I
MZ2OX8F)DJ*(,J*S.G/O[AMR5\!5K1BDYY^MTV<&V&?5=V_><'<[EO''/?NYG
M%83U^WK!GY<^6-/X]XY#&U7+PE@>Z+-Z6JL^:.8,[MJ#[@$U=[FZ.KKAQIN0
MI"LL1!JZXQ,117$4#81M<"2 VW$H706%5,!DZ^:.11;'ZDKV%TML<G;(W!SV
MB#W8SO61"X.7;(QRY[[>0_D/+-=#N[IRR>$KG2U#?&@XTO<IR=GR?;=+\ =C
MKX(XL_T(J+X&HWV[W.\HC&*YS_,:/:L[@I5;^.-CA+R*>Q?.<8O89+96(V'8
M=T<'D"JGG6DZ3H7X//.@)DX;-9\8C &Y;A-W#?O&._UT5O) V-RDC+G>I7S?
MHX7]MG,&QSY/N1+P;R%IZ0V)7-5\?W M[:M*C5',<WU-2&5BH]JM\HJ.1?KU
M!AB7TB)& VF12.\8<9!R/C^-;W6&4%3D-C!&""&\"/'(P?  YWKM\$T0N<X1
MX>SX@S!!J7B[ 5<0T?GTPM!RE4-Z?/YWN\QJLDCO+Y'JZ1ZJ]RJMDW;FE8D%
MFD8G//=R=\X'/G^@JJMA5&3R&<C(WY^??\JM7T-_5_->L>D$?=Y\N_/P[_AX
MU76-^9\]OKS[J[8(_LL5ZIX?)X_7Y1GZ$^OYE7\Z_P //U3K86\0C7)]IO?L
MH)P-_')/P\*ASR:V"CV5^9\?PY?$]]??U(J/1TI1TI7+)&]M5D8GX%_O(B?W
M57_^J_H_5^;]7462+22RC8\\#EG^52HI-6%/M=WF!_/QJ,:6A$U&<O\ ,G.<
MP+14EK1&/C3S(P6W!(KR',\^/+VPD2.;Y7PJ^/*I]>K%U(ZN 0RL&! W!4Y!
M'N/*KW19$>-P&1T9&4\F5@58'R()!I&B+DFV^SNV#;&>,BP!X9WF'G6)WI='
M+11W>, AG1_F2.9HH@+G)(U'/:]LJ-],K%6;< ?M!W [,DPG&!L%EQ*!X;!@
M/P[C4+@^K]GV,<F2\*):R%N;-:OZ,['S9HBWXTYG&X#*KCS!UD7^[KL7E@&+
MY5WE@=&".S\3O+G?AC3ZN57+^=?KU!8$LQ .['?'/?:IR^RN>>D?E4T_K^OU
M_P >J8/\/R_I]#:KJ\>$_5Y_Q_K]2)U323S7Y?TI7G^OZ^OU_P .JX/@?A2H
MGI\I#I3,<9*8\1V0UD6JBC9"V5#I8J&_H?@Y%=(SV(W1WTA/O-21R/&9'Z/3
M(KF7+D:NSG4I'+QQORWY5:5SC?D0?@"/YU+/'5N&\#\/Z5=]<Z\>$_5U33_A
MY?X?Z4KSX3^'^'G]'C\W^'TZKI/\/R_IX;>[:E'32? _"E+)P*.F=WO<A@T%
MCCCK>58MY"1$Y?;GBY1H KYL+(G)^30)X4L#U15:XCWT:C6L3S-O/61V4N,M
MZ,(GVWU6[O&G=W0]4 .X# K5\/3J9N)VX]@7QN(UQR2\ABFDYG[UUZ4W=G.>
M^N/V3MBEX"K;*)WKBNN0>9;5CE^OED_+FUAC<J_7SZXQVO\ *>?/J\I^?K!<
M#,G+("1KRS[* ?RK:#D/^2GNSH7./+^>:;/PG]?3_P"W[>L(4CDOR_I2O'A/
MU?U]/^'5-)_AY>7C^%*\^$_5]/Z_7Y^O[>JZ2?N^?L_TI48N,S%<7N0O'E/@
M?DK&UL8AFQ->PUUI065"Z*217M6%L++%Q*.8R17OA;&K6M>KVW#*JRA?:QW<
ML'/AOG]/"K2N2I\#GY8_#QJ3>$_4G_IU9I/\/RJZO/A/S^/K^OII//3OXXI1
MX3_'JND_PGX4HZ:3X'X4I9\I 1FNZ?E6K2!CP>1^.,1OV$LC]""&Y,HC#$B/
M<B^F64V*: MZN17M:/&GT3RKILA,EA;[;P33PG;?1($FC'+EKZXYVW/?6KA0
M0\6O=\"[MK2X SSEA,UO,Q\^J%HON7RKX.VU4*U7=-9/8U)BNX^_"]:-5%=!
M283 4\#%7_Q(U WJBI]/+W>?V8)1E8 !RBQC'++,<5M.Y=^X_P#]DA_G33_X
M_FZPZ3X'X4H\?X?J_K]'CII/\)\.5*\>$_KZ?U^?_P#/0 CDO^S_ $^OQIC-
M>?")^C_T^B]-)'W?E_2E1/#92'$9&BR<)DEC%1A-#C-EA:/(0C9))/<?"R25
MK%_**WTI(Y/"(OG]'56RS$Z.?=C/=CPY^=6JNE0N<X[^7U[JEG5-)\#\*NKQ
MX3Z+^E/Z_I/^/3!_A_'3O\<9I]<Z/2B__P"_K\JO_K^S_#]732?X?]GQY]W?
MWT^N=<+4T NJS&CRYJ-^#T=#;T!?EOJ;\+<5Y%<1Y;]?4WVB'>4_2GTZNC+1
MNCJ"&1E8$#D5((_(59)&LL;Q.,I(C(P/(JP*D?B#2,VE]9VOV<VMG/&0*P&X
M1W&(F%1JJL4-''<X%D;VL<JN>^O C63RY5<KU61/*N;U-N /VC(ZJ DDPG7
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MLT^;?$_7^0\ZIK'G\OUH]'[O^7_3II\V^--8\_E^M'H_=_R_Z=-/FWQ/UO\
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M!1X#+U.I6630@UJ0VKYS$LIG$I/,Y5D.26="7>AS/RB32)^CU?3QU5@"206
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M<Z/'JP-6G.!RK1?AKD*+E'C?,[)!80##AIP[FM'DDE@K[VH+GJK@89\S6$/
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M&B:+;T(CUD\^?;S\-CNWI']%;[BMR*I^)/'H5_I5LGH<EDG90D9S@ ?B0/\
M.F <@\M+$^X _GRK(/DFZE!S7<56PR3,^]=;PI'.L<CFM6.L[A\$"YKF_F<V
M<+76,,BN^OMO5B?21Z+V?&8]-AP)^1$?$$/B.KBM67YDYKS;[.YC)TFZ61$]
MGK^#SJ-\ZI'XL'/XZ(_K%,]V%GL;H8A&)X6UQFT-D>U/]ZVJTV$8,DCD<B.]
MGYV4L*.8[T?$3K&Z/W)$EXUO](=?\"'?N(R/CO7L?%5!2!]LZG7\"$/PV\*U
M,ZNP/ACY5I:.F!]>?^?X=U*.F!_3N^'*E1NWTP=/=Y2B(@)E)UQ]G7@2PI$L
M TM72'WL[RU?*R1L<@U?+#$L,<SEG?&CVLC5TC:X^0_F/Z4J2=4Q]9/?O2CJ
MN!X4HZI@?7GSI56<UDR0<7ZP:)7-?>"@9+W&M]:PMVEO7Y*0CT^IJK\.RZ=.
MOI<UZ)&JL5'(G5&[*L1@$*3Y; FJ@9(%9/\ *EX50Z'FJV$F=&]>V[N2 =Z5
M7\LT?C"XOHHWO\^MK$)S8\_J;X7W((_JGT\]=)%JZ,</+=W$+3G_ /$@N3R^
MN5>8<(F/_I-XE$/9EX/>9[QF#B'#%&#RV#D=^QKJ]DQ+@.0<FR#VXX9=)8TQ
M4BKX>H:<?ZOVQF^$7U-EM0:ISH_PIZH(WJOY)$7CY#F=<D]M6./>0_\ ([Y_
MG7MO$5!M1XI(A'O[2G\\_A6SW5^!X5H*.F!]>['U\>=*.FD>'+S/=2CJN!R[
MJ5%\5J@=QE:365HY0@-X&AHPQS86EPQK))$C9VCS3PH_S&J^(YI&^%3\7GRB
M-(!/C^GYTJ4=4P/KX?SI1U6E'5,#X=_?\>=*3_N3)FENZX=BO:/4<>ZR8E/+
M5BFGTMWF!P%5/HZ.0:/-636K]4E8:]J*WVU]<BS_ -/LE\9@V,G<)O\ +/CX
M5JN.X'!>),>ZV=0?-P4Q^()K)?DFV*DQW&E1+(Q0A>2NX @2+PWU1/AQ?![$
M5%3ZHJDZZXD<COJ[XI%_N^GK?](TT\4N6 ]NWX>WQMH5/X>K\N5:K[)).LZ-
MVRGG!<\8C'N;BMS*/';$N/+%:U=FQ<C\+I@94:GL:2L.'^K?4X0S%941KU8C
M4\,^+JS8VN57*]T<GE?P^$Y. Y5Q_#(X_)MO_JKNN)J!<Y'WHT8^9&4_\--]
MUFK7T=*4=*4=*4=*4=*4FO<P&L&AICT<JI:8;1AO;]$2-**]ST[%_O>7>^NB
M=]$;X8HZ*YWE[4ZE6 S?VIVV8^_)T[C\,C\:TW2$_P!C7H\57Y!OYXK)#F6N
M-$XVXNT4#9&"3]P/*E(XE8T]DAMU@>*$=#%(JJKG++CSXO,?A$DKS(W)ZH%Z
MZ#C[*_%;E>?565H/^T(8G[O*49'/\JU7V41M%T=A8C'I%[Q:49.^D<0F@S^)
MB)'EORK7+LS_ "^,TY:(J-&MZ2C5%\*CI LO4W3GM5%7QY9I(F*U41R+'ZOJ
MU[5ZX^$;2'QD)'_TJ/S!'X5WW$_])'E&OYL?YTX_6:M?1TI1TI49T(F7*+RC
M]&\-I@>FC+R2%FO#D?J&TMW#&P&-A$"'F?(Y[UZ!/:2Q1F$DJ.KA6RQ/'Y_7
MOI4FZ4HZ4HZ4J@^X.!4SV0M?0]T5'N(")G,]*)%\[R6OQPTDCE<GI;\=IA&-
M]/J<Z5\;$3\7E*'?3_RT^&M<_+^NU8Y3B&8\O52?'02/GBL@.6:HXSC_ +G;
MRNBDD+Q^7X?.8J1JZ))#.><3;M?(J^&^(!<:?/)&JHY\355J_@=X[/C#AK3@
M41[_ $\D#8XD2UC&._GG&V,X_#S?[.HBO2+I7<8[+2<&A4G^)6XJS#/_ ,Q.
M[!VIG?L_!))K>AL?*JP;CK;CR?A\^9#M#QE*SRY/"-54"D5$\?B\.5/'I7KB
MY!^]2^ 4#YG]*]FXH?50+_B8_P"RH^O?6KW5U:6CI2CI2H[;"YN:YRI%N\1M
MT)863LFDYCQR)+&:CL8;)@(S9XVGS)1.LI)87Q$)"*R8IK&.A29BE2+I2CI2
MCI2JGYO9(O&5^5&B^FH,S&A*\,=(Y*[-:RBT%FYK&HJJYM=6%.;^9J*B.<K6
MHJI:XRC#Q4_E50<$&LH=[0EZJ]Y?IPX7SRO[;.XTER1M5\C%)XVM,W%(V)/Q
MS.>7I!QVQL17N>0U41?"JG973A.CMFOCQ*V('DD%S\AGY\Z\IZ/QLWVBWTYY
M1<$O Q/>9>(\-(R?,(3CR/@:^'L%D*N=#QV62WWGE:RQ.-F;X8D<C,%N3XWM
M;^EKBQX8O0G]UDBKY_#UR%T@6\55Y(C<O<%^&X/T*]SOS^YC/-G7'OR3^0-;
MB=4K0T=*4=*4=*5&<:)EP<O3"8IX<F5@$1E(^O-?9!.#]R144<Z0@IY,?N+)
M^4<1*OGRWU?3PBE2;I2CI2CI2DR[F%D%T(+53\E>X.V6/THY55^5O*[WT>J(
MK(T\;$98T<OJF5)%:BI Y4E</&>(6I[P6 _'2?B=.!\.^M+TB/\ 8M\.XJ"?
MP#_KGWUD;S/76P.#X>T#$1M;8\W<R5+9?1ZDDAL\EPU%Z$>B(D;E/Q5PSTO5
M9'_#*YB^VU43?<>8/Q:\4_<M++'O6U@;O\.L([JUWV31F/HW:$_Z^[XO)O\
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MUU>WC7<S+DJ@552&(';4J*A<D  /(X&0 Q]/9MP+MN'*S1OY!&"%MD8'F*:
M"R'LQ)JZK*.*LM"#,/X="#IIYZQ!A;"(6VC&HAIK "NF(<''K6P9'<??QMX
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M@,R.:&M:C"V?Q8Y!6G%N"@):^Y+&B?\ $UEA24@4U3:PF0Q-*M;<]]:I%:+
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M:W)Q!J&T[["Q&$ M*-]E7'U[_K-!O]>'.I-1?:=\):JOH+3.\<\X6]7KEXO
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M*55UAGL_7\W<2A@4=."'4\=<N6-4('6!##5E@,=Q#G1CJ^"&!D01@^?L#Z*
MH9L<\5,:761O:$3- ]2K7FR>6(D#E(S6?GEKX(!0))J:NED!&&&/#&'#>\9S
MAH!Q+6T%@BA5D<0UD?!&UL1A#9%*K? 83#@7')B@XW*!*[D:D,<HF=J!E<7G
M./\ #"YXIRPAL52*$6.,:FG7\K5P,9""Z"-K6HI5@S8G&D>OXC)9B?W08:N3
MWJ&JE]RM&E$G'KG^L1WK!'G !FA$=Y'BE"$D9&UXT*L4J3]*4=*4=*4=*5PB
M\OFCX 13L[1&C5B2I6CEU(!,%>DT2PS(#%,.^,1)856*5(&Q^Y$JQO\ +5\=
M*5\4>%Q$4PI$6.RL<X+8F!3QYZH9,&R 6O @8+(T-'CMA!J:H.)L+F)&+65X
M[$2$(9D:E?=79C-5 4594YZCK*V"84B&OKJD (*$@*9A 4\0@P\4$<PD\<<X
MLK(T>/,QDD3F/:UR*5ZY\EE2B9C2<SGR#"2WGD%STU;*20?+5NHY#9IY!G2R
MER4CWT[R7N=,^K<ZO<]1'+"JE>J;%XX@U]E/D\U/8R3CE2'S457(;(2(8EB*
M0\IXKIW3C6#6G#S.D62$Q$*C<V=$?TI71JZ.EHXR(J6HJZ>(N=I14=77B5\9
M)+!1PF$$,$BA;-.P(,01LLB.D:**..CDB@B8U2NITI1TI1TI1TI1TI1TI1TI
M1TI1TI1TI1TI1TI1TI1TI1TI1TI1TI7P%556<766!M: 8?2D$%4QI08Y!=24
M6$16E$UA,L;Y@"":XLH B85\4DP1) LCG0321N4K[^E*^:(,."<HJ 4:$HYT
J3SB8H(HYS'P0M'@>5,QJ2$.A@8R")TSGK'"UL;%1C4:BE?3TI1TI7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g942137g92n73.jpg
<TEXT>
begin 644 g942137g92n73.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1424&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      %U    $     $       MP<FEN=$]U
M='!U=     <     0VQR4V5N=6T     0VQR4P    !21T)#     $YM("!4
M15A4    $0!! &0 ;P!B &4 ( !2 $< 0@ @ "@ ,0 Y #D .  I
M26YT965N=6T     26YT90    !#;')M     $UP0FQB;V]L 0    ]P<FEN
M=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    B %P 7 !0
M $@ 6 !& $( 50 M $T 5P!% "T 1@!0 #$ , !< $$ 6@ P #$ -0 Q "T
M6 !% %( 3P!8 "T ,0 X       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&GN
M!"         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE- _(       H
M /_______P  .$))300-       $    'CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M     )8   (5          $                          0
M   "%0   )8                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   )8     4F=H=&QO;F<   (5    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   "6     %)G
M:'1L;VYG   "%0    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3
M #8    ! #A"24T$(@     !?DE)*@ (    #    0,  0   !P"   ! 0,
M 0   )8    " 0,  P   )X    & 0,  0    (    2 0,  0    $    5
M 0,  0    ,    : 04  0   *0    ; 04  0   *P    H 0,  0    (
M   Q 0( '@   +0    R 0( %    -(   !IAP0  0   .@    @ 0  "  (
M  @ #*<? ! G   ,IQ\ $"<  $%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,34Z,#@Z,30@,3 Z-#8Z,S4    $  "0!P $    ,#(R,0&@ P !
M    __\   *@!  !    %0(   .@!  !    E@            8  P$#  $
M   &    &@$%  $   !N 0  &P$%  $   !V 0  * $#  $    "     0($
M  $   !^ 0   @($  $              $@    !    2     $    X0DE-
M _T       @          /_A 8!)22H "     P   $#  $    < @   0$#
M  $   "6     @$#  ,   ">    !@$#  $    "    $@$#  $
M%0$#  $    #    &@$%  $   "D    &P$%  $   "L    * $#  $    "
M    ,0$" !X   "T    ,@$" !0   #2    :8<$  $   #H    ( $   @
M"  ( , #   !    P ,   $   !!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#$U.C X.C$T(#$P.C0V.C,U    !   D < !    # R,C$!H ,
M 0   /__   "H 0  0   !4"   #H 0  0   )8            &  ,! P !
M    !@   !H!!0 !    ;@$  !L!!0 !    =@$  "@! P !     @    $"
M!  !    ?@$   ("!  !              #  P   0   , #   !    _^%!
MAVAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN
M/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)835 @0V]R
M92 U+C$N,B(^"B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N
M;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\B"B @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @('AM;&YS.G-T179T/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B
M"B @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @('AM;&YS.F1C/2)H='1P.B\O<'5R
M;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*(" @('AM;&YS.G!H;W1O<VAO<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(*(" @>&UP.DUO
M9&EF>41A=&4](C(P,34M,#@M,314,3 Z-#8Z,S4K,#4Z,S B"B @('AM<#I#
M<F5A=&5$871E/2(R,#$U+3 W+3$V5#$T.C Y.C Q+3 W.C P(@H@("!X;7 Z
M365T861A=&%$871E/2(R,#$U+3 X+3$T5#$P.C0V.C,U*S U.C,P(@H@("!X
M;7 Z0W)E871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M(@H@("!X;7!-33I$;V-U;65N=$E$/2(X1$,P-#DS.#DR.#5$,44Q-S)!1#8V
M13@P,4(Q,34T-2(*(" @>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#HP-C8X
M13%!,30S-#)%-3$Q.4,W1#E%,S=&03,P,#DS,"(*(" @>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/2(X1$,P-#DS.#DR.#5$,44Q-S)!1#8V13@P,4(Q,34T
M-2(*(" @9&,Z9F]R;6%T/2)I;6%G92]E<'-F(@H@("!P:&]T;W-H;W Z0V]L
M;W)-;V1E/2(T(CX*(" @/'AM<$U-.DAI<W1O<GD^"B @(" \<F1F.E-E<3X*
M(" @(" \<F1F.FQI"B @(" @('-T179T.F%C=&EO;CTB<V%V960B"B @(" @
M('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z1C8S,D)!1$-&.3)"134Q,4$X
M,S-#1C<W,T,R1D,P-D0B"B @(" @('-T179T.G=H96X](C(P,34M,#<M,394
M,30Z,34Z,C8M,#<Z,# B"B @(" @('-T179T.G-O9G1W87)E06=E;G0](D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(@H@(" @("!S=$5V=#IC:&%N
M9V5D/2(O(B\^"B @(" @/')D9CIL:0H@(" @("!S=$5V=#IA8W1I;VX](F-O
M;G9E<G1E9"(*(" @(" @<W1%=G0Z<&%R86UE=&5R<STB9G)O;2!I;6%G92]J
M<&5G('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W B+SX*(" @
M(" \<F1F.FQI"B @(" @('-T179T.F%C=&EO;CTB9&5R:79E9"(*(" @(" @
M<W1%=G0Z<&%R86UE=&5R<STB8V]N=F5R=&5D(&9R;VT@:6UA9V4O:G!E9R!T
M;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P(B\^"B @(" @/')D
M9CIL:0H@(" @("!S=$5V=#IA8W1I;VX](G-A=F5D(@H@(" @("!S=$5V=#II
M;G-T86YC94E$/2)X;7 N:6ED.D8W,S)"041#1CDR0D4U,3%!.#,S0T8W-S-#
M,D9#,#9$(@H@(" @("!S=$5V=#IW:&5N/2(R,#$U+3 W+3$V5#$T.C$U.C(V
M+3 W.C P(@H@(" @("!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*2(*(" @(" @<W1%=G0Z8VAA;F=E9#TB+R(O
M/@H@(" @(#QR9&8Z;&D*(" @(" @<W1%=G0Z86-T:6]N/2)S879E9"(*(" @
M(" @<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HP-38X13%!,30S-#)%-3$Q
M.4,W1#E%,S=&03,P,#DS,"(*(" @(" @<W1%=G0Z=VAE;CTB,C Q-2TP."TQ
M-%0Q,#HT-CHS-2LP-3HS,"(*(" @(" @<W1%=G0Z<V]F='=A<F5!9V5N=#TB
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RDB"B @(" @('-T179T.F-H
M86YG960](B\B+SX*(" @(" \<F1F.FQI"B @(" @('-T179T.F%C=&EO;CTB
M8V]N=F5R=&5D(@H@(" @("!S=$5V=#IP87)A;65T97)S/2)F<F]M(&%P<&QI
M8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9B(O/@H@
M(" @(#QR9&8Z;&D*(" @(" @<W1%=G0Z86-T:6]N/2)D97)I=F5D(@H@(" @
M("!S=$5V=#IP87)A;65T97)S/2)C;VYV97)T960@9G)O;2!A<'!L:6-A=&EO
M;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8B+SX*(" @(" \
M<F1F.FQI"B @(" @('-T179T.F%C=&EO;CTB<V%V960B"B @(" @('-T179T
M.FEN<W1A;F-E240](GAM<"YI:60Z,#8V.$4Q03$T,S0R134Q,3E#-T0Y13,W
M1D$S,# Y,S B"B @(" @('-T179T.G=H96X](C(P,34M,#@M,314,3 Z-#8Z
M,S4K,#4Z,S B"B @(" @('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I(@H@(" @("!S=$5V=#IC:&%N9V5D/2(O
M(B\^"B @(" \+W)D9CI397$^"B @(#PO>&UP34TZ2&ES=&]R>3X*(" @/'AM
M<$U-.D1E<FEV961&<F]M"B @("!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED
M.C U-CA%,4$Q-#,T,D4U,3$Y0S=$.44S-T9!,S P.3,P(@H@(" @<W12968Z
M9&]C=6UE;G1)1#TB.$1#,#0Y,S@Y,C@U1#%%,3<R040V-D4X,#%",3$U-#4B
M"B @("!S=%)E9CIO<FEG:6YA;$1O8W5M96YT240](CA$0S T.3,X.3(X-40Q
M13$W,D%$-C9%.# Q0C$Q-30U(B\^"B @/"]R9&8Z1&5S8W)I<'1I;VX^"B \
M+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( $4
M]P,!$0 "$0$#$0'_Q  ?  $   8# 0$             !08'" D* P0+ 0+_
MQ !&$  !! $# @0"!P4$!0T    # 0($!08 !P@1$@D3%"$5,0H6(B,R06$7
M48&1\"1QH?$X4E=BP1@H-#5#4W24EK&UU.'_Q  < 0$  @,! 0$
M    !08#! <" 0C_Q !-$0 " 0,# @0# P8("P<%   ! @,$!1$ $B$&$Q0B
M,4$'46$5,G$C0E*!D:$6,S=38G*Q\!<D-$-6<X*TP='QE)6VPM+3X55CDJ*S
M_]H # ,!  (1 Q$ /P#?XTTU@]\3+Q\N%7AMRK';VWL+#??D5& KDV0VQG0/
M/QPSQ,-&7<W-922:7 @R!D:]D!(V09<HR!E,Q-\ OK6[4%)+/A@-J'\]@<'Z
M*/5C^P?74;6W2FH_*Q,DOM%'R0?Z;>B?@<M\E(UJ6[V_2Z?$2SJRG,V:VZX_
M[$XZ\SEK!IC%UN;EL:-U=Y;)^097<Q\;GG1JIYAXV#5HGJUO9&%]KOD$MT(Q
MO9W.>1D*#], %A]>?P.H&3J"K8GMQQ1@YP"&=P/J<XSZ_F 8]B=5WS[Z0+XI
MD7ACQMY<;8;B[<Y -^19=M#R.H+?9S"YU5#W*J[A\_#K=S:F+5VU5"RO$S1T
M/'KI\"#'F.ACCM9(FL<^TUO35O:P6R[T44JDR3T5S'==]E6KEH) &9@BRPD9
M &T-M &6YKM'U9=5OEPM=9+$P$<59;]T$:!J9D"S(S(%+-%,#YMQ)4DG[IQD
MMW*^DK;A\+<?XG4G+[CG0[@;B;O[6AW"WD#M#>R]O[+;=+*1#2MBU.'Y8_,(
MMW/CJ2UK+"MG9=0")84IR@L@",T3=?J+I&&RT]IV5,QK:VB\75T\RILIR[+V
MD4HJLIY='#;SOC8C .!MV#KB>ZSW,S4D/@:2K\+35%.SAY@H(>1@[/&V2%=0
MA3R2+ZXR<WO!/Q>>!WB(P@1N/F\D >XGIG2;+97<0 \(W<JVB3O.H\8GRC1<
MFBQQJPDBUP>VRFFCH]HY%B([2!'2I:>6$^=>/9ARI_6/3\#@_35[I:^EK!^1
MD&[WC;RR#_9/K^*DCZZR9ZPZW-----------------------------------
M--------------------------------------:\/TAWQ9[/PX^-57MYLQ;A
MA<J.14>WJ, LV* \C:_!ZY0QLMW1=#(A$?;#=*'C^#MD#2-]89,F[<DL6+RJ
MV9N4=.)Y,M_%IC/](GT7^TGZ<9&0=1-VKS1PA8S^7FRL?OL' 9\?,9PN>-W)
MR 1KR[[J[N,EN+3(<AM;*^O[RPEV]S=7$V396UO:6!WRI]E96,TII<Z?-DE+
M(ERY)B'D&(\I7O>YSEG ,<>@''T&/0<#Z<#Z:H[%F8EB2Q)W,2222<DD\DY/
MX\\ZAG]?K[?EU3V^?Z_GK[^OT]_J??YCCY#V&OGZ_3W^I]_F./D/8:V&O 4A
M9!N/?\@]E<OP>#G7'2UI,+S?+1WZ>=2T.Y&,Y)&F82L:,5' /-O!0ILF8$?8
M1XL6KS'>X$;R3=-^'*R54ERH)Z=:BV/'!/.),E(ZJ&4-3D*>"TFURP'KV03P
MN#0NNF2FBM];%.U/<4DG@A*<224\L16?)]0J$@*?0-*V &.=8^O%2WFM=]>:
M.Z.:D!8!Q"&6'B6V1I8)(H=M@>)+(HX6249#M&V71Y1>1+W(($V.CHQV6+D8
M1ZL>[5;ZOKWN%]JZ@AA!D04A8, ]- >VLT>1YHY9%EE1E!'G)YY&I_IBB6@L
MM+!Y#*P:6J (RL\VV1DDP3^4A1DB(/(V>F,#5@>.9)D.'WM3E.)WMQC&2X_8
M1K6BR+'K*;37E-9PR--$LJJUKC1IU?.BF:A02XAPG"]J/&]JIUU5B,\'D$<K
M[?ASGVQ\]6!69&5D9E88(*D@@^HVGU' &/?6\9X*OTFZSLK;#N*WB29)'.ZQ
M-#QW;KEA/<V,9)AG"BU5!OFT8TC$;)*YD2-N@!L5 O<!V;QR-=89:**JJ(#,
MD ..2T?T^:>_^S^PGTU9[;>]Q6"L."?*DY]SP )?D3^GG'H&_2UO+@."4 ,F
M,84B-($,\>0 C"@. K$((P2C5PRB*-S7C(QSF/8Y'-545%U%ZLVN73333333
M333333333333333333333333333333333333333333333333333333333333
M37E-?21]_P"UWW\6SD1 +8&EXWL<+#MB\0C/?U%70\.QR%9Y2$0^YS&J;<3(
M,QDN(WJ\C2"\Q4[&C9/T*[*=3^GER,GG/ ]/Z('KCC5%O,W<KY1G*Q!8E&3[
M#+8Q\F9LY]?P(U@C_P ?\/?\^O\ E[?QUM?N_?Q[8_Z\_JU%?N_?Q[8_Z\_J
MU&<=QZ[RV_I<7QNKF7609%;5]'1T]>%TB?:V]K+#!KJ^&!B*\LF7+.&.!B>[
MB/1$]NBZRPQ23R1Q1*9))'6.-%&69W(544#U+%@,?,XSDG7QG2)&FE=4BB5G
MD=CA41!N8D_+&2W_ #R-;D=MMZ7PM_#%L,"V_@2;[DCNG"7'!/Q>OD6N0Y'O
M3N%5&#:2:&'7A/96,7;;%HEI(HO*CD8X.,!FR(PBVDM'=Q>F/2'234U,IDNM
M8O:':7=++7U*$.8E0%F%+$K=O"X_)!F4%V&N0QU ZHZG2HG*QVVD(E\[!(XZ
M.!PT?<+8C5JF5E$F<?QI4$A 1:9DO'*A\2;PY=NK3!,#^H'+7B!A\';>5@QJ
MF71V5W7X?4C _$#Q;(0)OILSJX@LGQ"1,\UL'+B6E*^4T<JYF:AY;7'U5TO3
M/3T_A[S9(%I&IV1HVE6! #"P8!L3HO>@9LA9]Z9P7;4LEPDZ;ZBJ4J)_$6B\
MS-4K.) ZQO,Y/=!4E<PL3%, .81&X&51=:P$V'+KIDJOGQ9$*?!D'AS84L)(
MTJ)*C%<&1&DQRM:4$@!6/$4)6M(,C7,>UKD5$Y$ZE&9&!4J<$$88$9R"#@@@
M\$8X/KSKI&0>5(*D J00<@C((/N"#ZCC\>-=7W]OW>_7K_E^7^/[]?..?GQC
M'_7W_=\M?>.?GQC'_7W_ '?+6^)]&"\9FVRPM!X:W)K*G6-M!K9#.*6?7\]Q
M)TZKIX+I4G8ZUG2GJLDE15Q)-CMN4Y%-\-BS<081S(>,0=1-=3!<S(,<_E%
M]S^</_-Z<\_,ZM5DN)?%%.V64?D&;U('K$3[E1RN?8;?89W?=1FK+IIIIIIJ
M1+;=#;>AM345WGF(U-S'> 9ZJQR"KASPDDB$:.PL4\EAAO,$P2B:YB*\96/:
MBM<BK+TU@OE93K64EHN532N&*5$%'42PN$)5RLB(RL%965B#P5(/IJ'J>H+%
M1U#4E7>+;352% ]-/6T\4ZEPK(&B>0."ZLK*",E6!'!!U/>HC4QIIIIIIIII
MIIIIIIIIIKJ2Y\& UCITV)#:15:-TN0&.U[FIU5&*9[$<J(J*J-ZJB+U762.
M&:8D0Q2RE1EA'&[X'L3M!QGVSZZQR30P@&:6.(-PIDD5 2/4 L1G'TUVFN:Y
MJ.:J.:Y$<US516N:J=45%3V5%3W14]E3W36,@@D$8(X(/!!'J"-9 00"#D'D
M$<@@^A!U]TTTTTTTTUT;*SKJ:!+M;:=$K:V !\F;/G'%%AQ(XTZD/)D&<P01
M,3W<0CFM:GS766"">JFCIZ:*2>>9Q'%#$C22R.WHB(H+,Q]@ 3K%//!2PR5%
M3-'!!"I>6:9UCBC0>K.[D*JCW)(&J=_MOV<_VI8#_P"JZ7_[FIO^"?4_^C]X
M_P"[ZK_VM0?\+>E_](;-_P!XTO\ [NIXH\DQ[)HGK\;O:>_A([M67364.SCH
M[_5<:$8PVN_W7.1WZ:B:NAK:"3M5U'54<N,B.J@EIW(^8654)'U QJ6I*^BN
M$?>H:RFK(LX,E+/%.@/R+1,P!^A.=1K6KK;TTTUUIDR'7QBS)\J-!B 1''E3
M#BC1@M<YK&N*<SF"&BO<UJ*]R(KG-:GNJ)K)%%+/(L4,<DTKG"1Q(TDC$ DA
M40%F. 3P#P"=8Y98H(VEFDCBB09>25U1%&0,L[$*,D@#)]2!ZG76C7-1-\KT
M=K6R_/(X(/33HI_.,R,R:\0O**[S"LAD9+<-G5[8SVG5$$Y'+[DI:F+=W:>>
M/8H9NY%(FU3(8@S;E&%,JM&&/!D!0'<"-8XZNEFV]JI@EWL43MRQON81B4JN
MUCEA$1(0.0A#'@YUY!GC1X_98QXK//2LMF%9*)R,SFZ8A?9SJ_)I(<DJ"M1!
MCZC/4V\(P5[?<+QKU>J][IJE.:>(#GR_V<'GVP1_;JCW,$5]4I'/=+?J8*P/
M/IQ@_@?7&L87]W\47W_+VZ]5ZHGZ?KK9_']1''OSC P3]?IK1_']1''OSC P
M3]?IK8J\!7AH+/,_O>7&<5C38QM=./C&UT:8%'!M-Q)$ 9+?(1B*-S"APZGL
M !A&]F?';@4B,5)=$5!].^'5B%14O>JA,Q4C&*D##(>J*@O+R""($8!"/SY,
MJ=T9US_KJ\>'IH[3 WY:J7NU1!Y6F!.V,D-G,SJQ(_FU(88D&9@\7KD'M5O%
MRXK^/^;;SYEL]B_'[' &J<TPS"BYU7@WCR]*VTN29/#K,JQN^B5M)BS:>LCV
M6- O;:MM378%K'_?!+FZTN='77I;;/73T4-MB\D\%.:A173;7?O!9HG54A[:
M!HNZZ.7\AY&OG2%OJJ.T&O@HX:N6X2^>":80,:.+<B=IFBD0L\A:0K*8U9 A
M#>AUP\)+SF5C.[^W;\'YDQ^6O'F3=0*S-J3;K>:%9[B8]B\MZ1@VSMKM]ZN'
MN#!^"%<";/I\=H9\R56@G5]7(;(DQ);?EADOD-=3>&O@O-L[BK414M>KU4<+
M<!_!W%%JE,>0SQQ1.S("J,&*L%[2S2T=1W[-]DW'8S0O5496G>4 DH:NA=J<
M]SD*[RJ Q5V& 1KYXX_A^LPN]D<R=I:5!8KE5C&A[V4-;&:P./Y7.>V/7Y\&
M.%.T59E)U% R)R,:D;)'QK$CC/R"2L1U_P!-""0WRBB'9F8+71JH BF8X6H
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M*3TLU)*^[=@LT?A5!V\+ PYWC;YTGTLKBY9;2>(E2\A8==(3#N4^U^-VY+1
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M6(J-D "=J+\T:8;2(B_JB.1-</D0QR/&3DH[(2/<JQ4G]VNZ1N)(TD P'17
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MM^Z2GC6Y0C.'I,F8+\VIFVR;L9\L)F ]-WMJ6MW6EEK=J32-;YR "M5CM$G
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MSW# X_F."QSWN8-6HKE5.NH6?XL]1F:8P16U8#+(85DI96D$1<]L.PJ@"X3
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M'9#Q>V]&1PP0J;<O+YT=7>Q9%C.Q>DK"/%T3HZ,.JMVM>K>JI*>U%^RNK?\
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>------------------------------------?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g942137g95u36.jpg
<TEXT>
begin 644 g942137g95u36.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X5.O:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I-;V1I9GE$871E/C(P,34M,#@M,3A4,3 Z-#@Z-3,M,#<Z,# \+WAM<#I-
M;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q-2TP."TQ
M.%0Q,#HT.#HU,BTP-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX
M;7 Z365T861A=&%$871E/C(P,34M,#@M,3A4,3 Z-#@Z-3,M,#<Z,# \+WAM
M<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O
M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^,3 T/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G06%!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E537EQ<%II1E9256LW04%9
M<6PQ)B-X03MH-6XX=&%J9%!A869Q,6YE6&-8.35B,CEX1DQ)=$LO85)'3$1P
M:7%'.#<K6E<X<BM5=%8X=TQ9>39I9$UT,W5"6G=B3R](>&%H-&]V)B-X03LR
M;F%H-'%#84=L3599<6XU=G,O;5ID1$=H>FIL2TQC6$131F8S>F%P.5)%4FIA
M34U*4'%F*VXX1#A8;R]&.6XT<U9:,W!E<5=E<#)A)B-X03LS;&UZ=$%Z>5(O
M=DDU25A$=WE.1DER4GEQ:G%69$-.>&EQ2WA6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X)B-X03M6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5E%V-T]+.7-B:7IM<C96>D4X36Q+5C1Y2U9.3U%)-DAU359E869L
M:THU=DY'<7AZ>5-8)B-X03M.<G!Z5'<R6#%J9S5J34TW46-L86E-1TMQ469G
M6'=W;$0Q3$%L,DMP3C53+S0U52\O8E(Q4"]U;S-'2W!Z:7)S5F1I<G-69&ER
M<U9D)B-X03MI<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&EQ;F,R.&1X8GE14T8Q4U93:D=*,VEC06EN)B-X03MW
M>5)L6%4K-FM(1EAL;FQ(6#=E>3@Y9F]E,71P83-%.7IB,VHS8T9S8FUS6F1K
M8UA-2'!Y3VIM2FUB,59::'1V=EA#:#9F<4]O,E=N)B-X03M7570W9E1,0F%W
M1&Q,2S-10W1",#,S2F]"9U-G9CA895=F<C,Q1#E*,B\Q>C%04SE$;4]83#%0
M47(O<2MV*S0U9EHY6#DS6#%0:'A6)B-X03M:-5,O-#55+R]B4C%0+W5O,T=+
M;VUB6&)'2%<W8E)N17AV8G%*-313<TUR4F5N2',U85E+63$T:W%$5G8R;"]M
M1F)":DII6F1!:FE&)B-X03LP;492;&%867%L;6IA+T1Q='IQ545D<E!!9$UU
M1&%Y=DU)=W)U1D0Q:C1/-4DT<W)F14(Q1U9W>6-23S-*>3E4<$1I:D%M551X
M>#1H)B-X03M6-T1Z<T1R9F9Y5%!,2$5D:7)S5F1567$W1EA9<3=&6%EQ-T95
M:W4O3BMK,G5I,F5Q>6-Y3"M+3V$P<VQ-9C%Q4DI/0DEI:$QG>75I)B-X03MY
M06Q)*U1(;V]::4%655AO,G1187-L>DI"1$EK3G9/,$-44'=-8S9H1F-445!'
M,&EY4DU(,DYA,4)59TU#35941$9867$W1EA9<3=&)B-X03M867$W1EA9<3=&
M6%EQ-T9867%S;FME2T-34DEM;F1&3$Q$1U9$=5%+:%9,<VE68F]/5$%E2GA6
M-70U43!I+W1F3V1X9C(V86I&1F5Y)B-X03M4=F9P8S)#44MY>7,P:65R8W1/
M5$M9:5%I37%S44YT;')H5C9&<6UN46%L<#@Y:D]714YW=D-4:E-P6'5#1T1+
M>6YO>7-#<D199V<P)B-X03MW2WAY2#AR4$IS3W%*<6%7<VXQ=4YG5F1P<$@K
M0F)Z.4I#36QI5TDK=B\V5%5N;'DK2&PV9G=9<6IV2FQN85%A1SEV1$)(1F)W
M-FAQ)B-X03M1:6A25E9%0S9J3U%&54-G;U%+57A6:'9M97=U669Z;#!+.# Q
M-THW;5!3<&A&<%4P<&=E5# O55-G2WA3.&53>3%48F-2<TYG37DX)B-X03MD
M2$-B:B]%4%8S8D@W=5A0*TPU>D4V1F-:2% P.4]C4#985W(U9G=2."M%9#5G
M,6Y8.5<X:5@Q>' K:U-7*W-U;U%X5T5J4UA6<DM#)B-X03M(6DIL27,U,6LT
M>4AA3EAR>7(X4T@T=&)Q;S5)>$ER9F]9;2\Q9FIM-V9S<4=L+TUX37!J=WAZ
M.%-01# O=T$K4'I).3=*9DHY-&PQ)B-X03LU9C K,G5R:&)N5F)/,71L,4M/
M46LS16,S<'%4-GE0*SA6>7DQ<3(U3RM3=WEU248W,74T;F%73&AZ4VQ'3EDU
M4VQW+WI33"]!26$R)B-X03MR,V-L2'EF1VE8;FU6155+:39S>7%O1D%!3$\R
M1D%-1TAN3"MT*V=.;F%0,%EF.$%H6"LO;7E$-G9B.'58<$IY4#=8158O82\U
M<F(W)B-X03MZ;'IR1C=2>'94;6]A:$)&4EAC145F:4%C5F%32TM.94-)<4I1
M1&EO049!2T1997=P:7$S-G9B.'58<$IY+VTT:78W6"].8F9E8U98)B-X03M.
M2$<Y3U-H<55)<4%D=U%2*TE">%9Y4E))=D)%5E5P5&E!04M!54=W.6AI<3!7
M.75'-4-*03,X,T56+V%0+T<W9F5C5EA02$<Y3V%H)B-X03MQ54EQ06%%145F
M:4%C5F-K8V-A:%DQ0TM+04MO049!2T1P-T1&54]U;&%7;W5!=&Y!;W4P5TLV
M06I197)':3A&4U1B-&Q64&A!4&)B)B-X03M&5F5+0T-)=5EO,6I-<D8U0V]!
M-4]105=A;E4P03-X5F9I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E4W
M;4@Q-V571&TX9G%O)B-X03MY97!'94QR>49/4W0R661J:7)Z:CAT3#(V:S@P
M83%:>39Z4'%%3FLY>F)24C-%,#AR3C95>4AM56M65FHY3EI6:C),8RMT4C!W
M<3E,)B-X03MW2S=&56TX<&8X8W%F+W1O-FXO,U5B:D95-7A6:&8U<F%+8FYY
M9G)&.6%);C$R1WEK17=E;G!Y,C969&QL56=H:D-#,'-*-G!*,$E$)B-X03M-
M1WI.1FMR2D5(;&8R+W0U2'EA<W-F4U5D-6)T=$\Q;GEX<&DS=')&1F4R14M7
M.'-6=5AH:W,U,6E66%-&,#13=S%7;$]$9D5H1D-Y)B-X03M%130K<7A!>DXW
M.7@O835/;3%%.%DY2G)V2$U(,V<W2#1P1#5+.'A3,FUP*V%)8C8S=68P9D)Q
M:F5R<DYW<4M!-&AJ:5!Q<6EO<7)3)B-X03M%35A554%91F=O,WI866-T1U%)
M3F-83C9(=%!2:6500UE'4$=C9C!$,VLW5U-B,W%J=5-$5FY:-DIM83@P-T98
M67$W1EA9<3=&6%EQ)B-X03LW1EA9<7AV>EAR=7,V5F175%=.<S$U03943E!B
M>'=Y>7EU555&44=18U5(:C%B=U4U:6%J3D]"2$-,9' R9G!-5V%-=4TX2C)O
M:V=$)B-X03MF-R]U-WE%:'5F4&9M,4Q/*V504DIF5V5/9CA!4GA72UIL-7A1
M<55A:&I6;5=2:GI5349.4&@V-6HO;3AM+W Y,U X054W0TA:5VU-)B-X03MO
M9S5"5G@T='@Q3R]8<'E.5T]V2D8V5C4Q.'E83W17.7!C84I);&YD>G9'3&YJ
M2W%X>'AO=$A"84U&:$EF:DA0:5%V=FLX97%M6E59)B-X03LW12MB5'%/>DU%
M8U)L2$E/2TU2='1U4V584'!Y,G9D0D1Z4C4Q*W%Z6%5N=U)X4E-K0F1/;EE3
M4W)*1VE,2'EK:F9I,W$Y5U55-&UO)B-X03LR>7-A:DQ22B]W0GDS+VMD3'A#
M235K:B]!0VMD:%)U.6E,,C98>EI6<F9M83,P5%%9.5=V:UHP26I%:7A!:C1P
M0C)$,$Y+*T\K8FI4)B-X03M9:FQ)034P.'IQ2FI(9F-#>%@O;&1V;'(O;&UU
M4'58*W5:=CAM5#=W-&8U-D1V.$%L9'9L<B]L;750=5@K=5 X;50W=W8U-D1V
M*U8R)B-X03LK5W8K5V$T*S5F-C0O=T%M5#=W=C4V1'8K5C(K5W8X06QM=5!U
M6"MU4#AM5#=W=C4V0S90.#8O3&)U<4,S=4MS44)S3RLS:FEE>EHY)B-X03LT
M4TYD0GHO;E@U8E(R43(Y>%93461H,4<S:FE/>EHY-%4V-D,S+VQD=FQR+T%*
M6G)J-VPO<FHO2FLK.$DO4%%D+W=!<G0X=&8X<S%X)B-X03LY>2\Q>"]K>69E
M1B]0459,9C@V4$QK.#AC2U<Y=T=L6E55:T-L5TY",WA06G-W3'-*1W1G5%0P
M1$YC-6IY>CAU3%A7679Z2#@P>EAD)B-X03MT-F-%-WI(-G=T2U-C8FHY>4IE
M0TMN<4MH8F]X8FE2>2M(:&A6-D0U:W-,,U5.175R2WEC4EA6=T933UEZ6$9V
M-F181EI/9'$P57@T)B-X03M,5G5#>4IZ<'<U;T<U04MW<4AY6"M:8V9M4DPQ
M=DUV<F%9:V=M83-E5UAK-R]P5&U3,&%O<UA%-E(K-#E-05(K<BLX0VAV:GA6
M:R]K)B-X03M23#503'I*9GI25#-I,RMP:65A0TIO26UF.4DS1E-K5'E4<V<Y
M:3=F4$9745EQ;UAT:EI8.7$Y<&97.%8Q87DP.5,S;E):23(T:TU/)B-X03M3
M34-$46=(2E)K66UW84M#3%-F53=&3D=P<D]L5S%&=$E&:'9.3V=505,R8U R
M4D5I,$%L9U5K>&=$-&A62V)Q>5=W;'@K;5(U.690)B-X03LY=E@U*SA%5G5%
M1C5',4A43"LX.#!'>G5O8G1$<6AC*VI):V=+4&%W2T<K16XT4U599E%F1$U7
M3TMC0V5)15=E;SAG-TQ7-5EY:FDT)B-X03M31'<T-DY(:V5/9C)Q,#$X+VQQ
M+S O5&QG86933E1U1G1B06@T:RMQ4W-#,V]N,4A3<U)25TUA<E5R5&=.:6EI
M<FE-0T(O0V58;"M/)B-X03MN>3=M,D])87%%<#-74T5E2UA0,41V,D(Y5C%X
M13@W-&HO15=46FM/<61I<G-69&ER<U9D:7)S5F1I<DAF3UAN2S(X<W)P-6QI
M33,Q)B-X03LR-$5C;U=V-W$S6&5A-$Y!,W=X9VEV>GI),"MN3U,O269B,TU*
M5'!H22]02V-25V-S;6EL1$XV6FYH37 U,&Q33C$Y4#1+3GE76E=8)B-X03LR
M>DTO:S1B*W!G33(S2D9F.')I;6]%*W$R3%-&0U,T=3(Y2E=%;U%/>FU)1# S
M0DY#2VYK<$)!,D]2+TE$=E!Y5#1R,&)48GHV-W Q)B-X03MR92MM,% Q;4=/
M8C!N*S!N<4M'-'0W:71-,3@T,%-/-7-"66HK8U@O04-H32]W1'AN:"\T;&U:
M,F0O92]">'1B+V1L-$9N44]L9&ER)B-X03MS5F1I<7!A+S<P=R\V-B]R>4UU
M4UDX=VYU:S9B-6-V1W56,5!55%I84FYB,&1J>#E.2VPK4C1K5F)L.$\O=T-Y
M9D5:4FMN359W:7<S)B-X03MW:$$S>$=J84MN,$1Y4D9)27@U9V%1*VQZ-7)#
M,TAL445)86-Q13AV;S9(26I,;% X4#)S:FEX9GIM>&]N:TIH5#E04TE22VE6
M341K)B-X03M.1U-/56XR9'%$=&HT;5@K8CEQ*TAI+VY+3C%P=FQI,75T3VLP
M:E9(=EIM=5EL;&AE37!X1D5*64U1=C=:24%W>&Y-9SA1<EI":$%%)B-X03MC
M2G9D.44S4#%J-G9,.5<T1S0T3C9):W%%-3 K2&QX,S0Q-C!Z;3-D=DQF>7!J
M=#$X-&59<%!5:6$U:VYU9E9G:6%5<$A-2&@K<V5M)B-X03M*231Z=UEM4&1M
M2C(R,G)H5C9T9U8R2W!.-5,O-#55+R]B4C%0+W5O,T=+<'II<G-69&ER>2\X
M04QF5C=N5"]-6&UJ5%IT34YH;V(V)B-X03MZ26QR9#!)4DQQ44MI=VUU=U=2
M15%X,&]!5U90,C!'8D15>$5O>$E.>31F<S,O8F9Z64%'2DXQ5CDT4%%F:C=/
M:DEF4&9L3"]!0D)Q)B-X03M8;#%N=$AU8F%X=3)L=3-39C!/15)51' Q8C1W
M<F9$=E)30E1L;6PQ1TAJ361R1G4Y-TLW42],-#AV<31:5&I1.4XW+T%.;&IU
M<VIU)B-X03M2;#%Q1W!796XS*VY3,U!(53=7,6MU3$,O6D90,6E+369B6DYL
M.5)$4EI13G1W=T-H=4MY;DUI2DA51%DY+S0V=$=01$-C-'I!.45P)B-X03M!
M4VHO041396PY>#5X-CAX=E9K,3!+5S9M,%=X;75P9E=U2EE)-4I:46]11FY5
M3CEK8D1R;&U):W="4$]N13%C67AY>45255%3161L)B-X03MJ:G5X5C)+=7A6
M,DMU>%9P:U)J5FQ"3D-U-')S96\K;6U.<7,K<C(O2E<Y2D]38F\S159',4YV
M;S)W,E97+U5R2W1F<3AD95!(-T,O)B-X03M:<E=N5'!H-&HS<7):1E=%+VY&
M+WEH32\O1V5(+VE76C-:,SDW.$A&,78X061L-$9N44]L9&ER<U9D:7%P82\W
M,'<O-C8O<GE-=5-9)B-X03LX=VE93'%+,3%34V%71F)H05IL351D0UA6;$(S
M0C9&<35%>'5.37A+<%=N<S$O-6%&,4)R66(Q2DIH3DA.;V]H4E)#2&IK:FI:
M6D5%)B-X03MA3G=016HT83E..&]%2C%W+V$S1V-,179S5GHU>3AT1S--369L
M,D<S63)P9TTV34AB;5<U<S%'56)/9F@X441S84-M4B],>G4K2SDR)B-X03M8
M-6E(.#-O>&93+RM/;EHO.%HT+RM*:DUQ9C!L>'-F,40S=G%(56MN9E1R<$QE
M8U=T=S!-9VAU5V]21S55.%A.9'%+9#@U4C9&:%@U)B-X03MD951R=E%D6C%E
M83AV3$\X=F)G2CEA94=39#=K1G9I:D4O<74S3#1A,&1X>E!J5$-R2G9/6&U#
M6'DU-54Q8EAO<DHY4F)3-V%3-DYN)B-X03M'-E)&,6E8:S-X=G-Q<6],3C%.
M0CA+<V%+47)%0BMC42]W059F;T4V45%054DK<RMS,SDQ*VUV,$='-&5J5&MB
M:C0K4$MN1&9L6&)&)B-X03M75F536C!U3D1K;FI$<6MM;V%M>6E22&EC039H
M8V9A4U%+-FXR27A64&-69&ER<U938E0O04-T6E=F-EE34V%7.70Y8FUE93AT
M<FM2)B-X03M'34=60D<V;T5J:E!&;S%684U4,#AA,75L;4HT96Y#>$5E9FUW
M<GI4<DAN,U%032]L8E-B4U-78E$W<2MJ9VTQ16]K>E-W>5-X:C9V)B-X03M/
M>DLW3$I'9V8Y-55&,4YD,E9J;5IH>#1P=VY)+U5">2]34#%D1W%C<$%G1&MY
M>CAW8EA33&IY9G%F-E9"1G1&0DDV>6]'.5-.*T)2)B-X03M746]#=U!X8U0R
M2VMG+T-333%/6$9X>$UE=E1P=3=8<S=5>G=:-'IJ,VDY<G-86C(V.2]V1FIC
M25@X<W14<V)N>6IP,7!!1$9,85<V)B-X03M),$PX=512:7%P3W9-06U/6&E7
M1DYG87 Q56I)-$)W>#14.5$X-R](-$1B,G-$3$Y,2TXT6D193E8O;6MD0U!0
M8VEP8VE'4E(V<G!C)B-X03MM;U,V8DAE45!Q34MI4V%Y5U)$36E':$1.1T1Y
M02M.9'E/-'EZ:48Q93=G;E0U0D%:1$4X0C53;S!F:GDV27)*3E1S5F1I<G-6
M9&ER)B-X03MS5F1I<G-69&EQ5F5:8D]Z=DY+84<X9U,U:#5Q5$9*57%31'0P
M27DS1$EX;%E.34UK45)266@O:&IY=B]!3E=E,2LU+RMA<WDO2'EF)B-X03MZ
M:3!E1$1U0W=E6'9+4DMG859::W989U!I,W Q<#AE4&HU4#5X6'=99'=A:CAV
M.$%L0U%6:C!U>F-51%98:U)2:%5(6BLT>#AF2B]/)B-X03M+*T1$=41O.4(X
M;GEM:V5M5V)N9EIE4C95<C!F,T=0:C50-7A8=UED=U9O+TQ0;&=32U)P1G%#
M0TM':BM0*W1I8RM4*V-61T=(8TA3)B-X03ME5V9,0FM9;E-,56MK,4Y(.&8X
M05=X1V9*+T]+;D1$=4-M,VQV>6]G<3)K,FEJ659)8T-P3D(K,6HT*U0K8U8X
M1TAC1S$X=&565T96)B-X03LP:3%)<5)50GIU1%%J-UAJ:C0K5"MC5CA'2&-&
M5S,X=&575G5);5A33%I75C%+<T$Y45%E=C)S0GHU2RMO<4U-3S1-,C%71S!N
M,'4X)B-X03MG=DLO53592D5U94YE6'!S:$0P-#%.95!H;4$U5$-024,K5S Q
M*S5I,&MY,TI72UHT-S$P;59J1$DP3'-T>3AY25I*;6Y,.$MB0TU!)B-X03MD
M83166CE.1$100SA->4Q,1$MP4U-.=T=6;%E52W-$<U%29U9B.51T4%8Y6#!)
M+U8Y5#%V531R>3E4,"]3-3%P6&PV9G=6-CAD=6U+)B-X03MP6#53+W=#3U90
M.$$Y=$A5+W=$=6\S1TMP>FER<U9D:7)S5E5R<3!T8GDS:W1R=49,:3)L2$=7
M1U91-DU00FQ914A$1U)"<TM1>$QZ)B-X03M:-60X=W8U63%(4SE-;695-V$W
M:&%+3S%N;3E/-VHU9C<W=3-Q2D551#=%=S5.53%L-D1-<D1K:'AG>496.'9L
M*W(U34-#0G-O84Q&)B-X03MP96XK6$Y,,')69G(R;#9H<&1S04Y2;E%G5S5O
M3U(K=6]S=&YW2G X1$]14E%-=F)+.5)H.%-:;$=U93%C+VQZ.2MZ9G Y5$Q(
M<V1W)B-X03ME66QY4'8X03%G9VIO47A4>6YR8U O2S5T9'8U-WDR=F)E9E0T
M;S%V3D]R3D4W570Q-3A),FY:1DAP='I,1VED,C-"27EA3T],14US)B-X03MG
M4FM*;S=(.$1K2$U/=FYN9TY.0W9#:#9O,EDS,7-8='AF56%!,U!C.44Q5'IZ
M;V1H2F\T5B]R<U=U6$%T8DLT=%I)2&DU:V=66FUL)B-X03M3<3<Y541E2%5G
M1T=+26U#45)S3&-02F=Y45!#67ES8SEU5WA/+W="4'5$24UG,75X5C)+=7A6
M,DMU>%8R2W5X5D%A-2]W06,Y=CA!)B-X03M76#EE5'@X,DUU5$=M54UP53E#
M2T@V8WE'=&=F+TMO9$Y%1'=X87AQ55%:1$A'>5-O1$5R2U594F9".%!W;F)W
M3R]5-$]&3G%U:F9L)B-X03M0<$=L2DA(1G%&-TY&2&%3,E!O>7E+63)J;&HY
M2W))<7%P2W(P,G!82&A7,'<P3'E"<'5I,V1P8U=S.&HO5E9K*T8Q:7$W>7%Q
M1C-D)B-X03M55GE11C(S<'5C4457>7!0='(X>&A6>B]!1S(K6GA62R]-3VE1
M-C-P8W5N5%-'2TM9<GI:5E)J>$)"6F9J1%4U1#1A:F9W24]*5F(U)B-X03MA
M,$-$44Y):3!U,VYM=5E94WA35S1B;DHX5$9T,F]+.6-11E1E2"LK:B\Q:"MV
M17%'5WIW>%1W>5%42TAI;%5P26@V1E=&0U!U>D5B)B-X03MK<C!8>6PU9#!3
M85-F4S=*3%=75F5%:G%82DLQ<E0T:64K2W!V:7%(=713,#8P;6=G=7)Q1T-E
M-F)H87A3>4MJ>7-#0E-.5TE,1W)$)B-X03MP-#1Q;%AL85(P,'5B:D4P;&13
M,4E%<58R<G%5=W%E5$PP0C5F24AV44963C1*-5I)*V(R.&M,54(Y3GI'5W%6
M1%4K0C-7;THT.65O)B-X03M086A+<3 S531C<CE4;4E&85!71V@K,S O958O
M64AB.71F.$%+-'%Q:VMR;U%&:&53<$%*57!T5FQ&5'E:96=9=#AG93E!5E9S
M13AS)B-X03MK6$XW95-&=4E0<'59>3%3;V)J.$1U=%%4>#8Y464Q0U96=C%Q
M9C%#=C%/8FE/:C%H;V9T.5 S;&8R0C(O8E@O04-U2W%P3$Q):%5,)B-X03M#
M.&=*04I5;TM66E9Q951,,$1&=FM$,V]#<3%$4$Q*1GIE,VMI86=0<'59>3%3
M;V)J.$1S=%%4>#8Y4C152E91;#="83,T3G9F858Y)B-X03MA9T)*06Y7,VMJ
M4#)X54MZ;BM19'8R,2]Y=4UO>DUE4G!32&TO=T-:;FM4>6DK<2M665E.35=Y
M1GAQ26AU5G-)26]K:V=C3'I-<&I6)B-X03M7,F-+1DYD9U<Y<S)';3%'47AN
M6DHY4&5F<S-A>4)%9V=$;C-$.&9O6E9:+VPY-6-T-T5X,D9H3'!H2S$T:U<Y
M,4I59TY3=#$Y8E=O)B-X03M,1F5T2V<Y<44V,'EN,&Y,-3,Y.75D*V%"3GEH
M0U@K8G<O-VIH5F9);FUP9&0P3DHW8E1,-C-T-V1J87!,9$IB>$=4,%%W3$MS
M8DEV)B-X03LW059U2T)1-31J6E=P9&YW;DA+:65).3=I;69%4V$T9DQF8C4R
M9G1:3$Q.26I+1F=E545G17%504975F%N:WDY07AB-4$Y-D$P<39#)B-X03M7
M4U)!>G=V05-!945H46M654=N=TTT,DIP,39J=V]3<6QM=F5:24Y(=4Y0:&UH
M6B\P;%!(87=30FQ69E=K;&I14B]%86QV5&0U84%F)B-X03M::F(R>%9J3"]N
M1C5F+U1V;#-427)A-$UF;4=394-'-6Q5>&5N3D)W0FI-8D1K,SDX=%<R4VY2
M;4\R2W U-6(X.6%,-6A.=CE34V5-)B-X03M8:5AC;&U::T-I5T]W;E,R=4A(
M1FXT:%I:5E=J54HV9U5X5FM/2W%.,E-)5%1X1T=+0V=E8F5**R]*<U=095DO
M>D$X<F583'5/,3%M)B-X03LO=T1Q<S!S66U51EI'06IA5DE1>DUO255C-4\O
M644Y06-5<&)A9FY$-4=U-%I*8F4K;&M32#%$2E-#96]%4S@S4#)/9U%-,WE6
M=D1&)B-X03M$271$.'AA8G)L;S$S<',U;6=347A->%9K*TE!3C!903!+<T=(
M<V-65$9886\S4%AX>%9Z3S%4=65V:FEQ13%(5C=85#%T,G5N9%)C)B-X03MZ
M>#)S4E989CDW365+0G5)4$5%-U9/,DMR3DHQ>7DQ84=A87EK6C!T-35,85AK
M1U5I4T9U3&EJ54]+;SE'8FUU-39J=FEQ6C57>F1I)B-X03MR<U99;#4T,'IY
M-TYQ3V=8*W)08W!-;#=$6C)3,C%#<GE3,U9V94ES=TMS46YR-F1%>%E%2&%L
M844T<7AV4DY%+TQX=%)B4DQF53EF)B-X03MM=DAV3&Q2=S%F6$5J-4Y094TY
M5VIU=4-H6F)+-&DU4%)N84UT=GE$37%Y:B]L5S-L,R]L<C%Z+T%,:BMT+SA!
M6EII<50V-354.&\R)B-X03ML,6)A43)Q82]B86IQ:U5X<S4P,7I7<$)%16%+
M1#%7-5AN1#1:<G%&47!R57-.=4E9:%9'860U3#AP-F<Q-'1V9&5906)'-&4P
M;D5U)B-X03MT-CE%9E525EDX4DID<5-P1&=Q,4M-3C%Q<$)+<4TO-59T-60O
M=T-7=EA0*S0O<F8O6EII<51A,35,.',R;7-E6#=)-G(U:'0U3E)U)B-X03LU
M;S!J:C%J5S5)-V=25U4X<&AL;$XR5FAP=SE64T-'67!15EAL:7%C+W=$2W1V
M3'8O3%AR;B]C9C%V.$$W3$U69"]Y<F)Y-R]!371E)B-X03MU9CA!8V8Q=B]S
M<WA6:DYP;VYK=5A8-$E2<2]M37@V;E=Y<W)+5%8Y8VI72S9T2'9$2WI-,3!S
M;TTV5VMN2&PX3DED<49X>59:3B]Y)B-X03MR8GDW+W=!=&5U9CEX+U<O*WEZ
M1E5(<69K=GEN<'$R>EA.,35G275R:4LP:4UE=#8Y24)*33-&4%5+6%I%83$R
M-4]12S!(,FE!5E=0)B-X03LK53E..&HV;S!.;6UR*UDW=39U>$QD>%-4-GAR
M54A#1V4U=6AB46M,94%65DQ35D8V:W)&>69D:'E66EHO=T%Q,CAU+SAT975F
M.7@O)B-X03M7+SA!<W-X5FAM=%AV-5DV6D9Q9W5D83AW-F),<&MS,79C6&,R
M<6$X=V=E1F)A<R]O>3-,97)'2DY1=#%8-$=$.'=11VIQ,DMV4DY")B-X03LX
M,396<FLY>$19:5AN87A7<SAV<6]52$,Y:3EA2VQE<#1F83A$:7%C67$W1EA9
M<7!82TTP4D-I<'%.<TE154@Y5VXO:T]4<TEP3&11)B-X03LX<&%,<54T;C%$
M4W)E-VY!54-784I(86EC=4EQ=THR.5)V=GAS3%-$6#AU+TMA>$=*9$-T1E%K
M;6EW;TYY47A.45!&4FI95VLQ<TY&)B-X03MT=%!H349J85(R,$Q/,&I2>$MQ
M2UAC,5IQ1$=W=$EO5S@Q4CA">'-,5&IB>E90=TA'=W1)5%5D0W1D4VA30R]T
M1759561:56IK05E")B-X03LP,U9Q2'5-8D,P,UEA2F)A9D<X5FIA2F)2>4]:
M2D9I54M'8V=!<V%D-DM".&AJ65=K571V34="-$AR:F$P;4=6<VY9<3=&54IQ
M1VQA)B-X03MD<5 Q8C8W07,O,4]D3'4R-58K0V5+=D-153=R531Q;S)N;'I2
M3%,T*W,R.6Y(2&-'5#%434ML*V1*051Y2DHS3GA+>#A79#(K,'I%)B-X03MQ
M<&II<4(Q1%$Y2S%'94,T=3=C4UA.<W-I5S@T3$I*1W-V2&U&9$-R0W)2;S-8
M-U-Q,S)L56A61E)7,$5-:S!K84)8=4A%:WI$.7!W)B-X03MI>&=N+UE);RMJ
M1E=&>'DK94AA-75D3E),<3-(-E9T<E9P3&=H-#=K6%8R63-E0C$T4V]P:'0T
M;R]W0C1P54TR,TA&56UV.$%1+WI6)B-X03MU3E=T<G57-5=9861D5%-73"MH
M8D])+U-S=G%Y,T%H*W-7-&,S9G%Y+T%Z:C V.5%-57!L-6=G+TY3-755='1.
M;D5.;V114S1.-'-6)B-X03MU:VDR<5@Y=6XQ8W%B:'%O3&(Q6FDO,G!+8T-S
M97ES;U5B1%A03CDS8UA6>&,K<F)F5TQB43=P3%953&5H8EAU<C-G;E)X,%=2
M8D%2)B-X03MR3S10=SAE6%E9<6Q43C5Q,5169$8U85=M:WHS3G%*25HW94Y*
M<&]:.55S8F@W<3A5>7E+22]Q3C O1W4W151&869'3U-Q36Q8.#(T)B-X03MF
M3#EL939J36LK<'=-:W-L;$598E97;"]29'DV>'E02$M6;$1A;DY"8FA&,E!!
M1VA$36-696Q81G1"8U)I3V1!-DLV4T)4+U!%-&M1)B-X03LO=T-X9%%C5E,S
M5%!+6&QV4S596G10,"M+,FQT-'91:61!86E0;3AG6&,W,&%A47)8<'IA;C)M
M<7%M,DMP4F4K55!,1CE,4$QE-EIB)B-X03LS5%A5:&UU4DUG:U=6:DA&1695
M5G%Q>3AB5T@T4T]02TY'<'E514MQ*VPK6#E','%385A4<E),85-E3T-+6FMR
M.%-7<V9P47%A;F]I)B-X03MB1$95=WA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X)B-X03M6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5B\O6CPO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU
M;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM
M<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @
M(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V
M96YT(R(^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z,C="
M.3=!-49$,30U134Q,3@U0S$X.#(T0D,T1$(P-$,\+WAM<$U-.D1O8W5M96YT
M240^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,C=".3=!
M-49$,30U134Q,3@U0S$X.#(T0D,T1$(P-$,\+WAM<$U-.DEN<W1A;F-E240^
M"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HS,S0Y
M8V4V8BTP,64T+30V9C<M8F(U9BUC8S=C-#AB.&5A,6,\+WAM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S
M/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP
M34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C(V0CDW035&1#$T
M-44U,3$X-4,Q.#@R-$)#-$1",#1#/"]S=%)E9CII;G-T86YC94E$/@H@(" @
M(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C(V0CDW035&1#$T
M-44U,3$X-4,Q.#@R-$)#-$1",#1#/"]S=%)E9CID;V-U;65N=$E$/@H@(" @
M(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z,S,T.6-E
M-F(M,#%E-"TT-F8W+6)B-68M8V,W8S0X8CAE83%C/"]S=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S
M<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X
M;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C0V0C@Y1CE%,C<T-44U
M,3$Y,38P038Q0SE!.#8U,3@S/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$U+3 X+3$W5#$T.C0P.C4U+3 W
M.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HR-T(Y-T$U1D0Q-#5%-3$Q.#5#,3@X,C1"0S1$
M0C T0SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C Q-2TP."TQ.%0Q,#HT.#HU,RTP-SHP,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA
M<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD
M8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^5%@X,$$\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@
M(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^2&%M>F$@4W5R:6$\+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R
M/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z
M<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE
M;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL
M;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @
M(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @
M(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!4
M4&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(
M87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E
M<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-C N,# P
M,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XT-2XP,# P,# \
M+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!I8V%S/"]S=$1I
M;3IU;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @
M(" @/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^0V%L:6)R:3PO<W1&
M;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M
M:6QY/D-A;&EB<FD\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO
M<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S
M:6]N4W1R:6YG/E9E<G-I;VX@-2XW,CPO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&
M;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I
M;&5.86UE/F-A;&EB<FDN='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1.86UE/D-A;&EB<FDM0F]L9#PO<W1&;G0Z9F]N=$YA;64^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D-A;&EB<FD\+W-T
M1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@
M-2XW,CPO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F-A;&EB<FEB+G1T
M9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&
M;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @
M(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U
M;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @
M(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SI%>'1E;G-I<T9O;G1396YS93TB:'1T<#HO
M+W=W=RYE>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O(CX*(" @(" @(" @
M/$5X=&5N<VES1F]N=%-E;G-E.G-L=6<^"B @(" @(" @(" @(#QR9&8Z0F%G
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9O
M;G1+:6YD/D]P96Y4>7!E("T@5%0\+T5X=&5N<VES1F]N=%-E;G-E.D9O;G1+
M:6YD/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F%M
M:6QY/D-A;&EB<FD\+T5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3X*(" @(" @
M(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ
M93XP/"]%>'1E;G-I<T9O;G1396YS93I/=71L:6YE1FEL95-I>F4^"B @(" @
M(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I&;W5N9')Y/DUI8W)O
M<V]F=#PO17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3X*(" @(" @(" @(" @
M(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX^-2XW,CPO17AT96YS
M:7-&;VYT4V5N<V4Z5F5R<VEO;CX*(" @(" @(" @(" @(" @(" @/$5X=&5N
M<VES1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U;3XP/"]%>'1E;G-I<T9O;G13
M96YS93I+97)N:6YG0VAE8VMS=6T^"B @(" @(" @(" @(" @(" @(#Q%>'1E
M;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/C(U,S8Y-3,U
M-SPO17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3X*
M(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M
M/C(U,S8Y-3,U-SPO17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^"B @(" @
M(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M
M93Y#86QI8G)I/"]%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^3W!E;E1Y<&4@+2!45#PO
M17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^"B @(" @(" @(" @(" @(" @
M(#Q%>'1E;G-I<T9O;G1396YS93I&86UI;'D^0V%L:6)R:3PO17AT96YS:7-&
M;VYT4V5N<V4Z1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&
M;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/C \+T5X=&5N<VES1F]N=%-E;G-E
M.D]U=&QI;F5&:6QE4VEZ93X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES
M1F]N=%-E;G-E.D9O=6YD<GD^36EC<F]S;V9T/"]%>'1E;G-I<T9O;G1396YS
M93I&;W5N9')Y/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N
M<V4Z5F5R<VEO;CXU+C<R/"]%>'1E;G-I<T9O;G1396YS93I697)S:6]N/@H@
M(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H
M96-K<W5M/C \+T5X=&5N<VES1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U;3X*
M(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9O;G1396YS
M95\Q+C)?0VAE8VMS=6T^-S$T,SDW-C,R/"]%>'1E;G-I<T9O;G1396YS93I&
M;VYT4V5N<V5?,2XR7T-H96-K<W5M/@H@(" @(" @(" @(" @(" @(" \17AT
M96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^-S$T,SDW-C,R/"]%>'1E;G-I<T9O
M;G1396YS93I#:&5C:W-U;3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES
M1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/D-A;&EB<FDM0F]L9#PO17AT96YS
M:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO17AT
M96YS:7-&;VYT4V5N<V4Z<VQU9SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( .\"60,!$0 "$0$#
M$0'_Q  >  $  04! 0$!            "04&!P@*! ," ?_$ %80   & P
M @4$# D'"P,%  (#! 4&!P !" D3$1(4%187&%98"ADA(E1UDY>9TM;8(S$Y
M4Y25N-35,S4X07BSM20E,C92='9WLK2V)F'1)T.2H:+_Q  > 0$   <! 0$
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M!*X+F86W;2&&!4:7C CV7[0+1>R+V>\$&UXFO2Y'[S"D"O$W>TD^WA0C.$G
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M1PV"-,4LJ:+!RM:;*76%S*Q)7%WAGCY<-D\P<&IB2NL9&R2-Y*(/?]^G^?\
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M?MQL1@86EP869GF"K9'FOK>VLKJXM21*X".*)0+#TH0^2/8<(O&EHNFT(:?
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M1%34E#TN@14XW(JN@Z5#SUY/R&I2(ZVEDU/Y$.<*^*^! !(UJ.>I"'5QB_\
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M&E)11N_)-&5HH[0BAC#O0<ICXLKC;V-F<YD5^I/4>]GX[&SQNC+V[]"YG-S
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M8^#D\IDLD,UH)DAD#R^&!"G2H]!&[.*E>/6DB(!:)+K0E&]:3I  2D:_@DX
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MT>]C,&+6Q#%]\+>]_=R)>]Q#G/<7  !Q<20 -@ 2=P .@'< H!H V  !.Y
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M&C;QA5:=]V@?^K@&YA>02YI=&=P0%OO2%U5YT/5T0N"K7PE_ADS;"G%N4@V
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M9X=N\EK3]X;18[7>FFNYA5U#@'F.P70-:_(5:[:LI>8JW9\R7<WBHV#9W25
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MMX>^%[BPD_B3ZS9KS82Q)DJ$3Y:$[C)D\?'U<QW\Z_39W"0-_C$+=FR-:'-
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MXNIF$F5FELJ1:Q(#3$).URC9\BDC1%&[9:8D7F&%>^7QO)4FA](4Y9@C3/N
M]&SY&QMYW'S=VCIU_&<&#]KAOZD:TO/*._8GX@7']@*_*VQ8LAF<-@9BT9S]
M/&.92*.>R%;5-ZEL@9\832(PYP)$).080;+F8*<L6][4^NI]3>MIAZP9&A[&
M;^<]KW-V[MF<H=U_YQ]PG*2USO0TM:??=S;=/^4KZ32Q(;7T-<K E3V6BB34
M6C$H<T*1P?C5!KBXI6=K0-+7'TCH[OSL\/"Y"SLS,R('!V>'9:D;&U$J7*2"
M!GR,8PO<=FC;J 7;[D  !H)<22  T$DD #=&M<YP:T;D^Z!W=223L   222
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M=_27!*"PIZ1T5SC/5_-/5#2'8]V%%DA0HG9Q)82]@CUU1(@!9$S9S]D%)Q.
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M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(M*+S_Z_*?Q8V_[H6;O@?\
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M(W![P>H6MT\XMY&L[2T4[YII"0JG$X!ZYT45K%$SZJ.!OTA,.?V]L2/8A?\
M:_Y?Z!Z^X/0M?<S9\?K?6.*Y/%^J,[69&TMCB;E+;H&-/H;7DE? /<_!]/0K
M"?%XVS_#T*<I_*?6A+O@=R<P^ A:U._A >'TXGGJVVC3X6L/ ,.U-?63:,(]
M00A#&$W26.S)"WF&$[,%HGVE&>66#?EZ+\O[S-GAXR\18FM9+GFWF-(/+D<9
MBK^X  Y>>S2DD .WG<KVDGKOOU6/=I?!N_%HB'<@DUYK%<[@[@DPRL)(]'J]
M"PA+_ JXYF10"G&9=*;TFUO386LN58^IFKTZ '>D),A97090=@+"#T:/T+U0
MA^^^\#Z*-_B7-F71OS^B>&VH'1'F:[,:*Q-V0$C8EKY6.Y''TE@&XW'<MOTQ
MJ#6NB&S,T1Q&XD:,CL;>$PZ6USJ/"0V0W<M;9BHWXHYV@DD"5KMB20HB_&*X
M8;>-><*P.@-]]%SB%2*UDT=45Q:,_,E\)9CBXC*'$M\96X:%*!I=!:2Z;]"3
M^62-*>> 18AB!L'3N$QT[K_4M?'Y'0'#RA7T^(M1TWX[ BC<AR6/NU9,;/C>
MPG9#7FJVRRR^01.)C88N7E>2*F9XJZ^T[A=6Y.'7&O)L_JC"RZ1NY9N5K2MO
M8'-M-7/XS4]F>A->RF/R6-;)6B@?;C<VX]ECM26.CEU!\*RMO$ LAONHGB2X
M$];)8N*(N4\9%;N2PBEQSF)]+9DS0YN$0D[.6Z(])G(WU70]L( 0J-& PS8A
M!W<>R"91T1GZ>I,/PXT/JJ_JQDDF??F;^7Q.:LV<1!5ITYH[=-T]6: 4W0UF
MLFK0F$U]^VE[8-BV7@IJ'0?$32&.T;QTXH<8M-XK0,DV,X=.TA@=+:FTO@L5
MFI9,EEH+N/R;Z&7@F=DF^$O?0L9%UED\;#7JBOVD\JXA>-'7HSDDYE/4QJ=&
M=H:5?6$!YKOP'E?Y<0E&S2XFYO @??\ JI@)"@'>J%%ZY6Q@WGG-W&#&0N(R
MOL;6./02/P6LK]J(MV\XQ,;'$]CN7?E#0X\VWG;KN#/8U\&L^QC]$^S8TC#V
MC7=G6XD:"OZ)L-DWY8VS3N;E:K&%Y;SR/E9RL)D$9:T[>[?5W9+-H&K$ZP[J
MJD>MEZ4'3OPDJH);R/6$$(A[/9I*Y'G)_2,O032B #,T:6(!>_6]&4O^V_A/
M%_'^!.J\=Z'&UFM4-:W?IN'1MFW&Y&QY#ON.G51__!GB7?YCI+V0OL<];=YA
MCT[Q*TQ//*&[GE,-VICFLD(:_=IL ,+'@O\ -*EZ\/VT9#:]72]\DG1<DZ26
MM\\4-()/*>>$?-SG&RRX^Q*MQC</1A"%V*+,5#=-/QH?-&8XF-V]^J@#K5O/
MJ[2.L7-OZ/T]8TY1K T[5.S>R=Z26XTF8S\^4@KSQ@PRQ1]FQICWC+M^<N X
MKQ%X/:^X+Y:GI[B#/A[.3R>/9FJ$^$RF&RU-^-EL3TF'PG"7;U8/\)IV#RR2
M-EY2UW)R.8YV^64%S],(F$3")A$PB81,(F$3")A$PB81,(F$3")A%A*=-[2I
M?S#5;.V+3MI4VMGJDNC3MAT$7JAV/8M?>AU]P.O1]S69W'R2MK@,FE8WG=YK
M';#T>C;TK'V0SM>K&./*.I!W]/J(5G>YV#Z.L?\ 0 _K9?=K8_29_E_8K?:/
M\U'\3OI)[G8/HZQ_T /ZV.UL?I,_R_L3:/\ -1_$[Z2>YV#Z.L?] #^MCM;'
MZ3/\O[$VC_-1_$[Z2>YV#Z.L?] #^MCM;'Z3/\O[$VC_ #4?Q.^DGN=@^CK'
M_0 _K8[6Q^DS_+^Q-H_S4?Q.^DGN=@^CK'_0 _K8[6Q^DS_+^Q-H_P U'\3O
MI)[G8/HZQ_T /ZV.UL?I,_R_L3:/\U'\3OI)[G8/HZQ_T /ZV.UL?I,_R_L3
M:/\ -1_$[Z2>YV#Z.L?] #^MCM;'Z3/\O[$VC_-1_$[Z2>YV#Z.L?] #^MCM
M;'Z3/\O[$VC_ #4?Q.^DGN=@^CK'_0 _K8[6Q^DS_+^Q-H_S4?Q.^DJFV-3&
M :SRV!F+V)L7@%L"((?7+$0+0RQ???= /7W!!_UZ^YE*66<B/>Q,?PL?>_N(
M=T/=WCT*HQK//_!QC:-W<#\74GO]S8^ZJ9[G8/HZQ_T /ZV5>UL?I,_R_L5/
M:/\ -1_$[Z2>YV#Z.L?] #^MCM;'Z3/\O[$VC_-1_$[Z2>YV#Z.L?] #^MCM
M;'Z3/\O[$VC_ #4?Q.^DGN=@^CK'_0 _K8[6Q^DS_+^Q-H_S4?Q.^DGN=@^C
MK'_0 _K8[6Q^DS_+^Q-H_P U'\3OI)[G8/HZQ_T /ZV.UL?I,_R_L3:/\U'\
M3OI)[G8/HZQ_T /ZV.UL?I,_R_L3:/\ -1_$[Z2>YV#Z.L?] #^MCM;'Z3/\
MO[$VC_-1_$[Z2>YV#Z.L?] #^MCM;'Z3/\O[$VC_ #4?Q.^DME/4!_V0_P#\
M=?\ XS5%DN8_<N_U7JPJR81,(F$3")A$PB81,(H-_LD;UOM,?7?J^CUO?7+7
MJ^MZ=!];YXW/OH];>M;WK7I_C]&M[]'\6L(I@SS;:^4R.$ID%=;IP4%D)DN<
M#W:2ALPBRPN\<#%$<<9RV446504UA%+C)"Y.;XC?T[N5'"&UJ4HU#FH3$^Y5
MBGJ>IOD] :E9* W:_P J24HQ"?*+%#7OR*?*846L7@=2X@*2:M+5-^<M2M(F
M;<3W9FBFPUZU%MC=M$5\$FVY\ILA)4(*XU388*R&11P)=Y,*S3[,$[/FI(CD
M+.-D#%4L%*8M1HQD<FU]62 ]V,?"5[4G1DH#SR*RT:GJ'<,I@QP9:$#82B8,
MA?0Z5')[#'#&J B;Y!N1JZ87GQ$M[D$P*=014#(WSAMC+*>WGR U>YIE*1N)
M6D^_W^_PJM'GW_[QNK25JI[;0G8FP7.AA[_--.+O)MQ=>-X*NHDN-B31UB+F
MFFQ,V*(*?*' V+B7K528EV+3H#"+\)C^@O:J-TK:J;TB4-R_?2@TS_-A*FAV
MU"3#&L%&EFQH)4C;C+'\I(O-GIL64DPGS'!.2>^Z"V;(J,\*>I PZ[S&!EH(
MVP$[\Z!YN2O$GL1/#G:+A9F/;(==[@BB*EZCS\9(!20#HF@;;)V\EF+8S4BI
M0M/7DIR*]E)MN?*/$2D:"N-U$.%2<R>+E+O)M6.EL4+A&-0Q)$6HID%&%T*/
M:A3,<G<7EY;GQ*X$1@MJ:UB94ZFHR*Q5*KJG5<N)J-DY^';>K0T2TH%,IL8N
MN3*7^4Y,4)P<78J'FR8JT-4SM6OTSIF4Z*;LX*9IV^ABHS7HLBOPHVVOE1=B
M3D%=:I4,#;#&-Q*=I**T3;/V]N87E&[,PV4,3(@8(YIG-;')&^J9":]C<R%3
M42@+2J#2*QD:GJ3<(J$QP9:!!9!\W9"[[1HY/8AD(;*W$-\U(UE0N)\1*?GR
M;E%AC0F1MF;7'F%0,Y\ O=4P4R Q43W_ +_?[E7)H^]OB*W [;*E^$B&!E%0
MQ^GR8_$3G*1,;D*1$VXE^'O=C&P%R7302RJ8:LD+B<QC<E*Y(G7EI4AI%X$:
MCHG>J)]O::6 )2E.WTWI'(9R;IF6? JLQ.&B=G1@G<E2[LS2!&<98&HF:&"B
M5N("Q/X"6LPBISHIZ?U&+Y&R,U"CF:=8[ZYA3NDFL(N,/#>&+-@F$R^5:2)&
MNL;6&3;;R0[DU\BE1!$6+;%2,]0[&JD9)/?5Y*CK?^4*$%(F^M]U29$)098Z
MU4\2<-A))Z%1&O@M+"&LIC%''&(')13#<H7OSNUO*503&M-+:K+4.@DI%8YZ
MGJ?Y.I2:F9.?]VV"RS2H2A/E%BAKI53ORBMQ9"Z4NI<0%)D%E[J43LL-:FEF
M<8L&Q2VYN \BC1RET3D5^@-MCY5%9)B"O-4EJ!)#4#D!VDF[4%:&WY6%<B5L
M@F742! @QCV$Y(YDR R0C?MJTQS0!O"2K$3[_?JK&0J>H]P*L#')EH,-H'3Q
MD*N=&AD]AF0)OK 3XYADBVL')1$2Y"\SPJ-!9SF1KE;2Q1Y0^&N:9>[ID!"5
M6H(KF =>'Q;:0#6VJ?@0F-L J44 >Y=\6N4O$VNXI21:2,4?]SLD;*>-,)3
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M+3G;-+T68+8P^F.XWVW&XZD;]1\'>H;';?8['H#MT/P]RN+(J"81,(JBV_\
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M/+*T\P: 1S$G;S=QN/=W]7I7SZ43QZ[("QMDAA?2T>116355:S&^0"KHC)Y
M2_J"9B<V-Q\)G4<L!,Z_#9S8%%/F5T@:G;0;)HN:6?[.:Y.#0DV>T;B0;%K@
M6M!.^SMMVD'N[G CO(]&Y2/=CCLZ,[AS3S.(&V[>N[2W;?O:>;N!].RSOS@.
MSAT55N[E9&V-V8&(MI<J8VI TM29M5$Z&4C3G-+ N=(^T.GNH" ;VT1YR7Q]
MK>AKT#&K4-2=(:*>/FY&\X =L-P-AM\ W .W?MTW[NBDDY>=W(26[]"=SO\
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ME-R2KW!HK:1M5OU<CIWIZ65]9"F1JXNZ2^+G."^B(U-(JFA<K8R3&"7JVV4
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F")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
